PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, H; Lun, Y; Ovchinnikov, D; Kokubo, H; Oberg, KC; Pepicelli, CV; Gan, L; Lee, B; Johnson, RL				Chen, H; Lun, Y; Ovchinnikov, D; Kokubo, H; Oberg, KC; Pepicelli, CV; Gan, L; Lee, B; Johnson, RL			Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome	NATURE GENETICS			English	Article							SONIC-HEDGEHOG; MOUSE; DOMAIN; GENES; EXPRESSION; POLARITY; REGION; CNS	Dorsal-ventral limb patterning in vertebrates is thought to be controlled by the LIM-homeodomain protein Lmx1b which is expressed in a spatially and temporally restricted manner along the dorsal-ventral limb axis(1,2). Here we describe the phenotype resulting from targeted disruption of Lmx1b. Our results demonstrate that Lmx1b is essential for the specification of dorsal limb fates at both the zeugopodal and autopodal level with prominent phenotypes including an absence of nails and patellae. These features are similar to those present in a dominantly inherited human condition called nail patella syndrome(3) (NPS), which also has renal involvement. Mouse Lmx1b maps to a region syntenic to that of the NPS gene(4), and kidneys of Lmx1b mutant mice exhibit pathological changes similar to that observed in NPS (refs 5,6), Our results demonstrate an essential function for Lmx1b in mouse limb and kidney development and suggest that NPS might result from mutations in the human LMX1B gene.	Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Harvard Univ, Dept Cellular & Mol Biol, Biolabs, Cambridge, MA 02138 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Harvard University	Johnson, RL (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	rjohnson@odin.mdacc.tmc.edu	Ovchinnikov, Dmitry/J-7963-2014	Ovchinnikov, Dmitry/0000-0001-9603-8385; Oberg, Kerby/0000-0002-1241-4273				Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cygan JA, 1997, DEVELOPMENT, V124, P5021; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DELPOZO E, 1970, AM J CLIN PATHOL, V54, P845; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hogan B, 1994, MANIPULATING MOUSE E; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Jones K. L., 1997, SMITHS RECOGNIZABLE; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1987, GENE DEV, V1, P521; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; McIntosh I, 1997, AM J HUM GENET, V60, P133; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORITA T, 1973, ARCH INTERN MED, V131, P271, DOI 10.1001/archinte.131.2.271; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; PILZ A, 1994, GENOMICS, V21, P104, DOI 10.1006/geno.1994.1230; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P61; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0	29	373	378	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					51	55		10.1038/ng0598-51	http://dx.doi.org/10.1038/ng0598-51			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590288				2022-12-25	WOS:000073346700016
J	Daniell, H; Datta, R; Varma, S; Gray, S; Lee, SB				Daniell, H; Datta, R; Varma, S; Gray, S; Lee, SB			Containment of herbicide resistance through genetic engineering of the chloroplast genome	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; transformation; tobacco; glyphosate	ISOLATED CUCUMBER ETIOPLASTS; HIGHER-PLANTS; BIOLISTIC DELIVERY; POLLEN DISPERSAL; FOREIGN DNA; EXPRESSION; INVITRO; TOBACCO; TRANSFORMATION; AMPLIFICATION	Glyphosate is a potent herbicide. It works by competitive inhibition of the enzyme 5-enol-pyruvyl shikimate-3-phosphate synthase (EPSPS), which catalyzes an essential step in the aromatic amino acid biosynthetic pathway. We report the genetic engineering of herbicide resistance by stable integration of the petunia EPSPS gene into the tobacco chloroplast genome using the tobacco or universal vector. Southern blot analysis confirms stable integration of the EPSPS gene into all of the chloroplast genomes (5000-10,000 copies per cell) of transgenic plants. Seeds obtained after the first self-cross of transgenic plants germinated and grew normally in the presence of the selectable marker, whereas the control seedlings were bleached. While control plants were extremely sensitive to glyphosate, transgenic plants survived sprays of high concentrations of glyphosate. Chloroplast transformation provides containment of foreign genes because plastid transgenes are not transmitted by pollen. The escape of foreign genes via pollen is a serious environmental concern in nuclear transgenic plants because of the high rates of gene flow from crops to wild weedy relatives.	Auburn Univ, Dept Bot & Microbiol, Mol Genet Program, Auburn, AL 36849 USA	Auburn University System; Auburn University	Daniell, H (corresponding author), Auburn Univ, Dept Bot & Microbiol, Mol Genet Program, Auburn, AL 36849 USA.		Daniell, Henry/L-3655-2019	Daniell, Henry/0000-0003-4485-1176	NIGMS NIH HHS [R01 GM063879] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063879] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brixey PJ, 1997, BIOTECHNOL LETT, V19, P395, DOI 10.1023/A:1018371405675; CARLSON PS, 1973, P NATL ACAD SCI USA, V70, P598, DOI 10.1073/pnas.70.2.598; CIOPPA GD, 1987, BIOTECHNOLOGY, V5, P579; DANIELL H, 1982, BIOCHEM BIOPH RES CO, V106, P466, DOI 10.1016/0006-291X(82)91133-0; DANIELL H, 1991, PLANT CELL REP, V9, P615, DOI 10.1007/BF00231800; DANIELL H, 1993, METHOD ENZYMOL, V217, P536; DANIELL H, 1990, P NATL ACAD SCI USA, V87, P88, DOI 10.1073/pnas.87.1.88; DANIELL H, 1987, P NATL ACAD SCI USA, V84, P6349, DOI 10.1073/pnas.84.18.6349; DANIELL H, 1983, BIOCHEM BIOPH RES CO, V111, P740, DOI 10.1016/0006-291X(83)90367-4; DANIELL H, 1986, BIOCHEM BIOPH RES CO, V135, P248, DOI 10.1016/0006-291X(86)90969-1; Daniell H, 1997, Methods Mol Biol, V62, P463; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; KING J, 1996, SCIENCE, V274, P180; Llewellyn D, 1996, MOL BREEDING, V2, P157, DOI 10.1007/BF00441430; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; MCBRIDE KE, 1995, BIO-TECHNOL, V13, P362, DOI 10.1038/nbt0495-362; Mikkelsen TR, 1996, NATURE, V380, P31, DOI 10.1038/380031a0; ROGERS SG, 1983, APPL ENVIRON MICROB, V46, P37, DOI 10.1128/AEM.46.1.37-43.1983; SHAH DM, 1986, SCIENCE, V233, P478, DOI 10.1126/science.233.4762.478; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; UMBECK PF, 1991, J ECON ENTOMOL, V84, P1943, DOI 10.1093/jee/84.6.1943; YE GN, 1990, PLANT MOL BIOL, V15, P809, DOI 10.1007/BF00039421	24	285	394	1	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					345	348		10.1038/nbt0498-345	http://dx.doi.org/10.1038/nbt0498-345			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555724	Green Accepted			2022-12-25	WOS:000072786200025
J	El Meziane, A; Lehtinen, SK; Hance, N; Nijtmans, LGJ; Dunbar, D; Holt, IJ; Jacobs, HT				El Meziane, A; Lehtinen, SK; Hance, N; Nijtmans, LGJ; Dunbar, D; Holt, IJ; Jacobs, HT			A tRNA suppressor mutation in human mitochondria	NATURE GENETICS			English	Article							PROTEIN-SYNTHESIS; TRANSFER-RNAS; DNA; ENCEPHALOMYOPATHIES; ANTICODON; DISEASES; MYOPATHY; PEDIGREE; DEAFNESS; DEFECTS	Mitochondrial mutations are associated with a wide spectrum of human diseases(1,2). A common class of point mutations affects tRNA genes, and mutations in the tRNA-leu(UUR) gene (MTTL1) are the most frequently detected. In earlier studies, we showed that lung carcinoma cybrid cells containing high levels (greater than 95%) of mutated mtDNA from a patient with the pathological nucleotide pair (np) 3243 tRNA-leu(UUR) mutation can remain genotypically stable over time, and exhibit severe defects in mitochondrial respiratory metabolism(3,4). From such a cybrid containing 99% mutated mtDNA, we have isolated a spontaneous derivative that retains mutant mtDNA at this level but which has nevertheless reverted to the wild-type phenotype, based on studies of respiration, growth in selective media, mitochondrial protein synthesis and biogenesis of mitochondrial membrane complexes. The cells are heteroplasmic for a novel anticodon mutation in tRNA-leu(CUN) at np 12300, predicted to generate a suppressor tRNA capable of decoding UUR leucine codons. The suppressor mutation represents approximately 10% of the total mtDNA, but was undetectable in a muscle biopsy sample taken from the original patient or in the parental cybrid. These results indicate that the primary biochemical defect in cells with high levels of np 3243 mutated mtDNA is the inability to translate UUR leucine codons.	Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Univ Cadi Ayyad, Fac Sci & Tech, Dept Biol, Marrakech, Morocco; Univ Dundee, Sch Med, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Tampere University; Cadi Ayyad University of Marrakech; University of Dundee; University of Glasgow	Jacobs, HT (corresponding author), Univ Tampere, Inst Med Technol, POB 607, FIN-33101 Tampere, Finland.		Jacobs, Howard T/G-2434-2011; Dunbar, Donald R/A-7093-2012	holt, ian/0000-0001-5468-0193; Jacobs, Howard/0000-0003-1895-6003				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CARBON J, 1970, J MOL BIOL, V52, P571, DOI 10.1016/0022-2836(70)90420-1; Chiu YH, 1997, GENETICS, V145, P707; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; Fadic R, 1996, SEMIN NEUROL, V16, P11, DOI 10.1055/s-2008-1040954; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; JEANFRANCOIS MJB, 1994, AUST NZ J MED, V24, P188, DOI 10.1111/j.1445-5994.1994.tb00556.x; Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873; MARTIN RP, 1990, BIOCHEMISTRY-US, V29, P956, DOI 10.1021/bi00456a016; MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murgola Emanuel J., 1995, P491; Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9; PAGES D, 1991, NUCLEIC ACIDS RES, V19, P867, DOI 10.1093/nar/19.4.867; Reid FM, 1997, HUM MOL GENET, V6, P443, DOI 10.1093/hmg/6.3.443; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; Yokoyama Shigeyuki, 1995, P207	25	86	87	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					350	353						4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537417				2022-12-25	WOS:000072755500017
J	Heneine, W; Switzer, WM; Sandstrom, P; Brown, J; Vedapuri, S; Schable, CA; Khan, AS; Lerche, NW; Schweizer, M; Neumann-Haefelin, D; Chapman, LE; Folks, TM				Heneine, W; Switzer, WM; Sandstrom, P; Brown, J; Vedapuri, S; Schable, CA; Khan, AS; Lerche, NW; Schweizer, M; Neumann-Haefelin, D; Chapman, LE; Folks, TM			Identification of a human population infected with simian foamy viruses	NATURE MEDICINE			English	Article							T-LYMPHOTROPIC VIRUS; IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; PREVALENCE; RETROVIRUS; ANTIBODY; MONKEYS; COLONY	Studying the transmission of simian retroviruses to humans can help define the importance of these infections to public health. We identified a substantial prevalence (4/231, 1.8%) of infection with simian foamy viruses (SFV) among humans occupationally exposed to nonhuman primates. Evidence of SFV infection included seropositivity, proviral DNA detection and isolation of foamy virus. The infecting SFV originated from an African green monkey (one person) and baboons (three people), These infections have not as yet resulted in either disease or sexual transmission, and may represent benign endpoint infections.	Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Immunol & Diagnost Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; US FDA, Ctr Biol Evaluat & Res, Lab Retrovirus Res, Bethesda, MD 20892 USA; Univ Calif Lawrence Livermore Natl Lab, Calif Reg Primate Res Ctr, Simian Retrovirus Lab, Livermore, CA 95616 USA; Univ Freiburg, Dept Virol, D-79104 Freiburg, Germany	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of Freiburg	Heneine, W (corresponding author), Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Atlanta, GA 30333 USA.							ACHONG BG, 1971, J NATL CANCER I, V46, P299; Ali M, 1996, AIDS RES HUM RETROV, V12, P1473, DOI 10.1089/aid.1996.12.1473; BIENIASZ PD, 1995, VIROLOGY, V207, P217, DOI 10.1006/viro.1995.1068; Digilio L, 1997, J VIROL, V71, P3684, DOI 10.1128/JVI.71.5.3684-3692.1997; FRANCHINI G, 1994, AIDS RES HUM RETROV, V10, P1047, DOI 10.1089/aid.1994.10.1047; FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; HENEINE W, 1995, J INFECT DIS, V171, P1210, DOI 10.1093/infdis/171.5.1210; HERCHENRODER O, 1994, VIROLOGY, V201, P187, DOI 10.1006/viro.1994.1285; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HOOKS JJ, 1975, BACTERIOL REV, V39, P169, DOI 10.1128/MMBR.39.3.169-185.1975; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002/rmv.1980030304; KHABBAZ RF, 1994, NEW ENGL J MED, V330, P172, DOI 10.1056/NEJM199401203300304; KUMAR S., 1993, MEGA MOL EVOLUTIONAR; LERCHE NW, 1994, LAB ANIM SCI, V44, P217; MCCLURE MO, 1994, J VIROL, V68, P7124, DOI 10.1128/JVI.68.11.7124-7130.1994; MURPHY FA, 1996, SCIENCE, V273, P726; MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373; NEUMANNHAEFELIN D, 1993, INTERVIROLOGY, V35, P196, DOI 10.1159/000150310; Otsyula M, 1996, ANN TROP MED PARASIT, V90, P65, DOI 10.1080/00034983.1996.11813027; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; RHODESFEUILLETTE A, 1979, J MED PRIMATOL, V8, P308; RUDOLPH DL, 1992, J CLIN MICROBIOL, V30, P858, DOI 10.1128/JCM.30.4.858-861.1992; SCHWEIZER M, 1995, AIDS RES HUM RETROV, V11, P161, DOI 10.1089/aid.1995.11.161; Schweizer M, 1997, J VIROL, V71, P4821, DOI 10.1128/JVI.71.6.4821-4824.1997; SCHWEIZER M, 1995, VIROLOGY, V207, P577, DOI 10.1006/viro.1995.1120; Sotir M, 1997, J MED PRIMATOL, V26, P233, DOI 10.1111/j.1600-0684.1997.tb00217.x; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; SWITZER WM, 1995, J VIROL, V69, P621, DOI 10.1128/JVI.69.2.621-632.1995; VanBrussel M, 1996, J GEN VIROL, V77, P347, DOI 10.1099/0022-1317-77-2-347; Yamamoto S, 1996, J VIROL METHODS, V61, P135, DOI 10.1016/0166-0934(96)02078-2	32	184	188	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					403	407		10.1038/nm0498-403	http://dx.doi.org/10.1038/nm0498-403			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546784				2022-12-25	WOS:000072906800033
J	Xu, HX; Gouras, GK; Greenfield, JP; Vincent, B; Naslund, J; Mazzarelli, L; Fried, G; Jovanovic, JN; Seeger, M; Relkin, NR; Liao, F; Checler, F; Buxbaum, JD; Chait, BT; Thinakaran, G; Sisodia, SS; Wang, R; Greengard, P; Gandy, S				Xu, HX; Gouras, GK; Greenfield, JP; Vincent, B; Naslund, J; Mazzarelli, L; Fried, G; Jovanovic, JN; Seeger, M; Relkin, NR; Liao, F; Checler, F; Buxbaum, JD; Chait, BT; Thinakaran, G; Sisodia, SS; Wang, R; Greengard, P; Gandy, S			Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides	NATURE MEDICINE			English	Article							PRECURSOR PROTEIN; IN-VIVO; HIPPOCAMPAL-NEURONS; SENILE PLAQUES; DISEASE; PRESENILIN-1; ESTRADIOL; SECRETION; VARIANTS; VITRO	Alzheimer's disease (AD) is characterized by the accumulation of cerebral plaques composed of 40- and 42-amino acid beta-amyloid (A beta) peptides, and autosomal dominant forms of AD appear to cause disease by promoting brain A beta accumulation. Recent studies indicate that postmenopausal estrogen replacement therapy may prevent or delay the onset of AD. Here we present evidence that physiological levels of 17 beta-estradiol reduce the generation of A beta by neuroblastoma cells and by primary cultures of rat, mouse and human embryonic cerebrocortical neurons. These results suggest a mechanism by which estrogen replacement therapy can delay or prevent AD.	NYU, NS Kline Inst, Orangeburg, NY 10962 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Rockefeller Univ, Fisher Ctr Res Alzheimer Dis, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spect, New York, NY 10021 USA; Cornell Univ, Coll Med, New York, NY 10021 USA; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; Johns Hopkins Med Inst, Neuropathol Lab, Baltimore, MD 21205 USA	Nathan Kline Institute for Psychiatric Research; New York University; Rockefeller University; Rockefeller University; Rockefeller University; Cornell University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Karolinska Institutet; Johns Hopkins University; Johns Hopkins Medicine	Gandy, S (corresponding author), NYU, NS Kline Inst, Orangeburg, NY 10962 USA.	gandy@nki.rfmh.org	Buxbaum, Joseph D/G-6001-2010; Wang, Rong/A-8721-2009; Gouras, Gunnar/B-3021-2010; Xu, Huaxi/AAV-7177-2021; Checler, Frederic/C-1241-2009	Gouras, Gunnar/0000-0002-5500-6325; Checler, Frederic/0000-0003-2098-1750; Vincent, Bruno/0000-0003-3876-2118; Greenfield, Jeffrey/0000-0003-1904-1040; Buxbaum, Joseph/0000-0001-8898-8313	NIA NIH HHS [AG09464, AG11508, AG13780] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009464, R01AG011508, R55AG011508, R01AG013780] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINGOLD KR, 1990, CECILS ESSENTIALS ME, P478; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1993, J BIOL CHEM, V268, P3021; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; LARSON GH, 1994, BIOL REPROD, V50, P357, DOI 10.1095/biolreprod50.2.357; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; PerezTur J, 1995, NEUROREPORT, V7, P297; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Simons M, 1996, J NEUROSCI, V16, P899; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; ToranAllerand CD, 1996, DEV NEUROSCI-BASEL, V18, P36, DOI 10.1159/000111393; Vincent B, 1996, J NEUROSCI, V16, P5049; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081	35	456	481	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					447	451		10.1038/nm0498-447	http://dx.doi.org/10.1038/nm0498-447			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546791				2022-12-25	WOS:000072906800040
J	Watanabe, A; Takeda, K; Ploplis, B; Tachibana, M				Watanabe, A; Takeda, K; Ploplis, B; Tachibana, M			Epistatic relationship between Waardenburg syndrome genes MITF and PAX3	NATURE GENETICS			English	Article							SYNDROME TYPE-I; ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTIONAL ACTIVATOR; FUSION PROTEIN; PAIRED DOMAIN; MUTATIONS; EXPRESSION; IDENTIFICATION; MECHANISMS; BINDING	Waardenburg syndrome (WS) is a hereditary disorder that causes hypopigmentation and hearing impairment. Depending on additional symptoms, WS is classified into four types(1): WS1, WS2, WS3 and WS4. Mutations in MITF (microphthalmia-associated transcription factor) and PAX3, encoding transcription factors, are responsible for WS2 and WS1/WS3, respectively(1). We have previously shown that MITF transactivates the gene for tyrosinase, a key enzyme for melanogenesis, and is critically involved in melanocyte differentiation(2). Absence of melanocytes affects pigmentation in the skin, hair and eyes, and hearing function in the cochlea(3). Therefore, hypopigmentation and hearing loss in WS2 are likely to be the results of an anomaly of melanocyte differentiation caused by MITF mutations(4,5). However, the molecular mechanism by which PAX3 mutations cause the auditory-pigmentary symptoms in WS1/WS3 remains to be explained. Here we show that PAX3, a transcription factor with a paired domain and a homeodomain, transactivates the MITF promoter. We further show that PAX3 proteins associated with WS1 in either the paired domain or the homeodomain fail to recognize and transactivate the MITF promoter. These results provide evidence that PAX3 directly regulates MITF, and suggest that the failure of this regulation due to PAX3 mutations causes the auditory-pigmentary symptoms in at least some individuals with WS1.	Natl Inst Deafness & Other Commun Disorders, Mol Genet Lab, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Tachibana, M (corresponding author), Natl Inst Deafness & Other Commun Disorders, Mol Genet Lab, NIH, 5 Res Court,Rm 2A31, Rockville, MD 20850 USA.							BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; HOTH CF, 1993, AM J HUM GENET, V52, P455; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; LALWANI AK, 1995, AM J HUM GENET, V56, P75; Latchman DS, 1996, NEW ENGL J MED, V334, P28, DOI 10.1056/NEJM199601043340108; MACINA RA, 1995, GENOMICS, V26, P1, DOI 10.1016/0888-7543(95)80076-X; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMENZA GL, 1994, HUM MUTAT, V3, P180, DOI 10.1002/humu.1380030304; SUBLETT JE, 1995, ONCOGENE, V11, P545; TACHIBANA M, 1992, MOL CELL NEUROSCI, V3, P433, DOI 10.1016/1044-7431(92)90055-7; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131	25	215	224	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					283	286		10.1038/ng0398-283	http://dx.doi.org/10.1038/ng0398-283			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500554				2022-12-25	WOS:000072325000030
J	Li, RX; Dowd, V; Stewart, DJ; Burton, SJ; Lowe, CR				Li, RX; Dowd, V; Stewart, DJ; Burton, SJ; Lowe, CR			Design, synthesis, and application of a Protein A mimetic	NATURE BIOTECHNOLOGY			English	Article							MONOCLONAL-ANTIBODIES; IMMUNOGLOBULIN BINDING; THIOPHILIC ADSORPTION; STAPHYLOCOCCUS-AUREUS; AFFINITY LIGANDS; DRUG DESIGN; AVID AL; PURIFICATION; CHROMATOGRAPHY; SEPARATION	Low-molecular-weight synthetic molecules that mimic the activity of native biological macromolecules have therapeutic potential, utility in large-scale production of biopharmaceuticals, and the capacity to act as probes to study molecular recognition events. We have developed a nonpeptidyl mimic for Staphylococcus aureus Protein A (SpA). The specific recognition and complexation elements between the B domain (Fb) of SpA and the Fc fragment of IgG were identified from the x-ray crystallographic structure, Computer-aided molecular modeling was used to design a series of biomimetic molecules around the Phe132-Tyr133 dipeptide involved in its binding to IgG. One of the ligands binds IgG competitively with SpA in solution and when immobilized on agarose beads, with an affinity constant of 10(5)-10(6) M-1. The immobilized artificial Protein A was used to purify IgG from human plasma and murine IgG from ascites fluid, and to remove bovine IgG from fetal calf serum.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Affin Chromatog Ltd, Cambridge CB3 OJX, England	University of Cambridge	Lowe, CR (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.		Rong Xiu, Li/C-9683-2010	Rong Xiu, Li/0000-0002-7491-0854; Lowe, Christopher R/0000-0001-5432-9109				ANDREWS P, 1986, TRENDS PHARMACOL SCI, V7, P148, DOI 10.1016/0165-6147(86)90292-0; BELEW M, 1987, J IMMUNOL METHODS, V102, P173, DOI 10.1016/0022-1759(87)90074-3; BOWEN JP, 1993, J CLIN PHARMACOL, V33, P1149, DOI 10.1002/j.1552-4604.1993.tb03915.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; ELKAK A, 1991, J CHROMATOGR-BIOMED, V570, P29, DOI 10.1016/0378-4347(91)80198-L; ELKAK A, 1992, J CHROMATOGR, V604, P29, DOI 10.1016/0021-9673(92)85525-X; FERSHT A, 1977, ENZYME STRUCTURE MEC, P236; FUGLISTALLER P, 1989, J IMMUNOL METHODS, V124, P171, DOI 10.1016/0022-1759(89)90350-5; GODFREY MAJ, 1993, J IMMUNOL METHODS, V160, P97, DOI 10.1016/0022-1759(93)90013-W; GOESER T, 1994, INT J CLIN PHARM TH, V32, P571; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; HEUNHOEFFER H, 1978, CHEM 1 2 3 TRIAZINES, P1; HILLSON JL, 1993, J EXP MED, V178, P331, DOI 10.1084/jem.178.1.331; HJELM H, 1975, SCAND J IMMUNOL, V4, P633, DOI 10.1111/j.1365-3083.1975.tb02671.x; HUTCHENS TW, 1986, ANAL BIOCHEM, V159, P217, DOI 10.1016/0003-2697(86)90331-3; ITO W, 1989, J MOL GRAPHICS, V7, P60, DOI 10.1016/0263-7855(89)80058-X; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; Lu B, 1996, ANALYST, V121, pR29, DOI 10.1039/an996210029r; MACARTHUR MW, 1994, TRENDS BIOTECHNOL, V12, P149, DOI 10.1016/0167-7799(94)90074-4; NGO TT, 1991, APPL BIOCHEM BIOTECH, V30, P111, DOI 10.1007/BF02922027; NGO TT, 1992, J CHROMATOGR, V597, P101, DOI 10.1016/0021-9673(92)80100-9; NGO TT, 1990, J CHROMATOGR, V510, P281, DOI 10.1016/S0021-9673(01)93762-8; NILSSON K, 1980, EUR J BIOCHEM, V112, P397, DOI 10.1111/j.1432-1033.1980.tb07218.x; OHLSON S, 1988, J IMMUNOL METHODS, V114, P175, DOI 10.1016/0022-1759(88)90170-6; ORLUCHI N, 1995, J NUCL MED, V36, P679; PORATH J, 1985, FEBS LETT, V185, P306, DOI 10.1016/0014-5793(85)80928-5; PORATH J, 1987, TRENDS BIOTECHNOL, V5, P225, DOI 10.1016/0167-7799(87)90052-7; POWELL MC, 1987, AM J OBSTET GYNECOL, V157, P28, DOI 10.1016/S0002-9378(87)80340-X; RODBARD D, 1970, STEROID ASSAY PROTEI, P79; SPARRMANN M, 1987, BIOL CHEM HOPPESEYLE, V368, P776; SPOONER RA, 1990, TRENDS BIOTECHNOL, V8, P189, DOI 10.1016/0167-7799(90)90171-S; STEAD CV, 1989, PROTEIN DYE INTERACT, P21; TAYLOR WR, 1994, TRENDS BIOTECHNOL, V12, P154, DOI 10.1016/0167-7799(94)90075-2; YARMUSH ML, 1992, BIOTECHNOL ADV, V10, P413, DOI 10.1016/0734-9750(92)90303-Q	39	250	286	2	61	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					190	195		10.1038/nbt0298-190	http://dx.doi.org/10.1038/nbt0298-190			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487529				2022-12-25	WOS:000071831300035
J	Mehta, D; George, SJ; Jeremy, JY; Izzat, MB; Southgate, KM; Bryan, AJ; Newby, AC; Angelini, GD				Mehta, D; George, SJ; Jeremy, JY; Izzat, MB; Southgate, KM; Bryan, AJ; Newby, AC; Angelini, GD			External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting	NATURE MEDICINE			English	Article							VENOUS ARTERIAL GRAFTS; HUMAN SAPHENOUS-VEIN; INTIMAL HYPERPLASIA; GENE-EXPRESSION; PROLIFERATION; ACCUMULATION; ANGIOPLASTY; OCCLUSION; SURGERY; BIOLOGY	Bypass of stenotic coronary arteries with autologous saphenous vein is an established treatment for ischemic heart disease. However, its long-term clinical success is limited(1,2). Late vein graft failure is the result of medial and intimal thickening consequent upon medial vascular smooth muscle cell migration, proliferation and extracellular matrix deposition, followed later by superimposed atherosclerosis(3). These changes directly compromise graft blood flow and provoke thrombosis. Vein graft wall thickening may represent an adaptation imposed by arterial hemodynamic factors(4-6), and these factors have been shown to promote vascular smooth muscle cell migration and proliferation through activation of key mediators including platelet-derived growth factor (PDGF)(7). Many pharmacological interventions aimed at preventing these long-term changes have proven unsuccessful in clinical evaluation(8). We recently demonstrated in a pig saphenous vein graft model that application of an external polyester stent to the outside of carotid interposition vein grafts reduced intimal hyperplasia and total wall thickness 1 month after implantation(9). However, it is not known whether the benefits of the stent are maintained in the longer term or what mechanisms underlie its effect. The present study therefore compared morphological changes and PDGF expression in stented grafts and contralateral unstented grafts in the same pigs, 6 months after graft implantation. Reduced medial thickening, neointima formation, and cell proliferation were sustained in externally stented grafts, and these effects were associated with a significant reduction in PDGF expression.	Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England	University of Bristol	Angelini, GD (corresponding author), Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.		Izzat, Mohammad Bashar/I-1987-2019	Izzat, Mohammad Bashar/0000-0001-6758-8716; angelini, gianni/0000-0002-1753-3730				ANGELINI GD, 1989, EUR HEART J, V10, P273, DOI 10.1093/oxfordjournals.eurheartj.a059476; ANGELINI GD, 1992, J THORAC CARDIOV SUR, V103, P1093; Angelini GD, 1996, J THORAC CARDIOV SUR, V112, P79, DOI 10.1016/S0022-5223(96)70180-0; BARKER SGE, 1993, ARTERIOSCLER THROMB, V13, P70, DOI 10.1161/01.ATV.13.1.70; BARKER SGE, 1994, ATHEROSCLEROSIS, V105, P131, DOI 10.1016/0021-9150(94)90043-4; BRYAN AJ, 1994, CURR OPIN CARDIOL, V9, P641, DOI 10.1097/00001573-199411000-00002; CAMPEAU L, 1983, CIRCULATION, V68, P1; DOBRIN PB, 1989, SURGERY, V105, P393; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FRANCIS SE, 1994, J THORAC CARDIOV SUR, V108, P540, DOI 10.1016/S0022-5223(12)70266-0; GALAND P, 1989, CELL TISSUE KINET, V22, P383, DOI 10.1111/j.1365-2184.1989.tb00223.x; George SJ, 1996, ATHEROSCLEROSIS, V120, P227, DOI 10.1016/0021-9150(95)05717-X; GOLDMAN S, 1994, CIRCULATION, V89, P1138, DOI 10.1161/01.CIR.89.3.1138; HOCH JR, 1994, SURGERY, V116, P463; HOCH JR, 1995, J VASC SURG, V22, P51, DOI 10.1016/S0741-5214(95)70088-9; Izzat MB, 1996, CIRCULATION, V94, P1741, DOI 10.1161/01.CIR.94.7.1741; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KARAYANNACOS PE, 1978, ANN SURG, V187, P183, DOI 10.1097/00000658-197802000-00016; KOHLER TR, 1989, J VASC SURG, V9, P277, DOI 10.1067/mva.1989.vs0090277; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; MORINAGA K, 1985, J VASC SURG, V2, P430, DOI 10.1067/mva.1985.avs0020430; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NEWBY AC, 1993, CARDIOVASC RES, V27, P1173, DOI 10.1093/cvr/27.7.1173; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUSSEL F, 1988, LAB ANIM, V22, P135, DOI 10.1258/002367788780864457; SOYOMBO AA, 1990, AM J PATHOL, V137, P1401; VIOLARIS AG, 1993, ANN THORAC SURG, V55, P667, DOI 10.1016/0003-4975(93)90273-K; ZILLA P, 1993, J CARDIAC SURG, V8, P32, DOI 10.1111/j.1540-8191.1993.tb00574.x; ZWOLAK RM, 1987, J VASC SURG, V5, P126, DOI 10.1067/mva.1987.avs0050126	29	125	148	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					235	239		10.1038/nm0298-235	http://dx.doi.org/10.1038/nm0298-235			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461200				2022-12-25	WOS:000072249800042
J	Garrick, D; Fiering, S; Martin, DIK; Whitelaw, E				Garrick, D; Fiering, S; Martin, DIK; Whitelaw, E			Repeat-induced gene silencing in mammals	NATURE GENETICS			English	Article							BETA-GLOBIN GENE; TRANSGENIC MICE; DNA-METHYLATION; EXPRESSION; ARABIDOPSIS; SUSCEPTIBILITY; INACTIVATION; RECOMBINASE; DROSOPHILA; PETUNIA	In both plants(1-3) and Drosophila melanogaster(4,5), expression from a transgenic locus may be silenced when repeated transgene copies are arranged as a concatameric array. This repeat-induced gene silencing is frequently manifested as a decrease in the proportion of cells that express the transgene, resulting in a variegated pattern of expression. There is also some indication that, in transgenic mammals, the number of transgene copies within an array can exert a repressive influence on expression, with several mouse studies reporting a decrease in the level of expression per copy as copy number increases(6-8). However, because these studies compare different sites of transgene integration as well as arrays with different numbers of copies, the expression levels observed may be subject to varying position effects as well as the influence of the multicopy array. Here we describe use of the lox/Cre system of site-specific recombination to generate transgenic mouse lines in which different numbers of a transgene are present at the same chromosomal location, thereby eliminating the contribution of position effects and allowing analysis of the effect of copy number alone on transgene silencing. Reduction in copy number results in a marked increase in expression of the transgene and is accompanied by decreased chromatin compaction and decreased methylation at the transgene locus. These findings establish that the presence of multiple homologous copies of a transgene within a concatameric array can have a repressive effect upon gene expression in mammalian systems.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Sydney; Fred Hutchinson Cancer Center	Whitelaw, E (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.		GARRICK, David/O-5734-2019; Garrick, David/F-1728-2017	GARRICK, David/0000-0001-7422-7986; Garrick, David/0000-0001-7422-7986; Fiering, Steven/0000-0003-0624-974X				ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; DAVIS BP, 1988, GENE DEV, V2, P13, DOI 10.1101/gad.2.1.13; DECARVALHO F, 1992, EMBO J, V11, P2595, DOI 10.1002/j.1460-2075.1992.tb05324.x; Dorer DR, 1997, TRANSGENIC RES, V6, P3, DOI 10.1023/A:1018460413680; Dorer DR, 1994, CELL, V77, P1; Garrick D, 1996, NUCLEIC ACIDS RES, V24, P4902, DOI 10.1093/nar/24.24.4902; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; INGELBRECHT I, 1994, P NATL ACAD SCI USA, V91, P10502, DOI 10.1073/pnas.91.22.10502; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LINN F, 1990, MOL GEN GENET, V222, P329, DOI 10.1007/BF00633837; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; MEYER P, 1993, PLANT J, V4, P89, DOI 10.1046/j.1365-313X.1993.04010089.x; NEUHUBER F, 1994, MOL GEN GENET, V244, P230, DOI 10.1007/BF00285450; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P5655, DOI 10.1093/nar/20.21.5655; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; Robertson G, 1996, NUCLEIC ACIDS RES, V24, P1465, DOI 10.1093/nar/24.8.1465; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; Sabl JF, 1996, GENETICS, V142, P447; SCHEID OM, 1991, MOL GEN GENET, V228, P104, DOI 10.1007/BF00282454; SHARPE JA, 1993, P NATL ACAD SCI USA, V90, P11262, DOI 10.1073/pnas.90.23.11262; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; Ye F, 1996, P NATL ACAD SCI USA, V93, P10881, DOI 10.1073/pnas.93.20.10881	31	504	540	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					56	59		10.1038/ng0198-56	http://dx.doi.org/10.1038/ng0198-56			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425901				2022-12-25	WOS:000071259600022
J	Deng, H; Lin, Q; Khavari, PA				Deng, H; Lin, Q; Khavari, PA			Sustainable cutaneous gene delivery	NATURE BIOTECHNOLOGY			English	Article						gene therapy; retroviral vectors	LAMELLAR ICHTHYOSIS; RETROVIRAL VECTOR; HUMAN-SKIN; EPIDERMOLYTIC HYPERKERATOSIS; HUMAN KERATINOCYTES; IN-VIVO; EXPRESSION; MUTATIONS; CHROMATIN; CELLS	Durable gene delivery to human skin is necessary for lasting correction of human genetic skin disease. Current cutaneous gene-delivery strategies, however, have achieved only transient gene expression, often only within a small percentage of tissue cells. The recent inability to sustain phenotypic correction of human genetic skin disease due to loss of therapeutic gene expression in regenerated epidermal tissue has highlighted this current limitation. In an effort to surmount this problem, we have generated gene delivery vectors that produce more durable gene delivery in human skin tissue in vivo.	VA PALO ALTO HLTH CARE SYST,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44012] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1996, B MED ETHICS; CHAKRABORTY AK, 1993, FASEB J, V7, P91; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; Choate KA, 1997, HUM GENE THER, V8, P895, DOI 10.1089/hum.1997.8.8-895; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; FAUSTINELLA F, 1994, HUM GENE THER, V5, P307, DOI 10.1089/hum.1994.5.3-307; Fenjves ES, 1996, J INVEST DERMATOL, V106, P576, DOI 10.1111/1523-1747.ep12344976; FREIBERG RA, 1997, HUM MOL GENET, V6, P937; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; Khavari PA, 1997, DERMATOL CLIN, V15, P27, DOI 10.1016/S0733-8635(05)70412-5; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Krall WJ, 1996, GENE THER, V3, P37; Lu B, 1997, J INVEST DERMATOL, V108, P803, DOI 10.1111/1523-1747.ep12292254; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MILLER AD, 1983, P NATL ACAD SCI-BIOL, V80, P4709, DOI 10.1073/pnas.80.15.4709; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SETOGUCHI Y, 1994, J INVEST DERMATOL, V102, P415, DOI 10.1111/1523-1747.ep12372181; TAICHMAN LB, 1994, KERATINOCYTE HDB, P543; Uitto J, 1996, MOL BIOL REP, V23, P35, DOI 10.1007/BF00357071; WOLFFE AP, 1994, CURR BIOL, V4, P85, DOI 10.1016/S0960-9822(00)00022-1; WOLFFE AP, 1992, FASEB J, V6, P3354, DOI 10.1096/fasebj.6.15.1464369	33	71	74	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1388	1391		10.1038/nbt1297-1388	http://dx.doi.org/10.1038/nbt1297-1388			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415892				2022-12-25	WOS:A1997YK36100031
J	Sacco, MG; Zecca, L; Bagnasco, L; Chiesa, G; Parolini, C; Bromley, P; Cato, EM; Roncucci, R; Clerici, LA; Vezzoni, P				Sacco, MG; Zecca, L; Bagnasco, L; Chiesa, G; Parolini, C; Bromley, P; Cato, EM; Roncucci, R; Clerici, LA; Vezzoni, P			A transgenic mouse model for the detection of cellular stress induced by toxic inorganic compounds	NATURE BIOTECHNOLOGY			English	Article						animal model; heat-shock promoter	MUTATIONS INVIVO; EUKARYOTIC CELLS; MICE; GENE; INDUCTION; PROTEINS; ANIMALS	Transgenic mice for genotoxicity testing have been developed, although no such models have been produced for the evaluation of toxic, nongenotoxic chemical compounds, We have developed a transgenic mouse model for the analysis of toxic inorganic compounds, We engineered a mouse lineage with the human growth hormone (hGH) gene under the control of the human hsp70 promoter, in which a plasma-detectable hGH response can be elicited by exposure to heat shock, In primary cell cultures from these mice, hGH release was observed following treatment with several toxic inorganics. Transgenic mice injected intraperitoneally with sodium arsenite, cadmium chloride, copper sulphate, or methylmercurium chloride showed significant hGH levels in plasma.	INST PHARMACOL SCI,I-20131 MILAN,ITALY; COMMISS EUROPEAN COMMUNITIES,JOINT RES CTR,INST ENVIRONM,ENVIRONM TOXICOL & HUMAN HLTH UNIT,I-21020 ISPRA,ITALY	European Commission Joint Research Centre; EC JRC ISPRA Site; Italian Institute for Environmental Protection & Research (ISPRA)	Sacco, MG (corresponding author), NATL RES COUNCIL,INST ADV BIOMED TECHNOL,VIA AMPERE 56,I-20131 MILAN,ITALY.		Chiesa, Giulia/G-8987-2012; Parolini, Cinzia/G-8984-2012; Vezzoni, Paolo/K-3197-2018; Vezzoni, Paolo/R-3416-2019	Chiesa, Giulia/0000-0001-5553-1210; Parolini, Cinzia/0000-0002-5699-0918; Vezzoni, Paolo/0000-0002-6382-3923				ALBERTINI RJ, 1994, ENVIRON MOL MUTAGEN, V23, P18, DOI 10.1002/em.2850230607; ARESINI G, 1995, EUR16248EN; BOERRIGTER METI, 1995, NATURE, V377, P657, DOI 10.1038/377657a0; BRADLEY A, 1992, BIO-TECHNOL, V10, P534, DOI 10.1038/nbt0592-534; CAMPBELL JA, 1986, IN VITRO CELL DEV B, V22, P443, DOI 10.1007/BF02623444; CLERICI L, 1989, MUTAT RES, V227, P47, DOI 10.1016/0165-7992(89)90067-5; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOUGLAS GR, 1995, P NATL ACAD SCI USA, V92, P7485, DOI 10.1073/pnas.92.16.7485; DREANO M, 1986, GENE, V49, P1, DOI 10.1016/0378-1119(86)90380-X; DREANO M, 1988, BIO-TECHNOL, V6, P1340, DOI 10.1038/nbt1188-1340; DREANO M, 1988, BIO-TECHNOL, V6, P953, DOI 10.1038/nbt0888-953; Festing MFW, 1997, NATURE, V388, P321, DOI 10.1038/40964; FISCHBACH M, 1993, CELL BIOL TOXICOL, V9, P177, DOI 10.1007/BF00757579; GOEHRING PL, 1993, TOXICOL APPL PHARM, V122, P139; GOEHRING PL, 1992, TOXICOL APPL PHARM, V113, P184; GOLDSWORTHY TL, 1994, FUND APPL TOXICOL, V22, P8, DOI 10.1006/faat.1994.1002; GOSSEN J, 1993, TRENDS GENET, V9, P27, DOI 10.1016/0168-9525(93)90069-T; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; Hightower LE, 1997, HEPATOLOGY, V25, P1279, DOI 10.1002/hep.510250539; HOGAN B, 1986, MANIPULATING MOUSE E; HONDA K, 1992, TERATOGENESIS CARCIN, V11, P235; Huggett RJ, 1992, BIOMARKERS BIOCH PHY; Innis MA, 1990, PCR PROTOCOLS GUIDE; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; MERLINO GT, 1991, FASEB J, V5, P2996, DOI 10.1096/fasebj.5.14.1752364; NOVER L, 1987, ENZYME MICROB TECHNO, V9, P129; OVELGONNE HH, 1995, TOXICOL APPL PHARM, V132, P146, DOI 10.1006/taap.1995.1095; OVELGONNE JH, 1995, TOXICOLOGY, V99, P19, DOI 10.1016/0300-483X(94)02990-C; PLUNKET ER, 1987, HDB IND TOXICOLOGY; RICHARDSON ML, 1993, DICT SUBSTANCES THEI; Robertson E, 1987, TERATOCARCINOMAS EMB; Roush W, 1996, SCIENCE, V274, P168, DOI 10.1126/science.274.5285.168; Salminen WF, 1996, TOXICOL APPL PHARM, V141, P117; Sambrook J., 2002, MOL CLONING LAB MANU	36	38	43	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1392	1397		10.1038/nbt1297-1392	http://dx.doi.org/10.1038/nbt1297-1392			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415893				2022-12-25	WOS:A1997YK36100032
J	Barro, F; Rooke, L; Bekes, F; Gras, P; Tatham, AS; Fido, R; Lazzeri, PA; Shewry, PR; Barcelo, P				Barro, F; Rooke, L; Bekes, F; Gras, P; Tatham, AS; Fido, R; Lazzeri, PA; Shewry, PR; Barcelo, P			Transformation of wheat with high molecular weight subunit genes results in improved functional properties	NATURE BIOTECHNOLOGY			English	Article						agricultural genetic engineering; glutenin subunits; dough elasticity	BREAD-MAKING QUALITY; GLUTENIN; EXPRESSION; MEMBER; FAMILY; DOUGH	The high molecular weight (HMW) subunits of wheat glutenin are major determinants of the elastic properties of gluten that allow the use of wheat doughs to make bread, pasta, and a range of other foods. There are both quantitative and qualitative effects of HMW subunits on the quality of the grain, the former being related to differences in the number of expressed HMW subunit genes. We have transformed bread wheat in order to increase the proportions of the HMW subunits and improve the functional properties of the flour A range of transgene expression levels was obtained with some of the novel subunits present at considerably higher levels than the endogenous subunits. Analysis of T-2 seeds expressing transgenes for one or two additional HMW subunits showed stepwise increases in dough elasticity, demonstrating the improvement of the functional properties of wheat by genetic engineering.	Univ Bristol, Long Ashton Res Stn, Dept Agr Sci, IACR, Bristol BS18 9AF, Avon, England; AFRC, Inst Arable Crops Res, Harpenden AL5 2JQ, Herts, England; CSIRO, Plant Sci CRC, N Ryde, NSW 2113, Australia	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Bristol; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Shewry, PR (corresponding author), Univ Bristol, Long Ashton Res Stn, Dept Agr Sci, IACR, Bristol BS18 9AF, Avon, England.	peter.shewry@bbscr.ac.uk; barcelo@bbsrc.ac.uk	Bekes, Ferenc/B-5933-2009; Barro, Francisco/J-3254-2014; Barro, Francisco/E-8572-2017	Barro, Francisco/0000-0002-7652-229X; Tatham, Arthur/0000-0001-5080-5585				Altpeter F, 1996, NAT BIOTECHNOL, V14, P1155, DOI 10.1038/nbt0996-1155; ANDERSON OD, 1989, NUCLEIC ACIDS RES, V17, P461, DOI 10.1093/nar/17.1.461; Barcelo P, 1995, Methods Mol Biol, V49, P113; BEKES F, 1992, CEREAL CHEM, V69, P229; Blechl AE, 1996, NAT BIOTECHNOL, V14, P875, DOI 10.1038/nbt0796-875; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; DOVIDIO R, 1994, THEOR APPL GENET, V88, P759, DOI 10.1007/BF01253982; DOvidio R, 1996, THEOR APPL GENET, V93, P1048, DOI 10.1007/BF00230123; Fido Roger J., 1995, V49, P423; GRAS PW, 1990, CEREAL FOOD WORLD, V35, P568; GRAS PW, 1996, GLUTEN 96, P506; HALFORD NG, 1992, THEOR APPL GENET, V83, P373, DOI 10.1007/BF00224285; HALFORD NG, 1989, PLANT SCI, V62, P207, DOI 10.1016/0168-9452(89)90083-6; LAWRENCE GJ, 1988, J CEREAL SCI, V7, P109, DOI [10.1016/S0733-5210(88)80012-2, 10.1006/jcrs.1997.0158]; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; RASCOGAUNT S, IN PRESS METHODS MOL, V6; SEILMEIER W, 1991, Z LEBENSM UNTERS FOR, V192, P124, DOI 10.1007/BF01202625; Shewry P, 1995, METHODS MOL BIOL PLA, V49, P423; SHEWRY PR, 1995, BIO-TECHNOL, V13, P1185, DOI 10.1038/nbt1195-1185; SHEWRY PR, 1992, J CEREAL SCI, V15, P105, DOI 10.1016/S0733-5210(09)80062-3; Stacey J, 1994, Methods Mol Biol, V28, P9; Tatham A. S., 1990, Advances in Cereal Science and Technology, V10, P1	22	248	323	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1295	1299		10.1038/nbt1197-1295	http://dx.doi.org/10.1038/nbt1197-1295			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359115				2022-12-25	WOS:000071342000034
J	Samadashwily, GM; Raca, G; Mirkin, SM				Samadashwily, GM; Raca, G; Mirkin, SM			Trinucleotide repeats affect DNA replication in vivo	NATURE GENETICS			English	Article							FRAGILE-X-SYNDROME; AGAROSE-GEL ELECTROPHORESIS; HUMAN HEREDITARY-DISEASES; CGG TRIPLET REPEATS; SYNTHESIS IN-VITRO; ESCHERICHIA-COLI; DELAYED REPLICATION; MISMATCH REPAIR; SWITCH REGION; CTG	(CCG)(n).(CCG)(n) and (CTG)(n).(CAG)(n) repeats of varying length were cloned into a bacterial plasmid, and the progression of the replication fork through these repeats was followed using electrophoretic analysis of replication intermediates. We observed stalling of the replication fork within repeated DNAs and found that this effect depends on repeat length, repeat orientation relative to the replication origin and the status of protein synthesis in a cell. Interruptions within repeated DNAs, similar to those observed in human genes, abolished the replication blockage. Our results suggest that the formation of unusual DNA structures by trinucleotide repeats in the lagging-strand template may account for the observed replication blockage and have relevance to repeat expansion in humans.	UNIV ILLINOIS, DEPT MOL GENET, CHICAGO, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Mirkin, Sergei/A-7310-2010; Mirkin, Sergei/AAR-7226-2020	Mirkin, Sergei/0000-0003-4576-7582				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; Cox R, 1997, P NATL ACAD SCI USA, V94, P5237, DOI 10.1073/pnas.94.10.5237; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; JODICE C, 1994, AM J HUM GENET, V54, P959; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; KOHWI Y, 1993, NUCLEIC ACIDS RES, V21, P5651; Kornberg A., 1992, DNA REPLICATION; Krasilnikov AS, 1997, NUCLEIC ACIDS RES, V25, P1339, DOI 10.1093/nar/25.7.1339; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; KURYAVYI VV, 1995, NAT GENET, V9, P339, DOI 10.1038/ng0495-339; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MCMURRAY CT, 1995, CHROMOSOMA, V104, P2; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; REABAN ME, 1994, J BIOL CHEM, V269, P21850; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; SAMADASHWILY GM, 1993, EMBO J, V12, P4975, DOI 10.1002/j.1460-2075.1993.tb06191.x; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Subramanian PS, 1996, AM J HUM GENET, V59, P407; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; WEBB T, 1992, AM J MED GENET, V43, P1057, DOI 10.1002/ajmg.1320430633; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; Yu A, 1997, BIOCHEMISTRY-US, V36, P3687, DOI 10.1021/bi9625410; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706; Zheng MX, 1996, J MOL BIOL, V264, P323, DOI 10.1006/jmbi.1996.0643	50	271	275	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					298	304		10.1038/ng1197-298	http://dx.doi.org/10.1038/ng1197-298			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354793				2022-12-25	WOS:A1997YD66700023
J	Hartmann, T; Bieger, SC; Bruhl, B; Tienari, PJ; Ida, N; Allsop, D; Roberts, GW; Masters, CL; Dotti, CG; Unsicker, K; Beyreuther, K				Hartmann, T; Bieger, SC; Bruhl, B; Tienari, PJ; Ida, N; Allsop, D; Roberts, GW; Masters, CL; Dotti, CG; Unsicker, K; Beyreuther, K			Distinct sites of intracellular production for Alzheimer's disease A beta 40/42 amyloid peptides	NATURE MEDICINE			English	Article							RAT HIPPOCAMPAL-NEURONS; PRECURSOR PROTEIN; BETA-PROTEIN; SECRETION; CELLS; METABOLISM; INHIBITION; FRAGMENTS; GOLD	The Alzheimer amyloid precursor protein (APP) is cleaved by several proteases, the most studied, but still unidentified ones, are those involved in the release of a fragment of APP, the amyloidogenic beta-protein A beta. Proteolysis by gamma-secretase is the last processing step resulting in release of A beta. Cleavage occurs after residue 40 of A beta [A beta(1-40)], occasionally after residue 42 [A beta(1-42)]. Even slightly increased amounts of this A beta(1-42) might be sufficient to cause Alzheimer's disease (AD) (reviewed in ref. 1, 2). It is thus generally believed that inhibition of this enzyme could aid in prevention of AD. Unexpectedly we have identified in neurons the endoplasmic reticulum (ER) as the site for generation of A beta(1-42) and the trans-Golgi network (TGN) as the site for A beta(1-40) generation. It is interesting that intracellular generation of A beta seemed to be unique to neurons, because we found that nonneuronal cells produced significant amounts of A beta(1-40) and A beta(1-42) only at the cell surface. The specific production of the critical A beta isoform in the ER of neurons links this compartment with the generation of A beta and explains why primarily ER localized (mutant) proteins such as the presenilins(3) could induce AD. We suggest that the earliest event taking place in AD might be the generation of A beta(1-42) in the ER.	DALHOUSIE UNIV, DEPT ANAT & NEUROBIOL, HALIFAX, NS B3H 4H2, CANADA; UNIV HEIDELBERG, DEPT ANAT & CELL BIOL, INF307, D-69120 HEIDELBERG, GERMANY; UNIV HELSINKI, DEPT NEUROL, FIN-00290 HELSINKI, FINLAND; SMITHKLINE BEECHAM, HARLOW CM19 5AW, ESSEX, ENGLAND; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY	Dalhousie University; Ruprecht Karls University Heidelberg; University of Helsinki; GlaxoSmithKline; University of Melbourne; European Molecular Biology Laboratory (EMBL)	Hartmann, T (corresponding author), UNIV HEIDELBERG ZMBH, ZENTRUM MOL BIOL, INF282, D-69120 HEIDELBERG, GERMANY.		Hartmann, Tobias/AAB-8297-2022; Allsop, David/B-9725-2008; Tienari, Pentti J/A-4893-2012; Dotti, Carlos G/I-5533-2015	Allsop, David/0000-0002-0513-5575; Dotti, Carlos G/0000-0003-4052-1719; Hartmann, Tobias/0000-0001-7481-6430				Allsop D, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P717; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1996, J BIOL CHEM, V271, P13208, DOI 10.1074/jbc.271.22.13208; HAYAT MA, 1981, FIXATION ELECTRON MI; Heym C, 1981, TECHNIQUES NEUROANAT; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Ida N, 1996, FEBS LETT, V394, P174, DOI 10.1016/0014-5793(96)00948-9; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; MONNING U, 1995, J BIOL CHEM, V270, P7104, DOI 10.1074/jbc.270.13.7104; OLKKONEN VM, 1993, J NEUROSCI RES, V35, P445, DOI 10.1002/jnr.490350412; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Simons M, 1996, J NEUROSCI, V16, P899; STRUM JM, 1971, J CELL BIOL, V51, P162, DOI 10.1083/jcb.51.1.162; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; VANDEPLAS P, 1993, METHOD CELL BIOL, V37, P241, DOI 10.1016/S0091-679X(08)60253-8; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	35	634	652	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1997	3	9					1016	1020		10.1038/nm0997-1016	http://dx.doi.org/10.1038/nm0997-1016			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288729				2022-12-25	WOS:A1997XT84200035
J	Yukimune, Y; Tabata, H; Higashi, Y; Hara, Y				Yukimune, Y; Tabata, H; Higashi, Y; Hara, Y			Methyl jasmonate-induced overproduction of paclitaxel and baccatin III in Taxus cell suspension cultures	NATURE BIOTECHNOLOGY			English	Article						paclitaxel; baccatin III; methyl jasmonate; Taxus cell suspension cultures	TAXOL PRODUCTION; ACID; BREVIFOLIA; GROWTH; ACCUMULATION; BIOSYNTHESIS; INITIATION; CUSPIDATA; AGENT; LEAF	Taxus cell culture may be an alternative source of paclitaxel and related taxane production. Significantly increased amounts of paclitaxel and baccatin III were observed in cultured cells of Taxus species after exposure to methyl jasmonate. Among the three species of Taxus tested, Taxus media showed the highest paclitaxel content while Taxus baccata showed the highest baccatin III content when 100 mu M of methyl jasmonate was added to the culture media. Furthermore, the activities of methyl jasmonate and related substances for inducing paclitaxel production were compared in cell suspension cultures of T. media. Methyl jasmonate and its free acid showed the strongest promoting activity. Reduction of the keto group at the C-3 position greatly reduced this activity. cis-Jasmone, which does not have a carboxyl group at the C-1 position, had almost no activity. These results suggest that these two regions of methyl jasmonate are important for promoting the production of paclitaxel and related taxanes in Taxus cell cultures.			Yukimune, Y (corresponding author), MITSUI PETROCHEM IND CO LTD,BIOSCI LAB,WAKI,YAMAGUCHI 740,JAPAN.							AA Christen, 1991, U. S. Patent, Patent No. 5019504; AERTS RJ, 1994, PLANT J, V5, P635, DOI 10.1111/j.1365-313X.1994.00635.x; BITSCH F, 1993, J CHROMATOGR-BIOMED, V615, P273, DOI 10.1016/0378-4347(93)80341-Z; BRINGI V, 1993, Patent No. 17121; CHMURNY GN, 1992, J NAT PROD, V55, P414, DOI 10.1021/np50082a002; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; FALKENSTEIN E, 1991, PLANTA, V185, P316, DOI 10.1007/BF00201050; FALZONE CJ, 1992, TETRAHEDRON LETT, V33, P1169, DOI 10.1016/S0040-4039(00)91887-2; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FETTNETO AG, 1995, J PLANT PHYSIOL, V146, P584, DOI 10.1016/S0176-1617(11)81918-8; FLEMING PE, 1994, J AM CHEM SOC, V116, P4137, DOI 10.1021/ja00088a083; FRANCESCHI VR, 1991, P NATL ACAD SCI USA, V88, P6745, DOI 10.1073/pnas.88.15.6745; GIBSON DM, 1993, PLANT CELL REP, V12, P479, DOI 10.1007/BF00236091; GUNDLACH H, 1992, P NATL ACAD SCI USA, V89, P2389, DOI 10.1073/pnas.89.6.2389; HOLTON RA, 1994, J AM CHEM SOC, V116, P1597, DOI 10.1021/ja00083a066; KIM JH, 1995, BIOTECHNOL LETT, V17, P101, DOI 10.1007/BF00134204; KODA Y, 1991, PHYTOCHEMISTRY, V30, P1435, DOI 10.1016/0031-9422(91)84180-Z; Lloyd GB, 1980, COMB P INT PLANT PRO, V30, P421; Mirjalili N, 1996, BIOTECHNOL PROGR, V12, P110, DOI 10.1021/bp9500831; MIRJALILI N, 1995, BIOTECHNOL BIOENG, V48, P123, DOI 10.1002/bit.260480206; MIZUKAMI H, 1993, PLANT CELL REP, V12, P706, DOI 10.1007/BF00233424; NICOLAOU KC, 1994, NATURE, V367, P630, DOI 10.1038/367630a0; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SLICHENMYER WJ, 1991, ANTI-CANCER DRUG, V2, P519, DOI 10.1097/00001813-199112000-00002; SRINIVASAN V, 1995, BIOTECHNOL BIOENG, V47, P666, DOI 10.1002/bit.260470607; UEDA J, 1981, PHYSIOL PLANTARUM, V52, P305, DOI 10.1111/j.1399-3054.1981.tb08511.x; VIDENSEK N, 1990, J NAT PROD, V53, P1609, DOI 10.1021/np50072a039; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WHITERUP K M, 1990, Journal of Natural Products (Lloydia), V53, P1249; WICKREMESINHE ERM, 1993, PLANT CELL TISS ORG, V35, P181, DOI 10.1007/BF00032968; WICKREMESINHE ERM, 1994, J PLANT PHYSIOL, V144, P183, DOI 10.1016/S0176-1617(11)80541-9	32	337	413	0	63	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1129	1132		10.1038/nbt0996-1129	http://dx.doi.org/10.1038/nbt0996-1129			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631065				2022-12-25	WOS:A1996VF84300036
J	Page, N; Kluepfel, D; Shareck, F; Morosoli, R				Page, N; Kluepfel, D; Shareck, F; Morosoli, R			Increased xylanase yield in Streptomyces lividans: Dependence on number of ribosome-binding sites	NATURE BIOTECHNOLOGY			English	Article						xylanase; secretion; ribosome-binding site; signal peptide	DNA-SEQUENCE; GENE; PURIFICATION; PROTEINS; PEPTIDE; ENZYME	The Streptomyces lividans xylanase A (XlnA) signal peptide (sp) was replaced with the signal peptides of either mannanase A (ManA) or cellulase A (CelA), two enzymes secreted by S. lividans. Depending on the location of the ribosome binding sites (RBS) with respect to a potential initiation codon, the length of the putative sps of ManA and CelA is either 34 or 43 amino acids and 27 or 46 amino acids, respectively, The sequences encoding these sps were fused to the xylanase A gene (xlnA), Clones harboring the short sps of ManA and CelA produced as much xylanase as the clone with the control wild-type sp sequence of XlnA. In clones containing the long sps of ManA and CelA, the XlnA production was enhanced 1.5- and 2.5-fold, respectively. These XlnA yields are reduced by half and one third respectively when the internal initiation codons of the long sp sequences of ManA and CelA are mutated. Since these clones exhibited the same transcription levels, the results indicate that both RBSs are used concomitantly in S. lividans to increase the enzyme production at the translational level, However, when the short and long sps of ManA were fused to the long CelA sp sequence, giving constructs containing respectively 3 and 4 RBSs, a decrease in xylanase production was observed.	UNIV QUEBEC, INST ARMAND FRAPPIER, CTR RECH MICROBIOL APPL, LAVAL, PQ H7N 4Z3, CANADA	University of Quebec								ARCAND N, 1993, BIOCHEM J, V290, P857, DOI 10.1042/bj2900857; BERTRAND JL, 1989, BIOTECHNOL BIOENG, V33, P791, DOI 10.1002/bit.260330618; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; GIBERT M, 1995, CRIT REV BIOTECHNOL, V15, P13, DOI 10.3109/07388559509150530; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; Hopwood D. A., 1985, GENETIC MANIPULATION; HURTUBISE Y, 1995, MOL MICROBIOL, V17, P367, DOI 10.1111/j.1365-2958.1995.mmi_17020367.x; KLUEPFEL D, 1992, APPL MICROBIOL BIOT, V36, P626; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSON JY, 1995, MICROBIOL-SGM, V141, P2629, DOI 10.1099/13500872-141-10-2629; Page N, 1996, APPL ENVIRON MICROB, V62, P109; PARK JS, 1991, AGR BIOL CHEM TOKYO, V55, P1745, DOI 10.1080/00021369.1991.10870877; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAYMER G, 1990, J BACTERIOL, V172, P7020, DOI 10.1128/jb.172.12.7020-7026.1990; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARECK F, 1991, GENE, V107, P75, DOI 10.1016/0378-1119(91)90299-Q; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; TAGUCHI S, 1991, MOL GEN GENET, V226, P328, DOI 10.1007/BF00273622; THEBERGE M, 1992, APPL ENVIRON MICROB, V58, P815; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4	24	13	16	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					756	759		10.1038/nbt0696-756	http://dx.doi.org/10.1038/nbt0696-756			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630985				2022-12-25	WOS:A1996UM76600033
J	Kelley, KJ				Kelley, KJ			Using host defenses to fight infectious diseases	NATURE BIOTECHNOLOGY			English	Article											Kelley, KJ (corresponding author), INTRABIOT PHARMACEUT,816 KIFER RD,SUNNYVALE,CA 94086, USA.								0	33	35	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					587	&		10.1038/nbt0596-587	http://dx.doi.org/10.1038/nbt0596-587			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630947				2022-12-25	WOS:A1996UL60400021
J	Blower, SM; Porco, TC; Darby, G				Blower, SM; Porco, TC; Darby, G			Predicting and preventing the emergence of antiviral drug resistance in HSV-2	NATURE MEDICINE			English	Article							HERPES-SIMPLEX VIRUS; GENITAL HERPES; TUBERCULOSIS EPIDEMICS; CONTROLLED TRIAL; ORAL ACYCLOVIR; TRANSMISSION; INFECTION; SUPPRESSION; FREQUENCY; TYPE-2	Genital herpes, caused by herpes simplex virus, is the most prevalent sexually transmitted disease worldwide. in many developing countries genital herpes is untreated, and in the United States only 10% of cases are treated. We present a mathematical model that we use as a health policy tool to predict the levels of antiviral drug resistance that would emerge, if treatment rates were increased, and to identify the key factors in determining the emergence of drug resistance. We use our results to suggest control measures for herpes epidemics that would prevent the emergence of substantial levels of antiviral drug resistance.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England; Univ Calif San Francisco, Dept Med, HSE, San Francisco, CA 94143 USA	GlaxoSmithKline; University of California System; University of California San Francisco	Blower, SM (corresponding author), Dept Publ Hlth, AIDS Off, 25 van Ness,Suite 500, San Francisco, CA 94102 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R29DA008153] Funding Source: NIH RePORTER; NIDA NIH HHS [R29DA08153] Funding Source: Medline; PHS HHS [R01-09531] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRY DW, 1985, SCAND J INFECT DIS, P155; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; BLOWER SM, IN PRESS J MOL MED; Collins P., 1991, REV MED VIROL, V1, P19; DARBY G, 1981, NATURE, V289, P81, DOI 10.1038/289081a0; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; HOOK EW, 1992, J INFECT DIS, V165, P251, DOI 10.1093/infdis/165.2.251; IMAN RL, 1988, RISK ANAL, V8, P71, DOI 10.1111/j.1539-6924.1988.tb01155.x; KAPLAN E, IN PRESS HDB HIV PRE; KOST RG, 1993, NEW ENGL J MED, V329, P1777, DOI 10.1056/NEJM199312093292405; LARDER BA, 1985, VIROLOGY, V146, P262, DOI 10.1016/0042-6822(85)90009-1; Marchant J, 1997, HERPES J, V4, P36; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; OBERLE MW, 1989, AM J TROP MED HYG, V41, P224, DOI 10.4269/ajtmh.1989.41.224; PORCO TC, IN PREESS IMA J MATH; PORCO TC, IN PRESS THEOR POPUL; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; Safrin S, 1997, REV MED VIROL, V7, P145, DOI 10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; WADE JC, 1983, J INFECT DIS, V148, P1077, DOI 10.1093/infdis/148.6.1077; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; WHITLEY RJ, 1992, NEW ENGL J MED, V327, P782; WILDY P, 1982, SOC GENERAL MICROBIO, V33, P133	36	101	103	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1998	4	6					673	678		10.1038/nm0698-673	http://dx.doi.org/10.1038/nm0698-673			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623975				2022-12-25	WOS:000074008300032
J	Jones, PL; Veenstra, GJC; Wade, PA; Vermaak, D; Kass, SU; Landsberger, N; Strouboulis, J; Wolffe, AP				Jones, PL; Veenstra, GJC; Wade, PA; Vermaak, D; Kass, SU; Landsberger, N; Strouboulis, J; Wolffe, AP			Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription	NATURE GENETICS			English	Article							CHROMATIN STRUCTURE; GENE; ISLAND	CpG methylation in vertebrates correlates with alterations in chromatin structure and gene silencing(1-4). Differences in DNA-methylation status are associated with imprinting phenomena and carcinogenesis(5-10). In Xenopus laevis oocytes, DNA methylation dominantly silences transcription through the assembly of a repressive nucleosomal array(11). Methylated DNA assembled into chromatin binds the transcriptional repressor MeCP2 which cofractionates with Sin3 and histone deacetylase. Silencing conferred by MeCP2 and methylated DNA can be relieved by inhibition of histone deacetylase, facilitating the remodeling of chromatin and transcriptional activation. These results establish a direct causal relationship between DNA methylation-dependent transcriptional silencing and the modification of chromatin.	NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Janssen Res Fdn, Dept Expt Mol Biol, B-2340 Beerse, Belgium; Univ Varese, Dipartimento Biol Strutturale & Funz, I-2100 Varese, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johnson & Johnson	Wolffe, AP (corresponding author), NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA.	awlme@helix.nih.gov	Veenstra, Gert Jan C./D-4963-2012; Wade, Paul A/D-2374-2019; Strouboulis, John/U-4459-2019	Veenstra, Gert Jan C./0000-0002-7787-4940; Wade, Paul A/0000-0002-6042-357X; Landsberger, Nicoletta/0000-0003-0820-3155; Strouboulis, John/0000-0002-6133-2872				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; GODE JS, 1990, J BIOL CHEM, V271, P24325; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUENBAUM Y, 1983, P NATL ACAD SCI-BIOL, V80, P4919, DOI 10.1073/pnas.80.16.4919; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JOENS PA, 1997, P ANTL ACAD SCI US, V94, P2103; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; Landsberger N, 1997, EMBO J, V16, P4361, DOI 10.1093/emboj/16.14.4361; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAN X, 1997, CELL, V88, P1; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	30	2015	2073	3	130	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					187	191		10.1038/561	http://dx.doi.org/10.1038/561			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620779				2022-12-25	WOS:000073865100030
J	Fussenegger, M; Schlatter, S; Datwyler, D; Mazur, X; Bailey, JE				Fussenegger, M; Schlatter, S; Datwyler, D; Mazur, X; Bailey, JE			Controlled proliferation by multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells	NATURE BIOTECHNOLOGY			English	Article						protein synthesis; cell cycle	DEPENDENT KINASE INHIBITOR; MAMMALIAN-CELLS; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; GENE-EXPRESSION; CYCLE CONTROL; P21; PROTEIN; P53; APOPTOSIS	The eukaryotic cell cycle is regulated by a complex network of many proteins. Effective reprogramming of this complex regulatory apparatus to achieve bioprocess goals, such as cessation of proliferation at high cell density to allow an extended period of high production, can require coordinated manipulation of multiple genes. Previous efforts to establish inducible cell-cycle arrest of Chinese hamster ovary (CHO) cells by regulated expression of the cyclin-dependent kinase inhibitor (CDI) p21 failed. By tetracycline-regulated coexpression of p21 and the differentiation factor CCAAT/enhancer-binding protein alpha (which both stabilizes and induces p21), we have achieved effective cell-cycle arrest. Production of a model heterologous protein (secreted alkaline phosphatase; SEAP) has been increased 10-15 times, on a per cell basis, relative to an isogenic control cell line. Because activation of apoptosis response is a possible complication in a proliferation-arrested culture, the survival gene bcl-x(L) was coexpressed with another CDI, p27, found to enable CHO cell-cycle arrest predominantly in G1 phase. CHO cells stably transfected with a tricistronic construct containing the genes for these proteins and for SEAP showed 30-fold higher SEAP expression than controls.	ETH Zurich, Inst Biotechnol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bailey, JE (corresponding author), ETH Zurich, Inst Biotechnol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland.							Alvarez MA, 1996, NAT BIOTECHNOL, V14, P335, DOI 10.1038/nbt0396-335; BEHRENS TW, 1994, J IMMUNOL, V153, P682; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERTELSEN AH, 1995, BIO-TECHNOL, V13, P127, DOI 10.1038/nbt0295-127; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; Clayman GL, 1996, ARCH OTOLARYNGOL, V122, P489; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fussenegger M, 1998, BIOTECHNOL BIOENG, V57, P1, DOI 10.1002/(SICI)1097-0290(19980105)57:1<1::AID-BIT1>3.0.CO;2-M; Fussenegger M, 1997, BIOTECHNOL BIOENG, V55, P927, DOI 10.1002/(SICI)1097-0290(19970920)55:6<927::AID-BIT10>3.0.CO;2-4; FUSSENGGER M, 1998, IN PRESS BIOTECHNOLO; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANA X, 1995, ONCOGENE, V11, P211; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Holmberg N, 1997, NAT BIOTECHNOL, V15, P244, DOI 10.1038/nbt0397-244; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; ITOH Y, 1995, BIOTECHNOL BIOENG, V48, P118, DOI 10.1002/bit.260480205; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Pennisi E, 1996, SCIENCE, V274, P342, DOI 10.1126/science.274.5286.342; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RENNER WA, 1995, BIOTECHNOL BIOENG, V47, P476, DOI 10.1002/bit.260470409; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Singh RP, 1996, BIOTECHNOL BIOENG, V52, P166, DOI 10.1002/(SICI)1097-0290(19961005)52:1<166::AID-BIT17>3.0.CO;2-M; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZANG M, 1995, BIO-TECHNOL, V13, P389, DOI 10.1038/nbt0495-389	37	232	237	0	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					468	472		10.1038/nbt0598-468	http://dx.doi.org/10.1038/nbt0598-468			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592397				2022-12-25	WOS:000073489600033
J	Cheynier, R; Gratton, S; Halloran, M; Stahmer, I; Letvin, NL; Wain-Hobson, S				Cheynier, R; Gratton, S; Halloran, M; Stahmer, I; Letvin, NL; Wain-Hobson, S			Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTED RHESUS-MONKEYS; IMMUNE ACTIVATION; T-LYMPHOCYTES; CELLS; HIV; PATHOGENESIS; INDIVIDUALS; INFLUENZA; DNA	The impact of antigenic stimulation on the dynamics of simian immunodeficiency virus (SIV) replication was studied following repeated intravenous BCC inoculation of a SIV infected macaque. At the site of a delayed type hypersensitivity reaction to purified protein derivative of M. tuberculosis, a distinctive SIV variant was noted, probably as a result of the infiltration of activated antigen-specific T cell clones as opposed to infection by blood borne virus in situ. The dynamics of SIV quasispecies in peripheral blood suggests sequential waves of viral replication, illustrating the role of antigenic stimulation as a driving force in viral dissemination and pathogenesis.	Inst Pasteur, Unite Retrovirol Mol, F-75724 Paris 15, France; Harvard Univ, Sch Med, Div Viral Pathogenesis, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Cheynier, R (corresponding author), Inst Pasteur, Unite Retrovirol Mol, 28 Rue Dr Roux, F-75724 Paris 15, France.		Cheynier, Remi/E-9921-2010	Cheynier, Remi/0000-0003-1146-660X	NIAID NIH HHS [AI-20729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020729, R01AI020729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bandelt HJ, 1992, MOL PHYLOGENET EVOL, V1, P242, DOI 10.1016/1055-7903(92)90021-8; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; BLEAVINS MR, 1995, TOXICOLOGY, V95, P103, DOI 10.1016/0300-483X(95)90402-6; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHEN ZW, 1993, J IMMUNOL, V151, P2177; CHEN ZW, 1992, J VIROL, V66, P3913, DOI 10.1128/JVI.66.6.3913-3917.1992; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Cheynier R, 1996, IMMUNOGENETICS, V43, P83; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; Dittmer U, 1997, J GEN VIROL, V78, P2523, DOI 10.1099/0022-1317-78-10-2523; DOPAZO J, 1993, P NATL ACAD SCI USA, V90, P10320, DOI 10.1073/pnas.90.21.10320; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; Galai N, 1997, LANCET, V349, P180, DOI 10.1016/S0140-6736(05)60982-8; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; Gerna G, 1998, AIDS, V12, P118; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; KURAMOTO Y, 1993, CLIN EXP DERMATOL, V18, P111, DOI 10.1111/j.1365-2230.1993.tb00989.x; Levy JA, 1996, J MED PRIMATOL, V25, P163, DOI 10.1111/j.1600-0684.1996.tb00013.x; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MCILROY D, 1995, J VIROL, V69, P4737, DOI 10.1128/JVI.69.8.4737-4745.1995; OBRIEN WA, 1995, BLOOD, V86, P1082; PELLETIER E, 1995, VIROLOGY, V208, P644, DOI 10.1006/viro.1995.1195; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PILKINGTON C, 1993, ARCH DIS CHILD, V69, P644, DOI 10.1136/adc.69.6.644; Ravn P, 1997, J IMMUNOL, V158, P1949; ROTA S, 1994, EUR J EPIDEMIOL, V10, P713, DOI 10.1007/BF01719287; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; STANLEY SK, 1996, NEW ENGL J MED, V334, P122; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; Weissman D, 1996, J EXP MED, V183, P687, DOI 10.1084/jem.183.2.687; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	38	41	42	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					421	427		10.1038/nm0498-421	http://dx.doi.org/10.1038/nm0498-421			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546787				2022-12-25	WOS:000072906800036
J	Good, L; Nielsen, PE				Good, L; Nielsen, PE			Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA	NATURE BIOTECHNOLOGY			English	Article						nucleic acid engineering; gene regulation; antibiotics	PEPTIDE NUCLEIC-ACID; ESCHERICHIA-COLI; DNA; COMPLEMENTARY; STRAND; RNA	Peptide nucleic acid (PNA) is a DNA mimic with attractive properties for developing improved gene-targeted antisense agents. To test this potential of PNA in bacteria, PNAs were designed to target the start codon regions of the Escherichia coli beta-galactosidase and beta-lactamase genes. Dose-dependent and specific gene inhibition was observed in vitro using low nanomolar PNA concentrations and in vivo using low micromolar concentrations. Inhibition was more efficient for a permeable E. coli strain relative to wild-type K-12. The potency of the anti-beta-lactamase PNAs was abolished by a six base substitution, and inhibition could be re-established using a PNA with compensating base changes. Antisense inhibition of the beta-lactamase gene was sufficient to sensitize resistant cells to the antibiotic ampicillin. The results demonstrate gene-and sequence-specific antisense inhibition in E. coli and open possibilities for antisense antibacterial drugs and gene function analyses in bacteria.	Univ Copenhagen, Panum Inst, Dept Biochem B, IMBG,Ctr Biomol Recognit, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Nielsen, PE (corresponding author), Univ Copenhagen, Panum Inst, Dept Biochem B, IMBG,Ctr Biomol Recognit, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	pen@biokemi.imbg.ku.dk		/0000-0001-8771-330X				BONHAM MA, 1995, NUCLEIC ACIDS RES, V23, P1197, DOI 10.1093/nar/23.7.1197; CHRISTENSEN L, 1996, J PEPT SCI, V1, P175; DEMIDOV V, 1994, BIOCHEM PHARMACOL, V48, P1309; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Gardner AD, 1940, NATURE, V146, P837, DOI 10.1038/146837b0; Gasparro F P, 1991, Antisense Res Dev, V1, P117; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; JAYARAMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P1537, DOI 10.1073/pnas.78.3.1537; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; KOBAYASHI S, 1988, ANTIMICROB AGENTS CH, V32, P1040, DOI 10.1128/AAC.32.7.1040; LAUER BA, 1981, J CLIN MICROBIOL, V14, P201, DOI 10.1128/JCM.14.2.201-205.1981; Miller J.H., 1972, EXPT MOL GENETICS; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; NIELSEN PE, 1995, CHEM SOC REV, V96, P73; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; SEKIGUCHI M, 1967, P NATL ACAD SCI USA, V58, P2315, DOI 10.1073/pnas.58.6.2315; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X; Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212; THORSON JS, IN PRESS METHODS MOL; WITTUNG P, 1995, FEBS LETT, V365, P27, DOI 10.1016/0014-5793(95)00409-3; WITTUNG P, 1994, NATURE, V368, P561, DOI 10.1038/368561a0; WREN BW, 1994, BIOTECHNIQUES, V16, P994	26	196	224	3	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					355	358		10.1038/nbt0498-355	http://dx.doi.org/10.1038/nbt0498-355			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555726				2022-12-25	WOS:000072786200027
J	Caddick, MX; Greenland, AJ; Jepson, I; Krause, KP; Qu, N; Riddell, KV; Salter, MG; Schuch, W; Sonnewald, U; Tomsett, AB				Caddick, MX; Greenland, AJ; Jepson, I; Krause, KP; Qu, N; Riddell, KV; Salter, MG; Schuch, W; Sonnewald, U; Tomsett, AB			An ethanol inducible gene switch for plants used to manipulate carbon metabolism	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; inveterase; Aspergillus nidulans	TRANSGENIC TOBACCO PLANTS; YEAST-DERIVED INVERTASE; ASPERGILLUS-NIDULANS; EXPRESSION SYSTEM; BINDING-SITES; CELLS; ALCR; AGROBACTERIUM; PROMOTERS; ACTIVATOR	Many transgenic plant studies use constitutive promoters to express transgenes. For certain genes, deleterious effects arise from constant expression in all tissues throughout development. We describe a chemically inducible plant gene expression system, with negligible background activity, that obviates this problem. We demonstrate its potential by showing inducible manipulation of carbon metabolism in transgenic plants. Upon rapid induction of yeast cytosolic invertase, a marked phenotype appears in developing leaves that is absent from leaves that developed before induction or after it has ceased.	Univ Liverpool, Sch Biol Sci, Donnan Labs, Liverpool L69 7ZD, Merseyside, England; Zeneca Agrochem, Plant Biotechnol, Bracknell RG42 6ET, Berks, England; IPK, D-06466 Gatersleben, Germany	University of Liverpool; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Tomsett, AB (corresponding author), Univ Liverpool, Sch Biol Sci, Donnan Labs, Liverpool L69 7ZD, Merseyside, England.	tomsett@liverpool.ac.uk	Sonnewald, Uwe/J-7875-2012	Sonnewald, Uwe/0000-0003-1835-5339				Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; ASHRAF M, 1986, NEW PHYTOL, V103, P299, DOI 10.1111/j.1469-8137.1986.tb00617.x; BALLANCE DJ, 1985, GENE, V36, P321, DOI 10.1016/0378-1119(85)90187-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Bussis D, 1997, PLANTA, V202, P126, DOI 10.1007/s004250050111; CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; FELENBOK B, 1991, J BIOTECHNOL, V17, P11, DOI 10.1016/0168-1656(91)90023-O; Fillinger S, 1996, MOL MICROBIOL, V20, P475, DOI 10.1046/j.1365-2958.1996.5301061.x; Gatz C, 1996, CURR OPIN BIOTECH, V7, P168, DOI 10.1016/S0958-1669(96)80008-5; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILSON P, 1990, PLANT CELL, V2, P651, DOI 10.1105/tpc.2.7.651; KACSER H, 1987, TRENDS BIOCHEM SCI, V12, P5, DOI 10.1016/0968-0004(87)90005-3; KOMARI T, 1989, PLANT SCI, V60, P223, DOI 10.1016/0168-9452(89)90170-2; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; KULMBURG P, 1992, J BIOL CHEM, V267, P21146; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; LERCHL J, 1995, PLANT CELL, V7, P259, DOI 10.1105/tpc.7.3.259; METT VL, 1993, P NATL ACAD SCI USA, V90, P4567, DOI 10.1073/pnas.90.10.4567; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; ROSAHL S, 1987, EMBO J, V6, P1155, DOI 10.1002/j.1460-2075.1987.tb02348.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENA M, 1991, P NATL ACAD SCI USA, V88, P10421, DOI 10.1073/pnas.88.23.10421; Schreiber U, 1994, ECOPHYSIOLOGY PHOTOS, V1, P49, DOI DOI 10.1007/978-3-642-79354-73; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; SONNEWALD U, 1991, PLANT J, V1, P95, DOI 10.1111/j.1365-313X.1991.00095.x; STITT M, 1989, METHOD ENZYMOL, V174, P518; STITT M, 1995, ANNU REV PLANT PHYS, V46, P341, DOI 10.1146/annurev.pp.46.060195.002013	30	197	239	0	33	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					177	180		10.1038/nbt0298-177	http://dx.doi.org/10.1038/nbt0298-177			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487526				2022-12-25	WOS:000071831300032
J	He, LZ; Guidez, F; Tribioli, C; Peruzzi, D; Ruthardt, M; Zelent, A; Pandolfi, PP				He, LZ; Guidez, F; Tribioli, C; Peruzzi, D; Ruthardt, M; Zelent, A; Pandolfi, PP			Distinct interactions of PML-RAR alpha and PLZF-RAR alpha with co-repressors determine differential responses to RA in APL	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACID RECEPTOR-ALPHA; TRANS-RETINOIC ACID; ZINC FINGER GENE; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTIONAL PROPERTIES; HISTONE DEACETYLASE; FUSION PROTEINS; DNA-BINDING; TRANSLOCATION	Acute promyelocytic leukaemia (APL), associated with chromosomal translocations involving the retinoic acid receptor alpha gene (RARA) and the PML gene, is sensitive to retinoic acid (RA) treatment, while APL patients harbouring translocations between RARA and the PLZF gene do not respond to RA. We have generated PML-RARA and PLZF-RARA transgenic mice and show here that these fusion proteins play a critical role in leukaemogenesis and in determining responses to RA in APL, because PLZF-RARA transgenic mice develop RA-resistant leukaemia, while PML-RARA mice are responsive to RA treatment. We demonstrate that both PML-RAR alpha and PLZF-RAR alpha fusion proteins can act as transcriptional repressors and are able to interact with nuclear receptor transcriptional co-repressors, such as SMRT. PLZF-RAR alpha, but not PML-RAR alpha, can form, via its PLZF moiety, co-repressor complexes which are insensitive to RA. Histone deacetylase inhibitors such as Trichostatin A (TSA), in combination with RA, can overcome the transcriptional repressor activity of PML-RAR alpha and PLZF-RAR alpha as well as the unresponsiveness of PLZF-RAR alpha-expressing leukaemic cells to RA. Thus, our findings unravel a crucial role for transcriptional silencing in APL pathogenesis and resistance to RA in APL.	Sloan Kettering Inst, Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Ist Europeo Oncol, Milan, Italy; Univ Frankfurt, Med Klin 3, Dept Haematol, D-6000 Frankfurt, Germany	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; IRCCS European Institute of Oncology (IEO); Goethe University Frankfurt	Pandolfi, PP (corresponding author), Sloan Kettering Inst, Mem Sloan Kettering Canc Ctr, Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		Guidez, Fabien/B-3750-2009; Zelent, Arthur/B-3532-2009; Guidez, Fabien/P-4220-2019	Guidez, Fabien/0000-0003-1380-4473; Ruthardt, Martin/0000-0003-1021-3811; Zelent, Arthur/0000-0002-7968-9888; TRIBIOLI, CARLA/0000-0003-2544-476X	NCI NIH HHS [CA-08748, CA 74031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074031, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding W., 1997, Blood, V90, p415A; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fenaux P, 1997, SEMIN ONCOL, V24, P92; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Goldman J M, 1997, Curr Opin Hematol, V4, P277; GRIGNANI F, 1994, BLOOD, V83, P10; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gudas Lorraine J., 1994, P443; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Jansen JH, 1996, BLOOD, V88, P3421; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kalantry S, 1997, J CELL PHYSIOL, V173, P288, DOI 10.1002/(SICI)1097-4652(199711)173:2<288::AID-JCP38>3.3.CO;2-Q; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; LAFAGEPOCHITALOFF M, 1995, BLOOD, V85, P1169, DOI 10.1182/blood.V85.5.1169.1169; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEA MA, 1995, ANTICANCER RES, V15, P879; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; NERVI C, 1992, CANCER RES, V52, P3687; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sambrook J., 2002, MOL CLONING LAB MANU; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	59	483	511	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					126	135		10.1038/ng0298-126	http://dx.doi.org/10.1038/ng0298-126			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462740				2022-12-25	WOS:000071779500019
J	Martins, VR; Graner, E; Garcia-Abreu, J; de Souza, SJ; Mercadante, AF; Veiga, SS; Zanata, SM; Neto, VM; Brentani, RR				Martins, VR; Graner, E; Garcia-Abreu, J; de Souza, SJ; Mercadante, AF; Veiga, SS; Zanata, SM; Neto, VM; Brentani, RR			Complementary hydropathy identifies a cellular prion protein receptor	NATURE MEDICINE			English	Article							GLUTATHIONE-S-TRANSFERASE; CLATHRIN-COATED PITS; MOLECULAR-BIOLOGY; SCRAPIE; FIBRONECTIN; DISEASES; CELLS; POLYPEPTIDES; ENDOCYTOSIS; PEPTIDES	Prions, the etiological agents for infectious degenerative encephalopathies, act by entering the cell and inducing conformational changes in PrPc (a normal cell membrane sialoglycoprotein), which result in cell death. A specific cell-surface receptor to mediate PrPc and prion endocytosis has been predicted. Complementary hydropathy let us generate a hypothetical peptide mimicking the receptor binding site. Antibodies raised against this peptide stain the surface of mouse neurons and recognize a 66-kDa membrane protein that binds PrPc both in vitro and in vivo. Furthermore, both the complementary prion peptide and antiserum against it inhibit the toxicity of a prion-derived peptide toward neuronal cells in culture. Such reagents might therefore have therapeutic applications.	Ludwig Inst Canc Res, BR-01509010 Sao Paulo, Brazil; Fundacao Antonio Prudente, BR-01509010 Sao Paulo, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, BR-21949900 Rio de Janeiro, Brazil	Ludwig Institute for Cancer Research; A.C.Camargo Cancer Center; Universidade Federal do Rio de Janeiro	Brentani, RR (corresponding author), Ludwig Inst Canc Res, Rua Prof Antonio Prudente,109-4A, BR-01509010 Sao Paulo, Brazil.		Graner, Edgard/K-4411-2012; Moura-Neto, VIVALDO/V-9913-2019; Abreu, Jose G/ABB-1199-2021; Martins, Vilma/N-5446-2019; Mercadante, Adriana Frohlich/AAG-7099-2020; Veiga, Silvio Sanches/C-2194-2013; Zanata, Silvio/AAC-9670-2021; de Souza, Sandro Jose/AAG-6270-2020; Martins, Vilma R/E-2547-2012; Abreu, Jose G/G-6159-2010; Graner, Edgard/P-4651-2019	Graner, Edgard/0000-0002-4737-7935; Moura-Neto, VIVALDO/0000-0002-6266-043X; Abreu, Jose G/0000-0002-1363-1755; Veiga, Silvio Sanches/0000-0002-9691-1225; Zanata, Silvio/0000-0003-2818-6954; Martins, Vilma R/0000-0002-2909-8502; Abreu, Jose G/0000-0002-9875-7786; 				ARVAN P, 1983, METHOD ENZYMOL, V98, P75; ASKANAS V, 1993, NEUROSCI LETT, V159, P111, DOI 10.1016/0304-3940(93)90811-X; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; BASTER K, 1986, CELL, V46, P417; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRENTANI RR, 1990, J MOL EVOL, V31, P239, DOI 10.1007/BF02109501; BRENTANI RR, 1988, J THEOR BIOL, V135, P495, DOI 10.1016/S0022-5193(88)80272-8; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GARCIAABREU J, 1995, J NEUROSCI RES, V40, P471, DOI 10.1002/jnr.490400406; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GOLDGABER D, 1991, NATURE, V351, P106, DOI 10.1038/351106a0; HALFTER W, 1989, EUR J NEUROSCI, V1, P297, DOI 10.1111/j.1460-9568.1989.tb00797.x; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; NETO VM, 1983, EMBO J, V2, P1243, DOI 10.1002/j.1460-2075.1983.tb01576.x; OESCH B, 1994, PHILOS T R SOC B, V343, P443, DOI 10.1098/rstb.1994.0042; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUZA S J D, 1992, Journal of Biological Chemistry, V267, P13763; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; WEISS S, 1995, J VIROL, V69, P4776, DOI 10.1128/JVI.69.8.4776-4783.1995; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130	32	156	158	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1997	3	12					1376	1382		10.1038/nm1297-1376	http://dx.doi.org/10.1038/nm1297-1376			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396608				2022-12-25	WOS:000072249500034
J	Guillam, MT; Hummler, E; Schaerer, E; Wu, JY; Birnbaum, MJ; Beermann, F; Schmidt, A; Deriaz, N; Thorens, B				Guillam, MT; Hummler, E; Schaerer, E; Wu, JY; Birnbaum, MJ; Beermann, F; Schmidt, A; Deriaz, N; Thorens, B			Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2	NATURE GENETICS			English	Article							BETA-CELLS; GLUCOSE-TRANSPORTER; INSULIN-SECRETION; RAT PANCREAS; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; TRANSGENIC MICE; MOUSE; HYPERGLYCEMIA; SIGNAL	Glut-2 is a low-affinity transporter present in the plasma membrane of pancreatic beta-cells, hepatocytes and intestine and kidney absorptive epithelial cells of mice(1). In beta-cells, Glut-2 has been proposed to be active in the control of glucose-stimulated insulin secretion (GSIS; ref. 2), and its expression is strongly reduced in glucose-unresponsive islets from different animal models of diabetes(2-4). However, recent investigations have yielded conflicting data on the possible role of Glut-2 in GSIS. Whereas some reports have supported a specific role for Glut-2 (refs 5,6), others have suggested that GSIS could proceed normally even in the presence of low(7) or almost undetectable(8) levels of this transporter. Here we show that homozygous, but not heterozygous, mice deficient in Glut-2 are hyperglycaemic and relatively hypo-insulinaemic and have elevated plasma levels of glucagon, free fatty acids and beta-hydroxybutyrate. In vivo, their glucose tolerance is abnormal. In vitro, beta-cells display loss of control of insulin gene expression by glucose and impaired GSIS with a loss of first phase but preserved second phase of secretion, while the secretory response to non-glucidic nutrients or to D-glyceraldehyde is normal. This is accompanied by alterations in the postnatal development of pancreatic islets, evidenced by an inversion of the alpha- to beta-cell ratio. Glut-2 is thus required to maintain normal glucose homeostasis and normal function and development of the endocrine pancreas. Its absence leads to symptoms characteristic of non-insulin-dependent diabetes mellitus.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND; NATL TAIWAN UNIV HOSP,DEPT FAMILY MED,TAIPEI,TAIWAN; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne; National Taiwan University; National Taiwan University Hospital; Howard Hughes Medical Institute; University of Pennsylvania; Swiss Institute Experimental Cancer Research				Birnbaum, Morris/0000-0001-9972-8680				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; HOLE RL, 1988, AM J PHYSIOL, V254, pE167, DOI 10.1152/ajpendo.1988.254.2.E167; HOPCROFT DW, 1985, HORM METAB RES, V17, P559, DOI 10.1055/s-2007-1013606; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; KERVRAN A, 1980, DIABETES, V29, P673, DOI 10.2337/diabetes.29.9.673; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Liang H, 1996, MOL BIOL CELL, V7, P1953, DOI 10.1091/mbc.7.12.1953; MA YH, 1995, EUR J ENDOCRINOL, V132, P370, DOI 10.1530/eje.0.1320370; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Offield MF, 1996, DEVELOPMENT, V122, P983; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; PHILIPPE J, 1994, DIABETES, V43, P523, DOI 10.2337/diabetes.43.4.523; RAHIER J, 1983, DIABETOLOGIA, V24, P366; RHOTEN WB, 1980, AM J PHYSIOL, V239, pE57, DOI 10.1152/ajpendo.1980.239.1.E57; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; SWENNE I, 1985, DIABETES, V34, P803, DOI 10.2337/diabetes.34.8.803; TAL M, 1992, P NATL ACAD SCI USA, V89, P5744, DOI 10.1073/pnas.89.13.5744; THORENS B, 1992, INT REV CYTOL, V137A, P209; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VALERA A, 1994, J BIOL CHEM, V269, P28543; WEIHEL ER, 1979, STEREOLOGICAL METHOD, P101; ZHOU YP, 1995, ENDOCRINOLOGY, V136, P3546, DOI 10.1210/en.136.8.3546	30	310	318	1	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					327	330		10.1038/ng1197-327	http://dx.doi.org/10.1038/ng1197-327			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354799				2022-12-25	WOS:A1997YD66700029
J	Mazzoli, S; Trabattoni, D; Caputo, SL; Piconi, S; Ble, C; Meacci, F; Ruzzante, S; Salvi, A; Semplici, F; Longhi, R; Fusi, ML; Tofani, N; Biasin, M; Villa, ML; Mazzotta, F; Clerici, M				Mazzoli, S; Trabattoni, D; Caputo, SL; Piconi, S; Ble, C; Meacci, F; Ruzzante, S; Salvi, A; Semplici, F; Longhi, R; Fusi, ML; Tofani, N; Biasin, M; Villa, ML; Mazzotta, F; Clerici, M			HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODY SERUM NEGATIVITY; CD8(+) T-CELLS; SEXUAL TRANSMISSION; RHESUS MACAQUES; HOMOSEXUAL MEN; INFECTION; VACCINE; TYPE-1; RESPONSES	HIV-specific mucosal and cellular immunity was analyzed in heterosexual couples discordant for HIV status in serum and in HIV-unexposed controls. HIV-specific IgA but not IgG was present in urine and vaginal wash samples from HIV-exposed seronegative individuals (ESN), whereas both IgA and IgG were observed in their HIV-seropositive partners; antibodies were not detected in low-risk controls. Envelope protein (Env) peptide-stimulated interleukin-2 (IL-2) production by peripheral blood mononuclear cells (PBMCs) was detected in 9 out of 16 ESNs, 5 out of 16 HIV-infected patients and 1 out of 50 controls. Env peptide-stimulated PBMCs of ESNs produced more IL-2 and less IL-10 compared with those of HIV-infected individuals; no differences were observed in chemokine production or in CCR5 expression. These data demonstrate that a compartmentalized immune response to pathogens is possible in humans and raise the possibility of protective roles for cell-mediated immunity and mucosal IgA in HIV-seronegative individuals exposed to HIV.	UNIV MILAN, PADIGL LITA, CATTEDRA IMMUNOL, I-20157 MILAN, ITALY; OSPED SM ANNUNZIATA, ASL 10, CTR MST UO MALATTIE INFETT, I-50100 FLORENCE, ITALY; OSPED L SACCO, DIV MALATTIE INFETT 1, I-21057 MILAN, ITALY; CNR, IST CHIM ORMONI, I-20131 MILAN, ITALY	University of Milan; University of Milan; Luigi Sacco Hospital; Consiglio Nazionale delle Ricerche (CNR)			Trabattoni, Daria/G-7424-2012; biasin, mara/G-7426-2012	Trabattoni, Daria/0000-0001-9535-3359; biasin, mara/0000-0003-3671-4235; Lo Caputo, Sergio/0000-0002-4729-7548; Mazzoli, Sandra/0000-0002-6266-5492; Clerici, Mario/0000-0001-5920-6191				ALEXANDER NJ, 1990, FERTIL STERIL, V54, P1; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BELEC L, 1994, LANCET, V343, P1046, DOI 10.1016/S0140-6736(94)90168-6; BUKAWA H, 1995, NAT MED, V1, P681, DOI 10.1038/nm0795-681; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLARICI M, 1994, JAMA-J AM MED ASSOC, V271, P42; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, AIDS, V7, P1427, DOI 10.1097/00002030-199311000-00004; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1994, AIDS, V8, P1391, DOI 10.1097/00002030-199410000-00004; Clerici M, 1996, AIDS, V10, P1432, DOI 10.1097/00002030-199610000-00019; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DEMARIA A, 1994, J INFECT DIS, V170, P1296, DOI 10.1093/infdis/170.5.1296; EMILIE D, 1992, J BIOL CHEM, V267, P20565; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; GIORGI JV, 1987, J IMMUNOL, V138, P3725; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HILLEMAN MR, 1995, NAT MED, V1, P1126, DOI 10.1038/nm1195-1126; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1297; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; Lehner T, 1996, ESSENTIALS OF MUCOSAL IMMUNOLOGY, P437, DOI 10.1016/B978-012394330-9/50033-8; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; Mazzoli S, 1996, Infect Dis Obstet Gynecol, V4, P136; MCKENZIE SW, 1996, AIDS, V10, P29; Miller C. J., 1992, Laboratory Investigation, V68, P129; Miller CJ, 1996, NAT MED, V2, P751, DOI 10.1038/nm0796-751; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PECKHAM CS, 1991, LANCET, V337, P253; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; ROBERTGUROFF M, 1988, AIDS RES HUM RETROV, V4, P343, DOI 10.1089/aid.1988.4.343; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; SALVATO MS, 1994, J MED PRIMATOL, V23, P125, DOI 10.1111/j.1600-0684.1994.tb00112.x; SHAFFERMAN A, 1989, AIDS RES HUM RETROV, V5, P33, DOI 10.1089/aid.1989.5.33; Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0; STAATS HF, 1996, IMMUNOLOGY HIV INFEC, P387; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; TURNER V, 1993, BIOTECHNOLOGY, V11, P696; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; URNOVITZ HB, 1993, LANCET, V342, P1458, DOI 10.1016/0140-6736(93)92934-L; Urnovitz HB, 1996, TRENDS BIOTECHNOL, V14, P361, DOI 10.1016/0167-7799(96)10048-2; *WHO, 1995, WEEKLY EPIDEMIOL REC, V70, P5; Zeitz M, 1996, ESSENTIALS OF MUCOSAL IMMUNOLOGY, P421, DOI 10.1016/B978-012394330-9/50032-6	54	363	374	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1250	1257		10.1038/nm1197-1250	http://dx.doi.org/10.1038/nm1197-1250			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359700				2022-12-25	WOS:A1997YD89600034
J	Splawski, I; TristaniFirouzi, M; Lehmann, MH; Sanguinetti, MC; Keating, MT				Splawski, I; TristaniFirouzi, M; Lehmann, MH; Sanguinetti, MC; Keating, MT			Mutations in the hminK gene cause long QT syndrome and suppress I-Ks function	NATURE GENETICS			English	Article							DEPENDENT K+ CHANNEL; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; K(V)LQT1; PROTEINS; SUBUNIT; FORM; KR	Ion-channel beta-subunits are ancillary proteins that co-assemble with alpha-subunits to modulate the gating kinetics and enhance stability of multimeric channel complexes(1,2). Despite their functional importance, dysfunction of potassium-channel beta-subunits has not been associated with disease. Recent physiological studies suggest that KCNE1 encodes beta-subunits (hminK) that co-assemble with KvLQT1 alpha-subunits to form the slowly activating delayed rectifier K+ (I-Ks) channel(3,4). Because KVLQT1 mutations cause arrhythmia susceptibility in the long QT syndrome (LQT)(5-7), we hypothesized that mutations in KCNE1 also cause this disorder. Here, we define KCNE1 missense mutations in affected members of two LQT families. Both mutations (S74L, D76N) reduced I-Ks by shifting the voltage dependence of activation and accelerating channel deactivation, D76N hminK also had a strong dominant-negative effect, The functional consequences of these mutations would be delayed cardiac repolarization and an increased risk of arrhythmia. This is the first description of KCNE1 as an LQT gene and confirms that hminK is an integral protein of the I-Ks channel.	UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PEDIAT,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; SINAI HOSP,ARRHYTHMIA CTR,DETROIT,MI 48235	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah			Sanguinetti, Michael/AAN-2615-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052338] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00064] Funding Source: Medline; NHLBI NIH HHS [R01 HL48074, P50-HL52338-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LIU DW, 1995, CIRC RES, V76, P351, DOI 10.1161/01.RES.76.3.351; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Splawski I, 1997, NEW ENGL J MED, V336, P1562, DOI 10.1056/NEJM199705293362204; SWANSON R, 1993, SEMIN NEUROSCI, V5, P117; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	17	602	622	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					338	340		10.1038/ng1197-338	http://dx.doi.org/10.1038/ng1197-338			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354802				2022-12-25	WOS:A1997YD66700032
J	Maw, MA; Kennedy, B; Knight, A; Bridges, R; Roth, KE; Mani, EJ; Mukkadan, JK; Nancarrow, D; Crabb, JW; Denton, MJ				Maw, MA; Kennedy, B; Knight, A; Bridges, R; Roth, KE; Mani, EJ; Mukkadan, JK; Nancarrow, D; Crabb, JW; Denton, MJ			Mutation of the gene encoding cellular retinaldehyde-binding protein in autosomal recessive retinitis pigmentosa	NATURE GENETICS			English	Article							TOCOPHEROL TRANSFER PROTEIN; LINKAGE ANALYSIS; HUMAN GENOME; VITAMIN-A; CLONING; HOMOLOGY; LOCALIZATION; EXPRESSION; LOCUS; CDNA	Inadequate levels of all-trans-retinol in the blood cause retinal dysfunction; hence, genes implicated in retinal vitamin-A metabolism represent candidates for inherited retinal degenerations(1,2). In the current study, molecular genetic analysis of a consanguineous pedigree segregating for non-syndromic autosomal recessive retinitis pigmentosa (arRP) indicated that the affected siblings were homozygous by descent for a G4763A nucleotide substitution in RLBP1, the gene encoding cellular retinaldehyde-binding protein (CRALBP). This substitution is predicted to replace an arginine with glutamine at residue 150. CRALBP is not expressed in photoreceptors but is abundant in the retinal pigment epithelium (RPE) and Muller cells of the neuroretina, where it carries 11-cis-retinol and 11-cis-retinaldehyde(3-5). When expressed in bacteria, recombinant CRALBP (rCRALBP) containing the R150Q substitution was less soluble than wild-type rCRALBP. Mutant rCRALBP was purified from the soluble cell lysate and the protein structure was verified by mass spectrometry. The mutant protein lacked the ability of bind 11-cis-retinaldehyde. These findings suggest that arRP in the current pedigree results from a lack of functional CRALBP, presumably leading to disruption of retinal vitamin-A metabolism.	W ALTON JONES CELL SCI CTR,PROT CHEM FACIL,LAKE PLACID,NY 12946; LITTLE FLOWER MED RES CTR,ANGAMALLY 683572,KERALA,INDIA; WOLSTON PK HOSP,QUEENSLAND CTR SCHIZOPHRENIA RES,BRISBANE,QLD,AUSTRALIA		Maw, MA (corresponding author), UNIV OTAGO,DEPT BIOCHEM,POB 56,DUNEDIN,NEW ZEALAND.		kennedy, Breandan/H-5643-2019	kennedy, Breandan/0000-0001-7991-4689; Mukkadan, Joseph Kurien/0000-0003-4032-4301	NEI NIH HHS [EY06603, F32 EY06807] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006807] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Algvere PV, 1997, ACTA OPHTHALMOL SCAN, V75, P1; ARITA M, 1995, BIOCHEM J, V306, P437, DOI 10.1042/bj3060437; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BOLHUIS PA, 1993, BIOCHIM BIOPHYS ACTA, V1182, P142, DOI 10.1016/0925-4439(93)90134-M; BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; Chinen K, 1996, CYTOGENET CELL GENET, V73, P218, DOI 10.1159/000134342; COTRAN PR, 1990, EXP EYE RES, V51, P15, DOI 10.1016/0014-4835(90)90164-P; CRABB JW, 1988, J BIOL CHEM, V263, P18688; CRABB JW, 1991, J BIOL CHEM, V266, P16674; CRABB JW, 1997, TECHNIQUES MOL BIOL, V89, P91; DELVECCHIO RL, 1994, J BIOL CHEM, V269, P19639; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; GAL S, 1997, NAT GENET, V17, P1994; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; INTRES R, 1994, J BIOL CHEM, V269, P25411; KAPRON JT, IN PRESS PROTEIN SCI; KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9; KNOWLES JA, 1994, HUM MOL GENET, V3, P1401, DOI 10.1093/hmg/3.8.1401; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LUCK LA, IN PRESS TECHNIQUES, V8; MAW M, IN PRESS HUM MUTAT; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; Saari John C., 1994, P351; SATO Y, 1993, J BIOL CHEM, V268, P17705; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SPARKES RS, 1992, GENOMICS, V12, P58, DOI 10.1016/0888-7543(92)90406-I; *WHIT I BIOM RES, 1996, MIT CTR GEN RES	30	246	253	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					198	200		10.1038/ng1097-198	http://dx.doi.org/10.1038/ng1097-198			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326942				2022-12-25	WOS:A1997XZ55500028
J	Sommer, A				Sommer, A			Clinical research and the human condition: Moving from observation to practice	NATURE MEDICINE			English	Editorial Material							VITAMIN-A SUPPLEMENTATION; TRIAL; MORTALITY; CHILDREN; MEASLES				Sommer, A (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, 615 N WOLFE ST SUITE 1041, BALTIMORE, MD 21205 USA.							BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; Beaton G. H., 1992, EFFECTIVENESS VITAMI; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; Ellison JB, 1932, BRIT MED J, V1932, P708, DOI 10.1136/bmj.2.3745.708; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; KEUSCH GT, 1990, NEW ENGL J MED, V323, P985, DOI 10.1056/NEJM199010043231408; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1983, LANCET, V2, P585; Sommer A, 1995, VITAMIN A DEFICIENCY, V3rd; Sommer A., 1996, VITAMIN A DEFICIENCY, P19; TARWOTJO I, 1987, AM J CLIN NUTR, V45, P1466, DOI 10.1093/ajcn/45.6.1466; *WHO, 1982, TECH REP SER, V672; 1987, WEEKLY EPIDEMIOLOGIC, V62, P133	13	12	12	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1997	3	10					1061	1063		10.1038/nm1097-1061	http://dx.doi.org/10.1038/nm1097-1061			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334706				2022-12-25	WOS:A1997XZ28700020
J	Norton, JC; Piatyszek, MA; Wright, WE; Shay, JW; Corey, DR				Norton, JC; Piatyszek, MA; Wright, WE; Shay, JW; Corey, DR			Inhibition of human telomerase activity by peptide nucleic acids	NATURE BIOTECHNOLOGY			English	Article						PNA; telomerase; phosphorothioate; oligonucleotide	DNA; RECOGNITION	We report the inhibition of human telomerase activity by peptide nucleic acids (PNAs). PNAs recognize the RNA component of human telomerase (hTR) and inhibit activity of the enzyme with IC50 values in the picomolar to nanomolar range. Inhibition depends on targeting exact functional boundaries of the hTR template and is 10- to 50-fold more efficient than inhibition by analogous phosphorothioate (PS) oligomers. In contrast to high selectivity of inhibition by PNAs, PS oligomers inhibit telomerase in a non-sequence-selective fashion. These results demonstrate that PNAs can control the enzymatic activity of ribonucleoproteins and possess important advantages relative to PS oligomers in both the affinity and the specificity of their recognition. These observations should facilitate the development of effective inhibitors of telomerase activity and affinity probes of telomerase structure.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Piatyszek, Mieczyslaw A./F-9365-2015; Shay, Jerry W/F-7878-2011	Piatyszek, Mieczyslaw A./0000-0003-0502-3239; 	NIA NIH HHS [AG07792] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; BACHETTI S, 1995, INT J ONCOL, V7, P423; BENIMETSKAYA L, 1995, NUCLEIC ACIDS RES, V23, P4239, DOI 10.1093/nar/23.21.4239; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BROWN DA, 1994, J BIOL CHEM, V269, P26801; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHU BCF, 1991, NUCLEIC ACIDS RES, V19, P6958, DOI 10.1093/nar/19.24.6958; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; DUEHOLM KL, 1994, J ORG CHEM, V59, P5767, DOI 10.1021/jo00098a042; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HAMILTON S, UNPUB; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRIEG AM, 1995, ANTISENSE RES DEV, V5, P241, DOI 10.1089/ard.1995.5.241; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NORTON JC, 1995, BIOORGAN MED CHEM, V3, P437, DOI 10.1016/0968-0896(95)00033-D; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; THOMSON SA, 1995, TETRAHEDRON, V51, P6179, DOI 10.1016/0040-4020(95)00286-H; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WILLUNG P, 1995, FEBS LETT, V356, P27; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	42	326	375	0	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					615	619		10.1038/nbt0596-615	http://dx.doi.org/10.1038/nbt0596-615			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630953				2022-12-25	WOS:A1996UL60400027
J	Cummings, CJ; Mancini, MA; Antalffy, B; DeFranco, DB; Orr, HT; Zoghbi, HY				Cummings, CJ; Mancini, MA; Antalffy, B; DeFranco, DB; Orr, HT; Zoghbi, HY			Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1	NATURE GENETICS			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; ESCHERICHIA-COLI; NEURODEGENERATIVE DISEASES; MOLECULAR CHAPERONES; GLUTAMINE REPEATS; HSP70; DEGRADATION; HOMOLOG; INVOLVEMENT; UBIQUITIN	Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of a polyglutamine tract in ataxin-1. In affected neurons of SCA1 patients and transgenic mice, mutant ataxin-1 accumulates in a single, ubiquitin-positive nuclear inclusion. In this study, we show that these inclusions stain positively for the 205 proteasome and the molecular chaperone HDJ-2/HSDJ. Similarly, HeLa cells transfected with mutant ataxin-1 develop nuclear aggregates which colocalize with the 205 proteasome and endogenous HDJ-2/HSDJ. Overexpression of wild-type HDJ-2/HSDJ in HeLa cells decreases the frequency of ataxin-1 aggregation. These data suggest that protein misfolding is responsible for the nuclear aggregates seen in SCA1, and that over-expression of a DnaJ chaperone promotes the recognition of a misfolded polyglutamine repeat protein, allowing its refolding and/or ubiquitin-dependent degradation.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Howard Hughes Med Inst, Houston, TX 77030 USA; Univ Pittsburgh, Dept Biol Sci & Pharmacol, Pittsburgh, PA USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.			Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X	NINDS NIH HHS [NS27699, NS22920] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022920, R01NS022920, R01NS027699] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams GM, 1997, J MOL BIOL, V273, P646, DOI 10.1006/jmbi.1997.1334; Attaix D, 1997, MOL BIOL REP, V24, P95, DOI 10.1023/A:1006806103675; BROWN IR, 1990, J NEUROSCI RES, V27, P247, DOI 10.1002/jnr.490270302; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Bush KT, 1997, J BIOL CHEM, V272, P9086; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DIENEL GA, 1986, J CEREBR BLOOD F MET, V6, P505, DOI 10.1038/jcbfm.1986.86; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; MATILLA T, 1997, NATURE, V389, P974; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SHERMAN MY, 1992, EMBO J, V11, P71; SHIBATANI T, 1995, ARCH BIOCHEM BIOPHYS, V321, P160, DOI 10.1006/abbi.1995.1381; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; Tang YT, 1997, MOL BIOL CELL, V8, P795, DOI 10.1091/mbc.8.5.795; Welch WJ, 1998, NATURE, V392, P23, DOI 10.1038/32049; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; ZHOU M, 1996, J BIOL CHEM, V271, P247; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8	44	690	715	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					148	154		10.1038/502	http://dx.doi.org/10.1038/502			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620770				2022-12-25	WOS:000073865100021
J	Marsh, DJ; Hollopeter, G; Kafer, KE; Palmiter, RD				Marsh, DJ; Hollopeter, G; Kafer, KE; Palmiter, RD			Role of the Y5 neuropeptide Y receptor in feeding and obesity	NATURE MEDICINE			English	Article							PARAVENTRICULAR NUCLEUS; FOOD-DEPRIVATION; OB/OB MICE; GENE; EXPRESSION; INGESTION; BEHAVIOR; LEPTIN; RATS	Neuropeptide Y (NPY), a 36-amino-acid neuromodulator abundantly expressed in the brain(1), has been implicated in the regulation of food intake and body weight(2-4). Pharmacological data suggest that NPY's stimulatory effect on appetite is transduced by the G-protein-coupled NPY Y5 receptor(5) (Y5R). We have inactivated the Y5R gene in mice and report that younger Y5R-null mice feed and grow normally; however, they develop mild late-onset obesity characterized by increased body weight, food intake and adiposity. Fasting-induced refeeding is unchanged in younger Y5R-null mice and they exhibit normal sensitivity to leptin. Their response to intracerebroventricular (icv) administration of NPY and related peptides is either reduced or absent. NPY deficiency attenuates the obesity syndrome of mice deficient for leptin(6) (ob/ob), but these effects are not mediated by NPY signaling through the Y5R because Y5R-null ob/ob mice are equally obese. These results demonstrate that the Y5R contributes to feeding induced by centrally administered NPY and its analogs, but is not a critical physiological feeding receptor in mice.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	palmiter@u.washington.edu						ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BECK B, 1990, BRAIN RES, V528, P245, DOI 10.1016/0006-8993(90)91664-3; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; DANIELS AJ, 1995, P NATL ACAD SCI USA, V92, P9067, DOI 10.1073/pnas.92.20.9067; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Kalra SP, 1997, NEURON, V19, P227, DOI 10.1016/S0896-6273(00)80934-4; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1985, PEPTIDES, V6, P1205, DOI 10.1016/0196-9781(85)90452-8; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STANLEY BG, 1984, LIFE SCI, V35, P2635, DOI 10.1016/0024-3205(84)90032-8; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	21	342	359	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					718	721		10.1038/nm0698-718	http://dx.doi.org/10.1038/nm0698-718			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623983				2022-12-25	WOS:000074008300040
J	Hoyle, R				Hoyle, R			In hot pursuit of extremophiles	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	2	2	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					312	312		10.1038/nbt0498-312	http://dx.doi.org/10.1038/nbt0498-312			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555712				2022-12-25	WOS:000072786200005
J	Sata, M; Walsh, K				Sata, M; Walsh, K			TNF alpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation	NATURE MEDICINE			English	Article							HUMAN ATHEROSCLEROTIC PLAQUE; SMOOTH-MUSCLE CELLS; LYMPHOCYTES-T; IN-VIVO; APOPTOSIS; IDENTIFICATION; ATHEROGENESIS; MACROPHAGES; REJECTION; MECHANISM	It is generally believed that the vascular endothelium serves as an inflammatory barrier by providing a nonadherent surface to leukocytes. Here, we report that Fas ligand (FasL) is expressed on vascular endothelial cells (ECs) and that it may function to actively inhibit leukocyte extravasation. TNF alpha downregulates FasL expression with an accompanying decrease in EC cytotoxicity toward co-cultured Fas-bearing cells. Local administration of TNF alpha to arteries down regulates endothelial Fast expression and induces mononuclear cell infiltration. Constitutive Fast expression markedly attenuates TNF alpha-induced cell infiltration and adherent mononuclear cells undergo apoptosis under these conditions. These findings suggest that endothelial Fast expression can negatively regulate leukocyte extravasation.	Tufts Univ, St Elizabeths Hosp, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA; Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Tufts Univ, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA	Tufts University; University of Massachusetts System; University of Massachusetts Worcester; Tufts University	Walsh, K (corresponding author), Tufts Univ, St Elizabeths Hosp, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA.	kwalsh@opal.tufts.edu		Walsh, Kenneth/0000-0001-7580-2276	NHLBI NIH HHS [HL50692, R01 HL050692-10] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197-11, R01 AR040197, AR40197] Funding Source: Medline; NIA NIH HHS [R01 AG015052-02, AG15052, R37 AG015052, R01 AG015052] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams MR, 1997, CIRCULATION, V95, P662, DOI 10.1161/01.CIR.95.3.662; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; EMESON EE, 1988, AM J PATHOL, V130, P369; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HANSSON GK, 1989, AM J PATHOL, V135, P169; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; LIBBY P, 1991, LAB INVEST, V64, P5; LOSORDO DW, 1994, CIRCULATION, V89, P785, DOI 10.1161/01.CIR.89.2.785; Luscinskas FW, 1996, ANNU REV MED, V47, P413, DOI 10.1146/annurev.med.47.1.413; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MUNRO JM, 1987, HUM PATHOL, V18, P375; Muruve DA, 1997, HUM GENE THER, V8, P955, DOI 10.1089/hum.1997.8.8-955; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Niehans GA, 1997, CANCER RES, V57, P1007; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; PFIEFFER K, 1993, CELL, V73, P457; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PICKERING JG, 1992, J AM COLL CARDIOL, V20, P1430, DOI 10.1016/0735-1097(92)90259-P; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TANAKA H, 1995, AM J PATHOL, V147, P617; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; VANDERWAL AC, 1989, LAB INVEST, V61, P166; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7	37	194	199	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					415	420		10.1038/nm0498-415	http://dx.doi.org/10.1038/nm0498-415			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546786	Green Accepted			2022-12-25	WOS:000072906800035
J	Choksi, S; Jameson, BA; Korngold, R				Choksi, S; Jameson, BA; Korngold, R			A structure-based approach to designing synthetic CD8 alpha peptides that can inhibit cytotoxic T-lymphocyte responses	NATURE MEDICINE			English	Article							CLASS-I MOLECULES; DIFFERENTIATION ANTIGEN; VARIABLE REGIONS; CELL ACTIVATION; ALPHA-3 DOMAIN; CD8; IMMUNOGLOBULIN; COMPLEX; BINDING; POLYPEPTIDES	CD8 molecules function as co-receptors on cytotoxic T lymphocytes (CTLs), interacting with a nonpolymorphic region of the major histocompatibility complex (MHC) class I a3 domain on antigen-presenting cells. Analogues were designed from a structural model of the mouse CD8a molecule to identify surfaces involved in CD8 function. Peptides were screened for in vitro biological activity on alloreactive CTLs, and analogue SC4 (p54-59) was found to be inhibitory during both the generation and effector stages. SC4 was also able to significantly prolong skin allograft survival across a MHC class I barrier, Thus, such CD8 analogues may have therapeutic potential as immunoregulators of CTL immune responses.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University	Korngold, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, 233 S 10th St, Philadelphia, PA 19107 USA.							BAILEY DW, 1960, TRANSPLAN B, V25, P424; CAI ZL, 1994, J EXP MED, V179, P2005, DOI 10.1084/jem.179.6.2005; CLAYBERGER C, 1994, J IMMUNOL, V153, P946; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DOHERTY PC, 1985, BRIT MED BULL, V41, P7, DOI 10.1093/oxfordjournals.bmb.a072028; EICHMANN K, 1991, J IMMUNOL, V147, P2075; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FRANCO MD, 1994, CELL IMMUNOL, V157, P341, DOI 10.1006/cimm.1994.1232; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P2834, DOI 10.1002/eji.1830231117; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; JAMESON BA, 1989, NATURE, V341, P465, DOI 10.1038/341465a0; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MASON DW, 1986, ANNU REV IMMUNOL, V4, P119, DOI 10.1146/annurev.immunol.4.1.119; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MESCHER MF, 1995, IMMUNOL REV, V146, P177, DOI 10.1111/j.1600-065X.1995.tb00689.x; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OROURKE AM, 1994, J IMMUNOL, V152, P4358; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SPRENT J, 1986, J EXP MED, V163, P998, DOI 10.1084/jem.163.4.998; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZINKERNAGEL RM, 1975, J EXP MED, V141, P1427, DOI 10.1084/jem.141.6.1427	35	19	19	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					309	314		10.1038/nm0398-309	http://dx.doi.org/10.1038/nm0398-309			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500604				2022-12-25	WOS:000073616200036
J	Gasser, T; Muller-Myhsok, B; Wszolek, ZK; Oehlmann, R; Calne, DB; Bonifati, V; Bereznai, B; Fabrizio, E; Vieregge, P; Horstmann, RD				Gasser, T; Muller-Myhsok, B; Wszolek, ZK; Oehlmann, R; Calne, DB; Bonifati, V; Bereznai, B; Fabrizio, E; Vieregge, P; Horstmann, RD			A susceptibility locus for Parkinson's disease maps to chromosome 2p13	NATURE GENETICS			English	Article							AUTOSOMAL-DOMINANT PARKINSONISM; LINKAGE ANALYSIS; GENETIC-LINKAGE; HUMAN GENOME; LEWY BODY; INHERITANCE	Parkinson's disease (PD) is a common degenerative neurologic disorder, which is pathologically characterized by a selective degeneration of dopaminergic neurons of the substantia nigra pars compacta, and the presence of characteristic eosinophilic inclusions, known as Lewy-bodies in affected brain areas(1). The cause of PD is unknown but, in recent years, genetic factors have been implicated in the aetiology of the disease(2). Firstly, clinico-genetic, epidemiologic and twin studies revealed inheritable effects(3) and questioned earlier studies which had denied such influences(4). Secondly, several family studies suggested autosomal-dominant inheritance of syndromes which, to variable degrees, resembled sporadic PD clinically(5) and in some cases also neuropathologically(6,7). Recently, a disease locus has been mapped to chromosome 4q21-22 in a large Mediterranean pedigrees, in which disease expression is clinically and pathologically within the spectrum of sporadic PD; being atypical only for a relatively young mean age at onset of 46 years and rapid course of 10 years from onset to death(9). In affected individuals of this family and of three unrelated Greek kindreds, a putative disease-causing mutation has been identified in the gene encoding alpha-synuclein(10). With the first variant being defined, genetic heterogeneity has become apparent, as in other families parkinsonism was not linked to the 4q-locus(11) and was not associated with the alpha-synuclein mutation (unpublished data). We describe a different genetic locus that appears to be involved in the development of parkinsonism closely resembling sporadic PD including a similar mean age of onset (59 years in the families, 59.7 years in sporadic PD; ref. 12). This locus was detected in a group of families of European origin. In two of these families, there is genetic evidence for a common founder. The penetrance of the mutation appears to be low, most likely below 40%. This is compatible with a possible role of this locus not only in familial, but also in typical (sporadic) PD.	Univ Munich, Klinikum Grosshadern, Neurol Klin, D-8000 Munich, Germany; Bernhard Nocht Inst Trop Med, Dept Mol Med, Hamburg, Germany; Univ Nebraska, Med Ctr, Dept Internal Med, Neurol Sect, Omaha, NE USA; Univ British Columbia, Ctr Neurodegenerat Disorders, Vancouver, BC V5Z 1M9, Canada; Univ Roma La Sapienza, Dipartimento Sci Neurol, Rome, Italy; Univ Lubeck, Neurol Klin, D-2400 Lubeck, Germany	University of Munich; Bernhard Nocht Institut fur Tropenmedizin; University of Nebraska System; University of Nebraska Medical Center; University of British Columbia; Sapienza University Rome; University of Lubeck	Gasser, T (corresponding author), Univ Munich, Klinikum Grosshadern, Neurol Klin, D-8000 Munich, Germany.	tgasser@brain.nefo.med.uni-muenchen.de	Wszolek, Zbigniew K./AAB-1431-2019; Gasser, Thomas/GNH-5293-2022; Müller-Myhsok, Bertram/A-3289-2013	Gasser, Thomas/0000-0002-1069-1146; 				ALEXI T, 1993, NEUROSCIENCE, V55, P903, DOI 10.1016/0306-4522(93)90307-2; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Denson MA, 1997, ANN NEUROL, V42, P638, DOI 10.1002/ana.410420415; DENSON MA, 1995, PARKINSONISM RELAT D, V1, P1; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DiRocco A, 1996, ADV NEUROL, V69, P3; DUBOVSKY J, 1995, HUM MOL GENET, V4, P449, DOI 10.1093/hmg/4.3.449; DUVOISIN RC, 1969, PROGR NEUROGENETICS, P492; Gasser T, 1997, SCIENCE, V277, P388; GASSER T, 1994, ANN NEUROL, V36, P387, DOI 10.1002/ana.410360310; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; Golbe LI, 1996, ANN NEUROL, V40, P767, DOI 10.1002/ana.410400513; HOFMANN K, 1994, GENOMICS, V24, P20, DOI 10.1006/geno.1994.1577; JELLINGER K, 1990, ADV NEUROL, V53, P1; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Mark MH, 1996, ADV NEUROL, V69, P315; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OTT J, 1986, GENET EPIDEMIOL, P251; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; VIEREGGE P, 1994, J NEURAL TRANSM-PARK, V8, P1, DOI 10.1007/BF02250916; WARD CD, 1990, ADV NEUROL, V53, P245; Wood N, 1997, J NEUROL NEUROSUR PS, V62, P305, DOI 10.1136/jnnp.62.4.305; Wszolek Z K, 1997, Parkinsonism Relat Disord, V3, P125, DOI 10.1016/S1353-8020(97)00013-8; WSZOLEK ZK, 1995, NEUROLOGY, V45, P502, DOI 10.1212/WNL.45.3.502; WSZOLEK ZK, 1993, NERVENARZT, V64, P331	29	382	394	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1998	18	3					262	265		10.1038/ng0398-262	http://dx.doi.org/10.1038/ng0398-262			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500549				2022-12-25	WOS:000072325000025
J	Goh, WC; Rogel, ME; Kinsey, CM; Michael, SF; Fultz, PN; Nowak, MA; Hahn, BH; Emerman, M				Goh, WC; Rogel, ME; Kinsey, CM; Michael, SF; Fultz, PN; Nowak, MA; Hahn, BH; Emerman, M			HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; RHESUS-MONKEYS; TYPE-1; GENE; INFECTION; PROTEIN; ARRESTS; G(2); DNA	The human immunodeficiency virus type 1 (HIV-1) encodes a protein, called Vpr, that prevents proliferation of infected cells by arresting them G(2) of the cell cycle. This Vpr-mediated cell-cycle arrest is also conserved among highly divergent simian immunodeficiency viruses, suggesting an important role in the virus life cycle. However, it has been unclear how this could be a selective advantage for the virus. Here we provide evidence that expression of the viral genome is optimal in the G(2) phase of the cell cycle, and that Vpr increases virus production by delaying cells at the point of the cell cycle where the long terminal repeat (LTR) is most active. Although Vpr is selected against when virus is adapted to tissue culture, we show that selection for Vpr function in vivo occurs in both humans and chimpanzees infected with HIV-1. These results suggest a novel mechanism for maximizing virus production in the face of rapid killing of infected target cells.	Fred Hutchinson Canc Res Ctr, Div Mol Med, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Oxford	Emerman, M (corresponding author), Fred Hutchinson Canc Res Ctr, Div Mol Med, Suite C2-023,1100 Fairview Ave N, Seattle, WA 98109 USA.		Nowak, Martin A/A-6977-2008	Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034748, R37AI030927, R01AI030927] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34748, AI 30927] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Aldrovandi GM, 1996, J VIROL, V70, P1505, DOI 10.1128/JVI.70.3.1505-1511.1996; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOCH J, 1995, J VIROL, V69, P4807, DOI 10.1128/JVI.69.8.4807-4813.1995; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; Lu MS, 1996, J VIROL, V70, P8850, DOI 10.1128/JVI.70.12.8850-8857.1996; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYERS G, 1994, HUMAN RETROVIRUSES A; NAKAYA T, 1994, FEBS LETT, V354, P17, DOI 10.1016/0014-5793(94)01074-9; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, BIOTECHNIQUES, V14, P70; PLANELLES V, 1995, J VIROL, V69, P5883, DOI 10.1128/JVI.69.9.5883-5889.1995; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; REITZ MS, 1994, AIDS RES HUM RETROV, V10, P1143, DOI 10.1089/aid.1994.10.1143; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sharp PM, 1996, NATURE, V383, P586, DOI 10.1038/383586a0; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Stivahtis GL, 1997, J VIROL, V71, P4331, DOI 10.1128/JVI.71.6.4331-4338.1997; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISS SH, 1988, SCIENCE, V239, P68, DOI 10.1126/science.3336776; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	39	432	436	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					65	71		10.1038/nm0198-065	http://dx.doi.org/10.1038/nm0198-065			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427608				2022-12-25	WOS:000072249700036
J	Jhappan, C; Morse, HC; Fleischmann, RD; Gottesman, MM; Merlino, G				Jhappan, C; Morse, HC; Fleischmann, RD; Gottesman, MM; Merlino, G			DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus	NATURE GENETICS			English	Article							DEPENDENT PROTEIN-KINASE; SEVERE COMBINED IMMUNODEFICIENCY; STRAND-BREAK-REPAIR; ATAXIA-TELANGIECTASIA GENE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; TRANSGENIC MICE; MUTATION; PHOSPHODIESTERASE; REQUIREMENT	Severe combined immunodeficiency (SCID) mice(1) are defective in their ability to rearrange their variable (V), diversity (D) and joining (J) genetic elements to generate functional immuno-globulin tig) and T-cell receptor (TCR) molecules; as a result, they lack mature B and T cells(2). These mice are highly sensitive to ionizing radiation, suggesting that the product of the scid gene plays a critical role in both V(D)I recombination and DNA double-strand break repair(3-5). Recent studies suggest that the SCID defect lies in the gene encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PK; refs 6-8), a nuclear protein made up of the Ku 70 and Ku 86 subunits as well as the large catalytic subunit, DNA-PKcs(9,10). Other reports have implied that the SCID phenotype correlates with nonsense mutations at the extreme 3' end of Prkdc, the DNA-PKcs gene(11-14). The identity of the gene remains in doubt, however, because the consequences of genetic inactivation of Prkdc have not been determined. This study shows that complete inactivation of Prkdc in a novel insertional mouse mutant recapitulates the SCID phenotype and that Prkdc and scid are allelic, Significantly, DNA-PKcs null mice demonstrate complete penetrance of thymic lymphoblastic lymphomas, strongly suggesting that Prkdc functions in mice as a T-cell tumour suppressor and, by virtue of its association with DNA repair and recombination, belongs to the 'caretaker' class of tumour-suppressor genes that includes ATM, BRCA1 and BRCA2 (ref. 15).	NIAID,IMMUNOPATHOL LAB,NIH,BETHESDA,MD 20892; NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jhappan, C (corresponding author), NCI,MOL BIOL LAB,NIH,37 CONVENT DR,BETHESDA,MD 20892, USA.			Morse, Herbert/0000-0002-9331-3705				Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CARROLL AM, 1989, J IMMUNOL, V143, P1087; CUSTER RP, 1985, AM J PATHOL, V120, P464; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin EK, 1997, J IMMUNOL, V158, P3565; STRADA SJ, 1984, ADV CYCLIC NUCL PROT, V16, P13; SUORANTA K, 1984, J BIOL CHEM, V259, P6964; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	30	118	120	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					483	486		10.1038/ng1297-483	http://dx.doi.org/10.1038/ng1297-483			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398856				2022-12-25	WOS:A1997YJ92400035
J	Lieber, A; He, CY; Kay, MA				Lieber, A; He, CY; Kay, MA			Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo	NATURE BIOTECHNOLOGY			English	Article						gene therapy; episomal vectors	PRECURSOR TERMINAL PROTEIN; CRE-MEDIATED EXCISION; NUCLEAR MATRIX; GENE-THERAPY; LIVER-REGENERATION; CELL-LINES; HEPATOCYTES; DYSTROPHIN; ANTIGENS; VECTORS	In the absence of host immunity, nonintegrating, first-generation adenoviral vectors remain stable in the nucleus of quiescent transduced cells in mice. A mini-adenoviral genome (9 kb) deleted for viral El, E2, E3, and late genes, but containing the viral inverted terminal repeats (ITRs), transgene expression cassette (human alpha(1)-antitrypsin), and the viral E4 genes was equally efficient at transducing cells in vitro or in vivo as first generation, E1-deleted vectors. In contrast to a first generation vector, gene expression as well as vector DNA was short-lived in cells transduced with the deleted adenoviral genome. We demonstrate that coexpression of the adenoviral E2-preterminal protein from the vector or in trans stabilizes the mini-genome in vitro and in vivo without evidence of cellular toxicity.	UNIV WASHINGTON, DEPT MED, DIV MED GENET, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle				Lieber, Andre/0000-0001-6742-6266; Kay, Mark/0000-0002-2799-2615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049022] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49022] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angeletti PC, 1996, J VIROL, V70, P3060, DOI 10.1128/JVI.70.5.3060-3067.1996; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BODNAR JW, 1989, J VIROL, V63, P4344, DOI 10.1128/JVI.63.10.4344-4353.1989; Boucher RC, 1996, TRENDS GENET, V12, P81, DOI 10.1016/0168-9525(96)81410-7; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FREDMAN JN, 1993, J VIROL, V67, P3384, DOI 10.1128/JVI.67.6.3384-3395.1993; GERTZENBERG RH, 1991, J CELL BIOCHEM, V47, P289; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HAY RT, 1995, MOL REPERTOIRE ADENO, V2, P31; KAY MA, 1995, HEPATOLOGY, V21, P815, DOI 10.1002/hep.1840210331; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; KumarSingh R, 1996, HUM MOL GENET, V5, P913, DOI 10.1093/hmg/5.7.913; Langer SJ, 1996, VIROLOGY, V221, P172, DOI 10.1006/viro.1996.0363; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; LIEBER A, 1995, HUM GENE THER, V6, P1029, DOI 10.1089/hum.1995.6.8-1029; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NELSON J, 1997, IN PRESS J VIROL; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Parks RJ, 1997, J VIROL, V71, P3293, DOI 10.1128/JVI.71.4.3293-3298.1997; Peeters MJTFDV, 1996, BIOTECHNIQUES, V20, P278; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; SCHAACK J, 1995, J VIROL, V69, P4079, DOI 10.1128/JVI.69.7.4079-4085.1995; Schowalter DB, 1997, GENE THER, V4, P351, DOI 10.1038/sj.gt.3300398; SHENK T, 1996, VIROLOGY, V2, P211; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; VANDEWATERBEEMD H, 1995, METH PRIN MED CHEM, V2, P1; WONG ML, 1989, NUCLEIC ACIDS RES, V17, P3535, DOI 10.1093/nar/17.9.3535; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Zhou HS, 1996, J VIROL, V70, P7030, DOI 10.1128/JVI.70.10.7030-7038.1996	30	35	46	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1383	1387		10.1038/nbt1297-1383	http://dx.doi.org/10.1038/nbt1297-1383			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415891				2022-12-25	WOS:A1997YK36100030
J	Weck, KE; Dal Canto, AJ; Gould, JD; O'Guin, AK; Roth, KA; Saffitz, JE; Speck, SH; Virgin, HW				Weck, KE; Dal Canto, AJ; Gould, JD; O'Guin, AK; Roth, KA; Saffitz, JE; Speck, SH; Virgin, HW			Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: A new model for virus-induced vascular disease	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; INFECTED ENDOTHELIAL-CELLS; CYTOMEGALOVIRUS-INFECTION; T-CELLS; TARGETED DISRUPTION; CORONARY-ARTERIES; APOLIPOPROTEIN-E; DEFICIENT MICE; SIMPLEX VIRUS; ATHEROSCLEROSIS	Fundamental issues remain unresolved regarding the possible contribution of viruses to vascular pathology, as well as the role of the immune system in regulating these processes. Here we demonstrate that infection of mice with gamma-herpesvirus 68 (gamma HV68) provides a novel model for addressing these issues. Interferon-gamma receptor-deficient (IFN gamma R-/-) mice died weeks to months after gamma HV68 infection from a severe large-vessel panarteritis. gamma HV68-infected B cell-deficient and normal weanling mice exhibited milder large-vessel arteritis. Immunohistochemical analyses demonstrated gamma HV68 antigen in arteritic lesions and revealed a striking tropism of gamma HV68 for smooth muscle cells. These studies demonstrate that IFN-gamma is essential for control of chronic vascular pathology induced by gamma HV68 and suggest gamma-herpesviruses as candidate etiologic agents for human vasculitis.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Virgin, HW (corresponding author), Washington Univ, Sch Med, Ctr Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Speck, Samuel/L-5893-2019	Roth, Kevin/0000-0002-0643-995X; Virgin, Herbert/0000-0001-8580-7628	NCI NIH HHS [CA 74730] Funding Source: Medline; NIAID NIH HHS [AI 39616, 1 K08 AI01279-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA074730, R01CA074730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039616, K08AI001279] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BLASKOVIC D, 1980, ACTA VIROL, V24, P468; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DANGLER CA, 1995, VET PATHOL, V32, P127, DOI 10.1177/030098589503200205; DUMMER S, 1994, J MED VIROL, V44, P305, DOI 10.1002/jmv.1890440316; Dutia BM, 1997, J VIROL, V71, P4278, DOI 10.1128/JVI.71.6.4278-4283.1997; EHTISHAM S, 1993, J VIROL, V67, P5247, DOI 10.1128/JVI.67.9.5247-5252.1993; ETINGIN OR, 1990, CELL, V61, P657, DOI 10.1016/0092-8674(90)90477-V; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FABRICANT CG, 1981, AM J PATHOL, V105, P176; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; GREENE NB, 1986, CHEST, V89, P605, DOI 10.1378/chest.89.4.605; HANSSON GK, 1989, J EXP MED, V170, P1595, DOI 10.1084/jem.170.5.1595; HENDRIX MGR, 1989, AM J PATHOL, V134, P1151; HENDRIX MGR, 1990, AM J PATHOL, V136, P23; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; HSU HY, 1995, J BIOL CHEM, V270, P19630, DOI 10.1074/jbc.270.33.19630; KERR GS, 1995, RHEUM DIS CLIN N AM, V21, P1041; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LIBBY P, 1991, LAB INVEST, V64, P5; LIE JT, 1987, PATHOL ANNU, V22, P125; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; MELNICK JL, 1995, BIOESSAYS, V17, P899, DOI 10.1002/bies.950171012; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MISTRIKOVA J, 1985, ACTA VIROL, V29, P312; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PERSOONS MCJ, 1994, CIRC RES, V75, P214, DOI 10.1161/01.RES.75.2.214; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RazaAhmad A, 1995, CAN J CARDIOL, V11, P1025; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sarawar SR, 1996, J VIROL, V70, P3264, DOI 10.1128/JVI.70.5.3264-3268.1996; Sarawar SR, 1997, J VIROL, V71, P3916, DOI 10.1128/JVI.71.5.3916-3921.1997; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051; SHIH JCH, 1989, J NUTR, V119, P294, DOI 10.1093/jn/119.2.294; SHIH JCH, 1995, ADV EXP MED BIOL, V369, P89; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; SIEGEL RJ, 1993, CARDIOVASCULAR DISOR, P517; SORLIE PD, 1994, J MED VIROL, V42, P33, DOI 10.1002/jmv.1890420107; STEMME S, 1994, ANN MED, V26, P141, DOI 10.3109/07853899409147881; STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P2347, DOI 10.1099/0022-1317-73-9-2347; SUNILCHANDRA NP, 1994, AM J PATHOL, V145, P818; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P3275, DOI 10.1099/0022-1317-73-12-3275; TANAKA S, 1992, J VASC SURG, V16, P274, DOI 10.1016/0741-5214(92)90118-R; TSUKADA T, 1987, AM J PATHOL, V126, P51; Usherwood EJ, 1996, J GEN VIROL, V77, P2819, DOI 10.1099/0022-1317-77-11-2819; VANDAMMIERAS MCE, 1992, THROMB HAEMOSTASIS, V68, P364; VIRGIN HW, 1991, J VIROL, V65, P6772, DOI 10.1128/JVI.65.12.6772-6781.1991; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; VISSER MR, 1993, EUR HEART J, V14, P39; Weck KE, 1996, J VIROL, V70, P6775, DOI 10.1128/JVI.70.10.6775-6780.1996; YAMASHIROYA HM, 1988, AM J PATHOL, V130, P71; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	60	180	186	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1997	3	12					1346	1353		10.1038/nm1297-1346	http://dx.doi.org/10.1038/nm1297-1346			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396604				2022-12-25	WOS:000072249500030
J	Neri, D; Carnemolla, B; Nissim, A; Leprini, A; Querze, G; Balza, E; Pini, A; Tarli, L; Halin, C; Neri, P; Zardi, L; Winter, G				Neri, D; Carnemolla, B; Nissim, A; Leprini, A; Querze, G; Balza, E; Pini, A; Tarli, L; Halin, C; Neri, P; Zardi, L; Winter, G			Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; single-chain antibody; oncofetal protein	SINGLE-CHAIN FV; ESCHERICHIA-COLI; FILAMENTOUS PHAGE; MESSENGER-RNA; PROTEINS; IMMUNIZATION; INVOLVEMENT; TECHNOLOGY; LIBRARY; SURFACE	The oncofetal fibronectin (B-FN) isoform is present in vessels of neoplastic tissues during angiogenesis but not in mature vessels, B-FN could therefore provide a target for diagnostic imaging and therapy of cancer, Phage display libraries have been used to isolate human antibody fragments with pan-species recognition of this isoform, We describe the use of these fragments in nude mice to target an aggressive tumor (grafted Fg murine teratocarcinoma). Imaging in real time was done by infrared photodetection of a chemically coupled fluorophore, The targeting was improved by use of affinity-matured fragments with law kinetic dissociation rates (k(off)=1.5x10(-4) s(-1)) and also by engineering dimeric fragments via a C-terminal amphipathic helix.	Univ Cambridge, Ctr Mrc, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England; ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Ist Nazl Ric Canc, Lab Biol Cellulare, I-16132 Genoa, Italy; Univ Siena, Dipartimento Biol Mol, Ctr Didatt Loc Scotte, I-53100 Siena, Italy	University of Cambridge; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Genoa; IRCCS AOU San Martino IST; University of Siena	Neri, D (corresponding author), Univ Cambridge, Ctr Mrc, Cambridge Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.		Neri, Dario/P-4368-2016; Pini, Alessandro/R-1359-2018	Neri, Dario/0000-0001-5234-7370; Pini, Alessandro/0000-0002-3832-8349; Halin, Cornelia/0000-0002-7899-2850				ADAMS GP, 1993, CANCER RES, V53, P4026; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; Berkower I, 1996, CURR OPIN BIOTECH, V7, P622, DOI 10.1016/S0958-1669(96)80073-5; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CASEY JL, 1995, J IMMUNOL METHODS, V179, P105, DOI 10.1016/0022-1759(94)00278-5; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLLI S, 1994, CANCER RES, V54, P2643; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GEORGE AJT, 1995, P NATL ACAD SCI USA, V92, P8358, DOI 10.1073/pnas.92.18.8358; Gibson T., 1984, THESIS U CAMBRIDGE C; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Hu SZ, 1996, CANCER RES, V56, P3055; HUANG H, 1997, SCIENCE, V275, P547; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KING DJ, 1994, CANCER RES, V54, P6176; LIBERATORE M, 1995, EUR J NUCL MED, V22, P1326, DOI 10.1007/BF00801622; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; MALONEY DG, 1994, BLOOD, V84, P2457; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Neri D, 1996, BIOTECHNIQUES, V20, P708; NERI D, 1996, NAT BIOTECHNOL, V14, P385; NERI D, 1997, IN PRESS THERAPY MAL; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PACK P, 1993, BIO-TECHNOL, V11, P1271; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Peters JH, 1996, CELL ADHES COMMUN, V4, P127, DOI 10.3109/15419069609010767; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; RIVA P, 1994, CANCER-AM CANCER SOC, V73, P1076, DOI 10.1002/1097-0142(19940201)73:3+<1076::AID-CNCR2820731347>3.0.CO;2-Z; SCHNEIDERGADICKE E, 1995, EUR J CANCER, V31A, P1326, DOI 10.1016/0959-8049(95)00279-R; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YOKOTA T, 1992, CANCER RES, V52, P3402	46	247	295	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1271	1275		10.1038/nbt1197-1271	http://dx.doi.org/10.1038/nbt1197-1271			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359110				2022-12-25	WOS:000071342000029
J	PetrijBosch, A; Peelen, T; vanVliet, M; vanEijk, R; Olmer, R; Drusedau, M; Hogervorst, FBL; Hageman, S; Arts, PJW; Ligtenberg, MJL; MeijersHeijboer, H; Klijn, JGM; Vasen, HFA; Cornelisse, CJ; vantVeer, LJ; Bakker, E; vanOmmen, GJB; Devilee, P				PetrijBosch, A; Peelen, T; vanVliet, M; vanEijk, R; Olmer, R; Drusedau, M; Hogervorst, FBL; Hageman, S; Arts, PJW; Ligtenberg, MJL; MeijersHeijboer, H; Klijn, JGM; Vasen, HFA; Cornelisse, CJ; vantVeer, LJ; Bakker, E; vanOmmen, GJB; Devilee, P			BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients	NATURE GENETICS			English	Article							EARLY-ONSET BREAST; OVARIAN-CANCER; FAMILIES; GENE	To date, more than 300 distinct small deletions, insertions and point mutations, mostly leading to premature termination of translation(1), have been reported in the breast/ovarian-cancer susceptibility gene BRCA1. The elevated frequencies of some mutations in certain ethnic subpopulations(2-4) are caused by founder effects(5,6), rather than by mutation hotspots. Here we report that the currently available mutation spectrum of BRCA1 has been biased by PCR-based mutation-screening methods, such as SSCP, the protein truncation test (PTT) and direct sequencing, using genomic DNA as template. Three large genomic deletions that are not detected by these approaches comprise 36% of all BRCA1 mutations found in Dutch breast-cancer families to date. A 510-bp Alu-mediated deletion comprising exon 22 was found in 8 of 170 breast-cancer families recruited for research purposes and in 6 of 49 probands referred to the Amsterdam Family Cancer Clinic for genetic counselling. In addition, a 3,835-bp Alu-mediated deletion encompassing exon 13 was detected in 6 of the 170 research families, while an deletion of approximately 14 kb was detected in a single family. Haplotype analyses indicated that each recurrent deletion had a single common ancestor.	LEIDEN UNIV,MED CTR,DEPT HUMAN GENET,NL-2300 RA LEIDEN,NETHERLANDS; LEIDEN UNIV,MED CTR,DEPT PATHOL,NL-2300 RA LEIDEN,NETHERLANDS; NETHERLANDS CANC INST,DEPT PATHOL,NL-1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,FAMILY CANC CTR,NL-1066 CX AMSTERDAM,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT HUMAN GENET,NL-6500 HB NIJMEGEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; DR DANIEL DEN HOED CANC CTR,NL-3008 AE ROTTERDAM,NETHERLANDS; FAMILY CANC CTR,ROTTERDAM,NETHERLANDS; FDN DETECT HEREDITARY TUMOURS,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; Netherlands Cancer Institute; Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute			Ligtenberg, Marjolijn/N-9666-2013; DEVILEE, PETER/ABR-2140-2022; Bakker, Egbert/D-3525-2009	Ligtenberg, Marjolijn/0000-0003-1290-1474; Bakker, Egbert/0000-0002-2843-7357; Vasen, Hans/0000-0003-2682-2603				Caligo MA, 1996, ONCOGENE, V13, P1483; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; Durocher F, 1996, J MED GENET, V33, P814, DOI 10.1136/jmg.33.10.814; EASTON DF, 1993, AM J HUM GENET, V52, P678; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Hamann U, 1997, GENE CHROMOSOME CANC, V18, P126, DOI 10.1002/(SICI)1098-2264(199702)18:2<126::AID-GCC7>3.3.CO;2-O; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; INOUE R, 1995, CANCER RES, V55, P3521; Katagiri T, 1996, HUM MUTAT, V7, P334, DOI 10.1002/(SICI)1098-1004(1996)7:4<334::AID-HUMU7>3.0.CO;2-8; NAROD SA, 1995, AM J HUM GENET, V56, P254; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; Peelen T, 1997, AM J HUM GENET, V60, P1041; Peelen T, 1996, EUR J HUM GENET, V4, P225; Puget N, 1997, CANCER RES, V57, P828; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Szabo CI, 1997, AM J HUM GENET, V60, P1013; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A	25	350	360	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					341	345		10.1038/ng1197-341	http://dx.doi.org/10.1038/ng1197-341			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354803	Green Published			2022-12-25	WOS:A1997YD66700033
J	Czubayko, F; LiaudetCoopman, EDE; Aigner, A; Tuveson, AT; Berchem, GJ; Wellstein, A				Czubayko, F; LiaudetCoopman, EDE; Aigner, A; Tuveson, AT; Berchem, GJ; Wellstein, A			A secreted FGF-binding protein can serve as the angiogenic switch in human cancer	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; FACTOR PLEIOTROPHIN; METASTASIS; EXPRESSION; TUMORIGENESIS; CLONING; LINE	The growth and metastatic spread of cancer is directly related to tumor angiogenesis(1), and the driving factors need to be understood to exploit this process therapeutically(2,3). However, tumor cells and their normal stroma express a multitude of candidate angiogenic factors(2), and very few specific inhibitors have been generated to assess which of these gene products are only innocent bystanders and which contribute significantly to tumor angiogenesis(4-6) and metastasis(6-8). Here we investigated whether the expression in tumors of a secreted fibroblast growth factor (FGF)-binding protein (FGF-BP)(9) that mobilizes and activates(10) locally stored FGFs (ref. 11) can serve as an angiogenic switch molecule(3). Developmental expression of the retinoid-regulated FGF-BP gene(12) is prominent in the skin and intestine during the perinatal phase and is down-modulated in the adult(13). The gene is, however, upregulated in carcinogen-induced skin tumors(13), in squamous cell carcinoma (SCC)(10) and in some colon cancer cell lines and tumor samples. To assess the significance of FGF-BP expression in tumors, we depleted human SCC (ME-180) and colon carcinoma (LS174T) cell lines of their endogenous FGF-BP by targeting with specific ribozymes. We found that the reduction of FGF-BP reduced the release of biologically active basic FCF (bFGF) from cells in culture. Furthermore, the growth and angiogenesis of xenograft tumors in mice was decreased in parallel with the reduction of FGF-BP. This suggests that human tumors can utilize FGF-BP as an angiogenic switch molecule.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University			Berchem, Guy/C-9364-2014; Aigner, Achim/R-4429-2017; Liaudet-Coopman, Emmanuelle/N-4744-2017	Berchem, Guy/0000-0003-0157-2257; Aigner, Achim/0000-0002-2778-6256; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASANO M, 1995, CANCER RES, V55, P5296; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN CJ, 1992, NUCLEIC ACIDS RES, V20, P4581, DOI 10.1093/nar/20.17.4581; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; KUAN SF, 1987, CANCER RES, V47, P5715; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1995, AM J PATHOL, V147, P9; WU DQ, 1991, J BIOL CHEM, V266, P16778	20	201	213	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1137	1140		10.1038/nm1097-1137	http://dx.doi.org/10.1038/nm1097-1137			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334727				2022-12-25	WOS:A1997XZ28700041
J	Simon, DB; Bindra, RS; Mansfield, TA; NelsonWilliams, C; Mendonca, E; Stone, R; Schurman, S; Nayir, A; Alpay, H; Bakkaloglu, A; RodriguezSoriano, J; Morales, JM; Sanjad, SA; Taylor, CM; Pilz, D; Brem, A; Trachtman, H; Griswold, W; Richard, GA; John, E; Lifton, RP				Simon, DB; Bindra, RS; Mansfield, TA; NelsonWilliams, C; Mendonca, E; Stone, R; Schurman, S; Nayir, A; Alpay, H; Bakkaloglu, A; RodriguezSoriano, J; Morales, JM; Sanjad, SA; Taylor, CM; Pilz, D; Brem, A; Trachtman, H; Griswold, W; Richard, GA; John, E; Lifton, RP			Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III	NATURE GENETICS			English	Article							EPITHELIAL SODIUM-CHANNEL; THICK ASCENDING LIMB; HYPOKALEMIC ALKALOSIS; MOLECULAR-GENETICS; HUMAN HYPERTENSION; HENLE LOOP; KIDNEY; DNA; COTRANSPORTER; HETEROGENEITY	Analysis of patients with inherited hypokalaemic alkalosis resulting from salt-wasting has proved fertile ground for identification of essential elements of renal salt homeostasis and blood-pressure regulation. We now demonstrate linkage of this phenotype to a segment of chromosome 1 containing the gene encoding a renal chloride channel, CLCNKB. Examination of this gene reveals loss-of-function mutations that impair renal chloride reabsorption in the thick ascending limb of Henle's loop. Mutations in seventeen kindreds have been identified, and they include large deletions and nonsense and missense mutations. Some of the deletions are shown to have arisen by unequal crossing over between CLCNKB and the nearby related gene, CLCNKA. Patients who harbour CLCNKB mutations are characterized by hypokalaemic alkalosis with salt-wasting, low blood pressure, normal magnesium and hyper-or normocalciuria; they define a distinct subset of patients with Bartter's syndrome in whom nephrocalcinosis is absent. These findings demonstrate the critical role of CLCNKB in renal salt reabsorption and blood-pressure homeostasis, and demonstrate the potential role of specific CLCNKB antagonists as diuretic antihypertensive agents.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,BOYER CTR MOL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOYER CTR MOL MED,NEW HAVEN,CT 06510; HOSP SANTA MARIA,UNIDADE NEFROL PEDIAT,LISBON,PORTUGAL; UNIV S FLORIDA,ALL CHILDRENS HOSP,DEPT PEDIAT,ST PETERSBURG,FL 33701; UNIV ISTANBUL,DEPT PEDIAT NEPHROL,ISTANBUL,TURKEY; HACETTEPE UNIV,CHILDRENS HOSP,DEPT PEDIAT NEPHROL,ANKARA,TURKEY; HOSP CRUCES,DEPT PEDIAT,BARACALDO,SPAIN; HOSP UNIV 12 OCTUBRE,DEPT MED,MADRID,SPAIN; KING FAISAL SPECIALIST HOSP & RES CTR,DEPT PEDIAT,RIYADH 11211,SAUDI ARABIA; CHILDRENS HOSP,DEPT NEPHROL,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND; UNIV WALES HOSP,INST MED GENET,CARDIFF CF4 4XW,S GLAM,WALES; RHODE ISL HOSP,DEPT PEDIAT NEPHROL,PROVIDENCE,RI 02903; SCHNEIDER CHILDRENS HOSP,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,NEW HYDE PK,NY 11040; CHILDRENS HOSP SAN DIEGO,DEPT PEDIAT,SAN DIEGO,CA 92123; UNIV FLORIDA,DEPT PEDIAT,GAINESVILLE,FL 32610; UNIV ILLINOIS,DEPT PEDIAT,CHICAGO,IL 60612	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Universidade de Lisboa; Hospital Santa Maria; State University System of Florida; University of South Florida; Istanbul University; Hacettepe University; Hospital Universitario Cruces; Hospital Universitario 12 de Octubre; King Faisal Specialist Hospital & Research Center; Cardiff University; Lifespan Health Rhode Island; Rhode Island Hospital; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Yeshiva University; State University System of Florida; University of Florida; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Stone, Rosario/0000-0002-7939-836X				ADACHI S, 1994, J BIOL CHEM, V269, P17677; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BETTINELLI A, 1992, J PEDIATR-US, V120, P38, DOI 10.1016/S0022-3476(05)80594-3; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; GILL JR, 1978, AM J MED, V65, P766, DOI 10.1016/0002-9343(78)90794-5; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; JENTSCH TJ, 1996, BIOESSAYS, V19, P117; JORGENSEN PL, 1980, PHYSIOL REV, V60, P864; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; MATSUMOTO J, 1989, AM J ROENTGENOL, V152, P1251, DOI 10.2214/ajr.152.6.1251; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OTT J, 1985, ANAL HUMAN GENETIC L; Reeves W B, 1994, Adv Nephrol Necker Hosp, V23, P177; SaitoOhara F, 1996, GENOMICS, V36, P372, DOI 10.1006/geno.1996.0479; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; VANDEWALLE A, 1995, AM J PHYSIOL, V272, pF678; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436	28	685	722	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					171	178		10.1038/ng1097-171	http://dx.doi.org/10.1038/ng1097-171			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326936				2022-12-25	WOS:A1997XZ55500022
J	Varley, AW; Geiszler, SM; Gaynor, RB; Munford, RS				Varley, AW; Geiszler, SM; Gaynor, RB; Munford, RS			A two-component expression system that responds to inflammatory stimuli in vivo	NATURE BIOTECHNOLOGY			English	Article						gene therapy; inflammatory response; acute phase response	TUMOR-NECROSIS-FACTOR; ADENOVIRUS-MEDIATED TRANSFER; GENE-EXPRESSION; TAT PROTEIN; MICE; ACTIVATION; BLOCKADE; THERAPY	A therapeutic dilemma often complicates the management of inflammatory diseases; the benefits gained from reducing inflammation must be balanced against the potentially harmful consequences of chronic immunosuppression. Gene therapy might address this dilemma by producing anti-inflammatory proteins in response to a patient's endogenous signals, so that recombinant drug production is linked to the intensity and duration of the inflammatory condition. To test this, we have developed inflammation-inducible systems for regulating recombinant protein production in vivo. We describe a two-component expression construct in which (1) the murine complement factor 3 (C3) promoter regulates production of the human immunodeficiency virus (HIV) transactivator of transcription (Tat), and (2) the Tat protein then stimulates protein expression from genes inserted downstream of the the HIV promoter. When incorporated into a nonreplicating adenovirus (Ad.CS-tat/HIV-luc) and studied in a murine model, the construct produces large amounts of recombinant protein in vivo in response to two different inflammatory stimuli.	UNIV TEXAS,SW MED CTR,MOL HOST DEF LAB,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DIV MOL VIROL,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIAID NIH HHS [AI38596] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038596] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Brigham K L, 1995, New Horiz, V3, P321; CONARY JT, 1994, J CLIN INVEST, V93, P1834, DOI 10.1172/JCI117169; Coulthard MG, 1996, INFECT IMMUN, V64, P1510, DOI 10.1128/IAI.64.5.1510-1515.1996; Fantuzzi G, 1996, J LEUKOCYTE BIOL, V59, P489, DOI 10.1002/jlb.59.4.489; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GERARD RD, 1995, DNA CLONING PRACTICA, P285; Greenberger MJ, 1996, J IMMUNOL, V157, P3006; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUARD J, 1995, GENE THER, V2, P107; KAWAMURA N, 1992, BIOCHEM J, V283, P705, DOI 10.1042/bj2830705; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; KOLLS JK, 1995, J INFECT DIS, V171, P570, DOI 10.1093/infdis/171.3.570; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; OU SHI, 1995, RETROVIRIDAE, V4, P97; ROGY MA, 1995, J EXP MED, V181, P2289, DOI 10.1084/jem.181.6.2289; SALKOWSKI CA, 1995, J IMMUNOL, V155, P3168; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; VARLEY AW, 1995, P NATL ACAD SCI USA, V92, P5346, DOI 10.1073/pnas.92.12.5346; Verhoef K, 1996, VIROLOGY, V225, P316, DOI 10.1006/viro.1996.0606; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	25	31	32	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					1002	1006		10.1038/nbt1097-1002	http://dx.doi.org/10.1038/nbt1097-1002			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335054				2022-12-25	WOS:A1997XZ28500033
J	Masuzaki, H; Ogawa, Y; Sagawa, N; Hosoda, K; Matsumoto, T; Mise, H; Nishimura, H; Yoshimasa, Y; Tanaka, I; Mori, T; Nakao, K				Masuzaki, H; Ogawa, Y; Sagawa, N; Hosoda, K; Matsumoto, T; Mise, H; Nishimura, H; Yoshimasa, Y; Tanaka, I; Mori, T; Nakao, K			Nonadipose tissue production of leptin: Leptin as a novel placenta-derived hormone in humans	NATURE MEDICINE			English	Article							OBESE GENE; MESSENGER-RNA; EXPRESSION; WEIGHT; CLONING; PROTEIN; CELLS; MICE	Leptin is a circulating hormone that is expressed abundantly and specifically in the adipose tissue(1-5). It is involved in the regulation of energy homeostasis, as well as the neuroendocrine and reproductive systems(6-11). Here, we demonstrate production of leptin by nonadipose tissue, namely, placental trophoblasts and amnion cells from uteri of pregnant women. We show that pregnant women secrete a considerable amount of leptin from the placenta into the maternal circulation as compared with nonpregnant obese women. Leptin production was also detected in a cultured human choriocarcinoma cell line, BeWo cells, and was augmented during the course of forskolin-induced differentiation of cytotrophoblasts into syncytiotrophoblasts. Plasma leptin levels were markedly elevated in patients with hydatidiform mole or choriocarcinoma and were reduced after surgical treatment or chemotherapy. Leptin is also produced by primary cultured human amnion cells and is secreted into the amniotic fluid. The present study provides evidence for leptin as a novel placenta-derived hormone in humans and suggests the physiologic and pathophysiologic significance of leptin in normal pregnancy and gestational trophoblastic neoplasms.	KYOTO UNIV,GRAD SCH MED,DEPT MED & CLIN SCI,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,GRAD SCH MED,DEPT GYNECOL & OBSTET,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,GRAD SCH HUMAN & ENVIRONM STUDIES,OTSUKA DEPT INT PREVENT NUTR MED,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University; Kyoto University				Ogawa, Yoshihiro/0000-0002-0834-2836				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BURRES NS, 1987, CANCER RES, V47, P5059; Butte NF, 1997, J CLIN ENDOCR METAB, V82, P585, DOI 10.1210/jc.82.2.585; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALLAS JL, 1995, SCIENCE, V269, P543; Hosoda K, 1996, BIOCHEM BIOPH RES CO, V221, P234, DOI 10.1006/bbrc.1996.0579; ITOH H, 1993, J CLIN ENDOCR METAB, V76, P907, DOI 10.1210/jc.76.4.907; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SANFILIPPO JS, 1987, HUMAN PLACENTA, P179; Satoh N, 1997, ENDOCRINOLOGY, V138, P947, DOI 10.1210/en.138.3.947; WICE B, 1990, EXP CELL RES, V186, P306, DOI 10.1016/0014-4827(90)90310-7; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	21	1003	1045	0	85	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1029	1033		10.1038/nm0997-1029	http://dx.doi.org/10.1038/nm0997-1029			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288733				2022-12-25	WOS:A1997XT84200039
J	Lee, Y; Yin, J				Lee, Y; Yin, J			Detection of evolving viruses	NATURE BIOTECHNOLOGY			English	Article						natural selection; fitness; population heterogeneity; bacteriophage replication; plaque morphology; image analysis	GROWING PLAQUE; RESISTANT; RNA; REPLICATION; EVOLUTION; POPULATION; SELECTION; VARIANTS; MODEL; WAVES	The spread of viruses on a homogeneous lawn of receptive hosts provides an opportunity to detect the dynamics of their evolution. We have previously found that when repeated virus passages are confined to the expanding perimeter of a growing plaque, the appearance and outgrowth of genetically diverse strains (all descended from the same parent strain) can be traced along different radii of the plaque. As a plaque grows, the random mutation and selection of new fast-growing strains reduce the roundness or circularity of the growing plaque. Here we have quantified such changes in growing plaques of bacteriophage T7 using a digital imaging system. We find that T7 populations not adapted for fast growth exhibit a broader diversity of growth rates than populations adapted for fast growth. These results provide a foundation for understanding how viruses exploit mutation and selection processes to persist in nature.	DARTMOUTH COLL,THAYER SCH ENGN,BIOTECHNOL & BIOCHEM ENGN PROGRAM,HANOVER,NH 03755	Dartmouth College				Yin, John/0000-0001-6146-0594				Adams MH, 1959, BACTERIOPHAGES; BAUER GJ, 1989, P NATL ACAD SCI USA, V86, P7937, DOI 10.1073/pnas.86.20.7937; BUONAGURIO DA, 1986, SCIENCE, V232, P980, DOI 10.1126/science.2939560; BUYNAK EB, 1966, P SOC EXP BIOL MED, V123, P768, DOI 10.3181/00379727-123-31599; CANE PA, 1995, J VIROL, V69, P2918, DOI 10.1128/JVI.69.5.2918-2925.1995; CLARKE DK, 1993, J VIROL, V67, P222, DOI 10.1128/JVI.67.1.222-228.1993; DEBYSER Z, 1993, MOL PHARMACOL, V43, P521; DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4; Domingo E, 1989, Prog Drug Res, V33, P93; DURBIN R, 1991, VIROLOGY, V183, P306, DOI 10.1016/0042-6822(91)90143-Y; ECOMOTO N, 1994, J HEPATOL, V20, P252; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; Gonzalez R. C., 1992, DIGITAL IMAGING PROC; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; HEINZ BA, 1989, J VIROL, V63, P2476, DOI 10.1128/JVI.63.6.2476-2485.1989; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; KONG DY, 1995, BIO-TECHNOL, V13, P583, DOI 10.1038/nbt0695-583; LARDER BA, 1991, J VIROL, V65, P5232, DOI 10.1128/JVI.65.10.5232-5236.1991; LINNEMANN CC, 1990, AIDS, V4, P577, DOI 10.1097/00002030-199006000-00014; LISZIEWICZ J, 1992, P NATL ACAD SCI USA, V89, P11209, DOI 10.1073/pnas.89.23.11209; MCCASKILL JS, 1993, P NATL ACAD SCI USA, V90, P4191, DOI 10.1073/pnas.90.9.4191; MERIGAN TC, 1994, J ACQ IMMUN DEF SYND, V1, pS14; Miller J.H., 1972, EXPT MOL GENETICS; PALCA J, 1992, SCIENCE, V256, P1387, DOI 10.1126/science.1604310; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TIKHONENKO AT, 1993, J VIROL, V67, P3635, DOI 10.1128/JVI.67.6.3635-3638.1993; YIN J, 1993, J BACTERIOL, V175, P1272, DOI 10.1128/JB.175.5.1272-1277.1993; YIN J, 1992, BIOPHYS J, V61, P1540, DOI 10.1016/S0006-3495(92)81958-6; YIN J, 1991, BIOCHEM BIOPH RES CO, V174, P1009, DOI 10.1016/0006-291X(91)91519-I	31	32	33	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					491	493		10.1038/nbt0496-491	http://dx.doi.org/10.1038/nbt0496-491			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630926	Bronze			2022-12-25	WOS:A1996UL58800034
J	D'Adamo, P; Menegon, A; Lo Nigro, C; Grasso, M; Gulisano, M; Tamanini, F; Bienvenu, T; Gedeon, AK; Oostra, B; Wu, SK; Tandon, A; Valtorta, F; Balch, WE; Chelly, J; Toniolo, D				D'Adamo, P; Menegon, A; Lo Nigro, C; Grasso, M; Gulisano, M; Tamanini, F; Bienvenu, T; Gedeon, AK; Oostra, B; Wu, SK; Tandon, A; Valtorta, F; Balch, WE; Chelly, J; Toniolo, D			Mutations in GDI1 are responsible for X-linked non-specific mental retardation	NATURE GENETICS			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; HIPPOCAMPAL-NEURONS; SYNAPTIC VESICLES; RAB PROTEINS; GENE; EXOCYTOSIS; XQ28; IDENTIFICATION; EXPRESSION	Rab GDP-dissociation inhibitors (GDI) are evolutionarily conserved proteins that play an essential role in the recycling of Rab GTPases required for vesicular transport through the secretory pathway We have found mutations in the GDI1 gene (which encodes alpha GDI) in two families affected with X-linked non-specific mental retardation. One of the mutations caused a non-conservative substitution (L92P) which reduced binding and recycling of RAB3A, the second was a null mutation. Our results show that both functional and developmental alterations in the neuron may account for the severe impairment of learning abilities as a consequence of mutations in GDI1, emphasizing its critical role in development of human intellectual and learning abilities.	CNR, Inst Genet Biochem & Evolut, I-27100 Pavia, Italy; Galliera Hosp, Lab Human Genet, Genoa, Italy; HSR, DIBIT, Milan, Italy; Inst Cochin Genet Mol, F-75014 Paris, France; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Adelaide, SA, Australia; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Scripps Res Inst, Dept Mol & Cell Biol, La Jolla, CA USA; Univ Milan, Dept Med Pharmacol, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Ente Ospedaliero Ospedali Galliera; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Womens & Childrens Hospital Australia; Erasmus University Rotterdam; Scripps Research Institute; University of Milan	Toniolo, D (corresponding author), CNR, Inst Genet Biochem & Evolut, I-27100 Pavia, Italy.	Toniola@igbe.pv.cnr.it	D'Adamo, Patrizia/AAN-3919-2020; Gulisano, Massimo/F-6609-2012; Flavia, Valtorta/F-3450-2012; Gedeon, Agi/G-7890-2011; menegon, andrea/AAN-3736-2020; Chelly, Jamel/J-7528-2015; Toniolo, Daniela/AAE-2969-2019; Grasso, Marina/AAC-8722-2019	D'Adamo, Patrizia/0000-0002-0312-5541; Gulisano, Massimo/0000-0001-8654-1745; Flavia, Valtorta/0000-0001-9556-4746; menegon, andrea/0000-0002-2396-756X; Chelly, Jamel/0000-0002-0939-8719; Toniolo, Daniela/0000-0001-9545-6032; s, hema/0000-0002-3440-9475; Grasso, Marina/0000-0001-5682-1789	NATIONAL EYE INSTITUTE [R01EY011606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033301] Funding Source: NIH RePORTER; NEI NIH HHS [EY11606] Funding Source: Medline; NIGMS NIH HHS [GM33301] Funding Source: Medline; Telethon [E.0297] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		BACHNER D, 1995, HUM MOL GENET, V4, P701, DOI 10.1093/hmg/4.4.701; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARTLETT WP, 1984, J NEUROSCI, V4, P1954; BEAN JA, 1997, NEURON, V19, P751; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; BIONE S, 1993, P NATL ACAD SCI USA, V90, P10977, DOI 10.1073/pnas.90.23.10977; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Chen EY, 1996, HUM MOL GENET, V5, P659, DOI 10.1093/hmg/5.5.659; Claes S, 1997, CLIN GENET, V52, P155; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; desPortes V, 1997, AM J HUM GENET, V60, P903; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Gedeon AK, 1996, AM J MED GENET, V64, P158, DOI 10.1002/(SICI)1096-8628(19960712)64:1<158::AID-AJMG26>3.3.CO;2-V; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Gulisano M, 1996, EUR J NEUROSCI, V8, P1037, DOI 10.1111/j.1460-9568.1996.tb01590.x; Hamel BCJ, 1996, AM J MED GENET, V64, P131, DOI 10.1002/(SICI)1096-8628(19960712)64:1<131::AID-AJMG22>3.0.CO;2-N; Lubs HA, 1996, AM J MED GENET, V64, P147, DOI 10.1002/(SICI)1096-8628(19960712)64:1<147::AID-AJMG25>3.0.CO;2-M; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEDLACEK Z, 1994, MAMM GENOME, V5, P633, DOI 10.1007/BF00411459; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; SUEDHOF TC, 1997, NEURON, V18, P519; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Turner G, 1996, AM J MED GENET, V64, P196, DOI 10.1002/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1	42	266	274	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					134	139		10.1038/487	http://dx.doi.org/10.1038/487			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620768				2022-12-25	WOS:000073865100019
J	Chase, M; Chung, RY; Chiocca, EA				Chase, M; Chung, RY; Chiocca, EA			An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy	NATURE BIOTECHNOLOGY			English	Article						gene therapy; herpes simplex virus type 1; prodrug activation	GENE-THERAPY; BRAIN-TUMORS; DNA-SYNTHESIS; VIRUS MUTANT; P53 GENE; CANCER; GLIOMAS; CELLS; ADENOVIRUS; ACTIVATION	Herpes simplex viruses type 1 (HSV-1) with an inactivated viral ribonucleotide reductase (Hsrr, ICP6) were designed to target tumor cells with upregulated mammalian ribonucleotide reductase (mRR), an enzyme whose expression is regulated by the p16/pRB tumor suppressor pathway. A recombinant HSV-1 was generated by knock-out of Hsrr and insertion of the rat CYP2B1 transgene responsible for the bioactivation of the prodrugs, cyclophosphamide and ifosfamide. The mutant virus replicated selectively in rat and human tumor cells that express mRR. Addition of cyclophosphamide potentiated oncolytic effects against cultured tumor cells and subcutaneous tumor xenografts established in athymic mice.	Harvard Univ, Sch Med, Mol Neurooncol Labs, Neurosurg Serv,Massachusetts Gen Hosp, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Chiocca, EA (corresponding author), Harvard Univ, Sch Med, Mol Neurooncol Labs, Neurosurg Serv,Massachusetts Gen Hosp, CNY6, Charlestown, MA 02129 USA.	Chiocca@helix.MGH.Harvard.edu						BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; Carroll NM, 1997, J SURG RES, V69, P413, DOI 10.1006/jsre.1997.5089; CHAMBERS R, 1995, P NATL ACAD SCI USA, V92, P1411, DOI 10.1073/pnas.92.5.1411; CHEN L, 1995, CANCER RES, V55, P581; Chen L, 1996, CANCER RES, V56, P1331; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLARKE L, 1989, CANCER RES, V49, P2344; COLVIN OM, 1993, CANC MED, P733; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GOPFERICH A, 1994, PHARMACEUT RES, V11, P1568, DOI 10.1023/A:1018901619230; KESARI S, 1995, LAB INVEST, V73, P636; LORENCE RM, 1994, JNCI-J NATL CANCER I, V86, P1228, DOI 10.1093/jnci/86.16.1228; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Marais R, 1996, CANCER RES, V56, P4735; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MINETA T, 1994, CANCER RES, V54, P3936; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MROZ PJ, 1993, HUM GENE THER, V4, P589, DOI 10.1089/hum.1993.4.5-589; MULDOON LL, 1995, AM J PATHOL, V147, P1840; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; NILAVER G, 1995, P NATL ACAD SCI USA, V92, P9829, DOI 10.1073/pnas.92.21.9829; Pyles RB, 1997, HUM GENE THER, V8, P533, DOI 10.1089/hum.1997.8.5-533; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; Rodriguez R, 1997, CANCER RES, V57, P2559; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Ueki K, 1996, CANCER RES, V56, P150; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wei MX, 1995, CLIN CANCER RES, V1, P1171; WEI MX, 1994, HUM GENE THER, V5, P969, DOI 10.1089/hum.1994.5.8-969	38	153	168	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					444	448		10.1038/nbt0598-444	http://dx.doi.org/10.1038/nbt0598-444			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592392				2022-12-25	WOS:000073489600028
J	Dreyer, SD; Zhou, G; Baldini, A; Winterpacht, A; Zabel, B; Cole, W; Johnson, RL; Lee, B				Dreyer, SD; Zhou, G; Baldini, A; Winterpacht, A; Zabel, B; Cole, W; Johnson, RL; Lee, B			Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome	NATURE GENETICS			English	Article							PROTEIN; DOMAIN; GENE	The LIM-homeodomain protein Lmx1b plays a central role in dorso-ventral patterning of the vertebrate limb(1). Targeted disruption of Lmx1b results in skeletal defects including hypoplastic nails, absent patellae and a unique form of renal dysplasia (see accompanying manuscript by Fl. Chen et al.; ref. 2). These features are reminiscent of the dominantly inherited skeletal malformation nail patella syndrome (NPS). We show that LMX1B maps to the NPS locus and that three independent NPS patients carry de novo heterozygous mutations in this gene. Functional studies show that one of these mutations disrupts sequence-specific DNA binding, while the other two mutations result in premature termination of translation. These data demonstrate a unique role for LMX1B in renal development and in patterning of the skeletal system, and suggest that alteration of Lmx1b/LMX1B function in mice and humans results in similar phenotypes, Furthermore, we provide evidence for the first described mutations in a LIM-homeodomain protein which account for an inherited form of abnormal skeletal patterning and renal failure.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Mainz, Dept Pediat, D-6500 Mainz, Germany; Hosp Sick Children, Dept Orthoped Surg, Toronto, ON M5G 1X8, Canada; Univ Texas, Sch Med, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Houston, TX USA	Baylor College of Medicine; Johannes Gutenberg University of Mainz; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Texas System; UTMD Anderson Cancer Center	Lee, B (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		genes, anthony/F-2541-2012; Baldini, Antonio/M-2355-2015	Baldini, Antonio/0000-0002-5330-0256				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALDINI A, 1994, IN SITU HYBRIDIZATIO, P75; Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; CAMPEAU E, 1995, AM J HUM GENET, V56, P243; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; DELPOZO E, 1970, AM J CLIN PATHOL, V54, P845; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; HOYER JR, 1972, KIDNEY INT, V2, P231, DOI 10.1038/ki.1972.99; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Jones K. L., 1997, SMITHS RECOGNIZABLE; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; MCINTOSH L, 1997, AM J HUM GENET, V60, P133; MORITA T, 1973, ARCH INTERN MED, V131, P271, DOI 10.1001/archinte.131.2.271; RENWICK JH, 1955, ANN HUM GENET, V19, P312, DOI 10.1111/j.1469-1809.1955.tb01356.x; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8	22	362	375	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					47	50		10.1038/ng0598-47	http://dx.doi.org/10.1038/ng0598-47			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590287				2022-12-25	WOS:000073346700015
J	Castilla, J; Pintado, B; Sola, I; Sanchez-Morgado, JM; Enjuanes, L				Castilla, J; Pintado, B; Sola, I; Sanchez-Morgado, JM; Enjuanes, L			Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk	NATURE BIOTECHNOLOGY			English	Article						applied immunology; antibody engineering; mucosal immunity; coronavirus	MATRIX-ATTACHMENT REGIONS; PROTEIN GENE PROMOTER; WHEY ACIDIC PROTEIN; TRANSMISSIBLE GASTROENTERITIS; IMMUNOGLOBULIN GENES; CHICKEN LYSOZYME; EXPRESSION; CORONAVIRUS; PIGS; IGA	Protection against enteric infections can be provided by the oral administration of pathogen-neutralizing antibodies. To provide passive immunity, 18 lines of transgenic mice secreting a recombinant monoclonal antibody (Mab) neutralizing transmissible gastroenteritis coronavirus (TGEV) into the milk were generated. The genes encoding a chimeric Mab with the variable modules of the murine TGEV-specific Mab 6A.C3 and the constant modules of a human IgG(1) isotype Mab were expressed under the control of regulatory sequences derived from the whey acidic protein, which is an abundant milk protein. The Mab 6A.C3 binds to a highly conserved epitope present in coronaviruses of several species, which does not allow the selection of neutralization escape mutants. Antibody expression titers of 10(6) were obtained in the milk of transgenic mice that reduced TGEV infectivity 10(6)-fold. The antibody was synthesized at high levels throughout lactation. Integration of matrix attachment region sequences with the antibody genes red to a 20- to 10,000-fold increase in the antibody titer in 50% of the transgenic animals. Antibody expression levels were transgene copy number independent and related to the site of integration. The generation of transgenic animals producing virus neutralizing antibodies in milk could provide an approach to protection against neonatal infections of the enteric tract.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Madrid 28049, Spain; Inst Nacl Invest Agr, Dept Anim Reprod & Zoogenet Resources Preservat, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA)	Enjuanes, L (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Sola, Isabel/E-1565-2017; Castilla, Joaquin/D-5261-2011; Sanchez-Morgado, José/I-2220-2019; Pintado, Belen/N-3233-2014; Castilla, Joaquín/J-8414-2019; Enjuanes, Luis/F-7845-2016	Castilla, Joaquin/0000-0002-2216-1361; Pintado, Belen/0000-0002-8485-2520; Castilla, Joaquín/0000-0002-2216-1361; Sola, Isabel/0000-0002-5704-1917; Sanchez Morgado, Jose M/0000-0002-6135-3278; Enjuanes, Luis/0000-0002-0854-0226				ANTON IM, 1995, VIROLOGY, V212, P746, DOI 10.1006/viro.1995.1535; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; Castilla J, 1997, J VIROL, V71, P5251, DOI 10.1128/JVI.71.7.5251-5258.1997; Enjuanes L., 1995, The coronaviridae., P337; FINK PS, 1991, BIOTECHNIQUES, V10, P447; GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X; Hennighausen L, 1990, Curr Opin Biotechnol, V1, P74, DOI 10.1016/0958-1669(90)90013-B; Hogan B, 1994, MANIPULATING MOUSE E; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KOOYMAN DL, 1994, TRANSGENIC RES, V3, P167, DOI 10.1007/BF01973984; LAMM ME, 1995, APMIS, V103, P241, DOI 10.1111/j.1699-0463.1995.tb01101.x; LIEW FY, 1984, EUR J IMMUNOL, V14, P350, DOI 10.1002/eji.1830140414; LIMONTA J, 1995, IMMUNOTECHNOLOGY, V1, P107, DOI 10.1016/1380-2933(95)00010-0; LIU AY, 1987, GENE, V54, P33, DOI 10.1016/0378-1119(87)90344-1; LO D, 1991, EUR J IMMUNOL, V21, P1001, DOI 10.1002/eji.1830210421; McKnight RA, 1996, MOL REPROD DEV, V44, P179, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;179::AID-MRD6&gt;3.0.CO;2-K; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; NAGASAWA H, 1979, LAB ANIM SCI, V29, P633; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; Reed WA, 1997, TRANSGENIC RES, V6, P337, DOI 10.1023/A:1018423015014; Saif L.J., 1992, DIS SWINE, P362; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8; SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z; SHAMAY A, 1991, J ANIM SCI, V69, P4552, DOI 10.2527/1991.69114552x; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; SOLA I, 1997, IN PRESS J VIROL; STAATS HF, 1994, CURR OPIN IMMUNOL, V6, P572, DOI 10.1016/0952-7915(94)90144-9; STONE SS, 1977, AM J VET RES, V38, P1285; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TORRES JM, 1995, VIROLOGY, V213, P503, DOI 10.1006/viro.1995.0023; VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003; WALL RJ, 1991, P NATL ACAD SCI USA, V88, P1696, DOI 10.1073/pnas.88.5.1696; WEIDLE UH, 1991, GENE, V98, P185, DOI 10.1016/0378-1119(91)90172-8; Yarus S, 1996, P NATL ACAD SCI USA, V93, P14118, DOI 10.1073/pnas.93.24.14118	41	56	61	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					349	354		10.1038/nbt0498-349	http://dx.doi.org/10.1038/nbt0498-349			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555725	Bronze, Green Published			2022-12-25	WOS:000072786200026
J	Minetti, C; Sotgia, F; Bruno, C; Scartezzini, P; Broda, P; Bado, M; Masetti, E; Mazzocco, M; Egeo, A; Donati, MA; Volonte, D; Galbiati, F; Cordone, G; Bricarelli, FD; Lisanti, MP; Zara, F				Minetti, C; Sotgia, F; Bruno, C; Scartezzini, P; Broda, P; Bado, M; Masetti, E; Mazzocco, M; Egeo, A; Donati, MA; Volonte, D; Galbiati, F; Cordone, G; Bricarelli, FD; Lisanti, MP; Zara, F			Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy	NATURE GENETICS			English	Article							HETEROTRIMERIC G-PROTEINS; EXPRESSION; IDENTIFICATION; SEQUENCE; ISOFORMS; CELLS	Limb-girdle muscular dystrophy (LGMD) is a clinically and genetically heterogeneous group of myopathies. including autosomal dominant and recessive forms(1-3). To date, two autosomal dominant forms have been recognized(2,3): LGMD1A, linked to chromosome 5q, and LGMD1B, associated with cardiac defects and linked to chromosome 1q11-21. Here we describe eight patients from two different families with a new form of autosomal dominant LGMD, which we propose to call LGMD1C, associated with a severe deficiency of caveolin-3 in muscle fibres. Caveolin-3 (or M-caveolin) is the muscle-specific form of the caveolin protein family, which also includes caveolin-1 and -2 (refs 4-9). Caveolins are the principal protein components of caveolae (50-100 nm invaginations found in most cell types) which represent appendages or sub-compartments of plasma membranes(10,11). We localized the human caveolin-3 gene (CAV3) to chromosome 3p25 and identified two mutations in the gene: a missense mutation in the membrane-spanning region and a micro-deletion in the scaffolding domain. These mutations may interfere with caveolin-3 oligomerization and disrupt caveolae formation at the muscle cell plasma membrane.	Univ Genoa, Ist Giannina Gaslini, Serv Malattie Neuromuscolari, I-16147 Genoa, Italy; EO Osped Galliera, Lab Genet Umana, Genoa, Italy; Columbia Univ, Dept Neurol, New York, NY USA; EO Osped Galliera, Div Neonatol, Genoa, Italy; Univ Florence, Dipartimento Pediat, Florence, Italy; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA	University of Genoa; IRCCS Istituto Giannina Gaslini; Ente Ospedaliero Ospedali Galliera; Columbia University; Ente Ospedaliero Ospedali Galliera; University of Florence; Yeshiva University; Albert Einstein College of Medicine	Minetti, C (corresponding author), Univ Genoa, Ist Giannina Gaslini, Serv Malattie Neuromuscolari, Largo Gaslini 5, I-16147 Genoa, Italy.	minettic@unige.it	Mazzocco, Michela/AFT-6759-2022; Lisanti, Michael P/C-6866-2013; Bruno, Claudio/A-3148-2015; Zara, Federico/U-3477-2017; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael/B-6131-2018; Minetti, Carlo/K-4666-2018	Bruno, Claudio/0000-0002-3426-2901; Zara, Federico/0000-0001-9744-5222; Lisanti, Michael/0000-0003-2034-1382; Minetti, Carlo/0000-0002-0640-1804; Sotgia, Federica/0000-0003-2826-4529; MARIA ALICE, DONATI/0000-0003-4769-5025; Broda, Paolo/0000-0002-4178-1128	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50443] Funding Source: Medline; Telethon [641] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Bushby K, 1996, NEUROMUSCULAR DISORD, V6, P439, DOI 10.1016/S0960-8966(96)00392-6; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MINETTI C, 1994, NEUROLOGY, V44, P1149, DOI 10.1212/WNL.44.6.1149; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; OKAMOTO T, IN PRESS J BIOL CHEM; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Scartezzini P, 1997, HUM GENET, V99, P387, DOI 10.1007/s004390050377; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; SPEER MC, 1992, AM J HUM GENET, V50, P1211; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; vanderKooi AJ, 1997, AM J HUM GENET, V60, P891; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	30	437	448	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1998	18	4					365	368		10.1038/ng0498-365	http://dx.doi.org/10.1038/ng0498-365			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537420				2022-12-25	WOS:000072755500020
J	Schneider, J; Gilbert, SC; Blanchard, TJ; Hanke, T; Robson, KJ; Hannan, CM; Becker, M; Sinden, R; Smith, GL; Hill, AVS				Schneider, J; Gilbert, SC; Blanchard, TJ; Hanke, T; Robson, KJ; Hannan, CM; Becker, M; Sinden, R; Smith, GL; Hill, AVS			Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara	NATURE MEDICINE			English	Article							BROAD SPECIES-SPECIFICITY; CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-BERGHEI; INTERFERON-GAMMA; INFLUENZA-VIRUS; IMMUNITY; IMMUNIZATION; INFECTION; EPITOPES; ANTIGEN	Immunization with irradiated sporozoites can protect against malaria infection and intensive efforts are aimed at reproducing this effect with subunit vaccines. A particular sequence of subunit immunization with pre-erythrocytic antigens of Plasmodium berghei, consisting of single dose priming with plasmid DNA followed by a single boost with a recombinant modified vaccinia virus Ankara (MVA) expressing the same antigen, induced unprecedented complete protection against P. berghei sporozoite challenge in two strains of mice. Protection was associated with very high levels of splenic peptide-specific interferon-gamma-secreting CD8+ T cells and was abrogated when the order of immunization was reversed. DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DS, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England; Univ London Imperial Coll Sci Technol & Med, Dept Pure & Appl Biol, Mol & Cellular Parasitol Grp, London SW7 2BB, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; Imperial College London	Schneider, J (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DS, England.	joerg.schneider@ndm.ox.ac.uk	HILL, Adrian V>S>/C-1306-2008; Smith, Geoffrey L/G-2894-2012; Gilbert, Sarah C./H-2857-2019	Gilbert, Sarah C./0000-0002-6823-9750; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; ALCAMI A, 1995, J VIROL, V69, P4633; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; An LL, 1996, INFECT IMMUN, V64, P1685, DOI 10.1128/IAI.64.5.1685-1693.1996; Bender BS, 1996, J VIROL, V70, P6418, DOI 10.1128/JVI.70.9.6418-6424.1996; BENNINK JR, 1984, NATURE, V311, P578, DOI 10.1038/311578a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; CARROLL MW, 1995, BIOTECHNIQUES, V19, P352; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Doolan DL, 1997, PARASITOL TODAY, V13, P171, DOI 10.1016/S0169-4758(97)01040-5; GAVIN MA, 1993, J IMMUNOL, V151, P3971; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; JAFFE RI, 1990, AM J TROP MED HYG, V42, P309, DOI 10.4269/ajtmh.1990.42.309; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; Lanar DE, 1996, INFECT IMMUN, V64, P1666, DOI 10.1128/IAI.64.5.1666-1671.1996; LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214; LOCKYER MJ, 1990, NUCLEIC ACIDS RES, V18, P376, DOI 10.1093/nar/18.2.376; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375; Moss B, 1996, Adv Exp Med Biol, V397, P7; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PLEBANSKI M, 1992, EUR J IMMUNOL, V22, P2353, DOI 10.1002/eji.1830220926; Plebanski M, 1997, J IMMUNOL, V158, P2849; Renggli J, 1997, PARASITE IMMUNOL, V19, P145, DOI 10.1046/j.1365-3024.1997.d01-190.x; Robson KJH, 1997, MOL BIOCHEM PARASIT, V84, P1, DOI 10.1016/S0166-6851(96)02774-0; RODRIGUES M, 1994, J IMMUNOL, V153, P4636; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SATCHIDANANDAM V, 1991, MOL BIOCHEM PARASIT, V48, P89, DOI 10.1016/0166-6851(91)90167-5; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SEDEGAH M, 1990, B WHO S, V68, P1009; SEGUIN MC, 1994, J EXP MED, V180, P353, DOI 10.1084/jem.180.1.353; Stickl H, 1971, Munch Med Wochenschr, V113, P1149; SUTTER G, 1994, VACCINE, V12, P1032, DOI 10.1016/0264-410X(94)90341-7; SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Thomson SA, 1996, J IMMUNOL, V157, P822; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; White KL, 1996, J IMMUNOL, V156, P3374	43	565	612	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1998	4	4					397	402		10.1038/nm0498-397	http://dx.doi.org/10.1038/nm0498-397			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546783				2022-12-25	WOS:000072906800032
J	Persidis, A				Persidis, A			Functional antigenics	NATURE BIOTECHNOLOGY			English	Editorial Material							DENDRITIC CELLS; HUMAN-MELANOMA; RESPONSES		Argonex Inc, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, 2044 India Rd,Suite 202, Charlottesville, VA 22901 USA.	apersidis@argonex.com						EVERS P, 1996, FINANCIAL TIMES MANA; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; KAWAKAMI Y, 1995, J IMMUNOL, V154, P3961; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; MELIEF CJM, 1988, ANN NY ACAD SCI, V532, P280, DOI 10.1111/j.1749-6632.1988.tb36346.x; Murphy G, 1996, PROSTATE, V29, P371; Persidis A, 1997, NAT BIOTECHNOL, V15, P1409, DOI 10.1038/nbt1297-1409; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; VAJDA S, 1990, BIOPOLYMERS, V29, P1755, DOI 10.1002/bip.360291408; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VOSE BM, 1982, NATURE, V296, P359, DOI 10.1038/296359a0	13	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					305	307		10.1038/nbt0398-305	http://dx.doi.org/10.1038/nbt0398-305			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528015	Bronze			2022-12-25	WOS:000072371000035
J	Drmanac, S; Kita, D; Labat, I; Hauser, B; Schmidt, C; Burczak, JD; Drmanac, R				Drmanac, S; Kita, D; Labat, I; Hauser, B; Schmidt, C; Burczak, JD; Drmanac, R			Accurate sequencing by hybridization for DNA diagnostics and individual genomics	NATURE BIOTECHNOLOGY			English	Article						genomics; DNA sequencing	MUTATIONS; ARRAYS	Medical DNA diagnostics will increasingly rely on an accurate and inexpensive identification of mutations that affect the function of a gene. To validate diagnostic sequencing by hybridization (SBH), a number of p53 samples were analyzed with the complete set of 8192 noncomplementary 7-mer oligonucleotides. In four repeated, blind experiments we accurately sequenced 1.1 kb per each of 12 homozygote and heterozygote samples possessing base substitutions, insertions, and deletions. This SBH variant offers a high throughput platform to inexpensively sequence individual gene or pathogen genome samples within the clinical laboratory setting.	Hyseq Inc, Sunnyvale, CA 94086 USA; SmithKline Beecham Pharmaceut Co, Dept Mol Diagnost, King Of Prussia, PA 19486 USA	GlaxoSmithKline	Drmanac, R (corresponding author), Hyseq Inc, 670 Almanor Ave, Sunnyvale, CA 94086 USA.			Schmidt, Carl/0000-0002-8386-4781				Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DRMANAC R, 1990, DNA CELL BIOL, V9, P527, DOI 10.1089/dna.1990.9.527; DRMANAC R, 1993, SCIENCE, V260, P1649, DOI 10.1126/science.8503011; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1987, Patent No. 57087; Drmanac RT, 1993, US Patent, Patent No. [5,202,231, 5202231]; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; OKAYAMA H, 1989, J LAB CLIN MED, V114, P105; STUDENCKI AB, 1984, DNA-J MOLEC CELL BIO, V3, P7, DOI 10.1089/dna.1.1984.3.7; Sugimoto N, 1996, NUCLEIC ACIDS RES, V24, P4501, DOI 10.1093/nar/24.22.4501; TAVTIGIAN SV, 1996, IN PRESS ACCOMPLISHM; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WALL J, 1995, HUM MUTAT, V5, P333, DOI 10.1002/humu.1380050411	15	137	222	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1998	16	1					54	58		10.1038/nbt0198-54	http://dx.doi.org/10.1038/nbt0198-54			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YP708	9447594				2022-12-25	WOS:000071306000029
J	Levine, HW				Levine, HW			The written-description requirement in UC v. Lilly	NATURE BIOTECHNOLOGY			English	Editorial Material									Finnegan Henderson Farabow Garrett & Dunner LLP, Washington, DC 20005 USA		Levine, HW (corresponding author), Finnegan Henderson Farabow Garrett & Dunner LLP, 1300 1st NW, Washington, DC 20005 USA.								0	2	2	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1998	16	1					87	88		10.1038/nbt0198-87	http://dx.doi.org/10.1038/nbt0198-87			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YP708	9447600				2022-12-25	WOS:000071306000035
J	Tanaka, M; Itai, T; Adachi, M; Nagata, S				Tanaka, M; Itai, T; Adachi, M; Nagata, S			Downregulation of Fas ligand by shedding	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-MEDIATED CYTOTOXICITY; FACTOR RECEPTOR; SOLUBLE FORM; CD40 LIGAND; EXPRESSION; APOPTOSIS; DISINTEGRIN; INHIBITOR; REJECTION	Apoptosis-inducing Fas ligand (FasL) is a type II membrane protein, predominantly expressed in the activated T cells. FasL is cleaved by a putative metalloproteinase to produce a soluble form. Here, we blocked the shedding of human FasL by deleting its cleavage site. Although human Jurkat cells and mouse primary hepatocytes that express a low level of Fas were resistant to the soluble form of FasL, they were efficiently killed by membrane-bound FasL. Furthermore, soluble FasL inhibited cytotoxicity of the membrane-bound FasL. These results indicate that the membrane-bound form of FasL is the functional form and suggest that shedding of FasL is to prevent the killing of the healthy bystander cells by cytotoxic T cells.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CHRVONSKY AV, 1997, CELL, V89, P17; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; ITOH N, 1997, J EXP MED, V186, P6183; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KARP SE, 1992, J IMMUNOL, V149, P2076; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Pietravalle F, 1996, EUR J IMMUNOL, V26, P725, DOI 10.1002/eji.1830260333; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Solorzano CC, 1997, J IMMUNOL, V158, P414; SUDA T, 1995, J IMMUNOL, V154, P3806; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; Tanaka M, 1997, J IMMUNOL, V158, P2303; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; WATANABE N, 1988, J BIOL CHEM, V263, P10262; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	45	600	622	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					31	36		10.1038/nm0198-031	http://dx.doi.org/10.1038/nm0198-031			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427603				2022-12-25	WOS:000072249700031
J	Geddes, BJ; Harding, TC; Lightman, SL; Uney, JB				Geddes, BJ; Harding, TC; Lightman, SL; Uney, JB			Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin	NATURE MEDICINE			English	Article							MESSENGER-RNA; NEUROHYPOPHYSEAL SYSTEM; NEUROPHYSIN; RESPONSES; VECTORS; NEURONS; STRESS	The ability of adenovirus (Ad) to transfect most cell types efficiently(1-3) has already resulted in human gene therapy trials involving the systemic administration of adenoviral constructs(4). However, because of the complexity of brain function and the difficulty in noninvasively monitoring alterations in neuronal gene expression, the potential of Ad gene therapy strategies for treating disorders of the CNS has been difficult to assess. In the present study, we have used an Ad encoding the arginine vasopressin cDNA (AdAVP)(5) in an AVP-deficient animal model of diabetes insipidus (the Brattleboro rat(6)), which allowed us to monitor chronically the success of the gene therapy treatment by noninvasive assays. Injection of AdAVP into the supraoptic nuclei (SON) of the hypothalamus resulted in expression of AVP in magnocellular neurons. This was accompanied by reduced daily water intake and urine volume, as well as increased urine osmolality lasting 4 months. These data show that a single gene defect leading to a neurological disorder can be corrected with an adenovirus-based strategy. This study highlights the potential of using Ad gene therapy for the long-term treatment of disorders of the CNS.	Univ Bristol, Dept Med Labs, Bristol BS2 8HW, Avon, England	University of Bristol	Uney, JB (corresponding author), Univ Bristol, Dept Med Labs, Marlborough St, Bristol BS2 8HW, Avon, England.			Lightman, Stafford/0000-0002-8546-9646	Biotechnology and Biological Sciences Research Council [GTH12528] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BENBARAK Y, 1985, J NEUROSCI, V5, P81; BURBACH JPH, 1984, NEUROENDOCRINOLOGY, V39, P582; Cheng DY, 1997, HUM GENE THER, V8, P755, DOI 10.1089/hum.1997.8.6-755; FOO NC, 1994, J BIOL CHEM, V269, P659; GAINER H, 1994, PHYSL REPROD, P4545; Geddes BJ, 1996, ENDOCRINOLOGY, V137, P5166, DOI 10.1210/en.137.11.5166; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705; IVELL R, 1990, FRONT NEUROENDOCRIN, V11, P313; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; POW DV, 1992, NEUROSCIENCE, V50, P503, DOI 10.1016/0306-4522(92)90442-5; REPASKE DR, 1992, PROG BRAIN RES, V93, P295; SCHMALE H, 1984, NATURE, V308, P705, DOI 10.1038/308705a0; SHERMAN TG, 1986, NEUROENDOCRINOLOGY, V44, P222, DOI 10.1159/000124649; SOFRONIEW MV, 1985, HDB CHEM NEUROANAT 1, V4, P35; VALTIN H, 1967, AM J MED, V42, P814, DOI 10.1016/0002-9343(67)90098-8; VANLEEUWEN FW, 1994, BRAIN RES, V635, P328, DOI 10.1016/0006-8993(94)91456-7; Wagner JA, 1997, ANNU REV MED, V48, P203; WHITNALL MH, 1985, J NEUROSCI, V5, P98	20	75	79	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1402	1404		10.1038/nm1297-1402	http://dx.doi.org/10.1038/nm1297-1402			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396613				2022-12-25	WOS:000072249500039
J	Ayyavoo, V; Mahboubi, A; Mahalingam, S; Ramalingam, R; Kudchodkar, S; Williams, WV; Green, DR; Weiner, DB				Ayyavoo, V; Mahboubi, A; Mahalingam, S; Ramalingam, R; Kudchodkar, S; Williams, WV; Green, DR; Weiner, DB			HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GLUCOCORTICOID-INDUCED APOPTOSIS; CELL GROWTH-FACTOR; T-CELLS; PROTEIN; INHIBITION; INFECTION; GENE; EXPRESSION; CYCLE	The HIV-l accessory gene product Vpr can influence viral pathogenesis by affecting viral replication as well as host cell transcription and proliferation. We have investigated the effects of Vpr on host cell activation and confirm that it influences cellular proliferation. However, we have also found that Vpr modulates T-cell receptor (TCR)-triggered apoptosis in a manner similar to that of glucocorticoids. In the absence of TCR-mediated activation, Vpr induces apoptosis whereas in its presence, Vpr interrupts the expected induction of apoptosis. This regulation of apoptosis is linked to Vpr suppression of NF-kappa B activity via the induction of I kappa B, an inhibitor of NF-kappa B. Further, Vpr suppresses expression of IL-2, IL-10, IL-12, TNF alpha and IL-4, all of which are NF-kappa B-dependent. The effects of Vpr could be reversed by RU486. Our finding that Vpr can regulate NF-kappa B supports the hypothesis that some aspects of viral pathogenesis are the consequence of cell dysregulation by Vpr.	UNIV PENN,DEPT PATHOL & LAB MED,STELLAR CHANCE LABS 505,PHILADELPHIA,PA 19104; LA JOLLA INST ALLERGY & IMMUNOL,SAN DIEGO,CA 92121; ROCHE INST MOL BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; UNIV PENN,DEPT RHEUMATOL,STELLAR CHANCE LABS 912,PHILADELPHIA,PA 19104	University of Pennsylvania; La Jolla Institute for Immunology; Roche Holding; University of Pennsylvania			Weiner, David B/H-8579-2014; Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Ayyavoo, Velpandi/0000-0002-9043-0885; Mahalingam, Sundarasamy/0000-0003-4460-3949; Williams, William/0000-0003-3611-9284				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BYRON KA, 1992, IMMUNOLOGY, V77, P624; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; CONNOR RI, 1995, VIROLOGY, V206, P936; DOEBERITZ MV, 1990, EUR J IMMUNOL, V20, P35, DOI 10.1002/eji.1830200106; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GILLIS S, 1979, J IMMUNOL, V123, P1624; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; Graziosi C, 1996, P NATL ACAD SCI USA, V93, P4386, DOI 10.1073/pnas.93.9.4386; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LU W, 1995, AIDS, V9, P35, DOI 10.1097/00002030-199501000-00005; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; Poli G, 1995, HUMAN CYTOKINES THEI, P421; Rafaeli Y, 1995, P NATL ACAD SCI USA, V92, P3621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; TOBLER A, 1992, BLOOD, V79, P45; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang B, 1996, VIROLOGY, V223, P224, DOI 10.1006/viro.1996.0471; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHAO Y, 1995, J IMMUNOL, V154, P6346	44	219	229	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1117	1123		10.1038/nm1097-1117	http://dx.doi.org/10.1038/nm1097-1117			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334723				2022-12-25	WOS:A1997XZ28700037
J	Broccoli, D; Smogorzewska, A; Chong, L; deLange, T				Broccoli, D; Smogorzewska, A; Chong, L; deLange, T			Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2	NATURE GENETICS			English	Article							DNA-BINDING DOMAIN; SEQUENCE; COMPLEX; YEAST; RAP1	Human telomeres are composed of long arrays of TTAGGG repeats that form a nucleoprotein complex required for the protection and replication of chromosome ends. One component of human telomeres is the TTAGGG repeat binding factor 1 (TRF1), a ubiquitously expressed protein, related to the protooncogene Myb, that is present at telomeres throughout the cell cycle(1-6). Recent evidence has implicated TRF1 in the control of telomere length(7). TRF1 is proposed to be an inhibitor of telomerase, acting in cis to limit the elongation of individual chromosome ends. Here we report the cloning of TRF2, a distant homologue of TRF1 that carries a very similar Myb-related DNA-binding motif. Like TRF1, TRF2 was ubiquitously expressed, bound specifically to duplex TTAGGG repeats in vitro and localized to all human telomeres in metaphase chromosomes. TRF2 was shown to have an architecture similar to that of TRF1 in that it carries a C-terminal Myb motif and a large TRF1-related dimerization domain near its N terminus. However, the dimerization domain of TRF1 and TRF2 did not interact, suggesting that these proteins exist predominantly as homodimers. While having similar telomere binding activity and domain organization, TRF2 differed from TRF1 in that its N terminus was basic rather than acidic, and TRF2 was much more conserved than TRF1. The results indicate that the TTAGGG repeat arrays at the ends of human and mouse chromosomes bind to two related proteins. Because TRF1 and TRF2 showed significant differences, we suggest that these factors have distinct functions at telomeres.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University			de Lange, Titia/B-8263-2011; Smogorzewska, Agata/B-8891-2011	de Lange, Titia/0000-0002-9267-367X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM07739] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Makalowski W, 1996, GENOME RES, V6, P846, DOI 10.1101/gr.6.9.846; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	19	733	766	0	33	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					231	235		10.1038/ng1097-231	http://dx.doi.org/10.1038/ng1097-231			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326950				2022-12-25	WOS:A1997XZ55500036
J	Xiong, SD; Gerloni, M; Zanetti, M				Xiong, SD; Gerloni, M; Zanetti, M			Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes	NATURE BIOTECHNOLOGY			English	Article						vaccine design; antibody engineering; rational protein design	FALCIPARUM CIRCUMSPOROZOITE PROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; SYNTHETIC VACCINE; IMMUNE-RESPONSES; MALARIA VACCINE; ANTIBODY; IMMUNOGENICITY; IMMUNIZATION	Antibodies engineered in their variable domain to express epitopes of heterologous antigens-antigenized antibodies-function as immunogens. Only the third complementarity-determining region (CDR3) of the H chain has been used as the site of epitope expression, as this loop has the highest natural variability in length and amino acid composition. We demonstrate that the CDR2 can be engineered to express a 12-amino acid peptide, which is a T-cell determinant that enhances the response to a B-cell epitope peptide of Plasmodium falciparum expressed in the CDR3 of the same variable domain. Mice with this gene inoculated into the spleen mounted an antibody response against the B-cell epitope higher than mice receiving the gene coding for the B-cell epitope only. In vitro studies established that the two epitopes were independently immunogenic in vivo.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Gerloni, Mara/AAG-1526-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036467] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36467] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BALLOU WR, 1987, LANCET, V1, P1277; BILLETTA R, 1995, EUR J IMMUNOL, V25, P776, DOI 10.1002/eji.1830250323; BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BILLETTA R, 1992, IMMUNOMETHODS, V1, P41; BRADLEY LM, 1993, J IMMUNOL, V150, P3119; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONRY RM, 1994, CANCER RES, V54, P1164; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; EISENBRAUN MD, 1993, DNA CELL BIOL, V12, P791, DOI 10.1089/dna.1993.12.791; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Gerloni M, 1997, DNA CELL BIOL, V16, P611, DOI 10.1089/dna.1997.16.611; Gerloni M, 1997, NAT BIOTECHNOL, V15, P876, DOI 10.1038/nbt0997-876; GLASEL JA, 1995, BIOTECHNIQUES, V18, P62; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HERRINGTON DA, 1992, VACCINE, V10, P841, DOI 10.1016/0264-410X(92)90047-N; KABAT EA, 1987, PROTEINS IMMUNOLOGIC; LANZA P, 1993, P NATL ACAD SCI USA, V90, P11683, DOI 10.1073/pnas.90.24.11683; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MORRISON SL, 1985, SCIENCE, V229, P1202, DOI 10.1126/science.3929380; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDIN EH, 1989, SCIENCE, V246, P1603, DOI 10.1126/science.2480642; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; Sambrook J., 2002, MOL CLONING LAB MANU; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SOLLAZZO M, 1990, PROTEIN ENG, V4, P215, DOI 10.1093/protein/4.2.215; SOLLAZZO M, 1989, EUR J IMMUNOL, V19, P453, DOI 10.1002/eji.1830190307; SOLLAZZO M, 1990, PROTEIN ENG, V3, P531, DOI 10.1093/protein/3.6.531; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TOGNA AR, 1986, J IMMUNOL, V137, P2956; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; Xiong SD, 1997, P NATL ACAD SCI USA, V94, P6352, DOI 10.1073/pnas.94.12.6352; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469; ZAGHOUANI H, 1995, P NATL ACAD SCI USA, V92, P631, DOI 10.1073/pnas.92.2.631; ZANETTI M, 1992, IMMUNOL REV, V130, P125, DOI 10.1111/j.1600-065X.1992.tb01524.x; ZANETTI M, 1992, NATURE, V355, P466; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	43	41	61	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					882	886		10.1038/nbt0997-882	http://dx.doi.org/10.1038/nbt0997-882			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306404				2022-12-25	WOS:A1997XW41000031
J	Xu, DG; Crocker, SJ; Doucet, JP; StJean, M; Tamai, K; Hakim, AM; Ikeda, JE				Xu, DG; Crocker, SJ; Doucet, JP; StJean, M; Tamai, K; Hakim, AM; Ikeda, JE			Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus	NATURE MEDICINE			English	Article							CHOLINE-ACETYLTRANSFERASE ACTIVITY; FOREBRAIN ISCHEMIA; GERBIL HIPPOCAMPUS; TRANSIENT ISCHEMIA; CEREBRAL-ISCHEMIA; CNS NEURONS; APOPTOSIS; PROTEIN; K-252A; DEATH	We show here that transient forebrain ischemia selectively elevates levels of neuronal apoptosis inhibitory protein (NAIP) in rat neurons that are resistant to the injurious effects of this treatment. This observation suggests that increasing NAIP levels may confer protection against ischemic cell death. Consistent with this proposal, we demonstrate that two other treatments that increase neuronal NAIP levels, systemic administration of the bacterial alkaloid K252a and intracerebral injection of an adenovirus vector capable of overexpressing NAIP in vivo, reduce ischemic damage in the rat hippocampus. Taken together, these findings suggest that NAIP may play a key role in conferring resistance to ischemic damage and that treatments that elevate neuronal levels of this antiapoptotic protein may have utility in the treatment of stroke.	UNIV OTTAWA,NEUROSCI RES INST,OTTAWA,ON K1H 8M5,CANADA; MED & BIOL LABS CO LTD,NAKA KU,NAGOYA,AICHI 460,JAPAN; TOKAI UNIV,INST MED SCI,KANAGAWA 25911,JAPAN; APOPOTOGEN INC,OTTAWA,ON K1H 8L1,CANADA; CHILDRENS HOSP EASTERN ONTARIO,MOL GENET RES LAB,OTTAWA,ON K1H 8L1,CANADA	University of Ottawa; Tokai University; University of Ottawa; Children's Hospital of Eastern Ontario	Xu, DG (corresponding author), UNIV OTTAWA,DEPT CELLULAR & MOL MED,OTTAWA,ON K1H 8M5,CANADA.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				CHENG B, 1994, J NEUROCHEM, V62, P1319; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; GLICKSMAN MA, 1993, J NEUROCHEM, V61, P210, DOI 10.1111/j.1471-4159.1993.tb03557.x; GLICKSMAN MA, 1995, J NEUROCHEM, V64, P1502; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Lawrence MS, 1996, J NEUROSCI, V16, P486; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; MARONEY AC, 1995, J NEUROCHEM, V64, P540; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MARUNO M, 1990, NEUROSCI LETT, V115, P155, DOI 10.1016/0304-3940(90)90447-H; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; NITATORI T, 1995, J NEUROSCI, V15, P1001; Olfert ED, 1993, GUIDE CARE USE EXPT; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; SmithSwintosky VL, 1996, EXP NEUROL, V141, P287, DOI 10.1006/exnr.1996.0163; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIDMANN R, 1991, J NEUROCHEM, V56, P789, DOI 10.1111/j.1471-4159.1991.tb01993.x; Xu DG, 1997, J COMP NEUROL, V382, P247	28	212	227	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					997	1004		10.1038/nm0997-997	http://dx.doi.org/10.1038/nm0997-997			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288726				2022-12-25	WOS:A1997XT84200032
J	Yang, XDW; Model, P; Heintz, N				Yang, XDW; Model, P; Heintz, N			Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome	NATURE BIOTECHNOLOGY			English	Article						BAC; homologous recombination; RU 49; transgenic	DNA FRAGMENTS; MESSENGER-RNA; CONSTRUCTION; YEAST; CLONING; YACS; TRANSFORMATION; PROPAGATION; EXPRESSION; SEGMENTS	Escherichia coli-based artificial chromosomes have become important tools for physical mapping and sequencing in various genome projects. The lack of a general method to modify these large bacterial clones, however, has limited their utility in functional studies. We developed a simple method to modify bacterial artificial chromosomes directly in the recombination-deficient E. coli host strain by homologous recombination for in vivo studies. The IRES-LacZ marker gene was introduced into a 131 kb BAC containing the murine zinc finger gene, RU49. No rearrangements or deletions were detected in the modified BACs. Furthermore, transgenic mice were generated by pronuclear injection of the modified BAG, and germline transmission of the intact BAC has been obtained. Proper expression of the lacZ transgene in the brain has been observed, which could not be obtained with conventional transgenic constructs.	ROCKEFELLER UNIV,MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University					PHS HHS [MG07739] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; Bradley A, 1996, NAT GENET, V14, P121, DOI 10.1038/ng1096-121; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; GNIRKE A, 1993, GENOMICS, V15, P659, DOI 10.1006/geno.1993.1121; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; HIEFER P, 1990, GENOME ANAL GENETIC, V1, P83; HOGAN B, 1986, MANIPULATING MOUSE E; HOSODA F, 1990, NUCLEIC ACIDS RES, V18, P3863, DOI 10.1093/nar/18.13.3863; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; KOUPRINA N, 1994, GENOMICS, V21, P7, DOI 10.1006/geno.1994.1218; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LARIONOV V, 1994, NUCLEIC ACIDS RES, V22, P4154, DOI 10.1093/nar/22.20.4154; MALOY SR, 1981, J BACTERIOL, V145, P110; MONACO AP, 1994, TRENDS BIOTECHNOL, V12, P280, DOI 10.1016/0167-7799(94)90140-6; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; PALMITER RD, 1985, CELL, V41, P343, DOI 10.1016/S0092-8674(85)80004-0; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Peterson KR, 1997, TRENDS GENET, V13, P61, DOI 10.1016/S0168-9525(97)01003-2; SCHEDL A, 1993, NUCLEIC ACIDS RES, V21, P4383; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Spencer F., 1993, Methods (Orlando), V5, P161, DOI 10.1006/meth.1993.1021; TSLEN JZ, 1996, CELL, V87, P1317; WANG M, 1994, GENOMICS, V24, P527, DOI 10.1006/geno.1994.1662; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WOO SS, 1994, NUCLEIC ACIDS RES, V22, P4922, DOI 10.1093/nar/22.23.4922; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XW, 1996, DEVELOPMENT, V122, P555	34	428	496	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					859	865		10.1038/nbt0997-859	http://dx.doi.org/10.1038/nbt0997-859			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306400				2022-12-25	WOS:A1997XW41000027
J	Panchal, RG; Cusack, E; Cheley, S; Bayley, H				Panchal, RG; Cusack, E; Cheley, S; Bayley, H			Tumor protease-activated, pore-forming toxins from a combinatorial library	NATURE BIOTECHNOLOGY			English	Article						drug delivery; immunotoxin; molecular trigger; transmembrane pore; tumor protease	CATHEPSIN-B; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; ALPHA-HEMOLYSIN; AMINO-ACIDS; SPECIFICITY; METALLOPROTEINASES; TRANSFORMATION; MUTAGENESIS; MIXTURES	We describe a library of two-chain molecular complementation mutants of staphylococcal alpha-hemolysin that features a combinatorial cassette encoding thousands of protease recognition sites in the central pore-forming domain. The cassette is flanked by a peptide extension that inactivates the protein. We screened the library to identify alpha-hemolysins that are highly susceptible to activation by cathepsin B, a protease that is secreted by certain metastatic tumor cells. Toxins obtained by this procedure should be useful for the permeabilization of malignant cells thereby leading directly to cell death or permitting destruction of the cells with drugs that are normally membrane impermeant.	WORCESTER FDN BIOMED RES, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research			; Panchal, Rekha/None	Bayley, Hagan/0000-0003-2499-6116; Panchal, Rekha/0000-0001-8621-9078				ARKIN AP, 1992, BIO-TECHNOL, V10, P297, DOI 10.1038/nbt0392-297; BARRETT AJ, 1973, BIOCHEM J, V131, P809, DOI 10.1042/bj1310809; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Bayley H, 1995, BIOORG CHEM, V23, P340, DOI 10.1006/bioo.1995.1023; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; GILLES AM, 1979, J BIOL CHEM, V254, P1462; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; HUENNEKENS FM, 1994, TRENDS BIOTECHNOL, V12, P234, DOI 10.1016/0167-7799(94)90122-8; HUFF JP, 1990, BIOTECHNIQUES, V9, P570; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; KEPPLER D, 1994, BIOCHEM SOC T, V22, P43, DOI 10.1042/bst0220043; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MENARD R, 1993, FEBS LETT, V328, P107, DOI 10.1016/0014-5793(93)80975-Z; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; PEDERZOLLI C, 1995, BIOCONJUGATE CHEM, V6, P166, DOI 10.1021/bc00032a003; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHWARTZ MK, 1995, CLIN CHIM ACTA, V237, P67, DOI 10.1016/0009-8981(95)06065-L; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TARLAP A, 1995, J BIOL CHEM, V270, P18036, DOI 10.1074/jbc.270.30.18036; ULLMANN D, 1994, EUR J BIOCHEM, V223, P865, DOI 10.1111/j.1432-1033.1994.tb19063.x; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; WALKER B, 1994, PROTEIN ENG, V7, P91, DOI 10.1093/protein/7.1.91; WALKER B, 1992, J BIOL CHEM, V267, P10902; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; YEMUL S, 1987, P NATL ACAD SCI USA, V84, P246, DOI 10.1073/pnas.84.1.246	35	57	66	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					852	856		10.1038/nbt0796-852	http://dx.doi.org/10.1038/nbt0796-852			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631009				2022-12-25	WOS:A1996UV62000034
J	Fueyo, J; Gomez-Manzano, C; Yung, WKA; Liu, TJ; Alemany, R; McDonnell, TJ; Shi, X; Rao, JS; Levin, VA; Kyritsis, AP				Fueyo, J; Gomez-Manzano, C; Yung, WKA; Liu, TJ; Alemany, R; McDonnell, TJ; Shi, X; Rao, JS; Levin, VA; Kyritsis, AP			Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; BINDING PROTEIN; CANCER-CELLS; P53 GENE; EXPRESSION; ADENOVIRUS; BRAIN; MICE; IDENTIFICATION	The transfer of apoptosis genes to tumors is one of the most promising strategies for cancer gene therapy. We have shown that massive apoptosis occurs when wild-type p53 expression is induced in glioma cells carrying a p53 gene mutation. However, adenovirus-mediated p53 gene transfer is ineffective in causing apoptosis in glioma cells that retain a wild-type p53 genotype. We evaluated the effect of E2F-1 overexpression on the growth of gliomas in vitro and in vivo. In the in vitro study, the adenovirus-mediated transfer of exogenous E2F-1 protein precipitated generalized apoptosis in gliomas. The treatment with Ad5CMV-E2F-1 of nude mice carrying subcutaneous gliomas arrested tumor growth. Our results indicate that E2F-1 has anti-glioma activity in vitro and in vivo.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Neurosurg, Houston, TX 77030 USA; Baxter Healthcare Corp, Unit Gene Therapy, Round Lake, IL 60073 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baxter International Inc	Fueyo, J (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335				Alemany R, 1997, J VIROL METHODS, V68, P147, DOI 10.1016/S0166-0934(97)00129-8; Alemany R, 1996, CANCER GENE THER, V3, P296; ARAP W, 1995, CANCER RES, V55, P1351; Attia M, 1996, CANCER RES, V126, P1787; EASTHAM JA, 1995, CANCER RES, V55, P5151; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fueyo J, 1996, ONCOGENE, V12, P103; FUEYO J, IN PRESS NEUROLOGY; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; GomezManzano C, 1996, CANCER RES, V56, P694; GOMEZMANZANO C, 1998, GENE TRANSFER THERAP, P201; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hunt KK, 1997, CANCER RES, V57, P4722; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JUNG JM, 1995, ONCOGENE, V11, P2021; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kyritsis AP, 1996, MOL CARCINOGEN, V15, P1; KYRITSIS AP, 1997, PRACTICE GUIDELINES, P473; LI Y, 1994, CANCER RES, V54, P6078; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STECK PA, 1986, J CELL BIOCHEM, V32, P1, DOI 10.1002/jcb.240320102; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	39	155	160	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					685	690		10.1038/nm0698-685	http://dx.doi.org/10.1038/nm0698-685			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623977				2022-12-25	WOS:000074008300034
J	LaBranche, H; Dupuis, S; Ben-David, Y; Bani, MR; Wellinger, RJ; Chabot, B				LaBranche, H; Dupuis, S; Ben-David, Y; Bani, MR; Wellinger, RJ; Chabot, B			Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase	NATURE GENETICS			English	Article							DNA-BINDING-PROTEINS; IMMORTAL CELLS; LENGTH; SENESCENCE; EXPRESSION; YEAST; GENE; RAP1	Telomeric DNA of mammalian chromosomes consists of several kilobase-pairs of tandemly repeated sequences with a terminal 3' overhang in single-stranded form. Maintaining the integrity of these repeats is essential for cell survival; telomere attrition is associated with chromosome instability and cell senescence, whereas stabilization of telomere length correlates with the immortalization of somatic cells(1), Telomere elongation is carried out by telomerase, an RNA-dependent DNA polymerase which adds single-stranded TAGGGT repeats to the 3' ends of chromosomes'. While proteins that associate with single-stranded telomeric repeats can influence tract lengths in yeast(2,3), equivalent factors have not yet been identified in vertebrates. Here, it is shown that the heterogeneous nuclear ribonucleoprotein Al participates in telomere biogenesis. A mouse cell line deficient in Al expression harbours telomeres that are shorter than those of a related cell line expressing normal levels of Al, Restoring Al expression in Al-deficient cells increases telomere length. Telomere elongation is also observed upon introduction of exogenous UP1, the amino-terminal fragment of A1. While both Al and UP1 bind to vertebrate single-stranded telomeric repeats directly and with specificity in vitro, only UP1 can recover telomerase activity from a cell lysate. These findings establish A1/UP1 as the first single-stranded DNA binding protein involved in mammalian telomere biogenesis and suggest possible mechanisms by which UP1 may modulate telomere length.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada	University of Sherbrooke; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Chabot, B (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada.	b.chabot@courrier.usherb.ca	Bani, Maria Rosa/AAB-3397-2020; Wellinger, Raymund/K-3207-2019; Chabot, Benoit/A-8943-2008	Bani, Maria Rosa/0000-0001-8178-1432; Wellinger, Raymund/0000-0001-6670-2759; Chabot, Benoit/0000-0003-0994-0042				AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; Blackburn EH, 1995, TELOMERES; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HUBBARD K, 1995, EXP CELL RES, V218, P241, DOI 10.1006/excr.1995.1152; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; LESTOURGEON WM, 1977, COLD SPRING HARB SYM, V42, P885, DOI 10.1101/SQB.1978.042.01.090; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PANDOLFO M, 1985, NUCLEIC ACIDS RES, V13, P6577, DOI 10.1093/nar/13.18.6577; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Strahl C, 1996, MOL CELL BIOL, V16, P53; VALENTINI O, 1985, NUCLEIC ACIDS RES, V13, P337, DOI 10.1093/nar/13.2.337; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	33	246	252	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					199	202		10.1038/575	http://dx.doi.org/10.1038/575			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620782				2022-12-25	WOS:000073865100033
J	Belaaouaj, A; McCarthy, R; Baumann, M; Gao, ZM; Ley, TJ; Abraham, SN; Shapiro, SD				Belaaouaj, A; McCarthy, R; Baumann, M; Gao, ZM; Ley, TJ; Abraham, SN; Shapiro, SD			Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis	NATURE MEDICINE			English	Article							LINEAGE	Neutrophil elastase (NE) is a potent serine proteinase(1,2) whose expression is limited to a narrow window during myeloid development. In neutrophils, NE is stored in azurophil granules along with other serine proteinases(3,4) (cathepsin G, proteinase 3 and azurocidin) at concentrations exceeding 5 mM (ref. 5). As a result of its capacity to efficiently degrade extracellular matrix, NE has been implicated in a variety of destructive diseases(6). Indeed, while much interest has focused on the pathologic effects of this enzyme, little is known regarding its normal physiologic function(s). Because previous in vitro data have shown that NE exhibits antibacterial activity(7-9), we investigated the role of NE in host defense against bacteria. Generating strains of mice deficient in NE (NE-/-) by targeted mutagenesis, we show that NE-/- mice are more susceptible than their normal littermates to sepsis and death following intraperitoneal infection with Gram negative (Klebsiella pneumoniae and Escherichia coli) but not Cram positive (Staphylococcus aureus) bacteria. Our data indicate that neutrophils migrate normally to sites of infection in the absence of NE, but that NE is required for maximal intracellular killing of Gram negative bacteria by neutrophils.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Genet, St Louis, MO 63110 USA; Duke Univ, Med Ctr, Dept Pathol & Microbiol, Durham, NC 27710 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Duke University	Shapiro, SD (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol, St Louis, MO 63110 USA.	sshapiro@imgate.wustl.edu	A, Bentaher/F-6531-2018; Bentaher, Abderrazzaq/M-4424-2017	A, Bentaher/0000-0001-6001-5456; 				BAKHA K, 1995, INFECT IMMUN, V63, P848; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; Belaaouaj K, 1997, MAMM GENOME, V8, P5, DOI 10.1007/s003359900337; Bieth JG, 1986, REGULATION MATRIX AC, P217; Blondin J., 1978, NEUTRAL PROTEASES HU, P39; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Liou TG, 1995, BIOCHEMISTRY-US, V34, P16171, DOI 10.1021/bi00049a032; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; MIYASAKI KT, 1991, INFECT IMMUN, V59, P3760, DOI 10.1128/IAI.59.10.3760-3767.1991; ODEBERG H, 1976, INFECT IMMUN, V14, P1269, DOI 10.1128/IAI.14.6.1269-1275.1976; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1334, DOI 10.1164/ajrccm/146.5_Pt_1.1334; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; THORNE KJI, 1976, INFECT IMMUN, V14, P555, DOI 10.1128/IAI.14.2.555-563.1976; WEWERS MD, 1988, J CLIN INVEST, V82, P1260, DOI 10.1172/JCI113724; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	17	501	515	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					615	618		10.1038/nm0598-615	http://dx.doi.org/10.1038/nm0598-615			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585238				2022-12-25	WOS:000073399900036
J	Fujii, I; Fukuyama, S; Iwabuchi, Y; Tanimura, R				Fujii, I; Fukuyama, S; Iwabuchi, Y; Tanimura, R			Evolving catalytic antibodies in a phage-displayed combinatorial library	NATURE BIOTECHNOLOGY			English	Article						protein engineering; molecular evolution; transition state	TRANSITION-STATE STABILIZATION; HYPERVARIABLE REGIONS; IMMUNE-SYSTEM; HIGH-AFFINITY; MUTAGENESIS; EVOLUTION; SITE; MATURATION; DIVERSITY; SELECTION	In vitro affinity maturation for evolving catalytic antibodies has been demonstrated by generating a diverse repertoire of the appropriate complementarity-determining regions on a phage surface. Phage display is followed by a selection based on binding to an altered antigen that was not used at the time of immunization, and provides variants with new catalytic activity and substrate specificity. This library format reduces the time needed to isolate the desired catalytic antibody fragments to under 2 weeks.	Biomol Engn Res Inst, Suita, Osaka 565, Japan; Prot Engn Res Inst, Suita, Osaka 565, Japan		Fujii, I (corresponding author), Biomol Engn Res Inst, 6-2-3 Furuedai, Suita, Osaka 565, Japan.		Tanimura, Ryuji/GOH-0166-2022	Tanimura, Ryuji/0000-0002-7865-5686				Baca M, 1997, P NATL ACAD SCI USA, V94, P10063, DOI 10.1073/pnas.94.19.10063; Barbas CF, 1996, TRENDS BIOTECHNOL, V14, P230, DOI 10.1016/0167-7799(96)10029-9; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7878; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; DESMET J, 1992, NATURE, V356, P839; FERSHT A, 1985, ENZYME STRUCTURE MEC, P324; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FUJII I, 1995, J AM CHEM SOC, V117, P6199, DOI 10.1021/ja00128a006; Guo Jincan, 1994, Journal of the American Chemical Society, V116, P6062, DOI 10.1021/ja00093a002; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; IWABUCHI Y, 1994, J AM CHEM SOC, V116, P771, DOI 10.1021/ja00081a049; JACKSON DY, 1991, P NATL ACAD SCI USA, V88, P58, DOI 10.1073/pnas.88.1.58; JACKSON JR, 1995, J IMMUNOL, V154, P3310; JACOBS JW, 1991, BIO-TECHNOL, V9, P258, DOI 10.1038/nbt0391-258; Kabat EA, 1991, SEQUENCES PROTEINS I; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MARKS JD, 1992, J BIOL CHEM, V267, P16007; Miyashita H, 1997, J MOL BIOL, V267, P1247, DOI 10.1006/jmbi.1997.0938; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; MURPHY DJ, 1995, BIOCHEMISTRY-US, V34, P4507, DOI 10.1021/bi00014a001; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; SCHMIDT RR, 1986, ANGEW CHEM INT EDIT, V25, P212, DOI 10.1002/anie.198602121; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; TANIMURA R, 1994, PROTEIN SCI, V3, P2358, DOI 10.1002/pro.5560031220; WADEMAYER GJ, 1997, SCIENCE, V276, P1665; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	32	72	75	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					463	467		10.1038/nbt0598-463	http://dx.doi.org/10.1038/nbt0598-463			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592396				2022-12-25	WOS:000073489600032
J	Zitvogel, L; Regnault, A; Lozier, A; Wolfers, J; Flament, C; Tenza, D; Ricciardi-Castagnoli, P; Raposo, G; Amigorena, S				Zitvogel, L; Regnault, A; Lozier, A; Wolfers, J; Flament, C; Tenza, D; Ricciardi-Castagnoli, P; Raposo, G; Amigorena, S			Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes	NATURE MEDICINE			English	Article							ANTITUMOR IMMUNITY; T-LYMPHOCYTES; ANTIGEN; GENERATION; COOPERATE; INDUCTION; THERAPY; LIGAND; ALPHA; MICE	Dendritic cells (DCs) are professional antigen presenting cells with the unique capacity to Induce primary and secondary immune responses in vivo. Here, we show that DCs secrete antigen presenting vesicles, called exosomes, which express functional Major Histocompatibility Complex class I and class II, and T-cell costimulatory molecules. Tumor peptide-pulsed DC-derived exosomes prime specific cytotoxic T lymphocytes in vivo and eradicate or suppress growth of established murine tumors in a T cell-dependent manner. Exosome-based cell-free vaccines represent an alternative to DC adoptive therapy for suppressing tumor growth.	Inst Curie, INSERM, CJF 95 01, F-75006 Paris, France; Inst Curie, UMR144 CNRS, F-75006 Paris, France; Inst Gustave Roussy, Dept Biol Clin, Lab Immunol Cellulaire, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS URA 1301, F-94805 Villejuif, France; Univ Milan, CNR, Ctr Cellular & Mol Pharmacol, I-20129 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Consiglio Nazionale delle Ricerche (CNR); University of Milan	Amigorena, S (corresponding author), Inst Curie, INSERM, CJF 95 01, 12 Rue Lhomond, F-75006 Paris, France.	s.amigorena@curie.fr		ZITVOGEL, laurence/0000-0003-1596-0998; Amigorena, Sebastian/0000-0001-8583-8416				AMBE K, 1989, CANCER, V63, P496, DOI 10.1002/1097-0142(19890201)63:3<496::AID-CNCR2820630318>3.0.CO;2-K; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cayeux S, 1997, J IMMUNOL, V158, P2834; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Dufour E, 1997, J IMMUNOL, V158, P3787; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P101, DOI 10.1006/cimm.1996.0139; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Girolomoni G, 1997, IMMUNOL TODAY, V18, P102, DOI 10.1016/S0167-5699(97)01030-X; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; Iwasaki A, 1997, J IMMUNOL, V159, P11; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Lotze MT, 1996, ANN NY ACAD SCI, V795, P440, DOI 10.1111/j.1749-6632.1996.tb52715.x; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mayordomo JI, 1997, STEM CELLS, V15, P94, DOI 10.1002/stem.150094; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; POPE M, 1995, J INVEST DERMATOL, V104, P11, DOI 10.1111/1523-1747.ep12613452; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; RAPOSO G, 1997, HDB EXPT IMMUNOLOGY, P1; Restifo NP, 1996, CURR OPIN IMMUNOL, V8, P658, DOI 10.1016/S0952-7915(96)80082-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schmidt W, 1997, P NATL ACAD SCI USA, V94, P3262, DOI 10.1073/pnas.94.7.3262; STAM NJ, 1986, J IMMUNOL, V137, P2299; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Tuting T, 1997, EUR J IMMUNOL, V27, P2702, DOI 10.1002/eji.1830271033; VONBOCKXMEER F, 1979, BIOCHIM BIOPHYS ACTA, V584, P76; Warnier G, 1996, INT J CANCER, V67, P303, DOI 10.1002/(SICI)1097-0215(19960717)67:2<303::AID-IJC24>3.0.CO;2-A; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Zitvogel L, 1996, EUR J IMMUNOL, V26, P1335, DOI 10.1002/eji.1830260624; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	35	1549	1677	6	288	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					594	600		10.1038/nm0598-594	http://dx.doi.org/10.1038/nm0598-594			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585234				2022-12-25	WOS:000073399900032
J	Crosby, JR; Seifert, RA; Soriano, P; Bowen-Pope, DF				Crosby, JR; Seifert, RA; Soriano, P; Bowen-Pope, DF			Chimaeric analysis reveals role of Pdgf receptors in all muscle lineages	NATURE GENETICS			English	Article							MOUSE CHIMERAS; DIFFERENTIATION; GROWTH; CELLS; EXPRESSION; MYOBLASTS; MICE; PROLIFERATION; DEFICIENT; FETAL	Blood vessels originate as simple endothelial cell tubes. It has been proposed that platelet-derived growth factor B polypeptide (Pdgfb) secreted by these endothelial cells drives the formation of the surrounding muscular wall by recruiting nearby mesenchymal cells(1,2). However. targetted inactivation of the Pdgfb gene(3) or the Pdgf receptor beta (Pdgfrb) gene(4), by homologous recombination, does not prevent the development of apparently normal large arteries and connective tissue. We have used an in vivo competition assay in which we prepared chimaeric blastocysts, composed of a mixture of wild-type (Pdgfrb(+/+)) and Pdgfrb(+/-) or wild-type and Pdgfrb(-/-) cells, and quantified the relative success of cells of the two component genotypes in competing for representation in different cell lineages as the chimaeric embryos developed. This study revealed that the participation of Pdgfrb(-/-) cells in all muscle lineages (smooth, cardiac, skeletal and pericyte) was reduced by eightfold compared with Pdgfrb(+/+) cells, and that participation of Pdgfrb(+/-) cells was reduced by twofold (eightfold for pericytes). Pdgfrb inactivation did not affect cell contribution to non-muscle mesodermal lineages, including fibroblasts and endothelial cells. Chimaera competition is therefore a sensitive, quantitative method for determining developmental roles of specific genes, even when those roles are not apparent from analysis of purebred mutants; most likely because they are masked by homeostatic mechanisms.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Bowen-Pope, DF (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X	NHLBI NIH HHS [HL-03174] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrett TB, 1996, J CELL PHYSIOL, V169, P126, DOI 10.1002/(SICI)1097-4652(199610)169:1<126::AID-JCP13>3.0.CO;2-B; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; JIN P, 1993, DIFFERENTIATION, V54, P47; JIN P, 1991, J BIOL CHEM, V266, P1245; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; LO CW, 1987, DIFFERENTIATION, V35, P37, DOI 10.1111/j.1432-0436.1987.tb00149.x; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; MUSCI TS, 1992, DEV BIOL, V152, P133, DOI 10.1016/0012-1606(92)90163-B; PALMER SJ, 1991, DEVELOPMENT, V112, P265; Quinn JC, 1996, GENE DEV, V10, P435, DOI 10.1101/gad.10.4.435; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; TERRACIO L, 1988, J CELL BIOL, V107, P1947, DOI 10.1083/jcb.107.5.1947; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; Wang YK, 1996, NATURE, V379, P823, DOI 10.1038/379823a0; West JD, 1996, GENET RES, V67, P135, DOI 10.1017/S0016672300033590; WEST JD, 1984, J EMBRYOL EXP MORPH, V84, P309; WILKENS AS, 1986, GENETIC ANAL ANIMAL; YABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623, DOI 10.1083/jcb.111.4.1623; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	26	97	98	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					385	388		10.1038/ng0498-385	http://dx.doi.org/10.1038/ng0498-385			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537425				2022-12-25	WOS:000072755500025
J	Arakawa, T; Chong, DKX; Langridge, WHR				Arakawa, T; Chong, DKX; Langridge, WHR			Efficacy of a food plant-based oral cholera toxin B subunit vaccine	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; vaccine design; mucosal antibodies	ANTIBODY-RESPONSES; BACTERIAL LUCIFERASE; TRANSGENIC PLANTS; ESCHERICHIA-COLI; VIBRIO-CHOLERAE; IMMUNITY; MUCOSAL; MICE; IMMUNOGENICITY; PROTEIN	Transgenic potatoes were engineered to synthesize a cholera toxin B subunit (CTB) pentamer with affinity for G(M1)-ganglioside. Both serum and intestinal CTB-specific antibodies were induced in orally immunized mice. Mucosal antibody titers declined gradually after the last immunization but were restored following an oral booster of transgenic potato. The cytopathic effect of cholera holotoxin (CT) on Vero cells was neutralized by serum from mice immunized with transgenic potato tissues. Following intraileal injection with CT, the plant-immunized mice showed up to a 60% reduction in diarrheal fluid accumulation in the small intestine. Protection against CT was based on inhibition of enterotoxin binding to the cell-surface receptor G(M1)-ganglioside, These results demonstrate the ability of transgenic food plants to generate protective immunity in mice against a bacterial enterotoxin.	Loma Linda Univ, Sch Med, Dept Microbiol & Mol Genet, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Biochem, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University; Loma Linda University	Langridge, WHR (corresponding author), Loma Linda Univ, Sch Med, Dept Microbiol & Mol Genet, Loma Linda, CA 92350 USA.							APTER FM, 1993, INFECT IMMUN, V61, P5271, DOI 10.1128/IAI.61.12.5271-5278.1993; Arakawa T, 1997, TRANSGENIC RES, V6, P403, DOI 10.1023/A:1018487401810; Bergerot I, 1997, P NATL ACAD SCI USA, V94, P4610, DOI 10.1073/pnas.94.9.4610; CLEMENS JD, 1991, J INFECT DIS, V163, P1235, DOI 10.1093/infdis/163.6.1235; CLEMENS JD, 1992, J INFECT DIS, V166, P1029, DOI 10.1093/infdis/166.5.1029; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DERTZBAUGH MT, 1993, INFECT IMMUN, V61, P384, DOI 10.1128/IAI.61.2.384-390.1993; DERTZBAUGH MT, 1993, INFECT IMMUN, V61, P48, DOI 10.1128/IAI.61.1.48-55.1993; DEVOS T, 1991, J IMMUNOL METHODS, V141, P285, DOI 10.1016/0022-1759(91)90155-9; ELSON CO, 1984, J IMMUNOL, V132, P2736; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FINKELSTEIN RA, 1995, ADV EXP MED BIOL, V371, P1633; FUJITA K, 1972, J INFECT DIS, V125, P647, DOI 10.1093/infdis/125.6.647; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HOLMGREN J, 1994, AM J TROP MED HYG, V50, P42; Holmgren Jan, 1996, P241, DOI 10.1016/B978-012410580-5/50019-4; Jackson RJ, 1996, J IMMUNOL METHODS, V190, P189, DOI 10.1016/0022-1759(95)00276-6; JERTBORN M, 1986, J CLIN MICROBIOL, V24, P203, DOI 10.1128/JCM.24.2.203-209.1986; KONCZ C, 1987, P NATL ACAD SCI USA, V84, P131, DOI 10.1073/pnas.84.1.131; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LANGRIDGE WHR, 1989, P NATL ACAD SCI USA, V86, P3219, DOI 10.1073/pnas.86.9.3219; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; LEVINE MM, 1979, T ROY SOC TROP MED H, V73, P3, DOI 10.1016/0035-9203(79)90119-6; LYCKE N, 1983, INT ARCH ALLER A IMM, V72, P119, DOI 10.1159/000234853; LYCKE N, 1989, INT ARCH ALLER A IMM, V88, P273, DOI 10.1159/000234806; MASON HS, 1995, TRENDS BIOTECHNOL, V13, P388, DOI 10.1016/S0167-7799(00)88986-6; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MEKALANOS JJ, 1994, SCIENCE, V265, P1387, DOI 10.1126/science.8073279; PUNYASHTHITI K, 1971, INFECT IMMUN, V4, P473, DOI 10.1128/IAI.4.4.473-478.1971; STAVRIC S, 1978, INFECT IMMUN, V21, P514, DOI 10.1128/IAI.21.2.514-517.1978; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; SVENNERHOLM AM, 1984, J INFECT DIS, V149, P884, DOI 10.1093/infdis/149.6.884; Svennerholm L, 1976, Adv Exp Med Biol, V71, P191; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; Waldor Matthew K., 1996, P229, DOI 10.1016/B978-012410580-5/50018-2	36	244	295	1	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					292	297		10.1038/nbt0398-292	http://dx.doi.org/10.1038/nbt0398-292			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528012				2022-12-25	WOS:000072371000032
J	Bull, PC; Lowe, BS; Kortok, M; Molyneux, CS; Newbold, CI; Marsh, K				Bull, PC; Lowe, BS; Kortok, M; Molyneux, CS; Newbold, CI; Marsh, K			Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria	NATURE MEDICINE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; ERYTHROCYTES; DIVERSITY; CYTOADHERENCE; EXPRESSION; ADHERENCE; RECEPTOR; PROTECTION; PHENOTYPES; PROTEINS	The feasibility of a malaria vaccine is supported by the fact that children in endemic areas develop naturally acquired immunity to disease. Development of disease immunity is characterized by a decrease in the frequency and severity of disease episodes over several years despite almost continuous infection(1), suggesting that immunity may develop through the acquisition of a repertoire of specific, protective antibodies directed against polymorphic target antigens(1-3). Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a potentially important family of target antigens, because these proteins are inserted into the red cell surface and are prominently exposed(4-6) and because they are highly polymorphic and undergo clonal antigenic variation(7,8,18), a mechanism of immune evasion maintained by a large family of vor genes(9-11). In a large prospective study of Kenyan children, we have used the fact that anti-PfEMP1 antibodies agglutinate infected erythrocytes in a variant-specific manner(10,12-16), to show that the PfEMP1 variants expressed during episodes of clinical malaria were less likely to be recognized by the corresponding child's own preexisting antibody response than by that of children of the same age from the same community. In contrast, a heterologous parasite isolate was just as likely to be recognized. The apparent selective pressure exerted by established anti-PfEMP1 antibodies on infecting parasites supports the idea that such responses provide variant-specific protection against disease.	Kenya Med Res Inst, CRC, Kilifi UNit, Kilifi, Kenya; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	Kenya Medical Research Institute; University of Oxford	Bull, PC (corresponding author), Kenya Med Res Inst, CRC, Kilifi UNit, POB 230, Kilifi, Kenya.	pbull@africaonline.co.ke	Molyneux, Catherine/HGB-8464-2022	Molyneux, Catherine/0000-0001-9522-416X; Newbold, Chris/0000-0002-9274-3789; Bull, Peter/0000-0002-7674-6752	Wellcome Trust [061524] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANITA R, 1996, P NATL ACAD SCI USA, V93, P985; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BIGGS BA, 1992, J IMMUNOL, V149, P2047; FORSYTH KP, 1989, AM J TROP MED HYG, V41, P259, DOI 10.4269/ajtmh.1989.41.259; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; INSELBURG J, 1984, EXP PARASITOL, V57, P48, DOI 10.1016/0014-4894(84)90061-4; IQBAL J, 1993, T ROY SOC TROP MED H, V87, P583, DOI 10.1016/0035-9203(93)90097-A; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MBOGO CNM, 1993, AM J TROP MED HYG, V49, P245, DOI 10.4269/ajtmh.1993.49.245; Molineaux L, 1996, ANN TROP MED PARASIT, V90, P379, DOI 10.1080/00034983.1996.11813067; NEWBOLD CI, 1992, EXP PARASITOL, V75, P281, DOI 10.1016/0014-4894(92)90213-T; REEDER JC, 1994, AM J TROP MED HYG, V51, P45, DOI 10.4269/ajtmh.1994.51.45; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROBERTS DJ, 1993, PARASITOL TODAY, V9, P281, DOI 10.1016/0169-4758(93)90121-U; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840	23	497	501	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					358	360		10.1038/nm0398-358	http://dx.doi.org/10.1038/nm0398-358			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500614	Green Accepted			2022-12-25	WOS:000073616200046
J	Hoyle, R				Hoyle, R			Genetically engineered organic food?	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					214	214		10.1038/nbt0398-214	http://dx.doi.org/10.1038/nbt0398-214			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9527990	Bronze			2022-12-25	WOS:000072371000004
J	Kren, BT; Bandyopadhyay, P; Steer, CJ				Kren, BT; Bandyopadhyay, P; Steer, CJ			In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides	NATURE MEDICINE			English	Article							BILIRUBIN-UDP-GLUCURONOSYLTRANSFERASE; TRIPLE-HELIX FORMATION; HOMOLOGOUS RECOMBINATION; DNA OLIGONUCLEOTIDE; MISMATCH REPAIR; CELL-CYCLE; IN-VIVO; EXPRESSION; THERAPY; DEFICIENCY	A chimeric RNA/DNA oligonucleotide was constructed to induce a sequence mutation in the rat factor IX gene, resulting in prolonged coagulation. Oligonucleotides were targeted to hepatocytes in cell culture or in vivo by intravenous injection. Nucleotide conversion was both site-specific and dose-dependent. The mutated gene was associated in vivo with significantly reduced factor IX coagulant activity and a marked prolongation of the activated partial thromboplastin time. The results demonstrate that single base-pair alterations can be introduced in hepatocytes in situ by RNA/DNA oligonucleotides, suggesting a potentially powerful strategy for hepatic gene repair without the use of viral vectors.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Kren, BT (corresponding author), Univ Minnesota, Sch Med, Dept Med, 420 Delaware St,SE, Minneapolis, MN 55455 USA.							Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; ARBONES ML, 1994, NAT GENET, V6, P90, DOI 10.1038/ng0194-90; Askari FK, 1996, GENE THER, V3, P381; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bowles N, 1995, ADV DRUG DELIVER REV, V17, P293, DOI 10.1016/0169-409X(95)00063-D; BULLA GA, 1992, GENE DEV, V6, P316, DOI 10.1101/gad.6.2.316; CHANG AGY, 1994, GASTROENTEROLOGY, V106, P1076, DOI 10.1016/0016-5085(94)90771-4; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; Connelly S, 1996, BLOOD, V87, P4671, DOI 10.1182/blood.V87.11.4671.bloodjournal87114671; Fan GS, 1996, ONCOGENE, V12, P1909; FANG WH, 1993, J BIOL CHEM, V268, P11838; GRAY GR, 1974, ARCH BIOCHEM BIOPHYS, V163, P426, DOI 10.1016/0003-9861(74)90495-0; Ilan Y, 1997, J CLIN INVEST, V99, P1098, DOI 10.1172/JCI119238; KEN BT, 1997, HEPATOLOGY, V25, P1462; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KMIEC EB, 1994, MOL CELL BIOL, V14, P7163, DOI 10.1128/MCB.14.11.7163; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kotani H, 1996, MOL GEN GENET, V250, P626; Kren BT, 1996, AM J PHYSIOL-GASTR L, V270, pG763, DOI 10.1152/ajpgi.1996.270.5.G763; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; MONIA BP, 1993, J BIOL CHEM, V268, P14514; PROUTY SM, 1993, ONCOGENE, V8, P899; REINER AP, 1995, METABOLIC MOL BASES, P3181; SAKAGAMI K, 1994, P NATL ACAD SCI USA, V91, P8527, DOI 10.1073/pnas.91.18.8527; SARKAR G, 1990, GENOMICS, V6, P133, DOI 10.1016/0888-7543(90)90458-7; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; STRAUSS M, 1994, GENE THER, V1, P156; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; Teckman JH, 1996, HEPATOLOGY, V24, P1504, DOI 10.1002/hep.510240635; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; WONG EA, 1987, MOL CELL BIOL, V7, P2294, DOI 10.1128/MCB.7.6.2294; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Ye XH, 1996, J BIOL CHEM, V271, P3639; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0	41	238	325	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					285	290		10.1038/nm0398-285	http://dx.doi.org/10.1038/nm0398-285			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500600				2022-12-25	WOS:000073616200032
J	Larsson, NG; Wang, JM; Wilhelmsson, H; Oldfors, A; Rustin, P; Lewandoski, M; Barsh, GS; Clayton, DA				Larsson, NG; Wang, JM; Wilhelmsson, H; Oldfors, A; Rustin, P; Lewandoski, M; Barsh, GS; Clayton, DA			Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice	NATURE GENETICS			English	Article							DNA; PROTEIN	The regulation of mitochondrial DNA (mtDNA) expression is crucial for mitochondrial biogenesis during development and differentiation. We have disrupted the mouse gene for mitochondrial transcription factor A (Tfam; formerly known as m-mtTFA) by gene targettimg of loxP-sites followed by cre-mediated excision in vivo. Heterozygous knockout mice exhibit reduced mtDNA copy number and respiratory chain deficiency in heart. Homozygous knockout embryos exhibit a severe mtDNA depletion with abolished oxidative phosphorylation. Mutant embryos proceed through implantation and gastrulation, but die prior to embryonic day (E)10.5. Thus, Tfam is the first mammalian protein demonstrated to regulate mtDNA copy number in vivo and is essential for mitochondrial biogenesis and embryonic development.	Dept Mol Med, Ctr Mol Med L8 02, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Woman & Child Hlth, S-17176 Stockholm, Sweden; Sahlgrenska Hosp, Dept Pathol, S-41345 Gothenburg, Sweden; Hop Necker Enfants Malad, INSERM, U393, F-75015 Paris, France; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Stanford, CA 94305 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute	Larsson, NG (corresponding author), Dept Mol Med, Ctr Mol Med L8 02, S-17176 Stockholm, Sweden.	nils-goran.larsson@cmm.ki.se	Larsson, Nils-Göran/GVS-5578-2022	Larsson, Nils-Göran/0000-0001-5100-996X; Oldfors, Anders/0000-0002-5758-7397; Lewandoski, Mark/0000-0002-1066-3735	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM33088-27] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; DAIRAGHI DJ, 1995, J MOL BIOL, V249, P11, DOI 10.1006/jmbi.1995.9889; EBERT KM, 1988, J REPROD FERTIL, V82, P145, DOI 10.1530/jrf.0.0820145; ENGLAND JM, 1978, J MOL BIOL, V119, P455, DOI 10.1016/0022-2836(78)90226-7; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HOGAN B, 1994, LAB MANUAL; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LANSMAN RA, 1975, J MOL BIOL, V99, P761, DOI 10.1016/S0022-2836(75)80183-5; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Larsson NG, 1997, MAMM GENOME, V8, P139, DOI 10.1007/s003359900373; Larsson NG, 1997, HUM MOL GENET, V6, P185, DOI 10.1093/hmg/6.2.185; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LEWANDOSKI M, IN PRESS COLD SPRING; MICHAEL NL, 1984, EMBO J, V3, P3165, DOI 10.1002/j.1460-2075.1984.tb02275.x; Ostronoff LK, 1995, BIOCHEM BIOPH RES CO, V217, P1094, DOI 10.1006/bbrc.1995.2881; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PIKO L, 1976, DEV BIOL, V49, P1, DOI 10.1016/0012-1606(76)90253-0; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; PIKO L, 1973, J CELL BIOL, V58, P357, DOI 10.1083/jcb.58.2.357; POLOSA PL, 1991, J BIOL CHEM, V266, P10011; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	29	1140	1186	2	67	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					231	236		10.1038/ng0398-231	http://dx.doi.org/10.1038/ng0398-231			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500544				2022-12-25	WOS:000072325000020
J	Duport, C; Spagnoli, R; Degryse, E; Pompon, D				Duport, C; Spagnoli, R; Degryse, E; Pompon, D			Self-sufficient biosynthesis of pregnenolone and progesterone in engineered yeast	NATURE BIOTECHNOLOGY			English	Article						metabolic engineering; Saccharomyces cerevisiae; steroid	SACCHAROMYCES-CEREVISIAE; STEROL BIOSYNTHESIS; EXPRESSION; CLONING; GENE; CHOLESTEROL; PATHWAYS; MUTANTS; VECTORS; SYSTEM	The first two steps of the steroidogenic pathway were reproduced in Saccharomyces cerevisiae. Engineering of sterol biosynthesis by disruption of the Delta 22-desaturase gene and introduction of the Arabidopsis thaliana Delta 7-reductase activity and coexpression of bovine side chain cleavage cytochrome P450, adrenodoxin, and adrenodoxin reductase, lead to pregnenolone biosynthesis from a simple carbon source. Following additional coexpression of human 3 beta-hydroxysteroid dehydrogenase/isomerase, pregnenolone is further metabolized to progesterone. Steroid formation appears to be coupled to yeast sterol biosynthesis.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Hoechst Marion Roussel, Dept Biotechnol, F-93235 Romainville, France; Transgene SA, Yeast Dept, F-67082 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France; Transgene SA	Pompon, D (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.							AKIYOSHISHIBATA M, 1991, DNA CELL BIOL, V10, P613, DOI 10.1089/dna.1991.10.613; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLACK SM, 1994, P NATL ACAD SCI USA, V91, P7247, DOI 10.1073/pnas.91.15.7247; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; CHENIVESSE X, 1996, Patent No. 96400301; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DEGRYSE E, 1995, YEAST, V11, P629, DOI 10.1002/yea.320110704; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HARMEN S, 1989, Patent No. 0360361; LADEVEZE V, 1993, LIPIDS, V28, P907, DOI 10.1007/BF02537499; Lecain E, 1996, J BIOL CHEM, V271, P10866, DOI 10.1074/jbc.271.18.10866; LIEBERMAN S, 1990, ENDOCR REV, V11, P469, DOI 10.1210/edrv-11-4-469; LORENZ RT, 1991, ANTIMICROB AGENTS CH, V35, P1532, DOI 10.1128/AAC.35.8.1532; Mahato SB, 1997, STEROIDS, V62, P332, DOI 10.1016/S0039-128X(96)00251-6; MATHEW PA, 1990, MOL CELL ENDOCRINOL, V73, P73, DOI 10.1016/0303-7207(90)90046-B; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Novikova L A, 1995, Biokhimiia, V60, P995; PARKS LW, 1995, ANNU REV MICROBIOL, V49, P95, DOI 10.1146/annurev.mi.49.100195.000523; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; Skaggs BA, 1996, GENE, V169, P105, DOI 10.1016/0378-1119(95)00770-9; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TUCKEY RC, 1993, EUR J BIOCHEM, V217, P209, DOI 10.1111/j.1432-1033.1993.tb18235.x; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WOODS GF, 1975, STEROID IMMUNOASSAY, P6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	93	110	7	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					186	189		10.1038/nbt0298-186	http://dx.doi.org/10.1038/nbt0298-186			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487528				2022-12-25	WOS:000071831300034
J	Rols, MP; Delteil, C; Golzio, M; Dumond, P; Cros, S; Teissie, J				Rols, MP; Delteil, C; Golzio, M; Dumond, P; Cros, S; Teissie, J			In vivo electrically mediated protein and gene transfer in murine melanoma	NATURE BIOTECHNOLOGY			English	Article						drug delivery; gene therapy; electropermeabilization	MAMMALIAN-CELLS; ANTITUMOR ELECTROCHEMOTHERAPY; PLASMID DNA; ELECTROPORATION; ELECTROPERMEABILIZATION; MEMBRANES; FIELD; EXPRESSION; HUMANS; PULSES	We show that efficient permeabilization of murine melanoma can be obtained in vivo by applying electric pulses. More than 80% of the cell population is affected as shown by the penetration of propidium iodide. A protein, beta-galactosidase, can be transferred and expressed into the cells by incorporating either the protein or a plasmid carrying the reporter gene with respective efficiencies of 20% and 4%, This is obtained by a direct injection of either the protein or the plasmid in the tumor, followed by the application of electric pulses with surface electrodes in contact with the skin. This approach is simple and safe to use, reproducible, and specific; moreover, it is potentially applicable to a wide variety of tissues, cell types, and animals.	Inst Pharmacol & Struct Biol, UPR 9062, F-31062 Toulouse, France		Teissie, J (corresponding author), Inst Pharmacol & Struct Biol, UPR 9062, 118 Route Narbonne, F-31062 Toulouse, France.		ROLS, Marie-Pierre/GLV-6546-2022; rols, marie-pierre/AAU-8093-2021; Teissie, Justin/AAA-5697-2019; Golzio, Muriel/F-4715-2019	Teissie, Justin/0000-0002-7588-8062; Golzio, Muriel/0000-0002-7470-3708; rols, marie-pierre/0000-0003-3100-6272				BELEHRADEK M, 1993, CANCER, V72, P3692; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DAGHER SF, 1991, EXP CELL RES, V198, P36; DEUTICKE B, 1989, ELECTROPORATION ELEC, P127; Domenge C, 1996, CANCER-AM CANCER SOC, V77, P956, DOI 10.1002/(SICI)1097-0142(19960301)77:5<956::AID-CNCR23>3.0.CO;2-1; GENCO I, 1993, BIOCHIM BIOPHYS ACTA, V1149, P10, DOI 10.1016/0005-2736(93)90019-V; GILBERT R, 1996, BIOCHIM BIOPHYS ACTA, V1334, P9; Goldman CK, 1997, NAT BIOTECHNOL, V15, P462, DOI 10.1038/nbt0597-462; HELLER R, 1995, BIOELECTROCH BIOENER, V36, P83, DOI 10.1016/0302-4598(94)05013-K; Heller R, 1996, FEBS LETT, V389, P225, DOI 10.1016/0014-5793(96)00590-X; HERLYN M, 1996, SKIN CANC FDN J, V14, P41; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; MARSZALEK P, 1990, BIOPHYS J, V58, P1053, DOI 10.1016/S0006-3495(90)82447-4; MIR LM, 1995, BIOELECTROCH BIOENER, V38, P203, DOI 10.1016/0302-4598(95)01823-W; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; Nishi T, 1996, CANCER RES, V56, P1050; Prausnitz MR, 1996, ADV DRUG DELIVER REV, V18, P395, DOI 10.1016/0169-409X(95)00081-H; ROLS MP, 1990, BIOPHYS J, V58, P1089, DOI 10.1016/S0006-3495(90)82451-6; ROLS MP, 1992, EUR J BIOCHEM, V206, P115, DOI 10.1111/j.1432-1033.1992.tb16908.x; ROLS MP, 1994, NUCLEIC ACIDS RES, V22, P540, DOI 10.1093/nar/22.3.540; ROLS MP, 1995, BIOCHEM BIOPH RES CO, V208, P26, DOI 10.1006/bbrc.1995.1300; ROLS MP, METHODS MOL BIOL FLO; Sersa G, 1996, BIOELECTROCH BIOENER, V39, P61, DOI 10.1016/0302-4598(95)01866-2; TEISSIE J, 1993, BIOPHYS J, V65, P409, DOI 10.1016/S0006-3495(93)81052-X; TEKLE E, 1994, P NATL ACAD SCI USA, V91, P11512, DOI 10.1073/pnas.91.24.11512; TITOMIROV AV, 1991, BIOCHIM BIOPHYS ACTA, V1088, P131, DOI 10.1016/0167-4781(91)90162-F; TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9; WOLF H, 1994, BIOPHYS J, V66, P524, DOI 10.1016/S0006-3495(94)80805-7	31	331	345	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					168	171		10.1038/nbt0298-168	http://dx.doi.org/10.1038/nbt0298-168			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487524				2022-12-25	WOS:000071831300030
J	Donzella, GA; Schols, D; Lin, SW; Este, JA; Nagashima, KA; Maddon, PJ; Allaway, GP; Sakmar, TP; Henson, G; De Clercq, E; Moore, JP				Donzella, GA; Schols, D; Lin, SW; Este, JA; Nagashima, KA; Maddon, PJ; Allaway, GP; Sakmar, TP; Henson, G; De Clercq, E; Moore, JP			AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SELECTIVE-INHIBITION; CHEMOKINE RECEPTORS; DISEASE PROGRESSION; CELL-LINES; IN-VIVO; INFECTION; POTENT; CORECEPTOR; BICYCLAMS	The bicyclam AMD3100 (formula weight 830) blocks HIV-1 entry and membrane fusion via the CXCR4 co-receptor, but not via CCR5. AMD3100 prevents monoclonal antibody 12G5 from binding to CXCR4 but has no effect on binding of monoclonal antibody 2D7 to CCR5. It also inhibits binding of the CXC-chemokine, SDF-1 alpha, to CXCR4 and subsequent signal transduction, bur does not itself cause signaling and has no effect on RANTES signaling via CCR5. Thus, AMD3100 prevents CXCR4 functioning as both a HIV-1 co-receptor and a CXC-chemokine receptor. Development of small molecule inhibitors of HIV-1 entry is feasible.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Progen Pharmaceut, Tarrytown, NY 10591 USA; AnorMED, Langley, BC V2Y 1N5, Canada	Rockefeller University; KU Leuven; Howard Hughes Medical Institute; Rockefeller University	Moore, JP (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	jmoore@adarc.org	Schols, Dominique/AAC-1309-2021; Schols, Dominique/S-9057-2017; Sakmar, Thomas P/D-1833-2015; Este, Jose/B-5509-2008	Schols, Dominique/0000-0003-3256-5850; Schols, Dominique/0000-0003-3256-5850; Sakmar, Thomas P/0000-0002-2836-8953; Este, Jose/0000-0002-1436-5823; De Clercq, Erik/0000-0002-2985-8890	NIAID NIH HHS [AI 41420] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Datema R, 1996, ANTIMICROB AGENTS CH, V40, P750, DOI 10.1128/AAC.40.3.750; DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668; DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DeVreese K, 1996, ANTIVIR RES, V29, P209, DOI 10.1016/0166-3542(95)00837-3; DeVreese K, 1996, J VIROL, V70, P689, DOI 10.1128/JVI.70.2.689-696.1996; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; KOITO A, 1995, VIROLOGY, V206, P878, DOI 10.1006/viro.1995.1010; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LAYNE SP, 1991, J VIROL, V65, P3293, DOI 10.1128/JVI.65.6.3293-3300.1991; Litwin V, 1996, J VIROL, V70, P6437, DOI 10.1128/JVI.70.9.6437-6441.1996; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PANTALEO G, 1993, EUR J IMMUNOL, V21, P1771; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Potempa S, 1997, J VIROL, V71, P4419, DOI 10.1128/JVI.71.6.4419-4424.1997; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; SAAG MS, 1994, J ACQ IMMUN DEF SYND, V7, pS2; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; Sylwester A, 1997, J IMMUNOL, V158, P3996; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TRKOLA A, IN PRESS J VIROL; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WU L, IN PRESS J EXP MED; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	49	648	697	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					72	77		10.1038/nm0198-072	http://dx.doi.org/10.1038/nm0198-072			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427609				2022-12-25	WOS:000072249700037
J	Jenne, DE; Reimann, H; Nezu, J; Friedel, W; Loff, S; Jeschke, R; Muller, D; Back, W; Zimmer, M				Jenne, DE; Reimann, H; Nezu, J; Friedel, W; Loff, S; Jeschke, R; Muller, D; Back, W; Zimmer, M			Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase	NATURE GENETICS			English	Article							CANCER; GENES; CHROMOSOME-5Q21; IDENTIFICATION; LOCUS; MAP	Peutz-Jeghers (PJ) syndrome is an autosomal-dominant disorder characterized by melanocytic macules of the lips, multiple gastrointestinal hamartomatous polyps and an increased risk for various neoplasms, including gastrointestinal cancer. The PJ gene was recently mapped to chromosome 19p13.3 by linkage analysis, with the highest lod score at marker D19S886. In a distance of 190 kb proximal to D19S886, we identified and characterized a novel human gene encoding the serine threonine kinase STK11. In a three-generation PJ family, we found an STK11 allele with a deletion of exons 4 and 5 and an inversion of exons 6 and 7 segregating with the disease. Sequence analysis of STK11 exons in four unrelated PJ patients has identified three nonsense and one acceptor splice site mutations. All five germline mutations are predicted to disrupt the function of the kinase domain, We conclude that germline mutations in STK11, probably in conjunction with acquired genetic defects of the second allele in somatic cells, cause the manifestations of PJ syndrome.	Max Planck Inst Psychiat, Dept Neuroimmunol, D-82152 Martinsried, Germany; Chugai Res Inst Mol Med, Ibaraki, Osaka 30041, Japan; Univ Bonn, Inst Human Genet, D-53111 Bonn, Germany; Univ Heidelberg, Mannheim Clin, Dept Pediat Surg, D-68135 Mannheim, Germany; Univ Wurzburg, Childrens Clin & Polyclin, D-97080 Wurzburg, Germany; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44139 Dortmund, Germany; Univ Heidelberg, Mannheim Clin, Dept Pathol, D-68135 Mannheim, Germany; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97078 Wurzburg, Germany	Max Planck Society; University of Bonn; Ruprecht Karls University Heidelberg; University of Wurzburg; Max Planck Society; Ruprecht Karls University Heidelberg; University of Wurzburg	Jenne, DE (corresponding author), Max Planck Inst Psychiat, Dept Neuroimmunol, Klopferspitz 18A, D-82152 Martinsried, Germany.		Jenne, Dieter Erich/AAP-1414-2020	Loff, Steffan/0000-0003-4788-3181				Amos CI, 1997, CANCER RES, V57, P3653; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOFF S, 1995, LANGENBECK ARCH CHIR, V380, P43; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PILAT D, 1994, GENOMICS, V24, P445, DOI 10.1006/geno.1994.1651; RACKWITZ HR, 1985, GENE, V40, P259, DOI 10.1016/0378-1119(85)90048-4; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	19	836	887	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					38	44		10.1038/ng0198-38	http://dx.doi.org/10.1038/ng0198-38			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425897				2022-12-25	WOS:000071259600018
J	Kohlhase, J; Wischermann, A; Reichenbach, H; Froster, U; Engel, W				Kohlhase, J; Wischermann, A; Reichenbach, H; Froster, U; Engel, W			Mutations in the SALL1 putative transcription factor gene cause Townes-Brocks syndrome	NATURE GENETICS			English	Article							HOMEOTIC GENE; DROSOPHILA EMBRYO; SPALT; REGION; HOMOLOG; SYSTEM; HEAD; DPP; EYE	Townes-Brocks syndrome (TBS, OMIM #107480) is a rare autosomal-dominant malformation syndrome with a combination of anal, renal, limb and ear anomalies(1), Cytogenetic findings(2) suggested that the gene mutated in TBS maps to chromosome 16q12.1, where SALL1 (previously known as HSAL1), a human homologue of spalt (sal), is located(3). SAL is a developmental regulator in Drosophila melanogaster(4-8) and is conserved throughout evolution(3,9-11). No phenotype has yet been attributed to mutations in vertebrate sal-like genes. The expression patterns of sal-like genes in mouse(9), Xenopus(10) and the fish Medaka(11), and the finding that Medaka sal is regulated by Sonic hedgehog (Shh; ref. 11), prompted us to examine SALL1 as a TBS candidate gene. Here we demonstrate that SALL1 mutations cause TBS in a family with vertical transmission of TBS12 and in an unrelated family with a sporadic case of TBS. Both mutations are predicted to result in a prematurely terminated SALL1 protein lacking all putative DNA binding domains. TBS therefore represents another human developmental disorder caused by mutations in a putative C2H2 zinc-finger transcription factor.	Univ Gottingen, Inst Human Genet, D-37073 Gottingen, Germany; Kinderkrankenhaus, Kinderchirurg Klin, D-50735 Cologne, Germany; Univ Leipzig Klinikum, Inst Human Genet, D-04103 Leipzig, Germany	University of Gottingen; Leipzig University	Kohlhase, J (corresponding author), Univ Gottingen, Inst Human Genet, Gosslerstr 12D, D-37073 Gottingen, Germany.							CAMERON TH, 1991, AM J MED GENET, V41, P1, DOI 10.1002/ajmg.1320410102; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DEPINANETO JM, 1984, AM J MED GENET, V18, P147, DOI 10.1002/ajmg.1320180118; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; FERRAZ FG, 1989, ANN GENET-PARIS, V32, P120; Hollemann T, 1996, MECH DEVELOP, V55, P19, DOI 10.1016/0925-4773(95)00485-8; Ishikiriyama S, 1996, AM J MED GENET, V61, P191, DOI 10.1002/ajmg.1320610203; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Koster R, 1997, DEVELOPMENT, V124, P3147; Kuhnlein RP, 1996, DEVELOPMENT, V122, P2215; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newman WG, 1997, CLIN DYSMORPHOL, V6, P57; Ott T, 1996, MECH DEVELOP, V56, P117, DOI 10.1016/0925-4773(96)00516-3; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROSSMILLER DR, 1994, OTOLARYNG HEAD NECK, V111, P175, DOI 10.1016/S0194-5998(94)70588-7; Serville F., 1993, Genetic Counseling, V4, P109; Sturtevant MA, 1997, DEVELOPMENT, V124, P21; Tickle C, 1996, DEV GENET, V19, P1, DOI 10.1002/(SICI)1520-6408(1996)19:1&lt;1::AID-DVG1&gt;3.0.CO;2-D; TOWNES PL, 1972, J PEDIATR-US, V81, P321, DOI 10.1016/S0022-3476(72)80302-0; Valentini RP, 1997, J BIOL CHEM, V272, P8466, DOI 10.1074/jbc.272.13.8466; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Wischermann A, 1997, MONATSSCHR KINDERH, V145, P382, DOI 10.1007/s001120050137	28	317	332	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					81	83		10.1038/ng0198-81	http://dx.doi.org/10.1038/ng0198-81			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425907				2022-12-25	WOS:000071259600028
J	Dolphin, CT; Janmohamed, A; Smith, RL; Shephard, EA; Phillips, IR				Dolphin, CT; Janmohamed, A; Smith, RL; Shephard, EA; Phillips, IR			Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome	NATURE GENETICS			English	Article							FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES; POLYMERASE CHAIN-REACTION; CONTAINING MONOOXYGENASE; SUBSTRATE-SPECIFICITY; GLUTATHIONE-REDUCTASE; ESCHERICHIA-COLI; SEQUENCE; EXPRESSION; TRIMETHYLAMINURIA; CLONING	Individuals with primary trimethylaminuria exhibit a body odour reminiscent of rotting fish, due to excessive excretion of trimethylamine (TMA; refs 1-3). The disorder, colloquially known as fish-odour syndrome, is inherited recessively as a defect in hepatic N-oxidation of dietary-derived TMA(4-6) and cannot be considered benign, as sufferers may display a variety of psychosocial reactions, ranging from social isolation to clinical depression and attempted suicide(6). TMA oxidation is catalyzed by flavin-containing mono-oxygenase (FMO; refs 7,8), and tissue localization(9,10) and functional studies(11) have established FMO3 as the form most likely to be defective in fish-odour syndrome. Direct sequencing of the coding exons of FMO3 amplified from a patient with fish-odour syndrome identified two missense mutations. Although one of these represented a common polymorphism, the other, a C-->T transition in exon 4, was found only in an affected pedigree, in which it segregated with the disorder. The latter mutation predicts a proline-->leucine substitution at residue 153 and abolishes FMO3 catalytic activity. Our results indicate that defects in FMO3 underlie fish-odour syndrome and that the Pro153-->Leu153 mutation described here is a cause of this distressing condition.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT BIOCHEM,MOL BIOL LAB,LONDON E1 4NS,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOL BIOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON W2 1PG,ENGLAND	University of London; Queen Mary University London; University of London; University College London; Imperial College London			Phillips, Ian R/A-7337-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABOAGYEKWARTENG T, 1992, MOL MICROBIOL, V6, P3089, DOI 10.1111/j.1365-2958.1992.tb01766.x; ALWAIZ M, 1987, CLIN PHARMACOL THER, V42, P608, DOI 10.1038/clpt.1987.207; ALWAIZ M, 1987, LANCET, V1, P634; ALWAIZ M, 1988, CLIN SCI, V74, P231, DOI 10.1042/cs0740231; AYESH R, 1988, BRIT J CLIN PHARMACO, V25, pP664; AYESH R, 1993, BRIT MED J, V307, P655, DOI 10.1136/bmj.307.6905.655; CHEN YCJ, 1988, J BACTERIOL, V170, P781, DOI 10.1128/jb.170.2.781-789.1988; DIXIT A, 1984, ARCH BIOCHEM BIOPHYS, V233, P50, DOI 10.1016/0003-9861(84)90600-3; Dolphin CT, 1996, EUR J BIOCHEM, V235, P683, DOI 10.1111/j.1432-1033.1996.00683.x; DOLPHIN CT, IN PRESS GENOMICS; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; GUT I, 1993, BIOCHEM PHARMACOL, V46, P239, DOI 10.1016/0006-2952(93)90409-P; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; Itagaki K, 1996, J BIOL CHEM, V271, P20102, DOI 10.1074/jbc.271.33.20102; LADDAGA RA, 1987, P NATL ACAD SCI USA, V84, P5106, DOI 10.1073/pnas.84.15.5106; Lake BG, 1987, BIOCH TOXICOLOGY PRA, P183; LAWTON MP, 1994, ARCH BIOCHEM BIOPHYS, V308, P254, DOI 10.1006/abbi.1994.1035; LOMRI N, 1993, CHEM RES TOXICOL, V6, P425, DOI 10.1021/tx00034a006; Mitchell SC, 1996, PERSPECT BIOL MED, V39, P514; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; OVERBY LH, 1995, ARCH BIOCHEM BIOPHYS, V317, P275, DOI 10.1006/abbi.1995.1163; PARK SB, 1993, CHEM RES TOXICOL, V6, P880, DOI 10.1021/tx00036a019; PHILLIPS IR, 1995, CHEM-BIOL INTERACT, V96, P17, DOI 10.1016/0009-2797(94)03580-2; SHELLEY ED, 1984, JAMA-J AM MED ASSOC, V251, P253, DOI 10.1001/jama.251.2.253; SHEPHARD EA, 1993, GENOMICS, V16, P85, DOI 10.1006/geno.1993.1144; Spellacy E, 1980, J Inherit Metab Dis, V2, P85; Suh JK, 1996, ARCH BIOCHEM BIOPHYS, V336, P268, DOI 10.1006/abbi.1996.0557; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZIEGLER DM, 1990, TRENDS PHARMACOL SCI, V11, P321, DOI 10.1016/0165-6147(90)90235-Z	30	203	235	1	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					491	494		10.1038/ng1297-491	http://dx.doi.org/10.1038/ng1297-491			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398858				2022-12-25	WOS:A1997YJ92400037
J	Everett, LA; Glaser, B; Beck, JC; Idol, JR; Buchs, A; Heyman, M; Adawi, F; Hazani, E; Nassir, E; Baxevanis, AD; Sheffield, VC; Green, ED				Everett, LA; Glaser, B; Beck, JC; Idol, JR; Buchs, A; Heyman, M; Adawi, F; Hazani, E; Nassir, E; Baxevanis, AD; Sheffield, VC; Green, ED			Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS)	NATURE GENETICS			English	Article							HORMONE RECEPTOR-BETA; CONGENITAL CHLORIDE DIARRHEA; PROTEIN-CODING REGIONS; THYROID-HORMONE; HUMAN GENOME; WAARDENBURG SYNDROME; HEARING-LOSS; SEQUENCE; LINKAGE; MAPS	Pendred syndrome is a recessively inherited disorder with the hallmark features of congenital deafness and thyroid goitre, By some estimates, the disorder may account for upwards of 10% of hereditary deafness, Previous genetic linkage studies localized the gene to a broad interval on human chromosome 7q22-31.1. Using a positional cloning strategy, we have identified the gene (PDS) mutated in Pendred syndrome and found three apparently deleterious mutations, each segregating with the disease in the respective families in which they occur. PDS produces a transcript of approximately 5 kb that was found to be expressed at significant levels only in the thyroid. The predicted protein, pendrin, is closely related to a number of known sulphate transporters. These studies provide compelling evidence that defects in pendrin cause Pendred syndrome thereby launching a new area of investigation into thyroid physiology, the pathogenesis of congenital deafness and the role of altered sulphate transport in human disease.	NATL HUMAN GENOME RES INST, GENOME TECHNOL BRANCH, NIH, BETHESDA, MD 20892 USA; HADASSAH UNIV HOSP, DEPT ENDOCRINOL & METAB, IL-91120 JERUSALEM, ISRAEL; UNIV IOWA, DEPT PEDIAT, DIV MED GENET, IOWA CITY, IA 52242 USA; RIVKA ZEEV HOSP, DEPT ENDOCRINOL, IL-16950 ZAFAD, ISRAEL; WESTERN GALILEE NAHARIYA HOSP, DEPT INTERNAL MED, IL-22100 NAHARIYYA, ISRAEL	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Hebrew University of Jerusalem; University of Iowa; Western Galilee Hospital			Glaser, Benjamin/F-8411-2017	Glaser, Benjamin/0000-0003-4711-5000; Sheffield, Val/0000-0002-6282-0835; Baxevanis, Andy/0000-0002-5370-0014	NHGRI NIH HHS [R01-HG00457] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000457] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P31, DOI 10.1093/nar/25.1.31; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALDWIN CT, 1995, HUM MOL GENET, V4, P1637, DOI 10.1093/hmg/4.9.1637; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BATSAKIS JG, 1962, ARCHIV OTOLARYNGOL, V76, P401; BAUMEISTER FAM, 1988, CELL TISSUE RES, V252, P349; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Boguski M, 1996, GENOME RES, V6, P771, DOI 10.1101/gr.6.9.771; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Bouffard GG, 1997, GENOME RES, V7, P59, DOI 10.1101/gr.7.1.59; Bouffard GG, 1997, GENOME RES, V7, P673, DOI 10.1101/gr.7.7.673; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; Byeon MK, 1996, ONCOGENE, V12, P387; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Coucke P, 1997, GENOMICS, V40, P48, DOI 10.1006/geno.1996.4541; Coyle B, 1996, NAT GENET, V12, P421, DOI 10.1038/ng0496-421; DEOL MS, 1973, J MED GENET, V10, P235, DOI 10.1136/jmg.10.3.235; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; FRASER GR, 1965, ANN HUM GENET, V28, P201; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gausden E, 1997, J MED GENET, V34, P126, DOI 10.1136/jmg.34.2.126; George DG, 1997, NUCLEIC ACIDS RES, V25, P24, DOI 10.1093/nar/25.1.24; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GREEN ED, 1995, GENOMICS, V25, P170, DOI 10.1016/0888-7543(95)80123-4; GREEN ED, 1991, GENOMICS, V11, P548, DOI 10.1016/0888-7543(91)90062-J; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HERZOG V, 1986, EUR J CELL BIOL, V39, P399; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; Hoglund P, 1996, GENOME RES, V6, P202, DOI 10.1101/gr.6.3.202; ILLUM P, 1972, ARCHIV OTOLARYNGOL, V96, P297; JOHNSEN T, 1986, ACTA OTO-LARYNGOL, V102, P239, DOI 10.3109/00016488609108673; JOHNSEN T, 1989, CLIN OTOLARYNGOL, V14, P395, DOI 10.1111/j.1365-2273.1989.tb00392.x; JOHNSEN T, 1987, J LARYNGOL OTOL, V101, P1187, DOI 10.1017/S0022215100103470; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; MARRA MA, IN PRESS GENOME RES; Mondini C., 1791, BONONIAE, V7, P419; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OLSON MV, 1995, SCIENCE, V270, P394, DOI 10.1126/science.270.5235.394; OMALLEY BW, 1995, HEARING RES, V88, P181, DOI 10.1016/0378-5955(95)00111-G; Pendred V, 1896, LANCET, V148, P532, DOI [DOI 10.1016/S0140-6736(01)74403-0, 10.1016/S0140-6736(01)74403-0]; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Reardon W, 1997, QJM-MON J ASSOC PHYS, V90, P443, DOI 10.1093/qjmed/90.7.443; Reardon W, 1996, J MED GENET, V33, P1037, DOI 10.1136/jmg.33.12.1037; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; Sheffield VC, 1996, NAT GENET, V12, P424, DOI 10.1038/ng0496-424; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; Stoesser G, 1997, NUCLEIC ACIDS RES, V25, P7, DOI 10.1093/nar/25.1.7; TAKEDA K, 1991, J CLIN INVEST, V87, P496, DOI 10.1172/JCI115023; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TROTTER WR, 1960, BRIT MED BULL, V16, P92, DOI 10.1093/oxfordjournals.bmb.a069828; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UZIEL A, 1981, ACTA OTO-LARYNGOL, V92, P469, DOI 10.3109/00016488109133286; VanCamp G, 1997, AM J HUM GENET, V60, P758; VANMIDDLESWORTH L, 1980, ENDOCRINOLOGY, V106, P1686, DOI 10.1210/endo-106-6-1686; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Xu Y, 1994, Genet Eng (N Y), V16, P241; Zhang JH, 1997, GENOME RES, V7, P649, DOI 10.1101/gr.7.6.649	74	871	974	2	37	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1997	17	4					411	422		10.1038/ng1297-411	http://dx.doi.org/10.1038/ng1297-411			12	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398842	Green Published			2022-12-25	WOS:A1997YJ92400021
J	Kupfer, GM; Naf, D; Suliman, A; Pulsipher, M; DAndrea, AD				Kupfer, GM; Naf, D; Suliman, A; Pulsipher, M; DAndrea, AD			The Fanconi anaemia proteins, FAA and FAG, interact to form a nuclear complex	NATURE GENETICS			English	Article							GROUP-C; ANEMIA; COMPLEMENTATION; GENE; POLYPEPTIDE; CLONING; FACC; PHOSPHORYLATION; EXPRESSION; CYTOPLASM	Fanconi anaemia (FA) is an autosomal-recessive disorder characterized by genomic instability, developmental defects, DNA crosslinking agent hypersensitivity and cancer susceptibility(1-3). Somatic-cell hybrid studies have revealed five FA complementation groups (A-E; refs 4-6) displaying similar phenotypes, suggesting that FA genes are functionally related(7). The two cloned FA genes, FAA and FAG, encode proteins that are unrelated to each other or to other proteins in GenBank(8-10). In the current study, we demonstrate that FAA and FAC bind each other and form a complex. Protein binding correlates with the functional activity of FAA and FAG, as patient-derived mutant FAC (L554P) fails to bind FAA. Although unbound FAA and FAC localize predominantly to the cytoplasm, the FAA-FAC complex is found in similar abundance in both cytoplasm and nucleus. Our results confirm the interrelatedness of the FA genes in a pathway, suggesting the cooperation of FAA and FAC in a nuclear function.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Kupfer, GM (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003420] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA39542] Funding Source: Medline; NHLBI NIH HHS [R01-HL5725, K08-HL03420] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER BP, 1993, HEMATOLOGY INFANCY C, V1, P216; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; BUCHWALD M, 1995, NAT GENET, V11, P228, DOI 10.1038/ng1195-228; DAndrea AD, 1996, NAT GENET, V14, P240, DOI 10.1038/ng1196-240; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; GAVISH H, 1993, HUM MOL GENET, V2, P123, DOI 10.1093/hmg/2.2.123; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LIU JM, 1994, BLOOD, V84, P3995, DOI 10.1182/blood.V84.12.3995.bloodjournal84123995; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; Yamashita T, 1996, BLOOD, V87, P4424, DOI 10.1182/blood.V87.10.4424.bloodjournal87104424; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975; Youssoufian H, 1996, J CLIN INVEST, V97, P957, DOI 10.1172/JCI118519	23	156	157	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					487	490		10.1038/ng1297-487	http://dx.doi.org/10.1038/ng1297-487			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398857				2022-12-25	WOS:A1997YJ92400036
J	Gilbert, SC; Plebanski, M; Harris, SJ; Allsopp, CEM; Thomas, R; Layton, GT; Hill, AVS				Gilbert, SC; Plebanski, M; Harris, SJ; Allsopp, CEM; Thomas, R; Layton, GT; Hill, AVS			A protein particle vaccine containing multiple malaria epitopes	NATURE BIOTECHNOLOGY			English	Article						vaccine design; antigen presentation	VIRUS-LIKE PARTICLES; CYTOTOXIC-T-LYMPHOCYTES; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; VIRAL-PROTEINS; RESPONSES; CELLS; INDUCTION; IMMUNIZATION; ANTIGEN	Ty virus-like particles consist of a single protein species that can be produced in yeast. Recombinant Ty-VLPs carrying a string of up to 15 defined cytotoxic T lymphocyte (CTL) epitopes from Plasmodium species prime protective CTL responses in mice following a single administration without adjuvant. Effective processing of epitopes from the string was demonstrated in vitro and in vivo and was not affected by flanking sequences.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England; Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; British Biotech Pharmaceut Ltd, Oxford OX4 5LY, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Hill, AVS (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England.		Gilbert, Sarah C./H-2857-2019; Plebanski, Magdalena/AAU-3144-2021; HILL, Adrian V>S>/C-1306-2008	Gilbert, Sarah C./0000-0002-6823-9750; , Magdalena/0000-0001-6889-3667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; Allsopp CEM, 1996, EUR J IMMUNOL, V26, P1951, DOI 10.1002/eji.1830260841; Bachmann MF, 1996, EUR J IMMUNOL, V26, P2595, DOI 10.1002/eji.1830261109; BORDIGNON PP, 1989, EUR J IMMUNOL, V19, P2237; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; Gilbert SC, 1997, PARASITOL TODAY, V13, P302, DOI 10.1016/S0169-4758(97)01091-0; Harris SJ, 1997, INT IMMUNOL, V9, P273, DOI 10.1093/intimm/9.2.273; Klavinskis LS, 1996, J IMMUNOL, V157, P2521; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; Layton GT, 1996, IMMUNOLOGY, V87, P171, DOI 10.1046/j.1365-2567.1996.464539.x; LAYTON GT, 1993, J IMMUNOL, V151, P1097; MARTIN SJ, 1993, AIDS, V7, P1315, DOI 10.1097/00002030-199310000-00003; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDIN E, 1992, MEM I O CRUZ, V3, P223; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; PLEBANSKI M, 1994, J IMMUNOL METHODS, V170, P15, DOI 10.1016/0022-1759(94)90241-0; PLEBANSKI M, 1995, EUR J IMMUNOL, V25, P1783, DOI 10.1002/eji.1830250645; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SCHIRMBECK R, 1995, VACCINE, V13, P857, DOI 10.1016/0264-410X(94)00038-O; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847; THOMSON SA, 1995, P NATL ACAD SCI USA, V92, P5845, DOI 10.1073/pnas.92.13.5845; VORDERMEIER HM, 1992, EUR J IMMUNOL, V22, P2631, DOI 10.1002/eji.1830221024; WHITTON JL, 1993, J VIROL, V67, P348, DOI 10.1128/JVI.67.1.348-352.1993; WIDMANN C, 1992, J IMMUNOL METHODS, V155, P95, DOI 10.1016/0022-1759(92)90275-X	28	134	156	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1280	1284		10.1038/nbt1197-1280	http://dx.doi.org/10.1038/nbt1197-1280			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359112				2022-12-25	WOS:000071342000031
J	Matsumoto, M; Takeda, J; Inoue, N; Hara, T; Hatanaka, M; Takahashi, K; Nagasawa, S; Akedo, H; Seya, T				Matsumoto, M; Takeda, J; Inoue, N; Hara, T; Hatanaka, M; Takahashi, K; Nagasawa, S; Akedo, H; Seya, T			A novel protein that participates in nonself discrimination of malignant cells by homologous complement	NATURE MEDICINE			English	Article							IMMUNITY; SYSTEM; INNATE; SELENOCYSTEINE; DEPOSITION; PATHWAY; LINES; SELF; GENE; MCP	The human complement (C) system protects an individual against substances of nonself origin, including xenografts and microbial pathogens'. Human cells express C-regulatory proteins, CD46 and CD55, thereby circumventing attack by C3, a major effector of C (ref. 2). Nevertheless, certain malignant cells, particularly those undergoing apoptotic stress, can activate homologous C, overcoming the regulatory actions of CD46 and/or CD55 (ref. 3-5). The molecular mechanisms whereby malignant cells are tagged by homologous C3 remain largely unknown. We identified a novel gene product that converts human cells into targets for homologous complement. Only malignant cells and cell lines exposed to Fas or X-irradiation stimuli produced this protein, designated M161Ag, which was an unglycosylated 43-kDa protein. Analysis of cloned cDNAs indicated that this molecule was a secretory protein containing five amino acids encoded by TGA codons. Its functions were unique in that once secreted from the tumor cells, it bound back to the surface of these cells and activated homologous complement (C3) via the alternative pathway, allowing for C3 deposition on the membrane. This molecule may offer new insight into innate immunity; surveillance of tumor cells by complement is a common feature in the human immune system.	OSAKA MED CTR CANC & CARDIOVASC DIS,DEPT IMMUNOL,HIGASHINARI KU,OSAKA 537,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; HOKKAIDO UNIV,DEPT PHARMACEUT SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; JAPAN SCI & TECHNOL CORP,PRESTO,KYOTO 61902,JAPAN	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University; Hokkaido University; Japan Science & Technology Agency (JST)			美佐子, 松本/A-4497-2012; Seya, Tsukasa/A-4336-2012					ATKINSON JP, 1987, IMMUNOL TODAY, V8, P212, DOI 10.1016/0167-5699(87)90167-8; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HILL KE, 1991, J BIOL CHEM, V266, P10050; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; IWAI K, 1988, ANAL BIOCHEM, V171, P277, DOI 10.1016/0003-2697(88)90486-1; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KIKKAWA S, 1996, JPN BIOCH SOC, V68, P703; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MATSUI H, 1994, FEBS LETT, V351, P419, DOI 10.1016/0014-5793(94)00897-3; MATSUMOTO M, 1992, BIOCHEM J, V281, P493, DOI 10.1042/bj2810493; MATSUMOTO M, 1993, EUR J IMMUNOL, V23, P2270, DOI 10.1002/eji.1830230933; MATSUMOTO M, 1995, J EXP MED, V181, P115, DOI 10.1084/jem.181.1.115; RAMOS OF, 1985, P NATL ACAD SCI USA, V82, P5470, DOI 10.1073/pnas.82.16.5470; SEYA T, 1990, J IMMUNOL, V145, P238; UMEMURA K, 1996, J BIOL CHEM, V271, P4581	19	26	28	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1266	1270		10.1038/nm1197-1266	http://dx.doi.org/10.1038/nm1197-1266			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359703				2022-12-25	WOS:A1997YD89600037
J	Quaderi, NA; Schweiger, S; Gaudenz, K; Franco, B; Rugarli, EI; Berger, W; Feldman, GJ; Volta, M; Andolfi, G; Gilgenkrantz, S; Marion, RW; Hennekam, RCM; Opitz, JM; Muenke, M; Ropers, HH; Ballabio, A				Quaderi, NA; Schweiger, S; Gaudenz, K; Franco, B; Rugarli, EI; Berger, W; Feldman, GJ; Volta, M; Andolfi, G; Gilgenkrantz, S; Marion, RW; Hennekam, RCM; Opitz, JM; Muenke, M; Ropers, HH; Ballabio, A			Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22	NATURE GENETICS			English	Article							LINEAR SKIN DEFECTS; ACUTE PROMYELOCYTIC LEUKEMIA; XENOPUS NUCLEAR FACTOR-7; FAT GLOBULE-MEMBRANE; SONIC-HEDGEHOG; PROTEIN; MICROPHTHALMIA; ANOMALIES; DOMAIN; XNF7	Opitz syndrome (OS) is an inherited disorder characterized by midline defects including hypertelorism, hypospadias, lip-palate-laryngotracheal clefts and imperforate anus. We have identified a new gene on Xp22, MIDI (Midline 1), which is disrupted in an OS patient carrying an X-chromosome inversion and is also mutated in several OS families. MID 1 encodes a member of the B-box family of proteins, which contain protein-protein interaction domains, including a RING finger, and are implicated in fundamental processes such as body axis patterning and control of cell proliferation. The association of MIDI with OS suggests an important role for this gene in midline development.	TELETHON INST GENET & MED,I-20132 MILAN,ITALY; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV HUMAN GENET & MOL BIOL,PHILADELPHIA,PA 19104; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; UNIV AMSTERDAM,INST HUMAN GENET,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTAH,DEPT PEDIAT HUMAN GENET & OBSTET & GYNECOL,SALT LAKE CITY,UT 84132; CATHOLIC UNIV NIJMEGEN,DEPT HUMAN GENET,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Max Planck Society; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Amsterdam; Utah System of Higher Education; University of Utah; Radboud University Nijmegen; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Quaderi, Nandita/V-8708-2019; Volta, Manuela/D-2147-2012; BALLABIO, Andrea/AAL-2672-2020; FRANCO, Brunella/S-2882-2018	Volta, Manuela/0000-0001-8468-0346; BALLABIO, Andrea/0000-0003-1381-4604; Muenke, Maximilian/0000-0002-7719-6545; FRANCO, Brunella/0000-0001-5588-4569; Rugarli, Elena/0000-0002-5782-1067	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD028732, R01HD029862] Funding Source: NIH RePORTER; NICHD NIH HHS [R29HD28732, R01HD29862] Funding Source: Medline; Telethon [TGM97000, TGM06S01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon)		ALGAZALI LI, 1990, J MED GENET, V27, P59, DOI 10.1136/jmg.27.1.59; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BERSHOF JF, 1992, J CRANIO MAXILL SURG, V20, P24, DOI 10.1016/S1010-5182(05)80192-1; BIRD LM, 1994, AM J MED GENET, V53, P141, DOI 10.1002/ajmg.1320530205; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BORDEN KLB, 1993, FEBS LETT, V335, P255, DOI 10.1016/0014-5793(93)80741-C; CAPPA M, 1987, AM J MED GENET, V28, P303, DOI 10.1002/ajmg.1320280207; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CORDERO JF, 1978, AM J MED GENET, V2, P145, DOI 10.1002/ajmg.1320020205; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FARNDON PA, 1983, CLIN GENET, V23, P446; FERRERO GB, 1995, HUM MOL GENET, V4, P1821, DOI 10.1093/hmg/4.10.1821; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; FRYNS JP, 1992, CLIN GENET, V42, P314; GRIGNANI F, 1994, BLOOD, V83, P10; GUIONALMEIDA ML, 1992, AM J MED GENET, V43, P918, DOI 10.1002/ajmg.1320430603; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HOWELL L, 1989, ANN OTO RHINOL LARYN, V98, P185, DOI 10.1177/000348948909800304; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Ishii T, 1995, BBA-GEN SUBJECTS, V1245, P285, DOI 10.1016/0304-4165(95)00102-6; JOHNSTON K, 1987, AM J MED GENET, V27, P603, DOI 10.1002/ajmg.1320270313; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LI XX, 1994, J CELL BIOL, V124, P7, DOI 10.1083/jcb.124.1.7; LI XX, 1993, J CELL SCI, V105, P389; LINDSAY EA, 1994, AM J MED GENET, V49, P229, DOI 10.1002/ajmg.1320490214; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACDONALD MR, 1993, AM J MED GENET, V46, P706, DOI 10.1002/ajmg.1320460622; Maniatis T., 1982, MOL CLONING; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MATHER IH, 1993, J DAIRY SCI, V76, P3832, DOI 10.3168/jds.S0022-0302(93)77726-7; May M, 1997, AM J MED GENET, V68, P244, DOI 10.1002/(SICI)1096-8628(19970120)68:2<244::AID-AJMG27>3.0.CO;2-T; MILLER M, 1991, DEVELOPMENT, V113, P569; Opitz, 1969, BIRTH DEFECTS OAS, VV, P95; Opitz J. M., 1969, BIRTH DEFECTS AOS, VV, P86; OPITZ JM, 1987, AM J MED GENET, V28, P275, DOI 10.1002/ajmg.1320280203; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Robin NH, 1996, AM J MED GENET, V62, P305, DOI 10.1002/(SICI)1096-8628(19960329)62:3<305::AID-AJMG20>3.0.CO;2-N; ROBIN NH, 1995, NAT GENET, V11, P459, DOI 10.1038/ng1295-459; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; SCHAEFER L, 1993, NAT GENET, V4, P272, DOI 10.1038/ng0793-272; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SEDANO HO, 1988, AM J MED GENET, V30, P847, DOI 10.1002/ajmg.1320300322; Shou WN, 1996, MOL CELL BIOL, V16, P990; STEVENS CA, 1988, J MED GENET, V25, P536, DOI 10.1136/jmg.25.8.536; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TEMPLE IK, 1990, J MED GENET, V27, P56, DOI 10.1136/jmg.27.1.56; TOLMIE JL, 1987, J MED GENET, V24, P688, DOI 10.1136/jmg.24.11.688; VERLOES A, 1995, AM J MED GENET, V59, P123, DOI 10.1002/ajmg.1320590124; VERLOES A, 1989, AM J MED GENET, V34, P313, DOI 10.1002/ajmg.1320340303; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WAPENAAR MC, 1994, HUM MOL GENET, V3, P1155, DOI 10.1093/hmg/3.7.1155; WAPENAAR MC, 1993, HUM MOL GENET, V2, P947, DOI 10.1093/hmg/2.7.947	60	295	302	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					285	291		10.1038/ng1197-285	http://dx.doi.org/10.1038/ng1197-285			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354791	Green Submitted			2022-12-25	WOS:A1997YD66700021
J	Scangos, G				Scangos, G			Drug discovery in the postgenomic era	NATURE BIOTECHNOLOGY			English	Editorial Material							GENOME		Exelixis Pharmaceut, S San Francisco, CA 94080 USA	Exelixis, Inc.	Scangos, G (corresponding author), Exelixis Pharmaceut, 260 Littlefield Ave, S San Francisco, CA 94080 USA.							Aaronson JS, 1996, GENOME RES, V6, P829, DOI 10.1101/gr.6.9.829; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1996, SCIENCE, V272, P629, DOI 10.1126/science.272.5262.629; CHRISTINE M, 1997, CELL, V90, P281; DUOJIA P, 1997, CELL, V90, P271; Fey R, 1996, LANCET, V347, P1389, DOI 10.1016/S0140-6736(96)91019-3; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Karim FD, 1996, GENETICS, V143, P315; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X	13	8	12	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1220	1221		10.1038/nbt1197-1220	http://dx.doi.org/10.1038/nbt1197-1220			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359092				2022-12-25	WOS:000071342000003
J	Takasaki, W; Kajino, Y; Kajino, K; Murali, R; Greene, MI				Takasaki, W; Kajino, Y; Kajino, K; Murali, R; Greene, MI			Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor	NATURE BIOTECHNOLOGY			English	Article						rational drug design; TNF inhibitor; inflammation	TUMOR-NECROSIS-FACTOR; COLLAGEN-INDUCED ARTHRITIS; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; MUTATIONAL ANALYSIS; SYNTHETIC PEPTIDE; FUSION PROTEINS; SEPTIC SHOCK; DISEASE; IDENTIFICATION	Exocyclic small peptidomimetics corresponding to three critical binding sites of tumor necrosis factor (TNF)-receptor(I) have been designed based on atomic features deduced from the crystal structures of TNF alpha. and the TNF beta/TNF-receptor(I) complex and a model of an anti-TNF alpha monoclonal antibody. TNF alpha antagonistic activities were evaluated by binding assays using soluble receptor or intact receptor on cells as well as an apoptosis/cytotoxicity assay. The most critical interaction site for rational design of peptidomimetics was localized to the loop1/domain3 of the TNF-receptor, The best antagonist showed 5 mu M inhibition in the binding assay, Biologically, the mimetics inhibited TNF alpha-mediated apoptosis.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Murali, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		Murali, Ramachandran/D-1132-2009; Kajino, Kiichi/F-6873-2012	Murali, Ramachandran/0000-0002-8384-2793	NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16520] Funding Source: Medline; NIDDK NIH HHS [DK-19525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGELETTI RH, 1996, TECHNIQUES PROTEIN C, V7, P81; BAKER D, 1994, EUR J IMMUNOL, V24, P2040, DOI 10.1002/eji.1830240916; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Baumgartner S., 1996, Arthritis and Rheumatism, V39, pS74; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTLER B, 1995, J INVEST MED, V43, P227; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HWANG C, 1991, P ROY SOC B-BIOL SCI, V245, P115, DOI 10.1098/rspb.1991.0096; JESPERS LS, 1994, BIO-TECHNOL, V12, P899, DOI 10.1038/nbt0994-899; Jones E Y, 1992, Immunol Ser, V56, P93; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LIE BL, 1992, BIOCHEM BIOPH RES CO, V188, P503, DOI 10.1016/0006-291X(92)91084-4; Lorenz HM, 1996, J IMMUNOL, V156, P1646; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419; ORFANOUDAKIS G, 1993, MOL IMMUNOL, V30, P1519, DOI 10.1016/0161-5890(93)90460-S; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Reinhart K, 1996, CRIT CARE MED, V24, P733, DOI 10.1097/00003246-199605000-00003; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, IMMUNOMETHODS, V1, P5; SCALLON BJ, 1995, CYTOKINE, V7, P759, DOI 10.1006/cyto.1995.0091; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUFFREDINI AF, 1995, J IMMUNOL, V155, P5038; SUITTERS AJ, 1994, J EXP MED, V179, P849, DOI 10.1084/jem.179.3.849; Tak PP, 1996, ARTHRITIS RHEUM, V39, P1077, DOI 10.1002/art.1780390702; TAUB R, 1992, BIOCHEMISTRY-US, V31, P7431, DOI 10.1021/bi00148a001; VANOSTADE X, 1991, EMBO J, V10, P527; Walker RE, 1996, J INFECT DIS, V174, P63, DOI 10.1093/infdis/174.1.63; WILLIAMS RO, 1995, IMMUNOLOGY, V84, P433; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; YONE K, 1995, J BIOL CHEM, V270, P19509, DOI 10.1074/jbc.270.33.19509; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	46	111	145	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1266	1270		10.1038/nbt1197-1266	http://dx.doi.org/10.1038/nbt1197-1266			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359109				2022-12-25	WOS:000071342000028
J	Wijnholds, J; Evers, R; vanLeusden, MR; Mol, CAAM; Zaman, GJR; Mayer, U; Beijnen, JH; vanderValk, M; Krimpenfort, P; Borst, P				Wijnholds, J; Evers, R; vanLeusden, MR; Mol, CAAM; Zaman, GJR; Mayer, U; Beijnen, JH; vanderValk, M; Krimpenfort, P; Borst, P			Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein	NATURE MEDICINE			English	Article							CONJUGATE EXPORT PUMP; ARACHIDONIC-ACID; BONE-MARROW; MAST-CELLS; GENE LEADS; MRP; GLUTATHIONE; TRANSPORTER; LEUKOTRIENES; OVEREXPRESSION	The multidrug resistance-associated protein (MRP) mediates the cellular excretion of many drugs, glutathione S-conjugates (CS-X) of lipophilic xenobiotics and endogenous cysteinyl leukotrienes(1-5). Increased MRP levels in tumor cells can cause multidrug resistance (MDR) by decreasing the intracellular drug concentration. The physiological role or roles of MRP remain ill-defined, however. We have generated MRP-deficient mice by using embryonic stem cell technology. Mice homozygous for the mrp mutant allele, mrp(-/-), are viable and fertile, but their response to an inflam matory stimulus is impaired. We attribute this defect to a decreased secretion of leukotriene C-4 (LTC4) from leukotriene-synthesizing cells. Moreover, the mrp(-/-) mice are hypersensitive to the anticancer drug etoposide. The phenotype of mrp(-/-) mice is consistent with a role for MRP as the main LTC4-exporter in leukotriene-synthesizing cells, and as an important drug exporter in drug-sensitive cells. Our results suggest that this ubiquitous(6) GS-X pump's is dispensable in mice, making treatment of MDR with MRP-specific reversal agents potentially feasible.	NETHERLANDS CANC INST, DIV MOL BIOL, NL-1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOL GENET, NL-1066 CX AMSTERDAM, NETHERLANDS; SLOTERVAART HOSP, DEPT PHARM, NL-1066 EC AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute; Slotervaart Hospital			Wijnholds, Jan/V-3896-2018	Wijnholds, Jan/0000-0003-0099-460X				CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DOMEN J, 1993, BLOOD, V82, P1445; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HAY DWP, 1995, TRENDS PHARMACOL SCI, V16, P304, DOI 10.1016/S0165-6147(00)89059-8; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Jedlitschky G, 1996, CANCER RES, V56, P988; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEIER I, 1994, J BIOL CHEM, V269, P27807; Lorico A, 1996, CANCER RES, V56, P5351; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Pulaski L, 1996, EUR J BIOCHEM, V241, P644, DOI 10.1111/j.1432-1033.1996.00644.x; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; Saxena M, 1996, BIOCHEM J, V320, P273, DOI 10.1042/bj3200273; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Stride BD, 1996, MOL PHARMACOL, V49, P962; VERHAGEN J, 1986, J CHROMATOGR, V378, P208, DOI 10.1016/S0378-4347(00)80714-8; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1; ZAMAN GJR, 1996, MULTIDRUG RESISTANCE, P95	29	381	386	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1275	1279		10.1038/nm1197-1275	http://dx.doi.org/10.1038/nm1197-1275			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359705				2022-12-25	WOS:A1997YD89600039
J	Lu, WN; Peissel, B; Babakhanlou, H; Pavlova, A; Geng, L; Fan, XH; Larson, C; Brent, G; Zhou, J				Lu, WN; Peissel, B; Babakhanlou, H; Pavlova, A; Geng, L; Fan, XH; Larson, C; Brent, G; Zhou, J			Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY; DISEASE; GENE; CELLS; PROTEIN; PRODUCT; FETAL; ADULT	PKD1 is the most common site for mutations in human autosomal dominant polycystic kidney disease (ADPKD). ADPKD is characterized by progressive replacement of kidney tissue by epithelial cysts and eventual renal failure. Hepatic and pancreatic cysts are also common(1). The PKD1 protein, polycystin, is a cell-surface protein(2,3) of unknown function that is widely expressed in epithelia and in vascular smooth muscle and myocardium(4-9). None of the genetic forms of murine polycystic disease map to the murine Pkd1 locus. We introduced into mice by homologous recombination a Pkd1 truncation mutation, Pkd1(-), that mimics a mutation found in ADPKD. Pkd1(-) heterozygotes have no discernible phenotype, whereas homozygotes die during the perinatal period with massively enlarged cystic kidneys, pancreatic ductal cysts and pulmonary hypoplasia. Renal cyst formation begins at embryonic day 15.5 (E15.5) in proximal tubules and progresses rapidly to replace the entire renal parenchyma. The timing of cyst formation indicates that full-length polycystin is required for normal morphogenesis during elongation and maturation of tubular structures in the kidney and pancreas.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RENAL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV THYROID, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Peissel, Bernard/E-8187-2017	Peissel, Bernard/0000-0001-9233-3571; Lu, Weining/0000-0002-6570-3044	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051050] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK51050] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; GENG L, 1994, J AM SOC NEPHROL, V5, P622; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Madsen OD, 1996, EUR J BIOCHEM, V242, P435, DOI 10.1111/j.1432-1033.1996.435rr.x; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; Peral B, 1996, AM J HUM GENET, V58, P86; Peters DJM, 1996, LAB INVEST, V75, P221; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; REEDERS ST, 1992, NAT GENET, V1, P235, DOI 10.1038/ng0792-235; SOROKIN L, 1992, KIDNEY INT, V41, P657, DOI 10.1038/ki.1992.101; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524	16	358	362	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1997	17	2					179	181		10.1038/ng1097-179	http://dx.doi.org/10.1038/ng1097-179			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326937				2022-12-25	WOS:A1997XZ55500023
J	Vindigni, A; Dang, QD; DiCera, E				Vindigni, A; Dang, QD; DiCera, E			Site-specific dissection of substrate recognition by thrombin	NATURE BIOTECHNOLOGY			English	Article						drug design; plasmin; serine proteases; trypsin	CHEMICAL SYNTHESIS; CRYSTAL-STRUCTURE; SURFACE RESIDUES; SERINE PROTEASES; BINDING; IDENTIFICATION; GEOMETRY	Current approaches to enzyme specificity focus on the identification of consensus sequences from combinatorial chemistry libraries or phage display. These synthetic substrates can also be used as sensitive probes for the molecular environment of the enzyme specificity sites to determine how they contribute to recognition in the transition state. Libraries constructed to include all relevant species for a site-specific analysis contain a relatively smart number of substrates and provide quantitative information on the energetics of recognition that can be exploited in studies of structure-function relations and rational drug design. We have constructed a library of substrates carrying substitutions at P1, P2, and P3 to probe the response of the specificity sites S1, S2, and S3 of thrombin. The library has been used to identify differences between the anticoagulant slow and procoagulant fast forms of thrombin and the structural origin of the effects, The results also offer new guidelines for the design of active-site inhibitors of thrombin.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R29HL049413, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; BODE W, 1992, PROTEIN SCI, V1, P426; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLAESON G, 1994, BLOOD COAGUL FIBRIN, V5, P411; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DEFILIPPIS V, 1995, BIOCHEMISTRY-US, V34, P9552, DOI 10.1021/bi00029a032; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Di Cera E., 1995, THERMODYNAMIC THEORY; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; MALIKAYIL JA, 1997, BIOCHEMISTRY-US, V26, P1034; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHARMA SK, 1990, THROMB RES, V57, P127, DOI 10.1016/0049-3848(90)90201-M; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tucker TJ, 1997, J MED CHEM, V40, P830, DOI 10.1021/jm960762y; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Wells JA, 1996, SCIENCE, V273, P449, DOI 10.1126/science.273.5274.449; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; ZHANG E, 1997, BIOPHYS CHEM, V63, P186	27	63	66	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					891	895		10.1038/nbt0997-891	http://dx.doi.org/10.1038/nbt0997-891			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306406				2022-12-25	WOS:A1997XW41000033
J	Zufferey, R; Nagy, D; Mandel, RJ; Naldini, L; Trono, D				Zufferey, R; Nagy, D; Mandel, RJ; Naldini, L; Trono, D			Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo	NATURE BIOTECHNOLOGY			English	Article						gene therapy; retroviral vectors; HIV	HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; PROVIRAL DNA-SYNTHESIS; NEF GENE; NONDIVIDING CELLS; MATRIX PROTEIN; T-LYMPHOCYTES; VPR GENE; TYPE-1; INFECTION	Retroviral vectors derived from lentiviruses such as HIV-1 are promising tools for human gene therapy because they mediate the in vivo delivery and long-term expression of transgenes in nondividing tissues. We describe an HIV vector system in which the virulence genes env, vif, vpr, vpu, and nef have been deleted. This multiply attenuated vector conserved the ability to transduce growth-arrested cells and monocyte-derived macrophages in culture, and could efficiently deliver genes in vivo into adult neurons. These data demonstrate the potential of lentiviral vectors in human gene therapy.	CELL GENESYS,FOSTER CITY,CA 94404; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Cell Genesys Inc; Salk Institute			Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X				Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; CHOWERS MY, 1995, VIROLOGY, V212, P451, DOI 10.1006/viro.1995.1502; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, IN PRESS P NATL ACAD; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PARK IW, 1994, J ACQ IMMUN DEF SYND, V7, P1228; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SANDERS WR, 1995, NAT MED, V1, P1137; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; Wang B, 1996, VIROLOGY, V223, P224, DOI 10.1006/viro.1996.0471; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32	40	1488	1701	3	96	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					871	875		10.1038/nbt0997-871	http://dx.doi.org/10.1038/nbt0997-871			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306402				2022-12-25	WOS:A1997XW41000029
J	Klussmann, S; Nolte, A; Bald, R; Erdmann, VA; Furste, JP				Klussmann, S; Nolte, A; Bald, R; Erdmann, VA; Furste, JP			Mirror-image RNA that binds D-adenosine	NATURE BIOTECHNOLOGY			English	Article						combinatorial libraries; SELEX; stable oligonucleotides; mirror-image RNA; adenosine	SINGLE-STRANDED-DNA; GROWTH-FACTOR; SELECTION; LIGANDS; OLIGONUCLEOTIDES; AMPLIFICATION; EVOLUTION; MOLECULES; RIBOZYMES; INVITRO	A 58-mer L-RNA ligand that binds to naturally occurring D-adenosine with a dissociation constant of 1.7 mu M in solution was identified from a combinatorial library employing mirror-design. The corresponding D-RNA ligand shows identical binding affinity to L-adenosine. Reciprocal chiral specificity was also evident from ligand discrimination; the binding affinity of the L-RNA ligand for D-adenosine was 9000-fold greater than its affinity for L-adenosine and vice versa, While the D-RNA ligand was rapidly degraded in human serum, the L-RNA ligand displayed an extraordinary stability, This indicates the potential application of specifically designed L-RNA ligands as stable monoclonal antibody analogues and the development of highly stable L-ribozymes.	FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY	Free University of Berlin				Klussmann, Jens Peter/0000-0002-8223-7954				ASHLEY GW, 1992, J AM CHEM SOC, V114, P9731, DOI 10.1021/ja00051a001; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; Connors K. A., 1987, BINDING CONSTANTS; EATON BE, 1995, ANNU REV BIOCHEM, V64, P837, DOI 10.1146/annurev.bi.64.070195.004201; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Fischer E., 1894, BER DTSCH CHEM GES, V27, P2985, DOI DOI 10.1002/CBER.18940270364; GARBESI A, 1993, NUCLEIC ACIDS RES, V21, P4159, DOI 10.1093/nar/21.18.4159; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; JONES JW, 1963, J AM CHEM SOC, V85, P193, DOI 10.1021/ja00885a019; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; Le Bel JA, 1874, B SOC CHIM FR, V22, P337; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229; LINDBERG M, 1975, EUR J BIOCHEM, V53, P481, DOI 10.1111/j.1432-1033.1975.tb04089.x; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; Nolte A, 1996, NAT BIOTECHNOL, V14, P1116, DOI 10.1038/nbt0996-1116; PASTEUR L, 1961, RECH DISSYMETRIE MOL; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; SOAI K, 1995, NATURE, V378, P767, DOI 10.1038/378767a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; URATA H, 1993, J AM CHEM SOC, V115, P9852, DOI 10.1021/ja00074a083; Vant Hoff J. H., 1874, ARCH NEERLANDAISES S, V9, P445; WREDE P, 1978, J MOL BIOL, V120, P83, DOI 10.1016/0022-2836(78)90296-6; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	37	287	315	6	61	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1112	1115		10.1038/nbt0996-1112	http://dx.doi.org/10.1038/nbt0996-1112			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631061				2022-12-25	WOS:A1996VF84300032
J	Sparks, AB; Hoffman, NG; McConnell, SJ; Fowlkes, DM; Kay, BK				Sparks, AB; Hoffman, NG; McConnell, SJ; Fowlkes, DM; Kay, BK			Cloning of ligand targets: Systematic isolation of SH3 domain-containing proteins	NATURE BIOTECHNOLOGY			English	Article						Src homology domain; genomics; signal transduction	GENE; IDENTIFICATION; ENCODES	Based on the prevalence of modular protein domains, such as Src homology domain 3 and 2 (SH3 and SH2), among important signaling molecules, we have sought to identify new SH3 domain-containing proteins. However, modest sequence similarity among these domains restricts the use of DNA-based methods for this purpose. To circumvent this limitation, we have developed a functional screen that permits the rapid cloning of modular domains based on their ligand-binding activity. Using operationally defined SH3 ligands from combinatorial peptide libraries, we screened a series of mouse and human cDNA expression libraries. We found that 69 of the 74 clones isolated encode at least one SH3 domain. These clones encode 18 different SH3-containing proteins, in of which have not been described previously. The isolation of entire repertoires of modular domain-containing proteins will prove invaluable in genome analysis and in bringing new targets into drug discovery programs.	UNIV N CAROLINA, DEPT BIOL, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; CYTOGEN CORP, PRINCETON, NJ 08540 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill								CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; ISHIKAWA R, 1994, J BIOL CHEM, V269, P29928; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MARGOLIS B, 1995, METHOD ENZYMOL, V255, P360; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; VAGNEDESCROIX M, 1991, EUR J BIOCHEM, V201, P53, DOI 10.1111/j.1432-1033.1991.tb16254.x; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	208	230	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					741	744		10.1038/nbt0696-741	http://dx.doi.org/10.1038/nbt0696-741			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630982				2022-12-25	WOS:A1996UM76600030
J	Zhang, X; PiatierTonneau, D; Auffray, C; Murali, R; Mahapatra, A; Zhang, FQ; Maier, CC; Saragovi, H; Greene, MI				Zhang, X; PiatierTonneau, D; Auffray, C; Murali, R; Mahapatra, A; Zhang, FQ; Maier, CC; Saragovi, H; Greene, MI			Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation	NATURE BIOTECHNOLOGY			English	Article						CD4 and MHC II interaction; rational drug design; complementarity determining region	COMPLEX; MOLECULES; ANTIGEN; REGION; SITE; FRAGMENT; MHC	We have developed peptide analogs to analyze precise human CD4 substructures involved in MHC class II binding. Forms of the complementarity determining-like regions (CDRs) of the D1 domain of human CD4 were reproduced as synthetic aromatically modified exocyclic (AME) analogs and tested for their ability to block CD4-MHC II interactions and T cell activation. The exocyclic derived from CDR3 (residues 82-89) of human CD4, which specifically associated with CD4 on the T cell surface to create a heteromeric CD4 complex, blocked IL-2 production and antagonized the normal function of the CD4 receptor. The approach of creating novel synthetic antagonistic receptor complexes may represent a new receptor specific pharmaceutical approach to modulate biological function.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; CNRS, UPR 420, VILLEJUIF, FRANCE; MCGILL UNIV, DEPT PHARMACOL, MONTREAL, PQ H3A 2T5, CANADA	University of Pennsylvania; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); McGill University			Murali, Ramachandran/D-1132-2009	Murali, Ramachandran/0000-0002-8384-2793	NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09140-21] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; DOUGALL WC, 1994, CELL BIOPHYS, V24-5, P209, DOI 10.1007/BF02789231; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; KONIG R, 1995, J EXP MED, V182, P779, DOI 10.1084/jem.182.3.779; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PIATIERTONNEAU D, 1991, IMMUNOGENETICS, V34, P121; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKLHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SCHEIRLE A, 1992, J IMMUNOL, V149, P1994; SETTE A, 1990, J IMMUNOL, V145, P1809; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	24	38	43	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					472	475		10.1038/nbt0496-472	http://dx.doi.org/10.1038/nbt0496-472			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630922				2022-12-25	WOS:A1996UL58800030
J	Liu, JW; Yap, WH; Thanabalu, T; Porter, AG				Liu, JW; Yap, WH; Thanabalu, T; Porter, AG			Efficient synthesis of mosquitocidal toxins in Asticcacaulis excentricus demonstrates potential of Gram-negative bacteria in mosquito control	NATURE BIOTECHNOLOGY			English	Article						insecticide; Asticcacaulis excentricus	THURINGIENSIS SUBSP ISRAELENSIS; BACILLUS-SPHAERICUS SSII-1; BIOLOGICAL-CONTROL; LARVICIDAL ACTIVITY; PROTEIN GENES; HOST-RANGE; EXPRESSION; CLONING; MALARIA	The control of mosquitoes with chemical insecticides pollutes the environment and leads to resistance in mosquito populations. Bacterial control of mosquito larvae with Bacillus sphaericus and Bacillus thuringiensis subsp. israelensis, which produce protein toxins, has proved useful, safe, and nonpolluting. These bacteria do, however, suffer from disadvantages, including rapid settling, UV sensitivity, and lack of persistance of spores, proteolysis of toxins, narrow host range, and high production costs. Here we show that the Gram-negative bacterium Asticcacaulis excentricus is a promising host for delivering toxins to mosquito larvae. Plasmid-transformed A. excentricus cells expressing the binary toxin of B. sphaericus exhibited toxicity to Culex and Anopheles mosquito larvae similar to that of the high-toxicity strains of B. sphaericus which produce several toxins. A. excentricus has potential advantages as a larvicide compared with the bacilli, especially persistance in the larval feeding zone, resistance to UV light, lack of toxin-degrading proteases, and low production costs.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Thanabalu, Thirumaran/A-2216-2011	Thanabalu, Thirumaran/0000-0001-5871-3829				BAR E, 1991, J INVERTEBR PATHOL, V57, P149, DOI 10.1016/0022-2011(91)90110-C; BAUMANN P, 1991, MICROBIOL REV, V55, P425, DOI 10.1128/MMBR.55.3.425-436.1991; BOSCH D, 1994, BIO-TECHNOL, V12, P915, DOI 10.1038/nbt0994-915; BOURGOUIN C, 1990, APPL ENVIRON MICROB, V56, P340, DOI 10.1128/AEM.56.2.340-344.1990; BURKE WF, 1983, APPL ENVIRON MICROB, V46, P954, DOI 10.1128/AEM.46.4.954-956.1983; COLLINS FH, 1994, SCIENCE, V264, P1874, DOI 10.1126/science.8009215; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; HONEE G, 1990, APPL ENVIRON MICROB, V56, P823; LERECLUS D, 1992, BIO-TECHNOL, V10, P418, DOI 10.1038/nbt0492-418; LIU JW, 1993, APPL ENVIRON MICROB, V59, P3470, DOI 10.1128/AEM.59.10.3470-3473.1993; Matsumura F., 1975, TOXICOLOGY INSECTICI; Miller J.H., 1972, EXPT MOL GENETICS; MILLER LH, 1992, SCIENCE, V257, P36, DOI 10.1126/science.1621092; MURPHY RC, 1992, APPL ENVIRON MICROB, V58, P1650, DOI 10.1128/AEM.58.5.1650-1655.1992; OEI C, 1992, J GEN MICROBIOL, V138, P1515, DOI 10.1099/00221287-138-7-1515; POINDEXTER JS, 1981, MICROBIOL REV, V45, P123, DOI 10.1128/MMBR.45.1.123-179.1981; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; POINDEXTER JS, 1989, BERGEYS MANUAL SYSTE, V3, P1939; PORTER AG, 1993, MICROBIOL REV, V57, P838, DOI 10.1128/MMBR.57.4.838-861.1993; PRIEST FG, 1992, J APPL BACTERIOL, V72, P357, DOI 10.1111/j.1365-2672.1992.tb01847.x; RAO DR, 1995, J AM MOSQUITO CONTR, V11, P1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT JM, 1981, PROKARYOTES HDB HABI, P466; Service M. W., 1986, BLOOD SUCKING INSECT; SILVAFILHA MH, 1995, J ECON ENTOMOL, V88, P525, DOI 10.1093/jee/88.3.525; SPIELMAN A, 1993, J MED ENTOMOL, V30, P6, DOI 10.1093/jmedent/30.1.6; THANABALU T, 1992, APPL ENVIRON MICROB, V58, P905, DOI 10.1128/AEM.58.3.905-910.1992; THANABALU T, 1991, J BACTERIOL, V173, P2776, DOI 10.1128/JB.173.9.2776-2785.1991; THANABALU T, 1992, J BACTERIOL, V174, P5051, DOI 10.1128/JB.174.15.5051-5056.1992; THANABALU T, 1995, APPL ENVIRON MICROB, V61, P4031, DOI 10.1128/AEM.61.11.4031-4036.1995; THANABALU T, 1996, IN PRESS GENE; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; TRISRISOOK M, 1990, APPL ENVIRON MICROB, V56, P1710, DOI 10.1128/AEM.56.6.1710-1716.1990; WILSON M, 1993, ANNU REV MICROBIOL, V47, P913, DOI 10.1146/annurev.mi.47.100193.004405; YAP WH, 1994, APPL ENVIRON MICROB, V60, P4199, DOI 10.1128/AEM.60.11.4199-4202.1994; YAP WH, 1994, J BACTERIOL, V176, P2603, DOI 10.1128/JB.176.9.2603-2610.1994	36	32	35	1	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					343	347		10.1038/nbt0396-343	http://dx.doi.org/10.1038/nbt0396-343			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630898				2022-12-25	WOS:A1996UL38000030
J	Scherer, PE; Bickel, PE; Kotler, M; Lodish, HF				Scherer, PE; Bickel, PE; Kotler, M; Lodish, HF			Cloning of cell-specific secreted and surface proteins by subtractive antibody screening	NATURE BIOTECHNOLOGY			English	Article						differential expression; adipocyte	HIGH-DENSITY-LIPOPROTEIN; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; 3T3-L1 ADIPOCYTES; AMINE OXIDASE; VI COLLAGEN; GLYCOPROTEIN; SEQUENCE; VIGILIN; RAT	To identify and clone genes that encode cell-or tissue-specific secreted and surface proteins, a polyclonal antiserum was raised against a complex mixture of surface or secreted proteins from the target cell, followed by immunodepletion of antibodies that recognize proteins from a nontarget cell or tissue. The depleted antiserum is used to screen bacteriophage cDNA expression libraries. Because of our interest in how adipocytes communicate with other cells, we have used this method to clone cDNAs encoding secreted and plasma membrane proteins that are induced during adipocyte differentiation. We describe several of these, including a novel plasma membrane-associated protein, S3-12.	Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Lodish, HF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lodish@wi.mit.edu	Bickel, Perry/Q-9185-2019; Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NIDDK NIH HHS [DK02219, DK47618] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002219, R01DK047618, R37DK047618] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barr VA, 1997, ENDOCRINOLOGY, V138, P4463, DOI 10.1210/en.138.10.4463; BARRAND MA, 1984, BIOCHEM J, V222, P467, DOI 10.1042/bj2220467; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BISWAS C, 1995, CANCER RES, V55, P434; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; CHIU DS, 1997, THROMB VASC BIOL, V17, P2350; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUCHS R, 1994, COMPUT APPL BIOSCI, V10, P171; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; HOKLAND B, 1992, J LIPID RES, V33, P1335; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; Kruse C, 1996, BIOCHEM J, V320, P247, DOI 10.1042/bj3200247; Kugler S, 1996, FEBS LETT, V382, P330, DOI 10.1016/0014-5793(96)00204-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MATTHEW WD, 1987, J IMMUNOL METHODS, V100, P73, DOI 10.1016/0022-1759(87)90174-8; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MISRA KB, 1994, J BIOL CHEM, V269, P23838; MU D, 1994, J BIOL CHEM, V269, P9926; NEHME CL, 1995, BIOCHEM J, V310, P693, DOI 10.1042/bj3100693; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; Onishi M, 1996, EXP HEMATOL, V24, P324; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PROWSE KR, 1990, J BIOL CHEM, V265, P10201; RAIMONDI L, 1991, BIOCHEM PHARMACOL, V41, P469, DOI 10.1016/0006-2952(91)90549-K; Sagerstrom CG, 1997, ANNU REV BIOCHEM, V66, P751, DOI 10.1146/annurev.biochem.66.1.751; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEULBERGER H, 1992, NEUROSCI LETT, V140, P93, DOI 10.1016/0304-3940(92)90690-9; SEULBERGER H, 1990, EMBO J, V9, P2151, DOI 10.1002/j.1460-2075.1990.tb07384.x; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VanEwijk W, 1997, P NATL ACAD SCI USA, V94, P3903, DOI 10.1073/pnas.94.8.3903	47	109	114	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					581	586		10.1038/nbt0698-581	http://dx.doi.org/10.1038/nbt0698-581			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624692				2022-12-25	WOS:000073930600037
J	Lorberth, R; Ritte, G; Willmitzer, L; Kossmann, J				Lorberth, R; Ritte, G; Willmitzer, L; Kossmann, J			Inhibition of a starch-granule-bound protein leads to modified starch and repression of cold sweetening	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; metabolic engineering; potato; antisense	POTATO; GLUCOSE; ORGANS; GENES; RNA	We have cloned a gene involved in starch metabolism that was identified by the ability of its product to bind to potato starch granules. Reduction in the protein level of transgenic potatoes leads to a reduction in the phosphate content of the starch. The complementary result is obtained when the protein is expressed in Escherichia coli, as this leads to an increased phosphate content of the glycogen. It is possible that this protein is responsible for the incorporation of phosphate into starch-like glucans, a process that is not understood at the biochemical level. The reduced phosphate content in potato starch has some secondary effects on its degradability, as the respective plants show a starch excess phenotype in leaves and a reduction in cold-sweetening in tubers.	Inst Genbiol Forsch Berlin GmbH, D-14195 Berlin, Germany; Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany; Univ Potsdam, Inst Biochem & Mol Physiol, D-14469 Potsdam, Germany	Max Planck Society; University of Potsdam	Kossmann, J (corresponding author), Inst Genbiol Forsch Berlin GmbH, Ihnestr 63, D-14195 Berlin, Germany.		Willmitzer, Lothar/F-7377-2011	Kossmann, Jens/0000-0001-8895-894X				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Ball S, 1996, CELL, V86, P349, DOI 10.1016/S0092-8674(00)80107-5; BAYSMIDT AM, 1994, STARCH-STARKE, V46, P167; DUWENIG E, 1996, THESIS U POTSDAM GER; HO LC, 1988, ANNU REV PLANT PHYS, V39, P355, DOI 10.1146/annurev.arplant.39.1.355; HOFGEN R, 1990, PLANT SCI, V66, P221, DOI 10.1016/0168-9452(90)90207-5; Jane J, 1996, CEREAL FOOD WORLD, V41, P827; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Muller-Thurgau H., 1882, LANDW JB, V11, P751; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; NIELSEN TH, 1994, PLANT PHYSIOL, V105, P111, DOI 10.1104/pp.105.1.111; ROBINSON KA, 1994, GENE, V151, P173, DOI 10.1016/0378-1119(94)90651-3; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; Smith AM, 1997, ANNU REV PLANT PHYS, V48, P65, DOI 10.1146/annurev.arplant.48.1.67; SWINKELS JJM, 1985, STARKE, V37, P1, DOI 10.1002/star.19850370102; TRETHEWEY RN, 1994, BIOCHEM J, V301, P449, DOI 10.1042/bj3010449	20	191	228	0	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					473	477		10.1038/nbt0598-473	http://dx.doi.org/10.1038/nbt0598-473			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592398				2022-12-25	WOS:000073489600034
J	Shan, XY; Kruger, WD				Shan, XY; Kruger, WD			Correction of disease-causing CBS mutations in yeast	NATURE GENETICS			English	Article							CYSTATHIONINE BETA-SYNTHASE; EXPRESSION; GENES	Mutations in cystathionine beta-synthase (CBS) are known to cause homocystinuria, a recessive disorder characterized by excessive levels of total homocysteine (tHcy) in plasma(1). The primary cause of mortality is thromboembolism induced by the excessive tHcy levels. Mild increases in tHcy levels are a significant risk factor in the development of vascular disease in the general population(2). This can result from heterozygosity at the CB5 locus or polymorphic variation in other enzymes involved in homocysteine re-methylation. We report here that a mutation which deletes the carboxy-terminal 145 amino acids of CBS can functionally suppress the phenotype of several CBS mutant alleles found in homocystinurics when expressed in yeast. This C-terminal domain of CB5 acts to inhibit enzymatic activity and is in turn regulated by S-adenosylmethionine (AdoMet), a positive effector of CBS. Our results indicate that most mutations found in homocystinurics do not cause dysfunction of the catalytic domain, but rather interfere with the activation of the enzyme. These findings suggest a new drug target to treat homocystinuria and homocysteine-related vascular disease.	Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kruger, WD (corresponding author), Fox Chase Canc Ctr, Div Populat Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	wd_kruger@fccc.edu	kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NHLBI NIH HHS [HL57299-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057299, R29HL057299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; GALLAGHER PM, 1995, HUM MUTAT, V6, P177, DOI 10.1002/humu.1380060211; Harlow E., 1988, ANTIBODIES LABORATOR, P511; Kim CE, 1997, HUM MOL GENET, V6, P2213, DOI 10.1093/hmg/6.13.2213; Kluijtmans LAJ, 1996, J CLIN INVEST, V98, P285, DOI 10.1172/JCI118791; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; KRUGER WD, 1995, HUM MOL GENET, V4, P1155, DOI 10.1093/hmg/4.7.1155; MUDD SH, 1995, METABOLIC BASIS INHE, P693; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3	12	103	107	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					91	93		10.1038/ng0598-91	http://dx.doi.org/10.1038/ng0598-91			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590298				2022-12-25	WOS:000073346700026
J	Odorisio, T; Rodriguez, TA; Evans, EP; Clarke, AR; Burgoyne, PS				Odorisio, T; Rodriguez, TA; Evans, EP; Clarke, AR; Burgoyne, PS			The meiotic checkpoint monitoring synapsis eliminates spermatocytes via p53-independent apoptosis	NATURE GENETICS			English	Article							P53 PROTEIN; MICE; SPERMATOGENESIS; CHROMOSOME; FERTILITY	Evidence is accumulating that meiosis is subject to 'checkpoints' that monitor the quality of this complex process. In yeast, unresolved double strand breaks (DSBs) in DNA are thought to trigger a 'recombination checkpoint' that leads to pachytene arrest(1). In higher eukaryotes, there is evidence for a checkpoint that monitors chromosome synapsis and in mammals the most compelling evidence relates to the sex chromosomes(2). In normal male mice, there is synapsis between the X and Y pseudoautosomal regions; in XSxr(a)O mice, with a single asynaptic sex chromosome, there is arrest at the first meiotic metaphase(3), the arrested cells being eliminated by apoptosis (our unpublished data). Satisfying the requirement for pseudoautosomal synapsis by providing a pairing partner for the XSxr(a) chromosome avoids this arrest(4). We have considered that this 'synapsis checkpoint' may be a modification of the yeast 'recombination checkpoint', with unresolved DSBs (a corollary of asynapsis) providing the trigger for apoptosis. DSBs induced by irradiation are known to trigger apoptosis in a number of cell types via a p53-dependent pathway(5,6), and we now show that irradiation-induced spermatogonial apoptosis is also p53-dependent. In contrast, the apoptotic elimination of spermatocytes with synaptic errors proved to be p53-independent.	Natl Inst Med Res, Lab Dev Genet, London NW7 1AA, England; MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	MRC National Institute for Medical Research; MRC Harwell; University of Edinburgh	Burgoyne, PS (corresponding author), Natl Inst Med Res, Lab Dev Genet, Ridgeway,Mill Hill, London NW7 1AA, England.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; ODORISIO, Teresa/0000-0001-8851-3502; Rodriguez, Tristan/0000-0002-3415-8493				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Allan D.J., 1987, P229; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Beumer TL, 1997, MOL REPROD DEV, V47, P240, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;240::AID-MRD2&gt;3.0.CO;2-L; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; Burgoyne PS, 1993, CHROMOSOMES TODAY, V11, P243; BURGOYNE PS, 1984, CONTROLLING EVENTS M, P349; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EICHER EM, 1991, CYTOGENET CELL GENET, V57, P221, DOI 10.1159/000133152; EVANS EP, 1964, CYTOGENETICS, V3, P289, DOI 10.1159/000129818; EVANS EP, 1975, NATURE, V256, P40, DOI 10.1038/256040a0; FORD CE, 1964, CYTOGENETICS, V3, P295, DOI 10.1159/000129819; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; HENRIKSEN K, 1996, J ANDROL, V17, P939; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; MAHADEVAIAH S, 1986, CYTOGENET CELL GENET, V41, P169, DOI 10.1159/000132222; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; READER CR, 1969, ACTA PHYSIOL LAT AM, V19, P249; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SUTCLIFFE MJ, 1991, MOL REPROD DEV, V30, P81, DOI 10.1002/mrd.1080300202; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	31	230	242	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					257	261		10.1038/ng0398-257	http://dx.doi.org/10.1038/ng0398-257			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500548				2022-12-25	WOS:000072325000024
J	Banerjee, P; Kleyn, PW; Knowles, JA; Lewis, CA; Ross, BM; Parano, E; Kovats, SG; Lee, JJ; Penchaszadeh, GK; Ott, J; Jacobson, SG; Gilliam, TC				Banerjee, P; Kleyn, PW; Knowles, JA; Lewis, CA; Ross, BM; Parano, E; Kovats, SG; Lee, JJ; Penchaszadeh, GK; Ott, J; Jacobson, SG; Gilliam, TC			TULP1 mutation in two extended Dominican kindreds with autosomal recessive Retinitis pigmentosa	NATURE GENETICS			English	Article							SPLICE-SITE; GENE; TUBBY; MOUSE; IDENTIFICATION; FAMILY	The RP14 autosomal recessive Retinitis pigmentosa (arRP) locus has been mapped to a 2cM region of chromosome 6p21.3 (refs 1-3). TULP1 (the gene encoding tubby-like protein 1) is a candidate target for the disease mutation because it maps to the RP14 minimum genetic region and because a mutation in the highly homologous mouse tub gene leads to obesity, deafness and early progressive retinal degeneration(4-6). Here we report a splice-site mutation (IVS14+1, G-->A) that is homozygous in all affected individuals (N=33) and heterozygous in all obligate carriers (N=50) from two RP14-linked kindreds. The mutation was not observed in 210 unrelated controls. The data indicate that impairment of TULP1 protein function is a rare cause of arRP and that the normal protein plays an essential role in the physiology of the retina.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, New York, NY 10032 USA; New York State Psychiat Inst, New York, NY 10032 USA; Millennium Pharmaceut, Cambridge, MA 02139 USA; Med Ctr, Carrabelle, FL 32322 USA; Univ Catania, Pediat Clin, Catania, Italy; CNR, IBFSNC, Catania, Italy; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA	Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University of Catania; Consiglio Nazionale delle Ricerche (CNR); Rockefeller University; University of Pennsylvania; Pennsylvania Medicine	Gilliam, TC (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA.			Jacobson, Samuel/0000-0003-2122-169X; PARANO, ENRICO/0000-0002-0713-7339				BANERJEE P, IN PRESS GENOMICS; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Fujita R, 1997, AM J HUM GENET, V61, P571, DOI 10.1086/515523; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; JACOBSON SG, 1994, INVEST OPHTH VIS SCI, V35, P2521; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; KNOWLES JA, 1994, HUM MOL GENET, V3, P1401, DOI 10.1093/hmg/3.8.1401; KRAWCZAK M, 1992, HUM GENET, V90, P41; LINCOLN AL, 1991, PRIMER COMPUTER PROG; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; North MA, 1997, P NATL ACAD SCI USA, V94, P3128, DOI 10.1073/pnas.94.7.3128; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; Reig C, 1996, HUM MUTAT, V8, P93, DOI 10.1002/(SICI)1098-1004(1996)8:1<93::AID-HUMU17>3.0.CO;2-M; SHUGART YY, 1995, AM J HUM GENET, V57, P499; SINGH RK, 1993, HUM MOL GENET, V2, P875	15	120	123	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					177	179		10.1038/ng0298-177	http://dx.doi.org/10.1038/ng0298-177			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462751				2022-12-25	WOS:000071779500030
J	van Zijl, PCM; Eleff, SM; Ulatowski, JA; Oja, JME; Ulug, AM; Traystman, RJ; Kauppinen, RA				van Zijl, PCM; Eleff, SM; Ulatowski, JA; Oja, JME; Ulug, AM; Traystman, RJ; Kauppinen, RA			Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging	NATURE MEDICINE			English	Article							HUMAN BRAIN-FUNCTION; MEAN TRANSIT TIME; GRADIENT-ECHO; SIGNAL CHANGES; RAT-BRAIN; CAT BRAIN; SENSORY STIMULATION; RELAXATION RATES; WATER PROTONS; IN-VIVO	The ability to measure the effects of local alterations in blood flow, blood volume and oxygenation by nuclear magnetic resonance has stimulated a surge of activity in functional MRI of many organs, particularly in its application to cognitive neuroscience. However, the exact description of these effects in terms of the interrelations between the MRI signal changes and the basic physiological parameters has remained an elusive goal. We here present this fundamental theory for spin-echo signal changes in perfused tissue and validate it in vivo in the cat brain by using the physiological alteration of hypoxic hypoxia. These experiments show that high-resolution absolute blood volume images can be obtained by using hemoglobin as a natural intravascular contrast agent. The theory also correctly predicts the magnitude of spin-echo MRI signal intensity changes on brain activation and thereby provides a sound physiological basis for these types of studies.	Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care, Baltimore, MD 21205 USA; Univ Kuopio, AI Virtanen Inst, NMR Res Grp, FIN-70211 Kuopio, Finland	Johns Hopkins University; Johns Hopkins University; University of Eastern Finland	van Zijl, PCM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol, 217 Traylor Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Kauppinen, Risto A/F-3274-2011; Van Zijl, Peter C/ABF-3732-2020; Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322	NATIONAL CANCER INSTITUTE [T32CA009630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031490] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09630] Funding Source: Medline; NINDS NIH HHS [NS 31490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLERHAND A, 1964, J CHEM PHYS, V41, P2115, DOI 10.1063/1.1726215; ATALAY MK, 1993, RADIOLOGY, V189, P759, DOI 10.1148/radiology.189.3.8234701; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BANDETTINI PA, 1994, NMR BIOMED, V7, P12, DOI 10.1002/nbm.1940070104; BANDETTINI PA, 1995, INT J IMAG SYST TECH, V6, P133, DOI 10.1002/ima.1850060203; Barinaga M, 1997, SCIENCE, V276, P196, DOI 10.1126/science.276.5310.196; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P4, DOI 10.1002/mrm.1910340103; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; BROOKS RA, 1980, J COMPUT ASSIST TOMO, V4, P489, DOI 10.1097/00004728-198008000-00016; BRYANT RG, 1990, MAGNET RESON MED, V13, P133, DOI 10.1002/mrm.1910130112; DECRESPIGNY AJ, 1992, MAGN RESON MED, V27, P391, DOI 10.1002/mrm.1910270220; EICHLING JO, 1974, CIRC RES, V35, P358, DOI 10.1161/01.RES.35.3.358; EKSTROMJODAL B, 1979, ACTA NEUROL SCAND, V60, P26; FABRY ME, 1983, BIOCHEMISTRY-US, V22, P4119, DOI 10.1021/bi00286a020; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; GILLIS P, 1995, MAGNET RESON MED, V33, P93, DOI 10.1002/mrm.1910330114; GOMORI JM, 1987, J COMPUT ASSIST TOMO, V11, P684, DOI 10.1097/00004728-198707000-00025; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HAACKE EM, 1995, INT J IMAG SYST TECH, V6, P153, DOI 10.1002/ima.1850060204; HERBST MD, 1989, AM J PHYSIOL, V256, pC1097, DOI 10.1152/ajpcell.1989.256.5.C1097; HOPPEL BE, 1993, MAGN RESON MED, V30, P715, DOI 10.1002/mrm.1910300609; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; JEZZARD P, 1994, NMR BIOMED, V7, P35, DOI 10.1002/nbm.1940070107; KARCZMAR GS, 1994, NMR BIOMED, V7, P3, DOI 10.1002/nbm.1940070103; KOEHLER RC, 1984, J CEREBR BLOOD F MET, V4, P115, DOI 10.1038/jcbfm.1984.16; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; MADSEN PL, 1995, J CEREBR BLOOD F MET, V15, P485, DOI 10.1038/jcbfm.1995.60; MEYER ME, 1995, MAGNET RESON MED, V34, P234, DOI 10.1002/mrm.1910340215; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; OGAWA S, 1993, MAGNET RESON MED, V29, P205, DOI 10.1002/mrm.1910290208; PAULSON OB, 1977, MICROVASC RES, V13, P113, DOI 10.1016/0026-2862(77)90120-0; PAWLIK G, 1981, BRAIN RES, V208, P35, DOI 10.1016/0006-8993(81)90619-3; PRIELMEIER F, 1994, MAGN RESON MED, V31, P678, DOI 10.1002/mrm.1910310615; ROBINSON SP, 1995, INT J RADIAT ONCOL, V33, P961; ROSTRUP E, 1995, NMR BIOMED, V8, P41, DOI 10.1002/nbm.1940080109; ROUSSEL SA, 1995, J CEREBR BLOOD F MET, V15, P578, DOI 10.1038/jcbfm.1995.71; SHARAN M, 1989, ANN BIOMED ENG, V17, P13, DOI 10.1007/BF02364271; SHOCKLEY RP, 1988, BRAIN RES, V454, P170, DOI 10.1016/0006-8993(88)90816-5; SHULMAN RG, 1993, P NATL ACAD SCI USA, V90, P3127, DOI 10.1073/pnas.90.8.3127; SLESJO BK, 1978, BRAIN ENERGY METABOL; SMITH AL, 1971, J APPL PHYSIOL, V31, P701, DOI 10.1152/jappl.1971.31.5.701; Song AW, 1996, MAGNET RESON MED, V35, P155, DOI 10.1002/mrm.1910350204; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; TURNER R, 1991, MAGNET RESON MED, V22, P159, DOI 10.1002/mrm.1910220117; UEKI M, 1992, ACTA ANAESTH SCAND, V36, P318, DOI 10.1111/j.1399-6576.1992.tb03474.x; Ulatowski JA, 1996, AM J PHYSIOL-HEART C, V270, pH466, DOI 10.1152/ajpheart.1996.270.2.H466; WU XS, 1992, CIRCULATION, V85, P730, DOI 10.1161/01.CIR.85.2.730; YE FQ, 1995, MAGNET RESON MED, V34, P713, DOI 10.1002/mrm.1910340510	53	395	399	1	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					159	167		10.1038/nm0298-159	http://dx.doi.org/10.1038/nm0298-159			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461188				2022-12-25	WOS:000072249800030
J	Bunting, KD; Sangster, MY; Ihle, JN; Sorrentino, BP				Bunting, KD; Sangster, MY; Ihle, JN; Sorrentino, BP			Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; RECEPTOR-GAMMA CHAIN; IMMUNE RECONSTITUTION; PERIPHERAL-BLOOD; LACKING JAK3; INTERLEUKIN-2; MUTATION; DEFECTS	Janus kinase-3 (JAK3) deficiency has recently been identified as a cause of severe combined immunodeficiency (SCID) in humans. We used a mouse model of Jak3-deficient SCID to test a gene therapy approach for treatment of this disease. Transfer of a Jak3 retroviral vector to repopulating hematopoietic stem cells resulted in increased numbers of T and B lymphocytes, reversal of hypogammaglobulinemia, restoration of T-cell activation upon stimulation with mitogens, and development of an antigen-specific immune response after immunization. Analysis for vector copy number in lymphoid and myeloid populations showed a large in vivo selective advantage for Jak3-expressing lymphoid cells. These results show that gene replacement is a feasible treatment strategy for this disease and that naturally occurring in vivo selection of corrected cells is an important advantage of this approach.	St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Sorrentino, BP (corresponding author), St Jude Childrens Res Hosp, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.			Sangster, Mark/0000-0002-1599-5894	NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAY JA, 1995, BLOOD, V85, P3342, DOI 10.1182/blood.V85.11.3342.bloodjournal85113342; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BODINE DM, 1991, EXP HEMATOL, V19, P206; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, 1993, SEMIN HEMATOL, V30, P92; Candotti F, 1996, BLOOD, V87, P3097, DOI 10.1182/blood.V87.8.3097.bloodjournal8783097; Candotti F, 1996, J EXP MED, V183, P2687, DOI 10.1084/jem.183.6.2687; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DROR Y, 1993, BLOOD, V81, P2021; HIRCHHORN R, 1993, PEDIATR RES, V33, pS35; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mardiney M, 1997, BLOOD, V89, P2268, DOI 10.1182/blood.V89.7.2268; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; ORKIN S, 1997, STUDY PANEL CHAIRS R; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Smith MR, 1997, FEBS LETT, V408, P327, DOI 10.1016/S0014-5793(97)00456-0; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Spencer HT, 1996, BLOOD, V87, P2579, DOI 10.1182/blood.V87.6.2579.bloodjournal8762579; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; Taylor N, 1996, BLOOD, V87, P3103, DOI 10.1182/blood.V87.8.3103.bloodjournal8783103; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VANLEEUWEN JEM, 1994, BLOOD, V84, P3936, DOI 10.1182/blood.V84.11.3936.bloodjournal84113936; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	34	119	136	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					58	64		10.1038/nm0198-058	http://dx.doi.org/10.1038/nm0198-058			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427607				2022-12-25	WOS:000072249700035
J	Williams, BC; Murphy, TD; Goldberg, ML; Karpen, GH				Williams, BC; Murphy, TD; Goldberg, ML; Karpen, GH			Neocentromere activity of structurally acentric mini-chromosomes in Drosophila	NATURE GENETICS			English	Article							POSITION-EFFECT VARIEGATION; KINESIN-LIKE PROTEIN; ALPHA-SATELLITE DNA; CENP-C; CENTROMERE PROTEIN; DICENTRIC CHROMOSOME; FISSION YEAST; P-ELEMENTS; CHROMATIN; HETEROCHROMATIN	Chromosome fragments that lack centromeric DNA (structurally acentric chromosomes) are usually not inherited in mitosis and meiosis. We previously described the isolation, after irradiation of a Drosophila melanogaster minichromosome, of structurally acentric mini-chromosomes that display efficient mitotic and meiotic transmission despite their small size (under 300 kb) and lack of centromeric DNA. Here we report that these acentric minichromosomes bind the centromere-specific protein ZW10 and associate with the spindle poles in anaphase. The sequences in these acentric mini-chromosomes were derived from the tip of the X chromosome, which does not display centromere activity or localize ZW10, even when separated from the rest of the X. We conclude that the normally non-centromeric DNAs present in these acentric mini-chromosomes have acquired centromere function, and suggest that this example of 'neocentromere' formation involves appropriation of a self-propagating centromeric chromatin structure. The potential relevance of these observations to the identity, propagation and function of normal centromeres is discussed.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Cornell Univ, Genet & Dev Sect, Ithaca, NY 14853 USA	Salk Institute; Cornell University	Karpen, GH (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			WILLIAMS, BYRON/0000-0002-1517-931X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048430] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM48430] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AJIRO K, 1985, J BIOL CHEM, V260, P5379; Albertson D, 1997, NEMATODE C ELEGANS, P47; ALFENITO MR, 1993, GENETICS, V135, P589; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; AULT JG, 1988, CHROMOSOMA, V97, P71, DOI 10.1007/BF00331796; BONNER JJ, 1984, CELL, V37, P979; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; BROWN W, 1995, TRENDS GENET, V11, P337, DOI 10.1016/S0168-9525(00)89100-3; Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; Cook KR, 1997, GENETICS, V145, P737; Dawe RK, 1996, P NATL ACAD SCI USA, V93, P8512, DOI 10.1073/pnas.93.16.8512; Depinet TW, 1997, HUM MOL GENET, V6, P1195, DOI 10.1093/hmg/6.8.1195; duSart D, 1997, NAT GENET, V16, P144; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; GOLDSTEIN LS, 1991, BIOESSAYS, V13, P675; GOLIC KG, 1994, GENETICS, V137, P551; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KARPEN GH, 1990, CELL, V63, P97; Khodjakov A, 1996, J CELL BIOL, V132, P1093, DOI 10.1083/jcb.132.6.1093; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; LE MH, 1995, GENETICS, V141, P283; Lindsley D.L., 1980, Genetics and Biology of Drosophila, V2d, P225; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; MARSCHALL LG, 1995, J CELL BIOL, V128, P445, DOI 10.1083/jcb.128.4.445; MASON JM, 1995, TRENDS GENET, V11, P58, DOI 10.1016/S0168-9525(00)88998-2; Mather K, 1933, J GENET, V28, P1, DOI 10.1007/BF02981766; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MERRY DE, 1985, AM J HUM GENET, V37, P425; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Ngan VK, 1997, MOL CELL BIOL, V17, P3305, DOI 10.1128/MCB.17.6.3305; PAGE SL, 1995, HUM MOL GENET, V4, P289, DOI 10.1093/hmg/4.2.289; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PIMPINELLI S, 1989, TRENDS GENET, V5, P310, DOI 10.1016/0168-9525(89)90114-5; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Rhoades M. M., 1952, Heterosis., P66; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; SUN X, 1997, CELL, V91; Taylor SS, 1996, CHROMOSOMA, V105, P70, DOI 10.1007/BF02509516; THERMAN E, 1974, AM J HUM GENET, V26, P83; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; TOWER J, 1993, GENETICS, V133, P347; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; Warburton PE, 1997, CHROMOSOMA, V106, P149, DOI 10.1007/s004120050234; WEVRICK R, 1992, GENOMICS, V14, P912, DOI 10.1016/S0888-7543(05)80112-0; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	65	167	172	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					30	37		10.1038/ng0198-30	http://dx.doi.org/10.1038/ng0198-30			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425896				2022-12-25	WOS:000071259600017
J	Zaitseva, M; Blauvelt, A; Lee, S; Lapham, CK; Klaus-Kovtun, V; Mostowski, H; Manischewitz, J; Golding, H				Zaitseva, M; Blauvelt, A; Lee, S; Lapham, CK; Klaus-Kovtun, V; Mostowski, H; Manischewitz, J; Golding, H			Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DENDRITIC CELLS; RHESUS MACAQUES; LYMPHOCYTE SUBSETS; GENITAL-TRACT; TRANSMISSION; ANTIGEN; BLOOD; REPLICATION; VARIANTS	Transmission of HIV-1 is predominantly restricted to macrophage (M Phi)-tropic strains. Langerhans cells (LCs) in mucosal epithelium, as well as macrophages located in the submucosal tissues, may be initial targets for HIV-1. This study was designed to determine whether restricted transmission of HIV-1 correlates with expression and function of HIV-1 co-receptors on LCs and macrophages. Using polyclonal rabbit IgGs specific for the HIV co-receptors cytokines CXCR4 and CCR5, we found that freshly isolated epidermal LCs (resembling resident mucosal LCs) expressed CCR5, but not CXCR, on their surfaces. In concordance with surface expression, fresh LCs fused with M Phi-tropic but not with T-tropic HIV-1 envelopes. However, fresh LCs did contain intracellular CXCR4 protein that was transported to the surface during in vitro culture. Macrophages expressed high levels of both co-receptors on their surfaces, but only CCR5 was functional in a fusion assay. These data provide several possible explanations for the selective transmission of M Phi-tropic HIV variants and for the resistance to infection conferred by the CCR5 deletion.	US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; US FDA, Div Cell & Gene Therapy, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NCI, Dermatol Branch, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Golding, H (corresponding author), US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bldg 29B,Room 4NN04,HFM 454,8800 Rockville Pike, Bethesda, MD 20892 USA.							AIBA S, 1990, J IMMUNOL, V145, P2791; Berger EA, 1997, AIDS, V11, pS3; BLAUVELT A, 1995, J IMMUNOL, V154, P3506; Blauvelt A, 1997, J CLIN INVEST, V100, P2043, DOI 10.1172/JCI119737; Blauvelt Andrew, 1997, American Journal of Medicine, V102, P16, DOI 10.1016/S0002-9343(97)00055-7; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158, DOI 10.1002/jlb.59.2.158; Cameron PU, 1996, J EXP MED, V183, P1851, DOI 10.1084/jem.183.4.1851; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; EDWARDS JNT, 1985, BRIT J OBSTET GYNAEC, V92, P974, DOI 10.1111/j.1471-0528.1985.tb03080.x; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Howell AL, 1997, J VIROL, V71, P3498, DOI 10.1128/JVI.71.5.3498-3506.1997; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MACATONIA SE, 1989, IMMUNOLOGY, V67, P285; MILLER CJ, 1992, LAB INVEST, V67, P628; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MILLER CJ, 1993, LAB INVEST, V68, P129; NUOVO GJ, 1993, AM J PATHOL, V143, P40; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; PARR MB, 1991, BIOL REPROD, V45, P261, DOI 10.1095/biolreprod45.2.261; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; ROMANI N, 1992, SPRINGER SEMIN IMMUN, V13, P265; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZAMBRUNO G, 1995, IMMUNOL TODAY, V16, P520, DOI 10.1016/0167-5699(95)80044-1; ZHANG L, 1993, J VIROL, V67, P3354; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	43	311	321	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1369	1375		10.1038/nm1297-1369	http://dx.doi.org/10.1038/nm1297-1369			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396607				2022-12-25	WOS:000072249500033
J	Smith, TF; Zhang, XL				Smith, TF; Zhang, XL			The challenges of genome sequence annotation or "the devil is in the details"	NATURE BIOTECHNOLOGY			English	Editorial Material									Boston Univ, Coll Engn, BioMol Engn Res Ctr, Boston, MA 02215 USA	Boston University	Smith, TF (corresponding author), Boston Univ, Coll Engn, BioMol Engn Res Ctr, 36 Cummington St, Boston, MA 02215 USA.							NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0	1	44	537	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1222	1223		10.1038/nbt1197-1222	http://dx.doi.org/10.1038/nbt1197-1222			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359093				2022-12-25	WOS:000071342000004
J	Chen, KS; Manian, P; Koeuth, T; Potocki, L; Zhao, Q; Chinault, AC; Lee, CC; Lupski, JR				Chen, KS; Manian, P; Koeuth, T; Potocki, L; Zhao, Q; Chinault, AC; Lee, CC; Lupski, JR			Homologous recombination of a flanking repeat gene cluster is a mechanism for a common contiguous gene deletion syndrome	NATURE GENETICS			English	Article							SMITH-MAGENIS SYNDROME; YEAST ARTIFICIAL CHROMOSOMES; POLYMERASE CHAIN-REACTION; IN-SITU HYBRIDIZATION; SPINAL MUSCULAR-ATROPHY; PRADER-WILLI-SYNDROME; SOMATIC-CELL HYBRIDS; HUMAN X-CHROMOSOME; DISTAL SHORT ARM; HUMAN GENOME	Smith-Magenis syndrome (SMS), caused by del(17)p11.2, represents one of the most frequently observed human microdeletion syndromes. We have identified three copies of a low-copy-number repeat (SMS-REPs) located within and flanking the SMS common deletion region and show that SMS-REP represents a repeated gene cluster. We have isolated a corresponding cDNA clone that identifies a novel junction fragment from 29 unrelated SMS patients and a different-sized junction fragment from a patient with dup(17)p11.2. Our results suggest that homologous recombination of a flanking repeat gene cluster is a mechanism for this common microdeletion syndrome.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Chen, Ken-Shiung/A-2204-2011		NCRR NIH HHS [M01 RR-00188] Funding Source: Medline; NHGRI NIH HHS [HG00210] Funding Source: Medline; NICHD NIH HHS [HD24064] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; BOTTO M, 1992, P NATL ACAD SCI USA, V89, P4957, DOI 10.1073/pnas.89.11.4957; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; Buetow K H, 1994, Science, V265, P2055, DOI 10.1126/science.8091228; Campbell HD, 1997, GENOMICS, V42, P46, DOI 10.1006/geno.1997.4709; CHANCE PF, 1994, HUM MOL GENET, V3, P223, DOI 10.1093/hmg/3.2.223; Chen K-S, 1996, MENTAL RETARD DEV DI, V2, P122; CHEN KS, 1995, AM J HUM GENET, V56, P175; CHEVILLARD C, 1993, HUM MOL GENET, V2, P1235, DOI 10.1093/hmg/2.8.1235; CHRISTIAN SI, 1995, AM J HUM GENET, V57, P40; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; DEHOSTOS EL, 1993, CELL MOTIL CYTOSKEL, V26, P181, DOI 10.1002/cm.970260302; DeLaurenzi V, 1996, NAT GENET, V12, P52; ELDER FFB, 1985, AM J MED GENET, V20, P519, DOI 10.1002/ajmg.1320200312; ELSEA SH, 1995, AM J HUM GENET, V57, P1342; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GREENBERG F, 1991, AM J HUM GENET, V49, P1207; Greenberg F, 1996, AM J MED GENET, V62, P247, DOI 10.1002/(SICI)1096-8628(19960329)62:3<247::AID-AJMG9>3.3.CO;2-9; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; GUZZETTA V, 1991, GENOMICS, V9, P31, DOI 10.1016/0888-7543(91)90217-3; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALFORD S, 1993, HUM MOL GENET, V2, P191, DOI 10.1093/hmg/2.2.191; HERZ J, 1990, FEBS LETT, V276, P103, DOI 10.1016/0014-5793(90)80518-N; HIRAOKA LR, 1995, GENOMICS, V25, P323, DOI 10.1016/0888-7543(95)80150-K; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; JI Y, 1996, AM J HUM GENET, V59, pA158; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; Jurado LAP, 1996, AM J HUM GENET, V59, P781; JUYAL RC, 1995, AM J MED GENET, V58, P286, DOI 10.1002/ajmg.1320580317; JUYAL RC, 1995, AM J MED GENET, V59, P406, DOI 10.1002/ajmg.1320590332; Juyal RC, 1996, AM J HUM GENET, V58, P998; KALLIONIEMI OP, 1994, GENOMICS, V20, P125, DOI 10.1006/geno.1994.1138; Kimura T, 1997, AM J MED GENET, V69, P320; KMIEC EB, 1985, CELL, V40, P139, DOI 10.1016/0092-8674(85)90317-4; Koyama K, 1996, CYTOGENET CELL GENET, V72, P78, DOI 10.1159/000134167; KRAWCZAK M, 1991, HUM GENET, V86, P425; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LEDBETTER DH, 1995, METABOLIC MOL BASES, V1, P811; LEE CC, 1995, HUM MOL GENET, V4, P1373, DOI 10.1093/hmg/4.8.1373; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LeGuern E, 1996, HUM MOL GENET, V5, P103, DOI 10.1093/hmg/5.1.103; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LI XM, 1992, NUCLEIC ACIDS RES, V20, P1117, DOI 10.1093/nar/20.5.1117; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MANIATIS T, 1980, ANNU REV GENET, V14, P145, DOI 10.1146/annurev.ge.14.120180.001045; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; Matsuda Y, 1996, GENOMICS, V33, P325, DOI 10.1006/geno.1996.0203; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NAKAMURA T, 1992, ONCOGENE, V7, P733; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; OCHMAN H, 1988, GENETICS, V120, P621; PEETERS BPH, 1988, MOL GEN GENET, V212, P450, DOI 10.1007/BF00330849; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Reiter LT, 1997, HUM MOL GENET, V6, P1595, DOI 10.1093/hmg/6.9.1595; ROA BB, 1994, ADV HUM GENET, V22, P117; ROA BB, 1993, NAT GENET, V5, P189, DOI 10.1038/ng1093-189; Roa BB, 1996, HUM GENET, V97, P642; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Shaffer LG, 1997, AM J MED GENET, V69, P325, DOI 10.1002/(SICI)1096-8628(19970331)69:3<325::AID-AJMG20>3.0.CO;2-S; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; SINGER BS, 1988, J MOL BIOL, V202, P233, DOI 10.1016/0022-2836(88)90454-8; SMITH ACM, 1986, AM J MED GENET, V24, P393, DOI 10.1002/ajmg.1320240303; STRATTON RF, 1986, AM J MED GENET, V24, P421, DOI 10.1002/ajmg.1320240305; TOWNSENDNICHOLSON A, 1995, GENOMICS, V25, P605, DOI 10.1016/0888-7543(95)80074-V; Trask BJ, 1996, HUM GENET, V98, P710, DOI 10.1007/s004390050291; van Tuinen P, 1987, Genomics, V1, P374, DOI 10.1016/0888-7543(87)90042-5; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHORISKEY SK, 1991, GENETICS, V127, P21; Wilgenbus KK, 1997, GENOMICS, V42, P1, DOI 10.1006/geno.1997.4707; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P241, DOI 10.1016/0167-4781(93)90193-H; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589; ZORI RT, 1993, AM J MED GENET, V47, P504, DOI 10.1002/ajmg.1320470414	83	293	297	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					154	163		10.1038/ng1097-154	http://dx.doi.org/10.1038/ng1097-154			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326934				2022-12-25	WOS:A1997XZ55500020
J	SupertiFurga, G; Jonsson, K; Courtneidge, SA				SupertiFurga, G; Jonsson, K; Courtneidge, SA			A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases	NATURE BIOTECHNOLOGY			English	Article						tyrosine kinase; tyrosine phosphatase; Src; Csk; Schizosaccharomyces pombe	C-SRC ACTIVITY; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; EXPRESSION; THIAMINE; ENCODES; FAMILY; PHOSPHATASE; CELLS	Tyrosine phosphorylation exerts a pivotal role in cell regulation processes of higher eukaryotes. Tight control of the activity of protein tyrosine kinases is crucial for ordered phosphorylation to occur. We have developed a functional screen for tyrosine kinase regulators using c-Src, the first cellular protein tyrosine kinase described, as a prototype; and fission yeast, Schizosaccharomyces pombe, as a genetically amenable host system. Inducible expression of c-Src in fission yeast is lethal. We have screened human cDNA libraries for clones able to counteract the lethal effect of Src. Two different classes of cDNAs, which we called SAS for sequences antagonizing Src, were obtained. The first class encodes for the protein tyrosine kinase Csk, known to regulate Src activity through phosphorylation of the C-terminal tyrosine. The second class consists of clones encoding three different tyrosine phosphatases, counter-acting Src action by dephosphorylation of Src substrates and by dephosphorylation of Src itself. The system described here can be applied to identify regulators of other heterologous tyrosine kinases, including receptor-type tyrosine kinases, which impair growth of S. pombe.			SupertiFurga, G (corresponding author), EUROPEAN MOLEC BIOL LAB, POSTFACH 102209 MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.		Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	Superti-Furga, Giulio/0000-0002-0570-1768				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BOLEN JB, 1993, ONCOGENE, V8, P2025; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORIO M, 1994, MOL BIOL CELL, V5, P283, DOI 10.1091/mbc.5.3.283; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Koegl M, 1995, ONCOGENE, V11, P2317; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MACAULEY A, 1993, ONCOGENE, V8, P117; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PARTANEN J, 1991, ONCOGENE, V6, P2013; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RUSSELL PR, 1983, J BIOL CHEM, V258, P143; SARAS J, 1994, J BIOL CHEM, V269, P24082; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALKENHORST J, 1996, IN PRESS ONCOGENE; YANG Q, 1993, J BIOL CHEM, V268, P6622; YI TL, 1991, BLOOD, V78, P2222	49	29	34	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					600	605		10.1038/nbt0596-600	http://dx.doi.org/10.1038/nbt0596-600			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630950				2022-12-25	WOS:A1996UL60400024
J	Stempfer, G; HollNeugebauer, B; Kopetzki, E; Rudolph, R				Stempfer, G; HollNeugebauer, B; Kopetzki, E; Rudolph, R			A fusion protein designed for noncovalent immobilization: Stability, enzymatic activity, and use in an enzyme reactor	NATURE BIOTECHNOLOGY			English	Article						fusion protein; enzyme immobilization; enzyme reactor; protein stability	YEAST ALPHA-GLUCOSIDASE; STABILIZATION; PURIFICATION; RESOLUTION	We have designed a new method for enzyme immobilization using a fusion protein of yeast cli-glucosidase containing at its C-terminus a polycationic hexa-arginine fusion peptide. This fusion protein can be directly adsorbed from crude cell extracts on polyanionic matrices in a specific, oriented fashion. Upon noncovalent immobilization by polyionic interactions, the stability of the fusion protein is not affected by pH-, urea-, or thermal-denaturation. Furthermore, the enzymatic properties (specific activity at increasing enzyme concentration, Michaelis constant, or activation energy of the enzymatic reaction) are not influenced by this noncovalent coupling. The operational stability of the coupled enzyme under conditions of continuous substrate conversion is, however, increased significantly compared to the soluble form. Fusion proteins containing polyionic peptide sequences are proposed as versatile tools for the production of immobilized enzyme catalysts.	UNIV HALLE WITTENBERG,INST BIOTECHNOL,D-06120 HALLE,GERMANY; BOEHRINGER MANNHEIM THERAPEUT,D-82377 PENZBERG,GERMANY	Martin Luther University Halle Wittenberg								ASTHER M, 1993, APPL BIOCHEM BIOTECH, V38, P57, DOI 10.1007/BF02916412; BODE W, 1976, J MOL BIOL, V106, P325, DOI 10.1016/0022-2836(76)90089-9; FLASCHEL E, 1993, BIOTECHNOL ADV, V11, P31, DOI 10.1016/0734-9750(93)90409-G; GAIKWAD SM, 1992, ENZYME MICROB TECH, V14, P855, DOI 10.1016/0141-0229(92)90104-V; GLOGER M, 1983, METHOD ENZYMAT AN, V1, P142; Halvorson H., 1966, METHODS ENZYMOL, V8, P559, DOI [10.1016/0076-6879(66)08101-1, DOI 10.1016/0076-6879(66)08101-1]; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HOLLNEUGEBAUER B, 1992, THESIS U REGENSBURG; JANECEK S, 1993, PROCESS BIOCHEM, V28, P435, DOI 10.1016/0032-9592(93)85026-C; KATCHALSKIKATZIR E, 1993, TRENDS BIOTECHNOL, V11, P471, DOI 10.1016/0167-7799(93)90080-S; KOPETZKI E, 1989, MOL GEN GENET, V216, P149, DOI 10.1007/BF00332244; KOPETZKI E, 1989, YEAST, V5, P11, DOI 10.1002/yea.320050104; LEON J, 1992, BIOCATALYSIS, V7, P29; MARTINEK K, 1977, BIOCHIM BIOPHYS ACTA, V485, P1, DOI 10.1016/0005-2744(77)90188-7; MICHALON P, 1993, ENZYME MICROB TECH, V15, P215, DOI 10.1016/0141-0229(93)90140-W; MONTERO MA, 1993, BIOCHEM MOL BIOL INT, V30, P685; Mozhaev V.V., 1990, BIOCATAL BIOTRANSFOR, V3, P179, DOI [10.3109/10242429008992060, DOI 10.3109/10242429008992060]; MOZHAEV VV, 1983, BIOTECHNOL BIOENG, V25, P1937, DOI 10.1002/bit.260250804; MOZHAEV VV, 1979, MOL BIOL+, V13, P52; NEEDLEMAN RB, 1978, BIOCHEMISTRY-US, V17, P4657, DOI 10.1021/bi00615a011; Nelson JM, 1916, J AM CHEM SOC, V38, P1109, DOI 10.1021/ja02262a018; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PILONE MS, 1992, BIOTECHNOL APPL BIOC, V16, P252; SADHUKHAN R, 1993, ENZYME MICROB TECH, V15, P801, DOI 10.1016/0141-0229(93)90013-R; SASSENFELD HM, 1990, TRENDS BIOTECHNOL, V8, P88, DOI 10.1016/0167-7799(90)90145-N; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SHANKAR V, 1992, INDIAN J BIOCH BIOPH, V30, P62; Stempfer G, 1996, NAT BIOTECHNOL, V14, P329, DOI 10.1038/nbt0396-329; TABATA S, 1984, BIOCHIM BIOPHYS ACTA, V197, P231; TOSA T, 1967, BIOTECHNOL BIOENG, V9, P603, DOI 10.1002/bit.260090413; ULBRICH R, 1989, ENZYMKATALYSE, P293	31	34	40	2	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					481	484		10.1038/nbt0496-481	http://dx.doi.org/10.1038/nbt0496-481			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630924				2022-12-25	WOS:A1996UL58800032
J	Jung, HC; Lebeault, JM; Pan, JG				Jung, HC; Lebeault, JM; Pan, JG			Surface display of Zymomonas mobilis levansucrase by using the ice-nucleation protein of Pseudomonas syringae	NATURE BIOTECHNOLOGY			English	Article						protein display; GPI anchor; bioconversion	ESCHERICHIA-COLI; OUTER-MEMBRANE; BINDING DOMAINS; BETA-LACTAMASE; CELL-SURFACE; GENE; EXPRESSION; LIPOPROTEIN; ANTIBODIES; TRANSPORT	The ice-nucleation protein (Inp) is a glycosyl phosphatidylinositol-anchored outer membrane protein found in some Gram-negative bacteria. Using Pseodomonas syringae Inp as an anchoring motif, we investigated the functional display of a foreign protein, Zymomonas mobilis levansucrase (LevU), on the surface of Escherichia coli. The cells expressing Inp-LevU were found to retain both the ice-nucleation and whole-cell levansucrase enzyme activities, indicating the functional expression of Inp-LevU hybrid protein on the cell surface. The surface localization was further verified by immunofluorescence microscopy, fluorescence-activated cell sorting flow cytometry and immunogold electron microscopical examination. No growth inhibition or changes in the outer membrane integrity were observed upon the induction of fusion protein synthesis. Viability of the cells was also maintained over 48 hours in the stationary phase. Surface-displayed levansucrases were found to be resistant to the externally added proteases unless the cells were treated with EDTA. When the levansucrase-displayed cells were used as the enzyme source, levan (44 g/L) was efficiently synthesized from sucrose (130 g/L) with 34% (wt/wt) conversion yield, generating glucose (65 g/L) as a by-product.	Univ Technol Compiegne, Dept Proc Biotechnol Genie Chim, F-60205 Compiegne, France	Picardie Universites; Universite de Technologie de Compiegne	Pan, JG (corresponding author), Univ Technol Compiegne, Dept Proc Biotechnol Genie Chim, BP529, F-60205 Compiegne, France.			JUNG, Heungchae/0000-0003-4226-8235				AGTERBERG M, 1990, GENE, V88, P37, DOI 10.1016/0378-1119(90)90057-X; ARNON R, 1986, TRENDS BIOCHEM SCI, V11, P521, DOI 10.1016/0968-0004(86)90088-5; Bommarius Andreas S., 1993, P427; CHARBIT A, 1988, GENE, V70, P181, DOI 10.1016/0378-1119(88)90116-3; DRAINAS C, 1995, APPL ENVIRON MICROB, V61, P273, DOI 10.1128/AEM.61.1.273-277.1995; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Fischetti Vincent A., 1993, Current Opinion in Biotechnology, V4, P603, DOI 10.1016/0958-1669(93)90084-A; FRANCISCO JA, 1993, BIO-TECHNOL, V11, P491, DOI 10.1038/nbt0493-491; FRANCISCO JA, 1992, P NATL ACAD SCI USA, V89, P2713, DOI 10.1073/pnas.89.7.2713; FUCHS P, 1991, BIO-TECHNOL, V9, P1369, DOI 10.1038/nbt1291-1369; Georgiou G, 1996, PROTEIN ENG, V9, P239, DOI 10.1093/protein/9.2.239; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; GREEN RL, 1988, MOL GEN GENET, V215, P165, DOI 10.1007/BF00331320; HANSSON M, 1992, J BACTERIOL, V174, P4239, DOI 10.1128/JB.174.13.4239-4245.1992; KEITH J, 1991, BIOTECHNOL BIOENG, V38, P557, DOI 10.1002/bit.260380515; KOZLOFF LM, 1991, J BACTERIOL, V173, P6528, DOI 10.1128/jb.173.20.6528-6536.1991; Kwak JW, 1996, BIOTECHNOL TECH, V10, P127, DOI 10.1007/BF00765195; LINDOW SE, 1989, MOL PLANT MICROBE IN, V2, P262, DOI 10.1094/MPMI-2-262; Maurer J, 1997, J BACTERIOL, V179, P794, DOI 10.1128/jb.179.3.794-804.1997; Murai T, 1997, APPL ENVIRON MICROB, V63, P1362, DOI 10.1128/AEM.63.4.1362-1366.1997; NEMECEKMARSHALL M, 1993, J BACTERIOL, V175, P4062, DOI 10.1128/JB.175.13.4062-4070.1993; Piard JC, 1997, J BACTERIOL, V179, P3068, DOI 10.1128/jb.179.9.3068-3072.1997; Richins RD, 1997, NAT BIOTECHNOL, V15, P984, DOI 10.1038/nbt1097-984; Schreuder MP, 1996, TRENDS BIOTECHNOL, V14, P115, DOI 10.1016/0167-7799(96)10017-2; Sleytr UB, 1997, TRENDS BIOTECHNOL, V15, P20, DOI 10.1016/S0167-7799(96)10063-9; SONG KB, 1994, BIOTECHNOL LETT, V16, P1305; SONG KB, 1993, BIOCHIM BIOPHYS ACTA, V1173, P320, DOI 10.1016/0167-4781(93)90130-6; Stahl S, 1997, TRENDS BIOTECHNOL, V15, P185, DOI 10.1016/S0167-7799(97)01034-2; STEIDLER L, 1993, MOL GEN GENET, V236, P187, DOI 10.1007/BF00277111; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Suzuki M., 1993, SCI TECHNOLOGY FRUCT; TAYLOR IM, 1990, MOL MICROBIOL, V4, P1259, DOI 10.1111/j.1365-2958.1990.tb00705.x; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WATANABE M, 1994, J FOOD ENG, V22, P453, DOI 10.1016/0260-8774(94)90047-7; WOLBER PK, 1993, ADV MICROB PHYSIOL, V34, P203, DOI 10.1016/S0065-2911(08)60030-2; WOLBER PK, 1986, P NATL ACAD SCI USA, V83, P7256, DOI 10.1073/pnas.83.19.7256; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	144	173	3	61	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					576	580		10.1038/nbt0698-576	http://dx.doi.org/10.1038/nbt0698-576			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624691				2022-12-25	WOS:000073930600036
J	Belin, V; Cusin, V; Viot, G; Girlich, D; Toutain, A; Moncla, A; Vekemans, M; Le Merrer, M; Munnich, A; Cormier-Daire, V				Belin, V; Cusin, V; Viot, G; Girlich, D; Toutain, A; Moncla, A; Vekemans, M; Le Merrer, M; Munnich, A; Cormier-Daire, V			SHOX mutations in dyschondrosteosis (Leri-Weill syndrome)	NATURE GENETICS			English	Article							LOCI; MAP	Dyschondrosteosis(1) (DCS) is an autosomal dominant(2) form of mesomelic dysplasia with deformity of the forearm (Madelung deformity; ref. 3). Based on the observation of XY translocations (p22,q12; refs 4-6) in DCS patients, we tested the pseudoautosomal region in eight families with DCS and showed linkage of the DCS gene to a microsatellite DNA marker at the DXYS233 locus (Zmax=6.26 at theta=0). The short stature homeobox-containing gene(7,8) (SHOX), involved in idiopathic growth retardation and possibly Turner short stature, maps to this region and was therefore regarded as a strong candidate gene in DCS. Here, we report large-scale deletions tin seven families) and a nonsense mutation tin one family) of SHOX in patients with DCS and show that Langer mesomelic dwarfism(9) results from homozygous mutations at the DCS locus.	Hop Enfants Malad, INSERM U393, Dept Genet, Paris, France; Hop Enfants Malad, INSERM U393, Unite Rech Handicaps Genet Enfant, Paris, France; Hop Clocheville, Serv Genet, Tours, France; Hop Enfants La Timone, Dept Genet, Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Tours; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Munnich, A (corresponding author), Hop Enfants Malad, INSERM U393, Dept Genet, Paris, France.		; cormier-daire, valerie/H-6520-2017	Girlich, Delphine/0000-0002-7698-2798; cormier-daire, valerie/0000-0002-2839-9856; Toutain, Annick/0000-0002-5999-5300				BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; CASTILLO S, 1985, CYTOGENET CELL GENET, V40, P601; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ellison JW, 1997, HUM MOL GENET, V6, P1341, DOI 10.1093/hmg/6.8.1341; ESPERITU C, 1975, AM J DIS CHILD, V129, P375; Guichet A, 1997, CLIN DYSMORPHOL, V6, P341, DOI 10.1097/00019605-199710000-00007; LERI A, 1929, B MEM SOC MED HOP P, V35, P1491; LICHTENSTEIN JR, 1980, J MED GENET, V17, P41, DOI 10.1136/jmg.17.1.41; Madelung V, 1878, ARCH KLIN CHIR, V23, P395; OGATA T, 1992, J MED GENET, V29, P624, DOI 10.1136/jmg.29.9.624; PFEIFFER RA, 1980, CYTOGENET CELL GENET, V26, P150, DOI 10.1159/000131436; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; TOUTAIN A, 1991, ANN PEDIATR-PARIS, V38, P37	14	260	267	2	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					67	69		10.1038/ng0198-67	http://dx.doi.org/10.1038/ng0198-67			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590292				2022-12-25	WOS:000073346700020
J	Bloom, BR; Widdus, R				Bloom, BR; Widdus, R			Vaccine visions and their global impact	NATURE MEDICINE			English	Editorial Material							INFECTION; DISEASE; IDENTIFICATION; RISK; DNA		Howard Hughes Med Inst, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA; Childrens Vaccine Initiat, CH-1211 Geneva, Switzerland	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Bloom, BR (corresponding author), Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; FREDRICKS DN, IN PRESS CURR CLIN T; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SANDERSON JD, 1992, GUT, V33, P890, DOI 10.1136/gut.33.7.890; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; THOMAS L, 1995, LIVES CELL NOTES BIO, P153; TYTGAT GNJ, 1993, GASTROENTEROL CLIN N, V22, P127; Weck KE, 1997, NAT MED, V3, P1346, DOI 10.1038/nm1297-1346; *WHO, 1998, STRAT PLAN; *WORLD BANK, 1993, WORLD DEV REP 1993 I; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; 1997, NATURE, V388, P211	17	24	25	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			480	484		10.1038/nm0598supp-480	http://dx.doi.org/10.1038/nm0598supp-480			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585190	Bronze			2022-12-25	WOS:000073453500008
J	Pajukanta, P; Nuotio, I; Terwilliger, JD; Porkka, KVK; Ylitalo, K; Pihlajamaki, J; Suomalainen, AJ; Syvanen, AC; Lehtimaki, T; Viikari, JSA; Laakso, M; Taskinen, MR; Ehnholm, C; Peltonen, L				Pajukanta, P; Nuotio, I; Terwilliger, JD; Porkka, KVK; Ylitalo, K; Pihlajamaki, J; Suomalainen, AJ; Syvanen, AC; Lehtimaki, T; Viikari, JSA; Laakso, M; Taskinen, MR; Ehnholm, C; Peltonen, L			Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23	NATURE GENETICS			English	Article							CORONARY HEART-DISEASE; LOCUS; STRATEGIES; PHENOTYPE; FINLAND; RISK	More than half of the patients with angiographically confirmed premature coronary heart disease (CHD) have a familiar lipoprotein disorder(1). Familial combined hyperlipidaemia (FCHL) represents the most common genetic dyslipidemia with a prevalence of 1.0-2.0% (refs 2,3). FCHL is estimated to cause 10-20% of premature CHD (ref. 1) and is characterized by elevated levels of cholesterol, triglycerides, or both(3,4). Attempts to characterize genes predisposing to FCHL have been hampered by its equivocal phenotype definition, unknown mode of inheritance and genetic heterogeneity. In order to minimize genetic heterogeneity, we chose 31 extended FCHL families from the isolated Finnish population(5) that fulfilled strictly defined criteria for the phenotype status. We performed linkage analyses with markers from ten chromosomal regions that contain lipid-metabolism candidate genes. One marker, D1S104. adjacent to the apolipoprotein A-II (APOA2) gene on chromosome 1, revealed a lod score of Z=3.50 assuming a dominant mode of inheritance. Multipoint analysis combining information from D1S104 and the neighbouring marker D1S1677 resulted in a lod score of 5.93. Physical positioning of known genes in the area (APOA2 and three selectin genes) outside the linked region suggests a novel locus for FCHL on 1q21-q23. A second paper in this issue (Castellani et al.) reports the identification of a mouse combined hyperlipidaemia locus in the syntenic region of the mouse genome(6), thus further implicating a gene in this region in the aetiology of FCHL.	Univ Helsinki, Natl Inst Publ Hlth, Dept Human Mol Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Turku, Dept Med, Turku, Finland; Columbia Univ, Dept Psychiat, New York, NY USA; Columbia Genome Ctr, New York, NY USA; Natl Publ Hlth Inst, Dept Biochem, Helsinki, Finland; Univ Helsinki, Dept Med, FIN-00014 Helsinki, Finland; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Tampere Univ Hosp, Tampere, Finland	University of Helsinki; University of Helsinki; University of Turku; Columbia University; Columbia University; Finland National Institute for Health & Welfare; University of Helsinki; University of Eastern Finland; Tampere University; Tampere University Hospital	Peltonen, L (corresponding author), Univ Helsinki, Natl Inst Publ Hlth, Dept Human Mol Genet, FIN-00014 Helsinki, Finland.	leena.peltonen@ktl.fi	Lehtimäki, Terho/AAD-1094-2022; Taskinen, Marja-Riitta/AAN-5432-2020	Lehtimäki, Terho/0000-0002-2555-4427; Taskinen, Marja-Riitta/0000-0002-6229-3588; Pihlajamaki, Jussi/0000-0002-6241-6859				AUSTIN MA, 1989, ARTERIOSCLEROSIS, V9, P335; CASTELLANI, 1998, NATURE GENET, V18, P372; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; CULLEN P, 1994, ARTERIOSCLER THROMB, V14, P1233, DOI 10.1161/01.ATV.14.8.1233; CUTHBERT JA, 1986, NEW ENGL J MED, V314, P879, DOI 10.1056/NEJM198604033141404; DallingaThie GM, 1997, J CLIN INVEST, V99, P953, DOI 10.1172/JCI119260; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; DURNER M, 1992, AM J HUM GENET, V51, P859; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; JARVIK GP, 1994, ARTERIOSCLER THROMB, V14, P1687, DOI 10.1161/01.ATV.14.11.1687; Kuokkanen S, 1996, NAT GENET, V13, P477, DOI 10.1038/ng0896-477; Kwiterovich Peter O. Jr., 1993, Current Opinion in Lipidology, V4, P133, DOI 10.1097/00041433-199304000-00009; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Marcil M, 1996, J LIPID RES, V37, P309; NIKKILA EA, 1973, LANCET, V1, P954; NISHINA PM, 1992, P NATL ACAD SCI USA, V89, P708, DOI 10.1073/pnas.89.2.708; Ott J., 1991, ANAL HUMAN GENETIC L; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; Pajukanta P, 1997, ARTERIOSCL THROM VAS, V17, P841, DOI 10.1161/01.ATV.17.5.841; PORKKA KVK, 1994, ACTA PAEDIATR, V83, P838, DOI 10.1111/j.1651-2227.1994.tb13155.x; REYMER PWA, 1995, HUM MOL GENET, V4, P1543, DOI 10.1093/hmg/4.9.1543; RISCH N, 1992, HUM HERED, V42, P77, DOI 10.1159/000154047; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; TERWILLIGER JD, 1993, GENET EPIDEMIOL, V10, P477, DOI 10.1002/gepi.1370100625; TERWILLIGER JD, IN PRESS ENCY BIOSTA; TERWILLIGER JD, IN PRESS HUM HERED; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; Weiss KM., 1995, GENETIC VARIATION HU; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0	33	215	221	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					369	373		10.1038/ng0498-369	http://dx.doi.org/10.1038/ng0498-369			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537421				2022-12-25	WOS:000072755500021
J	Barila, D; Superti-Furga, G				Barila, D; Superti-Furga, G			An intramolecular SH3-domain interaction regulates c-Abl activity	NATURE GENETICS			English	Article							PROTEIN-TYROSINE KINASES; SH3 DOMAINS; ACTIVATION; BINDING; SRC; ONCOGENE; STRESS; GROWTH; FORMS	The ABL1 proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase (c-Abl) that has been implicated in processes of cell differentiation, cell division, cell adhesion and stress response(1-4). Alterations of ABL1 by chromosomal rearrangement or viral transduction can lead to malignant transformation(5,6). Activity of the c-Abl protein is negatively regulated by its SH3 domain through an unknown mechanism, and deletion of the SH3 domain turns ABL1 into an oncogene(7-10). We present evidence for an intramolecular inhibitory interaction of the SH3 domain with the catalytic domain and with the linker between the SH2 and catalytic domain (SH2-CD linker). Site-directed mutations in each of these three elements activate c-Abl. Mutations in the linker cause a conformational change of the molecule and increase binding of the SH3 domain to peptide ligands. Individual mutation of two charged residues in the SH3 and catalytic domain activates c-Abl, while inhibition is restored in the double reciprocal mutant. We propose that regulators of c-Abl will have opposite effects on its activity depending on their ability to favour or disrupt these intramolecular interactions.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Superti-Furga, G (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	superti@embl-heidelberg.de	Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015; Barilà, Daniela/K-8506-2016	Superti-Furga, Giulio/0000-0002-0570-1768; Barilà, Daniela/0000-0002-6192-1562				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; REYNOLDS CH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P122, DOI 10.1016/0925-4439(93)90100-F; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; UAUSUBEL FM, 1987, CURRENT PROTOCOLS MO; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	30	174	178	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1998	18	3					280	282		10.1038/ng0398-280	http://dx.doi.org/10.1038/ng0398-280			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500553				2022-12-25	WOS:000072325000029
J	Prolla, TA; Baker, SM; Harris, AC; Tsao, EL; Yao, X; Bronner, CE; Zheng, BH; Gordon, M; Reneker, J; Arnheim, N; Shibata, D; Bradley, A; Liskay, RM				Prolla, TA; Baker, SM; Harris, AC; Tsao, EL; Yao, X; Bronner, CE; Zheng, BH; Gordon, M; Reneker, J; Arnheim, N; Shibata, D; Bradley, A; Liskay, RM			Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair	NATURE GENETICS			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; MICROSATELLITE INSTABILITY; HEREDITARY; HOMOLOG; CELLS; MSH2	Germline mutations in the human MSH2, MLH1, PMS2 and PMS1 DNA mismatch repair (MMR) gene homologues appear to be responsible for most cases of hereditary non-polyposis colorectal cancer (HNPCC; refs 1-5). An important role for DNA replication errors in colorectal tumorigenesis has been suggested by the finding of frequent alterations in the length of specific mononucleotide tracts within genes controlling cell growth, including TGF-beta receptor type II (ref. 6), BAX (ref. 7) and APC (ref. 8). A broader role for MMR deficiency in human tumorigenesis is implicated by microsatellite instability in a fraction of sporadic tumours, including gastric, endometrial and colorectal malignancies(9). To better define the role of individual MMR genes in cancer susceptibility and MMR functions, we have generated mice deficient for the murine homologues of the human genes MLH1, PMS1 and PMS2. Surprisingly, we find that these mice show different tumour susceptibilities, most notably, to intestinal adenomas and adenocarcinomas, and different mutational spectra. Our results suggest that a general increase in replication errors may not be sufficient for intestinal tumour formation and that these genes share overlapping, but not identical functions.	Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA; Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Mol Biol, Los Angeles, CA 90089 USA	Oregon Health & Science University; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Oregon Health & Science University; University of Southern California; University of Southern California	Liskay, RM (corresponding author), Oregon Hlth Sci Univ, Dept Mol & Med Genet, L103,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	liskay@ohsu.edu		Bradley, Allan/0000-0002-2349-8839; Arnheim, Norman/0000-0003-1247-1347				Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BOOTSMA D, 1994, MUTAT RES, V307, P15, DOI 10.1016/0027-5107(94)90273-9; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GUPTA RS, 1980, MUTAT RES, V69, P113, DOI 10.1016/0027-5107(80)90181-5; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Karran P, 1996, SEMIN CANCER BIOL, V7, P15, DOI 10.1006/scbi.1996.0003; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Luria SE, 1943, GENETICS, V28, P491; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reitmair AH, 1996, CANCER RES, V56, P3842; Shibata D, 1996, NAT MED, V2, P676, DOI 10.1038/nm0696-676; Tsao JL, 1997, AM J PATHOL, V151, P573; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#	24	298	304	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					276	279		10.1038/ng0398-276	http://dx.doi.org/10.1038/ng0398-276			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500552				2022-12-25	WOS:000072325000028
J	Persidis, A				Persidis, A			Catalytic antibodies	NATURE BIOTECHNOLOGY			English	Editorial Material							TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; ACTIVE-SITE; IMMUNIZATION; FAB		Argonex Inc, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, 2044 India Rd,Suite 202, Charlottesville, VA 22901 USA.							ANGELES TS, 1993, BIOCHEMISTRY-US, V32, P12128, DOI 10.1021/bi00096a025; Baca M, 1997, P NATL ACAD SCI USA, V94, P10063, DOI 10.1073/pnas.94.19.10063; Cashman J R, 1997, NIDA Res Monogr, V173, P225; CHARBONNIER JB, 1995, P NATL ACAD SCI USA, V92, P11721, DOI 10.1073/pnas.92.25.11721; FRIBOULET A, 1994, APPL BIOCHEM BIOTECH, V47, P229, DOI 10.1007/BF02787937; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; GUO JC, 1995, P NATL ACAD SCI USA, V92, P1694, DOI 10.1073/pnas.92.5.1694; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Paul S, 1996, MOL BIOTECHNOL, V5, P197, DOI 10.1007/BF02900358; Persidis A, 1997, NAT BIOTECHNOL, V15, P921, DOI 10.1038/nbt0997-921; POSNER B, 1994, TRENDS BIOCHEM SCI, V19, P145, DOI 10.1016/0968-0004(94)90273-9; RAYMOND JL, 1996, P NATL ACAD SCI USA, V93, P4251; ROBERTS VA, 1995, FASEB J, V9, P94, DOI 10.1096/fasebj.9.1.7821766; STEPHENS DB, 1993, BIOCHEM BIOPH RES CO, V192, P1439, DOI 10.1006/bbrc.1993.1577; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; Wade H, 1997, ANNU REV BIOPH BIOM, V26, P461, DOI 10.1146/annurev.biophys.26.1.461; Wentworth P, 1996, P NATL ACAD SCI USA, V93, P799, DOI 10.1073/pnas.93.2.799; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	19	4	4	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1313	+		10.1038/nbt1197-1313	http://dx.doi.org/10.1038/nbt1197-1313			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359117				2022-12-25	WOS:000071342000039
J	Vigh, L; Literati, PN; Horvath, I; Torok, Z; Balogh, G; Glatz, A; Kovacs, E; Boros, I; Ferdinandy, P; Farkas, B; Jaszlits, L; Jednakovits, A; Koranyi, L; Maresca, B				Vigh, L; Literati, PN; Horvath, I; Torok, Z; Balogh, G; Glatz, A; Kovacs, E; Boros, I; Ferdinandy, P; Farkas, B; Jaszlits, L; Jednakovits, A; Koranyi, L; Maresca, B			Bimoclomol: A nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects	NATURE MEDICINE			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; MYOCARDIAL PROTECTION; MYOGENIC CELLS; RAT HEARTS; EXPRESSION; YEAST; TEMPERATURE; MODULATION; RESPONSES	Preservation of the chemical architecture of a cell or of an organism under changing and perhaps stressful conditions is termed homeostasis. An integral feature of homeostasis is the rapid expression of genes whose products are specifically dedicated to protect cellular functions against stress. One of the best known mechanisms protecting cells from various stresses is the heat-shock response which results in the induction of the synthesis of heat-shock proteins (HSPs or stress proteins)(1-3). A large body of information supports that stress proteins - many of them molecular chaperones(4-8) - are crucial for the maintenance of cell integrity during normal growth as well as during pathophysiological conditions(9-11), and thus can be considered ''homeostatic proteins.'' Recently emphasis is being placed on the potential use of these proteins in preventing and/or treating diseases(12-14). Therefore, it would be of great therapeutic benefit to discover compounds that are clinically safe yet able to induce the accumulation of HSPs in patients with chronic disorders such as diabetes mellitus, heart disease or kidney failure. Here we show that a novel cytoprotective hydroxylamine derivative, [2-hydroxy-3-(1-piperidinyl) propoxy]-3-pyridinecarboximidoil-chloride maleate, Bimoclomol(15), facilitates the formation of chaperone molecules in eukaryotic cells by inducing or amplifying expression of heat-shock genes. The cytoprotective effects observed under several experimental conditions, including a murine model of ischemia and wound healing in the diabetic rat, are likely mediated by the coordinate expression of all major HSPs. This nontoxic drug, which is under Phase II clinical trials, has enormous potential therapeutic applications.	BIOREX RES & DEV CO,H-8200 VESZPREM,HUNGARY; ALBERT SZENT GYORGYI MED UNIV,DEPT DERMATOL,H-6720 SZEGED,HUNGARY; ALBERT SZENT GYORGYI MED UNIV,DEPT BIOCHEM,H-6720 SZEGED,HUNGARY; CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Szeged University; Szeged University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Vigh, L (corresponding author), HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOCHEM,TEMESVARI KRT 62,H-6721 SZEGED,HUNGARY.		Ferdinandy, Péter/H-9181-2019; Balogh, Gábor/AIC-8192-2022	Balogh, Gábor/0000-0002-4565-6850; Boros, Imre/0000-0001-8504-9687				BENSAUDE O, 1983, EMBO J, V2, P173, DOI 10.1002/j.1460-2075.1983.tb01401.x; BIRO K, 1994, DIABETOLOGIA S1, V37, P282; Carratu L, 1996, P NATL ACAD SCI USA, V93, P3870, DOI 10.1073/pnas.93.9.3870; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; DOXEY DL, 1995, LIFE SCI, V57, P1111, DOI 10.1016/0024-3205(95)02056-O; Ferdinandy P, 1995, CARDIOVASC RES, V30, P781, DOI 10.1016/S0008-6363(95)00136-0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FRYDMAN J, 1994, NATURE, V370, P96; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; HEGEDUS E, 1995, DIABETOLOGIA S1, V37, P137; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; HUTTER MM, 1994, CIRCULATION, V89, P355, DOI 10.1161/01.CIR.89.1.355; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JASZLITS L, 1993, J MOL CELL CARDIO S1, V25, P20; JEDNAKOVITS A, 1994, DIABETOLOGIA S1, V37, P19; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KNOWLTON AA, 1995, J MOL CELL CARDIOL, V27, P121, DOI 10.1016/S0022-2828(08)80012-0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOVIS C, 1994, RENAL FAILURE, V16, P179, DOI 10.3109/08860229409044859; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MAYTIN EV, 1995, J INVEST DERMATOL, V104, P448, DOI 10.1111/1523-1747.ep12605702; MESTRIL R, 1995, J MOL CELL CARDIOL, V27, P45, DOI 10.1016/S0022-2828(08)80006-5; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; NISHIZAWA J, 1996, CIRCULATION, V92, P3137; NOVEL, 1988, Patent No. 207988; OBERRINGER M, 1995, BIOCHEM BIOPH RES CO, V214, P1009, DOI 10.1006/bbrc.1995.2386; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Plumier JCL, 1996, CELL STRESS CHAPERON, V1, P13, DOI 10.1379/1466-1268(1996)001<0013:HSIMPA>2.3.CO;2; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; POLLA BS, 1990, DERMATOLOGICA, V180, P113, DOI 10.1159/000248008; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Sambrook J., 2002, MOL CLONING LAB MANU; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; VIGH L, 1993, P NATL ACAD SCI USA, V90, P9090, DOI 10.1073/pnas.90.19.9090; YELLON DM, 1992, J MOL CELL CARDIOL, V24, P113, DOI 10.1016/0022-2828(92)93148-D	41	243	262	2	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1150	1154		10.1038/nm1097-1150	http://dx.doi.org/10.1038/nm1097-1150			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334730				2022-12-25	WOS:A1997XZ28700044
J	Jones, JT; Sullenger, BA				Jones, JT; Sullenger, BA			Evaluating and enhancing ribozyme reaction efficiency in mammalian cells	NATURE BIOTECHNOLOGY			English	Article						ribozyme; trans-splicing; gene therapy	TETRAHYMENA RIBOZYME; RNA ENZYMES; CLEAVAGE; BINDING; SEQUENCE; SPECIFICITY; SITE; FRAMEWORK; PRECURSOR; INTRON	The ability of ribozymes to cleave specific transcripts and repair defective RNAs in the test tube has engendered speculation about their potential clinical utility. Therapeutic development has been hindered by an inability to evaluate and optimize the efficiency of RNA catalysis in vivo. We describe an experimental system that has allowed us to assess and enhance the efficiency with which a trans-splicing group I ribozyme reacts with a targeted RNA in mammalian cells. These results demonstrate that the ribozyme can convert up to 49% of a specific substrate RNA to product in the cellular environment and that the efficiency of this reaction is apparently a function of the ribozyme's ability to find and bind to the substrate RNA in the cell. These observations suggest that trans-splicing ribozymes may become useful reagents to repair a therapeutically significant fraction of mutant RNAs associated with a variety of genetic diseases.	DUKE UNIV, MED CTR, DEPT EXPT SURG, CTR CELLULAR & GENET THERAPIES, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT GENET, CTR CELLULAR & GENET THERAPIES, DURHAM, NC 27710 USA	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053525] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 RO1 GM53525-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH T R, 1988, Journal of the American Medical Association, V260, P3030, DOI 10.1001/jama.260.20.3030; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FORESTER AC, 1990, SCIENCE, V249, P783; GILLILAND G, 1990, PCR PROTOCOLS GUIDE; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SULLENGER BA, 1995, CHEM BIOL, V2, P249, DOI 10.1016/1074-5521(95)90043-8; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1989, BIOCHEMISTRY-US, V28, P980, DOI 10.1021/bi00429a010; YU M, 1994, GENE THER, V1, P13; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	29	51	55	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					902	905		10.1038/nbt0997-902	http://dx.doi.org/10.1038/nbt0997-902			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306408				2022-12-25	WOS:A1997XW41000035
J	Yoshimura, T; Yokoyama, H; Fujii, S; Takayama, F; Oikawa, K; Kamada, H				Yoshimura, T; Yokoyama, H; Fujii, S; Takayama, F; Oikawa, K; Kamada, H			In vivo EPR detection and imaging of endogenous nitric oxide in lipopolysaccharide-treated mice	NATURE BIOTECHNOLOGY			English	Article						nitric oxide; EPR imaging; spin-trapping; N-(dithiocarboxy)sarcosine; lipopolysaccharide	IN-VIVO; L-BAND; RESONANCE; SPECTROSCOPY; HEAD	Nitric oxide (NO), a simple diatomic free radical, is known to play a critical physiological role in diverse organisms. An iron complex, with N-(dithiocarboxy)sarcosine (Fe-DTCS), has a high affinity for endogenous NO and can trap, stabilize, and accumulate it. The stable NO adduct thus formed is detectable at room temperature with electron paramagnetic resonance (EPR) spectrometry. We report in vivo EPR imaging of endogenous NO, trapped by an Fe-DTCS complex, in the abdomen of a live mouse, To our knowledge, this is the first report on EPR imaging of endogenous free radicals produced in vivo. This EPR imaging method will be useful for the noninvasive investigation of the spatial distribution of NO in pathologic organs or tissues.	OITA MED UNIV,DEPT PHARMACOL,HASAMA,OITA 87955,JAPAN; YAMAGATA RES INST TECHOL,YAMAGATA 990,JAPAN	Oita University	Yoshimura, T (corresponding author), YAMAGATA TECHNOPOLIS FDN,INST LIFE SUPPORT TECHNOL,2-2-1 MATSUEI,YAMAGATA 990,JAPAN.							ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BERLINER LJ, 1992, BIOL MAGN RESON, V11, P307; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CHEN YJ, 1994, BIOCHEM BIOPH RES CO, V203, P1251, DOI 10.1006/bbrc.1994.2317; COLACICCHI S, 1993, J CHEM SOC PERK T 2, P2077, DOI 10.1039/p29930002077; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; ISHIDA S, 1992, MAGN RESON IMAGING, V10, P109, DOI 10.1016/0730-725X(92)90379-E; Jansson PA, 1984, DE CONVOLUTION APPL; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; KALYANARAMAN JB, 1993, BIOCHEM BIOPH RES CO, V192, P926; KORTH HG, 1994, J AM CHEM SOC, V116, P2767, DOI 10.1021/ja00086a010; KUBRINA LN, 1993, BIOCHIM BIOPHYS ACTA, V1176, P140; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORDVINTCEV P, 1991, ANAL BIOCHEM, V199, P142, DOI 10.1016/0003-2697(91)90282-X; NOGUCHI T, 1995, FEBS LETT, V358, P9, DOI 10.1016/0014-5793(94)01374-A; OIKAWA K, 1995, ANAL SCI, V11, P885, DOI 10.2116/analsci.11.885; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARATT JR, 1973, BRIT J PHARMACOL, V47, P12; SAKAI Y, 1980, TALANTA, V27, P1073, DOI 10.1016/0039-9140(80)80250-5; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; YOKOYAMA H, 1996, IN PRESS MAGNETIC RE, V14; YOSHIMURA T, 1995, CHEM LETT, P309, DOI 10.1246/cl.1995.309	27	205	205	1	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					992	994		10.1038/nbt0896-992	http://dx.doi.org/10.1038/nbt0896-992			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631037				2022-12-25	WOS:A1996UZ19900031
J	Mellon, M				Mellon, M			Ripen-on command: In a society with ample food, why bother?	NATURE BIOTECHNOLOGY			English	Editorial Material											Mellon, M (corresponding author), UNION CONCERNED SCIENTISTS,AGR & BIOTECHNOL PROGRAM,1616 P ST NW,SUITE 310,WASHINGTON,DC 20036, USA.								0	1	1	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					800	800		10.1038/nbt0796-800	http://dx.doi.org/10.1038/nbt0796-800			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9630991	Bronze			2022-12-25	WOS:A1996UV62000003
J	Krude, H; Biebermann, H; Luck, W; Horn, R; Brabant, G; Gruters, A				Krude, H; Biebermann, H; Luck, W; Horn, R; Brabant, G; Gruters, A			Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans	NATURE GENETICS			English	Article							STIMULATING-HORMONE-RECEPTOR; SCANNING MODEL; COAT COLOR; GENE; TRANSLATION; CODON; DELETION	Sequential cleavage of the precursor protein pre-pro-opiomelanocortin (POMC) generates the melanocortin peptides adrenocorticotrophin (ACTH), melanocyte-stimulating hormones (MSH) alpha, beta and gamma as well as the opioid-receptor ligand beta-endorphin(1) While a few cases of isolated ACTH deficiency have been reported (OMIM 201400), an inherited POMC defect has not been described so far(2). Recent studies in animal models elucidated a central role of alpha-MSH in the regulation of food intake by activation of the brain melanocortin-4-receptor (MC4-R; refs 3-5) and the linkage of human obesity to chromosome 2 in close proximity to the POMC locus(6), led to the proposal of an association of POMC with human obesity(7). The dual role of alpha-MSH in regulating food intake and influencing hair pigmentation predicts that the phenotype associated with a defect in POMC function would include obesity, alteration in pigmentation and ACTH deficiency. The observation of these symptoms in two probands prompted us to search for mutations within their POMC genes. Patient 1 was found to be a compound heterozygote for two mutations in exon 3 (G7013T. C7133 Delta) which interfere with appropriate synthesis of ACTH and alpha-MSH. Patient 2 was homozygous for a mutation in exon 2 (C3804A) which abolishes POMC translation. These findings represent the first examples of a genetic defect within the POMC gene and define a new monogenic endocrine disorder resulting in early-onset obesity, adrenal insufficiency and red hair pigmentation.	Humboldt Univ, Dept Pediat, Berlin, Germany; Med Hsch Hannover, Dept Clin Endocrinol, Hannover, Germany	Humboldt University of Berlin; Hannover Medical School	Gruters, A (corresponding author), Humboldt Univ, Dept Pediat, Campus Virchow, Berlin, Germany.	grueters@ukrv.de		Biebermann, Heike/0000-0002-2024-7778				BERGENHEM NCH, 1992, P NATL ACAD SCI USA, V89, P8798, DOI 10.1073/pnas.89.18.8798; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Chen WB, 1997, CELL, V91, P789, DOI 10.1016/S0092-8674(00)80467-5; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Joerg H, 1996, MAMM GENOME, V7, P317, DOI 10.1007/s003359900090; KLUNGLAND H, 1995, MAMM GENOME, V6, P636, DOI 10.1007/BF00352371; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MORLE F, 1985, EMBO J, V4, P1245, DOI 10.1002/j.1460-2075.1985.tb03767.x; NUSSEY SS, 1993, CLIN ENDOCRINOL, V39, P381, DOI 10.1111/j.1365-2265.1993.tb02381.x; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Rutishauser J, 1996, J CLIN ENDOCR METAB, V81, P192, DOI 10.1210/jc.81.1.192; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; SIRACUSA LD, 1994, TRENDS GENET, V10, P423, DOI 10.1016/0168-9525(94)90112-0; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; TAKAHASHI H, 1983, NUCLEIC ACIDS RES, V11, P6847, DOI 10.1093/nar/11.19.6847; TAKAHASHI H, 1981, FEBS LETT, V135, P97, DOI 10.1016/0014-5793(81)80952-0; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328	26	1180	1228	3	84	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					155	157		10.1038/509	http://dx.doi.org/10.1038/509			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620771				2022-12-25	WOS:000073865100022
J	Bartlett, JS; Samulski, RJ				Bartlett, JS; Samulski, RJ			Fluorescent viral vectors: A new technique for the pharmacological analysis of gene therapy	NATURE MEDICINE			English	Article							DYE LABELING REAGENTS; SUCCINIMIDYL ESTERS; HELA-CELLS; PROTEOGLYCAN; EXPRESSION; SULFATE; ENTRY		Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bartlett, JS (corresponding author), Univ N Carolina, Gene Therapy Ctr, CB 7352,Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	jbart@med.unc.edu			NHLBI NIH HHS [HL048347] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048347] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT JS, 1995, INTERNET BOOK GENE T, P27; BARTLETT JS, IN PRESS HUM GENE TH; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Blomer U, 1997, J VIROL, V71, P6641; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Leopold PL, 1998, HUM GENE THER, V9, P367, DOI 10.1089/hum.1998.9.3-367; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; PERSSON R, 1983, J VIROL, V46, P956, DOI 10.1128/JVI.46.3.956-963.1983; SANNES PL, 1993, AM J RESP CELL MOL, V8, P245, DOI 10.1165/ajrcmb/8.3.245; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; SVENSSON U, 1984, J VIROL, V51, P687, DOI 10.1128/JVI.51.3.687-694.1984; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; VARGA MJ, 1991, J VIROL, V65, P6061, DOI 10.1128/JVI.65.11.6061-6070.1991; WESSENDORF MW, 1992, HISTOCHEMISTRY, V98, P81, DOI 10.1007/BF00716998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	19	27	30	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					635	637		10.1038/nm0598-635	http://dx.doi.org/10.1038/nm0598-635			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585242				2022-12-25	WOS:000073399900042
J	Mansouri, A; Chowdhury, K; Gruss, P				Mansouri, A; Chowdhury, K; Gruss, P			Follicular cells of the thyroid gland require Pax8 gene function	NATURE GENETICS			English	Article							DEVELOPING EXCRETORY SYSTEM; MOUSE; DIFFERENTIATION; EXPRESSION; MIDBRAIN; LUNG	The thyroid gland develops from two distinct embryonic lineages: follicular cells (which produce thyroxine) and parafollicular C-cells (which produce calcitonin) are of endodermal and neural crest origin, respectively, Little is known about the molecular mechanisms governing the generation of these different cell types, Mice lacking the transcription factor Ttf1 lack both cell types and thus are unable to develop a thyroid gland. By analysis of Pax8(-/-) mice, we demonstrate that Pax8 is required for the formation of the follicular cells in the thyroid. We present evidence that Pax8 is necessary for providing cues for the differentiation of competent endoderm primordia into thyroxin-producing follicular cells.	MPI Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany	Max Planck Society	Gruss, P (corresponding author), MPI Biophys Chem, Dept Mol Cell Biol, Am Fassberg, D-37077 Gottingen, Germany.	pgruss@gwdg.de						ASANO M, 1992, MECH DEVELOP, V39, P29, DOI 10.1016/0925-4773(92)90023-D; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; FONTAINE J, 1979, GEN COMP ENDOCR, V37, P81, DOI 10.1016/0016-6480(79)90049-2; HILFER SR, 1968, EPITHELIAL MESENCHYM, P177; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Nagy A., 1993, Gene targeting: a practical approach., P147; PEARSE AGE, 1967, NATURE, V214, P929, DOI 10.1038/214929a0; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; STEEL KP, 1992, NAT GENET, V2, P75, DOI 10.1038/ng0992-75; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; TORRES M, 1994, CELL BIOL LAB HDB, P112; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WILKINSON DG, 1992, IN SITU HYBRIDISATIO	20	454	473	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					87	90		10.1038/ng0598-87	http://dx.doi.org/10.1038/ng0598-87			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590297				2022-12-25	WOS:000073346700025
J	Jevtovic-Todorovic, V; Todorovic, SM; Mennerick, S; Powell, S; Dikranian, K; Benshoff, N; Zorumski, CF; Olney, JW				Jevtovic-Todorovic, V; Todorovic, SM; Mennerick, S; Powell, S; Dikranian, K; Benshoff, N; Zorumski, CF; Olney, JW			Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin	NATURE MEDICINE			English	Article							RAT; PHENCYCLIDINE; NEURONS; CORTEX; MK-801	Extensive research has failed to clarify the mechanism of action of nitrous oxide (N2O, laughing gas), a widely used inhalational anesthetic and drug of abuse. Other general anesthetics are thought to act by one of two mechanisms-blockade of NMDA glutamate receptors or enhancement of GABAergic inhibition(1). Here we show that N2O, at anesthetically-relevant concentrations, inhibits both ionic currents and excitotoxic neurodegeneration mediated through NMDA receptors and, like other NMDA antagonists, produces neurotoxic side effects which can be prevented by drugs that enhance GABAergic inhibition. The favorable safety record of N2O may be explained by the low concentrations typically used and by the fact that it is usually used in combination with GABAergic anesthetics that counteract its neurotoxic potential.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Jevtovic-Todorovic, V (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Campus Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA.		Mennerick, Steven/O-2806-2017	Mennerick, Steven/0000-0003-0868-0664	NATIONAL EYE INSTITUTE [R01EY008089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08089] Funding Source: Medline; NIA NIH HHS [AG 11355] Funding Source: Medline; NIDA NIH HHS [DA 05072] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DOHRN CS, 1993, DRUG ALCOHOL DEPEN, V31, P265, DOI 10.1016/0376-8716(93)90009-F; Farber NB, 1995, BIOL PSYCHIAT, V38, P788, DOI 10.1016/0006-3223(95)00046-1; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; FRAGEN RJ, 1992, CLIN ANESTH, P385; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GONSOWSKI CT, 1994, ANESTH ANALG, V79, P710; HORNBEIN TF, 1982, ANESTH ANALG, V61, P553; ISHIMARU M, 1995, NEUROSCI LETT, V193, P1, DOI 10.1016/0304-3940(95)11650-L; JevtovicTodorovic V, 1997, J CEREBR BLOOD F MET, V17, P168, DOI 10.1097/00004647-199702000-00006; KOBLIN DD, 1981, ANESTH ANALG, V60, P138; LITTLE HJ, 1986, J PHYSIOL-LONDON, V374, P387, DOI 10.1113/jphysiol.1986.sp016086; LODGE D, 1982, EUR J PHARMACOL, V77, P203, DOI 10.1016/0014-2999(82)90022-X; Lodge D., 1987, EXCITATORY AMINO ACI, P83; MAHMOUDI NW, 1989, ANESTHESIOLOGY, V70, P345, DOI 10.1097/00000542-198902000-00027; MENNERICK S, 1995, J NEUROPHYSIOL, V73, P320, DOI 10.1152/jn.1995.73.1.320; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OLNEY JW, 1989, NEUROENDOCRINE PEPTI, P891; ROTHMAN SM, 1991, J NEUROSCI, V4, P1483; STEVENS RK, 1992, CLIN ANESTH, P6; STEVENS WC, 1992, CLIN ANESTH, P39; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	25	445	466	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					460	463		10.1038/nm0498-460	http://dx.doi.org/10.1038/nm0498-460			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546794				2022-12-25	WOS:000072906800043
J	Ferrer-Montiel, AV; Merino, JM; Blondelle, SE; Perez-Paya, E; Houghten, RA; Montal, M				Ferrer-Montiel, AV; Merino, JM; Blondelle, SE; Perez-Paya, E; Houghten, RA; Montal, M			Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic death	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; drug discovery; ion channel blockers; neuroprotection; glutamate receptor	PHARMACOLOGICAL CHARACTERIZATION; COMBINATORIAL LIBRARIES; ANTICONVULSANT MK-801; FUNCTIONAL EXPRESSION; GLUTAMATE RECEPTORS; MOLECULAR-CLONING; BINDING SITE; AMINO-ACIDS; HUMAN BRAIN; MEMANTINE	Excitotoxic neuronal death, associated with neurodegeneration and stroke, is triggered primarily by massive Ca2+ influx arising from overactivation of glutamate receptor channels of the N-methyl-D-aspartate (NMDA) subtype. To search for channel blockers, synthetic combinatorial libraries were assayed for block of agonist-evoked currents by the human NR1-NR2A NMDA receptor subunits expressed in amphibian oocytes. A set of arginine-rich hexapeptides selectively blocked the NMDA receptor channel with IC50 approximately 100 nM, a potency similar to clinically tolerated blockers such as memantine, and only marginally blocked on non-NMDA glutamate receptors. These peptides prevent neuronal cell death elicited by an excitotoxic insult on hippocampal cultures.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	University of California System; University of California San Diego; Torrey Pines Institute for Molecular Studies, California	Montal, M (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Merino, Jaime M./0000-0002-5316-9200				Avenet P, 1996, EUR J PHARMACOL, V296, P209, DOI 10.1016/0014-2999(95)00700-8; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; Ferrer-Montiel Antonio V., 1994, Methods (Orlando), V6, P60, DOI 10.1006/meth.1994.1008; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FerrerMontiel AV, 1996, BIOPHYS J, V71, P749, DOI 10.1016/S0006-3495(96)79274-3; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; GRILLI M, 1996, SCIENCE, V274, P383; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HERRERO JF, 1994, NEUROSCI LETT, V165, P37, DOI 10.1016/0304-3940(94)90703-X; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; Hunter AJ, 1997, INT REV NEUROBIOL, V40, P95; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; KORNHUBER J, 1995, NEUROSCI LETT, V195, P137, DOI 10.1016/0304-3940(95)11785-U; LEBOURDELLES B, 1994, J NEUROCHEM, V62, P2091; Li M, 1996, NAT BIOTECHNOL, V14, P986, DOI 10.1038/nbt0896-986; Lyden PD, 1997, INT REV NEUROBIOL, V40, P233; McBurney RN, 1997, INT REV NEUROBIOL, V40, P173; Meziere C, 1997, J IMMUNOL, V159, P3230; Nicotera P, 1997, Adv Neurol, V72, P95; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Parsons CG, 1996, EUR J NEUROSCI, V8, P446, DOI 10.1111/j.1460-9568.1996.tb01228.x; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PLANELLSCASES R, 1993, P NATL ACAD SCI USA, V90, P5057, DOI 10.1073/pnas.90.11.5057; Premkumar LS, 1996, NEURON, V16, P869, DOI 10.1016/S0896-6273(00)80107-5; Schinder AF, 1996, J NEUROSCI, V16, P6125; Snyder SH, 1996, NAT MED, V2, P965, DOI 10.1038/nm0996-965; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; SUN W, 1992, P NATL ACAD SCI USA, V89, P1443, DOI 10.1073/pnas.89.4.1443; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Wesemann W, 1980, J Neural Transm Suppl, P143; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	41	41	46	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					286	291		10.1038/nbt0398-286	http://dx.doi.org/10.1038/nbt0398-286			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528011				2022-12-25	WOS:000072371000031
J	Glushakova, S; Grivel, JC; Fitzgerald, W; Sylwester, A; Zimmerberg, J; Margolis, LB				Glushakova, S; Grivel, JC; Fitzgerald, W; Sylwester, A; Zimmerberg, J; Margolis, LB			Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency	NATURE MEDICINE			English	Article							ANTIBODY-RESPONSE; VIRAL BURDEN; B-CELLS; INFECTION; DISEASE; PATHOGENESIS; PROGRESSION; INDIVIDUALS; ACTIVATION; TETANUS	Both cellular and humoral immunodeficiency develop in vivo after prolonged infection with HIV-1, but the mechanisms are unclear(1). Initial infection with HIV-1 is transmitted by macrophage (M)-tropic/non-syncytia-inducing (NSI) viruses(2,3), which hyperactivate the immune system(4,5), and, in one view, cause immunodeficiency by "exhaustion"(4,6) of lymphoid tissue. An alternative hypothesis is that immunodeficiency is caused by the replacement of M-tropic viruses by T cell (T)-tropic/syncytia-inducing (SI) viruses, which are known to be highly cytopathic in vitro and emerge late in infected individuals around the time of transition to AIDS (refs. 1, 7-9). To test these two possibilities, we have developed an ex vivo model of humoral immunity to recall antigens using human lymphoid tissue. This tissue supports productive infection with both M-and T-tropic HIV-1 isolates when cultured ex vivo(10,11). We found that specific immune responses were enhanced by productive infection of the tissue with M-tropic/NSI HIV-1 isolates, but were blocked by T-tropic/SI HIV-1 isolates. The mechanism involves specific irreversible effect on B-cell activity. Our results support the hypothesis that the phenotype switch to T-tropic viruses is a key determinant of acquired humoral immunodeficiency in patients infected with HIV.	NIAID, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Margolis, LB (corresponding author), NIAID, Lab Cellular & Mol Biophys, NIH, Bldg 10,Room 10D14,10 Ctr Dr, Bethesda, MD 20892 USA.			Grivel, Jean-Charles/0000-0003-0365-3181				BARBI M, 1992, AIDS, V6, P1465, DOI 10.1097/00002030-199212000-00007; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CORNELISSEN M, 1995, J VIROL, V69, P1810, DOI 10.1128/JVI.69.3.1810-1818.1995; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Glushakova S, 1997, AIDS RES HUM RETROV, V13, P461, DOI 10.1089/aid.1997.13.461; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; HOFFMANN MK, 1973, NATURE, V243, P408, DOI 10.1038/243408a0; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; LANE HC, 1981, J EXP MED, V154, P1043, DOI 10.1084/jem.154.4.1043; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MISHELL RI, 1966, SCIENCE, V153, P1004, DOI 10.1126/science.153.3739.1004; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SNAPPER CM, 1995, J IMMUNOL, V154, P1177; TERSMETTE M, 1989, LANCET, V1, P983; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	22	93	95	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					346	349		10.1038/nm0398-346	http://dx.doi.org/10.1038/nm0398-346			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500611				2022-12-25	WOS:000073616200043
J	Qi, Y; Staerz, UD				Qi, Y; Staerz, UD			Specific inhibition of CD4(+) T lymphocytes by a hybrid antibody	NATURE BIOTECHNOLOGY			English	Article						applied immunology; immunosuppression; antibody engineering	MINOR HISTOCOMPATIBILITY ANTIGENS; SKIN ALLOGRAFT-REJECTION; MONOCLONAL-ANTIBODY; PRESENTING CELLS; ALPHA-3 DOMAIN; VETO; INVIVO; SUPPRESSOR; RESPONSES; MOLECULES	T lymphocytes are crucial in the defense against foreign intruders and cancerous growths. Yet, in circumstances such as transplantation or autoimmunity, T-cell-mediated responses can be detrimental. Inhibition of these deleterious responses is currently achieved by drugs that induce general immune suppression. These compounds also impair the patient's defenses against infections. Strategies are now being sought that induce selective rather than generalized immune unresponsiveness. One such strategy is the ability to inhibit the activation of CD8(+) T lymphocytes. As CD4(+) T lymphocytes similarly participate in graft rejection and in autoimmune diseases, we have now developed a reagent to delete their activity. It comprises CD4 and an anti-MHC class II antibody. By virtue of the antibody's specificity for MHC class II molecules, this hybrid antibody (Hab) binds to class II molecules, thereby bringing CD4 accessory molecules to the surface of class II-bearing stimulator cells where they occupy CD4 binding sites on class II molecules. As a consequence CD4(+) T cells with specificity to Hab-coated stimulator cells cannot engage their CD4 molecules and are no longer activated. This Hab technology provides a strategy to offer specific rather than generalized immune suppression.	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80220 USA; Natl Jewish Ctr Immunol & Resp Med, Dept Med, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Staerz, UD (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, 4200 E 9th Ave, Denver, CO 80220 USA.	staerzu@njc.org			NIAID NIH HHS [AI35194, AI22295] Funding Source: Medline; NICHD NIH HHS [HD26841] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035194, P01AI022295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COBBOLD S, 1986, TRANSPLANTATION, V41, P634, DOI 10.1097/00007890-198605000-00016; FANGMANN J, 1992, J EXP MED, V175, P1521, DOI 10.1084/jem.175.6.1521; FINK PJ, 1983, J EXP MED, V157, P141, DOI 10.1084/jem.157.1.141; HAMBAR JE, 1990, J IMMUNOL, V12, P930; HAMBOR JE, 1990, INT IMMUNOL, V2, P879, DOI 10.1093/intimm/2.9.879; HIRUMA K, 1992, J EXP MED, V175, P863, DOI 10.1084/jem.175.3.863; JOHNSON LL, 1987, TRANSPLANTATION, V44, P92, DOI 10.1097/00007890-198707000-00020; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; Liu CP, 1996, J EXP MED, V184, P1619, DOI 10.1084/jem.184.5.1619; LIU Z, 1993, J EXP MED, V177, P1643, DOI 10.1084/jem.177.6.1643; MARTIN DR, 1989, J EXP MED, V170, P679, DOI 10.1084/jem.170.3.679; MATIS LA, 1987, CELL, V51, P59, DOI 10.1016/0092-8674(87)90010-9; MILLER RG, 1980, NATURE, V287, P544, DOI 10.1038/287544a0; MIZUOCHI T, 1985, J EXP MED, V162, P427, DOI 10.1084/jem.162.2.427; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; OGARRA A, 1993, CURR OPIN IMMUNOL, V5, P880, DOI 10.1016/0952-7915(93)90100-7; OZATO K, 1980, J IMMUNOL, V124, P533; Qi Y, 1996, J EXP MED, V183, P1973, DOI 10.1084/jem.183.5.1973; Rammensee H G, 1989, Int Rev Immunol, V4, P175, DOI 10.3109/08830188909044780; RAMMENSEE HG, 1982, EUR J IMMUNOL, V12, P930, DOI 10.1002/eji.1830121107; RAMMENSEE HG, 1984, J IMMUNOL, V132, P668; ROSENBERG AS, 1992, ANNU REV IMMUNOL, V10, P333, DOI 10.1146/annurev.immunol.10.1.333; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; SAMBHARA SR, 1991, SCIENCE, V252, P1424; SMITH DM, 1994, J IMMUNOL, V153, P1054; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; STAERZ UD, 1987, EUR J IMMUNOL, V17, P571, DOI 10.1002/eji.1830170422; STAERZ UD, 1985, NATURE, V314, P628, DOI 10.1038/314628a0; STAERZ UD, 1986, P NATL ACAD SCI USA, V83, P1453, DOI 10.1073/pnas.83.5.1453; STEINMAN RM, 1979, J EXP MED, V149, P1, DOI 10.1084/jem.149.1.1; TAKAHASHI T, 1991, TRANSPL P, V23, P192; THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018; THOMAS JM, 1991, TRANSPLANT P, V23, P11; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; Vella A, 1997, J EXP MED, V186, P325, DOI 10.1084/jem.186.2.325; ZEPP F, 1988, NATURE, V336, P473, DOI 10.1038/336473a0; ZHANG L, 1994, J IMMUNOL, V152, P2221	39	4	4	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					271	275		10.1038/nbt0398-271	http://dx.doi.org/10.1038/nbt0398-271			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528008				2022-12-25	WOS:000072371000028
J	Riley, P; Anson-Cartwright, L; Cross, JC				Riley, P; Anson-Cartwright, L; Cross, JC			The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis	NATURE GENETICS			English	Article							MOUSE; GENE; EXPRESSION; HEART; CLONING; CELLS; IMPLANTATION; PROTEINS; ENCODES; SYSTEM	The placenta and cardiovascular system are the first organ systems to form during mammalian embryogenesis. We show here that a single gene is critical for development of both. The Hand1 gene, previously called Hxt, eHAND and Thing1, encodes a basic helix-loop-helix (bHLH) transcription factor that starts to be expressed during pre-implantation development. After implantation, Hand1 expression is restricted to placental trophoblast cells and later to embryonic cardiac and neural crest cells(1-3). We generated Hand1-null mutant mice by gene targetting. Homozygous mutant embryos arrested by embryonic day (E) 7.5 of gestation with defects in trophoblast giant cell differentiation. This early mortality could be rescued by aggregation of mutant embryos with wild-type tetraploid embryos, which contribute wild-type cells to the trophoblast, but not the embryo. By E10.5, however, the Hand1-null fetuses derived from tetraploid chimaeras died due to cardiac failure. Their heart tubes showed abnormal looping and ventricular myocardial differentiation. Therefore, Hand1 is essential for differentiation of both trophoblast and cardiomyocytes, which are embryologically distinct cell lineages.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto	Cross, JC (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev & Fetal Hlth, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Cross, James/AAU-2973-2020; Cross, James/F-4814-2011	Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378				Alexander CM, 1996, DEVELOPMENT, V122, P1723; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; JACKSON LL, 1986, P NATL ACAD SCI USA, V83, P8496, DOI 10.1073/pnas.83.22.8496; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Millen Kathleen J., 1996, P339; Nagy A., 1993, Gene targeting: a practical approach., P147; NIETO MA, 1992, DEVELOPMENT, V116, P227; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SMITH DE, 1992, DEVELOPMENT, V116, P1033; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Wurst W., 1993, Gene targeting: a practical approach., P33	31	402	414	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					271	275		10.1038/ng0398-271	http://dx.doi.org/10.1038/ng0398-271			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500551				2022-12-25	WOS:000072325000027
J	Veenstra, TD; Benson, LM; Craig, TA; Tomlinson, AJ; Kumar, R; Naylor, S				Veenstra, TD; Benson, LM; Craig, TA; Tomlinson, AJ; Kumar, R; Naylor, S			Metal mediated sterol receptor-DNA complex association and dissociation determined by electrospray ionization mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						protein/DNA interactions; vitamin B receptor	VITAMIN-D; HORMONE RECEPTORS; BINDING DOMAIN; ZINC; PROTEIN; SUPERFAMILY; TRANSPORT	The vitamin D receptor (VDR) binds to specific DNA sequences termed vitamin D response elements (VDREs) thereby enhancing or repressing transcription. We have used electrospray ionization mass spectrometry to examine the interaction between the DNA-binding domain of the vitamin D receptor (VDR DBD) with a double-stranded DNA (dsDNA) sequence containing the VDRE from the mouse osteopontin gene. The VDR DBD was shown to bind to the appropriate DNA sequence only when bound to 2 moles of zinc (Zn2+) or cadmium (Cd2+) per mole of protein. Additional binding of Zn2+ or Cd2+ by the protein caused the protein to dissociate from the dsDNA. These results show that the VDR DBD/DNA metal-dependent association occurs when the receptor is occupied by 2 moles of Zn2+ per mole of protein and that further binding of Zn2+ to the protein causes dissociation of the complex.	Mayo Clin & Mayo Fdn, Biomed Mass Spectrometry Facil, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Nephrol Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Clin Pharmacol Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Biomed Mass Spectrometry Facil, 200 1st St SW, Rochester, MN 55905 USA.	rkumar@mayo.edu; naylor.stephen@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057	NIDDK NIH HHS [DK25409, R01 DK025409] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025409] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONIOU LD, 1981, CLIN NEPHROL, V16, P181; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Cheng XH, 1996, P NATL ACAD SCI USA, V93, P7022, DOI 10.1073/pnas.93.14.7022; Cheng XH, 1996, ANAL BIOCHEM, V239, P35, DOI 10.1006/abio.1996.0287; Craig TA, 1997, BIOCHEMISTRY-US, V36, P10482, DOI 10.1021/bi970561b; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FLEET JC, 1993, AM J PHYSIOL, V264, pG1037, DOI 10.1152/ajpgi.1993.264.6.G1037; FREEDMAN LP, 1991, MOL ENDOCRINOL, V5, P1815, DOI 10.1210/mend-5-12-1815; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GOODLETT DR, 1993, BIOL MASS SPECTROM, V22, P181, DOI 10.1002/bms.1200220307; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Hanas JS, 1996, NUCLEIC ACIDS RES, V24, P924, DOI 10.1093/nar/24.5.924; Horseman ND, 1997, TRENDS ENDOCRIN MET, V8, P123, DOI 10.1016/S1043-2760(97)00001-5; Johnson KL, 1997, RAPID COMMUN MASS SP, V11, P939, DOI 10.1002/(SICI)1097-0231(199705)11:8<939::AID-RCM936>3.0.CO;2-3; KOWARSKI S, 1974, AM J PHYSIOL, V226, P401, DOI 10.1152/ajplegacy.1974.226.2.401; Loo JA, 1997, J AM SOC MASS SPECTR, V8, P234, DOI 10.1016/S1044-0305(96)00238-3; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nemirovskiy OV, 1997, J AM SOC MASS SPECTR, V8, P809, DOI 10.1016/S1044-0305(97)00086-X; Perret C, 1997, CURR OPIN NEPHROL HY, V6, P314; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Potier N, 1997, EUR J BIOCHEM, V243, P274, DOI 10.1111/j.1432-1033.1997.0274a.x; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Sarkar B, 1995, NUTRITION, V11, P646; Smith RD, 1997, CHEM SOC REV, V26, P191, DOI 10.1039/cs9972600191; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; Veenstra TD, 1997, BIOCHEMISTRY-US, V36, P3535, DOI 10.1021/bi9628329; Veenstra TD, 1998, J AM SOC MASS SPECTR, V9, P8, DOI 10.1016/S1044-0305(97)00229-8; Wu QY, 1997, J AM CHEM SOC, V119, P1157, DOI 10.1021/ja9630250; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	36	51	52	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					262	266		10.1038/nbt0398-262	http://dx.doi.org/10.1038/nbt0398-262			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528006				2022-12-25	WOS:000072371000026
J	Fisher, SE; Vargha-Khadem, F; Watkins, KE; Monaco, AP; Pembrey, ME				Fisher, SE; Vargha-Khadem, F; Watkins, KE; Monaco, AP; Pembrey, ME			Localisation of a gene implicated in a severe speech and language disorder	NATURE GENETICS			English	Article							MULTILOCUS LINKAGE ANALYSIS; HUMAN GENOME; DEFECTS; MAP	Between 2 and 5% of children who are otherwise unimpaired have significant difficulties in acquiring expressive and/or receptive language, despite adequate intelligence and opportunity(1,2) While twin studies indicate a significant role for genetic factors in developmental disorders of speech and language(1), the majority of families segregating such disorders show complex patterns of inheritance, and are thus not amenable for conventional linkage analysis(2). A rare exception is the KE family, a large three-generation pedigree in which approximately half of the members are affected with a severe speech and language disorder which appears to be transmitted as an autosomal dominant monogenic trait(3). This family has been widely publicised as suffering primarily from a defect in the use of grammatical suffixation rules(4-7), thus supposedly supporting the existence of genes specific to grammar. The phenotype, however, is broader in nature, with virtually every aspect of grammar and of language affected(8-10). in addition, affected members have a severe orofacial dyspraxia, and their speech is largely incomprehensible to the naive listener(10). We initiated a genome-wide search for linkage in the KE family and have identified a region on chromosome 7 which co-segregates with the speech and language disorder (maximum lod score = 6.62 at theta = 0.0), confirming autosomal dominant inheritance with full penetrance. Further analysis of microsatellites from within the region enabled us to fine map the locus responsible (designated SPCH1) to a 5.6-cM interval in 7q31, thus providing an important step towards its identification. Isolation of SPCH1 may offer the first insight into the molecular genetics of the developmental process that culminates in speech and language.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Inst Child Hlth, Wolfson Ctr, Cognit Neurosci Unit, London WC1N 2AP, England; Inst Child Hlth, Mothercare Unit Clin Genet & Fetal Med, London WC1N 1EH, England	University of Oxford; Wellcome Centre for Human Genetics; University of London; University College London; University of London; University College London	Pembrey, ME (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Monaco, Anthony P/A-4495-2010; Vargha-Khadem, Faraneh/C-2558-2008; Fisher, Simon E./E-9130-2012; Watkins, Kate E/A-6559-2012	Monaco, Anthony P/0000-0001-7480-3197; Fisher, Simon E./0000-0002-3132-1996; Watkins, Kate E/0000-0002-2621-482X; vargha-khadem, faraneh/0000-0003-4890-8379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BISHOP DVM, 1995, DEV MED CHILD NEUROL, V37, P56; Bouffard GG, 1997, GENOME RES, V7, P673, DOI 10.1101/gr.7.7.673; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLETCHER P, 1990, NATURE, V346, P226, DOI 10.1038/346226a0; GOPNIK M, 1990, NATURE, V344, P715, DOI 10.1038/344715a0; GOPNIK M, 1991, COGNITION, V39, P1, DOI 10.1016/0010-0277(91)90058-C; *INT MOL GEN STUD, IN PRESS HUM MOL GEN; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Pinker Steven, 1994, LANGUAGE INSTINCT; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; SARDA P, 1988, ANN GENET-PARIS, V31, P258; SCHINZEL A, 1997, HUMAN GENETICS DATAB; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SMITH SD, 1996, PRINCIPLES PRACTICE, P1767; Sobel E, 1996, AM J HUM GENET, V58, P1323; Szathmary E, 1995, MAJOR TRANSITIONS EV; VARGHAKHADEM F, 1995, P NATL ACAD SCI USA, V92, P930, DOI 10.1073/pnas.92.3.930; VARGHAKHADEM F, 1990, NATURE, V346, P226, DOI 10.1038/346226c0; [No title captured]	21	368	379	0	40	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					168	170		10.1038/ng0298-168	http://dx.doi.org/10.1038/ng0298-168			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462748	Green Published			2022-12-25	WOS:000071779500027
J	Wang, YMF; Tsirka, SE; Strickland, S; Stieg, PE; Soriano, SG; Lipton, SA				Wang, YMF; Tsirka, SE; Strickland, S; Stieg, PE; Soriano, SG; Lipton, SA			Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice	NATURE MEDICINE			English	Article							CUZN-SUPEROXIDE-DISMUTASE; ARTERY OCCLUSION; TRANSGENIC MICE; INFARCT VOLUME; NEUROLOGICAL DEFICIT; REPERFUSION INJURY; CELL-DAMAGE; RATS; MODEL; BRAIN	Intravenous tissue plasminogen activator (tPA) is used to treat acute stroke because of its thrombolytic activity and its ability to restore circulation to the brain(1,2). However, this protease also promotes neurodegeneration after intracerebral injection of excitotoxins such as glutamate, and neuronal damage after a cerebral infarct is thought to be mediated by excitotoxins(3-8). To investigate the effects of tPA on cerebral viability during ischemia/reperfusion, we occluded the middle cerebral artery in wild-type and tPA-deficient mice with an intravascular filament. This procedure allowed us to examine the role of tPA in ischemia, independent of its effect as a thrombolytic agent. tPA-deficient mice exhibited similar to 50% smaller cerebral infarcts than wild-type mice. Intravenous injection of tPA into tPA(-/-) or wild-type mice produced larger infarcts, indicating that tPA can increase stroke-induced injury. Since tPA promotes desirable (thrombolytic) as well as undesirable (neurotoxic) outcomes during stroke, future therapies should be aimed at countering the excitotoxic damage of tPA to afford even better neuroprotection after an acute cerebral infarct.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Cerebrovasc & Neurosci Res Inst, Boston, MA 02115 USA; Childrens Hosp, Neurosurg Serv, Boston, MA 02115 USA; Childrens Hosp, Anesthesiol Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; SUNY Stony Brook, Med Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lipton, SA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Cerebrovasc & Neurosci Res Inst, 221 Longwood Ave,LMRC 1st Floor, Boston, MA 02115 USA.	slipton@rics.bwh.harvard.edu	Soriano, Sulpicio/K-3501-2019; tao, li/G-7956-2011; Tsirka, Stella/AAD-4018-2019	Strickland, Sidney/0000-0002-3072-9244; Lipton, Stuart/0000-0002-3490-1259	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035843, R01NS035704] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD 29587] Funding Source: Medline; NINDS NIH HHS [R01 NS35704, R29 NS 35843] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BUCHAN AM, 1992, STROKE, V23, P273, DOI 10.1161/01.STR.23.2.273; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P574, DOI 10.1038/jcbfm.1994.71; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P217, DOI 10.1038/jcbfm.1994.28; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	31	544	568	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					228	231		10.1038/nm0298-228	http://dx.doi.org/10.1038/nm0298-228			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461198				2022-12-25	WOS:000072249800040
J	Papandreou, CN; Usmani, B; Geng, YP; Bogenrieder, T; Freeman, R; Wilk, S; Finstad, CL; Reuter, VE; Powell, CT; Scheinberg, D; Magill, C; Scher, HI; Albino, AP; Nanus, DM				Papandreou, CN; Usmani, B; Geng, YP; Bogenrieder, T; Freeman, R; Wilk, S; Finstad, CL; Reuter, VE; Powell, CT; Scheinberg, D; Magill, C; Scher, HI; Albino, AP; Nanus, DM			Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression	NATURE MEDICINE			English	Article							CELL CARCINOMAS; GROWTH-FACTORS; RAT-BRAIN; EXPRESSION; BOMBESIN; RECEPTOR; PEPTIDE; ENKEPHALINASE; ANTIGEN; GENE	Neutral endopeptidase 24.11 (NEP) is a cell-surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides implicated in the growth of androgen-independent prostate cancer (PC). We report that NEP expression and catalytic activity are lost in vitro in androgen-independent but not androgen-dependent PC cell lines. In vivo, NEP protein expression is commonly decreased in cancer cells of metastatic PC specimens from patients with androgen-independent but not androgen-dependent PC. Overexpression of NEP in androgen-independent PC cells or incubation with recombinant NEP inhibits PC cell growth. Furthermore, in androgen-dependent PC cells, expression of NEP is transcriptionally regulated by androgen and decreases with androgen withdrawal. These data suggest that decreased NEP expression, common in androgen-independent PCs, is facilitated by the elimination of androgens, and that NEP loss plays an important role in the development of androgen-independent PC by allowing Pt cells to use mitogenic neuropeptides as an alternate source to androgen in order to stimulate cell proliferation.	Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Res Lab, New York, NY 10021 USA; Cornell Univ, Coll Med,Genitourinary Oncol Serv, Mem Sloan Kettering Canc Ctr, Dept Med,Div Solid Tumor Oncol, New York, NY 10021 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Urol Oncol Res Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Hematopoiet Canc Immunochem Lab, New York, NY 10021 USA; Amer Hlth Fdn, San Francisco, CA 94080 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; American Health Foundation	Nanus, DM (corresponding author), New York Hosp, Cornell Med Ctr, Dept Med, Div Hematol & Med Oncol, 520 E 70th St,Suite ST-341, New York, NY 10021 USA.				NCI NIH HHS [CA 05826, CA 57475] Funding Source: Medline; NINDS NIH HHS [NS 17392] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826, R29CA057475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAMSSON PA, 1993, J ANDROL, V14, P307; APRIKIAN AG, 1994, J UROLOGY, V151, P914, DOI 10.1016/S0022-5347(17)35121-2; Bogenrieder T, 1997, PROSTATE, V33, P225; BOLOGNA M, 1989, CANCER, V63, P1714; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BORSON DB, 1991, AM J PHYSIOL, V260, pL83, DOI 10.1152/ajplung.1991.260.2.L83; CASEY ML, 1991, J BIOL CHEM, V266, P23041; CHECLER F, 1984, J NEUROCHEM, V43, P1295, DOI 10.1111/j.1471-4159.1984.tb05386.x; Cohen AJ, 1996, CANCER RES, V56, P831; COHEN R, 1991, BR J UROL, V68, P57; Cussenot O, 1996, J UROLOGY, V155, P1340, DOI 10.1016/S0022-5347(01)66261-X; DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103; Duncan MD, 1996, J SURG RES, V63, P359, DOI 10.1006/jsre.1996.0276; FOURNIEZALUSKI MC, 1979, BIOCHEM BIOPH RES CO, V91, P130, DOI 10.1016/0006-291X(79)90593-X; Frame KL, 1996, BRIT J CANCER, V74, P807, DOI 10.1038/bjc.1996.440; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG ME, 1993, CURRENT PROTOCOLS MO; Gschwend JE, 1997, PROSTATE, V33, P166; Hoffman AD, 1996, CLIN CANCER RES, V2, P1077; ISHIMARU F, 1995, BLOOD, V85, P3199, DOI 10.1182/blood.V85.11.3199.bloodjournal85113199; ISRAELI RS, 1994, CANCER RES, V54, P1807; KENNY AJ, 1989, LANCET, V2, P785; KENNY J, 1993, BIOCHEM SOC T, V21, P663, DOI 10.1042/bst0210663; Klocker Helmut, 1996, P28; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NABEYA Y, 1995, INT J CANCER, V64, P1; NANUS DM, 1989, J CLIN ONCOL, V7, P1105, DOI 10.1200/JCO.1989.7.8.1105; NANUS DM, 1989, J EXP MED, V169, P953, DOI 10.1084/jem.169.3.953; NANUS DM, 1993, J NATL CANCER I, V85, P1597, DOI 10.1093/jnci/85.19.1597; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NANUS DM, 1997, CELL SURFACE PEPTIDA, P353; Nelson JB, 1996, CANCER RES, V56, P663; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; Papandreou CN, 1996, INT J ONCOL, V8, P1237; PINSKI J, 1993, CANCER LETT, V71, P189, DOI 10.1016/0304-3835(93)90115-P; REILE H, 1994, PROSTATE, V25, P29, DOI 10.1002/pros.2990250105; ROZENGURT E, 1995, CANCER SURV, V24, P81; Scher HI, 1996, JNCI-J NATL CANCER I, V88, P1623, DOI 10.1093/jnci/88.22.1623; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; STEINER MS, 1995, J UROLOGY, V153, P1085, DOI 10.1016/S0022-5347(01)67516-5; SUNDAY ME, 1992, J CLIN INVEST, V90, P2517, DOI 10.1172/JCI116145; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026	48	242	244	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					50	57		10.1038/nm0198-050	http://dx.doi.org/10.1038/nm0198-050			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427606				2022-12-25	WOS:000072249700034
J	Carmeliet, P; Moons, L; Lijnen, HR; Baes, M; Lemaitre, V; Tipping, P; Drew, A; Eeckhout, Y; Shapiro, S; Lupu, F; Collen, D				Carmeliet, P; Moons, L; Lijnen, HR; Baes, M; Lemaitre, V; Tipping, P; Drew, A; Eeckhout, Y; Shapiro, S; Lupu, F; Collen, D			Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation	NATURE GENETICS			English	Article							ABDOMINAL AORTIC-ANEURYSM; ATHEROSCLEROTIC LESIONS; MICE; MACROPHAGES; DEGRADATION; ELASTIN; PATHOGENESIS; PROTEOGLYCAN; PROTEOLYSIS; EXPRESSION	The molecular mechanisms predisposing to atherosclerotic aneurysm formation remain undefined(1-5). Nevertheless, rupture of aortic aneurysms is a major cause of death in Western societies, with few available treatments and poor long-term prognosis. Indirect evidence suggests that matrix metalloproteinases (MMPs) and plasminogen activators (PAs) are involved in its pathogenesis (1,6-12). MMPs are secreted as inactive zymogens (pro-MMPs), requiring activation in the extracellular compartment(11,13). Plasmin, generated from the zymogen plasminogen by tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA; refs 14,15), has been proposed as a possible activator in vitro, but evidence for such a role in vivo is lacking(16,17) . Analysis of atherosclerotic aorta in mice with a deficiency of apoliprotein E (Apoe(-/-);ref. 18), singly or combined with a deficiency of t-PA (Apoe(-/-):Plat(-/-)) or of u-PA (Apoe(-/-):Plau(-/-); ref. 19), indicated that deficiency of u-PA protected against media destruction and aneurysm formation, probably by means of reduced plasmin-dependent activation of pro-MMPs. This genetic evidence suggests that plasmin is a pathophysiologically significant activator of pro-MMPs in vivo and may have implications for the design of therapeutic strategies to prevent aortic-wall destruction by controlling Plau gene function.	UNIV CATHOLIQUE LOUVAIN VIB, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN LA NEUVE, BELGIUM; KATHOLIEKE UNIV LEUVEN, LAB CLIN CHEM & PHARM, B-3001 LOUVAIN, BELGIUM; UNIV LOUVAIN, SCH MED, INT INST CELLULAR & MOL PATHOL, CELL BIOL UNIT, BRUSSELS, BELGIUM; MONASH UNIV, MONASH MED CTR, DEPT MED, CTR INFLAMMATORY DIS, CLAYTON, VIC 3168, AUSTRALIA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63130 USA; THROMBOSIS RES INST, VASC BIOL LAB, LONDON SW3 6LR, ENGLAND	Flanders Institute for Biotechnology (VIB); KU Leuven; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Monash University; Washington University (WUSTL); Thrombosis Research Institute			Lijnen, Roger/AAA-4085-2020; Lupu, Florea/C-3162-2009; Carmeliet, Peter/AAQ-5140-2020; Lupu, Florea/AAV-3257-2021	Lupu, Florea/0000-0003-1249-9278; Carmeliet, Peter/0000-0001-7961-1821; Lupu, Florea/0000-0003-1249-9278; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Baes, Myriam/0000-0002-2525-2269				Anidjar S, 1992, Ann Vasc Surg, V6, P298, DOI 10.1007/BF02000279; BRAVERMAN AC, 1994, CURR OPIN CARDIOL, V9, P591, DOI 10.1097/00001573-199409000-00014; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1997, CIRC RES, V81, P829; Carmeliet Peter, 1996, Seminars in Thrombosis and Hemostasis, V22, P525, DOI 10.1055/s-2007-999055; COLLEN D, 1991, BLOOD, V78, P3114; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DELAISSE JM, 1993, J CELL SCI, V106, P1071; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Halloran B G, 1995, Semin Vasc Surg, V8, P85; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; JOHNSTON KW, 1991, J VASC SURG, V13, P452, DOI 10.1067/mva.1991.26737; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; MACSWEENEY STR, 1994, BRIT J SURG, V81, P935, DOI 10.1002/bjs.1800810704; Murphy G, 1995, ACTA ORTHOP SCAND, V66, P55, DOI 10.3109/17453679509157648; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NEWMAN KM, 1994, J VASC SURG, V20, P814, DOI 10.1016/S0741-5214(94)70169-5; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PATEL MI, 1995, J AM COLL SURGEONS, V181, P371; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SCHNEIDERMAN J, 1995, J CLIN INVEST, V96, P639, DOI 10.1172/JCI118079; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340	29	546	559	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1997	17	4					439	444		10.1038/ng1297-439	http://dx.doi.org/10.1038/ng1297-439			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398846				2022-12-25	WOS:A1997YJ92400025
J	Connor, F; Bertwistle, D; Mee, PJ; Ross, GM; Swift, S; Grigorieva, E; Tybulewicz, VLJ; Ashworth, A				Connor, F; Bertwistle, D; Mee, PJ; Ross, GM; Swift, S; Grigorieva, E; Tybulewicz, VLJ; Ashworth, A			Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation	NATURE GENETICS			English	Article							CANCER SUSCEPTIBILITY GENE; EARLY EMBRYONIC LETHALITY; BREAST-CANCER; ATAXIA-TELANGIECTASIA; MDM2-DEFICIENT MICE; TARGETED DISRUPTION; OVARIAN-CANCER; DEFICIENT MICE; P53; DIFFERENTIATION	Germline mutation of the BRCA2 gene carries a high risk of developing breast cancer. To study the function of this gene, we generated a mutation in Brca2 in mice, Unlike other mutations in the Brca2 gene, which are lethal early in embryogenesis when homozygous, some of our homozygous mutant mice survive to adulthood. These animals have a wide range of defects, including small size, improper differentiation of tissues, absence of germ cells and the development of lethal thymic lymphomas. Fibroblasts cultured from Brca2(-/-)embryos have a defect in proliferation that may be mediated by over-expression of p53 and p21(Waf1/CIP1). We show that BrcaZ is required for efficient DNA repair, and our results suggest that loss of the p53 checkpoint may be essential for tumour progression triggered by mutations in BRCA2.	INST CANC RES,CHESTER BEATTY LABS,CRC,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,SECT GENE FUNCT & REGULAT,LONDON SW3 6JB,ENGLAND; NATL INST MED RES,DIV CELLULAR IMMUNOL,LONDON NW7 1AA,ENGLAND; NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND; INST CANC RES,ACAD UNIT RADIOTHERAPY & ONCOL,SUTTON SM2 5NG,SURREY,ENGLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5NG,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; MRC National Institute for Medical Research; MRC National Institute for Medical Research; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust				Tybulewicz, Victor/0000-0003-2439-0798				Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bishop DT, 1997, NAT GENET, V15, P226, DOI 10.1038/ng0397-226; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; IVANOV EL, 1997, CURR BIOL, V7, P492; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUNA RMD, 1995, NATURE, V378, P203; MEYN MS, 1995, CANCER RES, V55, P5991; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSS GM, 1995, CANCER RES, V55, P1235; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vaughn JP, 1996, CANCER RES, V56, P4590; Westphal CH, 1997, CANCER RES, V57, P1664; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	54	353	356	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					423	430		10.1038/ng1297-423	http://dx.doi.org/10.1038/ng1297-423			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398843				2022-12-25	WOS:A1997YJ92400022
J	White, JK; Auerbach, W; Duyao, MP; Vonsattel, JP; Gusella, JF; Joyner, AL; MacDonald, ME				White, JK; Auerbach, W; Duyao, MP; Vonsattel, JP; Gusella, JF; Joyner, AL; MacDonald, ME			Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion	NATURE GENETICS			English	Article							ABNORMAL BRAIN-DEVELOPMENT; GENE HOMOLOG HDH; TRANSGENIC MICE; TRINUCLEOTIDE REPEAT; EMBRYONIC LETHALITY; PROTEIN; MOUSE; POLYGLUTAMINE; PHENOTYPE; LOCALIZATION	Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder caused by a CAG repeat expansion that lengthens a glutamine segment in the novel huntingtin protein. To elucidate the molecular basis of HD, we extended the polyglutamine tract of the mouse homologue, Hdh, by targetted introduction of an expanded human HD CAG repeat, creating mutant Hdh(neoQ50) and Hdh(Q50) alleles that express reduced and wildtype levels of altered huntingtin, respectively. Mice homozygous for reduced levels displayed characteristic aberrant brain development and perinatal lethality, indicating a critical function for Hdh in neurogenesis. However, mice with normal levels of mutant huntingtin did not display these abnormalities, indicating that the expanded CAG repeat does not eliminate or detectably impair huntingtin's neurogenic function. Thus, the HD defect in man does not mimic complete or partial Hdh inactivation and appears to cause neurodegenerative disease by a gain-of-function mechanism.	MASSACHUSETTS GEN HOSP,MOL NEUROGENET UNIT,CHARLESTOWN,MA 02129; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,SKIRBALL INST BIOMOL MED,DEV GENET PROGRAM,NEW YORK,NY 10016; MASSACHUSETTS GEN HOSP,MOL NEUROPATHOL LAB,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; New York University; New York University; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016367, P01NS016367, R01NS032765] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32765, NS16367] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; Bao J, 1996, P NATL ACAD SCI USA, V93, P5037, DOI 10.1073/pnas.93.10.5037; BARNES GT, 1994, SOMAT CELL MOLEC GEN, V20, P87, DOI 10.1007/BF02290678; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; Gusella JF, 1997, MOL MED, V3, P238, DOI 10.1007/BF03401677; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; *HUNT DIS COLL RES, 1993, CELL, V72, P971; IDE K, 1995, BIOCHEM BIOPH RES CO, V209, P1119, DOI 10.1006/bbrc.1995.1613; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; MACDONALD ME, 1996, HDB COLD SPRING HARB, V61, P627; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; McNeil SM, 1997, HUM MOL GENET, V6, P775, DOI 10.1093/hmg/6.5.775; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; MYERS RH, 1989, AM J HUM GENET, V45, P615; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; PERSICHETTI F, 1995, NEUROBIOL DIS, V1, P159; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; SHAH V, 1995, NAT GENET, V10, P175; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; WARNER JP, 1993, MOL CELL PROBE, V7, P235, DOI 10.1006/mcpr.1993.1034; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; Wurst W., 1993, Gene targeting: a practical approach., P33; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	47	389	403	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					404	410		10.1038/ng1297-404	http://dx.doi.org/10.1038/ng1297-404			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398841				2022-12-25	WOS:A1997YJ92400020
J	Michael, NL; Louie, LG; Rohrbaugh, AL; Schultz, KA; Dayhoff, DE; Wang, CE; Sheppard, HW				Michael, NL; Louie, LG; Rohrbaugh, AL; Schultz, KA; Dayhoff, DE; Wang, CE; Sheppard, HW			The role of CCR5 and CCR2 polymorphisms in HTV-1 transmission and disease progression	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; TYPE-1; ALLELE; GENE; AIDS	Entry of human immunodeficiency virus type 1 (HIV-1) into target cells requires both CD4(ref. 1, 2) and one of a growing number of G-protein-coupled seven-transmembrane receptors'. Viruses predominantly use one, or occasionally both, of the major co-receptors CCR5 or CXCR4 although other receptors, including CCR2B and CCR3, function as minor co-receptors(4-6). CCR3 appears critical in central nervous system infection(7). A 32-base pair inactivating deletion in CCRS (Delta 32) common to Northern European populations(8) has been associated with reduced(9-15), but not absolute(16-19), HIV-1 transmission risk and delayed disease progression(11-15,20). A more commonly distributed transition causing a valine to isoleucine switch in transmembrane domain I of CCR2B (641) with unknown functional consequences was recently shown to delay disease progression but not reduce infection risk(21). Although we confirm the lack of association of CCR2B 641 with transmission, we cannot confirm the association with delayed progression. Although subjects with CCRS Delta 32 defects had significantly reduced median viral load at study entry, providing a plausible explanation for the association with delayed progression, this association was not seen with CCR2B 641. Further studies are needed to define the role of CCR2B 641 in HIV pathogenesis.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; HENRY M JACKSON FDN,ROCKVILLE,MD 20850; CALIF DEPT HLTH SERV,BERKELEY,CA 94704	University of California System; University of California Berkeley; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; California Department of Health Care Services	Michael, NL (corresponding author), WALTER REED ARMY INST RES,DIV RETROVIROL,13 TAFT COURT,SUITE 200,ROCKVILLE,MD 20850, USA.		McNulty, Amy/K-7368-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036661, R01AI034783, N01AI082515] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-34783, R01-AI-36661, N01-AI-82515] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balotta C, 1997, AIDS, V11, pF67, DOI 10.1097/00002030-199710000-00001; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Clapham PR, 1997, NATURE, V388, P230, DOI 10.1038/40758; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rappaport J, 1997, LANCET, V349, P922, DOI 10.1016/S0140-6736(05)62697-9; SAMPSON M, 1996, NATURE, V382, P722; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodorou I, 1997, LANCET, V349, P1219; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	28	216	228	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1160	1162		10.1038/nm1097-1160	http://dx.doi.org/10.1038/nm1097-1160			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334732				2022-12-25	WOS:A1997XZ28700046
J	Ng, ST; Zhou, JA; Adesanya, OO; Wang, J; LeRoith, D; Bondy, CA				Ng, ST; Zhou, JA; Adesanya, OO; Wang, J; LeRoith, D; Bondy, CA			Growth hormone treatment induces mammary gland hyperplasia in aging primates	NATURE MEDICINE			English	Article							FACTOR-I; BREAST-CANCER; GENE-EXPRESSION; PROLACTIN; SYSTEM; PROLIFERATION; THERAPY	The decline of growth hormone (CH) and insulin-like growth factor I (ICF-I) production during aging has been likened to the decrease in gonadal steroids in menopause. The repletion of GH/IGF-I levels in aging individuals is suggested to restore the lean tissue anabolism characteristic of youth(1). In addition to anabolic effects on musculoskeletal tissues, CH also stimulates mammary glandular growth in some species(2-4), although its effects on primate mammary growth remain unclear(5). Some clinical observations implicate GH in human mammary growth, for example, gynecomastia occurs in some children treated with CH (ref. 6), and tall stature and acromegaly are associated with an increased incidence of breast cancer(7,8). To investigate the effects of GH/ICF-I augmentation on mammary tissue in a model relevant to aging humans, we treated aged female rhesus monkeys with CH, IG F-l, GH + ICF-I or saline diluent for 7 weeks. ICF-I treatment was associated with a twofold increase, GH with a three-to fourfold increase, and GH + IGF-I with a four-to fivefold increase in mammary glandular size and epithelial proliferation index. These mitogenic effects were directly correlated with circulating GH and IGF-I levels, suggesting that either CH or its downstream effector ICF-I stimulates primate mammary epithelial proliferation.	NICHHD, DEV ENDOCRINOL BRANCH, BETHESDA, MD 20892 USA; NIDDKD, DIABET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Adesanya OO, 1996, J CLIN ENDOCR METAB, V81, P1967, DOI 10.1210/jc.81.5.1967; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; BONDY CA, 1994, ANN INTERN MED, V120, P593, DOI 10.7326/0003-4819-120-7-199404010-00011; DJIANE J, 1981, P NATL ACAD SCI-BIOL, V78, P7445, DOI 10.1073/pnas.78.12.7445; FORSYTH IA, 1991, BAILLIERE CLIN ENDOC, V5, P809, DOI 10.1016/S0950-351X(10)80016-3; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KLEINBERG DL, 1990, ENDOCRINOLOGY, V126, P3274, DOI 10.1210/endo-126-6-3274; KLEINBERG DL, 1985, J CLIN INVEST, V75, P1943, DOI 10.1172/JCI111910; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LeRoith D, 1996, ENDOCRINOLOGY, V137, P1071, DOI 10.1210/en.137.3.1071; MALOZOWSKI S, 1995, J PEDIATR-US, V126, P659, DOI 10.1016/S0022-3476(95)70372-1; MARTINEZ AJ, 1992, MAYO CLIN PROC, V67, P1011, DOI 10.1016/S0025-6196(12)60937-9; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; NABARRO JDN, 1987, CLIN ENDOCRINOL, V26, P481, DOI 10.1111/j.1365-2265.1987.tb00805.x; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; PLAUT K, 1993, ENDOCRINOLOGY, V133, P1843, DOI 10.1210/en.133.4.1843; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; Toogood AA, 1997, J CLIN ENDOCR METAB, V82, P1462, DOI 10.1210/jc.82.5.1462; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	23	152	155	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1997	3	10					1141	1144		10.1038/nm1097-1141	http://dx.doi.org/10.1038/nm1097-1141			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334728	Green Published			2022-12-25	WOS:A1997XZ28700042
J	WithersWard, ES; Amado, RG; Koka, PS; Jamieson, BD; Kaplan, AH; Chen, ISY; Zack, JA				WithersWard, ES; Amado, RG; Koka, PS; Jamieson, BD; Kaplan, AH; Chen, ISY; Zack, JA			Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SCID-HU MOUSE; PROTEASE INHIBITOR; MICE; VARIANTS; PATHOGENICITY; LYMPHOCYTES; REPLICATION; DEPLETION; MODEL	Stem cell gene therapy strategies for AIDS require that differentiation-inducing stromal elements of HIV-infected individuals remain functionally intact to support the maturation of exogenous progenitor cells into mature CD4(+) cells. To investigate the feasibility of stem cell reconstitution strategies in AIDS, we used the SCID-hu mouse to examine the ability of HIV-infected CD4(+) cell-depleted human thymic implants to support renewed thymopoiesis. Here we report that following treatment of these implants with antiretroviral drugs, new thymopoiesis is initiated. This suggests that antiviral therapies might allow de novo production of T lymphocytes and provides support for the concept of therapeutic strategies aimed at reconstitution of the peripheral CD4(+) T-cell compartment.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT IMMUNOL & MICROBIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV INFECT DIS,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOL GENET & MICROBIOL,LOS ANGELES,CA 90095; JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center					NIAID NIH HHS [AI 36554, AI 36555, AI 36059] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036554, R37AI036059, R01AI036059, R01AI036555] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKKINA RK, 1994, BLOOD, V84, P1393; Aldrovandi GM, 1996, J VIROL, V70, P1505, DOI 10.1128/JVI.70.3.1505-1511.1996; ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; An DS, 1997, J VIROL, V71, P1397, DOI 10.1128/JVI.71.2.1397-1404.1997; AUTRAN B, 1997, SCIENCE, V27, P112; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JAMIESON BD, 1995, J VIROL, V69, P6259, DOI 10.1128/JVI.69.10.6259-6264.1995; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; JAMIESON BD, IN PRESS J VIROL; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JOSHI VV, 1986, ARCH PATHOL LAB MED, V110, P837; KANESHIMA H, 1991, P NATL ACAD SCI USA, V88, P4523, DOI 10.1073/pnas.88.10.4523; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KOLLMANN TR, 1994, J EXP MED, V179, P513, DOI 10.1084/jem.179.2.513; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; ROSENZWEIG M, 1993, AIDS, V7, P1601, DOI 10.1097/00002030-199312000-00009; SATO A, 1995, ANTIVIR RES, V27, P151, DOI 10.1016/0166-3542(95)00004-6; SCHUURMAN HJ, 1989, AM J PATHOL, V134, P1329; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	30	55	55	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1102	1109		10.1038/nm1097-1102	http://dx.doi.org/10.1038/nm1097-1102			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334721				2022-12-25	WOS:A1997XZ28700035
J	Irwin, MH; Moffatt, RJ; Pinkert, CA				Irwin, MH; Moffatt, RJ; Pinkert, CA			Identification of transgenic mice by PCR analysis of saliva	NATURE BIOTECHNOLOGY			English	Article						transgenic mice; polymerase chain reaction; nested primers; saliva; gene integration; DNA purification	POLYMERASE CHAIN-REACTION; DNA; GENE	As an alternative to surgically obtaining samples (e.g., tail or tissue biopsy, toe dock, or blood sampling) from weanling mice to screen for transgene integration or other genetic monitoring procedures, we offer a simpler, nonsurgical method. A small amount of saliva, obtained from weanling mice by oral wash using a plastic pipet tip, contains enough oral epithelial cells and lymphocytes to yield sufficient DNA for nested primer polymerase chain reaction (PCR) analysis. The procedure can be repeated many times with minimal stress to the animal, in contrast to tissue biopsy procedures such as tail cutting. Sample analysis is rapid and straightforward; saliva is applied to sample collection paper and then purified using a solid phase DNA purification system. The paper, containing purified DNA, is added directly to PCR cocktail for the first round of amplification. For weanling mice, in the second round of amplification, a small amount of product from the first round is removed and added to PCR cocktail containing the second set of primers. With adult mice, an adequate volume of saliva may be obtained (dependent upon the sensitivity of the particular reaction) to eliminate the need for second-round amplification with nested primers, This technique is reliable, does not require organic solvents, and is more humane than protocols currently in use. Furthermore, this technique could replace hundreds of thousands of surgical biopsies on rodents annually, which are performed for both transgene determination and genetic monitoring procedures.	UNIV ALABAMA,DEPT COMPARAT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,UAB TRANSGEN ANIM ES CELL RES,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Pinkert, Carl/0000-0001-7460-3881	NCI NIH HHS [CA13148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		HOCHMEISTER MN, 1991, INT J LEGAL MED, V104, P229, DOI 10.1007/BF01369812; Hogan B, 1994, MANIPULATING MOUSE E; HOPKINS B, 1994, J FORENSIC SCI, V39, P526; Kelly C. L., 1995, American Journal of Human Genetics, V57, pA52; KLOOSTERMAN AD, 1993, INT J LEGAL MED, V105, P257, DOI 10.1007/BF01370382; KOOYMAN DL, 1994, TRANSGENIC RES, V3, P167, DOI 10.1007/BF01973984; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Overbeek Paul A., 1994, P69; PINKERT CA, 1990, BIOTECHNIQUES, V9, P38; PINKERT CA, 1995, ENCY MOL BIOL, P901; PINKERT CA, 1995, BARC 20 S BIOT ROL G, P43; Polites H. Greg, 1994, P15; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; TANIGUCHI S, 1993, BRIT J DERMATOL, V129, P637, DOI 10.1111/j.1365-2133.1993.tb00503.x; Tinkle Brad T., 1994, P221; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018	16	31	36	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1146	1148		10.1038/nbt0996-1146	http://dx.doi.org/10.1038/nbt0996-1146			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631068				2022-12-25	WOS:A1996VF84300039
J	LeSauteur, L; Cheung, NKV; Lisbona, R; Saragovi, HU				LeSauteur, L; Cheung, NKV; Lisbona, R; Saragovi, HU			Small molecule nerve growth factor analogs Image receptors in vivo	NATURE BIOTECHNOLOGY			English	Article						TrkA; imaging; NGF receptor; mimic; analog	EXPRESSION; PROTEINS; DESIGN	The in vivo targeting efficacy of small molecule analogs of nerve growth factor (NGF) that bind the NGF receptor p140 TrkA was evaluated and compared with that of a high-affinity anti-TrkA monoclonal antibody (Mab 5C3). Nuclear imaging studies were done after the injection of Tc-90m-labeled compounds in nude mice bearing tumors. Kinetics of tumor targetting, blood clearance, and bioavailability of NGF mimics were equivalent or better than Mab 5C3. Tumors that do not express TrkA were not targeted, demonstrating the specificity of NGF mimics in vivo. This comparative biodistribution study demonstrates that receptor-specific small molecule analogs designed from large polypeptides may be more useful than antibodies and may be effective agents for the detection, diagnosis, and possible treatment of neoplasias involving overexpressed oncogenic receptors such as TrkA.	MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL,PQ,CANADA; MCGILL CANC CTR,MONTREAL,PQ,CANADA; ROYAL VICTORIA HOSP,DEPT NUCL MED,MONTREAL,PQ H3A 1A1,CANADA; MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,NEW YORK,NY 10021	McGill University; McGill University; McGill University; Royal Victoria Hospital; Memorial Sloan Kettering Cancer Center								BARBACID M, 1994, J NEUROBIOL, V25, P1385; Cheung N K, 1994, Prog Clin Biol Res, V385, P319; ESTEBAN I, 1995, BRAIN RES BULL, V38, P539, DOI 10.1016/0361-9230(95)02025-9; FUJIMORI K, 1991, CANCER RES, V51, P4821; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KING TP, 1986, BIOCHEMISTRY-US, V25, P5774, DOI 10.1021/bi00367a064; KRAMER K, 1996, IN PRESS CLIN CANC R; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; LeSauteur L, 1996, J NEUROSCI, V16, P1308; LeSauteur L, 1996, J BIOL CHEM, V271, P1249, DOI 10.1074/jbc.271.2.1249; LOMENHOERTH C, 1995, J NEUROCHEM, V64, P1780; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; MICHITSCH RW, 1988, ADV NEUROBLASTOMA RE, V2, P103; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OELMANN E, 1995, CANCER RES, V55, P2212; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; SARAGOVI HU, 1992, IMMUNOMETHODS, V1, P3; SCHWARTZ DA, 1991, BIOCONJUGATE CHEM, V2, P333, DOI 10.1021/bc00011a007; TRALL PA, 1993, SCIENCE, V261, P212; YASUMURA Y, 1966, CANCER RES, V26, P529; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	22	40	41	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1120	1122		10.1038/nbt0996-1120	http://dx.doi.org/10.1038/nbt0996-1120			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631063				2022-12-25	WOS:A1996VF84300034
J	Fishwild, DM; ODonnell, SL; Bengoechea, T; Hudson, DV; Harding, F; Bernhard, SL; Jones, D; Kay, RM; Higgins, KM; Schramm, SR; Lonberg, N				Fishwild, DM; ODonnell, SL; Bengoechea, T; Hudson, DV; Harding, F; Bernhard, SL; Jones, D; Kay, RM; Higgins, KM; Schramm, SR; Lonberg, N			High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice	NATURE BIOTECHNOLOGY			English	Article						human monoclonal antibody; immunoglobulin transgenic mouse; CD4	YEAST ARTIFICIAL CHROMOSOME; NZB NZW F1-MICE; RHEUMATOID-ARTHRITIS; ANTI-CD4 ANTIBODY; HUMAN CD4; CLASS-II; T-CELLS; LOCUS; MOUSE; CHAIN	Human immunoglobulin transgenic mice provide a method of obtaining human monoclonal antibodies (Mabs) using conventional hybridoma technology. We describe a novel strain of human immunoglobulin transgenic mice and the use of this strain to generate multiple high-avidity human sequence IgG kappa Mabs directed against a human antigen. The light chain transgene is derived in part from a yeast artificial chromosome clone that includes nearly half of the germline human VK region. In addition, the heavy-chain transgene encodes both human lu and human yl constant regions, the latter of which is expressed via intratransgene class switching. We have used these animals to isolate human IgG kappa Mabs that are specific for the human T-cell marker CD4, have high binding avidities, and are immunosuppressive in vitro. The human Mab-secreting hybridomas display properties similar to those of wild-type mice including stability, growth, and secretion levels. Mabs with four distinct specificities were derived from a single transgenic mouse, consistent with an extensive diversity in the primary repertoire encoded by the transgenes.	GENPHARM INT,DEPT MOLEC BIOL,MT VIEW,CA 94043		Fishwild, DM (corresponding author), GENPHARM INT,DEPT HYBRIDOMA DEV,279 N BERNARDO AVE,MT VIEW,CA 94043, USA.							BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; BRUGGEMANN M, 1989, P NATL ACAD SCI USA, V86, P6709, DOI 10.1073/pnas.86.17.6709; CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CHOI TK, 1993, NAT GENET, V4, P117, DOI 10.1038/ng0693-117; Collins T L, 1993, Curr Top Microbiol Immunol, V184, P223; DALESANDRO MR, 1993, INT IMMUNOL, V5, P283, DOI 10.1093/intimm/5.3.283; DAVIES NP, 1993, BIO-TECHNOL, V11, P911, DOI 10.1038/nbt0893-911; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EHRLICH PH, 1988, CLIN CHEM, V34, P1681; ENGLEMAN EG, 1981, J EXP MED, V153, P193; FISHWILD DM, 1991, J IMMUNOL METHODS, V144, P27, DOI 10.1016/0022-1759(91)90226-6; GOLDBERG D, 1991, J AUTOIMMUN, V4, P617, DOI 10.1016/0896-8411(91)90181-B; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P385; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HALE G, 1988, LANCET, V2, P1394; HERZOG C, 1987, LANCET, V2, P1461; HORNEFF G, 1991, ARTHRITIS RHEUM, V34, P129, DOI 10.1002/art.1780340202; HUBER C, 1993, EUR J IMMUNOL, V23, P2860, DOI 10.1002/eji.1830231120; JAFFERS GJ, 1986, TRANSPLANTATION, V41, P572, DOI 10.1097/00007890-198605000-00004; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNOX SJ, 1991, BLOOD, V77, P20; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LAUTNERRIESKE A, 1992, EUR J IMMUNOL, V22, P1023, DOI 10.1002/eji.1830220422; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; Lonberg N, 1995, Int Rev Immunol, V13, P65, DOI 10.3109/08830189509061738; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; MALONEY DG, 1994, BLOOD, V84, P2457; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; MOREL P, 1992, CLIN IMMUNOL IMMUNOP, V64, P248, DOI 10.1016/0090-1229(92)90207-5; MORELAND LW, 1993, ARTHRITIS RHEUM, V36, P307, DOI 10.1002/art.1780360304; NEWMAN R, 1992, BIO-TECHNOL, V10, P1455, DOI 10.1038/nbt1192-1455; PARGENT W, 1991, EUR J IMMUNOL, V21, P1821, DOI 10.1002/eji.1830210807; RATH S, 1991, J IMMUNOL, V146, P2841; REITER C, 1991, ARTHRITIS RHEUM-US, V34, P525, DOI 10.1002/art.1780340504; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; STALL AM, 1988, P NATL ACAD SCI USA, V85, P3546, DOI 10.1073/pnas.85.10.3546; TAYLOR LD, 1994, INT IMMUNOL, V6, P579, DOI 10.1093/intimm/6.4.579; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; VANDERLUBBE PA, 1995, ARTHRITIS RHEUM, V38, P1097, DOI 10.1002/art.1780380812; VANDERLUBBE PA, 1993, ARTHRITIS RHEUM, V36, P1275; WAGNER SD, 1994, EUR J IMMUNOL, V24, P2672, DOI 10.1002/eji.1830241116; WAGNER SD, 1994, NUCLEIC ACIDS RES, V22, P1389, DOI 10.1093/nar/22.8.1389; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574; WEICHHOLD GM, 1993, GENOMICS, V16, P503, DOI 10.1006/geno.1993.1217; WENDLING D, 1991, J RHEUMATOL, V18, P325; WOFSY D, 1987, J IMMUNOL, V138, P3247; WOFSY D, 1985, J EXP MED, V161, P378, DOI 10.1084/jem.161.2.378	54	194	1057	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					845	851		10.1038/nbt0796-845	http://dx.doi.org/10.1038/nbt0796-845			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631008				2022-12-25	WOS:A1996UV62000033
J	Reddy, AS; Thomas, TL				Reddy, AS; Thomas, TL			Expression of a cyanobacterial Delta(6)-desaturase gene results in gamma-linolenic acid production in transgenic plants	NATURE BIOTECHNOLOGY			English	Article						tobacco; octadecatetraenoic acid; novel plant lipids	CARRIER-PROTEIN DESATURASE; TOBACCO; ENHANCEMENT; FORMS	Gamma-linolenic acid (GLA), a nutritionally important fatty acid in human and animal diets, is not produced in oil seed crops. Many oil seed plants, however, produce significant quantities of linoleic acid, a fatty acid that could be converted to GLA by the enzyme Delta(6)-desaturase if it were present. As a first step to producing GLA in oil seed crops, we have cloned a cyanobacterial Delta(6)-desaturase gene. Expression of this gene in transgenic tobacco resulted in GLA accumulation. Octadecatetraenoic acid, a highly unsaturated, industrially important fatty acid, was also found in transgenic tobacco plants expressing the cyanobacterial Delta(6)-desaturase. This is the first example of engineering the production of 'novel' polyunsaturated fatty acids in transgenic plants.	TEXAS A&M UNIV, DEPT BIOL, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station								ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BOGUE MA, 1990, MOL GEN GENET, V222, P49, DOI 10.1007/BF00283022; Brenner R R, 1977, Adv Exp Med Biol, V83, P85; BROWSE J, 1990, UCLA SYM BI, V129, P301; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; CAMPBELL WH, 1990, PLANT PHYSIOL, V92, P1, DOI 10.1104/pp.92.1.1; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHEN J, 1985, EMBO J, V4, P2145, DOI 10.1002/j.1460-2075.1985.tb03908.x; CRAIG BM, 1964, J AM OIL CHEM SOC, V41, P209, DOI 10.1007/BF03024649; DAHMER ML, 1989, J AM OIL CHEM SOC, V66, P543, DOI 10.1007/BF02885445; GRAYBURN WS, 1992, BIO-TECHNOL, V10, P675, DOI 10.1038/nbt0692-675; GRIFFITHS G, 1989, BIOL ROLE PLANT LIPI, P151; GROSS ATH, 1976, CAN J PLANT SCI, V56, P659, DOI 10.4141/cjps76-105; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUDSON BJ, 1984, JACCS, V61, P840; KRUTZON DS, 1992, P NATL ACAD SCI USA, V89, P2624; LEROUX B, 1989, Patent No. 508909; MURATA N, 1987, BIOCH PLANTS, V9, P315; POSTBEITTENMILLER MA, 1989, PLANT CELL, V1, P889, DOI 10.1105/tpc.1.9.889; REDDY AS, 1993, PLANT MOL BIOL, V27, P293; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; STYMNE S, 1986, BIOCHEM J, V240, P385, DOI 10.1042/bj2400385; THOMPSON GA, 1991, P NATL ACAD SCI USA, V88, P2578, DOI 10.1073/pnas.88.6.2578; TRAITLER H, 1988, J AM OIL CHEM SOC, V65, P755, DOI 10.1007/BF02542525; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0	28	88	112	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					639	642		10.1038/nbt0596-639	http://dx.doi.org/10.1038/nbt0596-639			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630958				2022-12-25	WOS:A1996UL60400032
J	Sioud, M; Sorensen, DR				Sioud, M; Sorensen, DR			A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth	NATURE BIOTECHNOLOGY			English	Article						gene expression; antisense; 2 '-amino pyrimidines	T7 RNA-POLYMERASE; HAMMERHEAD RIBOZYMES; EXPRESSION; INVIVO; STABILITY; ENZYMES; THERAPY; MODEL	We investigated the cleavage activity, stability. and efficacy of 2'-amino pyrimidine modified ribozymes on malignant glioma growth. A synthetic protein kinase C alpha (PKC alpha) ribozyme with complete pyrimidine nucleotide substitution retained a comparable cleavage activity compared with the unmodified ribozyme. The half-life of the modified ribozyme in serum was increased 14,000-fold compared with the unmodified version. The PKC alpha modified ribozyme inhibited glioma cell growth in vitro as a result of the inhibition of PKC alpha gene expression. A single injection of cationic liposome ribozyme complexes into glioma tumors inhibited tumor growth, demonstrating both the efficacy of the ribozyme and a major role of PKC alpha in tumor growth.	Norwegian Radium Hosp, Dept Immunol, Canc Res Inst, N-0310 Oslo, Norway; Natl Hosp Norway, Anim Unit, N-0027 Oslo, Norway	University of Oslo; University of Oslo; National Hospital Norway	Sioud, M (corresponding author), Norwegian Radium Hosp, Dept Immunol, Canc Res Inst, N-0310 Oslo, Norway.							AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; Burgin AB, 1996, BIOCHEMISTRY-US, V35, P14090, DOI 10.1021/bi961264u; CAMERON FH, 1989, P NATL ACAD SCI USA, V83, P8859; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; Chen H, 1997, NAT BIOTECHNOL, V15, P432, DOI 10.1038/nbt0597-432; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; HEIDENREICH O, 1993, FASEB J, V7, P90, DOI 10.1096/fasebj.7.1.7678566; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee SW, 1996, J EXP MED, V184, P315, DOI 10.1084/jem.184.2.315; MELLA O, 1990, J NEURO-ONCOL, V9, P93, DOI 10.1007/BF02427829; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; ROSSI JJ, 1995, TRENDS BIOTECHNOL, V13, P301, DOI 10.1016/S0167-7799(00)88969-6; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCANLON KJ, 1994, P NATL ACAD SCI USA, V91, P11123, DOI 10.1073/pnas.91.23.11123; Scherr M, 1997, J BIOL CHEM, V272, P14304, DOI 10.1074/jbc.272.22.14304; Sioud M, 1996, J MOL BIOL, V257, P775, DOI 10.1006/jmbi.1996.0201; Sioud M, 1997, NUCLEIC ACIDS RES, V25, P333, DOI 10.1093/nar/25.2.333; SIOUD M, 1994, J MOL BIOL, V242, P619, DOI 10.1006/jmbi.1994.1612; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918; YOSHITAKA O, 1988, NUCL ACIDS RS, V16, P5911	33	68	69	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					556	561		10.1038/nbt0698-556	http://dx.doi.org/10.1038/nbt0698-556			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624687				2022-12-25	WOS:000073930600032
J	Saldarini, RJ				Saldarini, RJ			For vaccines, the future is now	NATURE MEDICINE			English	Editorial Material									Wyeth Lederle Vaccines & Pediat, Radnor, PA 19087 USA	Pfizer	Saldarini, RJ (corresponding author), Wyeth Lederle Vaccines & Pediat, 280 King Prussia Rd, Radnor, PA 19087 USA.								0	4	4	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			485	487		10.1038/nm0598supp-485	http://dx.doi.org/10.1038/nm0598supp-485			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585191	Bronze			2022-12-25	WOS:000073453500009
J	George, JF; Sweeney, SD; Kirklin, JK; Simpson, EM; Goldstein, DR; Thomas, JM				George, JF; Sweeney, SD; Kirklin, JK; Simpson, EM; Goldstein, DR; Thomas, JM			An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow	NATURE MEDICINE			English	Article							ALLOGRAFT TOLERANCE; CHIMERISM; MICE; CELL; MECHANISM; CD8	Medawar and co-workers originally demonstrated that injection of donor bone marrow (DBM) into immune-incompetent neonatal rodents could induce tolerance to grafts from animals of the same strain as the bone marrow donor(1). Induction of tolerance in this manner can also be accomplished in mature mice, dogs and monkeys if the resident T-cell populations in the recipient are depleted by a polyclonal antithymocyte globulin or an anti-T cell immunotoxin(2-4.) The molecular mechanisms by which bone marrow cells mediate the induction of tolerance remain uncertain. Here we examined a well-established adult mouse model of antithymocyte globulin and DBM treatment and show that expression of functional pas ligand (Fast, also CD95L) an the injected bone marrow cells is required for tolerance induction. The results indicate that a state of microchimerism per se is insufficient for the induction of tolerance in T cell-depleted transplant recipients. Moreover, the results are consistent with the hypothesis that tolerance induced by DBM involves an apoptotic process leading to deletion of graft-reactive cells.	Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Jackson Laboratory	George, JF (corresponding author), Univ Alabama, Dept Surg, Room 739 ZRB, Birmingham, AL 35294 USA.		Simpson, Elizabeth/H-1183-2012	Simpson, Elizabeth/0000-0002-0654-4303; Goldstein, Daniel/0000-0001-6695-979X				Bergstrom DE, 1997, MAMM GENOME, V8, P510, DOI 10.1007/s003359900486; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; GOZZO J J, 1970, Surgical Forum (Chicago), V21, P281; HARTNER WC, 1987, TRANSPLANT P, V19, P476; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAUFMAN CL, 1994, BLOOD, V84, P2436; LUBAROFF DM, 1973, J IMMUNOL, V111, P65; MARTIN PJ, 1993, J EXP MED, V178, P703, DOI 10.1084/jem.178.2.703; MONACO AP, 1995, CHIMERISM TOLERANCE, P99; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; SAYEGH MH, 1995, J AM SOC NEPHROL, V6, P1143; SHARABI Y, 1992, BONE MARROW TRANSPL, V9, P191; SMITH JP, 1994, TRANSPLANTATION, V58, P324, DOI 10.1097/00007890-199408000-00013; Starzl TE, 1996, IMMUNOL TODAY, V17, P588; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; THOMAS JM, 1983, TRANSPLANTATION, V36, P104; THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018; VERBANAC KKM, 1994, TRANSPLANTATION, V57, P893, DOI 10.1097/00007890-199403270-00022; WOOD KJ, 1995, CHIMERISM TOLERANCE, P15; ZHANG L, 1995, J IMMUNOL, V155, P3464	21	85	87	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					333	335		10.1038/nm0398-333	http://dx.doi.org/10.1038/nm0398-333			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500608				2022-12-25	WOS:000073616200040
J	Wang, S; Wu, H; Jiang, JW; Delohery, TM; Isdell, F; Goldman, SA				Wang, S; Wu, H; Jiang, JW; Delohery, TM; Isdell, F; Goldman, SA			Isolation of neuronal precursors by sorting embryonic forebrain transfected with GFP regulated by the T alpha 1 tubulin promoter	NATURE BIOTECHNOLOGY			English	Article						stem cell biology; neurogenesis; green fluorescent protein	ADULT SONGBIRD BRAIN; GREEN FLUORESCENT PROTEIN; NEWLY GENERATED NEURONS; MAMMALIAN FOREBRAIN; ALPHA-TUBULIN; MOUSE BRAIN; ZONE CELLS; SUBVENTRICULAR ZONE; SUBEPENDYMAL ZONE; EXPLANT CULTURES	Neuronal precursor cells are widespread in the forebrain ventricular/subventricular zone, and may provide a cellular substrate for brain repair. Clonal lines derived from single progenitors can become progressively less representative of their parental precursors with time and passage in vitro. We have developed an alternative strategy for the isolation and enrichment of precursor cells, by fluorescence-activated cell sorting of forebrain cells transfected with the gene for green fluorescent protein, driven by the neuronal T alpha 1 tubulin promoter. Using this approach, neural precursors and young neurons can be identified and selectively harvested from a variety of samples, including both avian and mammalian forebrains at different developmental stages.	Cornell Univ, Med Ctr, Dept Neurol & Neurosci, New York, NY 10021 USA; Sloan Kettering Inst, Flow Cytometry Facil, New York, NY 10021 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Rockefeller University	Goldman, SA (corresponding author), Cornell Univ, Med Ctr, Dept Neurol & Neurosci, New York, NY 10021 USA.	sgoldm@mail.cornell.edu		Goldman, Steven/0000-0002-5498-4303	NICHD NIH HHS [N01-HD62915] Funding Source: Medline; NINDS NIH HHS [R01NS29813, R01NS33106] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033106, R01NS029813] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY KA, 1994, J NEUROSCI RES, V39, P166, DOI 10.1002/jnr.490390207; BANSAL R, 1989, J NEUROSCI RES, V24, P548, DOI 10.1002/jnr.490240413; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Goldman S A., 1995, NEUROSCIENTIST, V1, P338; GOLDMAN SA, 1992, J NEUROSCI, V12, P2532; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Goldman SA, 1996, J NEUROBIOL, V30, P505, DOI 10.1002/(SICI)1097-4695(199608)30:4<505::AID-NEU6>3.0.CO;2-7; GOLDMAN SA, 1993, GLIA, V8, P150, DOI 10.1002/glia.440080303; Goldman SA, 1997, J NEUROBIOL, V32, P554, DOI 10.1002/(SICI)1097-4695(19970605)32:6<554::AID-NEU2>3.0.CO;2-Z; GOLDMAN SA, 1992, DEV BRAIN RES, V68, P217, DOI 10.1016/0165-3806(92)90063-3; GOLDMAN SA, 1990, J NEUROSCI, V10, P2931; GOLDMAN SA, 1997, ISOLATION CHARACTERI, P43; Gritti A, 1996, J NEUROSCI, V16, P1091; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; LEMMON V, 1985, DEV BRAIN RES, V23, P111, DOI 10.1016/0165-3806(85)90010-0; Levy JP, 1996, NAT BIOTECHNOL, V14, P610, DOI 10.1038/nbt0596-610; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Luskin MB, 1997, MOL CELL NEUROSCI, V8, P351, DOI 10.1006/mcne.1996.0592; MARUSICH MF, 1992, DEV BIOL, V149, P295, DOI 10.1016/0012-1606(92)90285-O; MCCOY JP, 1991, CYTOMETRY, V12, P268, DOI 10.1002/cyto.990120310; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; MILLER FD, 1987, J CELL BIOL, V105, P3065, DOI 10.1083/jcb.105.6.3065; MILLER FD, 1989, J NEUROSCI, V9, P1452; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NEDERGAARD M, 1991, J NEUROSCI, V11, P2489; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; PINCUS DW, 1997, IN PRESS ANN NEUROL; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; VAYSSE PJJ, 1990, NEURON, V5, P227, DOI 10.1016/0896-6273(90)90160-H; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Weiss S, 1996, J NEUROSCI, V16, P7599; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7	44	58	74	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					196	201		10.1038/nbt0298-196	http://dx.doi.org/10.1038/nbt0298-196			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487530				2022-12-25	WOS:000071831300036
J	Bullido, MJ; Artiga, MJ; Recuero, M; Sastre, I; Garcia, MA; Aldudo, J; Lendon, C; Han, SW; Morris, JC; Frank, A; Vazquez, J; Goate, A; Valdivieso, F				Bullido, MJ; Artiga, MJ; Recuero, M; Sastre, I; Garcia, MA; Aldudo, J; Lendon, C; Han, SW; Morris, JC; Frank, A; Vazquez, J; Goate, A; Valdivieso, F			A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia	NATURE GENETICS			English	Article							APOLIPOPROTEIN-E; TYPE-4 ALLELE; DISEASE; FREQUENCY; RNA	The epsilon 4 allele of the apolipoprotein E gene (APOE) has been associated with an increased risk of developing Alzheimer's disease (AD; refs 1,2). However, it is apparent that the APOE epsilon 4 allele alone is neither necessary nor sufficient to cause the disease(3-5). We have recently found three new polymorphisms within the APOE transcriptional regulatory region (M.J.A. et al., manuscript submitted) and now establish an association between one of these polymorphisms (-491A/T) and dementia as observed in Cases Alzheimer's disease, in two independent clinical populations. The results suggest that homozygosity of a common variant (-491A) is associated with increased risk for AD, and that this association is independent of APOE epsilon 4 status. In vitro studies suggest that the -491A/T polymorphism may increase risk for AD by altering the level of ApoE protein expression.	Univ Autonoma Madrid, Dept Biol Mol, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol & Genet, St Louis, MO 63110 USA; Univ Autonoma Madrid, Hosp La Paz, Serv Neurol, Madrid 28034, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Washington University (WUSTL); Washington University (WUSTL); Autonomous University of Madrid; Hospital Universitario La Paz	Valdivieso, F (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, E-28049 Madrid, Spain.	fvaldivieso@cbm.uam.es	Morris, John C/A-1686-2012; Bullido, maria j/C-8509-2014; Vazquez, Jesus/B-7697-2015; García, Ana Frank/I-5159-2015	Bullido, maria j/0000-0002-6477-1117; Vazquez, Jesus/0000-0003-1461-5092; García, Ana Frank/0000-0003-3858-9116; Aldudo, Jesus/0000-0002-7098-4709; Goate, Alison/0000-0002-0576-2472	NIA NIH HHS [AG00634, AG05681] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENNETT C, 1995, AM J MED GENET, V60, P1, DOI 10.1002/ajmg.1320600102; Berg Leonard, 1994, P9; Blesa R, 1996, ANN NEUROL, V39, P548, DOI 10.1002/ana.410390419; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Garcia MA, 1996, J NEUROSCI, V16, P7550; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIXSON JE, 1990, J LIPID RES, V31, P545; Lambert JC, 1997, HUM MOL GENET, V6, P2151, DOI 10.1093/hmg/6.12.2151; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; Muros M, 1996, ATHEROSCLEROSIS, V121, P13, DOI 10.1016/0021-9150(95)06643-8; PAYAMI H, 1993, LANCET, V342, P738; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; SANTANA MA, 1996, J NEUROL S2, V243, P591; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Taddei K, 1997, NEUROSCI LETT, V223, P29, DOI 10.1016/S0304-3940(97)13394-8; YAMADA T, 1995, J NEUROL SCI, V129, P56, DOI 10.1016/0022-510X(94)00249-N	20	260	268	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1998	18	1					69	71		10.1038/ng0198-69	http://dx.doi.org/10.1038/ng0198-69			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425904				2022-12-25	WOS:000071259600025
J	Ashcroft, GS; Dodsworth, J; vanBoxtel, E; Tarnuzzer, RW; Horan, MA; Schultz, GS; Ferguson, MWJ				Ashcroft, GS; Dodsworth, J; vanBoxtel, E; Tarnuzzer, RW; Horan, MA; Schultz, GS; Ferguson, MWJ			Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta 1 levels	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RAT BONE; CELLS; EXPRESSION; SKIN; QUANTITATION; FIBROBLASTS; CYTOKINES; HORMONE	The cellular and molecular mechanisms underlying the effects of aging on human cutaneous wound healing are poorly understood, and the possible role of reproductive hormones in this process has never been investigated. We report that aging in healthy females was associated with a reduced rate of cutaneous wound healing, but an improved quality of scarring both microscopically and macroscopically, and with reduced levels of transforming growth factor-beta 1 (TCF-beta 1) immunostaining and steady-state mRNA in the wound. These age-related changes were reversed by the systemic administration of hormone replacement therapy (HRT). Moreover, ovariectomized young female rodents exhibited a marked delay in repair of acute incisional wounds, which was reversed by the topical application of estrogen. The cellular mechanism underlying these changes appears to Involve an estrogen-induced increase in latent TCF-beta 1 secretion by dermal fibroblasts. These results suggest that both the rate and quality of wound healing depend on reproductive hormone levels.	UNIV MANCHESTER, SCH BIOL SCI, CELLS IMMUNOL & DEV DIV, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV S MANCHESTER HOSP, DEPT GERIATR MED, MANCHESTER M20 2LR, LANCS, ENGLAND; UNIV FLORIDA, DEPT OBSTET & GYNECOL, GAINESVILLE, FL 32610 USA	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; State University System of Florida; University of Florida				Tarnuzzer, Roy/0000-0002-3725-4173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashcroft GS, 1997, J INVEST DERMATOL, V108, P430, DOI 10.1111/1523-1747.ep12289705; ASHCROFT GS, 1995, J ANAT, V187, P1; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BOLOGNIA JL, 1995, AM J MED, V98, pS99, DOI 10.1016/S0002-9343(99)80066-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLETTA AA, 1991, J CLIN INVEST, V87, P277, DOI 10.1172/JCI114983; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; FrazierJessen MR, 1996, J IMMUNOL, V156, P3036; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; MALET C, 1991, J CLIN ENDOCR METAB, V73, P8, DOI 10.1210/jcem-73-1-8; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; OVERALL CM, 1995, J CELL PHYSIOL, V164, P17, DOI 10.1002/jcp.1041640104; PICCINNI MP, 1995, J IMMUNOL, V155, P128; PIERARD GE, 1995, J AM GERIATR SOC, V43, P662, DOI 10.1111/j.1532-5415.1995.tb07202.x; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; SCHMIDT JB, 1994, MATURITAS, V20, P25, DOI 10.1016/0378-5122(94)90097-3; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Tarnuzzer RW, 1996, BIOTECHNIQUES, V20, P670; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075	22	407	423	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1209	1215		10.1038/nm1197-1209	http://dx.doi.org/10.1038/nm1197-1209			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359694				2022-12-25	WOS:A1997YD89600028
J	Plenge, RM; Hendrich, BD; Schwartz, C; Arena, JF; Naumova, A; Sapienza, C; Winter, RM; Willard, HF				Plenge, RM; Hendrich, BD; Schwartz, C; Arena, JF; Naumova, A; Sapienza, C; Winter, RM; Willard, HF			A promoter mutation in the XIST gene in two unrelated families with skewed X-chromosome inactivation	NATURE GENETICS			English	Article							DISTAL SHORT ARM; MENTAL-RETARDATION; CONSERVATION; METHYLATION; EXPRESSION; DELETIONS; LINKAGE; TISSUE	X-chromosome inactivation is the process by which a cell recognizes the presence of two copies of an X chromosome early in the development of XX embryos and chooses one to be active and one to be inactive(1) Although it is commonly believed that the initiation of X inactivation is random, with an equal probability (50:50) that either X chromosome will be the inactive X in a given cell, significant variation in the proportion of cells with either X inactive is observed both in mice heterozygous for alleles at the Xce locus(2) and among normal human females in the population(3-5). Families in which multiple females demonstrate extremely skewed inactivation patterns that are otherwise quite rare in the general population are thought to reflect possible genetic influences on the X-inactivation process(5-7). Here we report a rare cytosine to guanine mutation in the XIST minimal promoter that underlies both epigenetic and functional differences between the two X chromosomes in nine females from two unrelated families. All females demonstrate preferential inactivation of the X chromosome carrying the mutation, suggesting that there is an association between alterations in the regulation of XIST expression and X-chromosome inactivation.	CASE WESTERN RESERVE UNIV,SCH MED,CTR HUMAN GENET,DEPT GENET,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; GREENWOOD GENET CTR,JC SELF RES INST,GREENWOOD,SC 29646; UNIV MIAMI,SCH MED,DEPT PEDIAT,DIV GENET,MIAMI,FL; FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA; INST CHILD HLTH,MOTHERCARE UNIT CLIN GENET & FETAL MED,LONDON WC1N 1EH,ENGLAND	Case Western Reserve University; University Hospitals of Cleveland; Greenwood Genetic Center; University of Miami; University of London; University College London			Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Naumova, Anna K./0000-0001-8481-5765				ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Arena JF, 1996, AM J MED GENET, V64, P50, DOI 10.1002/(SICI)1096-8628(19960712)64:1<50::AID-AJMG7>3.3.CO;2-4; Ballabio Andrea, 1992, Human Molecular Genetics, V1, P221, DOI 10.1093/hmg/1.4.221; Belmont JW, 1996, AM J HUM GENET, V58, P1101; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BRUSQUE L, 1994, NUCLEIC ACIDS RES, V22, P697; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; Carrel L, 1996, AM J MED GENET, V64, P27, DOI 10.1002/(SICI)1096-8628(19960712)64:1<27::AID-AJMG3>3.0.CO;2-O; CATTANACH BM, 1969, GENET RES, V14, P223, DOI 10.1017/S0016672300002068; GALE RE, 1994, BLOOD, V83, P2899, DOI 10.1182/blood.V83.10.2899.2899; GIBBONS RJ, 1992, AM J HUM GENET, V51, P1136; HEARD E, 1994, HUM MOL GENET, V3, P1481, DOI 10.1093/hmg/3.suppl_1.1481; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Hendrich BD, 1997, NUCLEIC ACIDS RES, V25, P2661, DOI 10.1093/nar/25.13.2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; NANCE WE, 1964, COLD SPRING HARB SYM, V29, P415, DOI 10.1101/SQB.1964.029.01.043; Naumova AK, 1996, AM J HUM GENET, V58, P1111; Orstavik KH, 1996, AM J MED GENET, V64, P31, DOI 10.1002/(SICI)1096-8628(19960712)64:1<31::AID-AJMG4>3.0.CO;2-U; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; Rupert JL, 1995, EUR J HUM GENET, V3, P333; TAYLOR SAM, 1991, P NATL ACAD SCI USA, V88, P39, DOI 10.1073/pnas.88.1.39; Willard H, 1995, METABOLIC MOL BASES, P719; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	33	221	228	1	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					353	356		10.1038/ng1197-353	http://dx.doi.org/10.1038/ng1197-353			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354806				2022-12-25	WOS:A1997YD66700036
J	Scarlatti, G; Tresoldi, E; Bjorndal, A; Fredriksson, R; Colognesi, C; Deng, HK; Malnati, MS; Plebani, A; Siccardi, AG; Littman, DR; Fenyo, EM; Lusso, P				Scarlatti, G; Tresoldi, E; Bjorndal, A; Fredriksson, R; Colognesi, C; Deng, HK; Malnati, MS; Plebani, A; Siccardi, AG; Littman, DR; Fenyo, EM; Lusso, P			In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; V3 DOMAIN; INFECTION; TYPE-1; CELLS; CHILDREN; ENTRY; REQUIREMENTS; MIP-1-ALPHA	Following the identification of the C-C chemokines RANTES, MIP-1 alpha and MIP-1 beta as major human immunodeficiency virus (HIV)-suppressive factors produced by CD8(+) T cells(1), several chemokine receptors were found to serve as membrane co-receptors for primate immunodeficiency lentiretroviruses(2-8). The two most widely used co-receptors thus far recognized, CCR5 and CXCR4 are expressed by both activated T lymphocytes and mononuclear phagocytes. CCR5, a specific RANTES, MIP-1 alpha and MIP-1 beta receptor, is used preferentially by non-MT2-tropic HIV-1 and HIV-2 strains(3-7,9,10) and by simian immunodeficiency virus (SIV)(11), whereas CXCR4, a receptor for the C-X-C chemokine SDF-1 (ref. 12, 13), is used by MT2-tropic HIV-1 and HIV-2, but not by SIV (ref. 2-7, 9-11, 14). Other receptors with a more restricted cellular distribution, such as CCR2b, CCR3 and STRL33, can also function as co-receptors for selected viral isolates(4,6,8). The third variable region (V3) of the gp120 envelope glycoprotein of HIV-1 has been fingered as a critical determinant of the co-receptor choice(4,15). Here, we document a consistent pattern of evolution of viral co-receptor usage and sensitivity to chemokine-mediated suppression in a longitudinal follow-up of children with progressive HIV-1 infection. Viral isolates obtained during the asymptomatic stages generally used only CCR5 as a co-receptor and were inhibited by RANTES, MIP-1 alpha and MIP-1 beta, but not by SDF-1. By contrast, the majority of the isolates derived after the progression of the disease were resistant to C-C chemokines, having acquired the ability to use CXCR4 and, in some cases, CCR3, while gradually losing CCR5 usage. Surprisingly, most of these isolates were also insensitive to SDF-1, even when used in combination with RANTES. An early acquisition of CXCR4 usage predicted a poor prognosis. In children who progressed to AIDS without a shift to CXCR4 usage, all the sequential isolates were CCR5-dependent but showed a reduced sensitivity to C-C chemokines. Discrete changes in the V3 domain of gp120 were associated with the loss of sensitivity to C-C chemokines and the shift in co-receptor usage. These results suggest an adaptive evolution of HIV-1 in vivo, leading to escape from the control of the antiviral C-C chemokines.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; SAN RAFFAELE SCI INST,DIBIT,UNIT HUMAN VIROL,I-20132 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,UNIT IMMUNOBIOL HIV,I-20132 MILAN,ITALY; NYU,SKIRBALL INST BIOMOL MED,HOWARD HUGHES MED INST,NEW YORK,NY; UNIV MILAN,CLIN PEDIAT 1,I-20128 MILAN,ITALY	Karolinska Institutet; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Howard Hughes Medical Institute; New York University; University of Milan			Malnati, Mauro/AAN-4207-2020; scarlatti, gabriella/H-1482-2018; Plebani, Alessandro/C-8593-2011	scarlatti, gabriella/0000-0003-2316-2689; Malnati, mauro/0000-0001-5355-1680				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; ASJO B, 1986, LANCET, V2, P660; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; Heredia A, 1997, AIDS, V11, P1198, DOI 10.1097/00002030-199709000-00025; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Martin N, 1996, AIDS RES HUM RETROV, V12, P1565, DOI 10.1089/aid.1996.12.1565; MORIUCHI M, 1996, P NATL ACAD SCI USA, V93, P15341; MYERS G, 1995, HUMAN RETROVIRUSES A; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	34	530	549	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1259	1265		10.1038/nm1197-1259	http://dx.doi.org/10.1038/nm1197-1259			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359702				2022-12-25	WOS:A1997YD89600036
J	Vos, JMH				Vos, JMH			The simplicity of complex MACs	NATURE BIOTECHNOLOGY			English	Review						episome; gene therapy; centromere; viral vector; transgenesis	HUMAN-CELLS; CHROMOSOMES; MINICHROMOSOMES; MAINTENANCE; DNA	The development of mammalian artificial chromosomes (MACs) would be useful for biotechnology and biomedicine, including their use in functional genomics, transgenic animals and gene therapy. By analogy to large cloning systems in microorganisms, MACs may be engineered using endogenous chromosomal elements such as the yeast-based artificial chromosomes (YACs), or exogenous extra-chromosomal components derived from viruses and other cellular parasites such as the bacterial-based artificial chromosomes (BACs) and pi artificial chromosomes (PACs).	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Vos, JMH (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.							BANERJEE S, 1995, NAT MED, V1, P1303, DOI 10.1038/nm1295-1303; BROWN W, 1995, TRENDS GENET, V11, P337, DOI 10.1016/S0168-9525(00)89100-3; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; DUSART D, 1997, IN PRESS NATURE GEN; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; FEATHERSTONE T, 1993, GENOMICS, V17, P267, DOI 10.1006/geno.1993.1321; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; Kipling D, 1997, TRENDS GENET, V13, P141, DOI 10.1016/S0168-9525(97)01098-6; KOSZTOLANYI G, 1991, HUM GENET, V87, P320; NONET GH, 1993, SOMAT CELL MOLEC GEN, V19, P171, DOI 10.1007/BF01233532; Simpson K, 1996, MOL CELL BIOL, V16, P5117; Sun TQ, 1996, GENE THER, V3, P1081; SUN TQ, 1994, NAT GENET, V8, P33, DOI 10.1038/ng0994-33; TOMIZUKA, 1997, NATURE GENET, V16, P133; WANG F, 1995, HUM GENE THER, V6, P1005, DOI 10.1089/hum.1995.6.8-1005	16	20	22	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1257	1259		10.1038/nbt1197-1257	http://dx.doi.org/10.1038/nbt1197-1257			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359107				2022-12-25	WOS:000071342000026
J	Duncan, G; Wormstone, IM; Liu, CSC; Marcantonio, JM; Davies, PD				Duncan, G; Wormstone, IM; Liu, CSC; Marcantonio, JM; Davies, PD			Thapsigargin-coated intraocular lenses inhibit human lens cell growth	NATURE MEDICINE			English	Article							POSTERIOR CAPSULE OPACIFICATION; SURVIVAL	Cataract is responsible for rendering several million people blind throughout the world(1) and is also by far the most common cause of row visual acuity. Although cataract surgery is common, routine and effective, posterior capsule opacification (PCO) occurs in 30-50% of patients following modern cataract surgery. This condition arises from stimulated cell growth within the capsular bag after surgery(2). The resulting decline in visual acuity requires expensive laser treatment(2), and PCO therefore prevents modern cataract surgery from being carried out routinely in underdeveloped countries. The present study, using a human lens capsular bag culture system(3), has confirmed that cells from a wide age range of donors proliferate in the absence of added serum protein(4) and explains why PCO is such a common problem even in aged patients. This study also provides one possible solution for PCO by using polymethylmethacrylate (PMMA) implanted intraocular lenses as a drug delivery system. PMMA lenses coated with thapsigargin, a hydrophobic inhibitor of endoplasmic reticulum (ER) (Ca2+)-ATPase(5), greatly reduced cell growth in the capsular bag at relatively low coating concentrations (200 nM) but, more significantly, induced total cell death of the residual anterior epithelial cells at higher concentrations (> 2 mu M).	W NORWICH HOSP,NORWICH NR2 3TU,NORFOLK,ENGLAND		Duncan, G (corresponding author), UNIV E ANGLIA,SCH BIOL SCI,NORWICH NR4 7TJ,NORFOLK,ENGLAND.		Wormstone, Michael/D-1861-2009	Wormstone, Michael/0000-0002-6423-7766				APPLE DJ, 1992, SURV OPHTHALMOL, V37, P73, DOI 10.1016/0039-6257(92)90073-3; BEHARCOHEN FF, 1995, INVEST OPHTH VIS SCI, V36, P2434; COLE DF, 1974, EYE, P71; Duncan G, 1996, CELL CALCIUM, V19, P83, DOI 10.1016/S0143-4160(96)90015-9; Emery J., 1996, Investigative Ophthalmology and Visual Science, V37, pS758; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; IBARAKI N, 1995, AM J OPHTHALMOL, V119, P706, DOI 10.1016/S0002-9394(14)72774-6; ISHIZAKI Y, 1993, J CELL BIOL, V121, P899, DOI 10.1083/jcb.121.4.899; Liu CSC, 1996, INVEST OPHTH VIS SCI, V37, P906; POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2544; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; Wormstone IM, 1997, INVEST OPHTH VIS SCI, V38, P396	14	101	107	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1026	1028		10.1038/nm0997-1026	http://dx.doi.org/10.1038/nm0997-1026			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288732				2022-12-25	WOS:A1997XT84200038
J	Bains, W				Bains, W			Reconstructing the biochemical edifice	NATURE BIOTECHNOLOGY			English	Editorial Material											Bains, W (corresponding author), PA CONSULTING GRP,ROYSTON SG8 6DP,HERTS,ENGLAND.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					928	929		10.1038/nbt0896-928b	http://dx.doi.org/10.1038/nbt0896-928b			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631025				2022-12-25	WOS:A1996UZ19900005
J	Prunkard, D; Cottingham, I; Garner, I; Bruce, S; Dalrymple, M; Lasser, G; Bishop, P; Foster, D				Prunkard, D; Cottingham, I; Garner, I; Bruce, S; Dalrymple, M; Lasser, G; Bishop, P; Foster, D			High-level expression of recombinant human fibrinogen in the milk of transgenic mice	NATURE BIOTECHNOLOGY			English	Article						fibrinogen; transgenic animal; tissue sealant; mammary gland	ACTIVE HUMAN ALPHA-1-ANTITRYPSIN; GENE-EXPRESSION; MAMMARY-GLAND; SHEEP; SECRETION	Fibrinogen is a complex plasma protein composed of two each of three different polypeptide chains. We have targeted expression of r-human fibrinogen to the mammary gland of transgenic mice. Three expression cassettes, each containing the genomic sequence for one of the three human fibrinogen chains controlled by sheep whey protein beta-lactoglobulin promoter sequences, were coinjected into fertile mouse eggs. Southern blot analysis demonstrated that more than 80% of the transgenic founders contained all three fibrinogen genes. Reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis of milk from the highest producing founder animal demonstrated the presence of human fibrinogen subunits at concentrations of 2000 mu g/ml. In several animals with a balanced ratio of the individual fibrinogen subunits, up to 100% of the protein was incorporated into fully assembled fibrinogen hexamers. Incubation of the transgenic milk with thrombin and factor XIII resulted in a cross-linked fibrin clot, indicating that a major portion of the secreted fibrinogen was functional. These studies represent the first report of high-level biosynthesis and secretion of a functional, complex, hexameric protein in the milk of a transgenic animal.	PPL THERAPEUT, EDINBURGH EH25 9PP, MIDLOTHIAN, SCOTLAND		Prunkard, D (corresponding author), ZYNOGENET INC, 1201 EASTLAKE AVE E, SEATTLE, WA 98102 USA.							ARCHIBALD AL, 1990, P NATL ACAD SCI USA, V87, P5178, DOI 10.1073/pnas.87.13.5178; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; CARVER AS, 1993, BIO-TECHNOL, V11, P1263; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; GORDON K, 1987, BIO-TECHNOL, V5, P1183, DOI 10.1038/nbt1187-1183; HARRIS S, 1990, J REPROD FERTIL, V88, P707; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HUANG SM, 1993, J BIOL CHEM, V268, P8919; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; ROY SN, 1991, J BIOL CHEM, V266, P4758; Sambrook J, 1989, MOL CLONING LABORATO; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; VELANDER WH, 1992, ANN NY ACAD SCI, V665, P391, DOI 10.1111/j.1749-6632.1992.tb42602.x; Whitelaw C B, 1991, Transgenic Res, V1, P3, DOI 10.1007/BF02512991; WILMUT I, 1991, EXPERIENTIA, V47, P905, DOI 10.1007/BF01929881; WRIGHT G, 1991, BIO-TECHNOL, V9, P830, DOI 10.1038/nbt0991-830	19	40	50	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					867	871		10.1038/nbt0796-867	http://dx.doi.org/10.1038/nbt0796-867			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631012				2022-12-25	WOS:A1996UV62000037
J	McElroy, D				McElroy, D			The industrialization of plant transformation	NATURE BIOTECHNOLOGY			English	Article									UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley									0	9	9	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					715	716		10.1038/nbt0696-715	http://dx.doi.org/10.1038/nbt0696-715			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630976				2022-12-25	WOS:A1996UM76600024
J	Perl, A; Lotan, O; AbuAbied, M; Holland, D				Perl, A; Lotan, O; AbuAbied, M; Holland, D			Establishment of an Agrobacterium-mediated transformation system for grape (Vitis vinifera L): The role of antioxidants during grape-Agrobacterium interactions	NATURE BIOTECHNOLOGY			English	Article						Vitis vinifera; transformation; Agrobacterium; necrogenesis; antioxidants	PLANT TRANSFORMATION; SELECTABLE MARKERS; TRANSGENIC PLANTS; HOST RANGE; TUMEFACIENS; GENE	Very short exposures of embryogenic calli of Vitis vinifera cv. Superior Seedless grape plants to diluted cultures of Agrobacterium resulted in plant tissue necrosis and subsequent cell death. Antibiotics used for Agrobacterium elimination or as plant selectable markers were not responsible for this necrotic response. Rather, cell death seemed to be oxygen-dependent and correlated with elevated levels of peroxides. Therefore, we studied the effects on necrosis of various combinations of antioxidants during and after grape-Agrobacterium cocultivation. The combination of polyvinylpolypyrrolidone and dithiothreitol was found to improve plant viability. Tissue necrosis was completely inhibited by these antioxidants while Agrobacterium virulence was not effected. These treatments enabled the recovery of stable transgenic grape plants resistant to hygromycin.			Perl, A (corresponding author), AGR RES ORG,VOLCANI CTR,DEPT FRUIT TREE BREEDING & MOL GENET,POB 6,IL-50250 BET DAGAN,ISRAEL.							BARBAULT TJ, 1990, J EXP BOT, V41, P1045; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BERRES R, 1992, PLANT CELL REP, V11, P192, DOI 10.1007/BF00232531; COLBY SM, 1991, J AM SOC HORTIC SCI, V116, P356, DOI 10.21273/JASHS.116.2.356; FHANCE B, 1955, METHOD ENZYMOL, V2, P764; GRAY DJ, 1992, BIOTECHNOLOGY AGR, V8, P229; GUELLEC V, 1990, PLANT CELL TISS ORG, V20, P211; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; KIKKERT JR, 1995, IN PRESS PLANT CELL; KLEMENT Z, 1967, ANNU REV PHYTOPATHOL, V5, P17, DOI 10.1146/annurev.py.05.090167.000313; LAGRIMINI LM, 1992, PLANT PHYSIOL, V96, P26; LE GALL O, 1994, PLANT SCI, V102, P161, DOI 10.1016/0168-9452(94)90034-5; Lloyd GB, 1980, COMB P INT PLANT PRO, V30, P421; MARTINELLI L, 1994, THEOR APPL GENET, V88, P621, DOI 10.1007/BF01253963; Mathews H., 1993, Acta Horticulturae, P93; MATHEWS H, 1992, IN VITRO CELL DEV-PL, V28P, P172; MAYER AM, 1979, PHYTOCHEMISTRY, V18, P193, DOI 10.1016/0031-9422(79)80057-6; MULLINS MG, 1990, BIO-TECHNOL, V8, P1041, DOI 10.1038/nbt1190-1041; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PERL A, 1993, BIO-TECHNOL, V11, P715, DOI 10.1038/nbt0693-715; PERL A, 1995, PLANT SCI, V104, P193, DOI 10.1016/0168-9452(94)04013-7; Preece J.E., 1991, BIOTECHNOLOGY AGR FO, VI, P168, DOI 10.1007/978-3-642-76415-8_10; PU XA, 1992, PHYSIOL MOL PLANT P, V41, P241, DOI 10.1016/0885-5765(92)90024-P; REAM W, 1989, ANNU REV PHYTOPATHOL, V27, P583, DOI 10.1146/annurev.py.27.090189.003055; ROBERTSON T, 1983, ORGANIC CONSISTUENT; STAMP JA, 1988, SCI HORTIC-AMSTERDAM, V35, P235, DOI 10.1016/0304-4238(88)90117-3; STAMP JA, 1988, J AM SOC HORTIC SCI, V113, P941; STEENKAMP J, 1994, AM J ENOL VITICULT, V45, P102; THOMASHOW MF, 1980, NATURE, V283, P794, DOI 10.1038/283794a0; VANCANNEYT G, 1990, MOL GEN GENET, V220, P245, DOI 10.1007/BF00260489; VAUGHN KC, 1984, PHYSIOL PLANTARUM, V60, P106, DOI 10.1111/j.1399-3054.1984.tb04258.x; WALTER B, 1994, 74 GEN ASS INT VIN O, P1; YANOFSKY M, 1985, MOL GEN GENET, V201, P237, DOI 10.1007/BF00425665	33	149	171	1	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					624	628		10.1038/nbt0596-624	http://dx.doi.org/10.1038/nbt0596-624			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630955				2022-12-25	WOS:A1996UL60400029
J	Timpl, P; Spanagel, R; Sillaber, I; Kresse, A; Reul, JMHM; Stalla, GK; Blanquet, V; Steckler, T; Holsboer, F; Wurst, W				Timpl, P; Spanagel, R; Sillaber, I; Kresse, A; Reul, JMHM; Stalla, GK; Blanquet, V; Steckler, T; Holsboer, F; Wurst, W			Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1	NATURE GENETICS			English	Article							ETHANOL WITHDRAWAL; CENTRAL NUCLEUS; ADRENAL-CORTEX; AMYGDALA; ALCOHOL; CELLS; RAT; PHARMACOLOGY; EXPRESSION; PHYSIOLOGY	Corticotropin-releasing hormone (CRH) is a potent mediator of endocrine, autonomic, behavioural and immune responses to stress, and has been implicated in the stress-like and other aversive consequences of drug abuse, such as withdrawal from alcohol(1,2). Two CRH receptors, Crhr1 and Crhr2, have been identified in the mouse(3,4). Crhr1 is highly expressed in the anterior pituitary, neocortex, hippocampus, amygdala and cerebellum, and activation of this receptor stimulates adenylate cyclase(5,6). Here we show that in mice lacking Crhr1, the medulla of the adrenal gland is atrophied and stress-induced release of adrenocorticotropic hormone (ACTH) and corticosterone is reduced. The homozygous mutants exhibit increased exploratory activity and reduced anxiety-related behaviour under both basal conditions and following alcohol withdrawal. Our results demonstrate a key role of the Crhr1 receptor in mediating the stress response and anxiety-related behaviour.	Max Planck Inst Psychiat, D-80804 Munich, Germany; GSF Munich, Res Ctr, Inst Mammalian Genet, D-85764 Munich, Germany	Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Wurst, W (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany.	Wurst@mpipsykl.mpg.de	Steckler, Thomas/AAF-3975-2020; Reul, Johannes/B-4132-2019	Reul, Johannes/0000-0002-8787-4012; Wurst, Wolfgang/0000-0003-4422-7410				Aguilera G, 1988, Adv Exp Med Biol, V245, P83; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P657, DOI 10.1210/endo-113-2-657; BORNSTEIN SR, 1990, ENDOCRINOLOGY, V127, P900, DOI 10.1210/endo-127-2-900; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CONTI LH, 1994, PHARMACOL BIOCHEM BE, V48, P497, DOI 10.1016/0091-3057(94)90559-2; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; DeSouza EB, 1995, PSYCHONEUROENDOCRINO, V20, P789, DOI 10.1016/0306-4530(95)00011-9; EDWARDS AV, 1987, J PHYSIOL-LONDON, V390, P23, DOI 10.1113/jphysiol.1987.sp016683; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; HOLSBOER F, 1992, PROG BRAIN RES, V93, P385; Karanth S, 1997, ENDOCRINOLOGY, V138, P3476, DOI 10.1210/en.138.8.3476; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KRESSE A, 1995, BRAIN RES BULL, V36, P261, DOI 10.1016/0361-9230(94)00201-B; LIEBSCH G, 1995, REGUL PEPTIDES, V59, P229, DOI 10.1016/0167-0115(95)00099-W; MENZAGHI F, 1994, ANN NY ACAD SCI, V739, P176, DOI 10.1111/j.1749-6632.1994.tb19819.x; Moreau JL, 1997, NEUROREPORT, V8, P1697, DOI 10.1097/00001756-199705060-00027; OWENS MJ, 1991, PHARMACOL REV, V43, P425; PICH EM, 1995, J NEUROSCI, V15, P5439; RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S; Spanagel R, 1996, EUR J PHARMACOL, V305, P45, DOI 10.1016/0014-2999(96)00175-6; STALLA GK, 1988, ENDOCRINOLOGY, V122, P618; STENZELPOORE MP, 1994, J NEUROSCI, V14, P2579; SWANSON LW, 1989, J COMP NEUROL, V285, P413, DOI 10.1002/cne.902850402; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Wurst W., 1993, Gene targeting: a practical approach., P33	30	749	765	0	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					162	166		10.1038/520	http://dx.doi.org/10.1038/520			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620773				2022-12-25	WOS:000073865100024
J	Dunger, DB; Ong, KKL; Huxtable, SJ; Sherriff, A; Woods, KA; Ahmed, ML; Golding, J; Pembrey, ME; Ring, S; Bennett, ST; Todd, JA				Dunger, DB; Ong, KKL; Huxtable, SJ; Sherriff, A; Woods, KA; Ahmed, ML; Golding, J; Pembrey, ME; Ring, S; Bennett, ST; Todd, JA		ALSPAC Study Team	Association of the INS VNTR with size at birth	NATURE GENETICS			English	Article							POSTNATAL-GROWTH; INSULIN; FETAL; IDDM2; LOCUS	Size at birth is an important determinant of perinatal survival(1) and has also been associated with the risk for cardiovascular disease and type 2 diabetes in adult life(2). Common genetic variation that regulates fetal growth could therefore influence perinatal survival and predispose to the development of adult disease. We have tested the insulin gene (INS) variable number of tandem repeats (VNTR) locus, which in Caucasians has two main allele sizes (class I and class III; ref. 3), as a functional candidate polymorphism for association with size at birth, as it has been shown to influence transcription of INS (refs 3-5). In a cohort of 758 term singletons (Avon Longitudinal Study of Pregnancy and Childhood; ALSPAC(6)) followed longitudinally from birth to 2 years, we detected significant genetic associations with size at birth: class III homozygotes had larger mean head circumference (P=0.004) than class I homozygotes. These associations were amplified in babies who did not show postnatal realignment of growth (45%), and were also evident for length (P=0.015) and weight (P=0.009) at birth. The INS VNTR III/III genotype might have bestowed a perinatal survival during human history(7) by conferring larger size at birth. Common genetic variation of this kind may contribute to reported associations between birth size and adult disease.	Univ Oxford, Nuffield Dept Surg, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Bristol, Unit Paediat & Perinatal Epidemiol, Bristol BS8 1TQ, Avon, England; Inst Child Hlth, Mothercare Unit Clin Genet & Fetal Med, London WC1N 1EH, England; Southmead Gen Hosp, Lewis Labs, Mol Genet Unit, Bristol BS10 5NB, Avon, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Bristol; University of London; University College London; Southmead Hospital	Todd, JA (corresponding author), Univ Oxford, Nuffield Dept Surg, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.	david.dunger@paediatrics.ox.ac.uk; john.todd@well.ox.ac.uk	Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148; Dunger, Professor David/0000-0002-2566-9304; sherriff, andrea/0000-0002-1016-037X; Golding, Jean/0000-0003-2826-3307	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERMAN E, 1991, J ROY SOC MED, V84, P257, DOI 10.1177/014107689108400505; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Duvillie B, 1997, P NATL ACAD SCI USA, V94, P5137, DOI 10.1073/pnas.94.10.5137; FOWDEN AL, 1989, J DEV PHYSIOL, V12, P173; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; GEORGIEFF MK, 1986, CLIN PERINATOL, V13, P73, DOI 10.1016/S0095-5108(18)30839-X; GOLDING J, 1996, CONT REV OBSTET GYNA, V8, P89; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HILL DJ, 1989, BAILLIERE CLIN ENDOC, V3, P579, DOI 10.1016/S0950-351X(89)80059-X; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; NEEL JV, 1962, AM J HUM GENET, V14, P353; OUNSTED M, 1975, LANCET, V1, P1393, DOI 10.1016/S0140-6736(75)92605-7; SMITH DW, 1976, J PEDIATR-US, V89, P225, DOI 10.1016/S0022-3476(76)80453-2; TANNER J, 1994, WILKINS DIAGNOSIS TR; Tanner J. M., 1994, Acta Medica Auxologica (Milan), V26, P7; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; WERTHEIMER E, 1993, NAT GENET, V5, P71, DOI 10.1038/ng0993-71; Williams LA, 1997, BRIT MED J, V314, P1864, DOI 10.1136/bmj.314.7098.1864; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	22	233	236	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					98	100		10.1038/ng0598-98	http://dx.doi.org/10.1038/ng0598-98			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590300				2022-12-25	WOS:000073346700028
J	Smith, L; Liu, SJ; Goodrich, L; Jacobson, D; Degnin, C; Bentley, N; Carr, A; Flaggs, G; Keegan, K; Hoekstra, M; Thayer, MJ				Smith, L; Liu, SJ; Goodrich, L; Jacobson, D; Degnin, C; Bentley, N; Carr, A; Flaggs, G; Keegan, K; Hoekstra, M; Thayer, MJ			Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest	NATURE GENETICS			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMAS; ALVEOLAR RHABDOMYOSARCOMA; P53; EXPRESSION; PROTEIN; LOOP; GENE; DIFFERENTIATION; TRANSCRIPTION	Chromosome Sq alterations occur frequently in many types of tumours. In a genetic screen for loci present in rhabdomyosarcomas, we identified an isochromosome 3q [i(3q)], which inhibits muscle differentiation when transferred into myoblasts. The i(3q) inhibits MyoD function, resulting in a non-differentiating phenotype. Furthermore, the i(3q) induces a 'cut' phenotype, abnormal centrosome amplification, aneuploidy and loss of G1 arrest following gamma-irradiation, Testing candidate genes within this region reveals that forced expression of ataxia-telangiectasia and rad3-related (ATR) results in a phenocopy of the i(3q). Thus, genetic alteration of ATR leads to loss of differentiation as well as cell-cycle abnormalities.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med & Mol Genet, Portland, OR 97201 USA; Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; ICOS Corp, Bothell, WA 98021 USA	Oregon Health & Science University; Oregon Health & Science University; University of Sussex; Icos Corporation	Thayer, MJ (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	thayerm@ohsu.edu		Carr, Antony Michael/0000-0002-2028-2389; Smith, Leslie/0000-0001-6452-6624				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CAREY TE, 1993, J CELL BIOCHEM, P213; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; DAVIS RJ, 1994, CANCER RES, V54, P2869; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIAS P, 1990, AM J PATHOL, V137, P1283; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Favaloro J, 1980, Methods Enzymol, V65, P718; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; JIN YS, 1993, CANCER RES, V53, P2140; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MITCHELL CD, 1991, ONCOGENE, V6, P89; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RAO PH, 1994, CANCER GENET CYTOGEN, V77, P60, DOI 10.1016/0165-4608(94)90150-3; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RIED T, 1994, CANCER RES, V54, P1801; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SCRABLE HJ, 1990, P NATL ACAD SCI USA, V87, P2182, DOI 10.1073/pnas.87.6.2182; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPEICHER MR, 1995, CANCER RES, V55, P1010; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Trask B, 1990, FLOW CYTOMETRY; WeberHall SR, 1996, CANCER RES, V56, P3220; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yunis J J, 1978, Prog Clin Pathol, V7, P267	51	75	78	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					39	46		10.1038/ng0598-39	http://dx.doi.org/10.1038/ng0598-39			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590286				2022-12-25	WOS:000073346700014
J	Relaix, F; Wei, XJ; Wu, XW; Sassoon, DA				Relaix, F; Wei, XJ; Wu, XW; Sassoon, DA			Peg3/Pw1 is an imprinted gene involved in the TNF-NF kappa B signal transduction pathway	NATURE GENETICS			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; RING FINGER PROTEIN; CYTOPLASMIC DOMAIN; DEATH-DOMAIN; CELL-DEATH; ACTIVATION; APOPTOSIS; CD40; CHROMOSOME-7	Tumor necrosis factor (TNF) mediates a variety of biological activities including cell proliferation, differentiation and programmed cell death. The specific response to TNF depends upon cell type and reflects the presence of specific regulatory proteins that participate in the TNF response pathway. TNF signal transduction is mediated by TRAF2 which binds the TNF Receptor2 (TNFR2) and activates NF kappa B. We previously identified a gene Pw1, which encodes a large zinc-finger containing protein(1). We have determined that Pw1 is identical to Peg3, a paternally expressed gene of unknown function(2) (and will therefore be referred to as Peg3 throughout this text). We report here that Peg3 associates specifically with TRAF2 but not with other TRAF family members. Peg3 expression activates NF kappa B via I kappa B-NF kappa B dissociation and acts synergistically with TRAF2. Transfection of a truncated Peg3 containing the TRAF2 interaction site, abolishes NF kappa B activation by TRAF2 and/or TNF. We conclude that Peg3 is a regulator of the TNF response. These data reveal the involvement of an imprinted gene in this pathway.	Mt Sinai Med Ctr, Brookdale Ctr Mol & Dev Biol, New York, NY 10029 USA; Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Sassoon, DA (corresponding author), Mt Sinai Med Ctr, Brookdale Ctr Mol & Dev Biol, 1 Gustave Levy Pl, New York, NY 10029 USA.	dsassoo@smtplink.mssm.edu	SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X; Relaix, Frederic/0000-0003-1270-1472	PHS HHS [C873678/01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN SDM, 1993, GENOMICS, V18, P459, DOI 10.1006/geno.1993.1502; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; HERMEKING H, 1994, SCIENCE, V165, P1091; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Hurst LD, 1996, NAT GENET, V12, P234, DOI 10.1038/ng0396-234; JANSEN G, 1993, HUM MOL GENET, V2, P1221, DOI 10.1093/hmg/2.8.1221; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUBIO MP, 1994, CANCER RES, V54, P4760; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; YONG WH, 1995, J NEUROPATH EXP NEUR, V54, P622, DOI 10.1097/00005072-199509000-00002	36	128	134	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					287	291		10.1038/ng0398-287	http://dx.doi.org/10.1038/ng0398-287			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500555				2022-12-25	WOS:000072325000031
J	Robb, L; Li, RL; Hartley, L; Nandurkar, HH; Koentgen, F; Begley, CG				Robb, L; Li, RL; Hartley, L; Nandurkar, HH; Koentgen, F; Begley, CG			Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation	NATURE MEDICINE			English	Article							LEUKEMIA INHIBITORY FACTOR; BLASTOCYST IMPLANTATION; ALPHA-CHAIN; EXPRESSION; METALLOPROTEINASES; REQUIREMENT; PREGNANCY; CLONING; INVITRO; EMBRYO	During early pregnancy, ir! response to the implanting embryo, the surrounding uterine stroma undergoes a dramatic transformation into a specialized tissue known as the decidua. The decidua encapsulates the developing embryo, facilitating nutrient transfer and limiting trophoblast invasion. Here we show that female mice with a null mutation of the interleukin-11 receptor alpha chain are infertile because of defective decidualization. A temporal analysis revealed IL-11 expression is maximal in the normal pregnant uterus at the time of decidualization, and in situ hybridization studies showed expression of the IL-11 and the IL-ll receptor alpha chain in the developing decidual cells. These observations reveal a previously unrecognized critical role for IL-ll signaling in female reproduction.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Bone Marrow Res Labs, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital	Robb, L (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	robb@wehi.edu.au	Nandurkar, Harshal/AAO-7443-2020	Nandurkar, Harshal/0000-0002-8767-116X				Afonso S, 1997, DEVELOPMENT, V124, P3415; Alexander CM, 1996, DEVELOPMENT, V122, P1723; APLIN JD, 1994, REPROD BIOL, P327; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; Bilinski P, 1996, BIOCHEM J, V320, P359, DOI 10.1042/bj3200359; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; Chard T, 1995, HUM REPROD UPDATE, V1, P385, DOI 10.1093/humupd/1.4.385; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DEFEO VJ, 1967, CELLULAR BIOL UTERUS, P191; DEY SK, 1996, REPROD ENDOCRINOLOGY, P422; Du XX, 1996, J CELL PHYSIOL, V168, P362; DU XX, 1994, BLOOD, V83, P2023; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; KIRBY DRS, 1968, EPITHELIAL MESENCHYM, P64; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Nandurkar HH, 1996, ONCOGENE, V12, P585; Nandurkar HH, 1997, BLOOD, V90, P2148; Noble LS, 1996, J CLIN ENDOCR METAB, V81, P174, DOI 10.1210/jc.81.1.174; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; PSYCHOYOS A, 1973, HDB PHYSL, P187; Robb L, 1997, GENOMICS, V40, P387, DOI 10.1006/geno.1996.4579; Robb L, 1996, J BIOL CHEM, V271, P13754, DOI 10.1074/jbc.271.23.13754; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STEWART CL, 1994, MOL REPROD DEV, V39, P233, DOI 10.1002/mrd.1080390217; TOMIDA M, 1994, J BIOCHEM-TOKYO, V115, P557, DOI 10.1093/oxfordjournals.jbchem.a124375; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	30	359	372	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					303	308		10.1038/nm0398-303	http://dx.doi.org/10.1038/nm0398-303			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500603				2022-12-25	WOS:000073616200035
J	Martindale, D; Hackam, A; Wieczorek, A; Ellerby, L; Wellington, C; McCutcheon, K; Singaraja, R; Kazemi-Esfarjani, P; Devon, R; Kim, SU; Bredesen, DE; Tufaro, F; Hayden, MR				Martindale, D; Hackam, A; Wieczorek, A; Ellerby, L; Wellington, C; McCutcheon, K; Singaraja, R; Kazemi-Esfarjani, P; Devon, R; Kim, SU; Bredesen, DE; Tufaro, F; Hayden, MR			Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates	NATURE GENETICS			English	Article							SIMPLEX VIRUS TYPE-1; COLORIMETRIC ASSAY; TRANSGENIC MICE; CAG REPEAT; PROTEIN; PHENOTYPE; CELLS	It is unclear how polyglutamine expansion is associated with the pathogenesis of Huntington disease (HD). Here. we provide evidence that polyglutamine expansion leads to the formation of large intracellular aggregates in vitro and in vivo. In vitro these huntingtin-containing aggregates disrupt normal cellular architecture and increase in frequency with polyglutamine length. Huntingtin truncated at nucleotide 1955, close to the caspase-3 cleavage site, forms perinuclear aggregates more readily than full-length huntingtin and increases the susceptibility of cells to death following apoptotic stimuli. Further truncation of huntingtin to nucleotide 436 results in both intranuclear and perinuclear aggregates. For a given protein size, increasing polyglutamine length is associated with increased cellular toxicity. Asymptomatic transgenic mice expressing full-length huntingtin with 138 polyglutamines form exclusively perinuclear aggregates in neurons. These data support the hypothesis that proteolytic cleavage of mutant huntingtin leads to the development of aggregates which compromise cell viability, and that their localization is influenced by protein length.	Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z4, Canada; NeuroVir Inc, Vancouver, BC V6T 1Z3, Canada; Burnham Inst, Program Aging, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; Univ Saskatchewan, Coll Dent, Saskatoon, SK S7N 5E4, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of Saskatchewan	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V6T 1Z4, Canada.	mrh@ulam.generes.ca	Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Singaraja, Roshni/0000-0002-3418-3867	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NIA NIH HHS [AG12282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CARMICHAEL J, 1987, CANCER RES, V47, P936; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; CUNNINGHAM C, 1993, VIROLOGY, V197, P116, DOI 10.1006/viro.1993.1572; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DIFIGLIA M, 1997, SCIENCE, V277, P199; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; SAPP E, 1997, ANN NEUROL, V23, P2247; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; TELLEZNAGEL I, 1974, J NEUROPATH EXP NEUR, V33, P308, DOI 10.1097/00005072-197404000-00008; TELLEZNAGEL I, 1973, ADV NEUROL, V1, P387; VISTICA DT, 1991, CANCER RES, V51, P2515; Wellington CL, 1997, CURR OPIN NEUROL, V10, P291, DOI 10.1097/00019052-199708000-00003	27	393	406	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					150	154		10.1038/ng0298-150	http://dx.doi.org/10.1038/ng0298-150			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462744				2022-12-25	WOS:000071779500023
J	Schiedner, G; Morral, N; Parks, RJ; Wu, Y; Koopmans, SC; Langston, C; Graham, FL; Beaudet, AL; Kochanek, S				Schiedner, G; Morral, N; Parks, RJ; Wu, Y; Koopmans, SC; Langston, C; Graham, FL; Beaudet, AL; Kochanek, S			Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity	NATURE GENETICS			English	Article							HUMAN ALPHA-1-ANTITRYPSIN GENE; FULL-LENGTH DYSTROPHIN; CRE-MEDIATED EXCISION; HUMAN HPRT LOCUS; IN-VIVO; HELPER VIRUS; VIRAL GENES; MOUSE MODEL; THERAPY; MICE	Many applications for human gene therapy would be facilitated by high levels and long duration of physiologic gene expression, Adenoviral vectors are frequently used for gene transfer because of their high cellular transduction efficiency in vitro and in vivo. Expression of viral proteins and the low capacity for foreign DNA limits the clinical application of first-and second-generation adenoviral vectors(1-7). Adenoviral vectors with all viral coding sequences deleted(8-15) offer the prospect of decreased host immune responses to viral proteins, decreased cellular toxicity of viral proteins and increased capacity to accommodate large regulatory DNA regions. Currently most vectors used in vivo for preclinical and clinical studies express cDNAs under the control of heterologous eukaryotic or viral promoters. Using an adenoviral vector with all viral coding sequences deleted and containing the complete human alpha(1)-antitrypsin (PI) locus, we observed tissue-specific transcriptional regulation in cell culture and in vivo; intravenous injection in mice resulted in high levels of very stable expression for more than ten months and decreased acute and chronic toxicity. These results indicate significant advantages of regulated gene expression using genomic DNA for gene transfer and of adenoviral gene transfer vectors devoid of all viral coding sequences.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Howard Hughes Med Inst, Houston, TX 77030 USA; McMaster Univ, Dept Biol & Pathol, Hamilton, ON L8S 4K1, Canada; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; McMaster University; Baylor College of Medicine	Kochanek, S (corresponding author), Univ Cologne, Ctr Mol Med, Kerpenerstr 34, D-50931 Cologne, Germany.		Morral, Nuria/AAC-7149-2020	Morral, Nuria/0000-0002-8932-2887	NHLBI NIH HHS [HL51754] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051754] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMENTANO D, 1995, HUM GENE THER, V6, P1343, DOI 10.1089/hum.1995.6.10-1343; Chen HH, 1997, P NATL ACAD SCI USA, V94, P1645, DOI 10.1073/pnas.94.5.1645; Clemens PR, 1996, GENE THER, V3, P965; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; Fisher KJ, 1996, VIROLOGY, V217, P11, DOI 10.1006/viro.1996.0088; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Guo ZS, 1996, GENE THER, V3, P802; HAFEEZ W, 1992, J CLIN INVEST, V89, P1214, DOI 10.1172/JCI115705; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; KAY MA, 1995, HEPATOLOGY, V21, P815, DOI 10.1002/hep.1840210331; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; Krougliak V, 1995, HUM GENE THER, V6, P1575, DOI 10.1089/hum.1995.6.12-1575; KumarSingh R, 1996, HUM MOL GENET, V5, P913, DOI 10.1093/hmg/5.7.913; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; MITANI K, 1995, P NATL ACAD SCI USA, V92, P3854, DOI 10.1073/pnas.92.9.3854; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morral N, 1997, HUM GENE THER, V8, P1275, DOI 10.1089/hum.1997.8.10-1275; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Parks RJ, 1997, J VIROL, V71, P3293, DOI 10.1128/JVI.71.4.3293-3298.1997; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; SYKES RC, 1988, MOL GEN GENET, V212, P301, DOI 10.1007/BF00334700; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Wang Q, 1995, GENE THER, V2, P775; Yang YP, 1996, HUM MOL GENET, V5, P1703, DOI 10.1093/hmg/5.11.1703; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Zhou HS, 1996, J VIROL, V70, P7030, DOI 10.1128/JVI.70.10.7030-7038.1996	30	512	546	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					180	183		10.1038/ng0298-180	http://dx.doi.org/10.1038/ng0298-180			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462752				2022-12-25	WOS:000071779500031
J	Charlier, C; Singh, NA; Ryan, SG; Lewis, TB; Reus, BE; Leach, RJ; Leppert, M				Charlier, C; Singh, NA; Ryan, SG; Lewis, TB; Reus, BE; Leach, RJ; Leppert, M			A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family	NATURE GENETICS			English	Article							NEONATAL CONVULSIONS; GENERALIZED EPILEPSY; HETEROGENEITY; CHROMOSOME-8Q; CONFIRMATION; LOCUS; MAP	Epileptic disorders affect about 20-40 million people worldwide, and 40% of these are idiopathic generalized epilepsies (IGEs: ref. 1). Most of the IGEs that are inherited are complex, multigenic diseases. To address basic mechanisms for epilepsies, we have focused on one well-defined class of IGEs with an autosomal-dominant mode of inheritance: the benign familiar neonatal convulsions (BFNC: refs 2,3). Genetic heterogeneity of BFNC has been observed(4). Two loci, EBN1 and EBN2, have been mapped by linkage analysis to chromosome 20q13 (refs 5,6) and chromosome 8q24 (refs 7,8), respectively. By positional cloning, we recently identified the gene for EBN1 as KCNQ2 (ref. 9). This gene, a voltage-gated potassium channel, based on homology, is a member of the KQT-like family(10). Here we describe an additional member, KCNQ3. We mapped this new gene to chromosome 8, between markers D8S256 and D8S284 on a radiation hybrid map(11). We screened KCNQ3 for mutations in the large BFNC family(4,7) previously linked to chromosome 8q24 in the same marker interval. We found a missense mutation in the critical pore region in perfect co-segregation with the BFNC phenotype. The same conserved amino acid is also mutated in KVLQT1 (KCNQ1) in an LQT patient(12). KCNQ2, KCNQ3 and undiscovered genes of the same family of K+ channels are strong candidates for other IGEs.	Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pediat Neurol, Philadelphia, PA 19104 USA; Indiana Univ, Sch Med, Dept Med Genet, Indianapolis, IN 46902 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	Utah System of Higher Education; University of Utah; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; University of Texas Health San Antonio	Leppert, M (corresponding author), Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA.			Charlier, Carole/0000-0002-9694-094X; Leach, Robin/0000-0002-3201-5579	NCI NIH HHS [5P30CA42014] Funding Source: Medline; NHGRI NIH HHS [P01-HG00470] Funding Source: Medline; NINDS NIH HHS [R01-NS32666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEPPERT M, 1993, BRAIN PATHOL, V3, P357, DOI 10.1111/j.1750-3639.1993.tb00764.x; Letts VA, 1997, GENOMICS, V43, P62, DOI 10.1006/geno.1997.4780; LEWIS TB, 1993, AM J HUM GENET, V53, P670; LEWIS TB, 1995, GENOME RES, V5, P334, DOI 10.1101/gr.5.4.334; MALAFOSSE A, 1992, HUM GENET, V89, P54, DOI 10.1007/BF00207042; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Plouin P., 1994, IDIOPATHIC GEN EPILE, P39; REUTENS DC, 1995, NEUROLOGY, V45, P1469, DOI 10.1212/WNL.45.8.1469; RONEN GM, 1993, NEUROLOGY, V43, P1355, DOI 10.1212/WNL.43.7.1355; RYAN SG, 1991, ANN NEUROL, V29, P469, DOI 10.1002/ana.410290504; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Steinlein O, 1997, AM J MED GENET, V74, P445, DOI 10.1002/(SICI)1096-8628(19970725)74:4<445::AID-AJMG18>3.0.CO;2-I; STEINLEIN O, 1995, HUM GENET, V95, P411; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017; ZARA F, 1995, HUM MOL GENET, V4, P1201, DOI 10.1093/hmg/4.7.1201	25	754	809	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					53	55		10.1038/ng0198-53	http://dx.doi.org/10.1038/ng0198-53			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425900				2022-12-25	WOS:000071259600021
J	Liu, JL; Marino, MW; Wong, G; Grail, D; Dunn, A; Bettadapura, J; Slavin, AJ; Old, L; Bernard, CCA				Liu, JL; Marino, MW; Wong, G; Grail, D; Dunn, A; Bettadapura, J; Slavin, AJ; Old, L; Bernard, CCA			TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; FACTOR-ALPHA; DEFICIENT MICE; ENCEPHALOMYELITIS; LYMPHOTOXIN; DISEASE; IMMUNE; PREVENTION; ACTIVATION	Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) characterized by localized areas of demyelination(1). Although the etiology and pathogenesis of MS remain largely unknown, it is generally assumed that immune responses to myelin antigens contribute to the disease process(1,2). The exact sequence of events, as well as the molecular mediators that lead to myelin destruction, is yet to be defined(2,3) As a potent mediator of inflammation, the cytopathic cytokine, tumor necrosis factor (TNF) has been considered to be a strong candidate in the pathogenesis of MS and its animal model, experimental autoimmune encephalomyelitis (EAE)(3-5). However, its role in immune-mediated demyelination remains to be elucidated. To determine the contribution of TNF to the pathogenesis of the MS-like disease provoked by the myelin oligodendrocyte glycoprotein (MOG)(6), we have tested mice with an homologous disruption of the gene encoding TNF (ref. 7). Here we report that upon immunization with MOG, mice lacking TNF develop severe neurological impairment with high mortality and extensive inflammation and demyelination. We show further that inactivation of the TNF gene converts MOG-resistant mice to a state of high susceptibility. Furthermore, treatment with TNF dramatically reduces disease severity in both TNF-/- mice and in other TNF+/+ mice highly susceptible to the MOG-induced disease. These findings indicate that TNF is not essential for the induction and expression of inflammatory and demyelinating lesions, and that it may limit the extent and duration of severe CNS pathology.	La Trobe Univ, Neuroimmunol Lab, Melbourne, Vic 3083, Australia; Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York Branch, New York, NY 10021 USA; Genentech Inc, S San Francisco, CA 94090 USA; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Melbourne, Vic 3050, Australia	La Trobe University; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center; Roche Holding; Genentech; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Bernard, CCA (corresponding author), La Trobe Univ, Neuroimmunol Lab, Melbourne, Vic 3083, Australia.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Bernard CCA, 1997, J MOL MED-JMM, V75, P77, DOI 10.1007/s001090050092; BERNARD CCA, 1992, CURR OPIN IMMUNOL, V4, P760, DOI 10.1016/0952-7915(92)90058-M; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Ichikawa M, 1996, J IMMUNOL, V157, P919; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; Jayaram BM, 1996, J NEUROCHEM, V66, pS41; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LININGTON C, 1993, EUR J IMMUNOL, V23, P1364, DOI 10.1002/eji.1830230627; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Navikas V, 1996, J NEUROSCI RES, V45, P322, DOI 10.1002/(SICI)1097-4547(19960815)45:4<322::AID-JNR1>3.0.CO;2-B; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PAYA CV, 1990, INT IMMUNOL, V2, P909, DOI 10.1093/intimm/2.9.909; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; Rothwell NJ, 1996, NAT MED, V2, P746, DOI 10.1038/nm0796-746; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SELMAJ K, 1995, J NEUROIMMUNOL, V56, P135, DOI 10.1016/0165-5728(94)00139-F; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; Willenborg DO, 1996, J IMMUNOL, V157, P3223	26	469	485	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					78	83		10.1038/nm0198-078	http://dx.doi.org/10.1038/nm0198-078			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427610				2022-12-25	WOS:000072249700038
J	Southard-Smith, EM; Kos, L; Pavan, WJ				Southard-Smith, EM; Kos, L; Pavan, WJ			Sox10 mutation disrupts neural crest development in DOM Hirschsprung mouse model	NATURE GENETICS			English	Article							MICE LACKING GDNF; AUTOSOMAL SEX REVERSAL; ENDOTHELIN-B RECEPTOR; SRY-RELATED GENE; ENTERIC NEURONS; MESSENGER-RNA; CAMPOMELIC DYSPLASIA; MEGACOLON; MELANOCYTES; FAMILY	Hirschsprung disease (HSCR, MIM #142623) is a multigenic neurocristopathy (neural crest disorder) characterized by absence of enteric ganglia in a variable portion of the distal colon. Subsets of HSCR individuals also present with neural crest-derived melanocyte deficiencies (Hirschsprung-Waardenburg, HSCR-WS, MIM #277580). Murine models have been instrumental in the identification and analysis of HSCR disease genes. These include mice with deficiencies of endothelin B receptor (Ednrb(s-l); refs 1,2) endothelin 3 (Edn3(ls); refs 1,3) the tyrosine kinase receptor cRet(4) and glial-derived neurotrophic factor(5-7). Another mouse model of HSCR disease, Dom, arose spontaneously at the Jackson Laboratory(8). While Dom/+ heterozygous mice display regional deficiencies of neural crest-derived enteric ganglia in the distal colon, Dom/Dom homozygous animals are embryonic lethal(8). We have determined that premature termination of Sox10, a member of the SRY-like HMG box family of transcription factors, is responsible for absence of the neural crest derivatives in Dom mice. We demonstrate expression of Sox10 in normal neural crest cells, disrupted expression of both Sox10 and the HSCR disease gene Ednrb in Dom mutant embryos, and loss of neural crest derivatives due to apoptosis. Our studies suggest that Sox10 is essential for proper peripheral nervous system development. We propose SOX10 as a candidate disease gene for individuals with HSCR whose disease does not have an identified genetic origin.	Natl Human Genome Res Inst, Mouse Embryol Sect, Lab Genet Dis Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Pavan, WJ (corresponding author), Natl Human Genome Res Inst, Mouse Embryol Sect, Lab Genet Dis Res, NIH, Bldg 49,Room 4A82,49 Convent Dr,MSC 4472, Bethesda, MD 20892 USA.	bpavan@nhgri.nih.gov	Southard-Smith, Michelle/C-3488-2012	Pavan, William/0000-0001-8281-5120; Southard-Smith, E Michelle/0000-0003-4718-5869				BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GERSHON MD, 1995, CURR BIOL, V5, P601, DOI 10.1016/S0960-9822(95)00120-5; Hashimoto Y, 1996, CANCER RES, V56, P5266; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; KAPUR RP, 1995, DEVELOPMENT, V121, P3787; KAPUR RP, 1993, DEVELOPMENT, V117, P993; Kapur RP, 1996, DEV BIOL, V174, P360, DOI 10.1006/dbio.1996.0080; Lahav R, 1996, P NATL ACAD SCI USA, V93, P3892, DOI 10.1073/pnas.93.9.3892; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; PAVAN WJ, 1995, GENOME RES, V5, P29, DOI 10.1101/gr.5.1.29; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Pringault V, 1997, GENOMICS, V39, P86, DOI 10.1006/geno.1996.4476; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; PULITI A, 1995, MAMM GENOME, V6, P763, DOI 10.1007/BF00539000; Reid K, 1996, DEVELOPMENT, V122, P3911; ROTHMAN TP, 1993, DEV BIOL, V159, P559, DOI 10.1006/dbio.1993.1264; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Schilham MW, 1997, EUR J IMMUNOL, V27, P1292, DOI 10.1002/eji.1830270534; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; STEEL KP, 1992, DEVELOPMENT, V115, P1111; Stock DW, 1996, GENOMICS, V37, P234, DOI 10.1006/geno.1996.0548; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; SWIFT GH, 1982, P NATL ACAD SCI-BIOL, V79, P7263, DOI 10.1073/pnas.79.23.7263; Tani M, 1997, GENOMICS, V39, P30, DOI 10.1006/geno.1996.4483; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744	36	586	600	3	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1998	18	1					60	64		10.1038/ng0198-60	http://dx.doi.org/10.1038/ng0198-60			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425902	Green Published			2022-12-25	WOS:000071259600023
J	Xiao, S; Nalabolu, SR; Aster, JC; Ma, JL; Abruzzo, L; Jaffe, ES; Stone, R; Weissman, SM; Hudson, TJ; Fletcher, JA				Xiao, S; Nalabolu, SR; Aster, JC; Ma, JL; Abruzzo, L; Jaffe, ES; Stone, R; Weissman, SM; Hudson, TJ; Fletcher, JA			FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome	NATURE GENETICS			English	Article							FIBROBLAST GROWTH-FACTOR; T-CELL; CHROMOSOMAL TRANSLOCATIONS; LYMPHOBLASTIC LYMPHOMA; RECEPTOR; EOSINOPHILIA; ABERRATIONS; MALIGNANCY; ACTIVATION; MUTATIONS	Various histological subtypes of leukaemia and lymphoma are associated with diagnostic chromosome translocations(1-4), and substantial strides have been made in determining the specific oncogenes targetted by those translocations. We report the cloning of a novel fusion oncogene associated with a unique leukaemia/lymphoma syndrome. Patients afflicted with this syndrome present with lymphoblastic lymphoma and a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow, which generally progress to full-blown acute myelogenous leukaemia within a year of diagnosis(5-9). A specific chromosome translocation, t(8;13)(p11;q11-12), is found in both lymphoma and myeloid leukaemia cells from these patients, supporting bi-lineage differentiation from a transformed stem cell(6-8). We find that the 8p11 translocation breakpoints, in each of four patients, interrupt intron 8 of the fibroblast growth factor receptor 1 gene (FGFR1). These translocations are associated with aberrant transcripts in which four predicted zinc-finger domains, contributed by a novel and widely expressed chromosome-13 gene (ZNF198), are fused to the FGFR1 tyrosine-kinase domain. Transient expression studies show that the ZNF198-FGFR1 fusion transcript directs the synthesis of an approximately 87-kD polypeptide, localizing predominantly to the cytoplasm. Our studies demonstrate an FGFR1 oncogenic role and suggest a tumorigenic mechanism in which ZNF198-FGFR1 activation results from ZNF198 zinc-finger-mediated homodimerization.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Yale Univ, Sch Med, New Haven, CT 06536 USA; MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02142 USA; Univ Maryland, Med Ctr, Dept Pathol, Baltimore, MD 21201 USA; NCI, Hematopathol Sect, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Yale University; Massachusetts Institute of Technology (MIT); Whitehead Institute; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital	Xiao, S (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.		Jaffe, Elaine S/G-8984-2014	Jaffe, Elaine S/0000-0003-4632-0301	NATIONAL CANCER INSTITUTE [R01CA072791] Funding Source: NIH RePORTER; NCI NIH HHS [CA72791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRUZZO LV, 1992, AM J SURG PATHOL, V16, P236, DOI 10.1097/00000478-199203000-00003; Aster JC, 1997, J BIOL CHEM, V272, P11336; AVRAHAM H, 1994, BLOOD, V83, P2126; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CROCE CM, 1993, SEMIN ONCOL, V20, P31; DIB A, 1995, ONCOGENE, V10, P995; FAGAN K, 1993, CANCER GENET CYTOGEN, V65, P71, DOI 10.1016/0165-4608(93)90062-Q; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1994, BLOOD, V83, P907; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; ITOH N, 1990, BIOCHEM BIOPH RES CO, V169, P680, DOI 10.1016/0006-291X(90)90384-Y; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACDONALD D, 1995, LEUKEMIA, V9, P1628; NAEEM R, 1995, GENE CHROMOSOME CANC, V12, P148, DOI 10.1002/gcc.2870120210; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; OFFIT K, 1991, HEMATOL ONCOL CLIN N, V5, P853, DOI 10.1016/S0889-8588(18)30389-7; PARIMOO S, 1993, NUCLEIC ACIDS RES, V21, P4422, DOI 10.1093/nar/21.18.4422; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROWLEY JD, 1990, CANCER RES, V50, P3816; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Tong Q, 1997, J BIOL CHEM, V272, P9043; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; WILSON EL, 1991, BLOOD, V77, P954; XIAO S, 1995, AM J PATHOL, V147, P896	30	263	279	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					84	87		10.1038/ng0198-84	http://dx.doi.org/10.1038/ng0198-84			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425908				2022-12-25	WOS:000071259600029
J	LoidlStahlhofen, A; Kaufmann, S; Braunschweig, T; Bayerl, TM				LoidlStahlhofen, A; Kaufmann, S; Braunschweig, T; Bayerl, TM			The thermodynamic control of protein binding to lipid bilayers for protein chromatography	NATURE BIOTECHNOLOGY			English	Article						protein chromatography; phospholipid bilayer; temperature gradient	MAGNETIC-RESONANCE; PHASE-TRANSITIONS; LATERAL DIFFUSION; PHOSPHOLIPIDS	A new concept of charge-selective bioseparation with certain advantages over the established ion-exchange technique is reported. The procedure is based on the temperature-controlled creation and dispersion of domain structures in single phospholipid bilayers by means of the phase transition between the gel phase and the fluid phase of the bilayer. The bilayers are presented on a solid support of silica gel. Rather than altering the ionic strength of the buffer, protein elution is accomplished by a change of the chromatography column temperature. The application of temperature gradients improves the protein selectivity of phase transition chromatography.	NIMBUS BIOTECHNOL GMBH,D-04299 LEIPZIG,GERMANY; TECH UNIV MUNICH,PHYS DEPT E22,D-85747 GARCHING,GERMANY	Technical University of Munich	LoidlStahlhofen, A (corresponding author), UNIV WURZBURG,PHYS INST EP5,HUBLAND,D-97074 WURZBURG,GERMANY.			Loidl-Stahlhofen, Angelika/0000-0002-3158-9546				BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; CEVC G, 1993, BIOPHYSICS HDB MEMBR; COLLIER NC, 1982, J BIOL CHEM, V257, P6937; GALLA HJ, 1979, J MEMBRANE BIOL, V48, P215, DOI 10.1007/BF01872892; IPSEN JH, 1988, BIOCHIM BIOPHYS ACTA, V944, P121, DOI 10.1016/0005-2736(88)90425-7; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; KOCHY T, 1993, PHYS REV E, V47, P2109, DOI 10.1103/PhysRevE.47.2109; KUO AL, 1979, BIOCHEMISTRY-US, V18, P2300, DOI 10.1021/bi00578a026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AG, 1977, BIOCHIM BIOPHYS ACTA, V472, P237, DOI 10.1016/0304-4157(77)90018-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABREY S, 1976, P NATL ACAD SCI USA, V73, P3862, DOI 10.1073/pnas.73.11.3862; NAUMANN C, 1992, BIOPHYS J, V63, P1314, DOI 10.1016/S0006-3495(92)81708-3; Scopes R. K, 1994, PROTEIN PURIFICATION, V3rd, DOI 10.1007/978-1-4757-2333-5	14	37	40	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					999	1002		10.1038/nbt0896-999	http://dx.doi.org/10.1038/nbt0896-999			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631039				2022-12-25	WOS:A1996UZ19900033
J	Tzschaschel, BD; Guzman, CA; Timmis, KN; deLorenzo, V				Tzschaschel, BD; Guzman, CA; Timmis, KN; deLorenzo, V			An Escherichia coli hemolysin transport system-based vector for the export of polypeptides: Export of Shiga-like toxin IIeB subunit by Salmonella typhimurium aroA	NATURE BIOTECHNOLOGY			English	Article						expression vector; hemolysin; protein export; Shiga-like toxin; vaccine	GRAM-NEGATIVE BACTERIA; LOW-COPY-NUMBER; RESISTANCE SELECTION; ANTIBODY-RESPONSES; SECRETION SYSTEM; CLONING VECTORS; OUTER-MEMBRANE; FOREIGN GENES; PROTEINS; STRAINS	The export of Escherichia coli hemolysin across the cytoplasmic and the outer membranes requires the COOH-terminal signal sequence of HlyA, the two specific translocator proteins HlyB and HlyD, and the outer membrane protein TolC. We have developed an export cloning system that is composed of two vectors: one in which the fusion of the desired gene with the 3'-end of hlyA is generated, and a second in which the sequences containing the fusion are combined with the accessory genes hlyB and hlyD, thereby reconstructing the natural organization of the hly locus. in the second vector the fusion and the accessory genes are flanked by NotI sites, allowing subcloning of the whole cluster into a variety of minitransposons to achieve the stable integration of the constructs into the chromosome of Gram-negative bacteria. Since some applications may require the production of transcriptional fusions, an alternative version of the system provides the efficient translation initiation region of T7 phage gene 10 upstream of the fusion protein coding sequence. The usefulness of the system was assessed by constructing a fusion between the gene encoding the B subunit of Shiga-like toxin lie and the 3'-end of hlyA. An attenuated Salmonella typhimurium vaccine strain harboring the resulting construct, either in multicopy or monocopy, efficiently expressed and exported the chimeric protein. We anticipate that this system will lead to a higher stability of the engineered function and permit a faithful monitoring of the export of the recombinant peptide under physiologic single-copy conditions.	NATL RES CTR BIOTECHNOL, DIV MICROBIOL, D-38124 BRAUNSCHWEIG, GERMANY; CSIC, CTR INVEST BIOL, E-28006 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)				de Lorenzo, Victor/0000-0002-6041-2731				[Anonymous], 1982, MOL CLONING LAB MANU; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; GENTSCHEV I, 1990, MOL GEN GENET, V222, P211, DOI 10.1007/BF00633820; GENTSCHEV I, 1992, INFECT IMMUN, V60, P5091, DOI 10.1128/IAI.60.12.5091-5098.1992; GRAY L, 1986, MOL GEN GENET, V205, P127, DOI 10.1007/BF02428042; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HASHIMOTOGOTOH T, 1981, GENE, V16, P227, DOI 10.1016/0378-1119(81)90079-2; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HESS J, 1990, MOL GEN GENET, V224, P201, DOI 10.1007/BF00271553; HOLLAND IB, 1990, BIOCHIMIE, V72, P131, DOI 10.1016/0300-9084(90)90138-7; HOLLAND IB, 1990, MICROBIAL PRODUCTS N, P219; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KORONAKIS V, 1992, FEMS MICROBIOL IMMUN, V105, P45, DOI 10.1016/0378-1097(92)90074-X; KRISTENSEN CS, 1995, J BACTERIOL, V177, P52, DOI 10.1128/jb.177.1.52-58.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKMAN N, 1984, MOL GEN GENET, V196, P129, DOI 10.1007/BF00334104; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; NICAUD JM, 1986, FEBS LETT, V204, P331, DOI 10.1016/0014-5793(86)80838-9; OCALLAGHAN D, 1990, MOL GEN GENET, V223, P156, DOI 10.1007/BF00315809; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RICHARDS E, 1987, CURRENT PROTOCOLS MO, P1; SU GF, 1992, MICROB PATHOGENESIS, V13, P465, DOI 10.1016/0882-4010(92)90013-E; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER W, 1983, J BACTERIOL, V154, P200, DOI 10.1128/JB.154.1.200-210.1983; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WEINSTEIN DL, 1988, J BACTERIOL, V170, P4223, DOI 10.1128/jb.170.9.4223-4230.1988; WIELER LH, 1992, TIERAERZTL UMSCHAU, V47, P524; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	32	61	70	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					765	769		10.1038/nbt0696-765	http://dx.doi.org/10.1038/nbt0696-765			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630987				2022-12-25	WOS:A1996UM76600035
J	Cheng, LZ; Fu, J; Tsukamoto, A; Hawley, RG				Cheng, LZ; Fu, J; Tsukamoto, A; Hawley, RG			Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells	NATURE BIOTECHNOLOGY			English	Article						GFP; FACS; fluorescence microscopy; gene transduction; gene therapy	HELPER	Two mutants of the green fluorescent protein (GFP), RSGFP4 and GFPS65T, have been recently created which differ from the wildtype GFP of A. victoria in their excitation maxima. Here we show that human fibroblasts transfected with either of the two mutant GFP genes emit a green fluorescence that is 18-fold brighter than the cells transfected with the wildtype GFP gene. Retroviral vectors expressing the improved GFP gene were also constructed to determine their suitability for stable gene transduction into mammalian cells. The inclusion of the RSGFP4 gene in a retroviral vector did not reduce the viral titer and resulted in a fluorescent signal in viable transduced cells detectable by both fluorescence microscopy and fluorescence-activated cell sorter (FACS) analysis. Therefore, the improved mutant GFP provides a vital marker for monitoring gene transfer and expression in mammalian cells.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M1,CANADA; TORONTO HOSP,ONCOL RES LABS,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Cheng, LZ (corresponding author), SYSTEMIX INC,DIV RES,PALO ALTO,CA 94304, USA.			Hawley, Robert/0000-0003-3512-5818				CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; CORMACK BP, 1996, IN PRESS GENE; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HAWLEY RG, 1994, GENE THER, V1, P136; HEIM R, 1995, NATURE, V373, P63; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; KITTS P, 1995, CLONTECHNIQUES, V10, P1; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; STEARNS T, 1995, CURR BIOL, V5, P262, DOI 10.1016/S0960-9822(95)00056-X; WANG S, NATURE, V369, P400	16	150	189	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					606	609		10.1038/nbt0596-606	http://dx.doi.org/10.1038/nbt0596-606			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630951				2022-12-25	WOS:A1996UL60400025
J	Alvarez, MA; Fu, H; Khosla, C; Hopwood, DA; Bailey, JE				Alvarez, MA; Fu, H; Khosla, C; Hopwood, DA; Bailey, JE			Engineered biosynthesis of novel polyketides: Properties of the whiE aromatase/cyclase	NATURE BIOTECHNOLOGY			English	Article						Streptomyces; polyketide synthase; combinatorial biosynthesis; novel polyketides	STREPTOMYCES-COELICOLOR A3(2); NUCLEOTIDE-SEQUENCE; GENE-CLUSTER; DEDUCED FUNCTION; ANTIBIOTICS; GLAUCESCENS; SYNTHASE; ENCODES; CYCLASE; REGION	The ORFVI from the cluster of genes, which is responsible for the biosynthesis of the Streptomyces coelicolor spore pigment, the whiE cluster, has been described as a bifunctional aromatase/cyclase. In order to evaluate its potential use for generating novel polyketides, combinations of this gene with those encoding minimal polyketide synthase enzymes with or without a ketoreductase from S. coelicolor A3(2) were constructed and analyzed in vivo. Analysis of the polyketide products generated from these constructs indicates that the whiE-ORFVI enzyme has properties similar to those of TcmN, although the whiE aromatase/cyclase normally acts on a polyketide intermediate that is four carbons longer than the TcmN substrate. The whiE aromatase/cyclase can influence the regiospecificity of the first cyclization of unreduced, but not reduced, backbones and is also responsible for the second ring aromatization. An unusual new polyketide, EM18, was identified which is not seen in equivalent strains expressing the tcmN aromatase/cyclase or the act aromstase genes. The structure of EM18 suggests that the whiE-ORFVI product might have some unique properties within this family of polyketide synthase subunits, and may therefore be useful in the design of combinatorial biosynthetic strategies.	ETH ZURICH,INST BIOTECHNOL,CH-8093 ZURICH,SWITZERLAND; JOHN INNES CTR PLANT SCI RES,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND; STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305	Swiss Federal Institutes of Technology Domain; ETH Zurich; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Stanford University			Arias-Alvarez, M/L-6169-2014; Alvarez, Miguel A./F-2535-2013	Arias-Alvarez, M/0000-0001-7907-7454; Alvarez, Miguel A./0000-0001-9607-7480; Khosla, Chaitan/0000-0001-6529-495X				BERGH S, 1992, GENE, V117, P131, DOI 10.1016/0378-1119(92)90501-F; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BLANCO G, 1993, GENE, V130, P107, DOI 10.1016/0378-1119(93)90352-4; CERDAOLMEDO E, 1994, CRIT REV MICROBIOL, V20, P151, DOI 10.3109/10408419409113554; DAVIS NK, 1990, MOL MICROBIOL, V4, P1679, DOI 10.1111/j.1365-2958.1990.tb00545.x; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; FU H, 1994, BIOCHEMISTRY-US, V33, P9321, DOI 10.1021/bi00197a036; FU H, 1994, J AM CHEM SOC, V116, P6443, DOI 10.1021/ja00093a058; GRIMM A, 1994, GENE, V151, P1, DOI 10.1016/0378-1119(94)90625-4; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; Hopwood D. A., 1985, GENETIC MANIPULATION; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KIM ES, 1994, GENE, V141, P141, DOI 10.1016/0378-1119(94)90144-9; Maniatis T., 1982, MOL CLONING; MCANIEL R, 1995, NATURE, V375, P549; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1995, J AM CHEM SOC, V117, P6805, DOI 10.1021/ja00131a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; OHagan D., 1991, POLYKETIDE METABOLIT; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SUMMERS RG, 1993, J BACTERIOL, V175, P7571, DOI 10.1128/JB.175.23.7571-7580.1993; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; TSOI CJ, 1995, CHEM BIOL, V2, P355; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994; YU TW, 1995, THESIS U ANGLIA NORW	31	37	37	1	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					335	338		10.1038/nbt0396-335	http://dx.doi.org/10.1038/nbt0396-335			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630896				2022-12-25	WOS:A1996UL38000028
J	Ivanova, AV; Bonaduce, MJ; Ivanov, SV; Klar, AJS				Ivanova, AV; Bonaduce, MJ; Ivanov, SV; Klar, AJS			The chromo and SET domains of the Clr4 protein are essential for silencing in fission yeast	NATURE GENETICS			English	Article							POLYMERASE CHAIN-REACTION; SCHIZOSACCHAROMYCES-POMBE; DROSOPHILA; GENE; MUTATIONS; DISRUPT; REGION	Heritable inactivation of specific regions of the genome is a widespread, possibly universal phenomenon for gene regulation in eukaryotes. Self-perpetuating, clonally inherited chromatin structure has been proposed as the explanation for such phenomena as position-effect variegation(1,2) (PEV) and control of segment determination and differentiation in flies(3), X-chromosome inactivation and parental imprinting in mammals(4,5), gene silencing by paramutation in maize(6) and silencing of the mating-type loci in yeasts(7,8). We have now found that the clr4 gene, which is essential for silencing of centromeres(9) and the mating-type loci in Schizosaccharomyces pombe(8,10), encodes a protein with high homology to the product of Su(var)3-9, a gene affecting PEV in Drosophila(1). Like Su(var)3-9p, Clr4p contains SET and chrome domains, motifs found in proteins that modulate chromatin structure. Site-directed mutations in the conserved residues of the chrome domain confirm that it is required for proper silencing and directional switching of the mating type, like SET domain. Surprisingly, RNA differential display experiments demonstrated that clr4(+) can mediate transcriptional activation of certain other loci. These results show that clr4 plays a critical role in silencing at mating-type loci and centromeres through the organization of repressive chromatin structure and demonstrate a new, activator function for Clr4p.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Gene Regulat & Chromosome Biol Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Klar, AJS (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Gene Regulat & Chromosome Biol Lab, Frederick, MD 21702 USA.	klar@ncifcrf.gov		Ivanov, Sergey/0000-0001-9770-7237				Ainscough JFX, 1997, DEVELOPMENT, V124, P3621; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ALLSHIRE RC, 1996, EPIGENETIC MECH GENE, P443; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Ekwall K, 1996, J CELL SCI, V109, P2637; ENGELKE U, 1987, CURR GENET, V12, P535, DOI 10.1007/BF00419563; Grewal SIS, 1997, GENETICS, V146, P1221; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HOLLICK JB, 1995, GENETICS, V141, P709; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; Klar AJS, 1998, CIBA F SYMP, V214, P87; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LYON MF, 1986, J EMBRYOL EXP MORPH, V97, P75; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Sawin KE, 1996, P NATL ACAD SCI USA, V93, P15146, DOI 10.1073/pnas.93.26.15146; SINGH PB, 1994, J CELL SCI, V107, P2653; THON G, 1993, GENETICS, V134, P1045; THON G, 1994, GENETICS, V138, P29; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x	30	139	142	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					192	195		10.1038/566	http://dx.doi.org/10.1038/566			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620780				2022-12-25	WOS:000073865100031
J	Sipkins, DA; Cheresh, DA; Kazemi, MR; Nevin, LM; Bednarski, MD; Li, KCP				Sipkins, DA; Cheresh, DA; Kazemi, MR; Nevin, LM; Bednarski, MD; Li, KCP			Detection of tumor angiogenesis in vivo by alpha(v)beta(3)-targeted magnetic resonance imaging	NATURE MEDICINE			English	Article							PARAMAGNETIC POLYMERIZED LIPOSOMES; INTEGRIN ALPHA(V)BETA(3); BLOOD-VESSELS; CARCINOMA; DISEASE; CANCER	Angiogenesis, the formation of new blood vessels, is a requirement for malignant tumor growth and metastasis(1-3). In the absence of angiogenesis, local tumor expansion is suppressed at a few millimeters and cells lack routes for distant hematogenous spread. Clinical studies have demonstrated that the degree of angiogenesis is correlated with the malignant potential of several cancers, including breast cancer and malignant melanoma(4-7). Moreover, the expression of a specific angiogenesis marker, the endothelial integrin alpha(nu)beta(3), has been shown to correlate with tumor grade(8-10). However, studies of tumor angiogenesis such as these have generally relied on invasive procedures, adequate tissue sampling and meticulous estimation of histologic microvessel density. In the present report, we describe a novel approach to detecting angiogenesis in vivo using magnetic resonance imaging (MRI) and a paramagnetic contrast agent targeted to endothelial alpha(nu)beta(3), via the LM609 monoclonal antibody(11). This approach provided enhanced and detailed imaging of rabbit carcinomas by directly targeting paramagnetic agents to the angiogenic vasculature. In addition, angiogenic 'hot spots' not seen by standard MRI were detected. Our strategy for MR imaging of alpha(nu)beta(3) thus represents a non-invasive means to assess the growth and malignant phenotype of tumors.	Stanford Univ, Sch Med, Dept Radiol, Lucas MRS Res Ctr, Stanford, CA 94305 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Stanford University; Scripps Research Institute	Sipkins, DA (corresponding author), Stanford Univ, Sch Med, Dept Radiol, Lucas MRS Res Ctr, Stanford, CA 94305 USA.		Nevin, Linda/AAL-6321-2021	Nevin, Linda/0000-0003-4095-8574; Li, King/0000-0002-6473-2687	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54444] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TM, 1989, BIOCHIM BIOPHYS ACTA, V981, P27, DOI 10.1016/0005-2736(89)90078-3; Brasch Robert C., 1993, P1; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carrau RL, 1995, INVAS METAST, V15, P197; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gladson CL, 1996, J NEUROPATH EXP NEUR, V55, P1143, DOI 10.1097/00005072-199611000-00005; Gupta H, 1996, Magn Reson Imaging Clin N Am, V4, P171; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; JOLESZ FA, 1994, MAGN RESON QUART, V10, P85; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Storrs RW, 1995, JMRI-J MAGN RESON IM, V5, P719, DOI 10.1002/jmri.1880050617; STORRS RW, 1995, J AM CHEM SOC, V117, P7301, DOI 10.1021/ja00133a001; STRAULI P, 1984, B CANCER, V71, P447; Takebayashi Y, 1996, CANCER, V78, P226, DOI 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINREB JC, 1994, MAGN RESON QUART, V10, P67; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289	20	743	801	0	99	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					623	626		10.1038/nm0598-623	http://dx.doi.org/10.1038/nm0598-623			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585240				2022-12-25	WOS:000073399900038
J	Knapik, EW; Goodman, A; Ekker, M; Chevrette, M; Delgado, J; Neuhauss, S; Shimoda, N; Driever, W; Fishman, MC; Jacob, HJ				Knapik, EW; Goodman, A; Ekker, M; Chevrette, M; Delgado, J; Neuhauss, S; Shimoda, N; Driever, W; Fishman, MC; Jacob, HJ			A microsatellite genetic linkage map for zebrafish (Danio rerio)	NATURE GENETICS			English	Article							HUMAN GENOME; MOUSE; EMBRYOS	We have constructed a zebrafish genetic linkage map consisting of 705 simple sequence-length polymorphism markers (SSLPs). The map covers 2350 centimorgans (cM) of the zebrafish genome with an average resolution of 3.3 cM. It is a complete map in genetic mapping terms (there is one linkage group for each of the 25 chromosomes), and it has been confirmed by somatic-cell hybrids and centromere-mapping using half-tetrad analysis. The markers are highly polymorphic in the zebrafish strains used for genetic crosses and provide a means to compare genetic segregation of developmental mutations between laboratories. These markers will provide an initial infrastructure for the positional cloning of the nearly 600 zebrafish genes identified as crucial to vertebrate development,and will become the anchor for the physical map of the zebrafish genome.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Univ Ottawa, Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A4, Canada; Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada	Harvard University; Massachusetts General Hospital; University of Ottawa; Ottawa Hospital Research Institute; McGill University; McGill University	Knapik, EW (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, D-85758 Neuherberg, Germany.	fishman@cvrc-taco.mgh.harvard.edu	Knapik, Ela W./J-6172-2014; Neuhauss, Stephan/AAX-9915-2020	Knapik, Ela W./0000-0002-2977-3619; Neuhauss, Stephan/0000-0002-9615-480X; Driever, Wolfgang/0000-0002-9551-9141	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR008888] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08888] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BISHOP MD, 1994, GENETICS, V136, P619; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; CHIN AJ, 1997, DEV GENES EVOL, V207, P104; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; CRAWFORD AM, 1995, GENETICS, V140, P703; Daga RR, 1996, CHROMOSOME RES, V4, P29, DOI 10.1007/BF02254941; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; Driever W, 1996, J CLIN INVEST, V97, P1788, DOI 10.1172/JCI118608; Driever W, 1996, DEVELOPMENT, V123, P37; EKKER M, 1992, NEURON, V9, P27, DOI 10.1016/0896-6273(92)90217-2; Ekker M, 1996, GENOMICS, V33, P57, DOI 10.1006/geno.1996.0159; Fisher S, 1997, DEVELOPMENT, V124, P1301; GOFF DJ, 1992, GENOMICS, V14, P200, DOI 10.1016/S0888-7543(05)80309-X; Haffter P, 1996, DEVELOPMENT, V123, P1; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; Johnson SL, 1996, GENETICS, V142, P1277; Knapik EW, 1996, DEVELOPMENT, V123, P451; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LINCOLN SE, 1992, GENOMICS, V14, P604, DOI 10.1016/S0888-7543(05)80158-2; MARTINEZBARBERA JP, 1997, GENE, V198, P653; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Phillips RB, 1996, CAN J ZOOL, V74, P323, DOI 10.1139/z96-040; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; Rohrer GA, 1996, GENOME RES, V6, P371, DOI 10.1101/gr.6.5.371; Sambrooke J., 1989, MOL CLONING LAB MANU; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; STACHEL SE, 1993, DEVELOPMENT, V117, P1261	33	288	302	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1998	18	4					338	343		10.1038/ng0498-338	http://dx.doi.org/10.1038/ng0498-338			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537415				2022-12-25	WOS:000072755500015
J	Bull, LN; van Eijk, MJT; Pawlikowska, L; DeYoung, JA; Juijn, JA; Liao, M; Klomp, LWJ; Lomri, N; Berger, R; Scharschmidt, BF; Knisely, AS; Houwen, RHJ; Freimer, NB				Bull, LN; van Eijk, MJT; Pawlikowska, L; DeYoung, JA; Juijn, JA; Liao, M; Klomp, LWJ; Lomri, N; Berger, R; Scharschmidt, BF; Knisely, AS; Houwen, RHJ; Freimer, NB			A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis	NATURE GENETICS			English	Article							RECURRENT INTRAHEPATIC CHOLESTASIS; BYLER DISEASE; BILE; PHOSPHATIDYLCHOLINE; GLYCOPROTEIN; TRANSLOCASE; ABSENCE; VECTOR	Cholestasis, or impaired bile flow, is an important but poorly understood manifestation of liver disease. Two clinically distinct forms of inherited cholestasis, benign recurrent intrahepatic cholestasis (BRIC) and progressive familial intrahepatic cholestasis type 1 (PFIC1), were previously mapped to 18q21. Haplotype analysis narrowed the candidate region for both diseases to the same interval of less than 1 cM, in which we identified a gene mutated in BRIC and PFIC1 patients. This gene (called FIC1) is the first identified human member of a recently described subfamily of P-type ATPases; ATP-dependent aminophospholipid transport is the previously described function of members of this subfamily. NCI is expressed in several epithelial tissues and, surprisingly, more strongly in small intestine than in liver. Its protein product is likely to play an essential role in enterohepatic circulation of bile acids; further characterization of FIC1 will facilitate understanding of normal bile formation and cholestasis.	Univ Calif San Francisco, Dept Psychiat, Neurogenet Lab, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA; Wilhelmina Childrens Hosp, Dept Pediat Gastroenterol, Utrecht, Netherlands; Wilhelmina Childrens Hosp, Lab Metab Disorders, Utrecht, Netherlands; Chiron Corp, Emeryville, CA 94608 USA; UniPath LLC, Denver, CO 80218 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Wilhelmina Kinderziekenhuis; Wilhelmina Kinderziekenhuis; Novartis	Freimer, NB (corresponding author), Univ Calif San Francisco, Dept Psychiat, Neurogenet Lab, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA.	nelson@ngl.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050697, R01DK026270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001375] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26270, DK50697] Funding Source: Medline; NIMH NIH HHS [MH01375] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BIJLEVELD CMA, 1989, GASTROENTEROLOGY, V97, P427, DOI 10.1016/0016-5085(89)90079-6; BIJLEVELD CMA, 1989, HEPATOLOGY, V9, P532, DOI 10.1002/hep.1840090404; Bourke B, 1996, ARCH DIS CHILD, V75, P223, DOI 10.1136/adc.75.3.223; Bull LN, 1997, HEPATOLOGY, V26, P155; CARLTON VEH, 1995, HUM MOL GENET, V4, P1049, DOI 10.1093/hmg/4.6.1049; CLAYTON RJ, 1969, AM J DIS CHILD, V117, P112, DOI 10.1001/archpedi.1969.02100030114014; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; DEKONING TJ, 1995, AM J MED GENET, V57, P479, DOI 10.1002/ajmg.1320570324; FAGAN MJ, 1994, J MOL EVOL, V38, P57; HOFMAN F, 1997, SLEISENGER FORDTRANS, P937; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JACQUEMIN E, 1994, EUR J PEDIATR, V153, P424; Knisely AS, 1997, ARCH DIS CHILD, V77, P276, DOI 10.1136/adc.77.3.276; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIDOFSKY SD, 1997, SLEISENGER FORDTRANS, P220; LINARELLI LG, 1972, J PEDIATR-US, V81, P484, DOI 10.1016/S0022-3476(72)80174-4; LLOYDSTILL JD, 1981, J PEDIATR-US, V99, P580, DOI 10.1016/S0022-3476(81)80261-2; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sinke RJ, 1997, HUM GENET, V100, P382, DOI 10.1007/s004390050520; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; SUMMERSKILL WH, 1965, AM J MED, V38, P298, DOI 10.1016/0002-9343(65)90184-1; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TAZAWA Y, 1985, J PEDIATR GASTR NUTR, V4, P32, DOI 10.1097/00005176-198502000-00007; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Vlahcevic ZR, 1996, HEPATOLOGY TXB LIVER, V1, P376; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Wu CY, 1996, NUCLEIC ACIDS RES, V24, P2614, DOI 10.1093/nar/24.13.2614; Zhao J, 1997, BBA-MOL CELL RES, V1357, P57, DOI 10.1016/S0167-4889(97)00014-1	33	563	581	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1998	18	3					219	224		10.1038/ng0398-219	http://dx.doi.org/10.1038/ng0398-219			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500542				2022-12-25	WOS:000072325000018
J	Koole, LH; Kruft, MAB; Aldenhoff, YBJ; van't Oost, NE; van Kroonenburgh, MJPG; van der Veen, FH				Koole, LH; Kruft, MAB; Aldenhoff, YBJ; van't Oost, NE; van Kroonenburgh, MJPG; van der Veen, FH			Sustained local drug delivery from a radiopaque implanted reservoir	NATURE BIOTECHNOLOGY			English	Article							POLYMERIC BIOMATERIALS; SOLID TUMORS; CHEMOTHERAPY; ACCESS	A new polymeric biomaterial that contains covalently bound iodine, and is therefore radiopaque, was used to construct a sustained local drug-delivery device. A polymeric wall was designed to be porous (i.e., passage of low-molecular-weight molecules across the wall is possible), self-healing, and biocompatible. Once implanted, the sphere cavity can be filled and refilled with a concentrated solution of a (cytostatic) drug, which is subsequently released by slow diffusion into the tissue region surrounding the sphere, This principle of sustained local drug delivery is shown by a series of in vitro experiments on the release of 5-fluorouracil, and in vivo animal experiments, using x-ray fluoroscopic and scintigraphic techniques.	Univ Limburg, Ctr Biomat Res, NL-6200 MD Maastricht, Netherlands; Acad Hosp Maastricht, Dept Nucl Med, NL-6202 AZ Maastricht, Netherlands; Acad Hosp Maastricht, Dept Cardiol, NL-6202 AZ Maastricht, Netherlands	Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Koole, LH (corresponding author), Univ Limburg, Ctr Biomat Res, POB 616, NL-6200 MD Maastricht, Netherlands.							Benzina A, 1996, J BIOMED MATER RES, V32, P459, DOI 10.1002/(SICI)1097-4636(199611)32:3<459::AID-JBM20>3.0.CO;2-A; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; BREM H, 1996, SCI MED, V12, P52; Chasin Mark, 1995, P1; CHIRILA TV, 1993, BIOMATERIALS, V14, P26, DOI 10.1016/0142-9612(93)90072-A; Davy KWM, 1997, POLYM INT, V43, P143, DOI 10.1002/(SICI)1097-0126(199706)43:2<143::AID-PI717>3.0.CO;2-M; Dionne KE, 1996, BIOMATERIALS, V17, P257, DOI 10.1016/0142-9612(96)85563-3; DRENTH W, 1982, KINETICS APPL ORGANI; EATCOCK MM, 1996, CANC CHEMOTHER PHARM, V38, P110; Giovanini MA, 1996, NEUROSURGERY, V39, P404, DOI 10.1097/00006123-199608000-00039; Haaz MC, 1996, CANCER CHEMOTH PHARM, V38, P52, DOI 10.1007/s002800050447; Jain RK, 1996, ANN BIOMED ENG, V24, P457, DOI 10.1007/BF02648108; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079; Kruft MAB, 1997, BIOMATERIALS, V18, P31, DOI 10.1016/S0142-9612(96)00085-3; Kruft MAB, 1996, BIOMATERIALS, V17, P1803, DOI 10.1016/0142-9612(95)00339-8; Kruft MAB, 1996, MACROMOLECULES, V29, P5513, DOI 10.1021/ma951399s; KRUFT MAB, 1994, J BIOMED MATER RES, V28, P1259, DOI 10.1002/jbm.820281103; Laurencin Cato T., 1995, P59; Leroux JC, 1996, MICROENCAPSULATION M, P535; MOSZNER N, 1995, ANGEW MAKROMOL CHEM, V224, P115, DOI 10.1002/apmc.1995.052240112; OMMAYA AK, 1984, CANC DRUG DEL, V1, P169, DOI 10.1089/cdd.1984.1.169; TAMADA J, 1992, J BIOM SCI PE, V3, P305; TOGUCHI H, 1992, CLIN THER, V14, P121; WALTER KA, 1995, NEUROSURGERY, V37, P1129, DOI 10.1227/00006123-199512000-00013	25	12	12	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					172	176		10.1038/nbt0298-172	http://dx.doi.org/10.1038/nbt0298-172			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487525				2022-12-25	WOS:000071831300031
J	Melov, S; Schneider, JA; Day, BJ; Hinerfeld, D; Coskun, P; Mirra, SS; Crapo, JD; Wallace, DC				Melov, S; Schneider, JA; Day, BJ; Hinerfeld, D; Coskun, P; Mirra, SS; Crapo, JD; Wallace, DC			A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase	NATURE GENETICS			English	Article							CENTRAL-NERVOUS-SYSTEM; HEART-MITOCHONDRIA; ALZHEIMERS-DISEASE; MIMETIC PROTECTS; NITRIC-OXIDE; INJURY; MUTANT; ENERGY	Reactive oxygen species (ROS) have been implicated in a wide range of degenerative processes including amyotrophic lateral sclerosis, ischemic heart disease, Alzheimer disease, Parkinson disease and aging(1-5). ROS are generated by mitochondria as the toxic by-products of oxidative phosphorylation, their energy generating pathway(6,7). Genetic inactivation of the mitochondrial form of superoxide dismutase in mice results in dilated cardiomyopathy, hepatic lipid accumulation and early neonatal deaths. We report that treatment with the superoxide dismutase (SOD) mimetic Manganese 5, 10, 15, 20-tetrakis (4-benzoic acid) porphyrin (MnTBAP) rescues these Sod2(tm1Cje)(-/-) mutant mice from this systemic pathology and dramatically prolongs their survival. The animals instead develop a pronounced movement disorder progressing to total debilitation by three weeks of age. Neuropathologic evaluation reveals a striking spongiform degeneration of the cortex and specific brain stem nuclei associated with gliosis and intramyelinic vacuolization similar to that observed in cytotoxic edema and disorders associated with mitochondrial abnormalities such as Leighs disease and Canavans disease. We believe that due to the failure of MnTBAP to cross the blood brain barrier progressive neuropathology is caused by excessive mitochondrial production of ROS. Consequently, MnTBAP-treated Sod2(tm1Cje)(-/-) mice may provide an excellent model for examining the relationship between free radicals and neurodegenerative diseases and for screening new drugs to treat these disorders.	Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA; Rush Presbyterian St Lukes Med Ctr, Rush Inst Aging, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA; Emory Univ, Sch Med, Vet Affairs Med Ctr, Atlanta, GA 30033 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30033 USA	Emory University; Rush University; Rush University; Duke University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Wallace, DC (corresponding author), Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA.		Melov, Simon/AAC-9469-2020	Melov, Simon/0000-0001-8554-2834	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013154] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45572] Funding Source: Medline; NIA NIH HHS [AG13154] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADACHI M, 1967, J NEUROPATH EXP NEUR, V26, P164; Bancroft G.D., 1996, THEORY PRACTICE PATH, V4th ed.; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Day BJ, 1996, TOXICOL APPL PHARM, V140, P94, DOI 10.1006/taap.1996.0201; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HENSLEY K, 1995, P W PHARMACOL SOC, V38, P113; HIRANO A, 1968, J NEUROPATH EXP NEUR, V27, P571; KIMURA S, 1991, PEDIATR NEUROL, V7, P56, DOI 10.1016/0887-8994(91)90108-W; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MATTSON MP, 1994, ANN NY ACAD SCI, V747, P50; Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974; Schulz JB, 1995, ANN NY ACAD SCI, V765, P100, DOI 10.1111/j.1749-6632.1995.tb16565.x; SIMONIAN NA, 1996, ANN REV PHARM TOXICO, V36, P83106; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Wallace D., 1996, MOL GENETIC BASIS NE, P237; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	23	418	429	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					159	163		10.1038/ng0298-159	http://dx.doi.org/10.1038/ng0298-159			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462746				2022-12-25	WOS:000071779500025
J	Martens, UM; Zijlmans, JMJM; Poon, SSS; Dragowska, W; Yui, J; Chavez, EA; Ward, RK; Lansdorp, PM				Martens, UM; Zijlmans, JMJM; Poon, SSS; Dragowska, W; Yui, J; Chavez, EA; Ward, RK; Lansdorp, PM			Short telomeres on human chromosome 17p	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR; GENE; CARCINOMAS; (TTAGGG)N; MUTATIONS; SEQUENCE; 17P13.3; FUSION; CELLS; DNA	Human chromosomes terminate in a series of T(2)AG(3), repeats(1), which, together with associated proteins, are essential for chromosome stability(2,3). In somatic cells, these sequences are known to be gradually lost through successive cells divisions(4,5); however, information about changes on specific chromosomes is not available. Individual telomeres could mediate important biological effects as was shown in yeast, in which loss of a single telomere results in cell-cycle arrest and chromosome loss(6). We now demonstrate by quantitative fluorescence in situ hybridization (Q-FISH; ref. 7) that the number of T(2)AG(3) repeats on specific chromosome arms is very similar in different tissues from the same donor and varies only to some extent between donors. In all sixteen individuals studied, telomeres on chromosome 17p were shorter than the median telomere length-a finding confirmed by analysis of terminal restriction fragments from sorted chromosomes. These observations provide evidence of chromosome-specific factors regulating the number of T(2)AG(3) repeats in individual telomeres and raise the possibility that the relatively short telomeres on chromosome 17p contribute to the frequent loss of 17p alleles in human cancers.	British Columbia Canc Res Ctr, Terry Fox Lab Hematol Oncol, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Elect Engn, Ctr Integrated Comp Syst Res, Vancouver, BC, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Lansdorp, PM (corresponding author), British Columbia Canc Res Ctr, Terry Fox Lab Hematol Oncol, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.			Lansdorp, Peter/0000-0001-7435-1071	NIAID NIH HHS [AI29524] Funding Source: Medline; NIGMS NIH HHS [GM56162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029524, R21AI029524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Blackburn EH, 1995, TELOMERES; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; CORNELIS RS, 1994, CANCER RES, V54, P4200; DELANGE T, 1995, TELOMERES, P265; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; IJDO JW, 1991, P NATL ACAD SCI USA, V88, P9051, DOI 10.1073/pnas.88.20.9051; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LANSDORP PM, 1992, J EXP MED, V175, P1501, DOI 10.1084/jem.175.6.1501; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MONARD SP, 1995, HUMAN CHROMOSOMES PR, V2, P172; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; White GRM, 1996, BRIT J CANCER, V74, P863, DOI 10.1038/bjc.1996.449; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	30	297	305	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					76	80		10.1038/ng0198-018	http://dx.doi.org/10.1038/ng0198-018			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425906				2022-12-25	WOS:000071259600027
J	Siffert, W; Rosskopf, D; Siffert, G; Busch, S; Moritz, A; Erbel, R; Sharma, AM; Ritz, E; Wichmann, HE; Jakobs, KH; Horsthemke, B				Siffert, W; Rosskopf, D; Siffert, G; Busch, S; Moritz, A; Erbel, R; Sharma, AM; Ritz, E; Wichmann, HE; Jakobs, KH; Horsthemke, B			Association of a human G-protein beta 3 subunit variant with hypertension	NATURE GENETICS			English	Article							SODIUM-PROTON EXCHANGE; IMMORTALIZED LYMPHOBLASTS	Hypertension is a common disorder of multifactorial origin that constitutes a major risk factor for cardiovascular events such as stroke and myocardial infarction. Previous studies demonstrated an enhanced signal transduction via pertussis toxin-sensitive G proteins in lymphoblasts and fibroblasts from selected patients with essential hypertension. We have detected a novel polymorphism (C825T) in exon 10 of the gene encoding the beta 3 subunit of heterotrimeric G proteins (GNB3). The T allele is associated with the occurrence of a splice variant, GNB3-s (encoding G beta 3-s), in which the nucleotides 498-620 of exon 9 are deleted. This in-frame deletion causes the loss of 41 amino acids and one WD repeat domain of the G beta subunit. By western-blot analysis, G beta 3-s appears to be predominantly expressed in cells from individuals carrying the T allele. Significant enhancement of stimulated GTP gamma S binding to Sf9 insect cells expressing G beta 3-s together with G alpha(i)2 and G gamma 5 indicates that this splice variant is biologically active. Genotype analysis of 427 normotensive and 426 hypertensive subjects suggests a significant association of the T allele with essential hypertension.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany; Univ Essen Gesamthsch Klinikum, Abt Kardiol, D-45122 Essen, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Abt Endokrinol & Nephrol, D-12200 Berlin, Germany; Klinikum Univ Heidelberg, Sekt Nephrol, D-69115 Heidelberg, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Essen Gesamthsch Klinikum, Inst Human Genet, D-45122 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Duisburg Essen	Siffert, W (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Wichmann, Heinz Erich/AAA-5695-2022					AALKJAER C, 1989, J HYPERTENS, V7, P305; AnsariLari MA, 1996, GENOME RES, V6, P314, DOI 10.1101/gr.6.4.314; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cusi D, 1997, LANCET, V349, P1353, DOI 10.1016/S0140-6736(97)01029-5; Gruska S, 1997, J HYPERTENS, V15, P29, DOI 10.1097/00004872-199715010-00003; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Jin Y, 1996, J CLIN INVEST, V98, P1745, DOI 10.1172/JCI118973; KALKBRENNER RF, 1996, BIOCHIM BIOPHYS ACTA, V1314, P125; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Liu WG, 1997, NAT GENET, V16, P328, DOI 10.1038/ng0897-328; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Pietruck F, 1996, CIRC RES, V79, P974, DOI 10.1161/01.RES.79.5.974; ROSSKOPF D, 1993, J CLIN INVEST, V92, P2553, DOI 10.1172/JCI116865; ROSSKOPF D, 1993, HYPERTENSION, V21, P607, DOI 10.1161/01.HYP.21.5.607; ROSSKOPF D, 1992, J HYPERTENS, V10, P839; SIFFERT W, 1995, HYPERTENSION, V26, P649, DOI 10.1161/01.HYP.26.4.649; SIFFERT W, 1995, J CLIN INVEST, V96, P759, DOI 10.1172/JCI118120; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; StallingsMann ML, 1996, P NATL ACAD SCI USA, V93, P12394, DOI 10.1073/pnas.93.22.12394	25	687	762	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					45	48		10.1038/ng0198-45	http://dx.doi.org/10.1038/ng0198-45			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425898				2022-12-25	WOS:000071259600019
J	Wiestner, A; Schlemper, RJ; van der Maas, APC; Skoda, RC				Wiestner, A; Schlemper, RJ; van der Maas, APC; Skoda, RC			An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia	NATURE GENETICS			English	Article							FAMILIAL ESSENTIAL THROMBOCYTHEMIA; MOLECULAR-CLONING; DIFFERENTIATION; GROWTH; MICE	Essential thrombocythaemia (ET) is a chronic myeloproliferative syndrome due to sustained proliferation of megakaryocytes, which results in elevated numbers of circulating platelets, thrombotic or haemorrhagic episodes and occasional leukaemic transformation(1). The cause of ET is unknown. Hereditary thrombocythaemia (HT) with autosomal-dominant transmission has been described with manifestations similar to those of sporadic ET2-8. As the thrombopoietin gene (THPO) encodes a lineage-restricted growth factor with profound stimulatory effects on megakaryopoiesis and platelet production(9,10), we tested the hypothesis that HT results from a mutation in the human THPO gene. In a Dutch family with eleven affected individuals(7), the thrombopoietin protein (TPO) concentrations in serum were consistently elevated in individuals with HT. We derived an intragenic CA marker for the human THPO gene and performed linkage analysis in fourteen informative meioses in this family. This resulted in a lod score of 3.5 at theta=0, A G-->C transversion was found in the splice donor site of intron 3 of the THPO gene in all affected family members. This mutation leads to THPO mRNAs with shortened 5'-untranslated regions (UTR) that are more efficiently translated than the normal THPO transcripts. We conclude that a splice donor mutation in THPO leads to systemic overproduction of TPO and causes thrombocythaemia.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Fukuoka Univ, Sch Med, Dept Anat, Fukuoka 81480, Japan; Westeinde Hosp, Dept Internal Med, NL-2512 VA The Hague, Netherlands	University of Basel; Fukuoka University	Skoda, RC (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.							BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CHANG MS, 1995, J BIOL CHEM, V270, P511, DOI 10.1074/jbc.270.2.511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANDREA AD, 1994, NEW ENGL J MED, V330, P839; Eaton DL, 1997, EXP HEMATOL, V25, P1; EYSTER ME, 1986, AM J MED, V80, P497, DOI 10.1016/0002-9343(86)90727-8; FERNANDEZROBLES E, 1990, PEDIATR HEMAT ONCOL, V7, P373, DOI 10.3109/08880019009033414; FICKERS M, 1974, ACTA HAEMATOL-BASEL, V51, P257, DOI 10.1159/000208303; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Kamura T, 1997, J BIOL CHEM, V272, P11361; Kaushansky K, 1997, ANNU REV MED, V48, P1; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KIKUCHI M, 1995, BRIT J HAEMATOL, V89, P900; KRAWCZAK M, 1992, HUM GENET, V90, P41; Murphy S, 1997, SEMIN HEMATOL, V34, P29; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OTT J, 1976, AM J HUM GENET, V28, P528; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SCHLEMPER RJ, 1994, ANN HEMATOL, V68, P153, DOI 10.1007/BF01727421; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SLEE PHTJ, 1981, ACTA MED SCAND, V210, P321; SOHMA Y, 1994, FEBS LETT, V353, P57, DOI 10.1016/0014-5793(94)01008-0; Stoffel R, 1996, BLOOD, V87, P567, DOI 10.1182/blood.V87.2.567.bloodjournal872567; Tahara T, 1996, BRIT J HAEMATOL, V93, P783, DOI 10.1046/j.1365-2141.1996.d01-1741.x; vanDijken PJ, 1996, ACTA PAEDIATR, V85, P1132, DOI 10.1111/j.1651-2227.1996.tb14234.x; WILLIAMS EC, 1991, AM J HEMATOL, V37, P124, DOI 10.1002/ajh.2830370211; YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025; Zhou W, 1997, BLOOD, V89, P1551, DOI 10.1182/blood.V89.5.1551.1551_1551_1559	28	226	230	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					49	52		10.1038/ng0198-49	http://dx.doi.org/10.1038/ng0198-49			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425899				2022-12-25	WOS:000071259600020
J	Griffin, TJ; Tang, W; Smith, LM				Griffin, TJ; Tang, W; Smith, LM			Genetic analysis by peptide nucleic acid affinity MALDI-TOF mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						genomics; polymorphism	LASER DESORPTION; TYROSINASE GENE; DNA; MATRIX; OLIGONUCLEOTIDES; HYBRIDIZATION; MUTATIONS; PROBES; PNA	The ability to analyze multiple polymorphic sites rapidly and accurately is crucial in all areas of genetic analysis. We have developed an approach for the detection of multiple point mutations, using allele-specific, mass-labeled, peptide nucleic acid (PNA) hybridization probes, and direct analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The composite mass spectra produced contain peaks of distinct masses corresponding to each allele present, resulting in a mass spectral ''fingerprint'' for each DNA sample. The hybridization characteristics of PNA:DNA duplexes were found to be highly dependent on both base content and sequence. Results from the analysis of four polymorphic sites contained in exon 4 of the human tyrosinase gene show that this approach is simple, rapid, and accurate with potential applications in many areas of genetic analysis.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Griffin, Timothy/0000-0001-6801-2559				Butler JM, 1996, ANAL CHEM, V68, P3283, DOI 10.1021/ac960317a; CASKEY CT, 1987, SCIENCE, V263, P1223; Chou CW, 1996, RAPID COMMUN MASS SP, V10, P1410, DOI 10.1002/(SICI)1097-0231(199608)10:11<1410::AID-RCM671>3.0.CO;2-F; COTTON RGH, 1989, BIOCHEM J, V263, P1; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FORREST S, 1995, NAT GENET, V10, P375, DOI 10.1038/ng0895-375; GIEBEL LB, 1991, GENOMICS, V9, P435, DOI 10.1016/0888-7543(91)90409-8; Girault S, 1996, ANAL CHEM, V68, P2122, DOI 10.1021/ac960043r; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; JUNNKE C, 1996, ANAL BIOCHEM, V237, P174; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; Koster H, 1996, NAT BIOTECHNOL, V14, P1123, DOI 10.1038/nbt0996-1123; LANDEGREN U, 1988, SCIENCE, V242, P229, DOI 10.1126/science.3051381; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; TANG K, 1995, NUCLEIC ACIDS RES, V23, P3126, DOI 10.1093/nar/23.16.3126; Tomac S, 1996, J AM CHEM SOC, V118, P5544, DOI 10.1021/ja960495l; TRIPATHI RK, 1992, AM J MED GENET, V43, P865, DOI 10.1002/ajmg.1320430523; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; WU KJ, 1993, RAPID COMMUN MASS SP, V7, P142, DOI 10.1002/rcm.1290070206; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P3929, DOI 10.1093/nar/19.14.3929; ZHU L, 1995, J AM CHEM SOC, V117, P6048, DOI 10.1021/ja00127a018	24	94	116	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1368	1372		10.1038/nbt1297-1368	http://dx.doi.org/10.1038/nbt1297-1368			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415888				2022-12-25	WOS:A1997YK36100027
J	Tanelian, DL; Barry, MA; Johnston, SA; Le, T; Smith, GM				Tanelian, DL; Barry, MA; Johnston, SA; Le, T; Smith, GM			Semaphorin III can repulse and inhibit adult sensory afferents in vivo	NATURE MEDICINE			English	Article							GROWTH CONE GUIDANCE; FREE NERVE-ENDINGS; CORNEAL EPITHELIUM; SPINAL-CORD; A-DELTA; RABBIT; FIBER	During development, semaphorins (collapsin, fasciclin) mediate repulsive and inhibitory guidance of neurons(1-4). Semaphorin III, a secretable member of this family, is expressed by the ventral spinal cord at the time corresponding to projection of sensory afferents from the dorsal root ganglion (DRG) into the spinal cord(6). The inhibitory effect of E14 ventral cord is active only on nerve growth factor (NGF)-responsive sensory afferents (small-diameter A-delta and C fibers subserving sensations of temperature and pain)(5). Similarly, COS cells secreting recombinant semaphorin III are able to selectively repel DRG afferents whose growth is stimulated by NGF and not NT-3 (ref. 7). However, it is not known whether these molecules can exert a functional role in the fully developed adult peripheral nervous system. In this study, we demonstrated that gene gun transfection and production of semaphorin III in corneal epithelial cells in adult rabbits in vivo can cause repulsion of established A-delta and C fiber trigeminal sensory afferents. In addition, it is shown that, following epithelial wounding and denervation, semaphorin III is able to inhibit collateral nerve sprouts from innervating the reepithelialized tissue. These findings are significant in that they provide direct evidence that small-diameter adult sensory neurons retain the ability to respond to semaphorin III. In addition, the corneal gene gun technique may be generally used to study the in vivo effects of neural growth modulators by quantifying the amount of sensory nerve growth.	Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Mol Cardiol Labs, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Smith, GM (corresponding author), Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BEUERMAN RW, 1984, NEUROSCI LETT, V44, P99, DOI 10.1016/0304-3940(84)90228-3; EBENDAL T, 1983, EXP CELL RES, V148, P311, DOI 10.1016/0014-4827(83)90155-6; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; HELM R, 1995, NATURE, V373, P663; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MACIVER MB, 1993, J NEUROSCI, V13, P4511; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Nguyen DH, 1997, CORNEA, V16, P192; ROZSA AJ, 1982, PAIN, V14, P105, DOI 10.1016/0304-3959(82)90092-6; Smith GM, 1996, EXP NEUROL, V139, P156, DOI 10.1006/exnr.1996.0090; Tanelian DL, 1997, BIOTECHNIQUES, V23, P484, DOI 10.2144/97233st06; TANELIAN DL, 1984, EXP NEUROL, V84, P165, DOI 10.1016/0014-4886(84)90013-X; TANELIAN DL, 1995, J NEUROPHYSIOL, V73, P1568, DOI 10.1152/jn.1995.73.4.1568; TANELIAN DL, 1990, J NEUROSCI METH, V32, P213, DOI 10.1016/0165-0270(90)90143-4; WILLIAMS RS, 1995, P NATL ACAD SCI USA, V88, P361; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209	20	105	116	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1398	1401		10.1038/nm1297-1398	http://dx.doi.org/10.1038/nm1297-1398			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396612				2022-12-25	WOS:000072249500038
J	Chinery, R; Brockman, JA; Peeler, MO; Shyr, Y; Beauchamp, RD; Coffey, RJ				Chinery, R; Brockman, JA; Peeler, MO; Shyr, Y; Beauchamp, RD; Coffey, RJ			Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBP beta	NATURE MEDICINE			English	Article							NF-KAPPA-B; CYCLIN-DEPENDENT KINASES; VITAMIN-E; INDUCED APOPTOSIS; CDK INHIBITORS; IN-VIVO; CELLS; P53; ALPHA; P21	Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. Five-fluorouracil (5FU) remains the single most effective treatment for advanced disease, despite a response rate of only 20%. Herein, we show that the antioxidants pyrrolidinedithiocarbamate and vitamin E induce apoptosis in CRC cells. This effect is mediated by induction of p21(WAF1/CIP1), a powerful inhibitor of the cell cycle, through a mechanism involving C/EBP beta (a member of the CCAAT/enhancer binding protein family of transcription factors), independent of p53. Antioxidants significantly enhance CRC tumor growth inhibition by cytotoxic chemotherapy in vitro (5FU and doxorubicin) and in vivo (5FU). Thus, chemotherapeutic agents administered in the presence of antioxidants may provide a novel therapy for colorectal cancer.	VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT PREVENT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT SURG,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,VANDERBILT CANC CTR,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System				Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053319] Funding Source: NIH RePORTER; NCI NIH HHS [CA 4613, CA 69457] Funding Source: Medline; NIGMS NIH HHS [GM 53319] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ADV COL CANC MET, 1992, J CLIN ONCOL, V10, P896; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENDICH A, 1988, AM J CLIN NUTR, V48, P612, DOI 10.1093/ajcn/48.3.612; BOYLE P, 1985, INT J CANCER, V36, P9, DOI 10.1002/ijc.2910360103; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3313; CUMMINGS J, 1991, EUR J CANCER, V27, P532, DOI 10.1016/0277-5379(91)90209-V; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HARPER JW, 1993, CELL, V75, P805; HERRMANN R, 1990, CANCER TREAT REV, V17, P51, DOI 10.1016/0305-7372(90)90016-9; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEMARIE E, 1986, METHOD FIND EXP CLIN, V8, P51; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETERS GJ, 1995, EUR J CANCER, V31A, P1299, DOI 10.1016/0959-8049(95)00172-F; POLL V, 1990, CELL, V63, P643; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRAHBU NS, 1996, CLIN CANCER RES, V2, P1221; RAUTALAHTI M, 1993, ANN MED, V25, P435; REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stone WL, 1997, JNCI-J NATL CANCER I, V89, P1006, DOI 10.1093/jnci/89.14.1006; SUNDERMAN FW, 1991, ANN CLIN LAB SCI, V21, P70; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tsai JC, 1996, J BIOL CHEM, V271, P3667; TURLEY JM, 1995, CELL GROWTH DIFFER, V6, P655; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu GS, 1996, CLIN CANCER RES, V2, P623; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	311	316	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1233	1241		10.1038/nm1197-1233	http://dx.doi.org/10.1038/nm1197-1233			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359698				2022-12-25	WOS:A1997YD89600032
J	Moses, AV; Williams, SE; Strussenberg, JG; Heneveld, ML; Ruhl, RA; Bakke, AC; Bagby, GC; Nelson, JA				Moses, AV; Williams, SE; Strussenberg, JG; Heneveld, ML; Ruhl, RA; Bakke, AC; Bagby, GC; Nelson, JA			HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; MARROW STROMAL CELLS; ADHESION MOLECULE-1 VCAM-1; BONE-MARROW; KAPOSIS-SARCOMA; FUNCTIONAL CD40; IL-6 PRODUCTION; LEUKEMIA CELLS; TUMOR-CELLS; IN-VITRO	Human immunodeficiency virus (HIV)-1 infection is associated with the development of aggressive extranodal B-cell non-Hodgkin's lymphomas. Using microvascular endothelial cell (MVEC)enriched bone marrow stromal cultures, HIV infection of stromal MVECs from lymphoma patients induced the outgrowth of malignant B cells. MVECs were the only HIV-infected cells in the stroma, and purified brain MVECs also induced a phenotype supportive of neoplastic B-cell attachment and proliferation. HIV infection of MVECs stimulated surface expression of CD40 and allowed preferential induction of the vascular cell adhesion molecule VCAM-1 after CD40 triggering. B-lymphoma cells expressed the CD40 ligand (CD40L), and blocking of CD40-CD40L interactions between HIV-infected MVECs and B-lymphoma cells inhibited B-cell attachment and proliferation. These observations suggest that HIV promotes B-lymphoma cell growth through facilitating attachment of lymphoma cells to HIV-infected MVECs and represent a novel mechanism through which viruses may induce malignancies.	OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL & MED GENET,PORTLAND,OR 97201; VET AFFAIRS MED CTR,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL MICROBIOL & IMMUNOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University	Moses, AV (corresponding author), OREGON HLTH SCI UNIV,DEPT MOL MICROBIOL & IMMUNOL,L220,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Bagby, Grover/0000-0001-6830-2046	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051519] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49887] Funding Source: Medline; NIMH NIH HHS [MH 51519] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Astrin S M, 1992, Curr Top Microbiol Immunol, V182, P399; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BROSHOFF C, 1995, NAT MED, V1, P1274; CAMPANA D, 1993, BLOOD, V81, P1025; CANN AJ, 1990, J VIROL, V64, P4735, DOI 10.1128/JVI.64.10.4735-4742.1990; CASTLE BE, 1993, J IMMUNOL, V151, P1777; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; DELECLUSE HJ, 1993, BLOOD, V82, P552; DITTEL BN, 1993, BLOOD, V81, P2272; FREEDMAN AS, 1993, SEMIN HEMATOL, V30, P318; FREEDMAN AS, 1992, BLOOD, V79, P206; Gaidano G, 1995, ADV CANCER RES, V67, P113, DOI 10.1016/S0065-230X(08)60712-5; GAIDANO G, 1993, LEUKEMIA, V7, P1621; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GREEN DF, 1992, KIDNEY INT, V41, P956, DOI 10.1038/ki.1992.146; GROOPMAN JE, 1986, BLOOD, V67, P612; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Harris M, 1996, J GEN VIROL, V77, P2379, DOI 10.1099/0022-1317-77-10-2379; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; JACOBSEN K, 1990, EUR J IMMUNOL, V20, P2395, DOI 10.1002/eji.1830201106; JARVIS LJ, 1995, J IMMUNOL, V155, P2359; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P337; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LEVY JA, 1985, J INFECT DIS, V152, P734, DOI 10.1093/infdis/152.4.734; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MANABE A, 1994, BLOOD, V83, P758; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moses A V, 1996, J NeuroAIDS, V1, P85; Moses AV, 1996, BLOOD, V87, P919, DOI 10.1182/blood.V87.3.919.bloodjournal873919; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; Moses AV, 1996, J VIROL, V70, P3401, DOI 10.1128/JVI.70.6.3401-3406.1996; Pammer J, 1996, AM J PATHOL, V148, P1387; Panayiotidis P, 1996, BRIT J HAEMATOL, V92, P97, DOI 10.1046/j.1365-2141.1996.00305.x; PELLICI PG, 1986, J EXP MED, V164, P2049; Pinchuk LM, 1996, J IMMUNOL, V157, P4363; PREVOT S, 1993, HISTOPATHOLOGY, V22, P151, DOI 10.1111/j.1365-2559.1993.tb00094.x; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SHIRAMIZU B, 1992, J CLIN ONCOL, V10, P383, DOI 10.1200/JCO.1992.10.3.383; SIMMONS PJ, 1992, BLOOD, V80, P388; STEFFAN AM, 1992, P NATL ACAD SCI USA, V89, P1582, DOI 10.1073/pnas.89.5.1582; SUBAR M, 1988, BLOOD, V72, P667; TANG JH, 1993, BLOOD, V82, P3415; TELENTI A, 1990, J CLIN MICROBIOL, V28, P2187, DOI 10.1128/JCM.28.10.2187-2190.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WOLF ML, 1991, J IMMUNOL, V147, P3324; WONG D, 1995, MICROVASC RES, V49, P325, DOI 10.1006/mvre.1995.1028; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	55	39	41	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1242	1249		10.1038/nm1197-1242	http://dx.doi.org/10.1038/nm1197-1242			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359699				2022-12-25	WOS:A1997YD89600033
J	Akimaru, H; Hou, DX; Ishii, S				Akimaru, H; Hou, DX; Ishii, S			Drosophila CBP is required for dorsal-dependent twist gene expression	NATURE GENETICS			English	Article							NUCLEAR-PROTEIN CBP; DNA-BINDING SUBUNIT; NF-KAPPA-B; TRANSCRIPTIONAL COACTIVATOR; DORSOVENTRAL PATTERN; LOCALIZATION; GRADIENT; EMBRYOS; REL; MUTATIONS	Although CREB-binding protein (CBP) functions as a co-activator of many transcription factors(1-3), relatively little is known about the physiological role of CBP. Mutations in the human CBP gene are associated with Rubinstein-Taybi syndrome, a haplo-insufficiency disorder characterized by abnormal pattern formation(4). Recently we isolated a Drosophila CBP (dCBP) mutant(5), and found dCBP to be maternally expressed, suggesting that it plays a role in early embryogenesis. Mesoderm formation is one of the most important events during early embryogenesis. To initiate the differentiation of the mesoderm in Drosophila, multiple zygotic genes such as twist (twi) and snail (sna), which encode a basic-helix-loop-helix and a zinc finger transcription factor, respectively, are required(6,7). The transcription of these genes is induced by maternal dorsal (dl) protein (Dl; refs 8-10), a transcription factor that is homologous to the NF-kappa B family of proteins(11-13). The activity of dl is negatively regulated by cactus (cact), a Drosophila homologue of I kappa B-14. Here, we show that dCBP mutants fail to express twi and generate twisted embryos. This is explained by results showing the dCBP is necessary for dl-mediated activation of the twi promoter.	RIKEN,TSUKUBA LIFE SCI CTR,MOL GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	RIKEN			Hou, De-Xing/C-9296-2011; Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; CHOU TB, 1992, GENETICS, V131, P643; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ElGhouzzi V, 1997, NAT GENET, V15, P42; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOVIND S, 1993, DEVELOPMENT, V117, P135; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEPTIN M, 1990, DEVELOPMENT, V110, P73; NOCERA PPD, 1983, P NATL ACAD SCI USA, V82, P1025; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; WORTKAMP A, 1991, NATURE, V352, P539; ZALOKAR M, 1977, STAIN TECHNOL, V52, P89, DOI 10.3109/10520297709116753	31	96	97	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					211	214		10.1038/ng1097-211	http://dx.doi.org/10.1038/ng1097-211			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326945				2022-12-25	WOS:A1997XZ55500031
J	Erhard, M; vonDohren, H; Jungblut, P				Erhard, M; vonDohren, H; Jungblut, P			Rapid typing and elucidation of new secondary metabolites of intact cyanobacteria using MALDI-TOF mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						cyanobacteria; secondary metabolites; MALDI-TOF PSD; microcystin; anabaenopeptolins	ASSISTED LASER DESORPTION/IONIZATION; 2-DIMENSIONAL ELECTROPHORESIS; MICROCYSTIS-AERUGINOSA; IDENTIFICATION; DEPSIPEPTIDES; ANABAENA; BACTERIA; PROTEINS; STRAINS	Toxic cyanobacterial blooms are a threat because of secondary metabolite production. We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to identify intact microorganisms. Microgram quantities of prepared cells, including solvent (acetonitrile and ethanol) and alpha-cyano-4-hydroxycinnamic acid matrix, display spectra showing predominantly the secondary metabolites including known microcystins, micropeptin, and anabaenopeptolin. A new cyclic anabaenopeptolin has been identified using the Post-Source-Decay mode. Strains of various origins can easily be typed according to their cyclic peptide production, and toxic and nontoxic algal blooms can be differentiated within minutes.	TECH UNIV BERLIN, INST BIOCHEM & MOL BIOL, D-1000 BERLIN, GERMANY; MAX PLANCK INST INFECT BIOL, BERLIN, GERMANY	Technical University of Berlin; Max Planck Society			Jungblut, Peter R/A-1576-2011					Claydon MA, 1996, NAT BIOTECHNOL, V14, P1584, DOI 10.1038/nbt1196-1584; HARADA K, 1993, TETRAHEDRON LETT, V34, P6091, DOI 10.1016/S0040-4039(00)61736-7; HARADA K, 1995, TETRAHEDRON LETT, V36, P1511, DOI 10.1016/0040-4039(95)00073-L; Holland RD, 1996, RAPID COMMUN MASS SP, V10, P1227, DOI 10.1002/(SICI)1097-0231(19960731)10:10<1227::AID-RCM659>3.0.CO;2-6; ISHIDA K, 1995, TETRAHEDRON LETT, V36, P3535, DOI 10.1016/0040-4039(95)00547-P; Jungblut P, 1996, ELECTROPHORESIS, V17, P839, DOI 10.1002/elps.1150170505; Kleinkauf H, 1997, BIOTECHNOLOGY, V7, P277; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Krishnamurthy T, 1996, RAPID COMMUN MASS SP, V10, P883, DOI 10.1002/(SICI)1097-0231(19960610)10:8<883::AID-RCM594>3.3.CO;2-M; Liang XL, 1996, RAPID COMMUN MASS SP, V10, P1219, DOI 10.1002/(SICI)1097-0231(19960731)10:10<1219::AID-RCM660>3.0.CO;2-R; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MARTIN C, 1993, J ANTIBIOT, V46, P1550, DOI 10.7164/antibiotics.46.1550; Meissner K, 1996, FEMS MICROBIOL LETT, V135, P295; SANO T, 1995, TETRAHEDRON LETT, V36, P5933, DOI 10.1016/00404-0399(50)1198Q-; SHI L, 1995, ARCH MICROBIOL, V163, P7, DOI 10.1007/BF00262197; SIVONEN K, 1992, APPL ENVIRON MICROB, V58, P2495, DOI 10.1128/AEM.58.8.2495-2500.1992; Watanabe M.F., 1996, TOXIC MICROCYSTIS; Watanabe M.M., 1994, NIES COLLECTION LIST; Williams DE, 1996, J NAT PROD, V59, P570, DOI 10.1021/np960108l	19	130	135	0	40	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					906	909		10.1038/nbt0997-906	http://dx.doi.org/10.1038/nbt0997-906			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306409				2022-12-25	WOS:A1997XW41000036
J	Evans, D				Evans, D			Produce-on-demand: What's good for US markets is good for world markets too	NATURE BIOTECHNOLOGY			English	Editorial Material											Evans, D (corresponding author), DNA PLANT TECHNOL,BUSINESS DEV,6701 SAN PABLO AVE,OAKLAND,CA, USA.								0	0	0	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					802	802		10.1038/nbt0796-802	http://dx.doi.org/10.1038/nbt0796-802			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9630992				2022-12-25	WOS:A1996UV62000004
J	Molberg, O; Mcadam, SN; Korner, R; Quarsten, H; Kristiansen, C; Madsen, L; Fugger, L; Scott, H; Noren, O; Roepstorff, P; Lundin, KEA; Sjostrom, H; Sollid, LM				Molberg, O; Mcadam, SN; Korner, R; Quarsten, H; Kristiansen, C; Madsen, L; Fugger, L; Scott, H; Noren, O; Roepstorff, P; Lundin, KEA; Sjostrom, H; Sollid, LM			Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease	NATURE MEDICINE			English	Article							SMALL-INTESTINAL MUCOSA; MASS-SPECTROMETRY; CROSS-LINKING; BINDING; SPECIFICITY; ENDOCYTOSIS; PROTEINS; ANTIGEN	The action of tissue Transglutaminase(1) (TGase) on specific protein-bound glutamine residues plays a critical role in numerous biological processes(2-5). Here we provide evidence for a new role of this enzyme in the common, HLA-DQ2 (and DQ8) associated(6) enteropathy, celiac disease (CD). The intestinal inflammation in CD is precipitated by exposure to wheat gliadin in the diet(7) and is associated with increased mucosal activity of TGase(8). This enzyme has also been identified as the main target for CD-associated anti-endomysium autoantibodies(9), and is known to accept gliadin as one of its few substrates(10). We have examined the possibility that TGase could be involved in modulating the reactivity of gliadin specific T cells. This could establish a link between previous reports of the role of TGase in CD and the prevailing view of CD as a T-cell mediated disorder(7,11,12). We found a specific ef feet of TGase on T-cell recognition of gliadin. This effect was limited to gliadin-specific T cells isolated from intestinal CD lesions. We demonstrate that TGase mediates its effect through an ordered and specific deamidation of gliadins. This deamidation creates an epitope that binds efficiently to DQ2 and is recognized by gut-derived T cells. Generation of epitopes by enzymatic modification is a new mechanism that may be relevant for breaking of tolerance and initiation of autoimmune disease.	Univ Oslo, Rikshosp, Inst Transplantat Immunol, N-0027 Oslo, Norway; Univ Oslo, Rikshosp, Inst Pathol, LIIPAT, N-0027 Oslo, Norway; Odense Univ, Dept Mol Biol, DK-5230 Odense M, Denmark; Aarhus Univ Hosp, Skejby Sygehus, Dept Clin Immunol, DK-8200 Aarhus N, Denmark; Univ Copenhagen, Rigshosp, Dept Clin Immunol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Biochem C, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Southern Denmark; Aarhus University; Rigshospitalet; University of Copenhagen; University of Copenhagen	Lundin, KEA (corresponding author), Ulleval Hosp, Dept Med, Oslo, Norway.		Lundin, Knut E. A./AAW-9519-2021; Sollid, Ludvig/N-9691-2015; Körner, Roman/G-8565-2011	Lundin, Knut E. A./0000-0003-1713-5545; Sollid, Ludvig/0000-0001-8860-704X; Körner, Roman/0000-0001-9285-9290				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BRUCE SE, 1985, CLIN SCI, V68, P573, DOI 10.1042/cs0680573; COOKS RG, 1991, CHEM ENG NEWS, V69, P26, DOI 10.1021/cen-v069n012.p026; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FRAZER AC, 1959, LANCET, V2, P252; GJERTSEN HA, 1994, SCAND J IMMUNOL, V39, P567, DOI 10.1111/j.1365-3083.1994.tb03414.x; HALSTENSEN TS, 1992, PROG HISTOCHEM CYTOC, V26, P201, DOI 10.1016/S0079-6336(11)80096-3; HAMADA JS, 1994, CRIT REV FOOD SCI, V34, P283, DOI 10.1080/10408399409527664; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; Johansen BH, 1996, INT IMMUNOL, V8, P177, DOI 10.1093/intimm/8.2.177; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kwok WW, 1996, J EXP MED, V183, P1253, DOI 10.1084/jem.183.3.1253; LARRE C, 1994, J FOOD BIOCHEM, V17, P267; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LUNDIN KEA, 1994, HUM IMMUNOL, V41, P285, DOI 10.1016/0198-8859(94)90047-7; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MacDonald TT, 1992, COELIAC DISEASE, P283; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; Molberg O, 1998, GASTROENTEROLOGY, V114, P115, DOI 10.1016/S0016-5085(98)70639-0; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; Sollid LM, 1997, GUT, V41, P851, DOI 10.1136/gut.41.6.851; TESHIGAWARA K, 1985, MICROBIOL IMMUNOL, V29, P737, DOI 10.1111/j.1348-0421.1985.tb00877.x; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; vandeWal Y, 1996, IMMUNOGENETICS, V44, P246, DOI 10.1007/s002510050120; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WIESER H, 1995, COELIAC DIS, P191	33	869	889	3	74	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1998	4	6					713	717		10.1038/nm0698-713	http://dx.doi.org/10.1038/nm0698-713			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623982				2022-12-25	WOS:000074008300039
J	Folkers, GK; Fauci, AS				Folkers, GK; Fauci, AS			The role of US Government agencies in vaccine research and development	NATURE MEDICINE			English	Editorial Material							STATES		NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Folkers, GK (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							[Anonymous], 1997, MMWR-MORBID MORTAL W, V46, P624; Belshe RB, 1998, LANCET, V351, P460, DOI 10.1016/S0140-6736(98)22007-1; BLOOM BR, 1994, SCIENCE, V265, P1378, DOI 10.1126/science.8073275; *CDCP, 1998, MMWR-MORBID MORTAL W, V46, P1245; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P108; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR MORB MORTAL WKL, V46, P765; *DEP HHS, FISC YEAR 1999 JUST, V2; DOUGLAS RG, 1996, B NY ACAD MED, P113; Fauci AS, 1996, LANCET, V348, P1002; GELLIN B, 1998, JORDAN REPORT ACCELE; JENKS S, 1995, J NATL CANCER I, V87, P642, DOI 10.1093/jnci/87.9.642-a; Levine M.M., 1997, NEW GENERATION VACCI; Marcuse EK, 1997, PEDIATRICS, V100, P1015, DOI 10.1542/peds.100.6.1015; Marwick C, 1998, JAMA-J AM MED ASSOC, V279, P489, DOI 10.1001/jama.279.7.489; *NAT I ALL INF DIS, 1995, HIV AIDS RES AG; *NAT I ALL INF DIS, 1998, NIH AIDS RES REF REA; TANOUYE E, 1998, WALL STREET J   0225; *WHO, WORLD HLTH REP 1997; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269; 1997, NATURE, V388, P211; 1997, CVI STRATEGIC PLAN M	22	14	14	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			491	494		10.1038/nm0598supp-491	http://dx.doi.org/10.1038/nm0598supp-491			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585193	Bronze			2022-12-25	WOS:000073453500011
J	Phelan, A; Elliott, G; O'Hare, P				Phelan, A; Elliott, G; O'Hare, P			Intercellular delivery of functional p53 by the herpesvirus protein VP22	NATURE BIOTECHNOLOGY			English	Article						protein engineering; protein delivery; gene therapy	GENE-TRANSFER; CANCER-CELLS; LUNG-CANCER	The herpes simplex virus type 1 (HSV-1) virion protein VP22 exhibits the remarkable property of intercellular trafficking whereby the protein spreads from the cell in which it is synthesized to many surrounding cells. In addition to having implications for protein trafficking mechanisms, this function of VP22 might be exploited to overcome a major hurdle in gene therapy, i.e., efficient delivery of genes and gene products. We show that chimeric polypeptides, consisting of VP22 linked to the entire p53 protein, retain their ability to spread between cells and accumulate in recipient cell nuclei. Furthermore the p53-VP22 chimeric protein efficiently induces apoptosis in p53 negative human osteosarcoma cells resulting in a widespread cytotoxic effect. The intercellular delivery of functional p53-VP22 fusion protein is likely to prove beneficial in therapeutic strategies based on restoration of p53 function. These results, demonstrating intracellular transport of large functional proteins, indicate that VP22 delivery may have applications in gene therapy.	Marie Curie Res Inst, Surrey RH8 OTL, England		O'Hare, P (corresponding author), Marie Curie Res Inst, The Chart, Surrey RH8 OTL, England.	P.O'Hare@mcri.ac.uk		O'Hare, Peter/0000-0003-4508-5602				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; Hamada K, 1996, CANCER RES, V56, P3047; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Leslie J, 1996, VIROLOGY, V220, P60, DOI 10.1006/viro.1996.0286; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLAUCHLAN J, 1994, J GEN VIROL, V75, P2047, DOI 10.1099/0022-1317-75-8-2047; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Nielsen LL, 1997, CANCER GENE THER, V4, P129; PLENTENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998; Qazilbash MH, 1997, GENE THER, V4, P675, DOI 10.1038/sj.gt.3300444; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Xu M, 1997, HUM GENE THER, V8, P177, DOI 10.1089/hum.1997.8.2-177	18	263	311	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					440	443		10.1038/nbt0598-440	http://dx.doi.org/10.1038/nbt0598-440			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592391				2022-12-25	WOS:000073489600027
J	Scoles, DR; Huynh, DP; Morcos, PA; Coulsell, ER; Robinson, NGG; Tamanoi, F; Pulst, SM				Scoles, DR; Huynh, DP; Morcos, PA; Coulsell, ER; Robinson, NGG; Tamanoi, F; Pulst, SM			Neurofibromatosis 2 tumour suppressor schwannomin interacts with beta II-spectrin	NATURE GENETICS			English	Article							RETINAL-PIGMENT EPITHELIUM; NF2 GENE; ACTIN-BINDING; VESTIBULAR SCHWANNOMAS; CELL-ADHESION; TYPE-2; MEMBRANE; PRODUCT; MUTATIONS; PROTEIN	NF2 is the most commonly mutated gene in benign tumours of the human nervous system. The NF2 protein, called schwannomin or merlin, is absent in virtually all schwannomas, and many meningiomas and ependymomas(1-3). Using the yeast two-hybrid system, we identified beta II-spectrin (also known as fodrin) as a schwannomin-binding protein. Interaction occurred between the carboxy-terminal domain of schwannomin isoform 2 and the ankyrin-binding region of beta II-spectrin. Isoform 1 of schwannomin, in contrast, interacted weakly with beta II-spectrin, presumably because of its strong self-interaction. Thus, alternative splicing of NF2 may regulate beta II-spectrin binding. Schwannomin co-immunoprecipitated with beta II-spectrin at physiological concentrations. The two proteins interacted in vitro and co-localized in several target tissues and in STS26T cells. Three naturally occurring NF2 missense mutations showed reduced, but not absent, beta II-spectrin binding, suggesting an explanation for the milder phenotypes seen in patients with missense mutations. STS26T cells treated with NF2 antisense oligonucleotides showed alterations of the actin cytoskeleton. Schwannomin itself lacks the actin binding sites found in ezrin, radixin and moesin, suggesting that signalling to the actin cytoskeleton occurs via actin-binding sites on beta II-spectrin. Thus, schwannomin is a tumour suppressor directly involved in actin-cytoskeleton organization, which suggests that alterations in the cytoskeleton are an early event in the pathogenesis of some tumour types.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, CSMC Burns & Allen Res Inst,Neurogenet Lab, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, CSMC Burns & Allen Res Inst,Div Neurol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Pulst, SM (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, CSMC Burns & Allen Res Inst,Neurogenet Lab, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.				NINDS NIH HHS [NS01428-01A1, NS10524-01] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Claudio JO, 1997, NEUROREPORT, V8, P2025, DOI 10.1097/00001756-199705260-00044; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; DENBAKKER MA, 1995, ONCOGENE, V10, P757; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; DISCHER D, 1993, J BIOL CHEM, V268, P7186; EVANS DGR, 1995, J MED GENET, V32, P470, DOI 10.1136/jmg.32.6.470; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HU RJ, 1992, J BIOL CHEM, V267, P18715; Huynh DP, 1996, ONCOGENE, V13, P73; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; HUYNH DP, 1994, HUM MOL GENET, V3, P1075, DOI 10.1093/hmg/3.7.1075; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; Kluwe L, 1996, HUM GENET, V97, P224, DOI 10.1007/BF02265270; MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507; Mautner VF, 1996, NEUROSURGERY, V38, P880, DOI 10.1097/00006123-199605000-00004; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; Morcos P, 1996, MOL CELL BIOL, V16, P2496; POULLET P, 1995, METHOD ENZYMOL, V255, P488; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Sanderson J, 1996, BIOCHEM BIOPH RES CO, V218, P893, DOI 10.1006/bbrc.1996.0159; SANTOS A, 1994, RETINA-J RET VIT DIS, V14, P6, DOI 10.1097/00006982-199401000-00002; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; SIANO M, 1997, J CELL SCI, V110, P2249; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VYBIRAL T, 1992, CELL MOTIL CYTOSKEL, V21, P293, DOI 10.1002/cm.970210405; WINKELMANN JC, 1993, BLOOD, V81, P3173	34	126	128	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					354	359		10.1038/ng0498-354	http://dx.doi.org/10.1038/ng0498-354			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537418				2022-12-25	WOS:000072755500018
J	Hedley, ML; Curley, J; Urban, R				Hedley, ML; Curley, J; Urban, R			Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses	NATURE MEDICINE			English	Article							DNA VACCINES; INDUCTION; IMMUNIZATION		Pangaea Pharmaceut Inc, Cambridge, MA 02138 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Hedley, ML (corresponding author), Pangaea Pharmaceut Inc, 763E Concord Ave, Cambridge, MA 02138 USA.	mlhedley@pangaea-pharm.com						Anton LC, 1997, J IMMUNOL, V158, P2535; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; Fayolle C, 1996, IMMUNOLOGY, V89, P41, DOI 10.1046/j.1365-2567.1996.d01-704.x; IWASAKI A, 1997, IMMUNOLOGY, V159, P11; KANKE M, 1988, Journal of Parenteral Science and Technology, V42, P157; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; OKADA H, 1995, CRIT REV THER DRUG, V12, P1; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; TABATA Y, 1990, ADV POLYM SCI, V94, P107; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662	12	195	218	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					365	368		10.1038/nm0398-365	http://dx.doi.org/10.1038/nm0398-365			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500615				2022-12-25	WOS:000073616200047
J	Dietrich, G; Bubert, A; Gentschev, I; Sokolovic, Z; Simm, A; Catic, A; Kaufmann, SHE; Hess, J; Szalay, AA; Goebel, W				Dietrich, G; Bubert, A; Gentschev, I; Sokolovic, Z; Simm, A; Catic, A; Kaufmann, SHE; Hess, J; Szalay, AA; Goebel, W			Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes	NATURE BIOTECHNOLOGY			English	Article						vaccine development; DNA-delivery; plasmid-integration	MAMMALIAN-CELLS; GENE; IMMUNIZATION; VACCINE; EXPRESSION; BACTERIA; PROTEIN; EPITOPE	Eukaryotic expression vectors can be delivered to macrophages using attenuated self-destructing Listeria monocytogenes. L. monocytogenes cells are preferentially lysed in the host cell macrophage cytosol by the production of a P-aclA-dependent Listeria-specific phage lysin. Efficient expression of the cloned reporter genes by the macrophages and subsequent antigen presentation were achieved after the delivery of eukaryotic expression vectors by the attenuated suicide L. monocytogenes strain. After delivery by L. monocytogenes plasmid DNAs were found to integrate into the macrophage cell's genome at a frequency of about 10(-7).	Univ Wurzburg, Lehrstuhl Mikrobiol, D-97074 Wurzburg, Germany; Univ Wurzburg, Dept Physiol Chem, D-97074 Wurzburg, Germany; Univ Ulm, Dept Immunol, D-89070 Ulm, Germany; Max Planck Inst Infect Biol, D-10117 Berlin, Germany; Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA	University of Wurzburg; University of Wurzburg; Ulm University; Max Planck Society; Loma Linda University	Goebel, W (corresponding author), Univ Wurzburg, Lehrstuhl Mikrobiol, D-97074 Wurzburg, Germany.		Gentschev, Ivaylo/F-9454-2011; Gentschev, Ivaylo/AAJ-5819-2021; Kaufmann, Stefan HE/I-5454-2014	Gentschev, Ivaylo/0000-0003-3743-6329; Catic, Andre/0000-0002-3572-7598; Kaufmann, Stefan HE/0000-0001-9866-8268				Bohne J, 1996, MOL MICROBIOL, V20, P1189, DOI 10.1111/j.1365-2958.1996.tb02639.x; BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; CONRY RM, 1994, CANCER RES, V54, P1164; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Courvalin P, 1995, CR ACAD SCI III-VIE, V318, P1207; Davis HL, 1997, GENE THER, V4, P181, DOI 10.1038/sj.gt.3300380; DECHASTELLIER C, 1994, INFECT IMMUN, V62, P543, DOI 10.1128/IAI.62.2.543-553.1994; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; Ertl HCJ, 1996, J IMMUNOL, V156, P3579; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; Hassett DE, 1996, TRENDS MICROBIOL, V4, P307, DOI 10.1016/0966-842X(96)10048-2; Hauf N, 1997, P NATL ACAD SCI USA, V94, P9394, DOI 10.1073/pnas.94.17.9394; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; LOESSNER MJ, 1995, MOL MICROBIOL, V16, P1231, DOI 10.1111/j.1365-2958.1995.tb02345.x; PAMER EG, 1994, J IMMUNOL, V152, P686; PORTNOY DA, 1992, INFECT IMMUN, V60, P1263, DOI 10.1128/IAI.60.4.1263-1267.1992; Schubbert R, 1997, P NATL ACAD SCI USA, V94, P961, DOI 10.1073/pnas.94.3.961; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; WANG Y, 1996, BIOLUMINESCENCE CHEM, P419; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363	25	202	246	3	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					181	185		10.1038/nbt0298-181	http://dx.doi.org/10.1038/nbt0298-181			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487527	Bronze			2022-12-25	WOS:000071831300033
J	Treutiger, CJ; Heddini, A; Fernandez, V; Muller, WA; Wahlgren, M				Treutiger, CJ; Heddini, A; Fernandez, V; Muller, WA; Wahlgren, M			PECAM-1/CD31, an endothelial receptor for binding Plasmodium falciparum-infected erythrocytes	NATURE MEDICINE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CEREBRAL MALARIA; CELLS; CD31; IDENTIFICATION; SEQUESTRATION; MIGRATION; DOMAINS; CULTURE; GAMMA	Excessive binding of Plasmodium falciparum-infected red blood cells (pRBCs) to the vascular endothelium (cytoadherence) and to uninfected erythrocytes (resetting) may lead to occlusion of the microvasculature and thereby contribute directly to the acute pathology of severe human malaria(1,2). A number of endothelial receptors have been identified as targets for the pRBCs, including CD36, intercellular adhesion molecule-1 (ICAM-1) and chondroitin-4-sulfate (CSA)(3-5). In vitro, CD36 is the most frequent target of strains from patients with mild as well as severe P. falciparum malaria, but is expressed at low levels on the cerebral microvasculature(6) and therefore seems unlikely to be involved in the evolution of cerebral disease. Strains of P. falciparum that form rosettes are associated both with the occurrence of cerebral malaria and severe anemia(7-9). Here we report that malaria-infected RBCs adhere to platelet/endothelial cell adhesion molecule-1 (PECAM-1/CD31) on the vascular endothelium. pRBCs bind to endothelial cells, to PECAM-1/CD31 transfected cells, and directly to recombinant PECAM-1/CD31 absorbed onto plastic. Soluble PECAM-1/CD31 and monoclonal antibodies specific for the amino-terminal segment of PECAM-1/CD31 (domains 1-4) blocked the binding. Interferon-gamma (IFN-gamma)-essential for the development of cerebral malaria in the mouse-was found to augment adhesion of human pRBCs to PECAM-1/CD31 on endothelial cell monolayers. Our results suggest that PECAM-1/CD31 is a virulence-associated endothelial receptor of P. falciparum-infected RBCs.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Swedish Inst Infect Dis Control, S-17177 Stockholm, Sweden; Cornell Univ, Med Ctr, New York Hosp, Dept Pathol, New York, NY 10021 USA	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Cornell University; NewYork-Presbyterian Hospital	Wahlgren, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL146849, R01HL046849] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46849] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1997, LEUKOCYTE TYPING, V6; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; ROMER LH, 1995, J IMMUNOL, V154, P6582; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Rudin W, 1997, EUR J IMMUNOL, V27, P810, DOI 10.1002/eji.1830270403; Scholander C, 1996, NAT MED, V2, P204, DOI 10.1038/nm0296-204; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; Tang QZ, 1996, J EXP MED, V184, P1435, DOI 10.1084/jem.184.4.1435; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503; TURNER GDH, 1994, AM J PATHOL, V145, P1057; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; WAHLGREN M, 1994, PARASITOL TODAY, V10, P73, DOI 10.1016/0169-4758(94)90400-6; WILSON GA, 1996, CELL ADHESION MOL, P42	26	166	167	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1405	1408		10.1038/nm1297-1405	http://dx.doi.org/10.1038/nm1297-1405			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396614				2022-12-25	WOS:000072249500040
J	Hildebrandt, F; Otto, E; Rensing, C; Nothwang, HG; Vollmer, M; Adolphs, J; Hanusch, H; Brandis, M				Hildebrandt, F; Otto, E; Rensing, C; Nothwang, HG; Vollmer, M; Adolphs, J; Hanusch, H; Brandis, M			A novel gene encoding an SH3 domain protein is mutated in nephronophthisis type 1	NATURE GENETICS			English	Article							FAMILIAL JUVENILE NEPHRONOPHTHISIS; MESSENGER-RNA; NPH1; REGION; MARKERS; CONTIG; 2Q13; MB	Juvenile nephronophthisis (NPH), an autosomal recessive cystic kidney disease, is the primary genetic cause of chronic renal failure in children. About two thirds of patients with NPH carry a large homozygous deletion at the gene locus NPH1 on 2q13. We here identify a novel gene, NPHP1, which extends over most of this common deletion. The 4.5-kb transcript encodes a protein with an SH3 domain, which is highly conserved throughout evolution. The 11-kb interval between the 3' end of NPHP1 and an inverted repeat containing the distal deletion breakpoint was found to contain the first exon of a second gene, MALL. In patients with a hemizygous deletion of the NPH1 region, additional point mutations were found in NPHP1 but not in MALL.	MAX PLANCK INST MOL GENET, BERLIN, GERMANY	Max Planck Society	Hildebrandt, F (corresponding author), UNIV FREIBURG, CHILDRENS HOSP, HUGSTETTER STR 55, FREIBURG, GERMANY.		Rensing, Christopher/D-3947-2011; Nothwang, Hans G/C-5847-2011	Rensing, Christopher/0000-0002-5012-7953; Otto, Edgar/0000-0002-2387-9973; Nothwang, Hans Gerd/0000-0001-7695-6437				ANTIGNAC C, 1993, NAT GENET, V3, P342, DOI 10.1038/ng0493-342; CHOWDHURY K, 1991, NUCLEIC ACIDS RES, V19, P2792, DOI 10.1093/nar/19.10.2792; FANCONI G, 1951, Helv Paediatr Acta, V6, P1; Hildebrandt F, 1996, CYTOGENET CELL GENET, V73, P235, DOI 10.1159/000134346; HILDEBRANDT F, 1995, GENOMICS, V25, P360, DOI 10.1016/0888-7543(95)80034-J; HILDEBRANDT F, 1993, AM J HUM GENET, V53, P1256; Hildebrandt F, 1997, KIDNEY INT, V51, P261, DOI 10.1038/ki.1997.31; HILDEBRANDT F, 1996, DIS KIDNEY, P499; Karolyi L, 1997, HUM MOL GENET, V6, P17; KLEINKNECHT C, 1992, TXB CLIN NEPHROLOGY, P2188; Konrad M, 1995, GENOMICS, V30, P514, DOI 10.1006/geno.1995.1272; Konrad M, 1996, HUM MOL GENET, V5, P367, DOI 10.1093/hmg/5.3.367; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MEDHIOUB M, 1994, GENOMICS, V22, P296, DOI 10.1006/geno.1994.1387; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; NOTHWANG HG, IN PRESS GENOMICS; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; RANCANO C, 1994, GENOMICS, V21, P447, DOI 10.1006/geno.1994.1294; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH CH, 1945, AM J DIS CHILD, V69, P369; WALDHERR R, 1982, VIRCHOWS ARCH A, V394, P235, DOI 10.1007/BF00430668	22	250	255	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1997	17	2					149	153		10.1038/ng1097-149	http://dx.doi.org/10.1038/ng1097-149			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326933				2022-12-25	WOS:A1997XZ55500019
J	Lee, WS; Harder, JA; Yoshizumi, M; Lee, ME; Haber, E				Lee, WS; Harder, JA; Yoshizumi, M; Lee, ME; Haber, E			Progesterone inhibits arterial smooth muscle cell proliferation	NATURE MEDICINE			English	Article							POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS; EXPRESSION; CONTRACTION; ESTRADIOL; HORMONE; PROTEIN; INJURY; PLASMA	Mortality from atherosclerotic cardiovascular disease is lower in premenopausal women than in age-matched men. It is also lower in postmenopausal women who take estrogens and progestins together rather than estrogens alone. Progesterone receptors were detected in human and rat aortic smooth muscle cells in vivo and in vitro (in subculture). We examined the effect of progesterone on proliferation of smooth muscle cells, important constituents of atherosclerotic plaques. Progesterone at physiologic levels inhibited DNA synthesis and proliferation in these cells in a dose-dependent manner, and pretreatment with the progesterone receptor antagonist RU486 blocked inhibition. Cyclin A and E messenger RNA levels decreased after progesterone treatment but those of cyclin B and D1 did not change. This cell cycle-dependent inhibition of arterial smooth muscle cell proliferation by progesterone may represent a mechanism for the hormone's protective effect against atherosclerosis.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health					NIGMS NIH HHS [R01 GM53249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHALLIS JRG, 1981, J ENDOCRINOL, V89, P337, DOI 10.1677/joe.0.0890337; FARHAT MY, 1992, BRIT J PHARMACOL, V107, P679, DOI 10.1111/j.1476-5381.1992.tb14506.x; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; INGEGNO MD, 1988, LAB INVEST, V59, P353; Knauthe R, 1996, ENDOCRINOLOGY, V137, P3220, DOI 10.1210/en.137.8.3220; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE WS, 1990, P NATL ACAD SCI USA, V87, P5163, DOI 10.1073/pnas.87.13.5163; LEE WS, 1994, J BIOL CHEM, V269, P12032; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MCGILL HC, 1979, ATHER REV, V4, P157; Miyagawa K, 1997, NAT MED, V3, P324, DOI 10.1038/nm0397-324; MORGAN KG, 1985, PFLUG ARCH EUR J PHY, V405, P77, DOI 10.1007/BF00591101; MURRAY TR, 1990, J CELL PHYSIOL, V143, P26, DOI 10.1002/jcp.1041430105; SHAABAN MM, 1973, J OBSTET GYN BR COMM, V80, P776; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STAMLER J, 1953, CIRC RES, V1, P94, DOI 10.1161/01.RES.1.1.94; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WEIGENSBERG BI, 1984, ATHEROSCLEROSIS, V52, P253, DOI 10.1016/0021-9150(84)90055-8; Williams JK, 1997, NAT MED, V3, P273, DOI 10.1038/nm0397-273; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	24	96	97	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1005	1008		10.1038/nm0997-1005	http://dx.doi.org/10.1038/nm0997-1005			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288727				2022-12-25	WOS:A1997XT84200033
J	Gussoni, E; Wang, YM; Fraefel, C; Miller, RG; Blau, HM; Geller, AI; Kunkel, LM				Gussoni, E; Wang, YM; Fraefel, C; Miller, RG; Blau, HM; Geller, AI; Kunkel, LM			A method to codetect introduced genes and their products in gene therapy protocols	NATURE BIOTECHNOLOGY			English	Article						fluorescence in situ hybridization (FISH); immunohistochemistry	DUCHENNE MUSCULAR-DYSTROPHY; IN-SITU HYBRIDIZATION; FLUORESCENCE INSITU HYBRIDIZATION; COLI BETA-GALACTOSIDASE; MYOBLAST TRANSPLANTATION; TYROSINE-HYDROXYLASE; PARKINSONS-DISEASE; MOUSE SKELETAL; SMOOTH-MUSCLE; MESSENGER-RNA	To monitor the presence of introduced genes and the distribution of the encoded proteins in host tissues after gene transfer, we combined fluorescence in situ hybridization (FISH) and immunohistochemistry in two separate gene therapy paradigms. In brain tissue sections from animals injected with pHSVlac vector, we localized nuclei containing vector DNA both in cells expressing and not expressing Beta-galactosidase (beta-gal). This suggests that the efficiency of gene transfer is affected not only by gene delivery, but also by cellular controls on gene expression. In a second paradigm, following myoblast transplantation, we detected donor nuclei in the muscle of a patient with Duchenne's muscular dystrophy. The donor nuclei were either surrounded by host nuclei or apparently fused in the patient's muscle fiber producing dystrophin. The combined FISH and immunohistochemistry assay offers greater sensitivity and more information than currently used polymerase chain reaction and protein detection methods.	CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; CHILDRENS HOSP,DIV ENDOCRINOL,BOSTON,MA 02115; CALIF PACIFIC MED CTR,DEPT NEUROL,SAN FRANCISCO,CA 94115; STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; California Pacific Medical Center; Stanford University	Gussoni, E (corresponding author), CHILDRENS HOSP,DIV GENET,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Geller, Alfred/C-6469-2012; Gussoni, Emanuela/AAL-6150-2021	Gussoni, Emanuela/0000-0002-9915-3677; Fraefel, Cornel/0000-0001-7221-6706	NIA NIH HHS [AG10827] Funding Source: Medline; NINDS NIH HHS [NS23740] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010827] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACSADI G, 1994, HUM MOL GENET, V3, P579, DOI 10.1093/hmg/3.4.579; BEGGS AH, 1990, HUM GENET, V86, P45; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BLAU HM, 1995, NEW ENGL J MED, V333, P1554, DOI 10.1056/NEJM199512073332308; BLAU HM, 1995, NEW ENGL J MED, V333, P1204, DOI 10.1056/NEJM199511023331808; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; BUCKLE VJ, 1994, CURR OPIN GENET DEV, V4, P374, DOI 10.1016/0959-437X(94)90024-8; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; COUWENHOVEN RI, 1990, J HISTOCHEM CYTOCHEM, V38, P1853, DOI 10.1177/38.12.2254649; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DEMATTEO RP, 1995, ANN SURG, V222, P229, DOI 10.1097/00000658-199509000-00002; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DURING MJ, 1994, SCIENCE, V266, P1399, DOI 10.1126/science.266.5189.1399; FRAEFEL C, 1996, IN PRESS J VIROL; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P1149, DOI 10.1073/pnas.87.3.1149; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P8950, DOI 10.1073/pnas.87.22.8950; GELLER AI, 1993, P NATL ACAD SCI USA, V90, P7603, DOI 10.1073/pnas.90.16.7603; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GROSSMAN M, 1994, NAT GENET, V9, P325; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HAN KH, 1992, J VIROL METHODS, V37, P89, DOI 10.1016/0166-0934(92)90023-7; HEPPELMANN B, 1994, BRAIN RES, V635, P293, DOI 10.1016/0006-8993(94)91450-8; HUARD J, 1992, MUSCLE NERVE, V15, P550, DOI 10.1002/mus.880150504; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KNUUTILA S, 1993, CANCER GENET CYTOGEN, V68, P104, DOI 10.1016/0165-4608(93)90005-7; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; LANDON DN, 1982, SKELETAL MUSCLE PATH, V1, P1; LARSEN PJ, 1994, HISTOCHEMISTRY, V102, P415, DOI 10.1007/BF00269572; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LU QL, 1993, HISTOCHEMISTRY, V99, P23, DOI 10.1007/BF00268016; LYNCH CM, 1992, P NATL ACAD SCI USA, V89, P1138, DOI 10.1073/pnas.89.3.1138; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NISHIO Y, 1995, J CLIN INVEST, V96, P1759, DOI 10.1172/JCI118221; SMIALOWSKA M, 1988, NEUROSCIENCE, V26, P803, DOI 10.1016/0306-4522(88)90100-5; SPEEL EJM, 1994, J HISTOCHEM CYTOCHEM, V42, P961, DOI 10.1177/42.7.8014480; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; STREHL S, 1993, CYTOGENET CELL GENET, V63, P24, DOI 10.1159/000133494; TAJABAKHSH S, 1995, TRENDS GENET, V11, P42; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; VERMA RS, 1989, HUMAN CHROMOSOMES MA; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZAGON IS, 1979, BRAIN RES, V170, P443, DOI 10.1016/0006-8993(79)90963-6	50	36	37	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					1012	1016		10.1038/nbt0896-1012	http://dx.doi.org/10.1038/nbt0896-1012			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631042				2022-12-25	WOS:A1996UZ19900036
J	Gift, EA; Park, HJ; Paradis, GA; Demain, AL; Weaver, JC				Gift, EA; Park, HJ; Paradis, GA; Demain, AL; Weaver, JC			FACS-based isolation of slowly growing cells: Double encapsulation of yeast in gel microdrops	NATURE BIOTECHNOLOGY			English	Article						slowly growing cells; high throughput screening; double gel microdrops; flow cytometry	FLOW-CYTOMETRY	Isolating hyperproducing cells is important in biotechnology, but these cells usually grow slowly and can be overgrown by poorly producing cells. We describe a new method of isolating slowly growing cells from among rapidly growing cells, which has the potential for automation and high throughput (e.g., 100,000 cells/h). A model system is presented consisting of a mixed population of slowly growing mutant and rapidly growing wild-type yeast, which were encapsulated in double agarose gel microdrops (dGMDs); with most dGMDs initially containing single cells. Double encapsulation locates parent cells near dGMD centers, making microcolony measurement more accurate. After a 15-h incubation, fluorescent activated cell sorting was used to analyze and sort dGMDs with small microcolonies (slow growers) from dGMDs with large microcolonies (rapid growers). Successful isolation of slow growers from a mixed population of predominantly rapidly growing Saccharomyces cerevisiae cells was achieved.	HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM34077] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALRUBEAI M, 1993, BIO-TECHNOL, V11, P572, DOI 10.1038/nbt0593-572; BACKUS MP, 1955, MYCOLOGIA, V47, P429, DOI 10.2307/3755661; GIVAN AL, 1992, FLOW CYTOMETRY 1ST P; GRAY F, 1995, J IMMUNOL METHODS, V182, P155, DOI 10.1016/0022-1759(94)00319-R; Haugland R.P., 1992, HDB FLUORESCENT PROB; KENNEY JS, 1995, BIO-TECHNOL, V13, P787, DOI 10.1038/nbt0895-787; LAZZARI K, 1995, CYTOMETRY, V21, P111; MCKINNEY KL, 1991, BIOTECHNOL PROGR, V7, P445, DOI 10.1021/bp00011a010; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; OZTURK SS, 1990, HYBRIDOMA, V9, P167, DOI 10.1089/hyb.1990.9.167; POWELL KT, 1990, BIO-TECHNOL, V8, P333, DOI 10.1038/nbt0490-333; RYAN C, 1995, J CLIN MICROBIOL, V33, P1720, DOI 10.1128/JCM.33.7.1720-1726.1995; SAHAR E, 1994, CYTOMETRY, V15, P213, DOI 10.1002/cyto.990150306; Shapiro HM, 1994, PRACTICAL FLOW CYTOM; WEAVER J C, 1991, Methods (Orlando), V2, P234, DOI 10.1016/S1046-2023(05)80066-0; WEAVER JC, 1988, BIO-TECHNOL, V6, P1084, DOI 10.1038/nbt0988-1084; WEAVER JC, 1991, BIO-TECHNOL, V9, P873, DOI 10.1038/nbt0991-873; WEAVER JC, 1984, ANN NY ACAD SCI, V434, P363, DOI 10.1111/j.1749-6632.1984.tb29858.x; WEAVER JC, 1995, FLOW CYTOMETRY APPL, P39	19	16	21	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					884	887		10.1038/nbt0796-884	http://dx.doi.org/10.1038/nbt0796-884			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631016				2022-12-25	WOS:A1996UV62000041
J	Harding, TC; Geddes, BJ; Murphy, D; Knight, D; Uney, JB				Harding, TC; Geddes, BJ; Murphy, D; Knight, D; Uney, JB			Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system	NATURE BIOTECHNOLOGY			English	Article						gene therapy; gene regulation; hippocampus	MAMMALIAN-CELLS; GENE-EXPRESSION; VECTORS; TYPE-5	We have developed a tetracycline-regulatable adenoviral transfection system that mediates efficient long-term transfer of genes into neuronal cells in vivo. This system allows gene expression to be switched on, then off, and back on again simply by administering or removing doxycycline from the animals' drinking water. This regulatable adenoviral vector system should be of value in behavioral studies and in vivo studies of neuronal gene function, and may further the development of effective gene therapy strategies in the brain.	Univ Bristol, Dept Med, Bristol BS2 8HW, Avon, England	University of Bristol	Uney, JB (corresponding author), Univ Bristol, Dept Med, Marlborough St, Bristol BS2 8HW, Avon, England.	james.uney@bris.ac.uk	Murphy, David/C-3967-2012	Murphy, David/0000-0003-2946-0353	Biotechnology and Biological Sciences Research Council [GTH12528] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		BUJARD H, 1996, CONTROLLING GENE ACT; Fotaki ME, 1997, GENE THER, V4, P901, DOI 10.1038/sj.gt.3300487; Geddes BJ, 1997, NAT MED, V3, P1402, DOI 10.1038/nm1297-1402; Geddes BJ, 1996, ENDOCRINOLOGY, V137, P5166, DOI 10.1210/en.137.11.5166; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Harding TC, 1997, J NEUROCHEM, V69, P2620; Ho DY, 1996, MOL BRAIN RES, V41, P200, DOI 10.1016/0169-328X(96)00097-6; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W; Yin DX, 1996, ANAL BIOCHEM, V235, P195, DOI 10.1006/abio.1996.0112; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573	18	121	124	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					553	555		10.1038/nbt0698-553	http://dx.doi.org/10.1038/nbt0698-553			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624686				2022-12-25	WOS:000073930600031
J	Magliani, W; Polonelli, L; Conti, S; Salati, A; Rocca, PF; Cusumano, V; Mancuso, G; Teti, G				Magliani, W; Polonelli, L; Conti, S; Salati, A; Rocca, PF; Cusumano, V; Mancuso, G; Teti, G			Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; CAPSULAR POLYSACCHARIDE; IMMUNOLOGICAL PROPERTIES; III POLYSACCHARIDE; CONJUGATE VACCINE; IMMUNIZATION; PROTECTION; ANTIBODIES; BACTERIA; PROTEIN	We investigated whether immunization with recombinant anti-idiotypic antibody fragments mimicking the conformation of the capsular antigen can protect against infection by group B streptococcus, an important neonatal pathogen. Single-chain fragment-variable anti-idiotypes competed with the type III carbohydrate for binding to type-specific antibodies and elicited, in mice, the production of protective immunoglobulins reacting against the type III polysaccharide. Moreover, maternal immunization with soluble or phage-displayed fragments protected neonatal mice against streptococcal infection. These data indicate that recombinant anti-idiotypic antibodies may be useful in developing protein images of relevant carbohydrate epitopes and, ultimately, in preventing infections by encapsulated bacteria.	Univ Messina, Fac Med & Chirurg, Ist Microbiol, I-98125 Messina, Italy; Univ Parma, Fac Med & Chirurg, Ist Microbiol, I-43100 Parma, Italy	University of Messina; University of Parma	Teti, G (corresponding author), Univ Messina, Fac Med & Chirurg, Ist Microbiol, Via Consolare Valeria 1, I-98125 Messina, Italy.		Conti, Stefania/N-3558-2015	Conti, Stefania/0000-0001-9973-8352; Mancuso, Giuseppe/0000-0001-5454-3228				Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; ALAALDEEN DAA, 1995, MOL CLIN ASPECTS BAC; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BAKER CJ, 1981, PEDIATRICS, V68, P544; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BAKER CJ, 1995, NFECT DIS FETUS NEWB, P980; Cusumano V, 1996, INFECT IMMUN, V64, P2941, DOI 10.1128/IAI.64.8.2941-2944.1996; DISCHE Z, 1948, J BIOL CHEM, V175, P595; FINNE J, 1983, LANCET, V2, P355; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; GRIFFISS JM, 1987, REV INFECT DIS, V9, P176; Kaspar DL, 1996, J CLIN INVEST, V98, P2308, DOI 10.1172/JCI119042; KORTT AA, 1994, EUR J IMMUNOL, V23, P206; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; Larsson C, 1996, INFECT IMMUN, V64, P3518, DOI 10.1128/IAI.64.9.3518-3523.1996; MADOFF LC, 1992, INFECT IMMUN, V60, P4989, DOI 10.1128/IAI.60.12.4989-4994.1992; Magliani W, 1997, NAT BIOTECHNOL, V15, P155, DOI 10.1038/nbt0297-155; MANCUSO G, 1994, INFECT IMMUN, V62, P2748, DOI 10.1128/IAI.62.7.2748-2753.1994; Mancuso G, 1997, INFECT IMMUN, V65, P3731, DOI 10.1128/IAI.65.9.3731-3735.1997; MANCUSO G, 1994, INFECT IMMUN, V62, P4997, DOI 10.1128/IAI.62.11.4997-5002.1994; MCNAMARA MK, 1984, SCIENCE, V226, P1325, DOI 10.1126/science.6505692; PAOLETTI LC, 1994, INFECT IMMUN, V62, P3236, DOI 10.1128/IAI.62.8.3236-3243.1994; Paoletti LC, 1996, INFECT IMMUN, V64, P677, DOI 10.1128/IAI.64.2.677-679.1996; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; STEIN KE, 1984, J EXP MED, V160, P1001, DOI 10.1084/jem.160.4.1001; TETI G, 1992, HYBRIDOMA, V11, P13, DOI 10.1089/hyb.1992.11.13; TETI G, 1993, INFECT IMMUN, V61, P227, DOI 10.1128/IAI.61.1.227-235.1993; TETI G, 1992, J IMMUNOL RES, V4, P67; WESSELS MR, 1992, INFECT IMMUN, V60, P392, DOI 10.1128/IAI.60.2.392-400.1992; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; WESTERINK MAJ, 1988, INFECT IMMUN, V56, P1120, DOI 10.1128/IAI.56.5.1120-1127.1988; WESTERINK MAJ, 1990, IDIOTYPIC NETWORK DI, P107	34	50	54	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					705	709		10.1038/nm0698-705	http://dx.doi.org/10.1038/nm0698-705			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623980	Bronze			2022-12-25	WOS:000074008300037
J	Nishimura, DY; Swiderski, RE; Alward, WLM; Searby, CC; Patil, SR; Bennet, SR; Kanis, AB; Gastier, JM; Stone, EM; Sheffield, VC				Nishimura, DY; Swiderski, RE; Alward, WLM; Searby, CC; Patil, SR; Bennet, SR; Kanis, AB; Gastier, JM; Stone, EM; Sheffield, VC			The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25	NATURE GENETICS			English	Article							OPEN-ANGLE GLAUCOMA; PROTEIN-CODING REGIONS; HUMAN PAX6 GENE; RIEGER SYNDROME; 2ND LOCUS; DNA; ANIRIDIA; POLYSACCHARIDE; LOCALIZATION; TRANSLATION	A number of different eye disorders with the presence of early-onset glaucoma as a component of the phenotype have been mapped to human chromosome 6p25. These disorders have been postulated to be either allelic to each other or associated with a cluster of tightly linked genes. We have identified two primary congenital glaucoma (PCC) patients with chromosomal anomalies involving 6p25. In order to identify a gene involved in PCG, the chromosomal breakpoints in a patient with a balanced translocation between 6p25 and 13q22 were cloned. Cloning of the 6p25 breakpoint led to the identification of two candidate genes based on proximity to the breakpoint. One of these, FKHL7, encoding a forkhead transcription factor, is in close proximity to the breakpoint in the balanced translocation patient and is deleted in a second PCC patient with partial 6p monosomy. Furthermore, FKHL7 was found to harbour mutations in patients diagnosed with Rieger anomaly (RA), Axenfeld anomaly (AA) and iris hypoplasia (IH). This study demonstrates that mutations in FKHL7 cause a spectrum of glaucoma phenotypes.	Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Stanford Univ, Med Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; VitreoRetinal Surg, Minneapolis, MN 55435 USA	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; Stanford University	Sheffield, VC (corresponding author), Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.	val-sheffield@uiowa.edu	Alward, Wallace/AAY-4149-2020	Alward, Wallace/0000-0001-6368-9018; Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835	NEI NIH HHS [R01-EY-10564] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010564] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akarsu AN, 1996, HUM MOL GENET, V5, P1199, DOI 10.1093/hmg/5.8.1199; ALTSCHUL SF, 1990, J MOL BIOL, V215, P40; Alward WLM, 1998, AM J OPHTHALMOL, V125, P98, DOI 10.1016/S0002-9394(99)80242-6; Alward WLM, 1996, J GLAUCOMA, V5, P276; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CURRIE HL, 1995, CLIN DIAGN LAB IMMUN, V2, P554, DOI 10.1128/CDLI.2.5.554-562.1995; DORIN JR, 1992, HUM MOL GENET, V1, P53, DOI 10.1093/hmg/1.1.53; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; Gould DB, 1997, AM J HUM GENET, V61, P765; Graff C, 1997, HUM GENET, V101, P130, DOI 10.1007/s004390050601; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Jordan T, 1997, AM J HUM GENET, V61, P882, DOI 10.1086/514874; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAITINEN J, 1994, BIOTECHNIQUES, V17, P316; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; LI Y, 1995, VIROLOGY, V212, P134, DOI 10.1006/viro.1995.1462; Mears AJ, 1996, AM J HUM GENET, V59, P1321; Milot E, 1996, TRENDS GENET, V12, P123, DOI 10.1016/0168-9525(96)30019-X; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; NUSSBAUM RL, 1983, HUM GENET, V64, P148, DOI 10.1007/BF00327113; Phillips JC, 1996, AM J HUM GENET, V59, P613; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641; Stoilova D, 1996, GENOMICS, V36, P142, DOI 10.1006/geno.1996.0434; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Wirtz MK, 1997, AM J HUM GENET, V60, P296; Xu Y, 1994, Genet Eng (N Y), V16, P241	43	343	363	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					140	147		10.1038/493	http://dx.doi.org/10.1038/493			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620769				2022-12-25	WOS:000073865100020
J	Waterman, MJF; Stavridi, ES; Waterman, JLF; Halazonetis, TD				Waterman, MJF; Stavridi, ES; Waterman, JLF; Halazonetis, TD			ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins	NATURE GENETICS			English	Article							WILD-TYPE P53; ATAXIA-TELANGIECTASIA; TETRAMERIZATION DOMAIN; CANCER-THERAPY; DNA-BINDING; CHECKPOINT; APOPTOSIS; PATHWAYS; IRRADIATION; FIBROBLASTS	The p53 tumour-suppressor protein is a sequence-specific DNA-binding transcription factor that induces cell cycle arrest or apoptosis in response to genotoxic stress(1-6). Activation of p53 by DNA-damaging agents is critical for eliminating cells with damaged genomic DNA and underlies the apoptotic response of human cancers treated with ionizing radiation (IR) and radiomimetic drugs(7-8). The molecular mechanisms by which DNA damage activates p53 have not been elucidated. Both the levels of p53 protein and its affinity for specific DNA sequences increase in response to genotoxic stress(6,9-10). In vitro, the affinity of p53 for DNA is regulated by its carboxy-terminus(11-13). We therefore examined whether this region of p53 is targeted by DNA-damage signalling pathways in vivo. In nonirradiated cells, serines 376 and 378 of p53 were phosphorylated. IR led to dephosphorylation of Ser376, creating a consensus binding site for 14-3-3 proteins and leading to association of p53 with 14-3-3. In turn, this increased the affinity of p53 for sequence-specific DNA. Consistent with the lack of p53 activation by IR in ataxia telangiectasia (AT; refs 14, 15), neither Ser376 dephosphorylation, nor the interaction of p53 with 14-3-3 proteins occurred in AT cells.	Wistar Inst, Dept Mol Genet, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Program Mol Biol & Genet, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Halazonetis, TD (corresponding author), Wistar Inst, Dept Mol Genet, 3601 Spruce St, Philadelphia, PA 19104 USA.		Halazonetis, Thanos/D-7923-2011					Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	394	403	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					175	178		10.1038/542	http://dx.doi.org/10.1038/542			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620776				2022-12-25	WOS:000073865100027
J	Shears, DJ; Vassal, HJ; Goodman, FR; Palmer, RW; Reardon, W; Superti-Furga, A; Scambler, PJ; Winter, RM				Shears, DJ; Vassal, HJ; Goodman, FR; Palmer, RW; Reardon, W; Superti-Furga, A; Scambler, PJ; Winter, RM			Mutation and deletion of the pseudoautosomal gene SHOX cause Leri-Weill dyschondrosteosis	NATURE GENETICS			English	Article							TRANSLOCATION; WOMAN	Leri-Weill Dyschondrosteosis (LWD; OMIM 127300) is a dominantly inherited skeletal dysplasia characterized by disproportionate short stature with predominantly mesomelic limb shortening(9). Expression is variable and consistently more severe in females(2), who frequently display the Madelung deformity of the forearm (shortening and bowing of the radius with dorsal subluxation of the distal ulna). The rare Langer Mesomelic Dysplasia(3) (LD; OMIM 249700), characterized by severe short stature with hypoplasia/aplasia of the ulna and fibula, has been postulated to be the homozygous form of LWD (refs 4-6). In a six-generation pedigree with LWD, we established linkage to the marker DXYS6814 in the pseudoautosomal region (PAR1) of the X and Y chromosomes (Z max= 6.28; theta=0). Linkage analysis of three smaller pedigrees increased the lod score to 8.68 (theta=0). We identified submicroscopic PAR1 deletions encompassing the recently described short stature homeobox-containing gene SHOX (refs 7,8) segregating with the LWD phenotype in 5 families. A point mutation leading to a premature stop in exon 4 of SHOX was identified in one LWD family.	Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Inst Child Hlth, Dept Clin Genet, London WC1N 1EH, England; Inst Neurol, N Thames E Reg Cytogenet Unit, London WC1N 3BG, England; Univ Zurich, Childrens Hosp, Div Metab & Mol Dis, CH-8032 Zurich, Switzerland	University of London; University College London; University of London; University College London; University of London; University College London; University Children's Hospital Zurich; University of Zurich	Scambler, PJ (corresponding author), Inst Child Hlth, Mol Med Unit, 30 Guilford St, London WC1N 1EH, England.		Scambler, Peter J/C-4998-2008; Scambler, Peter/AAZ-6026-2020; superti-furga, andrea/E-9162-2015	Scambler, Peter J/0000-0002-1487-4628; Scambler, Peter/0000-0002-1487-4628; superti-furga, andrea/0000-0002-3543-7531; Reardon, Willie/0000-0001-7329-9179	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ellison JW, 1997, HUM MOL GENET, V6, P1341, DOI 10.1093/hmg/6.8.1341; ESPIRITU C, 1975, AM J DIS CHILD, V129, P375, DOI 10.1001/archpedi.1975.02120400075020; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; FRANCISCO RJL, 1997, AN ESP PEDIAT, V47, P167; FRYNS JP, 1979, HUM GENET, V46, P21, DOI 10.1007/BF00278898; Guichet A, 1997, CLIN DYSMORPHOL, V6, P341, DOI 10.1097/00019605-199710000-00007; KHUDR G, 1973, JAMA-J AM MED ASSOC, V226, P544, DOI 10.1001/jama.226.5.544; KUNZE J, 1980, EUR J PEDIATR, V134, P269, DOI 10.1007/BF00441485; KUZNETZOVA T, 1994, J MED GENET, V31, P649, DOI 10.1136/jmg.31.8.649; LANGER LO, 1967, RADIOLOGY, V89, P654, DOI 10.1148/89.4.654; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LERI A, 1929, B MEM SOC MED HOP P, V35, P1491; LICHTENSTEIN JR, 1980, J MED GENET, V17, P41, DOI 10.1136/jmg.17.1.41; OGATA T, 1995, J MED GENET, V32, P572, DOI 10.1136/jmg.32.7.572; Ogata T, 1997, J MED GENET, V34, P323, DOI 10.1136/jmg.34.4.323; OGATA T, 1995, HUM GENET, V95, P627; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; YOULTON R, 1985, REV MED CHILE, V113, P228	19	237	249	2	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					70	73		10.1038/ng0198-70	http://dx.doi.org/10.1038/ng0198-70			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590293				2022-12-25	WOS:000073346700021
J	Verhoeven, K; Van Laer, L; Kirschhofer, K; Legan, PK; Hughes, DC; Schatteman, I; Verstreken, M; Van Hauwe, P; Coucke, P; Chen, A; Smith, RJH; Somers, T; Offeciers, FE; Van de Heyning, P; Richardson, GP; Wachtler, F; Kimberling, WT; Willems, PJ; Govaerts, PJ; Van Camp, G				Verhoeven, K; Van Laer, L; Kirschhofer, K; Legan, PK; Hughes, DC; Schatteman, I; Verstreken, M; Van Hauwe, P; Coucke, P; Chen, A; Smith, RJH; Somers, T; Offeciers, FE; Van de Heyning, P; Richardson, GP; Wachtler, F; Kimberling, WT; Willems, PJ; Govaerts, PJ; Van Camp, G			Mutations in the human alpha-tectorin gene cause autosomal dominant non-syndromic hearing impairment	NATURE GENETICS			English	Article							TAMM-HORSFALL PROTEIN; MEMBRANE-PROTEIN; SEQUENCE; GRANULE; GP-2; GLYCOPROTEIN; HOMOLOGY; RECEPTOR; PANCREAS	The tectorial membrane is an extracellular matrix of the inner ear that contacts the stereocilia bundles of specialized sensory hair cells. Sound induces movement of these hair cells relative to the tectorial membrane, deflects the stereocilia, and leads to fluctuations in hair-cell membrane potential, transducing sound into electrical signals. alpha-tectorin is one of the major non-collagenous components of the tectorial membrane(1,2). Recently, the gene encoding mouse alpha-tectorin (Tecta) was mapped to a region of mouse chromosome 9, which shows evolutionary conservation with human chromosome 11q (ref. 3), where linkage was found in two families, one Belgian (DFNA12; ref. 4) and the other, Austrian (DFNA8; unpublished data), with autosomal dominant non-syndromic hearing impairment. We determined the complete sequence and the intron-exon structure of the human TECTA gene. In both families, mutation analysis revealed missense mutations which replace conserved amino-acid residues within the zona pellucida domain of TECTA. These findings indicate that mutations in TECTA are responsible for hearing impairment in these families, and implicate a new type of protein in the pathogenesis of hearing impairment.	Univ Instelling Antwerp, Dept Med Genet, B-2610 Wilrijk, Belgium; Univ Instelling Antwerp, Dept Otorhinolaryngol, B-2610 Wilrijk, Belgium; Univ Hosp Vienna, Clin Otorhinol, A-1090 Vienna, Austria; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Nottingham, MRC, Inst Hearing Res, Nottingham NG7 2RD, England; St Augustinus Hosp, Dept Otolaryngol, B-2610 Wilrijk, Belgium; Univ Iowa Hosp & Clin, Dept Otolaryngol, Iowa City, IA 52242 USA; Univ Vienna, Inst Histol & Embryol, A-1090 Vienna, Austria; Boys Town Natl Res Hosp, Omaha, NE 68131 USA	University of Antwerp; University of Antwerp; University Hospital Vienna; University of Sussex; University of Nottingham; University of Iowa; University of Vienna; Boys Town National Research Hospital	Van Camp, G (corresponding author), Univ Instelling Antwerp, Dept Med Genet, Universiteitsplein 1, B-2610 Wilrijk, Belgium.	gvcamp@uia.ua.ac.be	Hughes, David/AAB-9237-2019; Coucke, Paul J/AAO-2954-2020; Heyning, Paul H Vande/I-8278-2017; Van Camp, Guy/F-3386-2013	Hughes, David/0000-0002-4539-3093; Coucke, Paul J/0000-0001-7119-586X; Heyning, Paul H Vande/0000-0002-8424-3717; Van Camp, Guy/0000-0001-5105-9000; Smith, Richard/0000-0003-1201-6731; Legan, P. Kevin/0000-0002-7403-6415				BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; GOVAERTS PJ, IN PRESS AM J OTOL; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; Hughes DC, 1998, GENOMICS, V48, P46, DOI 10.1006/geno.1997.5159; KRAWCZAK M, 1992, HUM GENET, V90, P41; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LERACH H, 1990, GENOME ANAL, V1, P39; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PRASADAN K, 1995, BBA-GENE STRUCT EXPR, V1260, P328, DOI 10.1016/0167-4781(94)00240-4; RICHARDSON GP, 1987, HEARING RES, V25, P45, DOI 10.1016/0378-5955(87)90078-5; SULIK KK, 1995, HEREDITARY HEARING L, pCH4; Verhoeven K, 1997, AM J HUM GENET, V60, P1168; Wong SME, 1996, GENE, V171, P311, DOI 10.1016/0378-1119(96)00065-0; Yu Heron, 1994, Gene Expression, V4, P63	20	259	277	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					60	62		10.1038/ng0598-60	http://dx.doi.org/10.1038/ng0598-60			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590290				2022-12-25	WOS:000073346700018
J	Luxembourg, AT; Borrow, P; Teyton, L; Brunmark, AB; Peterson, PA; Jackson, MR				Luxembourg, AT; Borrow, P; Teyton, L; Brunmark, AB; Peterson, PA; Jackson, MR			Biomagnetic isolation of antigen-specific CD8(+) T cells usable in immunotherapy	NATURE BIOTECHNOLOGY			English	Article						applied immunology; cell purification	TOXIC LYMPHOCYTES-T; PEPTIDE-MHC COMPLEXES; CHORIOMENINGITIS VIRUS; TARGET-CELLS; RECEPTOR; AFFINITY; ACTIVATION; PURIFICATION; RECOGNITION; MOLECULES	Isolating antigen-specific T lymphocytes is hampered by the low frequency of the cells and the low affinity between T-cell receptors (TCR) and antigen. We describe the isolation and purification of antigen-specific CD8(+) T lymphocytes from mixed T-cell populations, Magnetic beads coated with major histocompatibility complex class I molecules loaded with specific peptide were used as a substrate for T-cell capture. Low-frequency T cells, as well as T cells with TCR of low affinity for the antigen were captured on the beads. Following isolation and expansion, recovered cells specifically killed target cells in vitro, and displayed antiviral effect in vivo.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Luxembourg, AT (corresponding author), La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA.	aluxembourg@liai.org		Borrow, Persephone/0000-0002-3877-9780				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BELLONE G, 1995, J CELL PHYSIOL, V163, P221, DOI 10.1002/jcp.1041630202; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; Cai ZL, 1996, J EXP MED, V183, P2247, DOI 10.1084/jem.183.5.2247; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DEBRUIJN MLH, 1992, EUR J IMMUNOL, V22, P3013, DOI 10.1002/eji.1830221137; DILLON SR, 1994, J IMMUNOL, V152, P1790; ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0; GLANTZ SA, 1996, PRIMER BIOSTATISTICS, P65; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; IRSCH J, 1994, P NATL ACAD SCI USA, V91, P1323, DOI 10.1073/pnas.91.4.1323; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KANE KP, 1993, J IMMUNOL, V150, P4788; KATO K, 1993, CYTOMETRY, V14, P384, DOI 10.1002/cyto.990140407; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MESCHER MF, 1995, IMMUNOL REV, V146, P177, DOI 10.1111/j.1600-065X.1995.tb00689.x; NAKANISHI M, 1983, MOL IMMUNOL, V20, P1227, DOI 10.1016/0161-5890(83)90147-5; RADBRUCH A, 1995, CURR OPIN IMMUNOL, V7, P270, DOI 10.1016/0952-7915(95)80014-X; RAMENSEE HG, 1995, IMMUNOGENETICS, V41, P178; RIDDELL SR, 1992, SCIENCE, V257, P238; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SNOW EC, 1983, J IMMUNOL, V130, P607; SPEISER DE, 1992, J IMMUNOL, V149, P972; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TALLQUIST MD, 1995, J IMMUNOL, V155, P2419; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; Udaka K, 1996, J IMMUNOL, V157, P670; vanderMost RG, 1996, J IMMUNOL, V157, P5543; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WUNDERLICH J, 1991, CURRENT PROTOCOLS IM	35	38	47	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					281	285		10.1038/nbt0398-281	http://dx.doi.org/10.1038/nbt0398-281			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528010				2022-12-25	WOS:000072371000030
J	Roberts, I				Roberts, I			A short history of walking	NATURE MEDICINE			English	Editorial Material							MORTALITY; INJURY		Inst Child Hlth, London WC1N 1EH, England	University of London; University College London	Roberts, I (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	Ian.Roberts@ich.ucl.ac.uk						CAIRD R, 1994, STORY HUMAN EVOLUTIO; CHATWI B, 1988, SONGLINES; *DEP ENV TRANSP RE, 1997, ROAD ACC GREAT BRIT; *DEP TRANSP, 1995, TRANSP STAT REP NAT; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hillman M., 1991, ONE FALSE MOVE STUDY; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; Morris JN, 1997, SPORTS MED, V23, P306, DOI 10.2165/00007256-199723050-00004; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; ROBERTS I, 1995, BRIT MED J, V310, P91, DOI 10.1136/bmj.310.6972.91; Roberts I, 1997, Inj Prev, V3, P89; Roberts I, 1996, BRIT MED J, V313, P784; Vander Post L., 1962, LOST WORLD KALAHARI; Ward H., 1994, PEDESTRIAN ACTIVITY	14	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					263	264		10.1038/nm0398-263	http://dx.doi.org/10.1038/nm0398-263			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500590				2022-12-25	WOS:000073616200021
J	Olthoff, KM; Judge, TA; Gelman, AE; da Shen, X; Hancock, WW; Turka, LA; Shaked, A				Olthoff, KM; Judge, TA; Gelman, AE; da Shen, X; Hancock, WW; Turka, LA; Shaked, A			Adenovirus-mediated gene transfer into cold-preserved liver allografts: Survival pattern and unresponsiveness following transduction with CTLA4Ig	NATURE MEDICINE			English	Article							IN-VIVO; IMMUNE-RESPONSES; EXPRESSION; TRANSPLANT; GRAFTS; RAT; HEPATOCYTES; REJECTION; MICE	The immune response of liver transplant recipients was modulated via adenovirus-mediated transduction of the cold-preserved liver with sequences encoding CTLA4lg. Transplanted allografts demonstrated rapid transient local expression and recombinant protein production shortly after revascularization, resulting in intact liver function, indefinite survival of the recipient, and the development of donor-specific unresponsiveness. Lymphocytic infiltration of the graft was mainly of the T helper 2 (Th2) subset and was not associated with injury to primary cellular targets of the alloimmune response. These findings demonstrate a successful outcome of a feasible and potentially clinically relevant system of gene delivery of sequences encoding proteins capable of inhibiting the alloimmune response.	Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Harvard Univ, New England Deaconess Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Pennsylvania; University of Pennsylvania; Harvard University; Harvard Medical School	Olthoff, KM (corresponding author), Univ Penn, Dept Surg, 4 Silverstein, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK46311-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046311] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUCHINCLOSS H, 1993, P NATL ACAD SCI USA, V90, P3373, DOI 10.1073/pnas.90.8.3373; BALIGA P, 1994, TRANSPLANTATION, V58, P1082, DOI 10.1097/00007890-199411270-00005; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; CSETE ME, 1994, TRANSPLANTATION, V57, P1502; DRAZAN KE, 1995, J SURG RES, V59, P299, DOI 10.1006/jsre.1995.1168; DRAZAN KE, 1995, TRANSPLANTATION, V59, P670, DOI 10.1097/00007890-199503150-00004; DRAZAN KE, 1994, SURGERY, V116, P197; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Judge TA, 1996, J IMMUNOL, V156, P2294; KAMADA N, 1979, TRANSPLANTATION, V28, P47, DOI 10.1097/00007890-197907000-00011; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIN H, 1990, J HEART TRANSPLANT, V9, P720; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SHAKED A, 1994, TRANSPLANTATION, V57, P1508; SHAKED A, 1994, TRANSPLANTATION, V57, P32, DOI 10.1097/00007890-199401000-00007; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; WANG J, 1992, TRANSPLANTATION, V53, P703; Yang Y, 1996, GENE THER, V3, P137; Yang YP, 1996, J VIROL, V70, P7209, DOI 10.1128/JVI.70.10.7209-7212.1996	25	122	128	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					194	200		10.1038/nm0298-194	http://dx.doi.org/10.1038/nm0298-194			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461193				2022-12-25	WOS:000072249800035
J	Agrawal, B; Krantz, MJ; Reddish, MA; Longenecker, BM				Agrawal, B; Krantz, MJ; Reddish, MA; Longenecker, BM			Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2	NATURE MEDICINE			English	Article							ACTIVE SPECIFIC IMMUNOTHERAPY; BREAST-CANCER; IN-VITRO; ACTIVATION MARKERS; SIALYL-TN; LYMPHOCYTES; EXPRESSION; CARCINOMA; CYCLOPHOSPHAMIDE; APOPTOSIS	A number of adenocarcinomas abundantly express and secrete underglycosylated MUC1 mucin. Underglycosylation exposes tandem repeat peptide sequences on cancer-associated MUC1 mucin that are normally cryptic. High levels of MUC1 mucin are correlated with a poor prognosis and immunosuppression in adenocarcinoma patients. In this report we show that cancer-associated MUC1 mucin, affinity-purified from ascites fluids of cancer patients, and synthetic tandem repeats of MUC1 mucin core peptide can suppress human T-cell proliferative responses. This MUC1 mucin-induced suppression of T-cell responses can be reversed by the addition of exogenous IL-2 or anti-CD28 monoclonal antibody. These results are consistent with other studies showing that lymphocytes present in the vicinity of tumor cells are anergic and can be reactivated with exogenous interleukin-2. Overcoming MUC1 mucin-induced immunosuppression with IL-2 combined with active specific immunotherapy might be an effective immunotherapeutic strategy against human adenocarcinomas.	Biomira Inc, Edmonton, AB T6N 1H1, Canada		Longenecker, BM (corresponding author), Biomira Inc, 2011-94 St,Edmonton Res Pk, Edmonton, AB T6N 1H1, Canada.							Agrawal B, 1996, J IMMUNOL, V157, P2089; Agrawal B, 1996, J IMMUNOL, V157, P3229; ALEXANDER RB, 1995, J IMMUNOTHER, V17, P39, DOI 10.1097/00002371-199501000-00005; APOSTOLOPOULOS V, 1995, J IMMUNOL, V155, P5089; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; BERD D, 1988, CANCER RES, V48, P1671; BERD D, 1982, CANCER RES, V42, P4862; BERD D, 1994, CANCER IMMUNOL IMMUN, V39, P141, DOI 10.1007/BF01533378; BERRUTI A, 1994, EUR J CANCER, V30A, P2082, DOI 10.1016/0959-8049(94)00356-A; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BOHMIG GA, 1994, J IMMUNOL, V152, P3720; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BURCHELL J, 1987, CANCER RES, V47, P5476; Chan DW, 1997, J CLIN ONCOL, V15, P2322, DOI 10.1200/JCO.1997.15.6.2322; Coventry BJ, 1996, J IMMUNOL, V156, P3486; DING L, 1992, CANCER IMMUNOL IMMUN, V36, P9; FONTENOT JD, 1993, CANCER RES, V53, P5386; FUNG PYS, 1991, CANCER RES, V51, P1170; FUNG PYS, 1990, CANCER RES, V50, P4308; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; KOBAYASHI H, 1992, J CLIN ONCOL, V10, P95, DOI 10.1200/JCO.1992.10.1.95; KUROSAKA A, 1988, J BIOL CHEM, V263, P8724; Luzzati AL, 1996, CLIN EXP IMMUNOL, V105, P403, DOI 10.1046/j.1365-2249.1996.d01-778.x; MacLean GD, 1997, J IMMUNOTHER, V20, P70, DOI 10.1097/00002371-199701000-00008; Mayumi H, 1996, IMMUNOBIOLOGY, V195, P129, DOI 10.1016/S0171-2985(96)80033-7; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; PARRY G, 1990, EXP CELL RES, V188, P302, DOI 10.1016/0014-4827(90)90174-9; Reddish MA, 1996, CANCER IMMUNOL IMMUN, V42, P303, DOI 10.1007/s002620050287; Reddish MA, 1992, J TUMOR MARKER ONCOL, V7, P19; Regimbald LH, 1996, CANCER RES, V56, P4244; SAD S, 1995, J EXP MED, V182, P1505, DOI 10.1084/jem.182.5.1505; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	38	259	280	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					43	49		10.1038/nm0198-043	http://dx.doi.org/10.1038/nm0198-043			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427605				2022-12-25	WOS:000072249700033
J	Barlow, C; Liyanage, M; Moens, PB; Deng, CX; Ried, T; WynshawBoris, A				Barlow, C; Liyanage, M; Moens, PB; Deng, CX; Ried, T; WynshawBoris, A			Partial rescue of the prophase I defects of Atm-deficient mice by p53 and p21 null alleles	NATURE GENETICS			English	Article							ATAXIA-TELANGIECTASIA; PARADIGM	Patients with the human disorder ataxia-telangiectasia (A-T; refs 1,2) and Atm-deficient mice(3-5) have a pleiotropic phenotype that includes infertility, Here we demonstrate that male gametogenesis is severely disrupted in Atm-deficient mice in the earliest stages of meiotic prophase I, resulting in apoptotic degeneration. Atm is required for proper assembly of Rad51 onto the chromosomal axial elements during meiosis. In addition, p53, p21 and Bar are elevated in testes from Atm-deficient mice. To determine whether these elevated protein levels are important factors in the meiotic disruption of Atm-deficient mice, we analysed the meiotic phenotype of Atm/p53 or Atm/p21 double mutants. In these double mutants, meiosis progressed to later stages but was only partly rescued. Assembly of Rad51 foci on axial elements remained defective, and gametogenesis proceeded only to pachytene of prophase I. Previous results demonstrated that mice homozygous for a null mutation in Rad51 (ref. 6) display an early embryonic lethal phenotype that can be partly rescued by removing p53 and/or p21. Because Atm-deficient mice are viable but completely infertile, our studies suggest that the Rad51 assembly defects and elevated levels of p53, p21 and Bar represent tissue-specific responses to the absence of Atm.	NIDDKD,LAB GENET DIS RES,NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD 20892; NIDDKD,GENOME TECHNOL BRANCH,NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD 20892; NIDDKD,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892; YORK UNIV,DEPT BIOL,DOWNSVIEW,ON M3J 1P3,CANADA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); York University - Canada			deng, chuxia/N-6713-2016					Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Boder E, 1975, Birth Defects Orig Artic Ser, V11, P255; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOBSON MJ, 1994, J CELL SCI, V107, P2749; DRESSER ME, 1979, EXP CELL RES, V121, P416, DOI 10.1016/0014-4827(79)90023-5; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Harlow E., 1988, ANTIBODIES LAB MANUA; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luna L.G., 1992, HISTOPATHOLOGICAL ME; MIYASHITA T, 1995, CELL, V80, P293; MOENS PB, 1995, CHROMOSOMA, V104, P169, DOI 10.1007/BF00352181; MOENS PB, IN PRESS CHROMOSOMA; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	23	104	105	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					462	466		10.1038/ng1297-462	http://dx.doi.org/10.1038/ng1297-462			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398851				2022-12-25	WOS:A1997YJ92400030
J	Rotino, GL; Perri, E; Zottini, M; Sommer, H; Spena, A				Rotino, GL; Perri, E; Zottini, M; Sommer, H; Spena, A			Genetic engineering of parthenocarpic plants	NATURE BIOTECHNOLOGY			English	Article						plant genetic engineering; iaaM gene; Nicotiana tabacum; Solanum melongena	GROWTH; FRUITS; IAA; DNA	Transgenic tobacco and eggplants expressing the coding region of the iaaM gene from Pseudomonas syringae pv. savastanoi, under the control of the regulatory sequences of the ovule-specific DefH9 gene from Antirrhinum majus, showed parthenocarpic fruit development Expression of the DefH9-iaaM chimeric transgene occurs during flower development in both tobacco and eggplant. Seedless fruits were produced by emasculated flowers. When pollinated, the parthenocarpic plants produced fruits containing seeds. In eggplant, the genetic manipulation allowed fruit set and growth under environmental conditions prohibitive for fruit setting in the untransformed line, which did not set fruit at all. Under normal environmental conditions, production of marketable fruits took place from pollinated and unpollinated transgenic flowers, while flowers of untransformed control plants did produce fruits of marketable size only from fertilized flowers.	UNIV VERONA,FAC SCI,I-37134 VERONA,ITALY; RES INST VEGETABLE CROPS,I-26836 MONTANASO LOMBARD,LO,ITALY; MPI ZUCHTUNGSFORSCH,D-50829 COLOGNE,GERMANY	University of Verona			Zottini, Michela/Y-3763-2019	zottini, michela/0000-0001-8930-2969				ARCHBOLD DD, 1985, J AM SOC HORTIC SCI, V110, P816; ARPAIA S, 1997, IN PRESS THEOR APPL; GAUDIN V, 1994, PLANT PHYSIOL BIOCH, V32, P11; GILLASPY G, 1993, PLANT CELL, V5, P1439, DOI 10.1105/tpc.5.10.1439; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; KAWAGUCHI M, 1991, PLANT CELL PHYSIOL, V32, P143, DOI 10.1093/oxfordjournals.pcp.a078058; KHISHNAMOORTHY HN, 1981, PLANT GROWTH SUBSTAN; KIHARA H, 1951, P AM SOC HORTIC SCI, V58, P217; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; LIN S, 1988, J HERED, V75, P62; Lipari V., 1988, Acta Horticulturae, P307; MAPELLI S, 1978, PLANT CELL PHYSIOL, V19, P1281; NITSCH JP, 1960, AM J BOT, V47, P566, DOI 10.2307/2439435; NITSCH JP, 1950, AM J BOT, V37, P211, DOI 10.2307/2437903; NORTHMAN J, 1979, SCI HORTIC, V11, P217; SPENA A, 1992, Current Opinion in Biotechnology, V3, P159, DOI 10.1016/0958-1669(92)90146-A; WANG D, 1980, ACTA HORTIC SINICA, V7, P31; YAMADA T, 1985, P NATL ACAD SCI USA, V82, P6522, DOI 10.1073/pnas.82.19.6522	18	157	194	1	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1398	1401		10.1038/nbt1297-1398	http://dx.doi.org/10.1038/nbt1297-1398			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415894				2022-12-25	WOS:A1997YK36100033
J	Bedwell, DM; Kaenjak, A; Benos, DJ; Bebok, Z; Bubien, JK; Hong, J; Tousson, A; Clancy, JP; Sorscher, EJ				Bedwell, DM; Kaenjak, A; Benos, DJ; Bebok, Z; Bubien, JK; Hong, J; Tousson, A; Clancy, JP; Sorscher, EJ			Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line	NATURE MEDICINE			English	Article							RECTIFYING CHLORIDE CHANNELS; CYSTIC-FIBROSIS GENE; MOLECULAR-BASIS; MESSENGER-RNA; REGULATOR; TERMINATION; TRANSPORT; PROTEIN; W1282X; CAMP	Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein(1). While 70% of CF chromosomes carry a deletion of the phenylalanine residue 508 (Delta F508) of CFTR, roughly 5% of all CF chromosomes carry a premature stop mutation(2). We reported that the aminoglycoside antibiotics C-418 and gentamicin can suppress two premature stop mutations [a stop codon in place of glycine residue 542 (G542X) and arginine residue 553 (R553X)] when expressed from a CFTR cDNA in HeLa cells(3). Suppression resulted in the synthesis of full-length CFTR protein and the appearance of a cAMP-activated anion conductance characteristic of CFTR function. However, it was unclear whether this approach could restore CFTR function in cells expressing mutant forms of CFTR from the nuclear genome. We now report that G-418 and gentamicin are also capable of restoring CFTR expression in a CF bronchial epithelial cell line carrying the CFTR W1282X premature stop mutation (a stop codon in place of tryptophan residue 1282). This conclusion is based on the reappearance of cAMP-activated chloride currents, the restoration of CFTR protein at the apical plasma membrane, and an increase in the abundance of CFTR mRNA levels from the W1282X allele.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bedwell, DM (corresponding author), UNIV ALABAMA,DEPT MICROBIOL,BEVILL BIOMED RES BLDG,ROOM 432,845 19TH ST S,BIRMINGHAM,AL 35294, USA.			Sorscher, Eric J./0000-0001-9341-3354; Bedwell, David/0000-0002-6605-818X				BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; *CYST FIBR GEN AN, 1994, HUM MUTAT, V4, P167; DEMOLOMBE S, 1994, EUR J CELL BIOL, V65, P214; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FULLER CM, 1992, AM J PHYSIOL, V262, pC396, DOI 10.1152/ajpcell.1992.262.2.C396; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; HASTY P, 1995, SOMAT CELL MOLEC GEN, V21, P177, DOI 10.1007/BF02254769; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; Tousson A, 1996, J CELL SCI, V109, P1325; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	20	251	269	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1280	1284		10.1038/nm1197-1280	http://dx.doi.org/10.1038/nm1197-1280			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359706				2022-12-25	WOS:A1997YD89600040
J	Lewandoski, M; Martin, GR				Lewandoski, M; Martin, GR			Cre-mediated chromosome loss in mice	NATURE GENETICS			English	Article							DNA; EXPRESSION; MOUSE; YEAST; CELLS; GENE	Chromosome loss in early human embryos is thought to cause a large proportion of spontaneous abortions(1); when it occurs in specific cell lineages in older embryos or adults, it can result in neoplasia(2). Although early embryonic chromosome loss can be modelled by breeding mice carrying robertsonian translocation chromosomes(3), there is currently no method for producing mice with tissue-specific monosomies. Here we demonstrate that DNA recombination mediated by the site-specific recombinase Cre(4) causes loss of a chromosome carrying loxP sites (Cre recognition sites) in an inverted orientation. Thus, when male mice carrying a Y-linked transgene containing inverted loxP sites are mated with females carrying a cre gene that is ubiquitously expressed in the early embryo, almost all their XY progeny lose the Y chromosome early in embryogenesis and develop as XO females. Because inverted loxP sites can be targetted to any mouse chromosome and mice can be produced that express cre in specific cell lineages, these data suggest a method for engineering tissue-specific loss of particular chromosomes to provide mouse models for human diseases caused by or associated with specific monosomies.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lewandoski, Mark/0000-0002-1066-3735	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025331] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD25331] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREASON GL, 1988, BIOTECHNIQUES, V6, P650; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; CATTANACH BM, 1962, GENET RES, V3, P487, DOI 10.1017/S0016672300003335; Epstein C.J, 1986, CONSEQUENCES CHROMOS; EPSTEIN CJ, 1985, TRENDS GENET, V1, P129, DOI 10.1016/0168-9525(85)90054-X; FALCO SC, 1982, CELL, V29, P573, DOI 10.1016/0092-8674(82)90173-8; GOLIC KG, 1994, GENETICS, V137, P551; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Heim S, 1995, CANC CYTOGENETICS; HOGAN B, 1994, MANIPULATING MOUSE E, P226; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LEWANDOSKI M, IN PRESS COLD SPRING; LUNAFINEMAN S, 1995, BLOOD, V85, P1985, DOI 10.1182/blood.V85.8.1985.bloodjournal8581985; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; NAGAMINE CM, 1987, NUCLEIC ACIDS RES, V15, P9227, DOI 10.1093/nar/15.22.9227; Nagy A., 1993, Gene targeting: a practical approach., P147; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	22	129	136	2	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					223	225		10.1038/ng1097-223	http://dx.doi.org/10.1038/ng1097-223			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326948				2022-12-25	WOS:A1997XZ55500034
J	Gerloni, M; Ballou, WR; Billetta, R; Zanetti, M				Gerloni, M; Ballou, WR; Billetta, R; Zanetti, M			Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization	NATURE BIOTECHNOLOGY			English	Article						vaccine design; DNA immunization; malaria	IMMUNODEFICIENCY-VIRUS TYPE-1; DIRECT GENE-TRANSFER; PLASMID DNA; CIRCUMSPOROZOITE PROTEIN; SKELETAL-MUSCLE; T-CELL; ANTIBODY; IMMUNOGLOBULIN; IMMUNOGENICITY; PROTECTION	Immunity against the human malaria parasite Plasmodium falciparum was induced using somatic transgene immunization, a method to effectively target B lymphocytes in vivo. A single inoculation of plasmid DNA containing an immunoglobulin heavy-chain gene coding in the complementarity-determining region 3 for three repeats of the sequence Asn-Ala-Asn-Pro (NANP), a B-cell epitope of Fl falciparum sporozoites, induced antibodies against NANP in all mice. A booster with an antibody antigenized with the NANP peptide, or challenge with P. falciparum sporozoites, demonstrated the establishment of immunologic memory, Immunity to a parasite antigen can be induced by exploiting mechanisms in which B lymphocytes are both the source of the immunogen as well as the effector mechanism of immunity. The results indicate that somatic transgene immunization is a potential approach for vaccination against foreign pathogens.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; WALTER REED ARMY INST RES, DEPT IMMUNOL, ROCKVILLE, MD USA	University of California System; University of California San Diego; University of California System; University of California San Diego; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)			Gerloni, Mara/AAG-1526-2020		NIAID NIH HHS [AI36467] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson R, 1996, INFECT IMMUN, V64, P3168, DOI 10.1128/IAI.64.8.3168-3173.1996; BALLOU WR, 1987, LANCET, V1, P1277; BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BILLETTA R, 1992, IMMUNOMETHODS, V1, P41; CALLE JMC, 1992, J IMMUNOL, V149, P2695; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; COX GJM, 1993, J VIROL, V67, P5664, DOI 10.1128/JVI.67.9.5664-5667.1993; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; EDELMAN R, 1993, J INFECT DIS, V168, P1066, DOI 10.1093/infdis/168.4.1066; EGAN JE, 1993, AM J TROP MED HYG, V49, P166, DOI 10.4269/ajtmh.1993.49.166; ETLINGER HM, 1993, PHILOS T R SOC B, V340, P69, DOI 10.1098/rstb.1993.0049; GERIONI M, 1997, DNA CELL BIOL, V16, P611; GERTONI M, 1997, IN PRESS EUR J IMMUN; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREEN TJ, 1984, INFECT IMMUN, V46, P668, DOI 10.1128/IAI.46.3.668-672.1984; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOFFMAN SL, 1991, SCIENCE, V252, P520, DOI 10.1126/science.2020852; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; LANZA P, 1993, P NATL ACAD SCI USA, V90, P11683, DOI 10.1073/pnas.90.24.11683; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDIN EH, 1979, SCIENCE, V206, P597, DOI 10.1126/science.386511; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; ROBINSON HL, 1993, VACCINE, V11, P957, DOI 10.1016/0264-410X(93)90385-B; SALK J, 1977, SCIENCE, V195, P834, DOI 10.1126/science.320661; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SOLLAZZO M, 1990, PROTEIN ENG, V4, P215, DOI 10.1093/protein/4.2.215; SOLLAZZO M, 1989, EUR J IMMUNOL, V19, P453, DOI 10.1002/eji.1830190307; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WIRTZ RA, 1987, EXP PARASITOL, V63, P166, DOI 10.1016/0014-4894(87)90158-5; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; Xiong SD, 1997, NAT BIOTECHNOL, V15, P882, DOI 10.1038/nbt0997-882; Xiong SD, 1997, P NATL ACAD SCI USA, V94, P6352, DOI 10.1073/pnas.94.12.6352; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469; ZAGHOUANI H, 1995, P NATL ACAD SCI USA, V92, P631, DOI 10.1073/pnas.92.2.631; ZANETTI M, 1992, NATURE, V355, P476, DOI 10.1038/355476a0; ZANETTI M, 1987, IMMUNOL TODAY, V8, P18, DOI 10.1016/0167-5699(87)90827-9; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	42	29	38	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					876	881		10.1038/nbt0997-876	http://dx.doi.org/10.1038/nbt0997-876			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306403				2022-12-25	WOS:A1997XW41000030
J	Tyshenko, MG; Doucet, D; Davies, PL; Walker, VK				Tyshenko, MG; Doucet, D; Davies, PL; Walker, VK			The antifreeze potential of the spruce budworm thermal hysteresis protein	NATURE BIOTECHNOLOGY			English	Article						antifreeze; thermal hysteresis; cryoprotection; overwintering	WINTER FLOUNDER; CHORISTONEURA-FUMIFERANA; ICE; SEQUENCE; BINDING; POLYPEPTIDE; ADSORPTION; INHIBITION; AMERICANUS; MECHANISM	Antifreeze proteins (AFP) inhibit ice growth by surface adsorption that results in a depression of the freezing point below the melting point. The maximum level of this thermal hysteresis shown by the four structurally unrelated fish AFP is approximately 1.5 degrees C. In contrast, hemolymph and crude extracts from insects can have 5 degrees to 10 degrees C of thermal hysteresis. Based on the isolation, cloning, and expression of a thermal hysteresis protein (THP) from spruce budworm (Choristoneura fumiferana), the vastly greater activity is attributable to a 9 kDa protein. This novel, threonine-and cysteine-rich THP has striking effects on ice crystal morphology, both before and during freezing. It is also 10 to 30 times more active than any known fish AFP, offering the prospect of superior antifreeze properties in cryoprotective applications.	QUEENS UNIV,DEPT BIOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAO H, 1995, FEBS LETT, V357, P183, DOI 10.1016/0014-5793(94)01357-7; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; DeLuca CI, 1996, BIOPHYS J, V71, P2346, DOI 10.1016/S0006-3495(96)79476-6; DUMAN J, 1983, ANNU REV PHYSIOL, V45, P261, DOI 10.1146/annurev.ph.45.030183.001401; DUMAN J, 1991, INSECTS LOW TEMPERAT; FOURNEY RM, 1984, CAN J ZOOL, V62, P28, DOI 10.1139/z84-006; GRAHAM LA, 1997, IN PRESS NATURE; HAN EN, 1993, CAN ENTOMOL, V125, P1043, DOI 10.4039/Ent1251043-6; HEW CL, 1983, CAN J ZOOL, V61, P2324, DOI 10.1139/z83-307; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; JLA Z, 1996, NATURE, V384, P285; JORGENSEN H, 1993, PROTEIN ENG, V6, P19, DOI 10.1093/protein/6.1.19; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LI XM, 1985, J BIOL CHEM, V260, P2904; NG NF, 1986, J BIOL CHEM, V261, P5690; RAMSAY JA, 1964, PHILOS T ROY SOC B, V248, P279, DOI 10.1098/rstb.1964.0013; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sanders C.J., 1991, TORTRICID PESTS THEI, P579; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; Sonnichsen FD, 1996, STRUCTURE, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; SONNICHSEN FD, 1995, PROTEIN SCI, V4, P460; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; ZACHARIASSEN KE, 1985, PHYSIOL REV, V65, P779	28	137	157	1	40	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					887	890		10.1038/nbt0997-887	http://dx.doi.org/10.1038/nbt0997-887			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306405				2022-12-25	WOS:A1997XW41000032
J	Robson, B				Robson, B			Doppelganger proteins as drug leads	NATURE BIOTECHNOLOGY			English	Editorial Material											Robson, B (corresponding author), GRYPHON SCI,250 E GRAND AVE,SUITE 90,S SAN FRANCISCO,CA 94080, USA.							DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; Milton S. C. F., 1992, SCIENCE, V256, P1445; MUI TW, 1994, BIOCHEMISTRY-US, V33, P7701; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; ZUWADZKE LE, 1993, PROTEIN-STRUCT FUNCT, V16, P301	5	11	11	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					892	893		10.1038/nbt0796-892	http://dx.doi.org/10.1038/nbt0796-892			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631018				2022-12-25	WOS:A1996UV62000043
J	Grison, R; GrezesBesset, B; Schneider, M; Lucante, N; Olsen, L; Leguay, JJ; Toppan, A				Grison, R; GrezesBesset, B; Schneider, M; Lucante, N; Olsen, L; Leguay, JJ; Toppan, A			Field tolerance to fungal pathogens of Brassica napus constitutively expressing a chimeric chitinase gene	NATURE BIOTECHNOLOGY			English	Article						chitinase; transgenic Brassica napus; disease tolerance	RI T-DNA; AGROBACTERIUM-RHIZOGENES; RHIZOCTONIA-SOLANI; NICOTIANA-TABACUM; PLANTS; TRANSFORMATION; PROTEINS; CLONING	Constitutive overexpression of a protein involved in plant defense mechanisms to disease is one of the strategies proposed to increase plant tolerance to fungal pathogens. A hybrid endochitinase gene under a constitutive promoter was introduced by Agrobacterium-mediated transformation into a winter-type oilseed rape (Brassica napus var. oleifera) inbred line. Progeny from transformed plants was challenged using three different fungal pathogens (Cylindrosporium concentricum, Phoma lingam, Sclerotinia sclerotiorum) in field trials at two different geographical locations. These plants exhibited an increased tolerance to disease as compared with the nontransgenic parental plants.	SANOFI RECH,CTR LABEGE,UNITE PHYTOTECHNOL,F-31676 LABEGE,FRANCE; RUST PROGRAM GENET,F-31700 MONDONVILLE,FRANCE; UNIV FRIBOURG,INST BIOL VEGETALE,CH-1700 FRIBOURG,SWITZERLAND; SANOFI RECH,CTR LABEGE,SERV DEV BIOTECHNOL,F-31676 LABEGE,FRANCE; CEA,CTR CADARACHE,F-13108 ST PAUL DURANCE,FRANCE	Sanofi-Aventis; Sanofi France; University of Fribourg; Sanofi-Aventis; Sanofi France; CEA				Schneider, Michel/0000-0002-2701-4731				BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BENHAMOU N, 1993, PLANT J, V4, P295, DOI 10.1046/j.1365-313X.1993.04020295.x; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BOULTER ME, 1990, PLANT SCI, V70, P91, DOI 10.1016/0168-9452(90)90036-N; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; BROGLIE KE, 1955, BIOTECHNOLOGY PLANT, P247; BRUN H, 1987, P 7 INT C RAP POZN, P1216; *CETIOM, 1992, MAL COLZ POINTS TECH; COLLINGE DB, 1987, PLANT MOL BIOL, V9, P389, DOI 10.1007/BF00014913; CONN K L, 1990, Canadian Plant Disease Survey, V70, P66; COOK RJ, 1978, 5TH P INT RAP C, P333; DUBOIS M, 1984, Patent No. 9201792; DURANDTARDIF M, 1985, J MOL BIOL, V186, P557, DOI 10.1016/0022-2836(85)90130-5; EVANS EJ, 1984, ASPECTS APPLIED BIOL, V6, P323; GUERCHE P, 1987, MOL GEN GENET, V206, P382, DOI 10.1007/BF00428875; JACH G, 1992, BIOPRACTICE, V1, P33; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LIN W, 1995, BIO-TECHNOL, V13, P686, DOI 10.1038/nbt0795-686; LINDHORST HJM, 1990, MOL PLANT MICROBE IN, V3, P252; MADDOCK SE, 1979, THESIS U CAMBRIDGE; MOLANO J, 1977, ANAL BIOCHEM, V83, P648, DOI 10.1016/0003-2697(77)90069-0; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; RASMUSSEN U, 1992, PLANT MOL BIOL, V20, P277, DOI 10.1007/BF00014495; RAWLINSON CJ, 1979, J AGR SCI, V93, P593, DOI 10.1017/S0021859600039009; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBY D, 1987, BIOCHEM BIOPH RES CO, V143, P885, DOI 10.1016/0006-291X(87)90332-9; *SAS I, 1991, SAS STAT US GUID REL; SEOUN FS, 1989, CAN J PLANT SCI, V69, P229; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; VIERHEILIG H, 1993, MOL PLANT MICROBE IN, V6, P261, DOI 10.1094/MPMI-6-261	31	166	203	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					643	646		10.1038/nbt0596-643	http://dx.doi.org/10.1038/nbt0596-643			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630959				2022-12-25	WOS:A1996UL60400033
J	Tavazoie, S; Church, GM				Tavazoie, S; Church, GM			Quantitative whole-genome analysis of DNA-protein interactions by in vivo methylase protection in E-coli	NATURE BIOTECHNOLOGY			English	Article						genomics; gene expression; cluster analysis	HOST FACTOR IHF; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BINDING-SITES; CONTROL REGION; GENE; EXPRESSION; OPERON; GATC; COMPLEX	A global methylation-based technique was used to identify, display, and quantitate the in vivo occupancy of numerous protein-binding sites within the Escherichia coli genome. The protein occupancy profiles of these sites showed variation across different growth conditions and genetic backgrounds. Of the 25 sites identified in this study, 24 occurred within 5' noncoding regions. Protein occupancy at 13 of these sites was supported by independent biochemical and genetic evidence. Most of the remaining 12 sites fell upstream of genes with no previously known function. A multivariate statistical analysis was utilized to group such uncharacterized genes with well-characterized ones, providing insights into their function based on a common pattern of transcriptional regulation.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Grad Program Biophys, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University	Church, GM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			church, george/0000-0001-6232-9969				ANDREWS SC, 1991, J GEN MICROBIOL, V137, P361, DOI 10.1099/00221287-137-2-361; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARRAS F, 1988, NUCLEIC ACIDS RES, V16, P9821, DOI 10.1093/nar/16.20.9821; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CARTWRIGHT IL, 1991, BIOTECHNIQUES, V11, P188; CHARLIER D, 1995, J MOL BIOL, V250, P383, DOI 10.1006/jmbi.1995.0384; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; HALE WB, 1994, J BACTERIOL, V176, P3438, DOI 10.1128/jb.176.11.3438-3441.1994; HALL BG, 1992, MOL BIOL EVOL, V9, P688; HOLST B, 1992, EMBO J, V11, P3635, DOI 10.1002/j.1460-2075.1992.tb05448.x; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; Jovanovic G, 1996, J BACTERIOL, V178, P1936, DOI 10.1128/jb.178.7.1936-1945.1996; KELLEHER JE, 1991, J BACTERIOL, V173, P5220, DOI 10.1128/jb.173.16.5220-5223.1991; KENDALL MG, 1980, MULTIVARIATE ANAL; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KUTSUKAKE K, 1989, J BACTERIOL, V177, P741; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; NORREGAARDMADSEN M, 1994, MOL MICROBIOL, V14, P989, DOI 10.1111/j.1365-2958.1994.tb01333.x; Prashar Y, 1996, P NATL ACAD SCI USA, V93, P659, DOI 10.1073/pnas.93.2.659; RAMSEIER TM, 1995, MICROBIOL-SGM, V141, P1901, DOI 10.1099/13500872-141-8-1901; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; RINQUIST S, 1992, P NATL ACAD SCI USA, V89, P4539; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SHEA CM, 1991, MOL MICROBIOL, V5, P1415, DOI 10.1111/j.1365-2958.1991.tb00788.x; WANG MX, 1992, NATURE, V360, P606, DOI 10.1038/360606a0; WEINER L, 1995, NUCLEIC ACIDS RES, V23, P2030, DOI 10.1093/nar/23.11.2030; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; XU JM, 1995, J BACTERIOL, V177, P5222, DOI 10.1128/jb.177.18.5222-5231.1995; YAMADA M, 1993, J BACTERIOL, V175, P568, DOI 10.1128/JB.175.2.568-571.1993; YAMADA M, 1988, J MOL BIOL, V203, P569, DOI 10.1016/0022-2836(88)90193-3; ZHANG XL, 1994, J BIOL CHEM, V269, P7066	34	70	71	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					566	571		10.1038/nbt0698-566	http://dx.doi.org/10.1038/nbt0698-566			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624689				2022-12-25	WOS:000073930600034
J	Zwacka, RM; Zhou, WH; Zhang, YL; Darby, CJ; Dudus, L; Halldorson, J; Oberley, L; Engelhardt, JF				Zwacka, RM; Zhou, WH; Zhang, YL; Darby, CJ; Dudus, L; Halldorson, J; Oberley, L; Engelhardt, JF			Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappa B activation	NATURE MEDICINE			English	Article							ISCHEMIA REPERFUSION INJURY; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; C-FOS; RECOMBINANT ADENOVIRUSES; MOUSE-LIVER; RAT-LIVER; JUN; PHOSPHORYLATION; EXPRESSION	Liver transplantation is the only therapeutic strategy for many inherited and acquired diseases. The formation of reactive oxygen species following ischemia/reperfusion is a cause of hepatocellular injury during transplantation. This report describes the therapeutic application of mitochondrial superoxide dismutase gene transfer to the liver for acute ischemia/reperfusion injury. Recombinant adenoviral expression of mitochondrial superoxide dismutase in mouse liver prior to lobar ischemia/reperfusion significantly reduced acute liver damage and associated redox activation of both NF-kappa B and AP1. These immediate early transcription factors represent common pathways by which cells respond to environmental stress. This work provides the foundation for redox-mediated gene therapies directed at ameliorating ischemia/reperfusion injury and associated acute rejection in orthotopic liver transplantation.	Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Engelhardt, JF (corresponding author), Univ Iowa, Dept Anat & Cell Biol, 51 Newton Rd, Iowa City, IA 52242 USA.			Zwacka, Ralf/0000-0003-2821-0387; Engelhardt, John/0000-0003-2389-9277	NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051315] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA-66081] Funding Source: Medline; NIDCR NIH HHS [P50 DE-10758] Funding Source: Medline; NIDDK NIH HHS [R01 DK-51315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARTHUR MJP, 1985, GASTROENTEROLOGY, V898, P114; ATALLA SL, 1985, TRANSPLANTATION, V40, P584, DOI 10.1097/00007890-198512000-00002; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bradham CA, 1997, HEPATOLOGY, V25, P1128, DOI 10.1002/hep.510250514; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; COLLETTI LM, 1995, J CLIN INVEST, V95, P134, DOI 10.1172/JCI117630; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENGELHARDT JF, 1996, METHODS ADENOVIRAL M, P169; GOODE HF, 1994, HEPATOLOGY, V19, P354; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAESCHKE H, 1988, BIOCHEM BIOPH RES CO, V150, P568, DOI 10.1016/0006-291X(88)90431-7; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIUCHI T, 1995, TRANSPLANTATION, V60, P49, DOI 10.1097/00007890-199507150-00010; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MATHEWS WR, 1994, FREE RADICAL BIO MED, V16, P763, DOI 10.1016/0891-5849(94)90191-0; OBERLEY TD, 1990, AM J PATHOL, V137, P199; Okuaki Y, 1996, LIVER, V16, P188; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Schlossberg H, 1996, HEPATOLOGY, V23, P1546, DOI 10.1053/jhep.1996.v23.pm0008675176; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shaked A, 1997, CLIN CHEM, V43, P1539; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STRASBERG SM, 1994, HEPATOLOGY, V20, P829, DOI 10.1002/hep.1840200410; SUZUKI S, 1994, TRANSPLANT P, V26, P3695; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175; Zwacka RM, 1997, J CLIN INVEST, V100, P279, DOI 10.1172/JCI119533; ZWACKA RM, IN PRESS HUMAN GENE	41	226	244	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					698	704		10.1038/nm0698-698	http://dx.doi.org/10.1038/nm0698-698			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623979				2022-12-25	WOS:000074008300036
J	Burton, DR; Moore, JP				Burton, DR; Moore, JP			Why do we not have an HIV vaccine and how can we make one?	NATURE MEDICINE			English	Editorial Material							VIRUS		Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; NYU, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Scripps Research Institute; Scripps Research Institute; New York University	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	burton@scripps.edu; jmoore@adarc.org						Baldridge JR, 1997, J VIROL, V71, P755, DOI 10.1128/JVI.71.1.755-758.1997; Berman PW, 1997, J INFECT DIS, V176, P384, DOI 10.1086/514055; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Corey L, 1998, J INFECT DIS, V177, P301, DOI 10.1086/514202; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Desrosiers R C, 1995, AIDS, V9 Suppl A, pS137; Excler JL, 1997, AIDS, V11, pS127; EZZELL C, 1997, J NIH RES, V9, P21; Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209; Hasenkrug KJ, 1997, P NATL ACAD SCI USA, V94, P7811, DOI 10.1073/pnas.94.15.7811; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; Jassoy C, 1997, SPRINGER SEMIN IMMUN, V18, P341, DOI 10.1007/BF00813502; LIU MA, 1998, NATURE MED; Moore J P, 1995, AIDS, V9 Suppl A, pS117; Nossal GJV, 1997, LANCET, V350, P1316, DOI 10.1016/S0140-6736(97)03257-1; Oldstone MBA, 1997, NEW ENGL J MED, V337, P1306, DOI 10.1056/NEJM199710303371811; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROWLANDJONES S, 1997, ADV IMMUNOL, V65, P448; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; Sharpe SA, 1997, J GEN VIROL, V78, P1923, DOI 10.1099/0022-1317-78-8-1923; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Stott EJ, 1996, J ANTIMICROB CHEMOTH, V37, P185, DOI 10.1093/jac/37.suppl_B.185; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; VanCott TC, 1997, J VIROL, V71, P4319, DOI 10.1128/JVI.71.6.4319-4330.1997	28	102	136	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5		S			495	498		10.1038/nm0598supp-495	http://dx.doi.org/10.1038/nm0598supp-495			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585194	Bronze			2022-12-25	WOS:000073453500012
J	Ophascharoensuk, V; Fero, ML; Hughes, J; Roberts, JM; Shankland, SJ				Ophascharoensuk, V; Fero, ML; Hughes, J; Roberts, JM; Shankland, SJ			The cyclin-dependent kinase inhibitor p27(Kip1) safeguards against inflammatory injury	NATURE MEDICINE			English	Article							MICE LACKING; CELL-CYCLE; GLOMERULONEPHRITIS; PROLIFERATION; HYPERPLASIA; APOPTOSIS; RATS	The cyclin-dependent kinase inhibitor p27(Kip1) controls cell proliferation in response to normal mitogenic stimuli. We show here that p27(Kip1) also safeguards against excessive cell proliferation in specific pathophysiologic settings. We used experimental glomerulonephritis as a paradigm for immune mediated inflammation and ureteral obstruction as a model for non-immune mediated inflammation. Renal function was substantially decreased in nephritic p27(-/-) mice compared with control mice, and this was associated with increased glomerular cell proliferation, apoptosis and matrix protein accumulation. Tubular epithelial cell proliferation and apoptosis was also increased in p27(-/-) mice following ureteral obstruction. p27(Kip1) may have a general role in protecting cells and tissues from inflammatory injury.	Univ Washington, Sch Med, Dept Med, Div Nephrol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center	Shankland, SJ (corresponding author), Univ Washington, Sch Med, Dept Med, Div Nephrol, Box 356521,1959 NE Pacific Ave, Seattle, WA 98195 USA.			Fero, Matthew/0000-0002-9967-4659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051096, R01DK052121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51096, DK 52121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkins RC, 1996, J AM SOC NEPHROL, V7, P2271; BAKER PJ, 1989, AM J PATHOL, V135, P185; Bisgaard HC, 1996, CLIN LAB MED, V16, P325, DOI 10.1016/S0272-2712(18)30272-5; BRADLEY GM, 1974, EXAMINATION URINE; BUTLER AR, 1975, CLIN CHIM ACTA, V59, P227, DOI 10.1016/0009-8981(75)90033-9; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COUSER WG, 1994, AM J KIDNEY DIS, V23, P193, DOI 10.1016/S0272-6386(12)80971-1; COUSER WG, 1985, AM J PHYSIOL, V249, P241; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Huang XR, 1997, KIDNEY INT, V51, P94, DOI 10.1038/ki.1997.12; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; KERR PG, 1997, DIS KIDNEY, P1619; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MACLEOD DC, 1994, J AM COLL CARDIOL, V23, P59, DOI 10.1016/0735-1097(94)90502-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; SALANT DJ, 1980, J CLIN INVEST, V66, P71, DOI 10.1172/JCI109837; Shankland SJ, 1997, KIDNEY INT, V51, P1088, DOI 10.1038/ki.1997.151; Shankland SJ, 1997, KIDNEY INT, V52, P404, DOI 10.1038/ki.1997.347; Shankland SJ, 1996, KIDNEY INT, V50, P1230, DOI 10.1038/ki.1996.432; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Thomas SE, 1998, J AM SOC NEPHROL, V9, P231; Truong LD, 1996, KIDNEY INT, V50, P200, DOI 10.1038/ki.1996.303; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WOLF NS, 1993, EXP HEMATOL, V21, P614	30	167	180	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					575	580		10.1038/nm0598-575	http://dx.doi.org/10.1038/nm0598-575			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585231				2022-12-25	WOS:000073399900029
J	Bothmann, H; Pluckthun, A				Bothmann, H; Pluckthun, A			Selection for a periplasmic factor improving phage display and functional periplasmic expression	NATURE BIOTECHNOLOGY			English	Article						protein expression; single-chain antibody; Escherichia coli	OUTER-MEMBRANE PROTEIN; DNA-BINDING PROTEIN; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; FILAMENTOUS PHAGE; OMPH GENE; SKP; ANTIBODY; IDENTITY	The efficiency of both phage display in Escherichia coli and periplasmic expression of recombinant proteins may be limited by the same periplasmic folding steps. To search for E. coli factors that improve the efficiency of both procedures, a library of E. coli proteins was coexpressed in a phagemid vector that contained a poorly folding single-chain Fv antibody (scFv) fragment fused to g3p. We enriched, by panning for antigen binding, those phagemids in which the amount of displayed scFv is highest. We thus identified the periplasmic protein Skp/OmpH/HlpA as improving phage display of a wide range of scFv fragments. This occurs as a result of an increase in the amount of hybrid protein displayed on the phage. Coexpression of skp also increases the functional yield of scFv fragments when expressed by secretion to the periplasm.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				AASLAND R, 1988, J BACTERIOL, V170, P5916, DOI 10.1128/jb.170.12.5916-5918.1988; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; DAY LA, 1969, J MOL BIOL, V39, P265, DOI 10.1016/0022-2836(69)90316-7; DELAMARCHE C, 1995, GENE, V161, P39, DOI 10.1016/0378-1119(95)00254-4; Dunn IS, 1996, CURR OPIN BIOTECH, V7, P547, DOI 10.1016/S0958-1669(96)80060-7; ELASPENAS A, 1997, MOL MICROBIOL, V24, P373; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GEYER R, 1979, EUR J BIOCHEM, V98, P27, DOI 10.1111/j.1432-1033.1979.tb13156.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HIRVAS L, 1991, J BACTERIOL, V173, P1223, DOI 10.1128/jb.173.3.1223-1229.1991; HIRVAS L, 1990, FEBS LETT, V262, P123, DOI 10.1016/0014-5793(90)80169-J; HOLCK A, 1988, GENE, V67, P117; HOLCK A, 1987, BIOCHIM BIOPHYS ACTA, V914, P49, DOI 10.1016/0167-4838(87)90160-9; Jung S, 1997, PROTEIN ENG, V10, P959, DOI 10.1093/protein/10.8.959; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; KOSKI P, 1990, GENE, V88, P117; KOSKI P, 1989, J BIOL CHEM, V264, P18973; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; Krebber C, 1997, J MOL BIOL, V268, P607, DOI 10.1006/jmbi.1997.0981; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; REESE MG, 1994, THESIS GERMAN CANC R; Sambrook J., 2002, MOL CLONING LAB MANU; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; TESAR M, 1995, IMMUNOTECHNOLOGY, V1, P53, DOI 10.1016/1380-2933(95)00005-4; THOME BM, 1990, FEBS LETT, V269, P113, DOI 10.1016/0014-5793(90)81132-8; THOME BM, 1991, MOL MICROBIOL, V5, P2815, DOI 10.1111/j.1365-2958.1991.tb01990.x; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; VUORIO R, 1991, BIOCHIM BIOPHYS ACTA, V1129, P124, DOI 10.1016/0167-4781(91)90226-C; WALL JG, 1995, CURR OPIN BIOTECH, V6, P507, DOI 10.1016/0958-1669(95)80084-0; WHITLOW M, 1995, PROTEIN ENG, V8, P749, DOI 10.1093/protein/8.8.749	45	165	186	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					376	380		10.1038/nbt0498-376	http://dx.doi.org/10.1038/nbt0498-376			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555730				2022-12-25	WOS:000072786200031
J	Phylactou, LA; Darrah, C; Wood, MJA				Phylactou, LA; Darrah, C; Wood, MJA			Ribozyme-mediated trans-splicing of a trinucleotide repeat	NATURE GENETICS			English	Article							MYOTONIC-DYSTROPHY; MESSENGER-RNA; CTG REPEAT; EXPANSION; TETRAHYMENA; EXPRESSION; SEQUENCE; MYOPATHY; DISEASE; INVITRO	Trinucleotide repeat expansions (TREs) are a recently described class of mutations characterized by a change in the size of the genomic fragment due to amplification of the repeated unit. A number of diseases have been attributed to TRE, including Huntington disease and myotonic dystrophy (DM; refs 1-3), but attempts at genetic therapy have yet to prove successful. A potential therapeutic approach would be to repair the expanded repeat using the trans-splicing ability of group I intron ribozymes(4). We have used DM as a model to test this hypothesis. A group I intron ribozyme (DMPK-RZ1) was designed to modify the TRE at the 3' end of the human myotonic dystrophy protein kinase (DMPK) transcript(5-8). DMPK-RZ1 was shown to ligate a small DMPK mRNA fragment, contained within the ribozyme, to a simple DMPK-target RNA in vitro. It also modified a larger target transcript, leading to replacement of twelve repeats with five repeats, both in vitro and in mammalian cells. Finally, this ribozyme successfully replaced the 3' end of endogenous DMPK mRNA in fibroblasts with a different 3' region. Ribozyme-mediated RNA repair may thus form a novel therapeutic strategy for diseases associated with repeat expansions.	Univ Oxford, Dept Human Anat, Oxford OX1 3QX, England	University of Oxford	Phylactou, LA (corresponding author), Univ Oxford, Dept Human Anat, S Parks Rd, Oxford OX1 3QX, England.	leonidas.phylactou@anat.ox.ac.uk	Wood, Matthew/HDN-1469-2022	Wood, Matthew/0000-0002-5436-6011				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; DAVIES KE, 1983, J MED GENET, V20, P259, DOI 10.1136/jmg.20.4.259; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; Hamshere MG, 1996, TRENDS GENET, V12, P332, DOI 10.1016/S0168-9525(96)80002-3; Harper P.S., 1989, MYOTONIC DYSTROPHY; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; JOHNSON KJ, 1996, BIOCHEM SOC T, V54, P510; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; KIEHNTOPF M, 1995, LANCET, V345, P1027, DOI 10.1016/S0140-6736(95)90762-9; Kilpatrick MW, 1996, HUM MOL GENET, V5, P1939, DOI 10.1093/hmg/5.12.1939; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Ohta Y, 1996, NUCLEIC ACIDS RES, V24, P938, DOI 10.1093/nar/24.5.938; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; ROSSI JJ, 1995, TRENDS BIOTECHNOL, V13, P301, DOI 10.1016/S0167-7799(00)88969-6; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHAW DJ, 1993, GENOMICS, V18, P673, DOI 10.1016/S0888-7543(05)80372-6; Shelbourne Peggy, 1992, Human Mutation, V1, P183, DOI 10.1002/humu.1380010302; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Timchenko LT, 1996, FASEB J, V10, P1589, DOI 10.1096/fasebj.10.14.9002550; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7	30	115	126	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					378	381		10.1038/ng0498-378	http://dx.doi.org/10.1038/ng0498-378			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537423				2022-12-25	WOS:000072755500023
J	Rojas, M; Donahue, JP; Tan, ZJ; Lin, YZ				Rojas, M; Donahue, JP; Tan, ZJ; Lin, YZ			Genetic engineering of proteins with cell membrane permeability	NATURE BIOTECHNOLOGY			English	Article						drug delivery; epidermal growth factor; protein delivery; SH2 domain	EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; NUCLEAR-LOCALIZATION SEQUENCE; RECEPTOR TYROSINE KINASES; ADAPTER PROTEIN; INTACT-CELLS; EGF RECEPTOR; GRB2; RAS; BINDS	The discovery of methods for generating proteins with inherent cell membrane-translocating activity will expand our ability to study and manipulate various intracellular processes in living systems. We report a method to engineer proteins with cell-membrane permeability. After a 12-amino acid residue membrane-translocating sequence (MTS) was fused to the C-terminus of glutathione S-transferase (GST), the resultant GST-MTS fusion proteins were efficiently imported into NIH 3T3 fibroblasts and other cells. To explore the applicability of this nondestructive import method to the study of intracellular processes, a 41-kDa GST-Grb2SH2-MTS fusion protein containing the Grb2 SH2 domain was tested for its effect on the epidermal growth factor (EGF)-stimulated signaling pathway. This fusion protein entered cells, formed a complex with phosphorylated EGF receptor (EGFR), and inhibited EGF-induced EGFR-Grb2 association and mitogen-activated protein kinase activation.	Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Div Infect Dis, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Lin, YZ (corresponding author), Vanderbilt Univ, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.	liny@ctrvax.vanderbilt.edu			NCI NIH HHS [CA68485] Funding Source: Medline; NIGMS NIH HHS [R01 GM52500] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052500] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DU C, 1908, J PEPT RES, V51, P235; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAJSTURA J, 1989, FOLIA HISTOCHEM CYTO, V27, P39; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Moore DD, 1995, GLOB MOB SURV; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rojas M, 1997, BIOCHEM BIOPH RES CO, V234, P675, DOI 10.1006/bbrc.1997.6694; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349	28	134	168	2	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					370	375		10.1038/nbt0498-370	http://dx.doi.org/10.1038/nbt0498-370			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555729				2022-12-25	WOS:000072786200030
J	Firulli, AB; McFadden, DG; Lin, Q; Srivastava, D; Olson, EN				Firulli, AB; McFadden, DG; Lin, Q; Srivastava, D; Olson, EN			Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1	NATURE GENETICS			English	Article							NEURAL CREST DERIVATIVES; GENE; EXPRESSION; PROTEINS	The basic helix-loop-helix (bHLH) transcription factors, Hand1 and Hand2 (refs 1,2), also called eHand/Hxt/Thing1 and dHand/Hed/Thing2 (refs 3,4), respectively, are expressed in the heart and certain neural-crest derivatives during embryogenesis. In addition, Hand1 is expressed in extraembryonic membranes, whereas Hand2 is expressed in the deciduum. Previous studies have demonstrated that Hand2 is required for formation of the right ventricle of the heart and the aortic arch arteries(5). We have generated a germline mutation in the mouse Hand1 gene by replacing the first coding exon with a beta-galactosidase reporter gene. Embryos homozygous for the Hand1 null allele died between embryonic days 8.5 and 9.5 and exhibited yolk sac abnormalities due to a deficiency in extraembryonic mesoderm, Heart development was also perturbed and did not progress beyond the cardiac-looping stage. Our results demonstrate important roles for Hand1 in extraembryonic mesodermal and heart development.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			/0000-0001-6687-8949	NHLBI NIH HHS [R01 HL061677, R01 HL061677-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061677] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; BARTH J, 1994, BIOTECHNIQUES, V17, P326; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; NG YK, 1994, DEVELOPMENT, V120, P3257; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154	16	292	301	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					266	270		10.1038/ng0398-266	http://dx.doi.org/10.1038/ng0398-266			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500550				2022-12-25	WOS:000072325000026
J	Peters, JM; Barnes, R; Bennett, L; Gitomer, WM; Bowcock, AM; Garg, A				Peters, JM; Barnes, R; Bennett, L; Gitomer, WM; Bowcock, AM; Garg, A			Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; EXTREMITIES; RECEPTOR; HUMANS; ARNT	Obesity is strongly implicated in the pathophysiology of insulin resistance, diabetes mellitus and dyslipidemia(1-3). The mechanisms, however, by which obesity causes these complications are not known, The study of single-gene disorders affecting adipose tissue may elucidate some of the mechanisms involved in these processes. Familial partial lipodystrophy, Dunnigan variety, (FPLD, OMIM 308980) is an autosomal-dominant condition characterized by marked loss of subcutaneous adipose tissue affecting the trunk and extremities but with excess fat deposition in the head and neck areas(4-14). Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus, dyslipidemia and acanthosis nigricans(4-14). The genetic basis of FPLD is unknown. We carried out a genome-wide scan with a set of highly polymorphic short tandem-repeats (STR) in individuals from five well-characterized pedigrees and mapped the FPLD locus to chromosome 1q21-22. The maximum two-point lod score obtained with a highly polymorphic microsatellite at D1S2624 at theta(max) = 0 was 5.84. Multipoint-linkage analysis yielded a peak lod score of 8.25 between D1S305 and D1S1600. There was no evidence for genetic heterogeneity (alpha=1) in the pedigrees.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Ctr Mineral Metab, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garg, A (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA.			Bennett, Lynda/0000-0001-7491-5797; Bowcock, Anne/0000-0001-8691-9090	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00633] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BURN J, 1986, J MED GENET, V23, P128, DOI 10.1136/jmg.23.2.128; DAVIDSON MB, 1975, DIABETOLOGIA, V11, P561, DOI 10.1007/BF01222107; DeFronzo RA, 1997, NETH J MED, V50, P191, DOI 10.1016/S0300-2977(97)00012-0; DUNNIGAN MG, 1974, Q J MED, V49, P33; FEDER J, 1985, AM J HUM GENET, V37, P635; Flagiello D, 1997, CYTOGENET CELL GENET, V76, P17, DOI 10.1159/000134502; HOOK B, 1984, HAUTARZT, V35, P530; Jackson SNJ, 1997, QJM-INT J MED, V90, P27; JOHNSON B, 1993, GENOMICS, V17, P592, DOI 10.1006/geno.1993.1377; KOBBERLING J, 1975, HUMANGENETIK, V29, P111, DOI 10.1007/BF00430347; KOBBERLING J, 1986, J MED GENET, V23, P120, DOI 10.1136/jmg.23.2.120; Kobberling J, 1981, VERH DTSCH GES INN M, V87, P958; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; Landsberg L, 1996, Hypertens Res, V19 Suppl 1, pS51, DOI 10.1291/hypres.19.SupplementI_S51; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LILLYSTONE D, 1975, ARCH DIS CHILD, V50, P737, DOI 10.1136/adc.50.9.737; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; OZER FL, 1973, CLIN RES, V21, P533; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROBBINS DC, 1982, METABOLISM, V31, P445, DOI 10.1016/0026-0495(82)90232-3; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Wanner R, 1996, BBA-MOL BASIS DIS, V1317, P105, DOI 10.1016/S0925-4439(96)00038-5	23	126	128	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					292	295		10.1038/ng0398-292	http://dx.doi.org/10.1038/ng0398-292			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500556				2022-12-25	WOS:000072325000032
J	Dunn-Coleman, N; Prade, R				Dunn-Coleman, N; Prade, R			Toward a global filamentous fungus genome sequencing effort	NATURE BIOTECHNOLOGY			English	Editorial Material									Genencor Int, Palo Alto, CA USA; Oklahoma State Univ, Dept Microbiol & Mol Genet, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Dunn-Coleman, N (corresponding author), Genencor Int, Palo Alto, CA USA.		Prade, Rolf/AAI-5104-2020	Prade, Rolf/0000-0002-8154-9286				Aramayo R, 1997, ASM NEWS, V63, P176; Bennett JW, 1997, FUNGAL GENET BIOL, V21, P3, DOI 10.1006/fgbi.1997.0969; Denning DW, 1997, ANTIMICROB AGENTS CH, V41, P1364, DOI 10.1128/AAC.41.6.1364; HAMMER L, 1997, FUNGAL GENET BIOL, V21, P8; Winzeler E, 1997, ASM NEWS, V63, P312	5	6	6	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1998	16	1					5	5		10.1038/nbt0198-5	http://dx.doi.org/10.1038/nbt0198-5			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YP708	9447576	Bronze			2022-12-25	WOS:000071306000005
J	Zion, D				Zion, D			Ethical considerations of clinical trials to prevent vertical transmission of HIV in developing countries	NATURE MEDICINE			English	Editorial Material									Univ Tokyo, Sch Int Hlth, Tokyo, Japan; Monash Univ, Ctr Human Bioeth, Clayton, Vic 3168, Australia	University of Tokyo; Monash University	Zion, D (corresponding author), Univ Tokyo, Sch Int Hlth, Tokyo, Japan.		Zion, Deborah/M-8806-2014					Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Raz J., 1986, MORALITY FREEDOM, P166; Wilkinson M, 1997, BIOETHICS, V11, P373, DOI 10.1111/1467-8519.00078; Williams B., 1973, UTILITARIANISM, P77; WOOD AW, 1995, SOC PHILOS POLICY, V12, P136, DOI 10.1017/S0265052500004702	5	4	4	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					11	12		10.1038/nm0198-011	http://dx.doi.org/10.1038/nm0198-011			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427593				2022-12-25	WOS:000072249700021
J	Schonermark, MP; Bock, O; Buchner, A; Steinmeier, R; Benbow, U; Lenarz, T				Schonermark, MP; Bock, O; Buchner, A; Steinmeier, R; Benbow, U; Lenarz, T			Quantification of tumor cell invasion using confocal laser scan microscopy	NATURE MEDICINE			English	Article							BREAST-CANCER CELLS; ASSAY; MEMBRANE; INHIBITION; METASTASIS; ACTIVATION; GROWTH		DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH 03755; UNIV HANNOVER,DEPT BIOPHYS,D-30175 HANNOVER,GERMANY	Dartmouth College; Leibniz University Hannover	Schonermark, MP (corresponding author), HANNOVER MED SCH,DEPT OTOLARYNGOL HEAD & NECK SURG,D-30623 HANNOVER,GERMANY.							ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FLUG M, 1995, ACTA ANAT, V152, P69; Gohla A, 1996, CLIN EXP METASTAS, V14, P451, DOI 10.1007/BF00128961; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107; Kleinman H. K, 1995, EXTRACELLULAR MATRIX, P289; KOHN EC, 1995, CANCER RES, V55, P1856; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MACKINNON WB, 1992, INVAS METAST, V12, P241; RUBIN M, 1994, CANCER RES, V54, P6549; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Sieuwerts AM, 1997, CLIN EXP METASTAS, V15, P53; STETLERSTEVENSO.WG, 1997, REGULATION ANGIOGENE, P413; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TEMPLETON NS, 1990, CANCER RES, V50, P5431; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; WATSON SA, 1995, CANCER RES, V55, P3629; WELCH DR, 1989, INT J CANCER, V43, P449, DOI 10.1002/ijc.2910430318; WILSON T, 1989, TRENDS NEUROSCI, V12, P486, DOI 10.1016/0166-2236(89)90104-5; YU M, 1995, CANCER RES, V55, P3272	24	14	14	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1167	1171		10.1038/nm1097-1167	http://dx.doi.org/10.1038/nm1097-1167			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334733				2022-12-25	WOS:A1997XZ28700047
J	Stilgenbauer, S; Schaffner, C; Litterst, A; Liebisch, P; Gilad, S; BarShira, A; James, MR; Lichter, P; Dohner, H				Stilgenbauer, S; Schaffner, C; Litterst, A; Liebisch, P; Gilad, S; BarShira, A; James, MR; Lichter, P; Dohner, H			Biallelic mutations in the ATM gene in T-prolymphocytic leukemia	NATURE MEDICINE			English	Article							ATAXIA-TELANGIECTASIA; LIPOPROTEIN RECEPTOR; DEFICIENT MICE; TCL1 ONCOGENE; PROTEIN; REGION; IDENTIFICATION; ORGANIZATION; EXPRESSION; NEOPLASMS	Ataxia-telangiectasia (AT) is an autosomal recessive disorder characterized by cerebellar ataxia, oculocutaneous telangiectasia, immune deficiency, genome instability and predisposition to malignancies, particularly T-cel[ neoplasms(1-3). The responsible gene, designated ataxia-telongiectasia mutated(ATM), was recently identified by positional cloning in the chromosomal region 11q22.3-23.1 (ref. 4, 5) ATM is 150 kb in length, consists of 66 exons and encodes a nuclear phosphoprotein of approximately 350 kDa (ref. 4-9). Although ATM is considered to be a tumorigenic factor in several human cancers, it has not yet been found mutated in tumors of non-AT patients. Given the marked predisposition of AT patients to develop neoplasms of the T-cell lineage(3), we analyzed a series of T-cell leukemias (T-prolymphocytic leukemia, or T-PLL) in non-AT patients in search of genomic changes associated with the development of this disease. Among the recurrent aberrations identified, deletion of the chromosome arm 11q was very frequent. Subsequent molecular cytogenetic analyses allowed us to define a small commonly deleted segment at 11q22.3-23.1 in 15 of 24 T-PLLs studied. Since this critical region contained ATM, we further analyzed the remaining copy of the gene in six cases showing deletions affecting one ATM allele. In all six cases, mutations of the second ATM allele were identified, leading to the absence, premature truncation or alteration of the ATM gene product. Thus, our study demonstrates disruption of both ATM alleles by deletion or point mutation in T-PLL, suggesting that ATM functions as a tumor-suppressor gene in tumors of non-AT individuals.	UNIV HEIDELBERG,MED KLIN & POLIKLIN 4,D-69115 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,ABT ORG KOMPLEXER GENOME,D-69120 HEIDELBERG,GERMANY; SACKLER SCH MED,DEPT HUMAN GENET,IL-9978 TEL AVIV,ISRAEL; UNIV OXFORD,NUFFIELD DEPT CLIN MED,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Tel Aviv University; Sackler Faculty of Medicine; University of Oxford; Wellcome Centre for Human Genetics			Stilgenbauer, Stephan/ABE-6609-2020; Döhner, Hartmut/C-8933-2016	Döhner, Hartmut/0000-0003-2116-5536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DOHNER H, 1993, J NATL CANCER I, V85, P658, DOI 10.1093/jnci/85.8.658; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FINAN J, 1978, VIRCHOWS ARCH B, V29, P121; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; HARRIS NL, 1994, BLOOD, V84, P1361; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Lakin ND, 1996, ONCOGENE, V13, P2707; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MALJAIE SH, 1995, LEUKEMIA, V9, P1694; MEYN MS, 1995, CANCER RES, V55, P5991; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; NOWAK R, 1995, SCIENCE, V268, P1700, DOI 10.1126/science.7792589; PITTMAN S, 1982, LEUKEMIA RES, V6, P33, DOI 10.1016/0145-2126(82)90041-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; STILGENBAUER S, 1993, BLOOD, V81, P2118; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Thick J, 1996, ONCOGENE, V12, P379; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; VANLEUVEN F, 1994, GENOMICS, V24, P78, DOI 10.1006/geno.1994.1584; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Vorechovsky I, 1996, CANCER RES, V56, P2726; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZECH L, 1984, NATURE, V308, P858, DOI 10.1038/308858a0	39	188	189	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1155	1159		10.1038/nm1097-1155	http://dx.doi.org/10.1038/nm1097-1155			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334731				2022-12-25	WOS:A1997XZ28700045
J	Ayub, R; Guis, M; BenAmor, M; Gillot, L; Roustan, JP; Latche, A; Bouzayen, M; Pech, JC				Ayub, R; Guis, M; BenAmor, M; Gillot, L; Roustan, JP; Latche, A; Bouzayen, M; Pech, JC			Expression of ACC oxidase antisense gene inhibits ripening of cantaloupe melon fruits	NATURE BIOTECHNOLOGY			English	Article						ethylene; cantaloupe Charentais melon; Cucumis melo	ETHYLENE-FORMING ENZYME; 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID; CUCUMIS-MELO; APPLE FRUITS; TOMATO; PLANTS; SENESCENCE; RNA	The plant hormone ethylene plays a major role in the ripening of climacteric fruit. We have generated transgenic cantaloupe Charentais melons expressing an antisense ACC oxidase gene; ACC oxidase catalyzes the last step of ethylene biosynthesis. Ethylene production of transgenic fruit was <1% of control untransformed fruit, and the ripening process was blocked both on and off the vine. The antisense phenotype could be reversed by exogenous ethylene treatment. Analysis of antisense ACC oxidase melons indicated that the ripening process includes ethylene-dependent and ethylene-independent pathways. Because the transgenic line we generated displays extended storage life and improved quality, it has a promising potential for commercial development.	ECOLE NATL SUPER AGRON TOULOUSE, UA INRA, F-31076 TOULOUSE, FRANCE	INRAE; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National Polytechnique de Toulouse			Ayub, Ricardo Antonio/AAB-6633-2019; Bouzayen, Mondher/AFQ-0802-2022	Ayub, Ricardo Antonio/0000-0003-3240-8417; 				An G., 1989, PLANT MOL BIOL MANUA, P1, DOI [DOI 10.1007/978-94-009-0951-9, 10.1007/978-94-017-5294-7_3]; BALAGUE C, 1993, EUR J BIOCHEM, V212, P27, DOI 10.1111/j.1432-1033.1993.tb17628.x; BOUZAYEN M, 1993, CURR PLANT SCI BIOT, V16, P76; DEVAUX RD, 1976, ANN TECHNOL AGR, V25, P309; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; DUPILLE E, 1993, PLANTA, V190, P65, DOI 10.1007/BF00195676; GALBRAITH DW, 1983, SCIENCE, V220, P1049, DOI 10.1126/science.220.4601.1049; GOOD X, 1994, PLANT MOL BIOL, V26, P781, DOI 10.1007/BF00028848; HAMILTON AJ, 1991, P NATL ACAD SCI USA, V88, P7434, DOI 10.1073/pnas.88.16.7434; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HOLDSWORTH MJ, 1988, PLANT MOL BIOL, V11, P81, DOI 10.1007/BF00015661; KARVOUNI Z, 1995, PLANT MOL BIOL, V27, P1153, DOI 10.1007/BF00020888; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KLEE HJ, 1993, PLANT PHYSIOL, V102, P911, DOI 10.1104/pp.102.3.911; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; LASSERRE E, 1996, IN PRESS MOL GEN GEN, V251; MANSOUR R, 1986, PHYSIOL PLANTARUM, V66, P495, DOI 10.1111/j.1399-3054.1986.tb05957.x; Murashige T., 1962, PHYSIOL PLANTARUM, V15, P437, DOI DOI 10.1111/J.1399-3054.1962.TB08052; Murray A. J., 1993, Postharvest Biology and Technology, V2, P301, DOI 10.1016/0925-5214(93)90035-2; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; PICTON S, 1993, PLANT J, V3, P469, DOI 10.1111/j.1365-313X.1993.tb00167.x; ROMBALDI C, 1994, PLANTA, V192, P453, DOI 10.1007/BF00203582; ROMOJARO F, 1979, REV AGROQUIM TECNOL, V19, P385; ROUSTAN JP, 1992, J PLANT PHYSIOL, V140, P485, DOI 10.1016/S0176-1617(11)80830-8; SALVEIT ME, 1993, PHYSIOL PLANTARUM, V89, P204; SEYMOUR GB, 1993, BIOCH FRUIT RIPENING, pCH9; SHELLIE KC, 1993, J EXP BOT, V44, P1403, DOI 10.1093/jxb/44.8.1403; THEOLOGIS A, 1993, DEV GENET, V14, P282, DOI 10.1002/dvg.1020140406; TONUTTI P, 1995, PLANT CELL ENVIRON, V18, P709, DOI 10.1111/j.1365-3040.1995.tb00573.x; VETTEN NC, 1992, PLANT CELL, V4, P1295; VOSS DH, 1992, HORTSCIENCE, V27, P1256, DOI 10.21273/HORTSCI.27.12.1256; WADSWORTH GJ, 1988, ANAL BIOCHEM, V172, P279, DOI 10.1016/0003-2697(88)90443-5	32	270	301	2	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					862	866		10.1038/nbt0796-862	http://dx.doi.org/10.1038/nbt0796-862			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631011				2022-12-25	WOS:A1996UV62000036
J	Vaughan, TJ; Williams, AJ; Pritchard, K; Osbourn, JK; Pope, AR; Earnshaw, JC; McCafferty, J; Hodits, RA; Wilton, J; Johnson, KS				Vaughan, TJ; Williams, AJ; Pritchard, K; Osbourn, JK; Pope, AR; Earnshaw, JC; McCafferty, J; Hodits, RA; Wilton, J; Johnson, KS			Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library	NATURE BIOTECHNOLOGY			English	Article						ScFv; diversity; off-rate	MONOCLONAL-ANTIBODIES; COMBINATORIAL LIBRARIES; GENE LIBRARIES; SELECTION; MATURATION; REPERTOIRE; SEGMENTS; INVITRO; PROTEIN	To generate a stable resource from which high affinity human antibodies to any given antigen can be rapidly isolated, functional V-gene segments from 43 non-immunized human donors were used to construct a repertoire of 1.4 x 10(10) single-chain Fv (scFv) fragments displayed on the surface of phage. Fragments were cloned in a phagemid vector, enabling both phage displayed and soluble scFv to be produced without subcloning. A hexahistidine tag has been incorporated to allow rapid purification of scFv by nickel chelate chromatography. This library format reduces the time needed to isolate monoclonal antibody fragments to under two weeks. All of the measured binding affinities show a K-d < 10 nM and off-rates of 10(-3) to 10(-4) s(-1), properties usually associated with antibodies from a secondary immune response. The best of these scFvs, an anti-fluorescein antibody (0.3 nM) and an antibody directed against the hapten DTPA (0.8 nM), are the first antibodies with subnanomolar binding affinities to be isolated from a naive library. Antibodies to doxorubicin, which is both immunosuppressive and toxic, as well as a high affinity and high specificity antibody to the steroid hormone oestradiol have been isolated. This work shows that conventional hybridoma technology may be superseded by large phage libraries that are proving to be a stable and reliable source of specific, high affinity human monoclonal antibodies.	MRC,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge	Vaughan, TJ (corresponding author), CAMBRIDGE ANTIBODY TECHNOL LTD,UNIT B3,SCI PK,MELBOURNE SG8 6JJ,CAMBS,ENGLAND.							BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P10164, DOI 10.1073/pnas.89.21.10164; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339; BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1319, DOI 10.1016/0161-5890(86)90017-9; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BOXER GM, 1994, BRIT J CANCER, V69, P307, DOI 10.1038/bjc.1994.56; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; CHUCHANA P, 1990, EUR J IMMUNOL, V20, P1317, DOI 10.1002/eji.1830200618; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; COOK GP, 1994, NAT GENET, V7, P162, DOI 10.1038/ng0694-162; COX JPL, 1994, EUR J IMMUNOL, V24, P827, DOI 10.1002/eji.1830240409; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; GOLDBERG ME, 1993, CURR OPIN IMMUNOL, V5, P278, DOI 10.1016/0952-7915(93)90018-N; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1992, EUR J IMMUNOL, V22, P867, DOI 10.1002/eji.1830220336; HODITS RA, 1995, J BIOL CHEM, V270, P24078, DOI 10.1074/jbc.270.41.24078; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; ISAACS J, 1992, LANCET, V26, P748; JOHNSON KS, 1993, CURR OPIN STRUC BIOL, V3, P564, DOI 10.1016/0959-440X(93)90084-X; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kabat EA, 1991, SEQUENCES PROTEINS I; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PERELSON AS, 1979, J THEOR BIOL, V81, P645, DOI 10.1016/0022-5193(79)90275-3; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RIXON MW, 1993, J IMMUNOL, V151, P6559; TOMLINSON IM, 1994, HUM MOL GENET, V3, P853; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; WATERHOUSE P, 1993, NUCLEIC ACIDS RES, V21, P2265, DOI 10.1093/nar/21.9.2265; WILLIAMS SC, 1993, EUR J IMMUNOL, V23, P1456, DOI 10.1002/eji.1830230709; WILLIAMSON RA, 1993, P NATL ACAD SCI USA, V90, P4141, DOI 10.1073/pnas.90.9.4141; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	44	796	1409	1	91	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					309	314		10.1038/nbt0396-309	http://dx.doi.org/10.1038/nbt0396-309			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630891				2022-12-25	WOS:A1996UL38000023
J	Matsuno, K; Eastman, D; Mitsiades, T; Quinn, AM; Carcanciu, ML; Ordentlich, P; Kadesch, T; Artavanis-Tsakonas, S				Matsuno, K; Eastman, D; Mitsiades, T; Quinn, AM; Carcanciu, ML; Ordentlich, P; Kadesch, T; Artavanis-Tsakonas, S			Human deltex is a conserved regulator of Notch signalling	NATURE GENETICS			English	Article							SIGNALING PATHWAY; ANKYRIN REPEATS; DNA-BINDING; DROSOPHILA; PROTEIN; GENE; ENHANCER; SPLIT; HAIRLESS; SUPPRESSOR	A fundamental cell-fate control mechanism regulating multicellular development is defined by the Notch-signalling pathway(1). Developmental and genetic studies of wild type and activated Notch-receptor expression in diverse organisms suggest that Notch plays a general role in development by governing the ability of undifferentiated precursor cells to respond to specific signals(1,2). Notch signalling has been conserved throughout evolution and controls the differentiation of a broad spectrum of cell types during development(1-3). Genetic studies in Drosophila have led to the identification of several components of the Notch pathway(1). Two of the positive regulators of the pathway are encoded by the suppressor of hairless [Su(H)] and deltex (dx) genes(5-8). Drosophila dr encodes a ubiquitous, novel cytoplasmic protein of unknown biochemical function(9). We have cloned a human deltex homologue and characterized it in parallel with its Drosophila counterpart in biochemical assays to assess deltex function. Both human and Drosophila deltex bind to Notch across species and carry putative Shy-binding domains. Using the yeast interaction trap system, we find that Drosophila and human deltex bind to the human SH3-domain containing protein Grb2 (ref. 10). Results from two different reporter assays allow us for the first time to associate deltex with Notch-dependent transcriptional events. We present evidence linking deltex to the modulation of basic helix-loop-helix (bHLH) transcription factor activity.	Yale Univ, Dept Cell Biol & Biol, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Dept Pathol, New Haven, CT 06511 USA; Univ Penn, Sch Med, Dept Genet, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; Yale University; Yale University; Howard Hughes Medical Institute; University of Pennsylvania	Artavanis-Tsakonas, S (corresponding author), Osaka Univ, Sch Med, Dept Neuroanat, Osaka, Japan.	spyros.artavnis@yale.edu	Mitsiadis, Thimios A/B-9249-2008; Mitsiadis, Thimios/B-5564-2016	Mitsiadis, Thimios/0000-0002-9812-9982				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, PERSPECT DEV NEUROBI, V4, P325; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BUSSEAU I, 1994, GENETICS, V136, P585; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; EASTMAN DS, IN PRESS MOL CELL BI; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIER D, 1992, MECH DEVELOP, V38, P143, DOI 10.1016/0925-4773(92)90006-6; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; XU T, 1990, GENETICS, V126, P665; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	162	167	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					74	78		10.1038/ng0598-74	http://dx.doi.org/10.1038/ng0598-74			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590294				2022-12-25	WOS:000073346700022
J	Qin, ZH; Richter, G; Schuler, T; Ibe, S; Cao, XT; Blankenstein, T				Qin, ZH; Richter, G; Schuler, T; Ibe, S; Cao, XT; Blankenstein, T			B cells inhibit induction of T cell-dependent tumor immunity	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELL; PROTEIN ANTIGENS; DEFICIENT MICE; LYMPH-NODES; MEMORY; LYMPHOCYTES; ANTIBODIES; TOLERANCE; RESPONSES; INVIVO	Cytotoxic T lymphocyte (CTL) mediated tumor immunity against major histocompatibility antigen (MHC) class I-positive but class Ii-negative tumors often requires help from CD4(+) T cells. These CD4 cells are activated by MHC class Ii-positive cells that present tumor derived antigens(1,2). Considering that different antigen presenting cells, such as B cells, macrophages and dendritic cells compete for antigen and influence the outcome of an immune response(3-13), we analyzed tumor immunity in B cell-deficient mice(14). These mice appear normal with regard to T cell immunity and tolerance to some pure foreign antigens(15-19), We show here that the low immunogenicity of tumors is caused by B cells whose presence in the priming phase results in disabled CD4(+) T cell help for CTL mediated tumor immunity. Instead, in the presence of B cells, a non-protective humoral immune response is induced. Our results may explain the enigmatic observation that tumor-reactive antibodies occur frequently in cancer patients(20).	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Second Mil Med Univ, Shanghai 200433, Peoples R China	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Naval Medical University	Qin, ZH (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.			Qin, Zhihai/0000-0001-9793-7964				Asano MS, 1996, J EXP MED, V183, P2165, DOI 10.1084/jem.183.5.2165; ASHWELL JD, 1988, J IMMUNOL, V140, P3697; AWWAD M, 1988, J EXP MED, V168, P2193, DOI 10.1084/jem.168.6.2193; Blankenstein T, 1996, REV PHYSIOL BIOCH P, V129, P1; CAVALLO F, 1992, J IMMUNOL, V149, P3627; Cayeux S, 1997, J IMMUNOL, V158, P2834; CONSTANT S, 1995, J IMMUNOL, V154, P4915; DiRosa F, 1996, J EXP MED, V183, P2153, DOI 10.1084/jem.183.5.2153; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; ELLENHORN JDI, 1990, J IMMUNOL, V144, P2840; EPSTEIN MM, 1995, J EXP MED, V182, P915, DOI 10.1084/jem.182.4.915; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; Feldman J D, 1972, Adv Immunol, V15, P167, DOI 10.1016/S0065-2776(08)60685-9; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; HOUBIERS JGA, 1995, BRIT J CANCER, V72, P637, DOI 10.1038/bjc.1995.386; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JANEWAY CA, 1987, J IMMUNOL, V138, P1051; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; Macaulay AE, 1998, J IMMUNOL, V160, P1694; MONACH PA, 1993, TRANSPLANTATION, V55, P1356; Phillips JA, 1996, J EXP MED, V183, P1339, DOI 10.1084/jem.183.4.1339; PREHN RT, 1971, J RETICULOENDOTH SOC, V10, P1; RON Y, 1987, J IMMUNOL, V138, P2848; ROWLEY DA, 1993, J EXP MED, V178, P835, DOI 10.1084/jem.178.3.835; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; Schreiber Hans, 1993, P1143; SCHULTZ KR, 1990, SCIENCE, V249, P921, DOI 10.1126/science.2118273; SIMITSEK PD, 1995, J EXP MED, V181, P1957, DOI 10.1084/jem.181.6.1957; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Stockinger B, 1996, J EXP MED, V183, P891, DOI 10.1084/jem.183.3.891; Vella AT, 1996, P NATL ACAD SCI USA, V93, P951, DOI 10.1073/pnas.93.2.951	35	320	327	1	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					627	630		10.1038/nm0598-627	http://dx.doi.org/10.1038/nm0598-627			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585241				2022-12-25	WOS:000073399900039
J	Nathanielsz, PW; Jenkins, SL; Tame, JD; Winter, JA; Guller, S; Giussani, DA				Nathanielsz, PW; Jenkins, SL; Tame, JD; Winter, JA; Guller, S; Giussani, DA			Local paracrine effects of estradiol are central to parturition in the rhesus monkey	NATURE MEDICINE			English	Article							TIME-TREND ANALYSIS; PROGESTERONE RATIO; MATERNAL SHEEP; PLASMA; OXYTOCIN; FETAL; ESTROGEN; LABOR; CONNEXIN-43; EXPRESSION	The central biochemical mechanisms involved in primate parturition are still unclear. Studies in both humans and nonhuman primates such as the baboon and rhesus monkey indicate that many factors play a part in the cascade of interactive positive feedforward loops that progressively promote parturition: changes in maternal endocrinology, a nocturnal switch in myometrial activity from low amplitude, infrequent contractures to high amplitude, high frequency contractions (see Fig. 1), dilation of the cervix and biochemical changes in the fetal membranes that lead to rupture(1). Here we demonstrate that infusion of the aromatase inhibitor 4-hydroxyandrostenedione (40HA) inhibits conversion of androgen to estrogen and prevents premature delivery caused by administration of androgen to pregnant rhesus monkeys at 0.8 of pregnancy term. 40HA also inhibited the androstenedione induced maternal endocrine and fetal membrane biochemical changes, and alteration of myometrial activity patterns. Secondly, peripheral estrogen infusions increased myometrial activity but did not produce preterm delivery or fetal membrane changes. We conclude that paracrine functions of estrogen at its site of production play critical and central roles in delivery in the non-human primate.	Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA; NYU, Med Ctr, Dept Obstet & Gynecol, New York, NY 10016 USA	Cornell University; New York University	Nathanielsz, PW (corresponding author), Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA.			Giussani, Dino/0000-0002-1308-1204; Nathanielsz, Peter/0000-0001-8410-6280	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021350] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 21350] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMICO JA, 1990, NEUROENDOCRINOLOGY, V51, P543, DOI 10.1159/000125389; AMICO JA, 1990, NEUROENDOCRINOLOGY, V51, P437, DOI 10.1159/000125371; BUSTER JE, 1979, J CLIN ENDOCR METAB, V48, P139, DOI 10.1210/jcem-48-1-139; BUSTER JE, 1979, J CLIN ENDOCR METAB, V48, P133, DOI 10.1210/jcem-48-1-133; CHALLIS JRG, 1971, NATURE, V229, P208, DOI 10.1038/229208a0; CIBBAR R, 1995, J CLIN ENDOCR METAB, V80, P567; DARNE J, 1987, BRIT MED J, V294, P270, DOI 10.1136/bmj.294.6567.270; ELSNER CW, 1980, ENDOCRINOLOGY, V107, P801, DOI 10.1210/endo-107-3-801; Farber DM, 1997, BIOL REPROD, V56, P557, DOI 10.1095/biolreprod56.2.557; GERMAIN AM, 1996, PRENAT NEONAT MED, V1, P57; Haluska GJ, 1997, AM J OBSTET GYNECOL, V176, P682, DOI 10.1016/S0002-9378(97)70570-2; LEFEBVRE DL, 1994, ENDOCRINOLOGY, V134, P2562, DOI 10.1210/en.134.6.2562; LYE SJ, 1993, ENDOCRINOLOGY, V132, P2380, DOI 10.1210/en.132.6.2380; MAGYAR DM, 1980, ENDOCRINOLOGY, V107, P155, DOI 10.1210/endo-107-1-155; Mecenas CA, 1996, NAT MED, V2, P443, DOI 10.1038/nm0496-443; NATHANIELSZ PW, 1982, ENDOCRINOLOGY, V110, P1402, DOI 10.1210/endo-110-4-1402; NOVY MJ, 1983, AM J OBSTET GYNECOL, V145, P920, DOI 10.1016/0002-9378(83)90841-4; NOVY MJ, 1981, FETAL ENDOCRINOLOGY, P66; OLSON DM, 1995, SEMIN PERINATOL, V19, P52, DOI 10.1016/S0146-0005(95)80047-6; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; SIITERI PK, 1981, FETAL ENDOCRINOLOGY, P1; STEELE PA, 1976, J ENDOCRINOL, V69, P239, DOI 10.1677/joe.0.0690239; WILSON L, 1991, AM J OBSTET GYNECOL, V165, P1487; Wu WX, 1996, BIOL REPROD, V55, P762, DOI 10.1095/biolreprod55.4.762; ZHANG J, 1991, BIOL REPROD, V45, P395, DOI 10.1095/biolreprod45.3.395	25	58	58	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					456	459		10.1038/nm0498-456	http://dx.doi.org/10.1038/nm0498-456			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546793				2022-12-25	WOS:000072906800042
J	Ferrara, N; Chen, H; Davis-Smyth, T; Gerber, HP; Nguyen, TN; Peers, D; Chisholm, V; Hillan, KJ; Schwall, RH				Ferrara, N; Chen, H; Davis-Smyth, T; Gerber, HP; Nguyen, TN; Peers, D; Chisholm, V; Hillan, KJ; Schwall, RH			Vascular endothelial growth factor is essential for corpus luteum angiogenesis	NATURE MEDICINE			English	Article							OVARIAN HYPERSTIMULATION SYNDROME; TYROSINE KINASE; FACTOR VEGF; IN-VIVO; RECEPTOR; EXPRESSION; FLT-1; NEOVASCULARIZATION; PROTEINS; BINDING	The development and endocrine function of the ovarian corpus luteum (CL) are dependent on the growth of new capillary vessels. Although several molecules have been implicated as mediators of CL angiogenesis, at present there is no direct evidence for the involvement of any. Here we report the unexpected finding that treatment with truncated soluble Flt-1 receptors, which inhibit vascular endothelial growth factor (VEGF) bioactivity, resulted in virtually complete suppression of CL angiogenesis in a rat model of hormonally induced ovulation. This effect was associated with inhibition of CL development and progesterone release. Failure of maturation of the endometrium was also observed. Areas of ischemic necrosis were demonstrated in the corpora lutea (CLs) of treated animals. However, no effect on the preexisting ovarian vasculature was observed. These findings demonstrate that, in spite of the redundancy of potential mediators, VEGF is essential for CL angiogenesis. Furthermore, they have implications for the control of fertility and the treatment of ovarian disorders characterized by hypervascularity and hyperplasia.	Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA; Genentech Inc, Dept Proc Sci, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, S San Francisco, CA 94080 USA.							AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHISHOLM V, 1995, DNA CLONING, V4, P1; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ENGEL T, 1972, AM J OBSTET GYNECOL, V112, P1052, DOI 10.1016/0002-9378(72)90180-9; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINNERTY H, 1993, ONCOGENE, V8, P2293; GATES AH, 1971, MAMMALIAN EMBRYOLOGY, P46; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; GOSPODAROWICZ D, 1978, P NATL ACAD SCI USA, V75, P847, DOI 10.1073/pnas.75.2.847; GOSPODAROWICZ D, 1985, ENDOCRINOLOGY, V117, P2283; KAMAT BR, 1995, AM J PATHOL, V146, P157; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5; MURTHY YS, 1970, OBSTET GYNECOL, V36, P758; PARK JE, 1994, J BIOL CHEM, V269, P25646; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; Rothchild I, 1981, Recent Prog Horm Res, V37, P183; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706	25	509	585	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					336	340		10.1038/nm0398-336	http://dx.doi.org/10.1038/nm0398-336			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500609				2022-12-25	WOS:000073616200041
J	Fu, YC; Wang, YB; Evans, SM				Fu, YC; Wang, YB; Evans, SM			Viral sequences enable efficient and tissue-specific expression of transgenes in Xenopus	NATURE BIOTECHNOLOGY			English	Article						animal models; development; adeno-associated virus; inverted terminal repeats; microinjection	ADENO-ASSOCIATED VIRUS; ADENOASSOCIATED VIRUS; GENE-EXPRESSION; LAEVIS EMBRYOS; DNA; REPLICATION; CELLS; INTEGRATION; EGGS	Expression of transgenes within a single generation by direct DNA injection into vertebrate embryos has been plagued by inefficient and nonuniform gene expression. We report a novel strategy for efficient and stable expression of transgenes driven by both ubiquitous and tissue-specific promoters by direct DNA injection into developing Xenopus laevis embryos. This strategy involves flanking expression cassettes of interest with inverted terminal repeat sequences (ITRs) from adeno-associated virus. Our results suggest that the ITR strategy may be generally applicable to other systems, such as zebra fish and embryonic stem cells, and may enable tissue-specific expression of transgenes in problematic contexts.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Evans, SM (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.		Evans, Sylvia/G-1980-2015	Wang, Yibin/0000-0003-0852-0767				BERNS KI, 1995, BIOESSAYS, V17, P237, DOI 10.1002/bies.950170310; ETKIN LD, 1987, DEVELOPMENT, V99, P15; FLOTTE TR, 1994, AM J RESP CELL MOL, V11, P517, DOI 10.1165/ajrcmb.11.5.7946381; HARLAND RM, 1991, XENOPUS LAEVIS PRACT, P685; KROLL KL, 1994, SCIENCE, V266, P650, DOI 10.1126/science.7939720; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LEBKOWSKI JS, 1988, MOL CELL BIOL, V8, P3988, DOI 10.1128/MCB.8.10.3988; LEFEBVRE RB, 1984, MOL CELL BIOL, V4, P1416, DOI 10.1128/MCB.4.7.1416; LUSBY E, 1980, J VIROL, V34, P402, DOI 10.1128/JVI.34.2.402-409.1980; MARINI NJ, 1991, MOL CELL BIOL, V11, P299, DOI 10.1128/MCB.11.1.299; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PHILIP R, 1994, MOL CELL BIOL, V14, P2411, DOI 10.1128/MCB.14.4.2411; PORTER SD, 1994, DEVELOPMENT, V120, P2103; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VIZE PD, 1991, XENOPUS LAEVIS PRACT, P367; WANG XS, 1995, J MOL BIOL, V250, P573, DOI 10.1006/jmbi.1995.0398; Weitzman MD, 1996, J VIROL, V70, P1845, DOI 10.1128/JVI.70.3.1845-1854.1996	18	39	46	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					253	257		10.1038/nbt0398-253	http://dx.doi.org/10.1038/nbt0398-253			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528004				2022-12-25	WOS:000072371000024
J	Xu, L; Sanchez, A; Yang, ZY; Zaki, SR; Nabel, EG; Nichol, ST; Nabel, GJ				Xu, L; Sanchez, A; Yang, ZY; Zaki, SR; Nabel, EG; Nichol, ST; Nabel, GJ			Immunization for Ebola virus infection	NATURE MEDICINE			English	Article							PLASMID DNA; GENE; VACCINATION; PROTECTION; INJECTION; IMMUNITY; PROTEIN; EXPRESSION; INHIBITION; INDUCTION	Infection by Ebola virus causes rapidly progressive, often fatal, symptoms of fever, hemorrhage and hypotension. Previous attempts to elicit protective immunity for this disease have not met with success. We report here that protection against the lethal effects of Ebola virus can be achieved in an animal model by immunizing with plasmids encoding viral proteins. We analyzed immune responses to the viral nucleoprotein (NP) and the secreted or transmembrane forms of the glycoprotein (sGP or GP) and their ability to protect against infection in a guinea pig infection model analogous to the human disease. Protection was achieved and correlated with antibody titer and antigen-specific T-cell responses to sGP or GP. Immunity to Ebola virus can therefore be developed through genetic vaccination and may facilitate efforts to limit the spread of this disease.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, 1150 W Med Ctr Dr,4520 MSRB 1, Ann Arbor, MI 48109 USA.							Arai H, 1997, NAT MED, V3, P843, DOI 10.1038/nm0897-843; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BOTTOMLY K, 1992, CURRENT PROTOCOLS IM; BOWEN ETW, 1977, LANCET, V1, P571; BURKREYEV AA, 1993, FEBS LETT, V323, P183; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; CLEGG JCS, 1997, NEW GENERATION VACCI, P749; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; HARRIS DT, 1987, J IMMUNOL, V138, P889; Iwasaki A, 1997, J IMMUNOL, V159, P11; Jahrling PB, 1996, ARCH VIROL, P135; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; KSIAZEK TG, 1991, LAB ANIM, V20, P34; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; MCCORMICK JB, 1983, J INFECT DIS, V147, P264, DOI 10.1093/infdis/147.2.264; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; Ohno T, 1997, GENE THER, V4, P361, DOI 10.1038/sj.gt.3300403; Peters C.J., 1996, FIELDS VIROLOGY, P1161; PETERS CJ, 1994, SEMIN VIROL, V5, P147, DOI 10.1006/smvy.1994.1015; RAZ E, 1993, P NATL ACAD SCI USA, V90, P4523, DOI 10.1073/pnas.90.10.4523; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Sambrook J, 1994, MOL CLONING LAB MANU; SANCHEZ A, 1993, VIRUS RES, V29, P215, DOI 10.1016/0168-1702(93)90063-S; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; SANCHEZ A, 1989, VIROLOGY, V170, P81, DOI 10.1016/0042-6822(89)90354-1; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; TAN BTG, 1985, HYBRIDOMA, V4, P115, DOI 10.1089/hyb.1985.4.115; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VOLCHKOV VE, 1992, FEBS LETT, V305, P181, DOI 10.1016/0014-5793(92)80662-Z; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P14, DOI 10.1016/S0167-5699(97)80008-4	37	181	212	0	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1998	4	1					37	42		10.1038/nm0198-037	http://dx.doi.org/10.1038/nm0198-037			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427604	Bronze			2022-12-25	WOS:000072249700032
J	Gebbia, M; Ferrero, GB; Pilia, G; Bassi, MT; Aylsworth, AS; PenmanSplitt, M; Bird, LM; Bamforth, JS; Burn, J; Schlessinger, D; Nelson, DL; Casey, B				Gebbia, M; Ferrero, GB; Pilia, G; Bassi, MT; Aylsworth, AS; PenmanSplitt, M; Bird, LM; Bamforth, JS; Burn, J; Schlessinger, D; Nelson, DL; Casey, B			X-linked situs abnormalities result from mutations in ZIC3	NATURE GENETICS			English	Article							LEFT-RIGHT ASYMMETRY; NODAL EXPRESSION; GENE FAMILY; LATERALITY; DEFECTS; EMBRYOS; XENOPUS; MEMBER; DNA	Vertebrates position unpaired organs of the chest and abdomen asymmetrically along the left-right (LR) body axis. Each structure comes to lie non-randomly with respect to the midline in an overall position designated sites solitus, exemplified in humans by placement of the heart, stomach and spleen consistently to the left. Aberrant LR axis development can lead to randomization of individual organ position (sites ambiguus) or to mirror-image reversal of all lateralized structures (sites inversus)(1). Previously we mapped a locus for sites abnormalities in humans, HTX1, to Xq26.2 by linkage analysis in a single family (LR1) and by detection of a deletion in an unrelated sites ambiguus male (Family LR2; refs 2,3). From this chromosomal region we have positionally cloned ZIC3, a gene encoding a putative zinc-finger transcription factor. One frameshift, two missense and two nonsense mutations have been identified in familial and sporadic sites ambiguus. The frameshift allele is also associated with sites inverses among some heterozygous females, suggesting that ZIC3 functions in the earliest stages of LR-axis formation. ZIC3, which has not been previously implicated in vertebrate LR-axis development, is the first gene unequivocally associated with human sites abnormalities.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; WASHINGTON UNIV, DEPT MOL MICROBIOL, ST LOUIS, MO 63130 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CTR NEUROSCI, CHAPEL HILL, NC 27599 USA; UNIV NEWCASTLE UPON TYNE, DEPT HUMAN GENET, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; CHILDRENS HOSP & HLTH CTR, SAN DIEGO, CA 92123 USA; UNIV ALBERTA HOSP, DEPT MED GENET, EDMONTON, AB T6G 2B7, CANADA	Baylor College of Medicine; Baylor College of Medicine; Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Newcastle University - UK; University of Alberta			Bird, Lynne/AAG-9533-2021; Ferrero, Giovanni Battista/K-5265-2018; Bassi, Maria Teresa T/A-3517-2014	Ferrero, Giovanni Battista/0000-0002-3793-5788; Bassi, Maria Teresa T/0000-0002-8236-1197; Bird, Lynne/0000-0003-4833-3747	NHGRI NIH HHS [HG00201] Funding Source: Medline; NICHD NIH HHS [5K08 HD01078, P30 HD24064] Funding Source: Medline; Telethon [E.0110, TGM06S01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001078] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aruga J, 1996, GENE, V172, P291, DOI 10.1016/0378-1119(96)00111-4; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Casey B, 1996, AM J MED GENET, V61, P325, DOI 10.1002/(SICI)1096-8628(19960202)61:4<325::AID-AJMG5>3.0.CO;2-T; CASEY B, 1993, NAT GENET, V5, P403, DOI 10.1038/ng1293-403; CIMBORA DM, 1995, DEV BIOL, V169, P580, DOI 10.1006/dbio.1995.1171; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DANOS MC, 1995, DEVELOPMENT, V121, P1467; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Ferrero GB, 1997, AM J HUM GENET, V61, P395, DOI 10.1086/514857; Gebbia M, 1996, CIRCULATION, V94, P1909, DOI 10.1161/01.CIR.94.8.1909; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KOSAKI K, IN PRESS SEMIN CELL; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Larsen WJ, 1993, HUMAN EMBRYOLOGY; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Pilia G, 1996, GENOMICS, V34, P55, DOI 10.1006/geno.1996.0240; Splitt MP, 1997, HEART, V77, P369, DOI 10.1136/hrt.77.4.369; WAPENAAR MC, 1994, HUM MOL GENET, V3, P1155, DOI 10.1093/hmg/3.7.1155	28	320	329	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1997	17	3					305	308		10.1038/ng1197-305	http://dx.doi.org/10.1038/ng1197-305			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354794				2022-12-25	WOS:A1997YD66700024
J	Kafri, T; Blomer, U; Peterson, DA; Gage, FH; Verma, IM				Kafri, T; Blomer, U; Peterson, DA; Gage, FH; Verma, IM			Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors	NATURE GENETICS			English	Article							LONG-TERM EXPRESSION; RECOMBINANT ADENOVIRUSES; SYSTEMIC DELIVERY; THERAPY; MYOBLASTS; CELLS; TRANSPLANTATION; PROTEIN; INVIVO	Successful gene therapy approaches will require efficient gene delivery and sustained expression of the transgene in recipients. A variety of methods, ranging from direct DNA delivery to infection with recombinant viruses containing foreign genes, have been developed, but they all have some major limitations that restrict their utility(1-4). We have described a human lentiviral (HIV)-based vector that can transduce non-dividing cells in vitro and deliver genes in vivo(5,6). With this vector, expression of transgenes in the brain has been detected for more than six months-the longest period tested so far(7). Because lentiviral vectors are pseudotyped with vesicular stomatitis virus G glycoprotein (VSVG; ref, 8), they can transduce a broad range of tissues and cell types. We now describe the ability of lentiviral vectors to introduce genes directly into liver and muscle. Sustained expression of green fluorescent protein (GFP), used as a surrogate for therapeutic protein, can be observed for more than 22 weeks in the liver. Similar long-term expression (more than eight weeks) was observed in transduced muscle. in contrast, little or no GFP could be detected in liver or muscle transduced with the Moloney murine leukaemia virus (M-MLV), a prototypic retroviral based vector. At a minimum, 3-4% of the total liver tissue was transduced by a single injection of 1-3x10(7) infectious units (I.U.) of recombinant HIV vector. Furthermore, no inflammation or recruitment of lymphocytes could be detected at the site of injection. Animals previously transduced with a lentiviral vector can be efficiently re-infected with lentiviral vectors. Additionally, we show that the requirement for lentiviral accessory proteins to establish efficient transduction in vivo is tissue dependent.	SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037	Salk Institute					NATIONAL INSTITUTE ON AGING [R37AG008514, R01AG008514] Funding Source: NIH RePORTER; NIA NIH HHS [AG08514] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; Blomer U, 1997, J VIROL, V71, P6641; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P343, DOI 10.1089/aid.1994.10.343; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PETERSON DA, 1994, J NEUROSCI, V14, P6872; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4	21	492	565	2	24	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					314	317		10.1038/ng1197-314	http://dx.doi.org/10.1038/ng1197-314			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354796				2022-12-25	WOS:A1997YD66700026
J	Petters, RM; Alexander, CA; Wells, KD; Collins, EB; Sommer, JR; Blanton, MR; Rojas, G; Hao, Y; Flowers, WL; Banin, E; Cideciyan, AV; Jacobson, SG; Wong, F				Petters, RM; Alexander, CA; Wells, KD; Collins, EB; Sommer, JR; Blanton, MR; Rojas, G; Hao, Y; Flowers, WL; Banin, E; Cideciyan, AV; Jacobson, SG; Wong, F			Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa	NATURE BIOTECHNOLOGY			English	Article						transgenic swine; retinal degeneration; rhodopsin mutation; night blindness; eye disease	RHODOPSIN GENE; RETINAL DEGENERATION; TRANSGENIC MICE; CELL-DEATH; HUMAN ROD; MUTATION; PHOTOTRANSDUCTION; EXPRESSION; PARAMETERS; DEFICIENCY	Patients with retinitis pigmentosa (RP) typically develop night blindness early in life due to loss of rod photoreceptors. The remaining cone photoreceptors are the mainstay of their vision; however, over years or decades, these cones slowly degenerate, leading to blindness. We created transgenic pigs that express a mutated rhodopsin gene (Pro347Leu). Like RP patients with the same mutation, these pigs have early and severe rod loss; initially their cones are relatively spared, but these surviving cones slowly degenerate. By age 20 months, there is only a single layer of morphologically abnormal cones and the cone electroretinogram is markedly reduced. Given the strong similarities in phenotype to that of RP patients, these transgenic pigs will provide a large animal model for study of the protracted phase of cone degeneration found in RP and for preclinical treatment trials.	DUKE UNIV,SCH MED,DEPT OPHTHALMOL,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT NEUROBIOL,DURHAM,NC; DUKE UNIV,SCH MED,DEPT PATHOL,DURHAM,NC; UNIV PENN,SCHEIE EYE INST,DEPT OPHTHALMOL,PHILADELPHIA,PA 19104; N CAROLINA STATE UNIV,DEPT ANIM SCI,RALEIGH,NC 27695	Duke University; Duke University; Duke University; University of Pennsylvania; Pennsylvania Medicine; University of North Carolina; North Carolina State University			Cideciyan, Artur V/A-1075-2007	Cideciyan, Artur V/0000-0002-2018-0905; Jacobson, Samuel/0000-0003-2122-169X	NATIONAL EYE INSTITUTE [R01EY009738, R01EY009047, R55EY009047] Funding Source: NIH RePORTER; NEI NIH HHS [EY09738, EY05627, EY09047] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ACLAND GM, 1989, EXP EYE RES, V49, P983, DOI 10.1016/S0014-4835(89)80021-1; Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696; Apfelstedt-Sylla E, 1992, Ger J Ophthalmol, V1, P319; BERSON EL, 1991, AM J OPHTHALMOL, V111, P614, DOI 10.1016/S0002-9394(14)73708-0; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cideciyan AV, 1996, VISION RES, V36, P2609, DOI 10.1016/0042-6989(95)00327-4; DRYJA TP, 1995, INVEST OPHTH VIS SCI, V36, P1197; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; FEENEYBURNS L, 1981, ARCH OPHTHALMOL-CHIC, V99, P664, DOI 10.1001/archopht.1981.03930010664013; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; FUJIKI K, 1992, JPN J HUM GENET, V37, P125, DOI 10.1007/BF01899733; Gal A, 1997, PROG RETIN EYE RES, V16, P51, DOI 10.1016/S1350-9462(96)00021-3; Gerke C. G. Jr., 1995, Hong Kong Medical Journal, V1, P302; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468; HOOD DC, 1994, INVEST OPHTH VIS SCI, V35, P2948; HUANG PC, 1993, P NATL ACAD SCI USA, V90, P8484, DOI 10.1073/pnas.90.18.8484; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JACOBSON SG, 1991, AM J OPHTHALMOL, V112, P256, DOI 10.1016/S0002-9394(14)76726-1; JACOBSON SG, 1994, INVEST OPHTH VIS SCI, V35, P2521; JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604; JACOBSON SG, 1987, EXP EYE RES, V45, P481, DOI 10.1016/S0014-4835(87)80059-3; KEMP CM, 1989, EXP EYE RES, V49, P49; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; LOLLEY RN, 1994, INVEST OPHTH VIS SCI, V35, P358; MASSOF RW, 1987, RES RETINITIS PIGMEN, V62, P29; NARFSTROM K, 1983, J HERED, V74, P273, DOI 10.1093/oxfordjournals.jhered.a109782; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Prince J.H., 1960, ANATOMY HISTOLOGY EY, P210; PURSEL VG, 1989, SCIENCE, V244, P1281, DOI 10.1126/science.2499927; Reiser MA, 1996, INVEST OPHTH VIS SCI, V37, P221; ROOF DJ, 1994, INVEST OPHTH VIS SCI, V35, P4049; Sambrook J., 1989, MOL CLONING; SempleRowland SL, 1996, FEBS LETT, V385, P47, DOI 10.1016/0014-5793(96)00345-6; SHARMA A, 1994, BIO-TECHNOL, V12, P55, DOI 10.1038/nbt0194-55; SHIONO T, 1992, JPN J OPHTHALMOL, V36, P69; Steinberg R. H., 1996, Investigative Ophthalmology and Visual Science, V37, pS698; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; SUNG CH, 1994, J NEUROSCI, V14, P5818; Travis GH, 1997, NAT GENET, V15, P115, DOI 10.1038/ng0297-115; TSO MOM, 1989, INVEST OPHTH VIS SCI, V30, P2430; WALL RJ, 1985, BIOL REPROD, V32, P645, DOI 10.1095/biolreprod32.3.645; Wong F, 1997, PROG RETIN EYE RES, V16, P353, DOI 10.1016/S1350-9462(96)00032-8	49	225	238	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					965	970		10.1038/nbt1097-965	http://dx.doi.org/10.1038/nbt1097-965			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335046				2022-12-25	WOS:A1997XZ28500025
J	Waldman, T; Zhang, YG; Dillehay, L; Yu, J; Kinzler, K; Vogelstein, B; Williams, J				Waldman, T; Zhang, YG; Dillehay, L; Yu, J; Kinzler, K; Vogelstein, B; Williams, J			Cell-cycle arrest versus cell death in cancer therapy	NATURE MEDICINE			English	Article							DNA-DAMAGE; ANTICANCER AGENTS; G(1) ARREST; P21; P53; FIBROBLASTS; CHECKPOINT; INHIBITOR; PROTEIN; KINASES	In response to anticancer therapeutics, human colon cancer cells growing in vitro either enter into a stable arrest or die, depending on the integrity of their cell-cycle checkpoints(1). To test whether altered checkpoints can modulate sensitivity to treatment in vivo, xenografts were established from isogenic lines differing only in their p21 checkpoint status. Although all tumors with intact checkpoint function underwent regrowth after treatment with gamma-radiation, a significant fraction of checkpoint-deficient tumors were completely cured. This difference in sensitivity was not detected by the clonogenic survival assay, because both arrest and death preclude outgrowth of colonies. These results demonstrate that checkpoint status affects sensitivity to anticancer treatments in vivo, and these findings have important implications for identifying and testing new therapeutic compounds.	PROGRAM HUMAN GENET,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,RADIOBIOL LAB,BALTIMORE,MD 21287	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Waldman, T (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231, USA.		Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KASTAN MB, 1991, CANCER RES, V51, P6304; LI CY, 1995, INT J ONCOL, V6, P233; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; REVESZ L, 1958, J NATL CANCER I, V20, P1157, DOI 10.1093/jnci/20.6.1157; REVESZ L, 1956, NATURE, V178, P1391, DOI 10.1038/1781391a0; TISHLER RB, 1995, CANCER RES, V55, P6021; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	17	345	354	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1034	1036		10.1038/nm0997-1034	http://dx.doi.org/10.1038/nm0997-1034			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288734				2022-12-25	WOS:A1997XT84200040
J	Watson, GE; Davis, BA; Raubertas, RF; Pearson, SK; Bowen, WH				Watson, GE; Davis, BA; Raubertas, RF; Pearson, SK; Bowen, WH			Influence of maternal lead ingestion on caries in rat pups	NATURE MEDICINE			English	Article							SALIVARY COMPOSITION; ENAMEL; EXPOSURE; HEALTH	Lead is one of the most toxic and pervasive pollutants in society, and although there has been some lowering of blood lead levels in recent years, the levels continue to be of concern for African Americans, central city residents, residents in the Northeast region of the United States, persons with low income, and those with low educational attainment(1). Notably, these are the persons and the region where the highest prevalence of dental caries is observed. Information relating lead toxicity to oral health is sparse, but the preponderance of epidemiological data shows a relation between lead in the environment and the prevalence of dental caries(2,3). Using our well-defined rat caries model(4), we found that pre- and perinatal exposure to lead results in an almost 40% increase in the prevalence of caries and a decrease in stimulated parotid function of nearly 30%. Levels of lead in milk from lead-treated darns were approximately 10 times as high as the corresponding blood lead levels, suggesting that lead is being concentrated by mammary glands. These findings may help in part to explain the comparatively high levels of dental caries observed in the inner cities of the United States where exposure to lead is common. Environmental sources of lead include drinking water, lead-based paint and, to a lesser extent, automobile and industrial emissions. In humans lead is accumulated and stored in bones (half-life of approximately 62 years(5)), and even maternal exposure to lead decades before pregnancy can subsequently result in exposure of the developing fetus to elevated levels of lead. Moreover, lead concentration in maternal blood has been shown to increase during pregnancy and lactation because of mobilization of stored lead from bone(6), and typically, lead is found in milk at a higher concentration than the level found in maternal plasma at the same time point(7).	UNIV ROCHESTER, SCH MED & DENT,DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT CLIN DENT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT BIOSTAT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT ENVIRONM HLTH, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester				Watson, Gene/0000-0002-3397-1116	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE011549] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11549, DE07165] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APPLETON J, 1991, ARCH ORAL BIOL, V36, P377, DOI 10.1016/0003-9969(91)90008-I; BATSCHELET E, 1979, J MATH BIOL, V8, P15, DOI 10.1007/BF00280582; BEACH JR, 1988, PEDIATR RES, V23, P58, DOI 10.1203/00006450-198801000-00013; BOWEN WH, 1980, J AM DENT ASSOC, V100, P677, DOI 10.14219/jada.archive.1980.0211; BOWEN WH, 1988, J DENT RES, V67, P21, DOI 10.1177/00220345880670010301; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BRUDEVOLD F, 1977, J DENT RES, V56, P1165, DOI 10.1177/00220345770560100701; CLEYMAET R, 1991, SCI TOTAL ENVIRON, V104, P175, DOI 10.1016/0048-9697(91)90071-L; CURZON MEJ, 1978, ARCH ORAL BIOL, V23, P647, DOI 10.1016/0003-9969(78)90189-9; de Champlain J, 1970, ACTA PHYSIOL SCAND, V80, P276, DOI 10.1111/j.1748-1716.1970.tb04791.x; Diggle PJ, 2002, ANAL LONGITUDINAL DA; Gil F, 1996, SCI TOTAL ENVIRON, V192, P183, DOI 10.1016/S0048-9697(96)05313-2; KEYES PAUL H., 1958, JOUR DENTAL RES, V37, P1077, DOI 10.1177/00220345580370060801; KEYES PAUL H., 1959, JOUR DENTAL RES, V38, P525, DOI 10.1177/00220345590380031401; Lawson B F, 1971, S C Dent J, V29, P5; NAVIA JM, 1977, ANIMAL MODELS DENT R, P169; PAN AYS, 1981, J TOXICOL ENV HEALTH, V7, P273, DOI 10.1080/15287398109529978; RYU JE, 1978, J PEDIATR-US, V93, P476, DOI 10.1016/S0022-3476(78)81169-X; SCHNEYER CA, 1970, AM J PHYSIOL, V219, P1268, DOI 10.1152/ajplegacy.1970.219.5.1268; Stack MV, 1983, TRACE ELEMENTS DENTA, P357; THOMPSON GN, 1985, MED J AUSTRALIA, V143, P131, DOI 10.5694/j.1326-5377.1985.tb122859.x; WATSON GE, 1989, J DENT RES, V68, P1739, DOI 10.1177/00220345890680120401; WATSON GE, 1990, ARCH ORAL BIOL, V35, P435, DOI 10.1016/0003-9969(90)90206-P; WOLFF MS, 1983, AM J IND MED, V4, P259, DOI 10.1002/ajim.4700040120; Young JA, 1978, MORPHOLOGY SALIVARY	25	46	47	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1997	3	9					1024	1025		10.1038/nm0997-1024	http://dx.doi.org/10.1038/nm0997-1024			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288731				2022-12-25	WOS:A1997XT84200037
J	Reznik, GO; Vajda, S; Smith, CL; Cantor, CR; Sano, T				Reznik, GO; Vajda, S; Smith, CL; Cantor, CR; Sano, T			Streptavidins with intersubunit crosslinks have enhanced stability	NATURE BIOTECHNOLOGY			English	Article						streptavidin; protein stability; chemical crosslinking; protein engineering	DIRECTED MUTAGENESIS; CORE STREPTAVIDIN; EXPRESSION	Natural tetrameric streptavidin has two subunit interfaces; one is a strong interface between subunits in a tightly associated dimer, and the other is a weak interface between a pair of such dimers (dimer-dimer interface). To test whether strengthening the weak dimer-dimer interface could provide streptavidin with additional structural stability, covalent crosslinks were introduced between adjacent subunits through the dimer-dimer interface, Specific crosslinking sites were designed by site-directed mutations of His-127 residues that are in close proximity in natural streptavidin. The first and second streptavidin constructs have a disulfide bond and an irreversible covalent bond, respectively, between two Cys-127 residues across the dimer-dimer interface. The third variant is a hybrid tetramer consisting of two different streptavidin species, one having lysine and the other aspartic acid at position 127, which are covalently crosslinked. All streptavidin constructs with intersubunit crosslinks showed higher biotin-binding ability than natural core streptavidin after heat treatment. All of these crosslinked streptavidins retained bound biotin more stably than natural core streptavidin in guanidine hydrochloride at very acidic pH. These results suggest that the introduction of covalent bonds across the dimer-dimer interface enhances the overall stability of streptavidin.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; BOSTON UNIV,DEPT BIOMED ENGN,BOSTON,MA 02215; BOSTON UNIV,DEPT PHARMACOL & EXPTL THERAPEUT,BOSTON,MA 02215	Boston University; Boston University; Boston University	Reznik, GO (corresponding author), BOSTON UNIV,CTR ADV BIOTECHNOL,BOSTON,MA 02215, USA.			Vajda, Sandor/0000-0003-1540-8220; Smith, Cassandra/0000-0002-0346-8907				CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; CHILKOTI A, 1995, BIOTECHNOLOGY, V11, P1198; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HOFMANN K, 1980, P NATL ACAD SCI-BIOL, V77, P4666, DOI 10.1073/pnas.77.8.4666; HUSAIN SS, 1968, BIOCHEM J, V110, P53, DOI 10.1042/bj1100053; HUSAIN SS, 1968, J CHEM SOC CHEM COMM, P310; LAEMMLI UK, 1970, NATURE, V227, P6580; Sambrook J., 2002, MOL CLONING LAB MANU; SANO T, 1995, J BIOL CHEM, V270, P28204; SANO T, 1990, P NATL ACAD SCI USA, V87, P142, DOI 10.1073/pnas.87.1.142; SANO T, 1993, BIO-TECHNOL, V11, P201, DOI 10.1038/nbt0293-201; SANO T, 1995, P NATL ACAD SCI USA, V92, P31580; Sano T., 1994, ADV BIOMAGNETIC SEPA, P21; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WEI R. D., 1970, Methods in Enzymology, V18A, P424, DOI 10.1016/0076-6879(71)18343-7	20	50	60	2	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					1007	1011		10.1038/nbt0896-1007	http://dx.doi.org/10.1038/nbt0896-1007			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631041				2022-12-25	WOS:A1996UZ19900035
J	Wagner, RW; Matteucci, MD; Grant, D; Huang, T; Froehler, BC				Wagner, RW; Matteucci, MD; Grant, D; Huang, T; Froehler, BC			Potent and selective inhibition of gene expression by an antisense heptanucleotide	NATURE BIOTECHNOLOGY			English	Article						RNA structure; C-5 propyne; phosphorothioate; oligonucleotide; RNase	IMMUNODEFICIENCY-VIRUS TYPE-1; RNA; OLIGONUCLEOTIDES; KINETICS; INVIVO	Factors that govern the specificity of an antisense oligonucleotide (ON) for its target RNA include accessibility of the targeted RNA to ON binding, stability of ON/RNA complexes in cells, and susceptibility of the ON/RNA complex to RNase H cleavage. ON specificity is generally proposed to be dependent on its length. To date, virtually all previous antisense experiments have used 12-25 nt-long ONs. We explored the antisense activity and specificity of short (7 and 8 nt) ONs modified with C-5 propyne pyrimidines and phosphorothioate internucleotide linkages. Gene-selective, mismatch sensitive, and RNase H-dependent inhibition was observed for a heptanucleotide ON. We demonstrated that the flanking sequences of the target RNA are a major determinant of specificity. The use of shorter ONs as anti-sense agents has the distinct advantage of simplified synthesis. These results may lead to a general, cost-effective solution to the development of antisense ONs as therapeutic agents.			Wagner, RW (corresponding author), GILEAD SCI,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							DEROUX I, 1995, NUCLEIC ACIDS RES, V23, P3411; FENSTER SD, 1994, BIOCHEMISTRY-US, V33, P8391, DOI 10.1021/bi00194a002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HOMANN M, 1993, J MOL BIOL, V233, P7, DOI 10.1006/jmbi.1993.1480; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; LIN KY, 1994, BIOORG MED CHEM LETT, V4, P1061, DOI 10.1016/S0960-894X(01)80681-8; MISHRA RK, 1994, SCI VIE, V317, P977; MORGAN R, 1993, NUCLEIC ACIDS RES, V21, P4615, DOI 10.1093/nar/21.19.4615; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; RITTNER K, 1993, NUCLEIC ACIDS RES, V21, P1381, DOI 10.1093/nar/21.6.1381; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305	19	104	147	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					840	844		10.1038/nbt0796-840	http://dx.doi.org/10.1038/nbt0796-840			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631007				2022-12-25	WOS:A1996UV62000032
J	Schopke, C; Taylor, N; Carcamo, R; Konan, NK; Marmey, P; Henshaw, GG; Beachy, RN; Fauquet, C				Schopke, C; Taylor, N; Carcamo, R; Konan, NK; Marmey, P; Henshaw, GG; Beachy, RN; Fauquet, C			Regeneration of transgenic cassava plants (Manihot esculenta Crantz) from microbombarded embryogenic suspension cultures	NATURE BIOTECHNOLOGY			English	Article						Manihot esculenta; embryogenic suspensions; microbombardment; transformation	PROMOTER	A protocol was established for the introduction of DNA into embryogenic suspension-derived tissues of cassava via microparticle bombardment, for the selection of genetically transformed cells, and for the regeneration of fully transgenic plants from these cells. The plasmid DNA used for bombardment contained a gene encoding neomycin phosphotransferase (nptII) and a gene encoding beta-glucuronidase (uidA). Selection of bombarded tissue with paromomycin resulted in the establishment of putative transgenic embryogenic calli. In most of these calli, beta-glucuronidase was detected histochemically. Molecular analysis of paromomycin-resistant embryogenic calli and of plants regenerated from these calli, confirmed the stable integration of bombarded DNA into the cassava genome.	SCRIPPS RES INST, DIV PLANT BIOL MRC7,INT LAB TROP AGR BIOTECHNOL, ORSTOM,TSRI, LA JOLLA, CA 92037 USA; UNIV BATH, SCH BIOL SCI, BATH BA2 7AY, AVON, ENGLAND	Scripps Research Institute; University of Bath			Taylor, Nigel/M-2851-2013	MARMEY, Philippe/0000-0003-3973-9868				[Anonymous], 2019, CASSAVA NEW POTENTIA; CALDERON A, 1988, THESIS VRIJE U BRUSS, P37; CHEN ZL, 1988, EMBO J, V7, P297, DOI 10.1002/j.1460-2075.1988.tb02812.x; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; ESCANDON AS, 1991, PHYSIOL PLANTARUM, V81, P367; Fauquet C., 1992, P287; HORSCH RB, 1986, P NATL ACAD SCI USA, V83, P4428, DOI 10.1073/pnas.83.12.4428; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KOCH BM, 1994, ACTA HORTIC, V375, P45; LUONG HT, 1995, PLANT SCI, V107, P105, DOI 10.1016/0168-9452(95)04101-Y; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ROCA WM, 1993, P 1 INT SCI M CASS B, P496; SALEHUZZAMAN SNIM, 1993, PLANT MOL BIOL, V23, P947, DOI 10.1007/BF00021811; SCHENK RU, 1972, CAN J BOTANY, V50, P199, DOI 10.1139/b72-026; SCHOPKE C, 1993, IN VITRO CELL DEV-AN, V29, pA64; SCHOPKE C, 1993, BIOTECHNOLOGY AGR FO, V23, P273; Sivamani E, 1996, PLANT CELL REP, V15, P322, DOI 10.1007/BF00232364; STAMP JA, 1982, Z PFLANZENPHYSIOL, V105, P183, DOI 10.1016/S0044-328X(82)80011-1; TAYLOR NJ, 1996, NATURE BIOTECHNOLOGY, V14, pR30; TORBERT KA, 1995, PLANT CELL REP, V14, P635, DOI 10.1007/BF00232728; WIDHOLM JM, 1972, STAIN TECHNOL, V47, P189, DOI 10.3109/10520297209116483; 1994, FOOD OUTLOOK, V10, P20	25	81	88	0	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					731	735		10.1038/nbt0696-731	http://dx.doi.org/10.1038/nbt0696-731			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630980				2022-12-25	WOS:A1996UM76600028
J	Mahajan, NP; Linder, K; Berry, G; Gordon, GW; Heim, R; Herman, B				Mahajan, NP; Linder, K; Berry, G; Gordon, GW; Heim, R; Herman, B			Bcl-2 and Bax interactions in mitochondria probed with green fluorescent protein and fluorescence resonance energy transfer	NATURE BIOTECHNOLOGY			English	Article						microscopy; protein interactions; apoptosis	DEATH	It has been hypothesized that interaction of Bcl-2 and Bax may regulate apoptosis. The spatial and temporal interaction of Bcl-2 and Bax at the single cell level has not, however, been demonstrated. To achieve this goal, we have developed two-fusion FRET (fluorescence resonance energy transfer). Using green fluorescent protein (GFP)-Bax and blue fluorescent protein (BFP)-Bcl-2 fusion proteins coexpressed in the same cell, we demonstrate a direct interaction between Bcl-2 and Bax in individual mitochondria. Mitochondrially localized cytochrome c-GFP and BFP-Bcl-2 showed little or no FRET, while nuclear-localized GFP-human papillomavirus E6 and BFP-Bcl-2 did not interact when coexpressed in the same cell. These findings indicate that two-fusion FRET provides an opportunity to examine the interaction between two different proteins coexpressed in single intact mammalian cells.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Aurora Biosci, La Jolla, CA 92093 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Herman, B (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA.	hermanb@UTHSCSA.EDU						Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GORDON GW, 1998, IN PRESS BIOPHYSICAL; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC., 1996, MECH LYMPHOCYTE ACTI, V406, P99, DOI [10.1007/978-1-4899-0274-0_10, DOI 10.1007/978-1-4899-0274-0_10]; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; TERRY BR, 1995, BIOCHEM BIOPH RES CO, V217, P21, DOI 10.1006/bbrc.1995.2740; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	26	240	289	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					547	552		10.1038/nbt0698-547	http://dx.doi.org/10.1038/nbt0698-547			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624685				2022-12-25	WOS:000073930600030
J	Pedrazzini, T; Seydoux, J; Kunstner, P; Aubert, JF; Grouzmann, E; Beermann, F; Brunner, HR				Pedrazzini, T; Seydoux, J; Kunstner, P; Aubert, JF; Grouzmann, E; Beermann, F; Brunner, HR			Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor	NATURE MEDICINE			English	Article							NEUROPEPTIDE-Y; METABOLIC-RATE; FOOD-INTAKE; GENE; TISSUE; BRAIN	Neuropeptide Y (NPY) is a 36-amino-acid neurotransmitter which is widely distributed throughout the central and peripheral nervous system(1). NPY involvement has been suggested in various physiological responses including cardiovascular homeostasis(2) and the hypothalamic control of food intake(3). At least six subtypes of NPY receptors have been described(4,5). Because of the lack of selective antagonists, the specific role of each receptor subtype has been difficult to establish. Here we describe mice deficient for the expression of the Y1 receptor subtype. Homozygous mutant mice demonstrate a complete absence of blood pressure response to NPY, whereas they retain normal response to other vasoconstrictors. Daily food intake, as well as NPY-stimulated feeding, are only slightly diminished, whereas fast-induced refeeding is markedly reduced. Adult mice lacking the NPY Y1 receptor are characterized by increased body fat with no change in protein content. The higher energetic efficiency of mutant mice might result, in part, from the lower metabolic rate measured during the active period, associated with reduced locomotor activity. These results demonstrate the importance of NPY Y1 receptors in NPY-mediated cardiovascular response and in the regulation of body weight through central control of energy expenditure. In addition, these data are also indicative of a role for the Y1 receptor in the control of food intake.	Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland; Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva 4, Switzerland; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	University of Lausanne; University of Geneva; Swiss Institute Experimental Cancer Research	Pedrazzini, T (corresponding author), Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland.	Thierry.Pedrazzini@chuv.hospvd.ch						AMINIAN K, 1993, MED BIOL ENG COMPUT, V31, P399, DOI 10.1007/BF02446695; Balasubramaniam A, 1997, PEPTIDES, V18, P445, DOI 10.1016/S0196-9781(96)00347-6; BARDE YA, 1975, J PHYSIOL-LONDON, V252, P523, DOI 10.1113/jphysiol.1975.sp011156; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; EDVINSSON L, 1984, BRIT J PHARMACOL, V83, P519, DOI 10.1111/j.1476-5381.1984.tb16516.x; ENTENMAN C, 1957, METHOD ENZYMOL, V3, P299, DOI 10.1016/S0076-6879(57)03395-9; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; GIRARDIER L, 1995, J PHYSIOL-LONDON, V488, P779, DOI 10.1113/jphysiol.1995.sp021009; GROUZMANN E, 1992, PEPTIDES, V13, P1049, DOI 10.1016/0196-9781(92)90004-M; GRUNDEMAR L, 1993, GEN PHARMACOL-VASC S, V24, P785, DOI 10.1016/0306-3623(93)90151-M; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; MARTEL JC, 1990, MOL PHARMACOL, V38, P494; MORLEY JE, 1987, AM J PHYSIOL, V253, pR516, DOI 10.1152/ajpregu.1987.253.3.R516; MULVANY MJ, 1976, NATURE, V260, P617, DOI 10.1038/260617a0; Nilsson Torun, 1996, Blood Pressure, V5, P164, DOI 10.3109/08037059609062125; OShea D, 1997, ENDOCRINOLOGY, V138, P196, DOI 10.1210/en.138.1.196; RUDOLF K, 1994, EUR J PHARMACOL, V271, pR11, DOI 10.1016/0014-2999(94)90822-2; Schaffhauser AO, 1997, DIABETES, V46, P1792, DOI 10.2337/diabetes.46.11.1792; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WAHLESTEDT C, 1990, AM J PHYSIOL, V258, pR736, DOI 10.1152/ajpregu.1990.258.3.R736; WEIR JBD, 1990, NUTRITION, V6, P213; Wiesel P, 1997, HYPERTENSION, V29, P1025, DOI 10.1161/01.HYP.29.4.1025	27	317	331	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					722	726		10.1038/nm0698-722	http://dx.doi.org/10.1038/nm0698-722			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623984				2022-12-25	WOS:000074008300041
J	Zawada, WM; Cibelli, JB; Choi, PK; Clarkson, ED; Golueke, PJ; Witta, SE; Bell, KP; Kane, J; de Leon, FAP; Jerry, DJ; Robl, JM; Freed, CR; Stice, SL				Zawada, WM; Cibelli, JB; Choi, PK; Clarkson, ED; Golueke, PJ; Witta, SE; Bell, KP; Kane, J; de Leon, FAP; Jerry, DJ; Robl, JM; Freed, CR; Stice, SL			Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats	NATURE MEDICINE			English	Article							FETAL VENTRAL MESENCEPHALON; FIBROBLAST GROWTH-FACTOR; DOPAMINERGIC-NEURONS; NEUROTROPHIC FACTOR; GRAFT-SURVIVAL; DISEASE; MODEL; IMPROVEMENT	Parkinson's disease symptoms can be improved by transplanting fetal dopamine cells into the putamen of parkinsonian patients. Because the supply of human donor tissue is limited and variable, an alternative and genetically modifiable non-human source of tissue would be valuable. We have generated cloned transgenic bovine embryos, 42% of which developed beyond 40 days. Dopamine cells collected from the ventral mesencephalon of the cloned fetuses 42 to 50 days post-conception survived transplantation into immunosuppressed parkinsonian rats and cells from cloned and wild-type embryos improved motor performance. Somatic cell cloning can efficiently produce transgenic animal tissue for treating parkinsonism.	Univ Colorado, Sch Med, Dept Med, Div Clin Pharmacol C237, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Div Clin Pharmacol C237, Denver, CO 80262 USA; Univ Colorado, Sch Med, Neurosci Training Program, Denver, CO 80262 USA; Adv Cell Technol Inc, Worcester, MA 01605 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Massachusetts System; University of Massachusetts Amherst	Freed, CR (corresponding author), Univ Colorado, Sch Med, Dept Med, Div Clin Pharmacol C237, 4200 E 9th Ave, Denver, CO 80262 USA.	Curt.Freed@UCHSC.edu		Cibelli, Jose/0000-0002-2176-3854; Ponce de Leon, Federico/0000-0001-8645-553X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018639] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD7408] Funding Source: Medline; NIGMS NIH HHS [GM 07063] Funding Source: Medline; NINDS NIH HHS [NS 18639] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Aki T, 1997, J BIOCHEM, V122, P271; BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; BRUNDIN P, 1986, EXP BRAIN RES, V65, P235; CHERNOVSKY AW, 1997, CELL, V889, P17; Clarkson ED, 1997, CELL TISSUE RES, V289, P207, DOI 10.1007/s004410050867; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; Doll RF, 1996, GENE THER, V3, P437; Dunnett S. B., 1992, NEURAL TRANSPLANTATI, P1; FAWCETT JW, 1995, EXP BRAIN RES, V106, P275; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREED CR, 1990, ARCH NEUROL-CHICAGO, V47, P505, DOI 10.1001/archneur.1990.00530050021007; FREEMAN TB, 1988, PROG BRAIN RES, V78, P473; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; Galpern WR, 1996, EXP NEUROL, V140, P1, DOI 10.1006/exnr.1996.0109; HUFFAKER TK, 1989, EXP BRAIN RES, V77, P329, DOI 10.1007/BF00274990; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Kopyov OV, 1996, CELL TRANSPLANT, V5, P327, DOI 10.1016/0963-6897(95)02035-7; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; PARK TH, 1992, BRAIN RES, V599, P83, DOI 10.1016/0006-8993(92)90855-4; Peel AL, 1997, GENE THER, V4, P16, DOI 10.1038/sj.gt.3300358; PESCHANSKI M, 1994, BRAIN, V117, P487, DOI 10.1093/brain/117.3.487; PRATHER RS, 1989, BIOL REPROD, V41, P414, DOI 10.1095/biolreprod41.3.414; PURSEL VG, 1993, J ANIM SCI, V71, P10, DOI 10.2527/1993.71suppl_310x; RICHARDS JB, 1990, PHARMACOL BIOCHEM BE, V36, P217, DOI 10.1016/0091-3057(90)90394-W; Saadi S, 1997, LIFE SCI, V62, P365, DOI 10.1016/S0024-3205(97)00964-8; SANDBERG PR, 1996, NAT BIOTECHNOL, V14, P1692; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Shedlock AM, 1997, BIOTECHNIQUES, V22, P394, DOI 10.2144/97223bm03; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; TAKAYAMA H, 1995, NAT MED, V1, P53, DOI 10.1038/nm0195-53; Wagener S, 1996, J BIOTECHNOL, V44, P59, DOI 10.1016/0168-1656(95)00093-3; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zawada WM, 1996, EXP NEUROL, V140, P60, DOI 10.1006/exnr.1996.0115	38	57	71	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					569	574		10.1038/nm0598-569	http://dx.doi.org/10.1038/nm0598-569			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585230				2022-12-25	WOS:000073399900028
J	Tavitian, B; Terrazzino, S; Kuhnast, B; Marzabal, S; Stettler, O; Dolle, F; Deverre, JB; Jobert, A; Hinnen, F; Bendriem, B; Crouzel, C; Di Giamberardino, L				Tavitian, B; Terrazzino, S; Kuhnast, B; Marzabal, S; Stettler, O; Dolle, F; Deverre, JB; Jobert, A; Hinnen, F; Bendriem, B; Crouzel, C; Di Giamberardino, L			In vivo imaging of oligonucleotides with positron emission tomography	NATURE MEDICINE			English	Article							ANTISENSE OLIGONUCLEOTIDES; IN-VIVO; PHARMACOKINETICS; PROBES; VIRUS; DNA		CEA, SHFJ, INSERM, U334, F-91401 Orsay, France; CEA, Serv Hosp Frederic Joliot, Dept Rech Med, Direct Sci Vivant, Orsay, France; CEA, Serv Pharmacol & Immunol, Gif Sur Yvette, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Tavitian, B (corresponding author), CEA, SHFJ, INSERM, U334, 4 Pl Gen Leclerc, F-91401 Orsay, France.	tavitian@shfj.cea.fr	Tavitian, Bertrand M/P-6578-2018; Dollé, Frédéric/R-5756-2017	Tavitian, Bertrand M/0000-0002-5349-8194; Kuhnast, Bertrand/0000-0002-5035-4072				AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002; Bendriem B., 1996, Journal of Nuclear Medicine, V37, p170P; Bijsterbosch MK, 1997, NUCLEIC ACIDS RES, V25, P3290, DOI 10.1093/nar/25.16.3290; Cammilleri S, 1996, EUR J NUCL MED, V23, P448, DOI 10.1007/BF01247375; Cammilleri S., 1995, Medecine Nucleaire, V19, P20; CROOKE ST, 1993, ANTISENSE RES APPL, P579; Deverre JR, 1997, NUCLEIC ACIDS RES, V25, P3584, DOI 10.1093/nar/25.18.3584; DEWANJEE MK, 1994, J NUCL MED, V35, P1054; Dolle F, 1997, J LABELLED COMPD RAD, V39, P319, DOI 10.1002/(SICI)1099-1344(199704)39:4<319::AID-JLCR970>3.0.CO;2-7; Dolle F., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P4; GECK P, 1983, ANAL BIOCHEM, V135, P264, DOI 10.1016/0003-2697(83)90681-4; Hildebrandt M, 1996, NUKLEARMED, V35, P126; Jones T, 1996, EUR J NUCL MED, V23, P807, DOI 10.1007/BF00843711; Jones T, 1996, EUR J NUCL MED, V23, P207, DOI 10.1007/BF01731847; Matteucci MD, 1996, NATURE, V384, P20; MOREAUGACHELIN F, 1986, J VIROL, V57, P349, DOI 10.1128/JVI.57.1.349-352.1986; Sambrook J., 2002, MOL CLONING LAB MANU; SRINIVASAN SK, 1995, J CLIN LAB ANAL, V9, P129, DOI 10.1002/jcla.1860090210; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; Stein D, 1997, ANTISENSE NUCLEIC A, V7, P151, DOI 10.1089/oli.1.1997.7.151; URBAIN JLC, 1995, EUR J NUCL MED, V22, P499, DOI 10.1007/BF00817271; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	22	173	193	2	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					467	471		10.1038/nm0498-467	http://dx.doi.org/10.1038/nm0498-467			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546795				2022-12-25	WOS:000072906800044
J	Warner, LE; Mancias, P; Butler, IJ; McDonald, CM; Keppen, L; Koob, KG; Lupski, JR				Warner, LE; Mancias, P; Butler, IJ; McDonald, CM; Keppen, L; Koob, KG; Lupski, JR			Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies	NATURE GENETICS			English	Article							TOOTH DISEASE TYPE-1A; ZINC-FINGER PROTEIN; NGFI-A; TRANSCRIPTION FACTORS; BINDING DOMAINS; KROX-20; NEUROPATHY; HINDBRAIN; KROX20	The early growth response 2 gene (EGR2) is part of a multigene family encoding Cys(2)-His(2) type zinc-finger proteins and may play a role in the regulation of cellular proliferation(1,2). Egr2, (also known as Krox20) is the mouse orthologue of human EGR2 and was first identified as an immediate-early response gene, encoding a protein that binds DNA in a sequence-specific manner and acts as a transcription factor(3-6). Stable expression of Egr2 is specifically associated with the onset of myelination in the peripheral nervous system (PNS; ref.7). Egr2(-/-) mice display disrupted hindbrain segmentation and development(8,9). and a block of Schwann-cell differentiation at an early stage(10). We hypothesized that Egr2 may be a transcription factor affecting late myelin genes and that human myelinopathies of the PNS may result from mutations in EGR2. In support of this hypothesis, we have identified one recessive and two dominant missense mutations in EGR2 (within regions encoding conserved functional domains) in patients with congenital hypomyelinating neuropathy (CHN) and a family with Charcot-Marie-Tooth type 1 (CMT1).	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Neurol, Sch Med, Houston, TX 77030 USA; Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, Sacramento, CA 95817 USA; Univ Calif Davis, Med Ctr, Dept Pediat, Sacramento, CA 95817 USA; Univ S Dakota, Sch Med, Dept Pediat & Adolescent Med, Sioux Falls, SD 57117 USA; Neurol Associates PC, Sioux Falls, SD 57105 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Texas Childrens Hosp, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Davis; University of California System; University of California Davis; University of South Dakota; Baylor College of Medicine; Baylor College of Medicine	Lupski, JR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.			McDonald, Craig/0000-0002-8779-3220	NICHD NIH HHS [HD94021] Funding Source: Medline; NIGMS NIH HHS [T32-GM08307] Funding Source: Medline; NINDS NIH HHS [R01 NS27042] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027042] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BROWN RS, 1986, NATURE, V324, P215, DOI 10.1038/324215a0; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; DEJONGHE P, 1997, J PERIPHER NERV SYST, V2, P370; Dyck P.J, 1993, PNP, P1094; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; HARATI Y, 1985, J NEUROL NEUROSUR PS, V48, P1269, DOI 10.1136/jnnp.48.12.1269; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUPSKI JR, 1993, JAMA-J AM MED ASSOC, V270, P2326, DOI 10.1001/jama.270.19.2326; Lupski JR, 1997, HOSP PRACT, V32, P83, DOI 10.1080/21548331.1997.11443485; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; Warner LE, 1996, NEURON, V17, P451, DOI 10.1016/S0896-6273(00)80177-4; WILSON TE, 1992, J BIOL CHEM, V267, P3718; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	30	372	384	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					382	384		10.1038/ng0498-382	http://dx.doi.org/10.1038/ng0498-382			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537424				2022-12-25	WOS:000072755500024
J	Rieger, R; Edenhofer, F; Lasmezas, CI; Weiss, S				Rieger, R; Edenhofer, F; Lasmezas, CI; Weiss, S			The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells	NATURE MEDICINE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; BINDING-PROTEIN; MAMMALIAN-CELLS; MOLECULAR-BIOLOGY; SCRAPIE; RESISTANT; GENE; INFECTIVITY; DISEASES; HAMSTERS	Prions are thought to consist of infectious proteins that cause transmissible spongiform encephalopathies'. According to overwhelming evidence, the pathogenic prion protein PrPSc converts its host encoded isoform PrPc into insoluble aggregates of PrPSc, concomitant with pathological modifications (for review, see refs. 1-3). Although the physiological role of PrPc is poorly understood(4), studies with PrP knockout mice demonstrated that PrPc is required for the development of prion diseases'. Using the yeast two-hybrid technology in Saccharomyces cerevisiae, we identified the 37-kDa laminin receptor precursor (LRP) as interacting with the cellular prion protein PrPc. Mapping analysis of the LRP-PrP interaction site in S. cerevisiae revealed that PrP and laminin share the same binding domain (amino acids 161 to 180)(6) on LRP. The LRP-PrP interaction was confirmed in vivo in insect (Sf9) and mammalian cells (COS-7). The LRP level was increased in scrapie-infected murine N(2)a cells and in brain and spleen of scrapie-infected mice. In contrast, the LRP concentration was not significantly altered in these organs from mice infected with the bovine spongiform encephalopathic agent (BSE), which have a lower PrPSc accumulation. LRP levels, however, were dramatically increased in brain and pancreas, slightly increased in the spleen and not altered in the liver of scrapie-infected hamsters. These data show that enhanced LRP concentrations are correlated with PrPSc accumulation in organs from mice and hamsters. The laminin receptor precursor, which is highly conserved among mammals and is located on the cell surface, may act as a receptor or coreceptor for the prion protein on mammalian cells.	Univ Munich, Inst Biochem, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany; CRSSA, CEA, Serv Neurovirol, DSV,DRM, F-92265 Fontenay Aux Roses, France	University of Munich; CEA; UDICE-French Research Universities; Universite Paris Saclay	Weiss, S (corresponding author), Univ Munich, Inst Biochem, Genzentrum, Mol Biol Lab, Feodor Lynen Str 25, D-81377 Munich, Germany.	Weiss@lmb.uni-muenchen.de	Edenhofer, Frank/ABG-9458-2020	Edenhofer, Frank/0000-0002-6489-714X				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Borchelt DR, 1996, CHEM BIOL, V3, P619, DOI 10.1016/S1074-5521(96)90128-3; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; Demianova M, 1996, J BIOL CHEM, V271, P11383, DOI 10.1074/jbc.271.19.11383; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; Edenhofer F., 1997, Angewande Chemie - International Edition in English, V36, P1674, DOI 10.1002/anie.199716741; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; Farquhar CF, 1996, J GEN VIROL, V77, P1941, DOI 10.1099/0022-1317-77-8-1941; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; Jackers P, 1996, ONCOGENE, V13, P495; Jackers P, 1996, BBA-GENE STRUCT EXPR, V1305, P98, DOI 10.1016/0167-4781(95)00206-5; JENDROSKA K, 1991, NEUROLOGY, V41, P1482, DOI 10.1212/WNL.41.9.1482; KEPPEL E, 1991, J CELL SCI, V100, P789; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; LANDOWSKI TH, 1995, BIOCHEMISTRY-US, V34, P11276, DOI 10.1021/bi00035a037; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; Ludwig GV, 1996, J VIROL, V70, P5592, DOI 10.1128/JVI.70.8.5592-5599.1996; MALINOFF HL, 1983, BIOCHEM BIOPH RES CO, V111, P804; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; OUZOUNIS C, 1995, NUCLEIC ACIDS RES, V23, P565, DOI 10.1093/nar/23.4.565; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; RUBENSTEIN R, 1991, J INFECT DIS, V164, P29, DOI 10.1093/infdis/164.1.29; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; WEISS S, 1995, J VIROL, V69, P4776, DOI 10.1128/JVI.69.8.4776-4783.1995; Weiss S, 1996, BIOCHEM BIOPH RES CO, V219, P173, DOI 10.1006/bbrc.1996.0201; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; YE X, 1994, J COMP PATHOL, V110, P153, DOI 10.1016/S0021-9975(08)80187-9; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	39	356	374	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1383	1388		10.1038/nm1297-1383	http://dx.doi.org/10.1038/nm1297-1383			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396609				2022-12-25	WOS:000072249500035
J	Santer, R; Schneppenheim, R; Dombrowski, A; Gotze, H; Steinmann, B; Schaub, J				Santer, R; Schneppenheim, R; Dombrowski, A; Gotze, H; Steinmann, B; Schaub, J			Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome	NATURE GENETICS			English	Article							AMINO-ACID; JAPANESE SUBJECTS; SEQUENCE; TRYPTOPHAN-412; POLYMORPHISMS; SUBSTITUTION; POLYMERASE; DNA	Fanconi-Bickel syndrome (FBS) is a rare autosomal-recessive inborn error of metabolism characterized by hepatorenal glycogen accumulation, Fanconi nephropathy and impaired utilization of glucose and galactose(1), To date, no underlying enzymatic defect in carbohydrate metabolism has been identified. Therefore, and because of (he impairment of both glucose and galactose metabolism, a primary defect of monosaccharide transport across membranes has been suggested(1-4). Here we report mutations in the gene encoding the facilitative glucose transporter 2 (GLUT2) in three FBS families, including the original patient described in 1949 by Fanconi and Bickel(5) Homozygous mutations were found in affected individuals, whereas all parents tested were heterozygous for the respective mutation. Because all detected mutations (Delta T446-449, C1251T and C1405T) predict truncated translation products that cannot be expected to have functional monosaccharide transport activity, GLUT2 mutations are probably the cause of FBS.	MUNICIPAL CHILDRENS HOSP,ESSLINGEN,GERMANY; UNIV ZURICH,DEPT PAEDIAT,DIV METAB & MOL DIS,CH-8006 ZURICH,SWITZERLAND	University of Zurich	Santer, R (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,DEPT PAEDIAT,SCHWANENWEG 20,D-24105 KIEL,GERMANY.							APERIA A, 1981, ACTA PAEDIATR SCAND, V70, P527, DOI 10.1111/j.1651-2227.1981.tb05735.x; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; Chen Y-T, 1995, METABOLIC MOL BASES, P935; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; FANCONI G., 1949, HELVETICA PAEDIATR ACTA, V4, P359; FELLERS FX, 1967, PEDIATR RES, V1, P304; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GITZELMANN R, 1957, Helv Paediatr Acta, V12, P425; HOLMAN GD, 1989, BIOCHEM SOC T, V17, P438, DOI 10.1042/bst0170438; ISHIHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P922, DOI 10.1016/S0006-291X(05)80274-8; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; LOWE T, 1990, NUCLEIC ACIDS RES, V18, P1757, DOI 10.1093/nar/18.7.1757; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MANZ F, 1987, PEDIATR NEPHROL, V1, P509, DOI 10.1007/BF00849262; MATSUBARA A, 1995, J CLIN ENDOCR METAB, V80, P3131, DOI 10.1210/jc.80.11.3131; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Muller D, 1997, J INHERIT METAB DIS, V20, P607, DOI 10.1023/A:1005375629820; Odievre M, 1966, Rev Int Hepatol, V16, P1; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PERMUTT MA, 1989, P NATL ACAD SCI USA, V86, P8688, DOI 10.1073/pnas.86.22.8688; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMADA F, 1995, DIABETOLOGIA, V38, P211, DOI 10.1007/s001250050272; TAKEDA J, 1993, DIABETES, V72, P773	28	198	204	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					324	326		10.1038/ng1197-324	http://dx.doi.org/10.1038/ng1197-324			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354798				2022-12-25	WOS:A1997YD66700028
J	Hall, RD; RiksenBruinsma, T; Weyens, GJ; Rosquin, IJ; Denys, PN; Evans, IJ; Lathouwers, JE; Lefebvre, MP; Dunwell, JM; vanTunen, A; Krens, FA				Hall, RD; RiksenBruinsma, T; Weyens, GJ; Rosquin, IJ; Denys, PN; Evans, IJ; Lathouwers, JE; Lefebvre, MP; Dunwell, JM; vanTunen, A; Krens, FA			A high efficiency technique for the generation of transgenic sugar beets from stomatal guard cells	NATURE BIOTECHNOLOGY			English	Article						Beta vulgaris; transformation; herbicide resistance	BETA-VULGARIS L; PLANT-PROTOPLASTS; PLASMID DNA; TRANSFORMATION; REGENERATION; ARABIDOPSIS; INTEGRATION; IMPROVEMENT; CULTURES; EVENTS	An optimized protocol has been developed for the efficient and rapid genetic modification of sugar beet (Beta vulgaris L.). A polyethylene glycol-mediated DNA transformation technique could be applied to protoplast populations enriched specifically for a single totipotent cell type derived from stomatal guard cells, to achieve high transformation frequencies. Bialaphos resistance, conferred by the pat gene, produced a highly efficient selection system. The majority of plants were obtained within 8 to 9 weeks and were appropriate for plant breeding purposes. All were resistant to glufosinate-ammonium-based herbicides. Detailed genomic characterization has verified transgene integration, and progeny analysis showed Mendelian inheritance.	SES EUROPE NV SA,B-3300 TIENEN,BELGIUM; ZENECA SEEDS,JEALOTTS HILL RES STN,BRACKNELL RG12 6EY,BERKS,ENGLAND; UNIV READING,DEPT AGR BOT,READING RG6 6AS,BERKS,ENGLAND	University of Reading	Hall, RD (corresponding author), DLO,CTR PLANT BREEDING & REPROD RES,DEPT CELL BIOL,POB 16,NL-6700 AA WAGENINGEN,NETHERLANDS.		Dunwell, Jim/AAS-6217-2020; HALL, ROBERT D/B-8707-2015; Dunwell, Jim M/E-5796-2012	HALL, ROBERT D/0000-0002-5786-768X; Dunwell, Jim/0000-0003-2147-665X				ALEXANDER MP, 1969, STAIN TECHNOL, V44, P117, DOI 10.3109/10520296909063335; BENEDIKTSSON I, 1995, EUPHYTICA, V85, P53, DOI 10.1007/BF00023930; COOKE DA, 1993, SUGAR BEET CROP; CREEMERSMOLENAAR J, 1992, PLANT SCI, V83, P87, DOI 10.1016/0168-9452(92)90065-T; DEBLOCK M, 1996, PLANTA, V197, P619; DEGREEF W, 1979, PLANT SCI LETT, V17, P55, DOI 10.1016/0304-4211(79)90109-3; DHALLUIN K, 1992, BIO-TECHNOL, V10, P309, DOI 10.1038/nbt0392-309; Draper J., 1988, PLANT GENETIC TRANSF, P69; FRY JE, 1991, MOL BIOL PLANT DEV; HALL RD, 1993, PLANT CELL REP, V12, P339, DOI 10.1007/BF00237431; HALL RD, 1995, PLANT PHYSIOL, V107, P1379, DOI 10.1104/pp.107.4.1379; HALL RD, 1996, IN PRESS J EXPER BOT; KRAMER C, 1993, PLANTA, V190, P454, DOI 10.1007/BF00224783; KRENS FA, 1982, NATURE, V296, P72, DOI 10.1038/296072a0; KRENS FA, 1990, THEOR APPL GENET, V79, P390, DOI 10.1007/BF01186084; KRENS FA, 1988, EUPHYTICA, P185; KRENS FA, 1996, IN PRESS PLANT SCI; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; LENZNER S, 1995, PHYSIOL PLANTARUM, V94, P342, DOI 10.1111/j.1399-3054.1995.tb05321.x; LINDSEY K, 1989, PLANT CELL REP, V8, P71, DOI 10.1007/BF00716841; MANSFIELD TA, 1990, ANNU REV PLANT PHYS, V41, P55, DOI 10.1146/annurev.pp.41.060190.000415; MELARAGNO JE, 1993, PLANT CELL, V5, P1661, DOI 10.1105/tpc.5.11.1661; PAUL H, 1987, PLANT CELL REP, V6, P379, DOI 10.1007/BF00269566; POSPISILOVA J, 1994, BIOL PLANTARUM, V36, P481, DOI 10.1007/BF02921169; Sack F. D., 1987, Stomatal function, P59; SANDER U, 1994, THESIS U HANNOVER GE; SANGWAN RS, 1992, PLANTA, V188, P439, DOI 10.1007/BF00192812; Scott RK, 1993, SUGARBEET CROP, P1; STEEN P, 1993, J SUGAR BEET RES, V30, P267; STRUHL K, 1976, P NATL ACAD SCI USA, V73, P1471, DOI 10.1073/pnas.73.5.1471	30	66	74	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1133	1138		10.1038/nbt0996-1133	http://dx.doi.org/10.1038/nbt0996-1133			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631066				2022-12-25	WOS:A1996VF84300037
J	Sousa, C; Cebolla, A; deLorenzo, V				Sousa, C; Cebolla, A; deLorenzo, V			Enhanced metalloadsorption of bacterial cells displaying poly-His peptides	NATURE BIOTECHNOLOGY			English	Article						heavy metals; metallotropism; biosorption; LamB	ESCHERICHIA-COLI; HEAVY-METALS; METALLOTHIONEIN; PROTEINS; SURFACE; BIOTECHNOLOGY; EXPRESSION; FUSION; GENE	The properties of Escherichia coli cells, acquired by cell surface presentation of one or two hexahistidine (His) clusters carried by the outer membrane LamB protein, have been examined. Strains producing LamB hybrids with the His chains accumulated greater than 11-fold more Cd2+ than E. coli cells expressing the protein without the His insert. Furthermore, the hexa-His chains on the cell surface caused cells to adhere reversibly to a Ni2+-containing solid matrix in a metal-dependent fashion. Thus, expression of poly-His peptides enables bacteria to act as a metalloaffinity adsorbent. These results open up the possibility for biosorption of heavy ions using engineered microorganisms.			Sousa, C (corresponding author), CSIC,CTR NACL BIOTECNOL,CAMPUS CANTOBLANCO,MADRID 28049,SPAIN.			Sousa Martin, Carolina/0000-0002-9235-9496; de Lorenzo, Victor/0000-0002-6041-2731				BEVERIDGE TJ, 1989, METAL IONS BACTERIA, P21; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; BROWN S, 1992, P NATL ACAD SCI USA, V89, P8651, DOI 10.1073/pnas.89.18.8651; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; CEBOLLA A, 1996, APPL ENVIRON MICROB, V622, P214; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; FRANCISCO JA, 1993, P NATL ACAD SCI USA, V90, P10444, DOI 10.1073/pnas.90.22.10444; FUCHS P, 1991, BIO-TECHNOL, V9, P1369, DOI 10.1038/nbt1291-1369; GADD GM, 1993, TRENDS BIOTECHNOL, V11, P353, DOI 10.1016/0167-7799(93)90158-6; GEORGIOU G, 1993, TRENDS BIOTECHNOL, V11, P6, DOI 10.1016/0167-7799(93)90068-K; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOFNUNG M, 1995, SCIENCE, V267, P473, DOI 10.1126/science.7824946; HOFNUNG M, 1991, METHOD CELL BIOL, V4, P77; HUTCHINS SR, 1986, ANNU REV MICROBIOL, V40, P311, DOI 10.1146/annurev.mi.40.100186.001523; JACOBS FA, 1989, GENE, V83, P95, DOI 10.1016/0378-1119(89)90407-1; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JI GY, 1995, J IND MICROBIOL, V14, P61, DOI 10.1007/BF01569887; KEMPER MA, 1993, J BACTERIOL, V175, P5690, DOI 10.1128/JB.175.17.5690-5696.1993; Kramer U, 1996, NATURE, V379, P635, DOI 10.1038/379635a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIB JE, 1985, BIOCHEMISTRY-US, V24, P1977, DOI 10.1021/bi00329a027; LITTLE M, 1993, TRENDS BIOTECHNOL, V11, P3, DOI 10.1016/0167-7799(93)90067-J; Lovely D.R., 1991, NATURE, V350, P413; Miller JH, 1972, EXPT MOL GENETICS, P201; MUROOKA Y, 1987, APPL ENVIRON MICROB, V53, P204, DOI 10.1128/AEM.53.1.204-207.1987; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; *QIAG INC, 1992, QIAEXPR HIGH LEV EXP; ROMEYER FM, 1988, J BIOTECHNOL, V8, P207, DOI 10.1016/0168-1656(88)90003-X; Sambrook J., 2002, MOL CLONING LAB MANU; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; Torma A. E., 1988, Biotechnology Volume 6b. Special Microbial Processes., P367; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	32	143	152	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					1017	1020		10.1038/nbt0896-1017	http://dx.doi.org/10.1038/nbt0896-1017			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631043				2022-12-25	WOS:A1996UZ19900037
J	Hoyle, R				Hoyle, R			Another salvo in the plant patent wars	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					680	&		10.1038/nbt0696-680	http://dx.doi.org/10.1038/nbt0696-680			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630967				2022-12-25	WOS:A1996UM76600005
J	Flores, N; Xiao, J; Berry, A; Bolivar, F; Valle, F				Flores, N; Xiao, J; Berry, A; Bolivar, F; Valle, F			Pathway engineering for the production of aromatic compounds in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article						amino acid overproduction; glucose transport; glycolysis; phosphoenolypyruvate	DELETIONS; STRAINS	Glucose is the preferred substrate for certain fermentation processes. During its internalization and concomitant formation of glucose-6-phosphate through the glucose phosphotransferase system (PTS), one molecule of phosphoenolpyruvate (PEP) is consumed. Together with erythrose 4-phosphate (E4P), PEP is condensed to form 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP), the first intermediate of the common segment of the aromatic pathway. From this metabolic route, several commercially important aromatic compounds can be obtained. We have selected Escherichia coli mutants that can transport glucose efficiently by a non-PTS uptake system. In theory, this process should increase the availability of PEP for other biosynthetic reactions. Using these mutants, in a background where the DAHP synthase (the enzyme that catalyzes the condensation of PEP and E4P into DAHP) was amplified, we were able to show that at least some of the PEP saved during glucose transport, can be redirected into the aromatic pathway. This increased carbon commitment to the aromatic pathway was enhanced still further upon amplification of the E. coli tktA gene that encodes for a transketolase involved in the biosynthesis of E4P.	UNIV NACL AUTONOMA MEXICO,INST BIOTECNOL,CUERNAVACA 62250,MORELOS,MEXICO; GENENCOR INT INC,S SAN FRANCISCO,CA 94080	Universidad Nacional Autonoma de Mexico								BIVILLE F, 1991, J GEN MICROBIOL, V137, P1775, DOI 10.1099/00221287-137-8-1775; BOCHNER BR, 1977, APPL ENVIRON MICROB, V33, P434, DOI 10.1128/AEM.33.2.434-444.1977; CORDARO JC, 1976, J BACTERIOL, V128, P785, DOI 10.1128/JB.128.3.785-793.1976; DRATHS KM, 1992, J AM CHEM SOC, V114, P3956, DOI 10.1021/ja00036a050; FRAENKEL DG, 1987, ESCHERICHIA COLI SAL, P142; Frost J., 1992, U.S. Patent, Patent No. [US 5168056, 5168056]; FROST JW, 1994, NEW J CHEM, V18, P341; HOLMS W, 1986, CURRENT TOPICS CELLU, P69; LEVY S, 1990, GENE, V86, P27, DOI 10.1016/0378-1119(90)90110-D; Maniatis T, 1989, DECONTAMINATION DILU; MASCARENHAS D, 1987, Patent No. 8701130; MORI M, 1987, Patent No. 62205782; MURDOCK D, 1993, BIO-TECHNOL, V11, P381, DOI 10.1038/nbt0393-381; PATNAIK R, 1994, APPL ENVIRON MICROB, V60, P3903, DOI 10.1128/AEM.60.11.3903-3908.1994; PATNAIK R, 1995, BIOTECHNOL BIOENG, V46, P361, DOI 10.1002/bit.260460409; PONCE E, 1995, J BACTERIOL, V177, P5719, DOI 10.1128/jb.177.19.5719-5722.1995; Postma P.W., 1987, ESCHERICHIA COLI SAL, P127; RAMSEIER TM, 1995, MOL MICROBIOL, V16, P1157, DOI 10.1111/j.1365-2958.1995.tb02339.x; SAIER MH, 1973, J BACTERIOL, V113, P512, DOI 10.1128/JB.113.1.512-514.1973; SILHAVY T, 1984, EXPT GENE FUSIONS, P110; SRINIVASAN PR, 1959, J BIOL CHEM, V234, P716; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	213	251	3	44	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					620	623		10.1038/nbt0596-620	http://dx.doi.org/10.1038/nbt0596-620			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630954				2022-12-25	WOS:A1996UL60400028
J	Niida, H; Matsumoto, T; Satoh, H; Shiwa, M; Tokutake, Y; Furuichi, Y; Shinkai, Y				Niida, H; Matsumoto, T; Satoh, H; Shiwa, M; Tokutake, Y; Furuichi, Y; Shinkai, Y			Severe growth defect in mouse cells lacking the telomerase RNA component	NATURE GENETICS			English	Article							ELONGATION; SENESCENCE; CANCER; YEAST; DNA	The ribonucleoprotein enzyme telomerase synthesizes telomeric DNA onto chromosome ends(1). Telomere length is maintained, by the presence of telomerase activity, in the vast majority of primary tumours and stem cells(2,3), suggesting that telomere maintenance is essential for cellular immortalization. Recently, the telomerase RNA component in human(4) and mouse(5) (TERC and Terc, respectively), a telomerase-associated protein TEP1/TLP1 (refs 6,7) and the human catalytic subunit protein TERT (refs 8,9) have been identified. To examine the role of telomerase in telomere maintenance and cellular viability, we established Terc-deficient embryonic stem (ES) cells. It is known that telomerase activity is absent in cells from Terc-knockout mice(10). Although the study showed that telomere shortening was observed in the Terc-deficient cells from first to six generation animals, whether telomerase-dependent telomere maintenance was essential for cellular viability remained to be elucidated. To address this issue, we examined Terc-deficient ES cells under long-term culture conditions. Accompanying the continual telomere shortening, the growth rate of Terc-deficient ES cells was gradually reduced after more than 300 divisions. An impaired growth rate was maintained to approximately 450 divisions, and then cell growth virtually stopped. These data clearly show that telomerase-dependent telomere maintenance is critical for the growth of mammalian cells.	Nippon Roche Res Ctr, Kamakura, Kanagawa 2478530, Japan; Agene Res Inst, Kamakura, Kanagawa 2478530, Japan	Roche Holding	Shinkai, Y (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, 53 Shogoin Kawara Cho, Kyoto 6068397, Japan.		Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484				BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	27	137	144	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					203	206		10.1038/580	http://dx.doi.org/10.1038/580			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620783				2022-12-25	WOS:000073865100034
J	Parkes, TL; Elia, AJ; Dickinson, D; Hilliker, AJ; Phillips, JP; Boulianne, GL				Parkes, TL; Elia, AJ; Dickinson, D; Hilliker, AJ; Phillips, JP; Boulianne, GL			Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons	NATURE GENETICS			English	Article							ZINC SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; MELANOGASTER; SPAN; MUTATIONS	Reactive oxygen (RO) has been identified as an important effector in ageing and lifespan determination(1-3). The specific cell types, however, in which oxidative damage acts to limit lifespan of the whole organism have not been explicitly identified. The association between mutations in the gene encoding the oxygen radical metabolizing enzyme CuZn superoxide dismutase (SOD1) and loss of motorneurons in the brain and spinal cord that occurs in the life-shortening paralytic disease, Familial Amyotrophic Lateral Sclerosis (FALS; ref. 4), suggests that chronic and unrepaired oxidative damage occurring specifically in motor neurons could be a critical causative factor in ageing. To test this hypothesis, we generated transgenic Drosophila which express human SOD1 specifically in adult motorneurons. We show that overexpression of a single gene, SOD1, in a single cell type, the motorneuron, extends normal lifespan by up to 40% and rescues the lifespan of a short-lived Sod null mutant. Elevated resistance to oxidative stress suggests that the lifespan extension observed in these flies is due to enhanced RO metabolism. These results show that SOD activity in motorneurons is an important factor in ageing and lifespan determination in Drosophila.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Zool, Toronto, ON, Canada	University of Guelph; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Phillips, JP (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	jphillip@uoguelph.ca						BRAND AH, 1993, DEVELOPMENT, V118, P401; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; LEE YM, 1981, J BIOL CHEM, V256, P8506; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; ORR WC, 1993, ARCH BIOCHEM BIOPHYS, V301, P34, DOI 10.1006/abbi.1993.1111; PARKES TL, IN PRESS GENOME; PHILLIPS JP, 1995, P NATL ACAD SCI USA, V92, P8574, DOI 10.1073/pnas.92.19.8574; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SETO NOL, 1990, P NATL ACAD SCI USA, V87, P4270, DOI 10.1073/pnas.87.11.4270; STAVELEY BE, 1990, GENOME, V33, P867, DOI 10.1139/g90-130; Tower J, 1996, BIOESSAYS, V18, P799, DOI 10.1002/bies.950181006; Umbreit WW, 1964, MANOMETRIC TECHNIQUE; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036	18	672	691	0	56	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					171	174		10.1038/534	http://dx.doi.org/10.1038/534			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620775				2022-12-25	WOS:000073865100026
J	Ruiz, PJ; Wolkowicz, R; Waisman, A; Hirschberg, DL; Carmi, P; Erez, N; Garren, H; Herkel, J; Karpuj, M; Steinman, L; Rotter, V; Cohen, IR				Ruiz, PJ; Wolkowicz, R; Waisman, A; Hirschberg, DL; Carmi, P; Erez, N; Garren, H; Herkel, J; Karpuj, M; Steinman, L; Rotter, V; Cohen, IR			Idiotypic immunization induces immunity to mutated p53 and tumor rejection	NATURE MEDICINE			English	Article							MUTATIONS; MIMICRY; PROTEIN	The p53 molecule might serve as a common tumor-associated antigen, as the tumor suppressor gene p53 is mutated and the p53 protein is often over-expressed in tumor cells. We report that effective immunity to p53 can be induced through an idiotypic network by immunization of mice with a monoclonal antibody (PAb-240) specific for mutated p53, or with a peptide derived from the complementarity determining region (CDR) 3 of the variable domain of the light chain (VL) of this antibody. The immunized mice produced IgG antibodies to p53 and mounted a cytotoxic reaction to a tumor line bearing mutated p53. The idiotypically immunized mice were resistant to challenge with the tumor cells. Thus antibodies to p53 might serve as immunogens for activating resistance to some tumors. At the basic level, these findings indicate that a network of p53 immunity may be organized naturally within the immune system.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Weizmann Inst Sci, Dept Cellular & Mol Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Stanford University; Weizmann Institute of Science; Weizmann Institute of Science	Steinman, L (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.		Cohen, Irun R/B-3542-2009; Waisman, Ari/C-7383-2015	Waisman, Ari/0000-0003-4304-8234; Erez, Neta/0000-0001-6506-9074; Steinman, Lawrence/0000-0002-2437-2250; Herkel, Johannes/0000-0001-9055-9999				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Bertholet S, 1997, EUR J IMMUNOL, V27, P798, DOI 10.1002/eji.1830270332; Bona CA, 1996, P SOC EXP BIOL MED, V213, P32; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; Coligan JE., 1994, CURRENT PROTOCOLS IM; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEPOM G, 1982, J EXP MED, V11, P155; NEPOM J T, 1982, Survey of Immunologic Research, V1, P255; NISONOFF A, 1991, J IMMUNOL, V147, P2429; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; Vierboom MPM, 1997, J EXP MED, V186, P695, DOI 10.1084/jem.186.5.695; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	19	60	66	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					710	712		10.1038/nm0698-710	http://dx.doi.org/10.1038/nm0698-710			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623981				2022-12-25	WOS:000074008300038
J	Heiss, NS; Knight, SW; Vulliamy, TJ; Klauck, SM; Wiemann, S; Mason, PJ; Poustka, A; Dokal, I				Heiss, NS; Knight, SW; Vulliamy, TJ; Klauck, SM; Wiemann, S; Mason, PJ; Poustka, A; Dokal, I			X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions	NATURE GENETICS			English	Article							FACTOR-VIII GENE; INCONTINENTIA PIGMENTI; XQ28; REGION; CANDIDATE; PROTEIN; DNA; IDENTIFICATION; AMPLIFICATION; TRANSCRIPTS	X-linked recessive dyskeratosis congenita (DKC) is a rare bone-marrow failure disorder linked to Xq28. Hybridization screening with 28 candidate cDNAs resulted in the detection of a 3' deletion in one DKC patient with a cDNA probe (derived from XAP101). Five different missense mutations in five unrelated patients were subsequently identified in XAP101, indicating that it is the gene responsible for X-linked DKC (DKC1). DKC1 is highly conserved across species barriers and is the orthologue of rat NAP57 and Saccharomyces cerevisiae CBF5. The peptide dyskerin contains two TruB pseudouridine (psi) synthase motifs, multiple phosphorylation sites, and a carboxy-terminal lysine-rich repeat domain. By analogy to the function of the known dyskerin orthologues, involvement in the cell cycle and nucleolar function is predicted for the protein.	Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, London W12 0NN, England; Hammersmith Hosp, London W12 0NN, England	Helmholtz Association; German Cancer Research Center (DKFZ); Imperial College London; Imperial College London	Poustka, A (corresponding author), Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	a.poustka@dkfz-heidelberg.de; i.dokal@rpms.ac.uk	Wiemann, Stefan/E-4424-2013; Mason, Philip J/B-1087-2008	Wiemann, Stefan/0000-0003-4683-3174; Dokal, Inderjeet/0000-0003-4462-4782	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNGRIMSSON R, 1993, J MED GENET, V30, P618, DOI 10.1136/jmg.30.7.618; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; BIONE S, 1993, P NATL ACAD SCI USA, V90, P10977, DOI 10.1073/pnas.90.23.10977; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; Cadwell C, 1997, MOL CELL BIOL, V17, P6175, DOI 10.1128/MCB.17.10.6175; Chen EY, 1996, HUM MOL GENET, V5, P659, DOI 10.1093/hmg/5.5.659; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CONNOR JM, 1986, HUM GENET, V72, P348, DOI 10.1007/BF00290963; COULTHARD S, 1997, BR J HEAMAT, V97, pS1; Coy JF, 1996, GENOMICS, V32, P309, DOI 10.1006/geno.1996.0124; COY JF, 1994, MAMM GENOME, V5, P131, DOI 10.1007/BF00352342; CROSS NCP, 1993, BRIT J HAEMATOL, V84, P67, DOI 10.1111/j.1365-2141.1993.tb03026.x; DAS S, 1994, AM J HUM GENET, V54, P922; Devriendt K, 1997, AM J HUM GENET, V60, P581; Dixon J, 1996, NAT GENET, V12, P130; Dokal I, 1996, BRIT J HAEMATOL, V92, P775, DOI 10.1046/j.1365-2141.1996.355881.x; DOKAL I, 1994, LEUKEMIA LYMPHOMA, V15, P1, DOI 10.3109/10428199409051671; DOKAL I, 1992, BLOOD, V80, P3090; DRACHTMAN RA, 1992, AM J PEDIAT HEMATOL, V14, P297; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Heiss NS, 1997, GENOMICS, V43, P329, DOI 10.1006/geno.1997.4810; Heiss NS, 1996, GENOME RES, V6, P478, DOI 10.1101/gr.6.6.478; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; Heiss NS, 1995, METHOD MOL CELL BIOL, V5, P337; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; Knight SW, 1996, J MED GENET, V33, P993, DOI 10.1136/jmg.33.12.993; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MEIER UT, 1992, CELL, V70, P127; Metzenberg Aida B., 1992, Human Molecular Genetics, V1, P97, DOI 10.1093/hmg/1.2.97; PARRISH JE, 1995, HUM MOL GENET, V4, P1557, DOI 10.1093/hmg/4.9.1557; ROGNER UC, 1994, HUM MOL GENET, V3, P2137, DOI 10.1093/hmg/3.12.2137; Rogner UC, 1996, GENOME RES, V6, P922, DOI 10.1101/gr.6.10.922; SEDLACEK Z, 1993, HUM MOL GENET, V2, P1865; Vulliamy TJ, 1997, BLOOD, V90, P2213; Wilgenbus KK, 1995, METHOD MOL CELL BIOL, V5, P214; WINKLER AA, IN PRESS YEAST	41	674	698	2	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					32	38		10.1038/ng0598-32	http://dx.doi.org/10.1038/ng0598-32			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590285				2022-12-25	WOS:000073346700013
J	Ikeno, M; Grimes, B; Okazaki, T; Nakano, M; Saitoh, K; Hoshino, H; McGill, NI; Cooke, H; Masumoto, H				Ikeno, M; Grimes, B; Okazaki, T; Nakano, M; Saitoh, K; Hoshino, H; McGill, NI; Cooke, H; Masumoto, H			Construction of YAC-based mammalian artificial chromosomes	NATURE BIOTECHNOLOGY			English	Article						alpha-satellite DNA; CENP-B boxes	ALPHA-SATELLITE DNA; CENP-B BOX; HUMAN TELOMERES; MOUSE CELLS; ROBERTSONIAN TRANSLOCATIONS; YEAST; SEQUENCE; CLONING; VECTORS; GENE	To construct a mammalian artificial chromosome (MAC), telomere repeats and selectable markers were introduced into a 100 kb yeast artificial chromosome (YAC) containing human centromeric DNA. This YAC, which has a regular repeat structure of alpha-satellite DNA and centromere protein B (CENP-B) boxes, efficiently formed MACs that segregated accurately and bound CENP-B, CENP-C, and CENP-E. The MACs appear to be about 1-5 Mb in size and contain YAC multimers. Structural analyses suggest that the MACs have not acquired host sequences and were formed by a de novo mechanism. The accurate segregation of the MACs suggests they have potential as vectors for introducing genes into mammals.	Nagoya Univ, Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Nagoya University; University of Edinburgh	Masumoto, H (corresponding author), Nagoya Univ, Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	g44478a@nucc.cc.nagoya-u.ac.jp						ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BROCCOLI D, 1990, CYTOGENET CELL GENET, V54, P182, DOI 10.1159/000132989; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHOO KH, 1991, NUCLEIC ACIDS RES, V19, P1179, DOI 10.1093/nar/19.6.1179; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; CROSS SH, 1989, THESIS U EDINBURGH S; duSart D, 1997, NAT GENET, V16, P144; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; FEATHERSTONE T, 1993, GENOMICS, V17, P267, DOI 10.1006/geno.1993.1321; HAAF T, 1995, J MOL EVOL, V41, P487, DOI 10.1007/BF00160320; HADLACZKY G, 1991, P NATL ACAD SCI USA, V88, P8106, DOI 10.1073/pnas.88.18.8106; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JAKOBOVITS A, 1993, NATURE, V362, P266; KALITSIS P, 1993, GENOMICS, V16, P104, DOI 10.1006/geno.1993.1147; KITAGAWA K, 1995, MOL CELL BIOL, V15, P1602; KOUPRINA N, 1994, GENOMICS, V21, P7, DOI 10.1006/geno.1994.1218; KRYSAN PJ, 1993, MOL CELL BIOL, V13, P2688, DOI 10.1128/MCB.13.5.2688; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LEDBETTER SA, 1990, GENOMICS, V6, P475, DOI 10.1016/0888-7543(90)90477-C; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MASUMOTO H, 1993, NATO ASI SERIES H, V72, P31; Muramatsu M, 1986, Adv Biophys, V21, P217, DOI 10.1016/0065-227X(86)90025-0; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PAVAN WJ, 1990, P NATL ACAD SCI USA, V87, P1300, DOI 10.1073/pnas.87.4.1300; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SCHEDI A, 1995, METHOD MOL BIOL, P281; SHERO JH, 1991, GENOMICS, V10, P505, DOI 10.1016/0888-7543(91)90343-D; SMITH DR, 1993, MAMM GENOME, V4, P141, DOI 10.1007/BF00352229; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SUN TQ, 1994, NAT GENET, V8, P33, DOI 10.1038/ng0994-33; Taylor SS, 1996, CHROMOSOMA, V105, P70, DOI 10.1007/BF02509516; TROWELL HE, 1993, HUM MOL GENET, V2, P1639, DOI 10.1093/hmg/2.10.1639; VISSEL B, 1992, CYTOGENET CELL GENET, V61, P81, DOI 10.1159/000133374; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x	48	353	377	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					431	439		10.1038/nbt0598-431	http://dx.doi.org/10.1038/nbt0598-431			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592390				2022-12-25	WOS:000073489600026
J	Hancock, REW; Alm, R; Bina, J; Trust, T				Hancock, REW; Alm, R; Bina, J; Trust, T			Helicobacter pylori: A surprisingly conserved bacterium	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ British Columbia, Dept Immunol & Microbiol, Vancouver, BC V6T 1Z3, Canada; ASTRA Res Ctr Boston Inc, Cambridge, MA 02139 USA	University of British Columbia	Hancock, REW (corresponding author), Univ British Columbia, Dept Immunol & Microbiol, Vancouver, BC V6T 1Z3, Canada.		Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; EXNER MM, 1995, INFECT IMMUN, V63, P1567, DOI 10.1128/IAI.63.4.1567-1572.1995; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; MARSHALL BJ, 1984, LANCET, V1, P1311; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	5	27	27	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					216	217		10.1038/nbt0398-216	http://dx.doi.org/10.1038/nbt0398-216			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9527991				2022-12-25	WOS:000072371000005
J	Igarashi, S; Koide, R; Shimohata, T; Yamada, M; Hayashi, Y; Takano, H; Date, H; Oyake, M; Sato, T; Sato, A; Egawa, S; Ikeuchi, T; Tanaka, H; Nakano, R; Tanaka, K; Hozumi, I; Inuzuka, T; Takahashi, H; Tsuji, S				Igarashi, S; Koide, R; Shimohata, T; Yamada, M; Hayashi, Y; Takano, H; Date, H; Oyake, M; Sato, T; Sato, A; Egawa, S; Ikeuchi, T; Tanaka, H; Nakano, R; Tanaka, K; Hozumi, I; Inuzuka, T; Takahashi, H; Tsuji, S			Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch	NATURE GENETICS			English	Article							DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; SPINOCEREBELLAR ATAXIA TYPE-1; TRINUCLEOTIDE CAG REPEAT; CATALYZED CROSS-LINKING; MACHADO-JOSEPH DISEASE; GLUTAMINE REPEATS; NEURODEGENERATIVE DISEASES; HUNTINGTONS-DISEASE; COMPLEMENTARY-DNA; TRANSGENIC MICE	To elucidate the molecular mechanisms whereby expanded polyglutamine stretches elicit a gain of toxic function, we expressed full-length and truncated DRPLA (dentatorubral-pallidoluysian atrophy) cDNAs with or without expanded CAG repeats in COS-7 cells. We found that truncated DRPLA proteins containing an expanded polyglutamine stretch form filamentous peri-and intranuclear aggregates and undergo apoptosis. The apoptotic cell death was partially suppressed by the transglutaminase inhibitors cystamine and monodansyl cadaverine (but not putrescine), suggesting involvement of a transglutaminase reaction and providing a potential basis for the development of therapeutic measures for GAG-repeat expansion diseases.	Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan; Niigata Univ, Brain Res Inst, Dept Pathol, Niigata 951, Japan	Niigata University; Niigata University	Tsuji, S (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurol, 1-757 Asahimachi, Niigata 951, Japan.	tsuji@cc.niigata-u.ac.jp		Sato, Toshiya/0000-0001-7844-9930; Hozumi, Isao/0000-0003-0984-6291				BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DICKSON RB, 1981, J BIOL CHEM, V256, P3454; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; IKEUCHI T, 1995, ANN NEUROL, V37, P769, DOI 10.1002/ana.410370610; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; JACKSON M, 1995, NEUROPATH APPL NEURO, V21, P18, DOI 10.1111/j.1365-2990.1995.tb01024.x; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KLEMAN JP, 1995, BIOCHEMISTRY-US, V34, P13768, DOI 10.1021/bi00042a007; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LORAND L, 1979, BIOCHEMISTRY-US, V18, P1756, DOI 10.1021/bi00576a019; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAITO H, 1982, NEUROLOGY, V32, P798, DOI 10.1212/WNL.32.8.798; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; ONODERA O, 1995, AM J HUM GENET, V57, P1050; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	38	305	317	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					111	117		10.1038/ng0298-111	http://dx.doi.org/10.1038/ng0298-111			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462738				2022-12-25	WOS:000071779500017
J	Portsteffen, H; Beyer, A; Becker, E; Epplen, C; Pawlak, A; Kunau, WH; Dodt, G				Portsteffen, H; Beyer, A; Becker, E; Epplen, C; Pawlak, A; Kunau, WH; Dodt, G			Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders	NATURE GENETICS			English	Article							ZELLWEGER SYNDROME; TARGETING SIGNAL; PTS1 RECEPTOR; GENE; MUTATIONS; IDENTIFICATION; HETEROGENEITY; TERMINUS; DEFECTS; ENCODES	Human peroxisome biogenesis disorders (PBDs) are a group of genetically heterogeneous autosomal-recessive diseases caused by mutations in PEX genes that encode peroxins, proteins required for peroxisome biogenesis, These lethal diseases include Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD) and infantile Refsum's disease (IRD)(1), three phenotypes now thought to represent a continuum of clinical features that are most severe in ZS, milder in NALD and least severe in IRD2. At least eleven PBD complementation groups have been identified by somatic-cell hybridization analysis(2-6) compared to the eighteen PEX complementation groups that have been found in yeast, We have cloned the human PEX1 gene encoding a 147-kD member of the AAA protein family ATPases associated with diverse cellular activities)(7), which is the putative orthologue of Saccharomyces cerevisiae Pex1p (ScPex1p). Human PEX1 has been identified by computer-based 'homology probing' using the ScPex1p sequence to screen databases of expressed sequence tags (dbEST) for human cDNA clones. Expression of PEX1 rescued the cells from the biogenesis defect in human fibroblasts of complementation group 1 (CG1), the largest PBD complementation group, We show that PEX1 is mutated in CG1 patients.	HOP HENRI MONDOR,U99 INSERM,F-94010 CRETEIL,FRANCE; RUHR UNIV BOCHUM,INST PHYSIOL CHEM,ABT ZELLBIOCHEM,D-44780 BOCHUM,GERMANY; RUHR UNIV BOCHUM,INST HUMAN GENET,D-44780 BOCHUM,GERMANY	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Ruhr University Bochum; Ruhr University Bochum			Pawlak, André/L-9044-2018; pawlak, andré/Q-2495-2019	Pawlak, André/0000-0002-5486-212X; pawlak, andré/0000-0002-5486-212X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beyer A, 1997, PROTEIN SCI, V6, P2043; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GARTNER J, 1994, J INHERIT METAB DIS, V17, P327, DOI 10.1007/BF00711820; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; LAZAROW PB, 1995, METABOLIC MOL BASES, V2, P2287; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOSER AB, 1995, J PEDIATR-US, V127, P13, DOI 10.1016/S0022-3476(95)70250-4; MOSER HW, 1980, ANN NEUROL, V7, P542, DOI 10.1002/ana.410070607; POULOS A, 1995, J PEDIATR-US, V127, P596, DOI 10.1016/S0022-3476(95)70121-4; ROSCHER AA, 1989, PEDIATR RES, V26, P67, DOI 10.1203/00006450-198907000-00019; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	26	110	112	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					449	452		10.1038/ng1297-449	http://dx.doi.org/10.1038/ng1297-449			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398848				2022-12-25	WOS:A1997YJ92400027
J	Reuber, BE; GermainLee, E; Collins, CS; Morrell, JC; Ameritunga, R; Moser, HW; Valle, D; Gould, SJ				Reuber, BE; GermainLee, E; Collins, CS; Morrell, JC; Ameritunga, R; Moser, HW; Valle, D; Gould, SJ			Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders	NATURE GENETICS			English	Article							TARGETING SIGNAL; PICHIA-PASTORIS; PROTEIN IMPORT; ZELLWEGER SYNDROME; PTS1 RECEPTOR; GENE; ENCODES; MEMBER; FAMILY; THIOLASE	The peroxisome biogenesis disorders (PBDs) are a group of lethal autosomal-recessive diseases caused by defects in peroxisomal matrix protein import, with the concomitant loss of multiple peroxisomal enzyme activities. Ten complementation groups (CGs) have been identified for the PBDs, with CG1 accounting for 51% of all PBD patients. We identified the human orthologue of yeast PEX1, a gene required for peroxisomal matrix protein import. Expression of human PEX1 restored peroxisomal protein import in fibroblasts from 30 CG1 patients, and PEX1 mutations were detected in multiple CG1 probands. A common PEX1 allele, C843D, is present in approximately half of CG1 patients and has a deleterious effect on PEX1 activity. Phenotypic analysis of PEX1-deficient cells revealed severe defects in peroxisomal matrix protein import and destabilization of PEX5, the receptor for the type-1 peroxisomal targetting signal, even though peroxisomes were present in these cells and capable of importing peroxisomal membrane proteins. These data demonstrate an important role for PEX1 in peroxisome biogenesis and suggest that mutations in this gene are the most common cause of the PBDs.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,PREDOCTORAL TRAINING PROGRAM HUMAN GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,KENNEDY KRIEGER INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT GENET & MOL BIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ANAT & CELL BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Germain-Lee, Emily/0000-0002-5727-610X	NICHD NIH HHS [HD10891, HD00989] Funding Source: Medline; NIDDK NIH HHS [DK45787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MICHAUD J, 1992, GENOMICS, V13, P389, DOI 10.1016/0888-7543(92)90258-T; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	26	177	181	1	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					445	448		10.1038/ng1297-445	http://dx.doi.org/10.1038/ng1297-445			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398847				2022-12-25	WOS:A1997YJ92400026
J	Bennett, ST; Wilson, AJ; Esposito, L; Bouzekri, N; Undlien, DE; Cucca, F; Nistico, L; Buzzetti, R; Bosi, E; Pociot, F; Nerup, J; CambonThomsen, A; Pugliese, A; Shield, JPH; McKinney, PA; Bain, SC; Polychronakos, C; Todd, JA; Pozzilli, P; Visalli, N; Baroni, M; Fioriti, E; Mesturino, C; Signore, A; Cavallo, M; Lucentini, L; Matteoli, M; Crino, A; Teodonio, C; Amoretti, R; Tombesi, A; Ruggeri, M; Pisano, L; Suraci, C; Pennafina, M; Boscherini, B; Stoduto, S; Fonte, M; Mancabitti, M; Multari, G; Suppa, M; DeMattia, G; Faldetta, MC; Laurenti, O; Marietti, G; Pitocco, D; Ferrazzoli, F; Bizzarri, C; Ghirlanda, G				Bennett, ST; Wilson, AJ; Esposito, L; Bouzekri, N; Undlien, DE; Cucca, F; Nistico, L; Buzzetti, R; Bosi, E; Pociot, F; Nerup, J; CambonThomsen, A; Pugliese, A; Shield, JPH; McKinney, PA; Bain, SC; Polychronakos, C; Todd, JA; Pozzilli, P; Visalli, N; Baroni, M; Fioriti, E; Mesturino, C; Signore, A; Cavallo, M; Lucentini, L; Matteoli, M; Crino, A; Teodonio, C; Amoretti, R; Tombesi, A; Ruggeri, M; Pisano, L; Suraci, C; Pennafina, M; Boscherini, B; Stoduto, S; Fonte, M; Mancabitti, M; Multari, G; Suppa, M; DeMattia, G; Faldetta, MC; Laurenti, O; Marietti, G; Pitocco, D; Ferrazzoli, F; Bizzarri, C; Ghirlanda, G			Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele	NATURE GENETICS			English	Article							SUSCEPTIBILITY LOCUS; MINISATELLITE LOCUS; GENE REGION; POLYMORPHISM; ASSOCIATION; PROTECTION; MELLITUS; IDDM2; MAPS	The IDDM2 type 1 diabetes susceptibility locus was mapped to(1-6) and identified as(7) allelic variation at the insulin gene (INS) VNTR regulatory polymorphism. In Caucasians, INS VNTR alleles divide into two discrete size classes'. Class I alleles (26 to 69 repeats) predispose in a recessive way to type 1 diabetes, while class III alleles (140 to more than 200 repeats) ape dominantly protective(8). The protective effect may be explained by higher levels of class III VNTR-associated INS mRNA in thymus such that elevated levels of preproinsulin protein enhance immune tolerance to preproinsulin, a key autoantigen in type 1 diabetes pathogenesis(9,10). The mode of action of IDDM2 is complicated, however, by parent-of-origin effects(2,7,11-14) and possible allelic heterogeneity within the two defined allele classes(7,15). We have now analysed transmission of specific VNTR alleles in 1,316 families and demonstrate that a particular class I allele does not predispose to disease when paternally inherited, suggestive of polymorphic imprinting(16). But this paternal effect is observed only when the father's untransmitted allele is a class III. This allelic interaction is reminiscent of epigenetic phenomena observed in plants (for example, paramutation; ref. 17) and in yeast (for example, trans-inactivation; ref. 18). If untransmitted chromosomes can have functional effects on the biological properties of transmitted chromosomes, the implications for human genetics and disease are potentially considerable.	HOP PURPAN,CTR IMMUNOPATHOL & GENET HUMAINE,CNRS,UPR 8291,F-31300 TOULOUSE,FRANCE; NATL HOSP NORWAY,INST TRANSPLANTAT IMMUNOL,N-0027 OSLO,NORWAY; S MICHELE HOSP,DEPT PAEDIAT,CAGLIARI,SARDINIA,ITALY; UNIV ROMA LA SAPIENZA,INST MED CLIN 2,I-00161 ROME,ITALY; UNIV MILAN,IST SCI SAN RAFFAELE,DEPT INTERNAL MED,I-20122 MILAN,ITALY; STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; UNIV MIAMI,SCH MED,DIABET RES INST,MIAMI,FL 33136; UNIV BRISTOL,ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,AVON,ENGLAND; UNIV LEEDS,RES SCH MED,PAEDIAT EPIDEMIOL GRP,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND; UNIV BIRMINGHAM,BIRMINGHAM HEARTLANDS HOSP,DEPT MED,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; MONTREAL CHILDRENS HOSP,MONTREAL,PQ H3H 1A4,CANADA	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; University of Oslo; National Hospital Norway; Sapienza University Rome; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Steno Diabetes Center; University of Miami; Bristol Royal Hospital For Children; University of Bristol; University of Leeds; Heart of England NHS Foundation Trust; University of Birmingham; McGill University	Bennett, ST (corresponding author), UNIV OXFORD,NUFFIELD DEPT SURG,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.		Baroni, Marco/A-1555-2012; Bizzarri, Carla/AAI-2429-2019; Nisticò, Lorenza/N-7470-2017; Buzzetti, Raffaella/K-3090-2016; Pozzilli, Paolo/A-5235-2010; Todd, John A/A-3542-2010; Signore, Alberto/E-5812-2010; Nisticò, Lorenza/AAD-1662-2021; Shield, Julian PH/D-6297-2014; Polychronakos, Constantin/B-8151-2008; Pitocco, Dario/K-4210-2018; Baroni, Marco Giorgio/AAH-3476-2020	Bizzarri, Carla/0000-0002-5616-9185; Nisticò, Lorenza/0000-0003-1805-6240; Buzzetti, Raffaella/0000-0003-1490-6041; Todd, John A/0000-0003-2740-8148; Signore, Alberto/0000-0001-8923-648X; Nisticò, Lorenza/0000-0003-1805-6240; Shield, Julian PH/0000-0003-2601-7575; Baroni, Marco Giorgio/0000-0002-3224-6078; cavallo, maria gisella/0000-0001-6630-8049; CUCCA, Francesco/0000-0002-7414-1995; Crino, Antonino/0000-0003-3548-7114; Polychronakos, Constantin/0000-0002-7624-6635; Wilson, Amanda/0000-0001-5681-9611; matteoli, maria cristina/0000-0003-1461-6220; Pociot, Flemming/0000-0003-3274-5448	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Bennett ST, 1996, J AUTOIMMUN, V9, P415, DOI 10.1006/jaut.1996.0057; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; BENNETT ST, 1995, NAT GENET, V10, P379, DOI 10.1038/ng0895-379; BENNETT ST, 1996, PCR ESSENTIAL TECHNI, P32; Bui MM, 1996, J AUTOIMMUN, V9, P97, DOI 10.1006/jaut.1996.0012; GIANNOUKAKIS N, IN PRESS J BIOL CHEM; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Hollick JB, 1997, TRENDS GENET, V13, P302, DOI 10.1016/S0168-9525(97)01184-0; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; JULIER C, 1994, AM J HUM GENET, V55, P1247; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; POLYCHRONAKOS C, 1995, DIABETOLOGIA, V38, P715, DOI 10.1007/s001250050343; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; PUGLIESE A, 1994, J AUTOIMMUN, V7, P687, DOI 10.1006/jaut.1994.1053; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; TODD JA, 1995, P NATL ACAD SCI USA, V92, P8560, DOI 10.1073/pnas.92.19.8560; UNDLIEN DE, 1995, DIABETES, V44, P620, DOI 10.2337/diabetes.44.6.620; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; Xu YQ, 1997, ONCOGENE, V14, P1041, DOI 10.1038/sj.onc.1200926	28	153	157	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					350	352		10.1038/ng1197-350	http://dx.doi.org/10.1038/ng1197-350			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354805				2022-12-25	WOS:A1997YD66700035
J	Huang, LP; Gitschier, J				Huang, LP; Gitschier, J			A novel gene involved in zinc transport is deficient in the lethal milk mouse	NATURE GENETICS			English	Article							ACRODERMATITIS-ENTEROPATHICA; SACCHAROMYCES-CEREVISIAE; MUTATION; PROTEIN; RESISTANCE; EXPRESSION; METABOLISM; OTOLITH; DISEASE; SYSTEM	We have identified the gene responsible for the inherited zinc deficiency in the lethal milk (lm) mouse. The gene, here designated Znt4, encodes a 430-amino-acid protein that is homologous to two proteins, ZnT2 and ZnT3, responsible for sequestration of zinc into endosomal/lysosomal compartments and synaptic vesicles, respectively. We show that the Znt4 gene confers zinc resistance to a zinc-sensitive yeast strain and that it is abundantly expressed in the mammary epithelia and brain. The lethal milk mutant: has a nonsense mutation at arginine codon 297 in the Znt4 gene.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ACKLAND ML, 1992, J NUTR, V122, P1214, DOI 10.1093/jn/122.6.1214; CHAPLIN DD, 1994, CURRENT PROTOCOLS MO; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; DICKIE MM, 1969, MOUSE NEWS LETT, V41, P30; ECKHERT CD, 1977, SCIENCE, V195, P789, DOI 10.1126/science.836589; ERWAY LC, 1984, J HERED, V75, P480, DOI 10.1093/oxfordjournals.jhered.a109990; Glover M T, 1988, Pediatr Dermatol, V5, P10, DOI 10.1111/j.1525-1470.1988.tb00877.x; GREEN MC, 1973, MOUSE NEWS LETT, V49, P32; Gwynn B., 1996, Molecular Biology of the Cell, V7, p550A; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KURAMOTO Y, 1991, SEMIN DERMATOL, V10, P309; LEE DY, 1992, J NUTR, V122, P2233, DOI 10.1093/jn/122.11.2233; Lyon M., 1989, GENETIC VARIANTS STR; MOYNAHAN EJ, 1974, LANCET, V2, P399; NIES DH, 1989, P NATL ACAD SCI USA, V86, P7351, DOI 10.1073/pnas.86.19.7351; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PALMITER RD, 1995, EMBO J, V14, P633; PILETZ JE, 1978, AM J CLIN NUTR, V31, P560, DOI 10.1093/ajcn/31.4.560; PILETZ JE, 1978, SCIENCE, V199, P181, DOI 10.1126/science.619449; PURICHIA N, 1972, DEV BIOL, V27, P395, DOI 10.1016/0012-1606(72)90178-9; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Roberts E, 1931, SCIENCE, V74, P569, DOI 10.1126/science.74.1927.569; ROBINSON PJ, 1981, IMMUNOGENETICS, V14, P449, DOI 10.1007/BF00373326; Siracusa LD, 1996, MAMM GENOME, V6, pS51; Theophilos MB, 1996, HUM MOL GENET, V5, P1619, DOI 10.1093/hmg/5.10.1619; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VANWOUWE JP, 1989, EUR J PEDIATR, V149, P2, DOI 10.1007/BF02024322; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; ZHAO H, 1996, J BIOL CHEM, V271, P23202	32	284	301	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					292	297		10.1038/ng1197-292	http://dx.doi.org/10.1038/ng1197-292			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354792				2022-12-25	WOS:A1997YD66700022
J	Ball, S; Borman, N				Ball, S; Borman, N			Pharmacogenetics and drug metabolism	NATURE BIOTECHNOLOGY			English	Editorial Material									NOVARTIS PHARMACEUT,GEN & EXPT TOXICOL,E HANOVER,NJ 07936	Novartis	Ball, S (corresponding author), WYETH AYERST RES,DRUG METABOLISM,CN 8000,PRINCETON,NJ 08543, USA.							BALL SE, 1995, DRUG CHEM TOXICOL, V18, P1, DOI 10.3109/01480549509017855; DALY AK, 1995, J MOL MED-JMM, V73, P539; IDLE JR, 1979, DRUG METAB REV, V9, P301, DOI 10.3109/03602537908993896; Nebert DW, 1997, AM J HUM GENET, V60, P265; Rendic S, 1997, DRUG METAB REV, V29, P413, DOI 10.3109/03602539709037591; 1996, NAT BIOTECHNOL, V14, P1516	6	10	10	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					925	926		10.1038/nbt1097-925	http://dx.doi.org/10.1038/nbt1097-925			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335033				2022-12-25	WOS:A1997XZ28500003
J	Ciapponi, L; Maione, D; Scoumanne, A; Costa, P; Hansen, MB; Svenson, M; Bendtzen, K; Alonzi, T; Paonessa, G; Cortese, R; Ciliberto, G; Savino, R				Ciapponi, L; Maione, D; Scoumanne, A; Costa, P; Hansen, MB; Svenson, M; Bendtzen, K; Alonzi, T; Paonessa, G; Cortese, R; Ciliberto, G; Savino, R			Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist	NATURE BIOTECHNOLOGY			English	Article						cytokine; receptor antagonist; autoimmunity; autoantibody	FACTOR-ALPHA CA2; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; MULTIPLE-MYELOMA; TRANSGENIC MICE; CELLS; EXPRESSION; BINDING; PURIFICATION; THERAPY	Neutralization of cytokine activity by monoclonal antibodies or receptor antagonists is beneficial in the treatment of immune and neoplastic diseases, but the necessity for continuous parenteral delivery of these anticytokine agents poses considerable practical limitations. A viable alternative is to induce a neutralizing antibody response, Using transgenic mice with high circulating levels of human interleukin-6 (hIL-6), we show that injection of the hIL-6 receptor antagonist Sant1 (an IL-6 variant with seven amino-acid substitutions) induces a strong anti-hIL-antibody response. The elicited antibodies bind circulating hIL-6 with very high affinity, totally masking it, and neutralize hIL-6 bioactivity both in vitro and in vivo.	IRBM P ANGELETTI,I-00040 POMEZIA,ROME,ITALY; UNIV COPENHAGEN HOSP,RIGSHOSP,INST INFLAMMAT RES,DK-2100 COPENHAGEN,DENMARK; UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT CLIN IMMUNOL,DK-2100 COPENHAGEN,DENMARK	Merck & Company; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen			Ciapponi, Laura/H-6867-2013; Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605; Savino, Rocco/0000-0002-4046-1472; CIAPPONI, LAURA/0000-0002-0817-1862				ALLEGRETTA M, 1986, J CLIN IMMUNOL, V6, P481, DOI 10.1007/BF00915254; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DEBETS R, 1994, IMMUNOL TODAY, V15, P455, DOI 10.1016/0167-5699(94)90187-2; DIAMANT M, 1994, J IMMUNOL METHODS, V173, P229, DOI 10.1016/0022-1759(94)90301-8; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; FATTORI E, 1994, BLOOD, V83, P2570; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; GREGORY B, 1994, J IMMUNOL METHODS, V170, P47, DOI 10.1016/0022-1759(94)90244-5; HANSEN MB, 1995, BLOOD, V85, P1145, DOI 10.1182/blood.V85.4.1145.bloodjournal8541145; HANSEN MB, 1993, CYTOKINE, V5, P72, DOI 10.1016/1043-4666(93)90026-2; HANSEN MB, 1991, SCAND J IMMUNOL, V33, P777, DOI 10.1111/j.1365-3083.1991.tb02552.x; HANSEN MB, 1995, LEUKEMIA, V9, P1113; HANSEN MB, 1995, EUR J IMMUNOL, V25, P348, DOI 10.1002/eji.1830250207; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; MONTEROJULIAN FA, 1995, BLOOD, V85, P917, DOI 10.1182/blood.V85.4.917.bloodjournal854917; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Poplonski L, 1996, EUR J IMMUNOL, V26, P601, DOI 10.1002/eji.1830260315; RONGHWA L, 1991, J EXP MED, V173, P1433; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; SUZUKI H, 1992, EUR J IMMUNOL, V22, P1989, DOI 10.1002/eji.1830220806; SVENSON M, 1993, J CLIN INVEST, V92, P2533, DOI 10.1172/JCI116862; TTRIPATHY SK, 1996, NAT MED, V2, P545; VALLBRACHT A, 1981, NATURE, V289, P496, DOI 10.1038/289496a0	35	35	36	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					997	1001		10.1038/nbt1097-997	http://dx.doi.org/10.1038/nbt1097-997			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335053				2022-12-25	WOS:A1997XZ28500032
J	Grimsby, J; Toth, M; Chen, K; Kumazawa, T; Klaidman, L; Adams, JD; Karoum, F; Gal, J; Shih, JC				Grimsby, J; Toth, M; Chen, K; Kumazawa, T; Klaidman, L; Adams, JD; Karoum, F; Gal, J; Shih, JC			Increased stress response and p-phenylethylamine in MAOB-deficient mice	NATURE GENETICS			English	Article							MONOAMINE-OXIDASE-A; NORRIE DISEASE; GENES; ASSOCIATION; INHIBITORS; SEROTONIN; BEHAVIOR; DOPAMINE; CLONING; PATIENT	MAOA and MAOB are key iso-enzymes that degrade biogenic and dietary amines(1-5). MAOA preferentially oxidizes serotonin (5-hydroxytryptamine, or 5-HT) and norepinephrine (NE), whereas MAOB preferentially oxidizes beta-phenylethylamine (PEA). Both forms can oxidize dopamine (DA). A mutation in MAOA results in a clinical phenotype characterized by borderline mental retardation and impaired impulse control(6,7). X-chromosomal deletions which include MAOB were found in patients suffering from atypical Norrie's disease(8,9), which is characterized by blindness and impaired hearing. Reduced MAOB activity has been found in type-II alcoholism and in cigarette smokers(10,11). Because most alcoholics smoke, the effects of alcohol on MAOB activity remain to be determined. Here we show that targetted inactivation of MAOB in mice increases levels of PEA but not those of 5-HT, NE and DA, demonstrating a primary role for MAOB in the metabolism of PEA. PEA has been implicated in modulating mood and affect(12,13). Indeed, MAOB-deficient mice showed an increased reactivity to stress. In addition, mutant mice were resistant to the neurodegenerative effects of MPTP, a toxin that induces a condition reminiscent of Parkinson's disease.	UNIV SO CALIF,SCH PHARM,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT CELL & NEUROBIOL,LOS ANGELES,CA 90033; CORNELL UNIV MED COLL,DEPT PHARMACOL,NEW YORK,NY 10021; NIMH,ST ELIZABETHS HOSP,DEPT PSYCHOL & PHARMACOL,WASHINGTON,DC 20032	University of Southern California; University of Southern California; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Toth, Miklos/O-3343-2017		NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039085, R01MH037020, K05MH000796] Funding Source: NIH RePORTER; NIMH NIH HHS [K05 MH00796, R37 MH39085, R01 MH37020] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS JD, 1989, BRAIN RES BULL, V23, P1, DOI 10.1016/0361-9230(89)90157-3; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BERRY MD, 1994, BRIT J PHARMACOL, V113, P1159, DOI 10.1111/j.1476-5381.1994.tb17119.x; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; BRUNNER HG, 1993, AM J HUM GENET, V52, P1032; Cases O, 1996, NEURON, V16, P297, DOI 10.1016/S0896-6273(00)80048-3; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Chen K, 1996, J NEUROCHEM, V66, P797; CHEN K, 1994, MOL PHARMACOL, V46, P1226; COLLINS FA, 1992, AM J MED GENET, V42, P127, DOI 10.1002/ajmg.1320420126; DEVOR EJ, 1993, AM J MED GENET, V48, P209, DOI 10.1002/ajmg.1320480407; DIUZEN D, 1992, NEUROPHARMACOLOGY, V31, P1223; Fowler JS, 1996, NATURE, V379, P733, DOI 10.1038/379733a0; FOZARD J R, 1984, British Journal of Pharmacology, V82, p309P; Gerlach M, 1996, NEUROLOGY, V47, pS137, DOI 10.1212/WNL.47.6_Suppl_3.137S; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; JUORIO AV, 1988, N-S ARCH PHARMACOL, V338, P644, DOI 10.1007/BF00165628; KUMAZAWA T, 1988, COMP BIOCHEM PHYS C, V91, P571; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; Lenders JWM, 1996, J CLIN INVEST, V97, P1010, DOI 10.1172/JCI118492; LINNOILA M, 1983, BIOL PSYCHIAT, V18, P513; MCFARLAND DJ, 1989, PHARMACOL BIOCHEM BE, V32, P723, DOI 10.1016/0091-3057(89)90024-5; PATERSON IA, 1990, J NEUROCHEM, V55, P1827, DOI 10.1111/j.1471-4159.1990.tb05764.x; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Potkin S G, 1980, Psychopharmacol Bull, V16, P52; SABELLI HC, 1986, J CLIN PSYCHIAT, V47, P66; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SAURA J, 1994, NEUROBIOL AGING, V15, P399, DOI 10.1016/0197-4580(94)90071-X; WU HF, 1993, MOL PHARMACOL, V43, P888	30	199	203	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					206	210		10.1038/ng1097-206	http://dx.doi.org/10.1038/ng1097-206			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326944				2022-12-25	WOS:A1997XZ55500030
J	Nolte, A; Klussmann, S; Bald, R; Erdmann, VA; Furste, JP				Nolte, A; Klussmann, S; Bald, R; Erdmann, VA; Furste, JP			Mirror-design of L-oligonucleotide ligands binding to L-arginine	NATURE BIOTECHNOLOGY			English	Article						in vitro selection; mirror-design; L-RNA; arginine	IN-VITRO SELECTION; CHEMICAL SYNTHESIS; GROWTH-FACTOR; RNA LIGANDS; DNA; EVOLUTION; INVITRO; ANALOGS; ENZYME	The high affinity and selectivity of nucleic acid ligands have clearly demonstrated that RNA can be targeted to a variety of molecules. In practice, however, the use of unmodified aptamers is impeded by the low stability of RNA in biological fluids, Here we describe the mirror-design of a stable 38-mer L-oligoribonucleotide ligand that binds to L-arginine. This L-RNA ligand was also able to bind to a short peptide containing the basic region of the human immunodeficiency virus type-1 Tat-protein, The L-RNA ligand displayed the expected stability in human serum, These findings may contribute to the identification of novel diagnostics and pharmaceuticals.	FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY	Free University of Berlin				Klussmann, Jens Peter/0000-0002-8223-7954				ABE Y, 1980, CHEM PHARM BULL, V28, P1324; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; Connors K. A., 1987, BINDING CONSTANTS; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; FLOCKERZI D, 1981, LIEBIGS ANN CHEM, P1568; GELGER A, 1996, NUCLEIC ACIDS RES, V24, P1029; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; Greenbaum NL, 1996, STRUCTURE, V4, P5, DOI 10.1016/S0969-2126(96)00003-2; HOLY A, 1972, COLLECT CZECH CHEM C, V37, P4072, DOI 10.1135/cccc19724072; HOLY A, 1973, COLLECT CZECH CHEM C, V38, P423, DOI 10.1135/cccc19730423; HOLY A, 1969, COLLECT CZECH CHEM C, V34, P3383, DOI 10.1135/cccc19693383; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229; MILECKI J, 1989, NUCLEOS NUCLEOT, V8, P463, DOI 10.1080/07328318908054189; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MUIR TW, 1995, STRUCTURE, V3, P649, DOI 10.1016/S0969-2126(01)00200-3; NIEUWLANDT D, 1995, BIOCHEMISTRY-US, V34, P5651, DOI 10.1021/bi00016a041; NOLTE A, 1995, FEBS LETT, V374, P292, DOI 10.1016/0014-5793(95)01136-3; PRUDENT JR, 1994, SCIENCE, V264, P1924; RECONDO EF, 1959, HELV CHIM ACTA, V42, P1171, DOI 10.1002/hlca.19590420409; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; TI GS, 1982, J AM CHEM SOC, V104, P1316, DOI 10.1021/ja00369a029; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VORBRUGGEN H, 1981, CHEM BER-RECL, V114, P1234, DOI 10.1002/cber.19811140404; WREDE P, 1978, J MOL BIOL, V120, P83, DOI 10.1016/0022-2836(78)90296-6; ZOU R, 1987, CAN J CHEM, V65, P1436, DOI 10.1139/v87-243; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	38	159	193	3	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1116	1119		10.1038/nbt0996-1116	http://dx.doi.org/10.1038/nbt0996-1116			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631062				2022-12-25	WOS:A1996VF84300033
J	IshizakiNishizawa, O; Fujii, T; Azuma, M; Sekiguchi, K; Murata, N; Ohtani, T; Toguri, T				IshizakiNishizawa, O; Fujii, T; Azuma, M; Sekiguchi, K; Murata, N; Ohtani, T; Toguri, T			Low-temperature resistance of higher plants is significantly enhanced by a nonspecific cyanobacterial desaturase	NATURE BIOTECHNOLOGY			English	Article						low-temperature resistance; transgenic plants; membrane lipids; Delta 9 desaturase; cyanobacteria	ACYL-LIPID DESATURASES; CHILLING SENSITIVITY; ANABAENA-VARIABILIS; FATTY-ACIDS; BIOSYNTHESIS; TOLERANCE; SAFFLOWER; TRANSPORT; PROTEIN; COLD	A broad-specificity Delta 9 desaturase gene was cloned from the cyanobacterium Anacystis nidulans. The enzyme introduces a cis-double bond at the Delta 9 position of both 16 and 18 carbon saturated fatty acids linked to many kinds of membrane lipids. The gene was stably introduced into tobacco plants under transcriptional control of the cauliflower mosaic virus 35S promoter, and the enzyme was targeted into plastids by the transit peptide of the pea RuBisCO small subunit, The transgenic plants had a highly reduced level of saturated fatty acid content in most membrane lipids and exhibited a significant increase in chilling resistance.	NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	IshizakiNishizawa, O (corresponding author), KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,1-13-5 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.		Murata, Norio/E-6569-2010; Murata, Norio/O-7945-2019	Murata, Norio/0000-0002-6605-5800				BISHOP DG, 1986, PLANT CELL PHYSIOL, V27, P1593; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWSE J, 1993, J BIOL CHEM, V268, P16345; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; KODAMA H, 1994, PLANT PHYSIOL, V105, P601, DOI 10.1104/pp.105.2.601; LEM NW, 1984, PLANT PHYSIOL, V74, P134, DOI 10.1104/pp.74.1.134; LYONS JM, 1973, ANNU REV PLANT PHYS, V24, P445, DOI 10.1146/annurev.pp.24.060173.002305; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; MURATA N, 1992, NATURE, V356, P710, DOI 10.1038/356710a0; MURATA N, 1995, BIOCHEM J, V308, P1; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; SAKAMOTO T, 1994, J BIOL CHEM, V269, P25576; SATO N, 1982, BIOCHIM BIOPHYS ACTA, V710, P279; SCHREIER PH, 1985, EMBO J, V4, P25, DOI 10.1002/j.1460-2075.1985.tb02312.x; Silvius J. R., 1982, LIPID PROTEIN INTERA; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SOMERVILLE C, 1995, P NATL ACAD SCI USA, V92, P6215, DOI 10.1073/pnas.92.14.6215; TASAKA Y, 1990, PLANT CELL PHYSIOL, V31, P545; WADA H, 1993, J BACTERIOL, V175, P6056, DOI 10.1128/JB.175.18.6056-6058.1993	20	116	136	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					1003	1006		10.1038/nbt0896-1003	http://dx.doi.org/10.1038/nbt0896-1003			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631040				2022-12-25	WOS:A1996UZ19900034
J	Levy, JP; Muldoon, RR; Zolotukhin, S; Link, CJ				Levy, JP; Muldoon, RR; Zolotukhin, S; Link, CJ			Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells	NATURE BIOTECHNOLOGY			English	Article						retrovirus; green fluorescent protein; gene transfer; vector producer cell		Over two-thirds of the current gene therapy protocols use retroviral gene transfer systems. We have developed an efficient retroviral-based method that allows rapid identification of gene transfer in living mammalian cells. Cells were generated containing a gene for an improved (humanized, red-shifted) version of the Aequorea victoria green fluorescent protein (hRGFP) from a retroviral vector. The hRGFP gene was used to produce an amphotropic vector producer cell line that demonstrated vibrant green fluorescence after excitation with blue light. A375 melanoma cells transduced with the retroviral vector demonstrated stable green fluorescence. Both PA317 murine fibroblasts and A375 human cell lines containing the vector were easily detected by FACS analysis. These vectors represent a substantial improvement over currently available gene transfer marking systems. Bright, long-term expression of the hRGFP gene in living eukaryotic cells will advance the study of gene transfer, gene expression, and gene product function in vitro and in vivo particularly for human gene therapy applications.	CENT IOWA HLTH SYST,HUMAN GENE THERAPY RES INST,MOLEC ONCOL LAB,DES MOINES,IA 50309; UNIV FLORIDA,CTR GENE THERAPY,GAINESVILLE,FL 32610	State University System of Florida; University of Florida								CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; DESCHAMPS JR, 1995, PROTEIN EXPRES PURIF, V6, P555, DOI 10.1006/prep.1995.1073; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; IKAWA M, 1995, DEV GROWTH DIFFER, V37, P455, DOI 10.1046/j.1440-169X.1995.t01-2-00012.x; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; PEROZZO MA, 1988, J BIOL CHEM, V263, P7713; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; SHIMOMURA O, 1979, FEBS LETT, V104, P220, DOI 10.1016/0014-5793(79)80818-2; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; ZOLOTUKHIN S, 1996, IN PRESS J VIROL	19	89	103	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					610	614		10.1038/nbt0596-610	http://dx.doi.org/10.1038/nbt0596-610			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630952				2022-12-25	WOS:A1996UL60400026
J	Evans, DM; Williams, KP; McGuinness, B; Tarr, G; Regnier, F; Afeyan, N; Jindal, S				Evans, DM; Williams, KP; McGuinness, B; Tarr, G; Regnier, F; Afeyan, N; Jindal, S			Affinity-based screening of combinatorial libraries using automated, serial-column chromatography	NATURE BIOTECHNOLOGY			English	Article						combinatorial libraries; screening; endotoxin; molecular diversity; beta-endorphin	IDENTIFICATION; PEPTIDES	We have developed an automated serial chromatographic technique for screening a library of compounds based upon their relative affinity for a target molecule. A ''target'' column containing the immobilized target molecule is set in tandem with a reversed-phase column. A combinatorial peptide library is injected onto the target column. The target-bound peptides are eluted from the first column and transferred automatically to the reversed-phase column. The target-specific peptide peaks from the reversed-phase column are identified and sequenced. Using a monoclonal antibody (3E-7) against beta-endorphin as a target, we selected a single peptide with sequence YGGFL from approximately 5800 peptides present in a combinatorial library. We demonstrated the applicability of the technology towards selection of peptides with predetermined affinity for bacterial lipopolysaccharide (LPS, endotoxin). We expect that this technology will have broad applications for high throughput screening of chemical libraries or natural product extracts.	PERSEPT BIOSYST, FRAMINGHAM, MA 01701 USA									AFEYAN NB, 1990, J CHROMATOGR, V519, P1, DOI 10.1016/0021-9673(90)85132-F; AFEYAN NB, 1991, LC GC-MAG SEP SCI, V9, P824; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; ECKER DJ, 1995, BIO-TECHNOL, V13, P351, DOI 10.1038/nbt0495-351; EVANS DM, 1995, ANAL BIOCHEM, V229, P42, DOI 10.1006/abio.1995.1376; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; GORDON M, 1994, J MED CHEM, V37, P1233; HOUGHTEN RA, 1992, PEPTIDE RES, V5, P351; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEBL M, 1995, BIOPOLYMERS, V37, P177, DOI 10.1002/bip.360370303; PINILLA C, 1995, BIOPOLYMERS, V37, P221, DOI 10.1002/bip.360370306; QUESNEL A, 1995, PEPTIDE RES, V8, P44; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; Scott Jamie K., 1994, Current Opinion in Biotechnology, V5, P40, DOI 10.1016/S0958-1669(05)80068-0; SEBESTYEN F, 1993, BIOORG MED CHEM LETT, V3, P413, DOI 10.1016/S0960-894X(01)80223-7; SOLE NA, 1992, J ORG CHEM, V57, P5399, DOI 10.1021/jo00046a022; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZUCKERMANN RN, 1992, P NATL ACAD SCI USA, V89, P4505, DOI 10.1073/pnas.89.10.4505	21	23	25	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					504	507		10.1038/nbt0496-504	http://dx.doi.org/10.1038/nbt0496-504			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630929				2022-12-25	WOS:A1996UL58800037
J	Dattani, MT; Martinez-Barbera, JP; Thomas, PQ; Brickman, JM; Gupta, R; Martensson, IL; Toresson, H; Fox, M; Wales, JKH; Hindmarsh, PC; Krauss, S; Beddington, RSP; Robinson, ICAF				Dattani, MT; Martinez-Barbera, JP; Thomas, PQ; Brickman, JM; Gupta, R; Martensson, IL; Toresson, H; Fox, M; Wales, JKH; Hindmarsh, PC; Krauss, S; Beddington, RSP; Robinson, ICAF			Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse	NATURE GENETICS			English	Article							ANTERIOR NEURAL PLATE; CRYSTAL-STRUCTURE; CORPUS-CALLOSUM; HOMEODOMAIN; TRANSCRIPTION; AGENESIS; EMBRYO; DNA; ORGANIZATION; EXPRESSION	During early mouse development the homeobox gene Hesx1 is expressed in prospective forebrain tissue, but later becomes restricted to Rathke's pouch, the primordium of the anterior pituitary gland. Mice lacking Hesx1 exhibit variable anterior CNS defects and pituitary dysplasia. Mutants have a reduced prosencephalon, anopthalmia or micropthalmia, defective olfactory development and bifurcations in Rathke's pouch. Neonates exhibit abnormalities in the corpus callosum, the anterior and hippocampal commissures, and the septum pellucidum. A comparable and equally variable phenotype in humans is septo-optic dysplasia (SOD). We have cloned human HESX1 and screened for mutations in affected individuals. Two siblings with SOD were homozygous for an Arg53Cys missense mutation within the HESX1 homeodomain which destroyed its ability to bind target DNA. These data suggest an important role for Hesx1/HESX1 in forebrain, midline and pituitary development in mouse and human.	Natl Inst Med Res, London NW7 1AA, England; Inst Child Hlth, London Ctr Paediat Endocrinol & Metab, London, England; Univ Lund, Dept Mol & Cell Biol, S-22100 Lund, Sweden; Wallenberg Neurosci Ctr, Neurobiol Unit, Lund, Sweden; MRC, Human Biochem Genet Unit, Galton Lab, London, England; Childrens Hosp, Sheffield S10 2TH, S Yorkshire, England; Univ Tromso, Dept Mol Genet, Inst Med Biol, N-9037 Breiviklia, Norway	MRC National Institute for Medical Research; University of London; University College London; Lund University; University of London; University College London; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; UiT The Arctic University of Tromso	Robinson, ICAF (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	irobins@nimr.mrc.ac.uk	Thomas, Paul Q/K-4497-2012; DATTANI, MEHUL/C-5401-2008; Hindmarsh, P C/C-4964-2008; Martinez-Barbera, Juan Pedro/AAE-9284-2020; Wales, Jerry/A-6797-2011	Martinez-Barbera, Juan Pedro/0000-0002-5292-7276; Wales, Jerry/0000-0002-8769-648X; Brickman, Joshua/0000-0003-1580-7491; Gupta, Rajeev/0000-0001-9573-0505; Krauss, Stefan/0000-0001-6992-8091; Martensson, Inga-Lill/0000-0003-3415-0560				ARSLANIAN SA, 1984, ACTA ENDOCRINOL-COP, V107, P282, DOI 10.1530/acta.0.1070282; Benassayag C, 1997, MECH DEVELOP, V63, P187, DOI 10.1016/S0925-4773(97)00040-3; BENNER JD, 1990, AM J OPHTHALMOL, V109, P632, DOI 10.1016/S0002-9394(14)72430-4; BLETHEN SL, 1985, AM J MED GENET, V21, P123, DOI 10.1002/ajmg.1320210118; BRNELLI S, 1996, NAURE GENET, V2, P94; BROOK CGD, 1972, BMJ-BRIT MED J, V3, P811, DOI 10.1136/bmj.3.5830.811; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DE MORSIER G, 1956, Schweiz Arch Neurol Psychiatr, V77, P267; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Gage PJ, 1996, MOL ENDOCRINOL, V10, P1570, DOI 10.1210/me.10.12.1570; GILLETT GT, 1993, GENOMICS, V15, P332, DOI 10.1006/geno.1993.1065; Hermesz E, 1996, DEVELOPMENT, V122, P41; HOYT WF, 1970, LANCET, V1, P893; IZENBERG N, 1984, CLIN PEDIATR, V23, P632, DOI 10.1177/000992288402301105; Kaufmann M. H., 1994, ATLAS MOUSE DEV; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LALWANI AK, 1995, AM J HUM GENET, V56, P75; LAM KSL, 1986, ACTA ENDOCRINOL-COP, V112, P305, DOI 10.1530/acta.0.1120305; Latinkic BV, 1997, GENE DEV, V11, P3265, DOI 10.1101/gad.11.23.3265; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee SMK, 1997, DEVELOPMENT, V124, P959; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; MASERA N, 1994, ARCH DIS CHILD, V70, P51, DOI 10.1136/adc.70.1.51; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; NARTA N, 1997, DEV BIOL, V189, P270; Oliver G, 1995, DEVELOPMENT, V121, P4045; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REEVES DL, 1941, J HOPKINS HOSPITAL B, V69, P61; Rhinn M, 1998, DEVELOPMENT, V125, P845; RMOIN DL, 1976, GROWTH PROBLEMS CLIN, P15; ROESSMANN U, 1989, J CLIN NEURO-OPHTHAL, V9, P156; ROESSMANN U, 1987, J NEUROPATH EXP NEUR, V46, P597, DOI 10.1097/00005072-198709000-00008; SAMBROOK J, 1989, MOL CLONINB LAB MANU; SAMOKHVALOV IM, 1994, DOKL AKAD NAUK, V334, P12; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; Shimamura K, 1997, DEVELOPMENT, V124, P2709; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Smith ST, 1996, DEVELOPMENT, V122, P3141; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; THOMAS P, IN PRESS S QUANTITAT, V62; THOMAS PQ, 1995, J BIOL CHEM, V270, P3869, DOI 10.1074/jbc.270.8.3869; VALENTINO KL, 1982, J NEUROCYTOL, V11, P583, DOI 10.1007/BF01262426; Varlet I, 1997, DEVELOPMENT, V124, P1033; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; Wales JKH, 1996, ACTA PAEDIATR, V85, P391, DOI 10.1111/j.1651-2227.1996.tb14044.x; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WEBB GC, 1993, GENOMICS, V18, P464, DOI 10.1006/geno.1993.1505; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147; YOUNG ID, 1985, CLIN GENET, V28, P225; Zaias B, 1978, Trans Am Neurol Assoc, V103, P273; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	58	513	530	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					125	133		10.1038/477	http://dx.doi.org/10.1038/477			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620767				2022-12-25	WOS:000073865100018
J	Mielcarek, N; Riveau, G; Remoue, F; Antoine, R; Capron, A; Locht, C				Mielcarek, N; Riveau, G; Remoue, F; Antoine, R; Capron, A; Locht, C			Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis	NATURE BIOTECHNOLOGY			English	Article						applied immunology; vaccine vector; mucosal administration	FILAMENTOUS HEMAGGLUTININ; CONTROLLED TRIAL; TOXIN; VACCINE; INFECTION; VIRULENT; SUBUNIT; ADHESIN; HEPARIN	While single-dose mucosal immunization is best achieved by the use of attenuated live microorganisms, attenuation generally results in decreased immunogenicity. We attenuated Bordetella pertussis by the deletion of the pertussis toxin gene. A single intranasal administration of this strain protected against subsequent challenge as well as did the parent strain and better than immunization with commercial vaccine. Unexpectedly, this attenuation resulted in increased immunogenicity against the protective antigen filamentous hemagglutinin (FHA). In addition, immunogenicity was also enhanced against the Schistosoma mansoni Sm28GST genetically fused to FHA, resulting in protection against the parasite, as characterized by a reduction in worm burden and egg charge, after a single intranasal administration. Thus, attenuated recombinant B. pertussis strains are promising vectors for the simultaneous protection against pertussis and heterologous diseases by a single intranasal administration.	Inst Pasteur, INSERM, U447, F-59019 Lille, France; Inst Pasteur, INSERM, U167, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Locht, C (corresponding author), Inst Pasteur, INSERM, U447, 1 Rue Prof Calmette, F-59019 Lille, France.	camille.locht@pasteur-lille.fr	Antoine, Rudy/L-1630-2018; Locht, Camille/L-3516-2018; Antoine, Rudy/CAH-6653-2022	Antoine, Rudy/0000-0002-7369-0626; Antoine, Rudy/0000-0002-7369-0626; Mielcarek, Nathalie/0000-0002-5968-9442				*AD HOC GROUP STUD, 1988, LANCET, V331, P1238; ANTOINE R, 1990, INFECT IMMUN, V58, P1518, DOI 10.1128/IAI.58.6.1518-1526.1990; BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; BLACK WJ, 1988, SCIENCE, V240, P656, DOI 10.1126/science.2896387; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Greenberg Louis, 1947, CANADIAN JOUR PUBL HEALTH, V38, P279; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; HIRABAYASHI Y, 1990, VACCINE, V8, P243, DOI 10.1016/0264-410X(90)90053-O; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; KHELEF N, 1994, INFECT IMMUN, V62, P2893, DOI 10.1128/IAI.62.7.2893-2900.1994; LAMBERT HJ, 1965, PUBLIC HEALTH REP, V80, P365, DOI 10.2307/4592424; LEHRER SB, 1975, J IMMUNOL, V114, P34; LOBET Y, 1993, J EXP MED, V177, P79, DOI 10.1084/jem.177.1.79; LOCHT C, 1993, MOL MICROBIOL, V9, P653, DOI 10.1111/j.1365-2958.1993.tb01725.x; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; MENOZZI FD, 1994, INFECT IMMUN, V62, P769, DOI 10.1128/IAI.62.3.769-778.1994; MENOZZI FD, 1991, FEMS MICROBIOL LETT, V78, P59; Mielcarek N, 1997, INFECT IMMUN, V65, P544, DOI 10.1128/IAI.65.2.544-550.1997; RenauldMongenie G, 1996, P NATL ACAD SCI USA, V93, P7944, DOI 10.1073/pnas.93.15.7944; Robinson K, 1997, NAT BIOTECHNOL, V15, P653, DOI 10.1038/nbt0797-653; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO Y, 1984, LANCET, V1, P122; SHAHIN RD, 1992, INFECT IMMUN, V60, P1482, DOI 10.1128/IAI.60.4.1482-1488.1992; Sweden Ad Hoc Group for the Study of Pertussis Vaccines, 1988, Lancet, Vi, P955; VOGEL FR, 1985, INFECT IMMUN, V49, P90, DOI 10.1128/IAI.49.1.90-97.1985; WARREN KS, 1982, IMMUNOL REV, V61, P189, DOI 10.1111/j.1600-065X.1982.tb00377.x; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; Wu HY, 1997, IMMUNOL RES, V16, P187, DOI 10.1007/BF02786362; [No title captured]	31	61	68	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					454	457		10.1038/nbt0598-454	http://dx.doi.org/10.1038/nbt0598-454			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592394				2022-12-25	WOS:000073489600030
J	Lee, H; Veazey, R; Williams, K; Li, M; Guo, J; Neipel, F; Fleckenstein, B; Lackner, A; Desrosiers, RC; Jung, JU				Lee, H; Veazey, R; Williams, K; Li, M; Guo, J; Neipel, F; Fleckenstein, B; Lackner, A; Desrosiers, RC; Jung, JU			Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus	NATURE MEDICINE			English	Article							OPEN READING FRAME; DNA-SEQUENCES; SAIMIRI; AIDS; IDENTIFICATION; DELETION; PROTEIN; VIRUS; KSHV	At a position equivalent to the gene encoding the saimiri transforming protein (STP) of herpesvirus saimiri (HVS), Kaposi's sarcoma-associated herpesvirus (KSHV) contains a distinct open reading frame called K1. Although KSHV and HVS are related members of the rhadinovirus subgroup of gamma herpesviruses, K1 and STP exhibit no similarity in amino acid sequence or in structural organization. Since STP is required for the oncogenic potential of HVS, we investigated the functional consequence of K1 expression. Expression of the K1 gene in rodent fibroblasts produced morphologic changes and focus formation indicative of transformation. A recombinant herpesvirus in which the STP oncogene of HVS was replaced with K1, immortalized primary T lymphocytes to IL-2 independent growth and induced lymphoma in common marmosets. These results demonstrate the transforming potential of the K1 gene of KSHV.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-8520 Erlangen, Germany	Harvard University; University of Erlangen Nuremberg	Jung, JU (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, 1 Pine Hill Dr, Southborough, MA 01772 USA.	jjung@warren.harvard.med.edu			NCI NIH HHS [CA31363] Funding Source: Medline; NCRR NIH HHS [RR07000] Funding Source: Medline; NIAID NIH HHS [AI38131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albini A, 1996, INT J ONCOL, V9, P5; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Desrosiers RC, 1997, J VIROL, V71, P9764, DOI 10.1128/JVI.71.12.9764-9769.1997; DESROSIERS RC, 1986, J VIROL, V57, P701, DOI 10.1128/JVI.57.2.701-705.1986; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; Duboise SM, 1996, P NATL ACAD SCI USA, V93, P11389, DOI 10.1073/pnas.93.21.11389; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; GANEM D, 1995, CURR BIOL, V5, P469, DOI 10.1016/S0960-9822(95)00093-5; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; GUO J, IN PRESS J VIROL; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KOOMEY JM, 1984, J VIROL, V50, P662, DOI 10.1128/JVI.50.2.662-665.1984; LANGUNOFF M, 1997, VIROLOGY, V236, P147; Lee H, 1997, J VIROL, V71, P3817, DOI 10.1128/JVI.71.5.3817-3825.1997; LI M, 1997, VIROLOGY, V71, P1984; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Marchioli CC, 1996, J CLIN MICROBIOL, V34, P2635, DOI 10.1128/JCM.34.10.2635-2638.1996; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; THORNE M, 1997, NATURE, V386, P517; WANG D, 1987, CELL, P831	39	223	237	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					435	440		10.1038/nm0498-435	http://dx.doi.org/10.1038/nm0498-435			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546789				2022-12-25	WOS:000072906800038
J	Poeschla, EM; Wong-Staal, F; Looney, DJ				Poeschla, EM; Wong-Staal, F; Looney, DJ			Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors	NATURE MEDICINE			English	Article							NUCLEOTIDE-SEQUENCE; GENE; INFECTION; ORGANIZATION; INVITRO; GENOME; LINES	The molecular bases for species barriers to lentiviral replication are not well understood, but are of interest for explaining lentiviral pathogenesis, devising therapeutic strategies, and adapting lentiviruses to gene therapy. HIV-l-based lentiviral vectors efficiently transduce nondividing cells', but present complex safety concerns(2). Nonprimate (ungulate or feline) lentiviruses might provide safer alternatives, but these viruses display highly restricted tropisms, and their potential for adaptation as replication-defective vectors capable of transducing human cells is unknown. Feline immunodeficiency virus (FIV) does not infect humans or other non-Felidae despite prevalent natural exposure. Although long terminal repeat (LTR)-directed FIV expression was found to be negligible in human cells, promoter substitution enabled an env-deleted, three-plasmid, human cell-FIV lentiviral vector system to express high levels of FIV proteins and FIV vectors in human cells, thus bypassing the hazards of feline vector producer cells. Pseudotyped FIV vectors efficiently transduced dividing, growth-arrested, and postmitotic human targets. The experiments delineate mechanisms involved in species-restricted replication of this lentivirus and show that human cells support both productive- and infective-phase mechanisms of the FIV life cycle needed for efficient lentiviral vector transduction. Nonprimate lentiviral vectors may offer safety advantages, and FIV vectors provide unique experimental opportunities.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, San Diego Vet Adm Med Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Poeschla, EM (corresponding author), Univ Calif San Diego, Dept Med, 0655, La Jolla, CA 92093 USA.	epoeschla@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, U19AI036612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001408] Funding Source: NIH RePORTER; NIAID NIH HHS [1U19 AI3661203, 2P30AI3621404] Funding Source: Medline; NIDDK NIH HHS [3K12-DK01408-10S1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Bachmann MH, 1997, J VIROL, V71, P4241, DOI 10.1128/JVI.71.6.4241-4253.1997; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; ELDER JH, 1993, INFECT AGENT DIS, V2, P361; Emerman M, 1996, NAT BIOTECHNOL, V14, P943, DOI 10.1038/nbt0896-943; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; MIYAZAWA T, 1992, J GEN VIROL, V73, P1543, DOI 10.1099/0022-1317-73-6-1543; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P8088, DOI 10.1073/pnas.86.20.8088; OLMSTED RA, 1992, J VIROL, V66, P6008, DOI 10.1128/JVI.66.10.6008-6018.1992; Pedersen N. C., 1993, The Retroviridae, volume 2., P181; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; REMINGTON KM, 1991, J VIROL, V65, P308, DOI 10.1128/JVI.65.1.308-312.1991; SPARGER EE, 1992, VIROLOGY, V187, P165, DOI 10.1016/0042-6822(92)90305-9; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; TOMONAGA K, 1994, J VET MED SCI, V56, P199, DOI 10.1292/jvms.56.199; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	19	349	372	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					354	357		10.1038/nm0398-354	http://dx.doi.org/10.1038/nm0398-354			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500613				2022-12-25	WOS:000073616200045
J	Perry, WL; Hustad, CM; Swing, DA; O'Sullivan, TN; Jenkins, NA; Copeland, NG				Perry, WL; Hustad, CM; Swing, DA; O'Sullivan, TN; Jenkins, NA; Copeland, NG			The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a(18H) mice	NATURE GENETICS			English	Article							MOTH-EATEN; RECEPTOR; MOUSE; GENE; POLYUBIQUITINATION; DEGRADATION; PATHOLOGY; MUTATIONS; PATHWAY; DOMAIN	Non-agouti-lethal 18H (a(18H)) mice are dark agouti with black pinna hairs. What makes these mice unique is that they develop a spectrum of immunological diseases not seen in other agouti mutant mice(1). On the JU/Ct background, a(18H) mice develop an inflammatory disease of the large intestine, On the C57BL/6J background, they develop a fatal disease characterized by pulmonary chronic interstitial inflammation and alveolar proteinosis, inflammation of the glandular stomach and skin resulting in scarring due to constant itching, and hyperplasia of lymphoid cells, haematopoietic cells and the forestomach epithelium. Previous studies suggested that the a(18H) mutation results from a paracentric inversion that affects two loci: agouti and another, as yet unidentified locus designated itchy (the provisional gene symbol is Itch), that is responsible for the immunological phenotype of a(18H) mice(1). Here we confirm that a(18H) results from an inversion and show that Itch encodes a novel E3 ubiquitin protein ligase, a protein involved in ubiquitin-mediated protein degradation. Our results indicate that ubiquitin-dependent proteolysis is an important mediator of the immune response in vivo and provide evidence for itch's role in inflammation and the regulation of epithelial and haematopoietic cell growth.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Mammalian Genet Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Copeland, NG (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Mammalian Genet Lab, Frederick, MD 21702 USA.	copeland@ncifcrf.gov						CATTANACH BM, 1987, MOUSE NEWS LETT, V77, P123; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; FERRY WL, 1995, GENETICS, V140, P267; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUSTAD CM, 1995, GENETICS, V140, P255; Jiao HY, 1997, EXP HEMATOL, V25, P592; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1993, J BIOL CHEM, V268, P577; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIDMAN CL, 1978, J IMMUNOL, V121, P2392; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VRIELING HD, 1994, P NATL ACAD SCI USA, V91, P170; WARD JM, 1978, VET PATHOL, V15, P170, DOI 10.1177/030098587801500203	25	268	278	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1998	18	2					143	146		10.1038/ng0298-143	http://dx.doi.org/10.1038/ng0298-143			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462742				2022-12-25	WOS:000071779500021
J	Kleeberger, SR; Levitt, RC; Zhang, LY; Longphre, M; Harkema, L; Jedlicka, A; Eleff, SM; DiSilvestre, D; Holroyd, KJ				Kleeberger, SR; Levitt, RC; Zhang, LY; Longphre, M; Harkema, L; Jedlicka, A; Eleff, SM; DiSilvestre, D; Holroyd, KJ			Linkage analysis of susceptibility to ozone-induced lung inflammation in inbred mice	NATURE GENETICS			English	Article							TUMOR-NECROSIS-FACTOR; TNF-ALPHA; AIRWAY INFLAMMATION; EXPOSURE; CYTOTOXICITY; RESPONSES; TRAITS; MOUSE; GENE	Exposures to the common air pollutant ozone (O-3) cause decrements in pulmonary function and induce airway inflammation that is characterized by infiltration of polymorphonuclear neutrophils (PMNs; refs 1-4). Because of the impact that O-3 may have on public health, it is critical to identify susceptibility factors. Highly reproducible, significant inter-individual variations in human pulmonary function responses to O-3 support the hypothesis that genetic background is an important determinant(5,6). Initial analysis of PMN responses to O-3 exposure in segregant populations derived from inflammation-prone (susceptible) C57BL/6J (B6) and inflammation-resistant C3H/HeJ (C3) inbred mice indicated that susceptibility was controlled by a locus we termed Inf2 (ref. 7). Subsequent analyses with recombinant inbred strains suggested that a more complex interaction of genes is involved(8). In this report, we identify a quantitative trait locus (QTL) for O-3 susceptibility on chromosome 17. Candidate genes for the locus include Tnf, the gene encoding the proinflammatory cytokine tumour necrosis factor-alpha (Tnf). Antibody neutralization of the protein product of this putative candidate gene significantly protected against O-3 injury in susceptible mice. These results strongly support linkage of O-3 susceptibility to a QTL on chromosome 17 and Tnf as a candidate gene.	JOHNS HOPKINS MED INST,DEPT ANESTHESIOL CRIT CARE MED,BALTIMORE,MD 21205; MAGAININ PHARMACEUT,MAGAININ INST MOL MED,PLYMOUTH,PA 19462; MICHIGAN STATE UNIV,COLL VET MED,DEPT PATHOL,E LANSING,MI 48824	Johns Hopkins University; Johns Hopkins Medicine; Michigan State University	Kleeberger, SR (corresponding author), JOHNS HOPKINS MED INST,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21205, USA.		Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452; Holroyd, Kenneth/0000-0001-6050-3935	NHLBI NIH HHS [HL-51697] Funding Source: Medline; NIEHS NIH HHS [ES-03819, ES-03505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, P01ES003505] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agostini C, 1996, AM J RESP CRIT CARE, V153, P1359, DOI 10.1164/ajrccm.153.4.8616567; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; *CAS W RES U DEP E, 1994, STAT AN GEN EP REL 2; Casale TB, 1996, AM J RESP CELL MOL, V15, P35, DOI 10.1165/ajrcmb.15.1.8679220; Claudio E, 1996, EXP CELL RES, V224, P63, DOI 10.1006/excr.1996.0111; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; DISILVESTRE D, 1995, MAMM GENOME, V6, P281, DOI 10.1007/BF00352417; ELSTON RC, 1984, GENETICS, V108, P733; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; KLEEBERGER SR, 1993, AM J PHYSIOL, V264, pL15, DOI 10.1152/ajplung.1993.264.1.L15; Kleeberger SR, 1995, TOXICOL LETT, V82-3, P295, DOI 10.1016/0378-4274(95)03564-8; KLEEBERGER SR, 1993, AM J PHYSIOL, V264, pL21, DOI 10.1152/ajplung.1993.264.1.L21; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LINCOLN S, 1992, MAPPING GENES CONTRO; Longphre M, 1996, J APPL PHYSIOL, V80, P1322, DOI 10.1152/jappl.1996.80.4.1322; LUKACS NW, 1995, J IMMUNOL, V154, P5411; MANLY KF, 1996, MAP MANAGER QT; MCDONNELL WF, 1985, AM REV RESPIR DIS, V131, P36; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; Silver L.M., 1995, MOUSE GENETICS CONCE; SMART SJ, 1994, AM J PHYSIOL, V266, pL238, DOI 10.1152/ajplung.1994.266.3.L238; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WEINMANN GG, 1995, AM J RESP CRIT CARE, V151, P33, DOI 10.1164/ajrccm.151.1.7812569	30	150	152	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					475	478		10.1038/ng1297-475	http://dx.doi.org/10.1038/ng1297-475			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398854				2022-12-25	WOS:A1997YJ92400033
J	Mayer, U; Saher, G; Fassler, R; Bornemann, A; Echtermeyer, F; vonderMark, H; Miosge, N; Poschl, E; vonderMark, K				Mayer, U; Saher, G; Fassler, R; Bornemann, A; Echtermeyer, F; vonderMark, H; Miosge, N; Poschl, E; vonderMark, K			Absence of integrin alpha 7 causes a novel form of muscular dystrophy	NATURE GENETICS			English	Article							SKELETAL-MUSCLE; EXTRACELLULAR-MATRIX; MYOTENDINOUS JUNCTION; CYTOPLASMIC DOMAINS; LAMININ; EXPRESSION; GENE; MYOBLASTS; BINDING; MOTILITY	Integrin alpha 7 beta 1 is a specific cellular receptor for the basement membrane protein laminin-l (refs 1,2), as well as for the laminin isoforms -2 and -4 (ref. 3). The alpha 7 subunit is expressed mainly in skeletal and cardiac muscle(4) and has been suggested to be involved in differentiation and migration processes during myogenesis(5,6). Three cytoplasmic and two extracellular splice variants that have been described are developmentally regulated and expressed in different sites in the muscle(7-9). In adult muscle, the alpha 7A and alpha 7B subunits are concentrated in myotendinous junctions(10) but can also be detected in neuromuscular junctions and along the sarcolemmal membrane(11). To study the potential involvement of alpha 7 integrin during myogenesis and its role in muscle integrity and function, we generated a null allele of the alpha 7 gene (Itga7) in the germline of mice by homologous recombination in embryonic stent(ES) cells. Surprisingly, mice homozygous for the mutation are viable and fertile, indicating that the alpha 7 beta 1 integrin is riot essential far myogenesis. However, histological analysis of skeletal muscle revealed typical symptoms of a progressive muscular dystrophy starting soon after birth, but with a distinct variability in different muscle types. The observed histopathological changes strongly indicate an impairment of function of the myotendinous junctions, These findings demonstrate that alpha 7 beta 1 integrin represents an indispensable linkage between the muscle fibre and the extracellular matrix that is independent of the dystrophin-dystroglycan complex-mediated interaction of: the cytoskeleton with the muscle basement membrane.	UNIV TUBINGEN,INST BRAIN RES,D-72076 TUBINGEN,GERMANY; UNIV ERLANGEN NURNBERG,INST EXPT MED,D-91054 ERLANGEN,GERMANY; UNIV GOTTINGEN,INST HISTOL,D-37075 GOTTINGEN,GERMANY	Eberhard Karls University of Tubingen; University of Erlangen Nuremberg; University of Gottingen	Mayer, U (corresponding author), MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY.		Saher, Gesine/AAH-1826-2021; Miosge, Nicolai/E-3244-2010	Saher, Gesine/0000-0003-3507-9604; Mayer, Ulrike/0000-0003-2328-0052				BAO ZZ, 1993, J CELL SCI, V106, P579; BRABANT MC, 1993, DEV BIOL, V157, P49, DOI 10.1006/dbio.1993.1111; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COLLO G, 1993, J BIOL CHEM, V268, P19019; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KARNOVSKY M, 1965, ACTA HISTOCHEM, V88, P25; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LAW DJ, 1993, AM J PATHOL, V142, P1513; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; Settles DL, 1996, MUSCLE NERVE, V19, P147, DOI 10.1002/(SICI)1097-4598(199602)19:2<147::AID-MUS4>3.0.CO;2-E; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Talts JF, 1997, INT J DEV BIOL, V41, P39; TIDBALL JG, 1994, DEV BIOL, V163, P447, DOI 10.1006/dbio.1994.1161; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598; Ziober BL, 1996, J BIOL CHEM, V271, P22915, DOI 10.1074/jbc.271.37.22915; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773	30	357	369	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					318	323		10.1038/ng1197-318	http://dx.doi.org/10.1038/ng1197-318			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354797				2022-12-25	WOS:A1997YD66700027
J	Perez, GI; Knudson, CM; Leykin, L; Korsmeyer, SJ; Tilly, JL				Perez, GI; Knudson, CM; Leykin, L; Korsmeyer, SJ; Tilly, JL			Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction	NATURE MEDICINE			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; GRANULOSA-CELLS; PRIMORDIAL FOLLICLES; ICE/CED-3 PROTEASE; P53 PROTEIN; RAT OVARY; IN-VIVO; DEATH; BCL-2; EXPRESSION	Female sterility resulting from oocyte destruction is an unfortunate, and in many cases inevitable, consequence of chemotherapy. We show that unfertilized mouse oocytes exposed to therapeutic levels of the antitumor drug, doxorubicin (DXR), undergo apoptosis; however, fertilized oocytes do not initiate apoptosis, but enter cell-cycle arrest, when treated with DXR. Apoptosis induced by DXR in oocytes is blocked by sphingosine-1-phosphate, an inhibitor of ceramide-promoted cell death. Oocytes from Bax-deficient, but not p53-null, female mice display complete resistance to DXR-induced apoptosis in vivo and in vitro. Pretreatment of oocytes with a specific peptide inhibitor of caspases also abrogates the apoptotic response to DXR. These findings indicate that oocyte destruction caused by chemotherapy can be prevented by manipulation of apoptosis-associated signaling pathways.	MASSACHUSETTS GEN HOSP,VINCENT CTR REPROD BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT OBSTET & GYNECOL,BOSTON,MA 02114; WASHINGTON UNIV,SCH MED,DEPT MED,DIV MOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV MOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)			Perez, Gloria I/GMX-1286-2022	Knudson, Charles Michael/0000-0003-3964-5466	NCI NIH HHS [R01-CA49712] Funding Source: Medline; NIA NIH HHS [R01-AG12279] Funding Source: Medline; NICHD NIH HHS [R01-HD34226] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERTS DS, 1971, CLIN PHARMACOL THER, V12, P96; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FAMILIARI G, 1993, HUM REPROD, V8, P2080, DOI 10.1093/oxfordjournals.humrep.a137985; FLAWS JA, 1995, ENDOCRINOLOGY, V136, P5042, DOI 10.1210/en.136.11.5042; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KALPIA A, 1996, ENDOCRINOLOGY, V137, P4864; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUGU K, IN PRESS CELL DEATH; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARAVEI DV, IN PRESS CELL DEATH; Martimbeau S, 1997, CLIN ENDOCRINOL, V46, P241, DOI 10.1046/j.1365-2265.1997.00157.x; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REICHMAN BS, 1994, MONOGR NATL CANC I, V16, P125; RIED HL, 1994, SEMIN ROENTGENOL, V29, P6, DOI 10.1016/S0037-198X(05)80068-9; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; Tilly J. L., 1996, CONTEMP OBSTET GYNEC, V41, P59; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Tilly JL, 1997, CELL DEATH DIFFER, V4, P180, DOI 10.1038/sj.cdd.4400238; TILLY KI, 1995, ENDOCRINOLOGY, V136, P1394, DOI 10.1210/en.136.4.1394; TUCKER MJ, 1995, CURR OPIN OBSTET GYN, V7, P188, DOI 10.1097/00001703-199506000-00006; WANG E, 1991, J BIOL CHEM, V266, P14486; WAXMAN J, 1983, J ROY SOC MED, V76, P144, DOI 10.1177/014107688307600212; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	48	280	298	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1228	1232		10.1038/nm1197-1228	http://dx.doi.org/10.1038/nm1197-1228			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359697				2022-12-25	WOS:A1997YD89600031
J	Wrighton, NC; Balasubramanian, P; Barbone, FP; Kashyap, AK; Farrell, FX; Jolliffe, LK; Barrett, RW; Dower, WJ				Wrighton, NC; Balasubramanian, P; Barbone, FP; Kashyap, AK; Farrell, FX; Jolliffe, LK; Barrett, RW; Dower, WJ			Increased potency of an erythropoietin peptide mimetic through covalent dimerization	NATURE BIOTECHNOLOGY			English	Article						protein engineering; rational design	CELL-SURFACE RECEPTORS; HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; PROTEIN HORMONE; EXPRESSION; ACTIVATION; CLONING; LIBRARY; LIGANDS; COMPLEX	We have synthesized a chemically defined, dimeric form of an erythropoietin mimetic peptide (EMP) that displays 100-fold increased affinity far the erythropoietin receptor (EPOR) and correspondingly elevated potency in cell-based assays and in mice. The dimeric EMP1 was synthesized using a C-terminal lysine residue as a branch point. A beta-alanine residue was coupled to the main-chain (alpha) amino group of the lysine residue in order to provide a pseudosymmetrical scaffold where both the side-chain and main-chain were of approximately equal length. Using an orthogonal protection system, independently disulphide-cylized EMP1 moieties were synthesized upon this scaffold. The proposed mechanism of increased potency of the dimer over the parental compound EMP1 is consistent with the structure of a cocrystal of EMP1 and the extracellular domain of the EPOR in which a noncovalent peptide dimer is seen spanning the cleft between two molecules of the EPOR extracellular domain.	Affymax Res Inst, Palo Alto, CA 94304 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Johnson & Johnson; Johnson & Johnson USA	Wrighton, NC (corresponding author), Affymax Res Inst, 4001 Miranda Ave, Palo Alto, CA 94304 USA.	nick@wrighton.com						CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; COTES PM, 1961, NATURE, V191, P1065, DOI 10.1038/1911065a0; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JONES SS, 1990, BLOOD, V76, P31; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KRANTZ SB, 1991, BLOOD, V77, P419; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WEICH NS, 1993, EXP HEMATOL, V21, P647; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	21	105	135	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1261	1265		10.1038/nbt1197-1261	http://dx.doi.org/10.1038/nbt1197-1261			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359108				2022-12-25	WOS:000071342000027
J	Bandara, LR; Girling, R; LaThangue, NB				Bandara, LR; Girling, R; LaThangue, NB			Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor	NATURE BIOTECHNOLOGY			English	Article						E2F antagonist; peptide therapeutics; tumor suppressor; apoptosis	RETINOBLASTOMA GENE-PRODUCT; PRB PHOSPHORYLATION; CYCLE PROGRESSION; DIRECT BINDING; S-PHASE; PROTEIN; INHIBITION; FAMILY; MICE; TRANSACTIVATION	A variety of studies implicate the E2F transcription factor as a critical regulator of the mammalian cell cycle. The E2F pathway is aberrant in most, if not all, human tumor cells; therefore, therapeutic regimes that modulate E2F activity may provide an approach for reinstating growth control in situations where normal physiological control is lost. To elucidate the role of E2F in the cell cycle and assess its value as a therapeutic target, we have introduced peptides that functionally antagonize E2F DNA binding activity into mammalian cells. Introduction of these peptides into mammalian tumor cells caused the rapid onset of apoptosis, an outcome that correlates with the inactivation of physiological E2F.	PROLIFIX LTD,LONDON NW7 1AD,ENGLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; NATL INST MED RES,MRC,EUKARYOT MOL GENET LAB,LONDON NW7 1AA,ENGLAND	University of Glasgow; MRC National Institute for Medical Research								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JACKS T, 1992, NATURE, V359, P395; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU FH, 1995, J CELL SCI, V108, P2945; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	37	36	39	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					896	901		10.1038/nbt0997-896	http://dx.doi.org/10.1038/nbt0997-896			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306407				2022-12-25	WOS:A1997XW41000034
J	Taylor, NJ; Edwards, M; Kiernan, RJ; Davey, CDM; Blakesley, D; Henshaw, GG				Taylor, NJ; Edwards, M; Kiernan, RJ; Davey, CDM; Blakesley, D; Henshaw, GG			Development of friable embryogenic callus and embryogenic suspension culture systems in cassava (Manihot esculenta Crantz)	NATURE BIOTECHNOLOGY			English	Article						somatic embryogenesis; genetic transformation	CARROT DAUCUS-CAROTA; SOMATIC EMBRYOGENESIS; PLANT-REGENERATION; ESTABLISHMENT	Procedures for the production of a new and highly prolific embryogenic culture system have been developed in cassava, The importance of the basal salts and type of auxin in controlling the development of cassava embryogenic tissues has been demonstrated, with culture: on Gresshoff and Doy basal medium in the presence of 4-amino-3,5,6,trichloro-picolinic acid (picloram) inducing the formation of friable embryogenic callus from which highly totipotent embryogenic suspension cultures could be established, Plants have been regenerated from these cultures. The availability of embryogenic suspension cultures is considered to have important implications for the application of genetic transformation and other biotechnologies in the agronomic improvement of cassava.	YORK UNIV, DEPT BIOL, YORK YO1 5YW, N YORKSHIRE, ENGLAND	University of York - UK	Taylor, NJ (corresponding author), UNIV BATH, SCH BIOL & BIOCHEM, BATH BA2 7AY, SOMERSET, ENGLAND.		Taylor, Nigel/M-2851-2013					ANTHONY P, 1995, PLANT CELL TISS ORG, V42, P299, DOI 10.1007/BF00030004; ARMSTRONG CL, 1985, PLANTA, V164, P207, DOI 10.1007/BF00396083; CHRISTOU P, 1992, PLANT J, V2, P275, DOI 10.1111/j.1365-313X.1992.00275.x; CHU CC, 1975, SCI SINICA, V18, P659; FAUQUET M, 1993, P 1 INT SCI M CASS B, P493; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GRESSHOFF PM, 1974, Z PFLANZENPHYSIOL, V73, P132, DOI 10.1016/S0044-328X(74)80084-X; HUNOLD R, 1994, PLANT J, V5, P593, DOI 10.1046/j.1365-313X.1994.5040593.x; LLOYD G, 1981, INT PROP SOC P, V30, P593; LYNAM JH, 1993, P 1 INT SCI M CASS B, P22; MATHEWS H, 1993, PLANT CELL REP, V12, P328, DOI 10.1007/BF00237429; MCWILLIAM AA, 1974, ANN BOT-LONDON, V38, P243, DOI 10.1093/oxfordjournals.aob.a084808; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NITSCH JP, 1969, SCIENCE, V163, P85, DOI 10.1126/science.163.3862.85; NOVAK FJ, 1989, BIO-TECHNOL, V7, P154, DOI 10.1038/nbt0289-154; RAEMAKERS CJJM, 1993, ANN BOT-LONDON, V71, P289, DOI 10.1006/anbo.1993.1037; SCHENK RU, 1972, CAN J BOTANY, V50, P199, DOI 10.1139/b72-026; SCHOPKE C, 1996, NAT BIOTECHNOL, V14, pR30; SCHOPKE C, 1993, BIOTECHNOLOGY AGR FO, V23, P273; SMITH SM, 1974, ANN BOT-LONDON, V38, P223, DOI 10.1093/oxfordjournals.aob.a084807; STAMP JA, 1982, Z PFLANZENPHYSIOL, V105, P183, DOI 10.1016/S0044-328X(82)80011-1; STAMP JA, 1987, PLANT CELL TISS ORG, V10, P227, DOI 10.1007/BF00037307; STAMP JA, 1987, ANN BOTANY, V59, P45; SZABADOS L, 1987, PLANT CELL REP, V6, P248, DOI 10.1007/BF00268492; TAYLOR NJ, 1993, P 1 INT SCI M CASS B, P134; VASIL IK, 1992, PHYSIOL PLANTARUM, V85, P279, DOI [10.1111/j.1399-3054.1992.tb04734.x, 10.1034/j.1399-3054.1992.850220.x]; Vasil IK, 1995, CURR PLANT SCI BIOT, V22, P5; WIDHOLM JM, 1972, STAIN TECHNOL, V47, P189, DOI 10.3109/10520297209116483	28	74	84	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					726	730		10.1038/nbt0696-726	http://dx.doi.org/10.1038/nbt0696-726			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630979				2022-12-25	WOS:A1996UM76600027
J	Mandal, C; Kingery, BD; Anchin, JM; Subramaniam, S; Linthicum, DS				Mandal, C; Kingery, BD; Anchin, JM; Subramaniam, S; Linthicum, DS			ABGEN: A knowledge-based automated approach for antibody structure modeling	NATURE BIOTECHNOLOGY			English	Article						antibody; antigen; molecular models; computers	COMBINING SITES; HYPERVARIABLE REGIONS; MONOCLONAL-ANTIBODIES; SEARCH; IMMUNOGLOBULINS; SPECIFICITY; ALGORITHM; SEQUENCE; LOOPS	Immunoglobulin (Ig) amino acid sequences are highly conserved and often have sequence homology ranging from 70 to 95%. Antigen binding fragments (Fab), variable region fragments (Fv), and single chain Fv (scFv) of more than 50 myeloma proteins and monoclonal antibodies (mAb) have been crystallized and display a high degree of structural similarity. Based on this observation, several homology modeling approaches have been developed for the prediction of Fab and Fv structures prior to their experimental determination. We have extracted features from existing Ig sequences, 44 known Fab and Fv structures to create an automated AntiBody structure GENeration (ABGEN) algorithm for obtaining structural models of antibody fragments. ABGEN utilizes a homology based scaffolding technique, and includes the use of invariant and strictly conserved residues, structural motifs of known Fab, canonical features of hypervariable loops, torsional constraints for residue replacements and key inter-residue interactions. The validity of the ABGEN algorithm has been tested using a five-fold cross validation with the existing Fab structures. Molecular mechanics and dynamics methods have been implemented with ABGEN models to accurately predict two Fab structures of anti-sweetener antibodies prior to crystallographic determinations.	TEXAS A&M UNIV,DEPT VET PATHOBIOL,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT COMP SCI,COLLEGE STN,TX 77843; UNIV ILLINOIS,BECKMAN INST,CTR BIOPHYS & COMPUTAT BIOL,URBANA,IL 61801	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Illinois System; University of Illinois Urbana-Champaign					NIGMS NIH HHS [GM46535] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046535] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANCHIN JM, 1993, MOL IMMUNOL, V30, P1463, DOI 10.1016/0161-5890(93)90108-N; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; KABAT EA, 1977, J BIOL CHEM, V252, P6609; KABAT EA, 1991, US DEP HHS NIH PUBLI; KINGERY BD, 1996, SOFTWARE J, V12, P20; MARTIN ACR, 1989, P NATL ACAD SCI USA, V86, P9268, DOI 10.1073/pnas.86.23.9268; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PURVIS GD, 1986, J MOL GRAPHICS, V4, P88, DOI 10.1016/0263-7855(86)80003-0; REES AR, 1986, TRENDS BIOCHEM SCI, V11, P144, DOI 10.1016/0968-0004(86)90070-8; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; THORNTON JM, 1991, CIBA F SYMP, V159, P55; VISWANATHAN M, 1995, BIOPHYS J, V69, P741, DOI 10.1016/S0006-3495(95)79950-7	20	39	43	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					323	328		10.1038/nbt0396-323	http://dx.doi.org/10.1038/nbt0396-323			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630894				2022-12-25	WOS:A1996UL38000026
J	Kato, M; Wang, HM; Kainulainen, V; Fitzgerald, ML; Ledbetter, S; Ornitz, DM; Bernfield, M				Kato, M; Wang, HM; Kainulainen, V; Fitzgerald, ML; Ledbetter, S; Ornitz, DM; Bernfield, M			Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; SURFACE PROTEOGLYCAN; ENDOTHELIAL-CELLS; RECEPTOR; BINDING; LOCALIZATION; MITOGENESIS	The activity of fibroblast growth factor 2 (FGF-2) is stringently controlled. Inactive in undisturbed tissues, it is activated during injury and is critical for tissue repair. We find that this control can be imposed by the soluble syndecan-1 ectodomain, a heparan sulfate proteoglycan shed from cell surfaces into wound fluids. The ectodomain potently inhibits heparin-mediated FGF-2 mitogenicity because of the poorly sulfated domains in its heparin sulfate chains. Degradation of these regions by platelet heparanase produces heparin-like heparin sulfate fragments that markedly activate FCF-2 mitogenicity and are found in wound fluids. These results establish a novel physiological control for FGF-2 and suggest new ways to modulate FGF activity.	Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Genzyme Corp, Framingham, MA 01710 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation; Washington University (WUSTL)	Bernfield, M (corresponding author), Harvard Univ, Sch Med, Dept Pediat, 300 Longwood Ave, Boston, MA 02115 USA.	bernfield@a1.tch.harvard.edu		Ornitz, David/0000-0003-1592-7629	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046491] Funding Source: NIH RePORTER; NCI NIH HHS [CA28735] Funding Source: Medline; NHLBI NIH HHS [HL46491] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; FRIZE LMS, 1985, J CELL BIOL, V100, P1041; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HUMPHRIES DE, 1992, ADV EXP MED BIOL, V313, P59; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P1881; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KODA JE, 1985, J BIOL CHEM, V260, P8157; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MALI M, 1994, J BIOL CHEM, V269, P27795; MASCATELLI D, 1992, J BIOL CHEM, V267, P25803; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; WALKER A, 1994, J BIOL CHEM, V269, P931; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; Wang HM, 1998, BIOCHEM BIOPH RES CO, V242, P248, DOI 10.1006/bbrc.1997.7864; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	49	285	293	3	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					691	697		10.1038/nm0698-691	http://dx.doi.org/10.1038/nm0698-691			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623978				2022-12-25	WOS:000074008300035
J	Lorson, CL; Strasswimmer, J; Yao, JM; Baleja, JD; Hahnen, E; Wirth, B; Le, T; Burghes, AHM; Androphy, EJ				Lorson, CL; Strasswimmer, J; Yao, JM; Baleja, JD; Hahnen, E; Wirth, B; Le, T; Burghes, AHM; Androphy, EJ			SMN oligomerization defect correlates with spinal muscular atrophy severity	NATURE GENETICS			English	Article							MOTOR-NEURON GENE; MOLECULAR ANALYSIS; DELETIONS; PHENOTYPE; 5Q13	Spinal muscular atrophy (SMA) is a motor-neuron disorder resulting from anterior-horn-cell death. The autosomal recessive form has a carrier frequency of 1 in 50 and is the most common genetic cause of infant death. SMA is categorized as types I-III, ranging from severe to mild, based upon age of onset and clinical course. Two closely flanking copies of the survival motor neuron (SMN) gene are on chromosome 5913 (ref. 1). The telomeric SMN (SMN1) copy is homozygously deleted or converted in >95% of SMA patients, while a small number of SMA disease alleles contain missense mutations within the carboxy terminus. We have identified a modular oligomerization domain within exon 6 of SMN1. All previously identified missense mutations map within or immediately adjacent to this domain. Comparison of wild-type to mutant SMN proteins of type I, II and III SMA patients showed a direct correlation between oligomerization and clinical type. Moreover, the most abundant centromeric SMN product, which encodes exons 1-6 but not 7, demonstrated reduced self-association. These findings identify decreased SMN self-association as a biochemical defect in SMA, and imply that disease severity is proportional to the intracellular concentration of oligomerization-competent SMN proteins.	New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany; Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University; University of Bonn; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Androphy, EJ (corresponding author), New England Med Ctr, Dept Dermatol, 750 Washington St, Boston, MA 02111 USA.		Wirth, Brunhilde/H-3192-2019	Burghes, Arthur/0000-0001-9031-1555; Androphy, Elliot/0000-0002-8104-0703; Wirth, Brunhilde/0000-0003-4051-5191; strasswimmer, john/0000-0002-5790-2633				Brahe C, 1996, HUM MOL GENET, V5, P1971, DOI 10.1093/hmg/5.12.1971; Breiding DE, 1996, VIROLOGY, V221, P34, DOI 10.1006/viro.1996.0350; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; BUSSAGLIA E, 1995, NAT GENET, V11, P355; Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DiDonato CJ, 1997, ANN NEUROL, V41, P230, DOI 10.1002/ana.410410214; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; Hahnen E, 1997, HUM MOL GENET, V6, P821, DOI 10.1093/hmg/6.5.821; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; vanderSteege G, 1996, AM J HUM GENET, V59, P834; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257	25	396	407	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					63	66		10.1038/ng0598-63	http://dx.doi.org/10.1038/ng0598-63			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590291				2022-12-25	WOS:000073346700019
J	Strand, S; Hofmann, WJ; Grambihler, A; Hug, H; Volkmann, M; Otto, G; Wesch, H; Mariani, SM; Hack, V; Stremmel, W; Krammer, PH; Galle, PR				Strand, S; Hofmann, WJ; Grambihler, A; Hug, H; Volkmann, M; Otto, G; Wesch, H; Mariani, SM; Hack, V; Stremmel, W; Krammer, PH; Galle, PR			Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; INDIAN CHILDHOOD CIRRHOSIS; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; COPPER; FAS; INDUCTION; LIGAND; EXPRESSION	Wilson's disease can result in fulminant liver failure due to hepatic copper overload. The CD95 system mediates apoptosis and has been demonstrated to be involved in liver disease. In this study CD95 mediated apoptosis was investigated in patients with fulminant hepatic failure in the course of Wilson's disease and in an in vitro model of copper treated human hepatoma cells. In patients, hepatic expression of CD95 and CD95L mRNA and apoptosis were detected. Copper overload in vitro resulted in hepatocytic apoptosis which could be reduced with a neutralizing anti-CD95L antibody. Copper treatment of hepatocytes results in activation of the CD95 system and induction of apoptosis which is operative during the course of hepatic failure in acute Wilson's disease.	Univ Heidelberg Hosp, Dept Gastroenterol, D-69115 Heidelberg, Germany; Inst Pathol, D-69120 Heidelberg, Germany; ZMBH, Ctr Mol Biol, D-69120 Heidelberg, Germany; Dept Surg, D-69120 Heidelberg, Germany; German Canc Res Ctr, Tumorimmunol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Radiol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Immunochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Galle, PR (corresponding author), Univ Heidelberg Hosp, Dept Gastroenterol, Bergheimerstr 58, D-69115 Heidelberg, Germany.	peter_galle@ukl.uni-heidelberg.de	Galle, Peter R/T-5292-2018	Galle, Peter R/0000-0001-8294-0992; Stremmel, Wolfgang/0000-0002-8545-1753				AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BENEDETTI A, 1988, J HEPATOL, V7, P319, DOI 10.1016/S0168-8278(88)80004-7; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Danks DM, 1995, MOL METABOLIC BASIS, P4125; DHEIN J, 1992, J IMMUNOL, V149, P3166; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; Hochstein P, 1980, Ann N Y Acad Sci, V355, P240, DOI 10.1111/j.1749-6632.1980.tb21342.x; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LAU SJ, 1974, J BIOL CHEM, V249, P5878; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; LEITHAUSER F, 1993, LAB INVEST, V69, P415; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OGRADY JG, 1993, DIS LIVER, P1078; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; PIMENTEL JC, 1975, AM REV RESPIR DIS, V111, P189; POPPER H, 1979, LANCET, V1, P1205; Ray SD, 1996, J PHARMACOL EXP THER, V279, P1470; Scheinberg I. H., 1984, MAJOR PROBLEMS INTER, P1; SELLINS KS, 1987, J IMMUNOL, V139, P3199; STERNLIEB I, 1980, GASTROENTEROLOGY, V78, P1615; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STREMMEL W, 1991, ANN INTERN MED, V115, P720, DOI 10.7326/0003-4819-115-9-720; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vierling J M, 1981, Semin Liver Dis, V1, P293, DOI 10.1055/s-2008-1040733; VOLKMANN M, 1994, ONCOGENE, V9, P195; WESCH H, 1974, NBS SPECIAL PUBLICAT, V422; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	42	209	214	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					588	593		10.1038/nm0598-588	http://dx.doi.org/10.1038/nm0598-588			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585233				2022-12-25	WOS:000073399900031
J	Morrison, C; Smith, GCM; Stingl, L; Jackson, SP; Wagner, EF; Wang, ZQ				Morrison, C; Smith, GCM; Stingl, L; Jackson, SP; Wagner, EF; Wang, ZQ			Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis	NATURE GENETICS			English	Article							DEPENDENT PROTEIN-KINASE; COMBINED IMMUNE-DEFICIENCY; STRAND BREAK REPAIR; SCID MUTATION; POLY(ADP-RIBOSE) POLYMERASE; MICE; REARRANGEMENT; DIFFERENTIATION; THYMOCYTES; RADIATION	Poly(ADP-ribose) polymerase (PARP) and DNA-dependent protein kinase (DNA-PK) are DNA break-activated molecules(1,2). Although mice that lack PARP display no gross phenotype and normal DNA excision repair(3), they exhibit high levels of sister chromatid exchange(4), indicative of elevated recombination rates. Mutation of the gene for DNA-PK catalytic subunit (Prkdc) causes defective antigen receptor V(D)J recombination and arrests B-and T-lymphocyte development in severe combined immune-deficiency (SCID) mice(5,6). SCID V(D)J recombination can be partly rescued in T-lymphocytes by either DNA-damaging agents (gamma-irradiation and bleomycin)(7,8) or a null mutation of the p53 gene(9-10), possibly because of transiently elevated DNA repair activity in response to DNA damage or to delayed apoptosis in the absence of p53. To determine whether the increased chromosomal recombination observed in PARP-deficient cells affects SCID V(D)J recombination, we generated mice lacking both PARP and DNA-PK. Here, we show that thymocytes of SCID mice express both CD4 and CD8 co-receptors, bypassing the SCID block. Double-mutant T-cells in the periphery express TCR beta, which is attributable to productive TCR beta joints. Double-mutant mice develop a high frequency of T-cell lymphoma. These results demonstrate that increased recombination activity after the loss of PARP anti-recombinogenic function can rescue V(D)J recombination in SCID mice and indicate that PARP and DNA-PK cooperate to minimize genomic damage caused by DNA strand breaks.	RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; UNIV CAMBRIDGE,WELLCOME TRUST CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; INT AGCY RES CANC,F-69008 LYON,FRANCE	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Cambridge; University of Cambridge; World Health Organization; International Agency for Research on Cancer (IARC)			Morrison, Ciaran/B-6568-2008; Jackson, Stephen Philip/R-4548-2019; Morrison, Ciaran/AAH-2034-2019; Dry, Kate/I-2328-2014	Morrison, Ciaran/0000-0003-2401-7029; Jackson, Stephen Philip/0000-0001-9317-7937; Morrison, Ciaran/0000-0003-2401-7029; Wagner, Erwin F/0000-0001-7872-0196	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CARROLL AM, 1989, J IMMUNOL, V143, P1087; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Levelt CN, 1995, IMMUNITY, V3, P667, DOI 10.1016/1074-7613(95)90056-X; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Livak F, 1996, J EXP MED, V184, P419, DOI 10.1084/jem.184.2.419; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHALL S, 1995, BIOCHIMIE, V77, P313, DOI 10.1016/0300-9084(96)88140-5; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; ZUNIGAPFLUCKER JC, 1994, J EXP MED, V180, P1517, DOI 10.1084/jem.180.4.1517	28	156	167	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					479	482		10.1038/ng1297-479	http://dx.doi.org/10.1038/ng1297-479			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398855				2022-12-25	WOS:A1997YJ92400034
J	Jay, P; Rougeulle, C; Massacrier, A; Moncla, A; Mattei, MG; Malzac, P; Roeckel, N; Taviaux, S; Lefranc, JLB; Cau, P; Berta, P; Lalande, M; Muscatelli, F				Jay, P; Rougeulle, C; Massacrier, A; Moncla, A; Mattei, MG; Malzac, P; Roeckel, N; Taviaux, S; Lefranc, JLB; Cau, P; Berta, P; Lalande, M; Muscatelli, F			The human necdin gene, NDN, is maternally imprinted and located in the Prader-Willi syndrome chromosomal region	NATURE GENETICS			English	Article							NUCLEAR-PROTEIN; MOUSE-BRAIN; YAC CONTIG; SNRPN GENE; EXPRESSION; 15Q11-Q13; LOCUS; CLUSTER; REPEATS	Prader-Willi syndrome (PWS) is a neurogenetic disorder that results from the absence of a normal paternal contribution to the 15q11-13 region(1-3) The clinical manifestations of PWS are a transient severe hypotonia in the newborn period, with mental retardation, hypogonadism and obesity observed later in development(4). Five transcripts with exclusive expression from the paternal allele have been isolated, but none of these has been shown to be involved in PWS5,6. In this study, we report the isolation and characterization of NDN, a new human imprinted gene, NDN is exclusively expressed from the paternal allele in the tissues analysed and is located in the PWS region. It encodes a putative protein homologous to the mouse brain-specific NECDIN protein(7), NDN; as in mouse, expression in brain is restricted to post-mitotic neurons. NDN displays several characteristics of an imprinted locus, including allelic DNA methylation and asynchronous DNA replication, A complete lack of NDN expression in PWS brain and fibroblasts indicates that the gene is expressed exclusively from the paternal allele in these tissues and suggests a possible role of this new gene in PWS.	INSERM,U406,F-13385 MARSEILLE,FRANCE; CTR RECH BIOCHIM MACROMOL,CNRS,ERS 115,INSERM,U249,F-34033 MONTPELLIER,FRANCE; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115; BIOL CELLULAIRE LAB,F-13385 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Jay, Philippe/ABD-9223-2020; Jay, Philippe/I-7116-2016; Muscatelli, Françoise/P-4650-2016; Cau, Pierre/M-3541-2016	Jay, Philippe/0000-0003-0156-5700; Jay, Philippe/0000-0003-0156-5700; Muscatelli, Françoise/0000-0003-4001-6528; Rougeulle, Claire/0000-0003-3861-4940; Mattei, Marie-Genevieve/0000-0002-6027-7058				AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; BERGELEFRANC JL, 1993, HUM MOL GENET, V5, P1637; CLAYTONSMITH J, 1992, AM J MED GENET, V44, P256, DOI 10.1002/ajmg.1320440236; GASTALDI M, 1997, MOL BRAIN RES, V192, P222; GLATT K, 1994, GENOMICS, V19, P157, DOI 10.1006/geno.1994.1027; Glenn CC, 1996, AM J HUM GENET, V58, P335; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; HOLM VA, 1993, PEDIATRICS, V91, P398; HORSTHEMKE B, 1995, GENOMIC IMPRINTING C, P295; HUNTRISS JD, 1994, MOL BIOL REP, V20, P19, DOI 10.1007/BF00999851; Jay P, 1997, GENOMICS, V39, P104, DOI 10.1006/geno.1996.4470; LALANDE M, 1997, ANNU REV GENET, V30, P173; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; Maruyama E, 1996, BIOCHEM J, V314, P895, DOI 10.1042/bj3140895; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MASCARI MJ, 1992, NEW ENGL J MED, V326, P1599, DOI 10.1056/NEJM199206113262404; Moore DD, 1995, GLOB MOB SURV; MUTIRANGURA A, 1993, GENOMICS, V18, P546, DOI 10.1016/S0888-7543(11)80011-X; Mutirangura A., 1992, Human Molecular Genetics, V1, P139, DOI 10.1093/hmg/1.2.139-a; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; Ning Y, 1996, GENOME RES, V6, P742, DOI 10.1101/gr.6.8.742; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; Rougeulle C, 1997, NAT GENET, V17, P14, DOI 10.1038/ng0997-14; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; Schulze A, 1996, NAT GENET, V12, P452, DOI 10.1038/ng0496-452; Sun YM, 1996, HUM MOL GENET, V5, P517, DOI 10.1093/hmg/5.4.517; UETSUKI T, 1996, J BIOL CHEM, V12, P918; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; WALKER AP, 1992, HUM MOL GENET, V1, P579, DOI 10.1093/hmg/1.8.579; WATRIN F, IN PRESS EUR J HUM G	31	201	206	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					357	361		10.1038/ng1197-357	http://dx.doi.org/10.1038/ng1197-357			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354807				2022-12-25	WOS:A1997YD66700037
J	deRuyter, PGGA; Kuipers, OP; Meijer, WC; deVos, WM				deRuyter, PGGA; Kuipers, OP; Meijer, WC; deVos, WM			Food-grade controlled lysis of Lactococcus lactis for accelerated cheese ripening	NATURE BIOTECHNOLOGY			English	Article						cheese ripening; lysin; holin; Lactococcus lactis	BACTERIOPHAGE LYSIS; AMINOPEPTIDASE-N; GENE-EXPRESSION; ACID BACTERIA; SYSTEMS; CLONING; HOLINS; NISIN; PHAGE	An attractive approach to accelerate cheese ripening is to induce lysis of Lactococcus lactis starter strains for facilitated release of intracellular enzymes involved in flavor formation. Controlled expression of the lytic genes lytA and lytH, which encode the lysin and the holin proteins of the lactococcal bacteriophage Phi US3, respectively, was accomplished by application of a food-grade nisin-inducible expression system. Simultaneous production of lysin and holin is essential to obtain efficient lysis and concomitant release of intracellular enzymes as exemplified by complete release of the debittering intracellular aminopeptidase N. Production of holin alone leads to partial lysis of the host cells, whereas production of lysin alone does not cause significant lysis. Model cheese experiments in which the inducible holin-lysin overproducing strain was used showed a fourfold increase in release of L-lactate dehydrogenase activity into the curd relative to the control strain and the holin-overproducing strain, demonstrating the suitability of the system for cheese applications.	NIZO,DEPT BIOPHYS CHEM,GENET GRP,NL-6710 BA EDE,NETHERLANDS; NIZO,DEPT MICROBIOL,NL-6710 BA EDE,NETHERLANDS	NIZO Food Research; NIZO Food Research			Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				Blasi U, 1996, MOL MICROBIOL, V21, P675, DOI 10.1046/j.1365-2958.1996.331395.x; BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; deRuyter PGGA, 1996, J BACTERIOL, V178, P3434, DOI 10.1128/jb.178.12.3434-3439.1996; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; DEVOS WM, 1994, ENETICS BIOTECHNOLOG, P52; Gasson MJ, 1996, ANTON LEEUW INT J G, V70, P147, DOI 10.1007/BF00395931; HILLIER AJ, 1982, METHOD ENZYMOL, V89, P362; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; OSullivan DJ, 1996, BIO-TECHNOL, V14, P82, DOI 10.1038/nbt0196-82; Platteeuw C, 1996, APPL ENVIRON MICROB, V62, P1008, DOI 10.1128/AEM.62.3.1008-1013.1996; PLATTEEUW C, 1992, GENE, V118, P115, DOI 10.1016/0378-1119(92)90257-P; SABLE S, 1995, APPL MICROBIOL BIOT, V43, P1, DOI [10.1007/BF00170613, 10.1007/s002530050360]; Sambrok J., 1989, MOL CLONING LAB MANU; SHEARMAN CA, 1994, APPL ENVIRON MICROB, V60, P3063, DOI 10.1128/AEM.60.9.3063-3073.1994; SHEARMAN CA, 1992, BIO-TECHNOL, V10, P196, DOI 10.1038/nbt0292-196; TAN PST, 1993, APPL ENVIRON MICROB, V59, P1430, DOI 10.1128/AEM.59.5.1430-1436.1993; VANALENBOERRIGTER IJ, 1991, APPL ENVIRON MICROB, V57, P2555, DOI 10.1128/AEM.57.9.2555-2561.1991; VOS P, 1989, J BACTERIOL, V171, P2795, DOI 10.1128/jb.171.5.2795-2802.1989; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; YOUNG R, 1995, FEMS MICROBIOL REV, V17, P191, DOI 10.1016/0168-6445(94)00079-4; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992	22	121	129	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					976	979		10.1038/nbt1097-976	http://dx.doi.org/10.1038/nbt1097-976			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335048	Green Published			2022-12-25	WOS:A1997XZ28500027
J	Robson, PRH; McCormac, AC; Irvine, AS; Smith, H				Robson, PRH; McCormac, AC; Irvine, AS; Smith, H			Genetic engineering of harvest index in tobacco through overexpression of a phytochrome gene	NATURE BIOTECHNOLOGY			English	Article						genetic engineering; harvest index; plant architecture; phytochrome; tobacco; transgenic plants	OAT PHYTOCHROME; LIGHT; COMPETITION; FAMILY; PERCEPTION; QUALITY; SIGNAL; PLANTS	The phytochrome photoreceptor family regulates plant architecture in response to environmental light signals. Phytochromes mediate the shade avoidance syndrome, in which plants react to far-red radiation reflected from neighbors by elongation growth, occurring at the expense of leaf and storage organ production. We show that transgenic overproduction of phytochrome A in tobacco suppresses shade avoidance, causing proximity-conditional dwarfing. At high densities in the field, assimilates show an enhanced allocation to leaves, with a concomitant increase in harvest index. Transfer of this approach to other crop plants could provide significant improvements in productivity.			Robson, PRH (corresponding author), UNIV LEICESTER,DEPT BOT,UNIV RD,LEICESTER LE1 7RH,LEICS,ENGLAND.			Robson, Paul/0000-0003-1841-3594				CHERRY JR, 1991, PLANT PHYSIOL, V96, P775, DOI 10.1104/pp.96.3.775; Harper J. L, 1977, POPULATION BIOL PLAN; MCCORMAC A, 1992, PLANTA, V188, P173, DOI 10.1007/BF00216811; Pratt L. H., 1979, Photochemical and Photobiological Reviews, V4, P59; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHMITT J, 1993, TRENDS ECOL EVOL, V8, P47, DOI 10.1016/0169-5347(93)90157-K; Schmitt J, 1995, AM NAT, V146, P937, DOI 10.1086/285832; SHARROCK RA, 1989, GENE DEV, V3, P534; SMITH H, 1990, PLANT CELL ENVIRON, V13, P73, DOI 10.1111/j.1365-3040.1990.tb01301.x; SMITH H, 1990, PLANT CELL ENVIRON, V13, P695, DOI 10.1111/j.1365-3040.1990.tb01084.x; SMITH H, 1982, ANNU REV PLANT PHYS, V33, P481, DOI 10.1146/annurev.pp.33.060182.002405; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; Smith Harry, 1994, Seminars in Cell Biology, V5, P315, DOI 10.1006/scel.1994.1038; WEINER J, 1990, TRENDS ECOL EVOL, V5, P360, DOI 10.1016/0169-5347(90)90095-U; WHITELAM GC, 1994, PLANT CELL ENVIRON, V17, P615, DOI 10.1111/j.1365-3040.1994.tb00153.x	17	122	142	2	24	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					995	998		10.1038/nbt0896-995	http://dx.doi.org/10.1038/nbt0896-995			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631038				2022-12-25	WOS:A1996UZ19900032
J	Hahnenberger, KM; Krystal, M; Esposito, K; Tang, WM; Kurtz, S				Hahnenberger, KM; Krystal, M; Esposito, K; Tang, WM; Kurtz, S			Use of microphysiometry for analysis of heterologous ion channels expressed in yeast	NATURE BIOTECHNOLOGY			English	Article						microphysiometry; ion channels; S-cerevisiae; drug screening	POTASSIUM CHANNELS; SACCHAROMYCES-CEREVISIAE; KILLER TOXIN; SHAKER; GENE; DROSOPHILA; MEMBRANE; PROTEIN; ATPASE; CDNA	Measurement of extracellular acidification rates by microphysiometry provides a means to analyze the function of ion channels expressed in yeast cells. These measurements depend on the proton pumping action of the H+-ATPase, a central component of the yeast plasma membrane. We used microphysiometry to analyze the activity of two ion channels expressed in yeast. In one example, an inwardly rectifying K+ channel, gpIRK1, provides a potassium uptake function when expressed in a potassium transporter-defective yeast strain. Rates of acidification in gpIRK1-expressing cells directly reflect channel function. Addition of cesium, an inhibitor of gpIRK1 activity, results in an immediate reduction in acidification rates. In a second example, expression of a nonselective cation channel, the influenza virus M2 protein, is believed to interfere with the maintenance of the electrochemical proton gradient by the H+-ATPase. In cells expressing the M2 channel, addition of inhibitors increases the rate of proton extrusion. Moreover, functional differences between two M2 inhibitors, amantadine and BL-1743, are distinguished by the microphysiometer. This application demonstrates the utility of the microphysiometer for functional studies of ion channels; it is adaptable to a screening process for compounds that modulate ion channel activity.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; MOLEC DEVICES CORP,SUNNYVALE,CA 94089; HEWLETT PACKARD CORP,BIOSCI RES & DEV,PALO ALTO,CA 94304; BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT VIROL,WALLINGFORD,CT 06492	Bristol-Myers Squibb; Hewlett-Packard; Bristol-Myers Squibb								BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BUSSEY H, 1990, EXPERIENTIA, V46, P193, DOI 10.1007/BF02027313; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; GABER RF, 1992, INT REV CYTOL, V137A, P299; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; HAFEMAN DG, 1988, SCIENCE, V240, P1182, DOI 10.1126/science.3375810; Hahnenberger KM, 1996, P NATL ACAD SCI USA, V93, P5031, DOI 10.1073/pnas.93.10.5031; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HAWORTH RS, 1991, BIOCHIM BIOPHYS ACTA, V1098, P79; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAGAN BL, 1983, NATURE, V302, P709, DOI 10.1038/302709a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MILLER DL, 1993, BIOPHYS J, V54, P813; MILLER DL, 1994, CANADIAN J PHYSL S1, V72, P378; OWICKI JC, 1994, ANNU REV BIOPH BIOM, V23, P87, DOI 10.1146/annurev.bb.23.060194.000511; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; Sherman F., 1983, METHODS YEAST GENETI; TANG WM, 1995, MOL BIOL CELL, V6, P1231, DOI 10.1091/mbc.6.9.1231; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TU Q, 1996, IN PRESS J VIROLOGY	29	11	16	1	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					880	883		10.1038/nbt0796-880	http://dx.doi.org/10.1038/nbt0796-880			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631015				2022-12-25	WOS:A1996UV62000040
J	Bax, RP; Anderson, R; Crew, J; Fletcher, P; Johnson, T; Kaplan, E; Knaus, B; Kristinsson, K; Malek, M; Strandberg, L				Bax, RP; Anderson, R; Crew, J; Fletcher, P; Johnson, T; Kaplan, E; Knaus, B; Kristinsson, K; Malek, M; Strandberg, L			Antibiotic resistance - what can we do?	NATURE MEDICINE			English	Editorial Material							PENICILLIN; PNEUMONIA; MORTALITY; BACTERIA		SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Bax, RP (corresponding author), SmithKline Beecham Pharmaceut, 3rd Ave, Harlow CM19 5AW, Essex, England.							Bax RP, 1997, CLIN INFECT DIS, V24, pS151, DOI 10.1093/clinids/24.Supplement_1.S151; BAX RP, 1988, J ANTIMICROB CHEMOTH, V21, P278, DOI 10.1093/jac/21.3.278; Chopra I, 1996, JAMA-J AM MED ASSOC, V275, P401, DOI 10.1001/jama.275.5.401; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Felmingham D, 1996, J ANTIMICROB CHEMOTH, V38, P1; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; Klugman KP, 1996, J ANTIMICROB CHEMOTH, V38, P133, DOI 10.1093/jac/38.suppl_A.133; NYSTROM PO, 1990, WORLD J SURG, V14, P148, DOI 10.1007/BF01664867; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Sack RB, 1997, CLIN INFECT DIS, V24, pS102, DOI 10.1093/clinids/24.Supplement_1.S102; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	13	75	78	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					545	546		10.1038/nm0598-545	http://dx.doi.org/10.1038/nm0598-545			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585218				2022-12-25	WOS:000073399900016
J	Piatek, AS; Tyagi, S; Pol, AC; Telenti, A; Miller, LP; Kramer, FR; Alland, D				Piatek, AS; Tyagi, S; Pol, AC; Telenti, A; Miller, LP; Kramer, FR; Alland, D			Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis	NATURE BIOTECHNOLOGY			English	Article						pathogen screening; molecular probes; genetic testing; rifampin	PULMONARY TUBERCULOSIS; MUTATIONS; DNA; POLYMORPHISMS; RIFAMPIN	We developed a new approach to DNA sequence analysis that uses fluorogenic reporter molecules-molecular beacons--and demonstrated their ability to discriminate alleles in real-time PCR assays of genomic DNA. A set of overlapping molecular beacons was used to analyze an 81-bp region of the Mycobacterium tuberculosis rpoB gene for mutations that confer resistance to the antibiotic rifampin. In a blinded study of 52 rifampin-resistant and 23 rifampin-susceptible clinical isolates, this method correctly detected mutations in all of the resistant strains and in none of the susceptible strains. The assay was carried out entirely in sealed PCR tubes and was simple to perform and interpret. This approach can be used to analyze any DNA sequence of moderate length with single base pair accuracy.	Montefiore Med Ctr, Dept Med, Div Infect Dis, Bronx, NY 10467 USA; Publ Hlth Res Inst City New York Inc, Dept Mol Genet, New York, NY 10016 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Rutgers State University New Brunswick; Rutgers State University Medical Center	Alland, D (corresponding author), Montefiore Med Ctr, Dept Med, Div Infect Dis, Bronx, NY 10467 USA.	Dalland404@aol.com	Telenti, Amalio/AAY-1674-2021; Tyagi, Sanjay/F-1109-2010	Tyagi, Sanjay/0000-0001-7303-5827	NHLBI NIH HHS [HL 43521] Funding Source: Medline; NIAID NIH HHS [AI 37015, AI 45244] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045244, R01AI037015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P961; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; DEBEENHOUWER H, 1995, TUBERCLE LUNG DIS, V76, P425, DOI 10.1016/0962-8479(95)90009-8; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Heifets L B, 1986, Semin Respir Infect, V1, P242; Kent PT, 1985, GUIDE LEVEL 3 LAB; KOX LFF, 1995, J CLIN MICROBIOL, V33, P3225, DOI 10.1128/JCM.33.12.3225-3233.1995; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; Nash KA, 1997, J INFECT DIS, V176, P533, DOI 10.1086/517283; OMATA M, 1990, NEW ENGL J MED, V322, P178; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; TOMPKINS LS, 1992, NEW ENGL J MED, V327, P1290; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; WILLIAMS DL, 1994, ANTIMICROB AGENTS CH, V38, P2380, DOI 10.1128/AAC.38.10.2380	28	326	406	1	51	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					359	363		10.1038/nbt0498-359	http://dx.doi.org/10.1038/nbt0498-359			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555727				2022-12-25	WOS:000072786200028
J	Hodgson, J; Marshall, A				Hodgson, J; Marshall, A			Pharmacogenomics: Will the regulators approve?	NATURE BIOTECHNOLOGY			English	Article																		Marshall A, 1997, NAT BIOTECHNOL, V15, P954, DOI 10.1038/nbt1097-954; MEYER UA, 1997, EVOLUTION HLTH DIS; *US FDA, 1997, GUID IND DRUG MET DR	3	22	23	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					243	+		10.1038/nbt0398-243	http://dx.doi.org/10.1038/nbt0398-243			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528002				2022-12-25	WOS:000072371000022
J	Donahue, RE; Bunnell, BA; Zink, MC; Metzger, ME; Westro, RP; Kirby, MR; Unangst, T; Clements, JE; Morgan, RA				Donahue, RE; Bunnell, BA; Zink, MC; Metzger, ME; Westro, RP; Kirby, MR; Unangst, T; Clements, JE; Morgan, RA			Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELLS; IMMUNIZATION; EXPRESSION; THERAPY; MUTANTS; MODELS; VIVO	Simian immunodeficiency virus (SIV) infection of nonhuman primates is one of the most relevant animals models of HIV infection in humans. To test a potential anti-HIV gene therapy strategy in this model, CD4-enriched lymphocytes from three rhesus macaques were subjected to retrovirally mediated gene transfer with a vector expressing an antisense tat/rev gene. This group of animals and three control macaques were subsequently infected with SIVmac239. Blood and lymph nodes from all macaques were sampled for more than a year to monitor the progress of infection. Although all animals became infected, the animals that received the lymphocytes engineered with the antisense vector demonstrated a significant reduction in viral load in both peripheral blood and lymph nodes, had sustained numbers of CD4(+) cells, and exhibited little disruption of lymph node architecture.	NIH, Natl Human Genome Res Inst, Clin Gene Therapy Branch, Bethesda, MD 20892 USA; NHLBI, Hematol Branch, NIH, Rockville, MD 20901 USA; Johns Hopkins Univ, Sch Med, Div Comparat Med, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University	Morgan, RA (corresponding author), NIH, Natl Human Genome Res Inst, Clin Gene Therapy Branch, Bldg 10,Room 10C103,10 Ctr Dr, Bethesda, MD 20892 USA.			Bunnell, Bruce/0000-0001-6196-3722	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035751, P01NS032208] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 53248] Funding Source: Medline; NINDS NIH HHS [NS 35751, NS 32208] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUNNELL BA, 1995, P NATL ACAD SCI USA, V92, P7739, DOI 10.1073/pnas.92.17.7739; Bunnell BA, 1997, BLOOD, V89, P1987, DOI 10.1182/blood.V89.6.1987; CLEMENTS JE, 1995, J VIROL, V69, P2737, DOI 10.1128/JVI.69.5.2737-2744.1995; Donahue RE, 1996, BLOOD, V87, P1644, DOI 10.1182/blood.V87.4.1644.bloodjournal8741644; ENDRES CL, 1995, J VIROL, V69, P5164, DOI 10.1128/JVI.69.8.5164-5166.1995; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; GARDNER MB, 1994, VIRUSES, V3, P133; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KINDT TJ, 1992, ADV IMMUNOL, V52, P425, DOI 10.1016/S0065-2776(08)60880-9; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LOHMAN BL, 1994, J VIROL, V68, P7021, DOI 10.1128/JVI.68.11.7021-7029.1994; MANKOWSKI JL, 1994, J VIROL, V68, P8202, DOI 10.1128/JVI.68.12.8202-8208.1994; Morgan RA, 1996, HUM GENE THER, V7, P1281, DOI 10.1089/hum.1996.7.10-1281; Pantaleo G, 1997, NAT MED, V3, P483, DOI 10.1038/nm0597-483; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; VANDENDRIESSCHE T, 1995, J VIROL, V69, P4045, DOI 10.1128/JVI.69.7.4045-4052.1995; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889	22	35	43	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1998	4	2					181	186		10.1038/nm0298-181	http://dx.doi.org/10.1038/nm0298-181			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461191				2022-12-25	WOS:000072249800033
J	Lin, YA; Goebels, J; Xia, GL; Ji, P; Vandeputte, M; Waer, M				Lin, YA; Goebels, J; Xia, GL; Ji, P; Vandeputte, M; Waer, M			Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELL; CARDIAC XENOGRAFT SURVIVAL; ENDOTHELIAL-CELLS; TRANSGENIC MICE; REJECTION; ANTIBODIES; ACTIVATION; ANTIGENS; RAT; XENOTRANSPLANTATION	After transplantation of primarily vascularized xenografts (Xgs), T-independent mechanisms may lead to Xg rejection before T-cell activation even takes place. The possibility of achieving T-independent xenotolerance was evaluated in nude rats that normally reject hamster cardiac Xgs within 4 days by non-T cell-mediated mechanisms. After donor antigen infusion, temporary NK-cell depletion and a 4-week administration of Leflunomide, hamster heart grafts survived even after withdrawal of immunosuppression. Tolerant rats accepted second hamster hearts, but promptly rejected mouse heart Xgs. In vivo immunization and in vitro cytotoxicity assays indicated that this species-specific tolerance was based on B-lymphocyte and NK-cell tolerance respectively.	Katholieke Univ Leuven, Lab Expt Transplantat, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Waer, M (corresponding author), Katholieke Univ Leuven, Lab Expt Transplantat, Campus Gasthuisberg,O-N,Herestr 49, B-3000 Louvain, Belgium.	Mark.Waer@Med.KULeuven.ac.be						AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BAKER PJ, 1989, AM J PATHOL, V135, P185; Candinas D, 1996, TRANSPLANTATION, V62, P1920, DOI 10.1097/00007890-199612270-00042; CHAN EYT, 1993, EUR J IMMUNOL, V23, P357, DOI 10.1002/eji.1830230209; COLIGAN JE, 1994, CURRENT PROTOCOLS IM, P11; Collins Braldey H., 1994, Xenotransplantation, V1, P36, DOI 10.1111/j.1399-3089.1994.tb00048.x; Cramer DV, 1997, TRANSPL P, V29, P945, DOI 10.1016/S0041-1345(96)00271-0; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GILES GR, 1970, TRANSPLANT P, V2, P522; Goodman DJ, 1996, TRANSPLANTATION, V61, P763, DOI 10.1097/00007890-199603150-00016; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; Gustavsson ML, 1996, TRANSPLANTATION, V61, P957, DOI 10.1097/00007890-199603270-00019; HANCOCK WW, 1993, TRANSPLANT P, V25, P2932; HOMAN WP, 1981, TRANSPLANTATION, V31, P164, DOI 10.1097/00007890-198103000-00004; KABAT EA, 1961, EXPERIMENTAL IMMUNOC, P149; KAKITA A, 1975, J SURG RES, V19, P99, DOI 10.1016/0022-4804(75)90113-4; KIYOHARA T, 1987, CELL IMMUNOL, V106, P223, DOI 10.1016/0008-8749(87)90166-3; LEVENTHAL JR, 1993, TRANSPLANTATION, V55, P857, DOI 10.1097/00007890-199304000-00033; Lin Y, 1997, J IMMUNOL, V158, P5658; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MALNATI MS, 1993, J EXP MED, V178, P961, DOI 10.1084/jem.178.3.961; MOLLER JR, 1985, P NATL ACAD SCI USA, V82, P2456, DOI 10.1073/pnas.82.8.2456; PERPER ROBERT J., 1966, TRANSPLANTATION, V4, P377, DOI 10.1097/00007890-196607000-00002; PIERSON RN, 1989, J EXP MED, V170, P991, DOI 10.1084/jem.170.3.991; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; PLATT JL, 1991, TRANSPLANTATION, V52, P1037, DOI 10.1097/00007890-199112000-00019; REYNOLDS CW, 1981, J IMMUNOL, V127, P282; RODER JC, 1979, J EXP MED, V150, P471, DOI 10.1084/jem.150.3.471; RODER JC, 1982, J CLIN IMMUNOL, V2, P249, DOI 10.1007/BF00915064; ROONEY CM, 1984, IMMUNOLOGY, V51, P193; ROOZEMOND RC, 1984, ANN INST PASTEUR IMM, VD135, P247, DOI 10.1016/S0769-2625(84)81189-7; SACHS DH, 1990, HUM IMMUNOL, V28, P245, DOI 10.1016/0198-8859(90)90025-K; Salam A, 1996, TRANSPLANTATION, V61, P826, DOI 10.1097/00007890-199603150-00025; SCHAAPHERDER AFM, 1994, TRANSPLANTATION, V57, P1376, DOI 10.1097/00007890-199405150-00016; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; SILVA HT, 1997, MED SCI, V313, P289; SUNDSTROM JB, 1993, INFECT IMMUN, V61, P1340, DOI 10.1128/IAI.61.4.1340-1345.1993; SYKES M, 1993, J EXP MED, V178, P223, DOI 10.1084/jem.178.1.223; SYKES M, 1994, IMMUNOL REV, V141, P245, DOI 10.1111/j.1600-065X.1994.tb00880.x; Umesue M, 1996, TRANSPLANTATION, V61, P116, DOI 10.1097/00007890-199601150-00023; Wu MF, 1997, J IMMUNOL, V158, P1628; Zhao Y, 1996, NAT MED, V2, P1211, DOI 10.1038/nm1196-1211; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x	48	75	78	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					173	180		10.1038/nm0298-173	http://dx.doi.org/10.1038/nm0298-173			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461190				2022-12-25	WOS:000072249800032
J	Calleja, C; Pascussi, JM; Mani, JC; Maurel, P; Vilarem, MJ				Calleja, C; Pascussi, JM; Mani, JC; Maurel, P; Vilarem, MJ			The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor	NATURE MEDICINE			English	Article							CYCLOSPORINE-A OXIDASE; GENE-EXPRESSION; PRIMARY CULTURES; BINDING DOMAIN; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; HUMAN HEPATOCYTES; CYTOCHROMES P450; MAMMALIAN-CELLS; PLASMA-PROTEIN	The glucocorticoid receptor (GR) belongs to a superfamily of ligand-regulated nuclear steroid hormone receptors. The steps in the signal transduction parkway leading to the biological effects of glucocorticoids (GCs) include sequentially binding of the steroid to the GR ligand binding domain (LBD), receptor transformation(1-3), nuclear translocation and either positive or negative gene transactivation(4). Rifampicin (RIF) is a macrocyclic antibiotic used as an antituberculosis agent(5). As the incidence of tuberculosis has been increasing, in part because of the AIDS epidemic, a growing number of patients are being exposed to the adverse effects of this antibiotic(6). Indeed, this compound, as are the GCs (ref. 7), is often implicated in noxious drug interactions, because elf its strong ability to induce drug-metabolizing enzymes(8,9). Moreover, in humans, RIF, as are the GCs (ref. 10), has been described as a potential immunodepressor, associated notably with the reduction of mitogenic responsiveness of human peripheral blood lymphocytes(11,12). Here, we report that RIF activates the human glucocorticoid receptor (hGR). Transient expression of wild-type, deleted or mutated GRs; sucrose density gradient sedimentation; and the BIAcore technique strongly suggest that RIF binds to the receptor with the physiological consequence that this antibiotic acts as an immunodepressor. Given the wide use of RIF in the treatment of coinfection of tuberculosis and HIV, this report is highly relevant to current medical practice.	CNRS, INSERM, U129, IFR 24, F-34293 Montpellier, France; Fac Pharm, UMR 9921, F-34060 Montpellier 1, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Vilarem, MJ (corresponding author), CNRS, INSERM, U129, IFR 24, BP 5051,1919 Route Mende, F-34293 Montpellier, France.	vilarem@xerxes.crbm.cnrs-mop.fr	pascussi, jean marc/F-9311-2013	pascussi, jean marc/0000-0002-5168-5383				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BHAKOO HS, 1981, CANCER RES, V41, P1695; CORCOS L, 1992, DRUG METAB DISPOS, V20, P797; CRESTEIL T, 1983, BRIT J CLIN PHARMACO, V16, P651, DOI 10.1111/j.1365-2125.1983.tb02236.x; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FAGERSTAM LG, 1993, HDB AFFINITY CHROMAT, V63, P229; FAGERSTAM LG, 1993, IMMUNOCHEMISTRY, P949; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GRADIN K, 1994, J BIOL CHEM, V269, P23800; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1987, NATURE, V325, P7578; IBRAHIM MS, 1987, CHEMIOTERAPIA, V6, P426; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MCGREGOR DB, 1991, MUTAT RES, V261, P29, DOI 10.1016/0165-1218(91)90095-4; MITCHELL L, 1995, LANCET, V4, P555; MITCHISON DA, 1992, J ANTIMICROB CHEMOTH, V29, P477, DOI 10.1093/jac/29.5.477; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; NESSI R, 1974, ARZNEIMITTELFORSCH, V24, P832; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NING YM, 1993, J BIOL CHEM, V268, P6073; OMALLEY BW, 1992, BIOL REPROD, V46, P163, DOI 10.1095/biolreprod46.2.163; OSHANESSY DJ, 1994, METHOD ENZYMOL, V249, P323; Ourlin JC, 1997, ANAL BIOCHEM, V247, P34, DOI 10.1006/abio.1997.2025; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; PICHARD L, 1992, MOL PHARMACOL, V41, P1047; RINGOLD GM, 1985, ANNU REV PHARMACOL, V25, P529, DOI 10.1146/annurev.pa.25.040185.002525; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YU CY, 1995, BIOCHEMISTRY-US, V34, P14163, DOI 10.1021/bi00043a022	43	90	95	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					92	96		10.1038/nm0198-092	http://dx.doi.org/10.1038/nm0198-092			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427613				2022-12-25	WOS:000072249700041
J	Kerr, DE; Liang, FX; Bondioli, KR; Zhao, HP; Kreibich, G; Wall, RJ; Sun, TT				Kerr, DE; Liang, FX; Bondioli, KR; Zhao, HP; Kreibich, G; Wall, RJ; Sun, TT			The bladder as a bioreactor: Urothelium production and secretion of growth hormone into urine	NATURE BIOTECHNOLOGY			English	Article						genetic engineering; transgenic mice; agricultural biotechnology	ASYMMETRIC UNIT MEMBRANE; TRANSGENIC MICE; UROPLAKIN-I; DIFFERENTIATION; EXPRESSION; PROTEINS; MILK; GENE; EPITHELIUM; PROMOTER	Uroplakin genes are expressed in a bladder-specific and differentiation-dependent fashion. Using a 3.6-kb promoter of mouse uroplakin II gene, we have generated transgenic mice that express human growth hormone (hGH) in their bladder epithelium, resulting in its secretion into the urine at 100-500 ng/ml. The levels of urine hGH concentration remain constant for longer than 8 months. hGH is present as aggregates mostly in the uroplakin-delivering cytoplasmic vesicles that are targeted to fuse with the apical surface. Using the bladder as a bioreactor offers unique advantages, including the utility of all animals throughout their lives. Using urine, which contains little protein and lipid, as a starting material facilitates recombinant protein purification.	USDA ARS, Beltsville Agr Res Ctr, Gene Evaluat & Mapping Lab, Beltsville, MD 20705 USA; NYU, Sch Med, Ronald Perelman Dept Dermatol, Epithelial Biol Unit,Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, Kaplan Canc Ctr, New York, NY 10016 USA	United States Department of Agriculture (USDA); New York University; New York University; New York University; New York University	Wall, RJ (corresponding author), USDA ARS, Beltsville Agr Res Ctr, Gene Evaluat & Mapping Lab, Beltsville, MD 20705 USA.	bobwall@ggpl.arsusda.gov	Liang, Feng/GZK-4305-2022; Liang, Fenghua/HHM-3798-2022; Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Liang, Fengxia/0000-0003-0037-4590	NIDDK NIH HHS [DK39753, DK49469] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039753, R01DK049469] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISHOP JO, 1982, EMBO J, V1, P615, DOI 10.1002/j.1460-2075.1982.tb01217.x; CHANG A, 1994, AM J PHYSIOL-CELL PH, V267, pC1483, DOI 10.1152/ajpcell.1994.267.5.C1483; GLUDICE E, 1994, HUM REPROD, V9, P2299; GORDON K, 1987, BIO-TECHNOL, V5, P1183, DOI 10.1038/nbt1187-1183; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; HOUDEBINE LM, 1994, J BIOTECHNOL, V34, P269, DOI 10.1016/0168-1656(94)90062-0; Jennings JC, 1996, DRUGS, V52, P313, DOI 10.2165/00003495-199652030-00002; LIN JH, 1994, J BIOL CHEM, V269, P1775; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; MAGA EA, 1995, BIO-TECHNOL, V13, P1452, DOI 10.1038/nbt1295-1452; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; Nerurkar LS, 1981, MANUAL MACROPHAGE ME, P229; Parfentjev IA, 1932, P SOC EXP BIOL MED, V29, P1285; RUMKE P, 1964, ACTA ENDOCRINOL-COP, V47, P156, DOI 10.1530/acta.0.0470156; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; Sun TT, 1996, MOL BIOL REP, V23, P3, DOI 10.1007/BF00357068; SURYA B, 1990, J CELL SCI, V97, P419; SWANSON ME, 1992, BIO-TECHNOL, V10, P557, DOI 10.1038/nbt0592-557; Wall RJ, 1997, J DAIRY SCI, V80, P2213, DOI 10.3168/jds.S0022-0302(97)76170-8; WALZ T, 1995, J MOL BIOL, V248, P887, DOI 10.1006/jmbi.1995.0269; WILKINS TD, 1992, J CELL BIOCHEM, V49, P333, DOI 10.1002/jcb.240490403; WILLIAMS LS, 1994, CAN MED ASSOC J, V151, P1009; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1994, J BIOL CHEM, V269, P13716; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171	27	74	91	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1998	16	1					75	79		10.1038/nbt0198-75	http://dx.doi.org/10.1038/nbt0198-75			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YP708	9447598				2022-12-25	WOS:000071306000033
J	Gauduin, MC; Parren, PWHI; Weir, R; Barbas, CF; Burton, DR; Koup, RA				Gauduin, MC; Parren, PWHI; Weir, R; Barbas, CF; Burton, DR; Koup, RA			Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 NEUTRALIZATION; CD4 BINDING; INFECTION; GP120; CHIMPANZEES; AIDS; XENOGRAFTS; EPITOPE; PLASMA	How well antibodies can protect against disease due to HIV-1 infection remains a pivotal but unresolved issue with important implications for vaccine design and the use of prophylactic antibody to prevent infection after accidental exposure to the virus and to interrupt transmission of virus from mother to child. Strong doubts about the possible utility of antibodies in vivo have been raised because of the relative resistance of primary viruses to antibody neutralization in vitro. Primary viruses are likely to be close to the viruses transmitted during natural infection in humans. Vaccine studies have been of little value in assessing antibody efficacy in vivo because none of the strategies described to date have elicited significant neutralizing antibody responses to primary viruses (reviewed in ref. 1). Passive immunization studies are similarly hindered by the paucity of reagents able to neutralize primary viruses effectively(2) and a single study has suggested some benefit(3). Here we describe experiments to explore the ability of passive antibody to protect against primary virus challenge in hu-PBL-SCID mice. In this model, severe combined immunodeficient (SCID) mice are populated with human peripheral blood mononuclear cells (PBMCs) and infected with HIV-1 (ref. 4). We find that the potent neutralizing human monoclonal antibody lgG1b12 at high dose is able to completely protect even when given several hours after viral challenge. The results are encouraging for antibody-based postexposure prophylaxis and support the notion that antibody induction could contribute to an effective vaccine.	Scripps Res Inst, Dept Immunol IMM2, La Jolla, CA 92037 USA; Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Rockefeller Univ, New York, NY 10016 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Rockefeller University; Scripps Research Institute	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol IMM2, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Parren, Paul/0000-0002-4365-3859	NIAID NIH HHS [AI 37470, AI 35522, AI 33292] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037470, R01AI035522, R01AI033292, R37AI035522, R37AI033292] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Burton DR, 1997, AIDS, V11, pS87; COHEN J, 1993, SCIENCE, V262, P980, DOI 10.1126/science.8235635; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; CUMMINS LM, 1991, BLOOD, V77, P1111; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; GAUDUIN MC, 1995, J INFECT DIS, V171, P1203, DOI 10.1093/infdis/171.5.1203; Gauduin MC, 1996, J VIROL, V70, P2586, DOI 10.1128/JVI.70.4.2586-2592.1996; Girard M, 1996, ANTIBIOT CHEMOTHER, V48, P121; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; HESSELTON RM, 1993, J INFECT DIS, V168, P630, DOI 10.1093/infdis/168.3.630; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1991, P NATL ACAD SCI USA, V88, P8949, DOI 10.1073/pnas.88.20.8949; Kessler JA, 1997, AIDS RES HUM RETROV, V13, P575, DOI 10.1089/aid.1997.13.575; Klasse PJ, 1996, J VIROL, V70, P3668, DOI 10.1128/JVI.70.6.3668-3677.1996; Koup R A, 1996, Semin Immunol, V8, P263, DOI 10.1006/smim.1996.0033; KOUP RA, 1994, AIDS RES HUM RETROV, V10, P279, DOI 10.1089/aid.1994.10.279; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1994, TECHNIQUES HIV RES, P107; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Lambert JS, 1997, J INFECT DIS, V175, P283, DOI 10.1093/infdis/175.2.283; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MATTHEWS TJ, 1994, AIDS RES HUM RETROV, V10, P631, DOI 10.1089/aid.1994.10.631; Moore J P, 1995, AIDS, V9 Suppl A, pS117; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; MOSIER DE, 1988, NATURE, V355, P728; PARREN PWHI, 1995, AIDS, V9, pF1, DOI 10.1097/00002030-199506000-00001; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; SAFRIT JT, 1993, AIDS, V7, P15, DOI 10.1097/00002030-199301000-00002; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022; ZollaPazner S, 1995, AIDS RES HUM RETROV, V11, P1449, DOI 10.1089/aid.1995.11.1449; ZUCKIER LS, 1989, SEMIN NUCL MED, V19, P166, DOI 10.1016/S0001-2998(89)80012-1	46	229	240	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1389	1393		10.1038/nm1297-1389	http://dx.doi.org/10.1038/nm1297-1389			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396610				2022-12-25	WOS:000072249500036
J	Goodell, MA; Rosenzweig, M; Kim, H; Marks, DF; DeMaria, M; Paradis, G; Grupp, SA; Sieff, CA; Mulligan, RC; Johnson, RP				Goodell, MA; Rosenzweig, M; Kim, H; Marks, DF; DeMaria, M; Paradis, G; Grupp, SA; Sieff, CA; Mulligan, RC; Johnson, RP			Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species	NATURE MEDICINE			English	Article							LONG-TERM-CULTURE; UMBILICAL-CORD BLOOD; HUMAN FETAL LIVER; BONE-MARROW; PROGENITOR CELLS; GENE-THERAPY; IN-VITRO; DIFFERENTIATION; PURIFICATION; ENGRAFTMENT	We previously described a method for isolating murine hematopoietic stem cells capable of reconstituting lethally irradiated recipients, which depends solely on dual-wavelength flow cytometric analysis of murine bone marrow cells stained with the fluorescent DNA-binding dye Hoechst 33342. This method, which appears to rely on the differential ability of stem cells to efflux the Hoechst dye, defines an extremely small and homogeneous population of cells (termed SP cells). We show here that dual-wavelength analysis of Hoechst dye-stained human, rhesus and miniature swine bone marrow cells reveals a small, distinct population of cells that efflux the dye in a manner identical to murine SP cells. Like the murine SP cells, both human and rhesus SP cells are primarily CD34-negative and lineage marker-negative. In vitro culture studies demonstrated that rhesus SP cells are highly enriched for long-term culture-initiating cells (LTC-ICs), an indicator of primitive hematopoietic cells, and have the capacity for differentiation into T cells. Although rhesus SP cells do not initially possess any hematopoietic colony-forming capability, they acquire the ability to form colonies after long-term culture on bone marrow stroma, coincident with their conversion to a CD34-positive phenotype. These studies suggest the existence of a hitherto unrecognized population of hematopoietic stem cells that lack the CD34 surface marker classically associated with primitive hematopoietic cells.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA; MIT, Flow Cytometry Lab, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02115 USA; Partners AIDS Res Ctr, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital	Mulligan, RC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.			Goodell, Margaret A./0000-0003-1111-2932	NCRR NIH HHS [RR-00055] Funding Source: Medline; NHLBI NIH HHS [HL54785] Funding Source: Medline; NIAID NIH HHS [AI-36550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036550] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARCENA A, 1993, BLOOD, V82, P3401; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; BERENSON RJ, 1991, BLOOD, V77, P1717; BROXMEYER HE, 1990, INT J CELL CLONING, V8, P76, DOI 10.1002/stem.5530080708; Civin CI, 1996, J CLIN ONCOL, V14, P2224, DOI 10.1200/JCO.1996.14.8.2224; Dunbar CE, 1996, ANNU REV MED, V47, P11; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; *GUID CAR US LAB A, 1985, DHHS PUBL, V8523; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; Jones RJ, 1996, BLOOD, V88, P487, DOI 10.1182/blood.V88.2.487.bloodjournal882487; KATAYAMA N, 1993, BLOOD, V82, P2353; KAWAI T, 1994, TRANSPLANT P, V26, P1845; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KRAUSE DS, 1994, BLOOD, V84, P691; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; METCALF D, 1971, HAEMOPOIETIC CELLS, P550; Morel F, 1996, BLOOD, V88, P3774, DOI 10.1182/blood.V88.10.3774.bloodjournal88103774; MULDER AH, 1984, CELL IMMUNOL, V88, P401, DOI 10.1016/0008-8749(84)90173-4; OKADA S, 1992, BLOOD, V80, P3044; Olweus J, 1994, Immunomethods, V5, P179, DOI 10.1006/immu.1994.1054; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470; Rosenzweig M, 1996, BLOOD, V87, P4040, DOI 10.1182/blood.V87.10.4040.bloodjournal87104040; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SUTHERLAND DR, 1994, CULTURE HEMATOPOIETI, P139; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054	31	866	913	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1997	3	12					1337	1345		10.1038/nm1297-1337	http://dx.doi.org/10.1038/nm1297-1337			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396603				2022-12-25	WOS:000072249500029
J	Weinrich, SL; Pruzan, R; Ma, LB; Ouellette, M; Tesmer, VM; Holt, SE; Bodnar, AG; Lichtsteiner, S; Kim, NW; Trager, JB; Taylor, RD; Carlos, R; Andrews, WH; Wright, WE; Shay, JW; Harley, CB; Morin, GB				Weinrich, SL; Pruzan, R; Ma, LB; Ouellette, M; Tesmer, VM; Holt, SE; Bodnar, AG; Lichtsteiner, S; Kim, NW; Trager, JB; Taylor, RD; Carlos, R; Andrews, WH; Wright, WE; Shay, JW; Harley, CB; Morin, GB			Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT	NATURE GENETICS			English	Article							EXPRESSION; DNA; POLYMERASES; MECHANISM; CANCER; ENZYME; VECTOR; CELLS; GENES	The maintenance of chromosome termini, or telomeres, requires the action of the enzyme telomerase, as conventional DNA polymerases cannot fully replicate the ends of linear molecules(1-4). Telomerase is expressed and telomere length is maintained in human germ cells and the great majority of primary human tumours(5,6). However, telomerase is not detectable in most normal somatic cells; this corresponds to the gradual telomere loss observed with each cell division(7-9). It has been proposed that telomere erosion eventually signals entry into senescence or cell crisis and that activation of telomerase is usually required for immortal cell proliferation(10). In addition to the human telomerase RNA component (hTR; ref, 11), TP1/TLP1 (refs 12,13), a protein that is homologous to the p80 protein associated with the Tetrahymena enzyme(14), has been identified in humans. More recently, the human telomerase reverse transcriptase (hTRT; refs 15, 16), which is homologous to the reverse transcriptase (RT)like proteins associated with the Euplotes aediculatus (Ea_p123), Saccharomyces cerevisiae (Est2p) and Schizosaccharomyces pombe (SpTrt1) telomerases(15,17), has been reported to be a telomerase protein subunit. A catalytic function has been demonstrated for Est2p in the RT-like class but not for p80 or its homologue(17,18). We now report that in vitro transcription and translation of hTRT when co-synthesized or mixed with hTR reconstitutes telomerase activity that exhibits enzymatic properties like those of the native enzyme, Single amino-acid changes in conserved telomerase-specific and RT motifs reduce or abolish activity, providing direct evidence that hTRT is the catalytic protein component of telomerase. Normal human diploid cells transiently expressing hTRT possessed telomerase activity, demonstrating that hTRT is the limiting component necessary for restoration of telomerase activity in these cells. The ability to reconstitute telomerase permits further analysis of its biochemical and biological roles in cell aging and carcinogenesis.	GERON CORP,MENLO PK,CA 94025; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011; Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374	NIA NIH HHS [AG07992, AG05747] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARRINGTON I, 1997, SCIENCE, V274, P973; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; LIN JH, 1994, GENE, V147, P287, DOI 10.1016/0378-1119(94)90083-3; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morin GB, 1997, EUR J CANCER, V33, P750, DOI 10.1016/S0959-8049(97)00061-0; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NAKAYAMA JI, 1997, CELL, V88, P1; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; PRUZAN R, 1990, J BIOL CHEM, V265, P2804; SHAY JW, 1997, EUR J CANCER, V33, P777; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0	31	814	891	0	40	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					498	502		10.1038/ng1297-498	http://dx.doi.org/10.1038/ng1297-498			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398860				2022-12-25	WOS:A1997YJ92400039
J	Dahme, M; Bartsch, U; Martini, R; Anliker, B; Schachner, M; Mantei, N				Dahme, M; Bartsch, U; Martini, R; Anliker, B; Schachner, M; Mantei, N			Disruption of the mouse L1 gene leads to malformations of the nervous system	NATURE GENETICS			English	Article							CELL-ADHESION MOLECULE; NEURITE OUTGROWTH; CEREBELLAR NEURONS; PERIPHERAL-NERVES; CLINICAL SPECTRUM; N-CAM; EXPRESSION; ANTIBODIES; SHOW; HYDROCEPHALUS	The adhesion molecule L1 is a member of the immunoglobulin superfamily(1). L1 is involved in various recognition processes in the CNS and PNS2,3, and binding to LI can activate signal transduction pathways(4,5). Mutations in the human LI gene are associated with a variable phenotype, including mental retardation and anomalous development of the nervous system, referred to as 'CRASH' (corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraplegia, and hydrocephalus)(6). We generated an animal model of these conditions by gene targetting, Mutant mice were smaller than wild-type and were less sensitive to touch and pain, and their hind-legs appeared weak and uncoordinated, The size of the corticospinal tract was reduced and, depending on genetic background, the lateral ventricles were often enlarged, Non-myelinating Schwann cells formed processes not associated with axons and showed reduced association with axons, In vitro, neurite outgrowth on an L1 substrate and fasciculation were impaired, The mutant mouse described here will help to elucidate the functions of L1 in the nervous system and how these depend on genetic influences.	ETH HONGGERBERG, SWISS FED INST TECHNOL, DEPT NEUROBIOL, CH-8093 ZURICH, SWITZERLAND; UNIV WURZBURG, DEPT NEUROL, DEV NEUROBIOL SECT, D-97080 WURZBURG, GERMANY; UNIV HAMBURG, ZENTRUM MOL NEUROBIOL, D-20246 HAMBURG, GERMANY	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf				Martini, Rudolf/0000-0002-5463-5592				APPEL F, 1993, J NEUROSCI, V13, P4764; APPEL F, 1995, J NEUROBIOL, V28, P297, DOI 10.1002/neu.480280304; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; CONSTAM DB, 1994, EUR J NEUROSCI, V6, P766, DOI 10.1111/j.1460-9568.1994.tb00988.x; Doherty P, 1996, PERSPECT DEV NEUROBI, V4, P157; FISCHER G, 1986, J NEUROSCI, V6, P605; FRANSEN E, 1995, EUR J HUM GENET, V3, P273; Fransen E, 1996, AM J MED GENET, V64, P73, DOI 10.1002/(SICI)1096-8628(19960712)64:1<73::AID-AJMG11>3.0.CO;2-P; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Kadmon G, 1997, DIFFERENTIATION, V61, P143, DOI 10.1046/j.1432-0436.1997.6130143.x; KLINZ SG, 1995, J NEUROCHEM, V65, P84; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; MAH C, 1980, J COMP PHYSIOL PSYCH, V94, P1160, DOI 10.1037/h0077742; Maness PF, 1996, PERSPECT DEV NEUROBI, V4, P169; MARTINI R, 1995, NAT GENET, V11, P281, DOI 10.1038/ng1195-281; MARTINI R, 1994, J NEUROCYTOL, V23, P1, DOI 10.1007/BF01189813; MARTINI R, 1995, J NEUROSCI, V15, P4488; MIURA M, 1992, J BIOL CHEM, V267, P10752; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Ramanathan R, 1996, J CELL BIOL, V133, P381, DOI 10.1083/jcb.133.2.381; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; SADOUL K, 1988, J NEUROCHEM, V50, P510, DOI 10.1111/j.1471-4159.1988.tb02941.x; SCHRANDERSTUMPEL C, 1995, AM J MED GENET, V57, P107, DOI 10.1002/ajmg.1320570122; SEILHEIMER B, 1989, J CELL BIOL, V109, P3095, DOI 10.1083/jcb.109.6.3095; STALLCUP WB, 1985, P NATL ACAD SCI USA, V82, P1276, DOI 10.1073/pnas.82.4.1276; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2	28	388	391	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1997	17	3					346	349		10.1038/ng1197-346	http://dx.doi.org/10.1038/ng1197-346			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354804				2022-12-25	WOS:A1997YD66700034
J	Bilaud, T; Brun, C; Ancelin, K; Koering, CE; Laroche, T; Gilson, E				Bilaud, T; Brun, C; Ancelin, K; Koering, CE; Laroche, T; Gilson, E			Telomeric localization of TRF2, a novel human telobox protein	NATURE GENETICS			English	Article							CHROMOSOMES; CHROMATIN; MYB	Natural chromosomal ends are stabilized by proteins that bind duplex telomeric DNA repeats. In human cells, the TTAGGG Repeat factor 1 (TRF1) was identified by two independent studies, one screening for factors that bind duplex telomeric DNA(1,2) and the other screening for proteins containing a particular Myb motif called the telobox, which is required for telomeric repeat recognition (Fig. 1a; refs 3-5). A second human open reading frame, orf2, contains a telobox sequence and encodes a polypeptide that specifically recognizes mammalian telomeric repeat DNA in vitro(3). We show that two proteins of 65 and 69 kD, expressed in HeLa cells, contain the orf2 telobox sequence. These proteins are collectively termed TRF2. Affinity-purified antibodies specific for anti-TRF2 label the telomeres of intact human chromosomes, strengthening the correlation between occurrence of telobox and telomere-repeat recognition in vivo.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,CNRS,UMR 49,F-69364 LYON 07,FRANCE; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Swiss Institute Experimental Cancer Research			Ancelin, Katia/R-1719-2019; Brun, Christine/B-4922-2008	Brun, Christine/0000-0002-5563-6765; Ancelin, Katia/0000-0002-2117-9754				ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Brun C, 1997, TRENDS CELL BIOL, V7, P317, DOI 10.1016/S0962-8924(97)01092-1; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; GASSER SM, 1987, EXP CELL RES, V173, P85, DOI 10.1016/0014-4827(87)90334-X; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Lipsick JS, 1996, ONCOGENE, V13, P223; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; MUYLDERMANS S, 1994, NUCLEIC ACIDS RES, V22, P5635, DOI 10.1093/nar/22.25.5635; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	19	391	404	0	25	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					236	239		10.1038/ng1097-236	http://dx.doi.org/10.1038/ng1097-236			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326951				2022-12-25	WOS:A1997XZ55500037
J	BulfonePaus, S; Ungureanu, D; Pohl, T; Lindner, G; Paus, R; Ruckert, R; Krause, H; Kunzendorf, U				BulfonePaus, S; Ungureanu, D; Pohl, T; Lindner, G; Paus, R; Ruckert, R; Krause, H; Kunzendorf, U			Interleukin-15 protects from lethal apoptosis in vivo	NATURE MEDICINE			English	Article							ANTI-FAS ANTIBODY; T-CELLS; IL-2 RECEPTOR; GROWTH-FACTOR; GAMMA-CHAIN; ALPHA-CHAIN; BETA-CHAIN; B-CELLS; DEATH; EXPRESSION	Interleukin-15 shares many biological activities with IL-2 and signals through the IL-2 receptor beta and gamma chains(1-3). However, IL-15 and IL-2 differ in their controls of expression and secretion, their range of target cells and their functional activities(3-7). These dissimilarities may include differential effects on apoptosis. For ex ample, IL-2 induces or inhibits T-cell apoptosis in vitro, depending on T-cell activation(8), whereas IL-15 inhibits cytokine deprivation-induced apoptosis in activated T cells(9). Studying whether and how IL-15 modulates distinct apoptosis pathways(10-12), we show here that apoptosis induced by anti-fas, anti-CD3, dexamethasone, and/or anti-IgM in activated human T and B cells in vitro is inhibited by IL-15 in a manner dependent on RNA synthesis. In vivo, anti-fas-induced lethal multisystem apoptosis in mice is suppressed by a novel IL-15-IgG2b fusion protein. Only IL-15, but not IL-2, completely protected from lethal hepatic failure. Thus, IL-15 is a potent, general inhibitor of apoptosis in vitro and in vivo with intriguing therapeutic potential.	FREE UNIV BERLIN,BENJAMIN FRANKLIN MED CTR,DEPT UROL,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,BENJAMIN FRANKLIN MED CTR,DEPT NEPHROL,D-12200 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,DEPT DERMATOL,D-10117 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	BulfonePaus, S (corresponding author), FREE UNIV BERLIN,BENJAMIN FRANKLIN MED CTR,INST IMMUNOL,D-12200 BERLIN,GERMANY.			Lindner, Gerd/0000-0003-2336-2058; Krause, Hans/0000-0001-8713-8229; Ungureanu, Daniela/0000-0002-9314-4972				Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194; COHEN JJ, 1984, J IMMUNOL, V132, P38; Coligan JE., 1994, CURRENT PROTOCOLS IM; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Kunzendorf U, 1996, J CLIN INVEST, V97, P1204, DOI 10.1172/JCI118534; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; ORIU A, 1997, J IMMUNOL, V158, P255; Scott DW, 1996, J IMMUNOL, V156, P2352; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Watanabe D, 1995, INT IMMUNOL, V7, P1949, DOI 10.1093/intimm/7.12.1949; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	26	276	282	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1124	1128		10.1038/nm1097-1124	http://dx.doi.org/10.1038/nm1097-1124			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334724				2022-12-25	WOS:A1997XZ28700038
J	Eliasson, MJL; Sampei, K; Mandir, AS; Hurn, PD; Traystman, RJ; Bao, J; Pieper, A; Wang, ZQ; Dawson, TM; Snyder, SH; Dawson, VL				Eliasson, MJL; Sampei, K; Mandir, AS; Hurn, PD; Traystman, RJ; Bao, J; Pieper, A; Wang, ZQ; Dawson, TM; Snyder, SH; Dawson, VL			Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; ZINC SUPEROXIDE-DISMUTASE; CORTICAL CULTURES; TRANSGENIC MICE; DNA-DAMAGE; GLUTAMATE NEUROTOXICITY; ENDOTHELIAL-CELLS; NADPH DIAPHORASE; ISLET CELLS; ACTIVATION	Nitric oxide (NO) and peroxynitrite, formed from NO and superoxide anion, have been implicated as mediators of neuronal damage following focal ischemia, but their molecular targets have not been defined. One candidate pathway is DNA damage leading to activation of the nuclear enzyme, poly(ADP-ribose) polymerase (PARP), which catalyzes attachment of ADP ribose units from NAD to nuclear proteins following DNA damage. Excessive activation of PARP can deplete NAD and ATP, which is consumed in regeneration of NAD, leading to cell death by energy depletion. We show that genetic disruption of PARP provides profound protection against glutamate-NO-mediated ischemic insults in vitro and major decreases in infarct volume after reversible middle cerebral artery occlusion. These results provide compelling evidence for a primary involvement of PARP activation in neuronal damage following focal ischemia and suggest that therapies designed towards inhibiting PARP may provide benefit in the treatment of cerebrovascular disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,BALTIMORE,MD 21287; INT AGCY RES CANC,F-69008 LYON,FRANCE	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; World Health Organization; International Agency for Research on Cancer (IARC)			Dawson, Valina/Y-9757-2019; Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577; Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033142, R01NS033277, K08NS001578] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33142, NS33277, NS01578] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BANASIK M, 1994, MOL CELL BIOCHEM, V138, P185, DOI 10.1007/BF00928461; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; CHAN PH, 1990, STROKE, V21, P80; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, J NEUROSCI, V10, P2493; Dawson Ted M., 1997, P319; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; ENDRES M, IN PRESS J CEREB BLO; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; HUDAK BB, 1995, AM J PHYSIOL-LUNG C, V269, pL59, DOI 10.1152/ajplung.1995.269.1.L59; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KIRKLAND JB, 1991, BIOCHIM BIOPHYS ACTA, V1092, P319, DOI 10.1016/S0167-4889(97)90007-0; Kupper JH, 1996, HISTOCHEM J, V28, P391, DOI 10.1007/BF02331402; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MIZUMOTO K, 1993, BIOCHEM PHARMACOL, V46, P1811, DOI 10.1016/0006-2952(93)90587-M; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SUTO MJ, 1991, ANTI-CANCER DRUG DES, V6, P107; Szabo C, 1997, AM J RESP CELL MOL, V16, P105, DOI 10.1165/ajrcmb.16.2.9032115; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TAKAHASHI K, IN PRESS NEUROSCI AB; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WANG ZQ, IN PRESS GENES DEV; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	47	868	891	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1089	1095		10.1038/nm1097-1089	http://dx.doi.org/10.1038/nm1097-1089			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334719				2022-12-25	WOS:A1997XZ28700033
J	Pereira, L; Andrikopoulos, K; Tian, J; Lee, SY; Keene, DR; Ono, R; Reinhardt, DP; Sakai, LY; Biery, NJ; Bunton, T; Dietz, HC; Ramirez, F				Pereira, L; Andrikopoulos, K; Tian, J; Lee, SY; Keene, DR; Ono, R; Reinhardt, DP; Sakai, LY; Biery, NJ; Bunton, T; Dietz, HC; Ramirez, F			Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome	NATURE GENETICS			English	Article							DEVELOPING MOUSE AORTA; MICROFIBRILS; MUTATIONS; ORGANIZATION; COMPONENT; EXPRESSION; DELETION; REVEALS; MATRIX	Aortic aneurysm and dissection account for about 2% of all deaths in industrialized countries; they are also components of several genetic diseases, including Marfan syndrome (MFS)(1). The vascular phenotype of MFS results from mutations in fibrillin-1 (FBN1), the major constituent of extracellular microfibrils(2,3). Microfibrils, either associated with or devoid of elastin, give rise to a variety of extracellular networks in elastic and non-elastic tissues(3). It is believed that microfibrils regulate elastic fibre formation by guiding tropo-elastin deposition during embryogenesis and early post-natal life(4). Hence, vascular disease in MFS is thought to result when FBN1 mutations preclude elastic fibre maturation by disrupting microfibrillar assembly, Here we report a gene-targetting experiment in mice that indicates that fibrillin-1 microfibrils are predominantly engaged in tissue homeostasis rather than elastic matrix assembly. This finding, in turn, suggests that aortic dilation is due primarily to the failure by the microfibrillar array of the adventitia to sustain physiological haemodynamic stress, and that disruption of the elastic network of the media is a secondary event.	CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; UNIV SAO PAULO,INST BIOCIENCIAS,DEPT BIOL,BR-05508 SAO PAULO,BRAZIL; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129; SHRINERS HOSP CHILDREN,PORTLAND,OR 97201; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT COMPARAT MED & PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Universidade de Sao Paulo; Harvard University; Harvard Medical School; Massachusetts General Hospital; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University			Reinhardt, Dieter P/A-3102-2008; Pereira, Lygia V/C-1049-2012	Reinhardt, Dieter P/0000-0001-6535-9872; Pereira, Lygia V/0000-0002-0002-725X	NIAMS NIH HHS [AR41135, AR42044] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042044] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; DAVIS EC, 1994, J CELL SCI, V107, P727; DAVIS EC, 1993, LAB INVEST, V68, P89; DIETZ HC, 1994, ADV HUM GENET, V22, P153; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; EWART AK, 1994, J CLIN INVEST, V93, P1071, DOI 10.1172/JCI117057; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; GAUSE WC, 1989, PCR PRIMER LAB MANUA, P293; Hogan B, 1994, MANIPULATING MOUSE E; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P935; HURLE JM, 1994, J CELL SCI, V107, P2623; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KEENE DR, IN PRESS J HISTOCHEM; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAMBROOK E, 1989, MOL CLONING LAB MANU; Tilson MD, 1990, CAUSE MANAGEMENT ANE, P97; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	27	292	304	0	22	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					218	222		10.1038/ng1097-218	http://dx.doi.org/10.1038/ng1097-218			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326947				2022-12-25	WOS:A1997XZ55500033
J	Horwitz, MS; Evans, CF; McGavern, DB; Rodriguez, M; Oldstone, MBA				Horwitz, MS; Evans, CF; McGavern, DB; Rodriguez, M; Oldstone, MBA			Primary demyelination in transgenic mice expressing interferon-gamma	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS LESIONS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; VIRUS-INDUCED DEMYELINATION; ANTIGEN EXPRESSION; GENE-EXPRESSION; CELL EXPRESSION; SJL/J MICE; OLIGODENDROCYTES; NEURONS; INDUCTION	Ever since the use of interferon-gamma to treat patients with multiple sclerosis resulted in enhanced disease, the role of IFN-gamma in demyelination has been under question. To address this issue directly, transgenic mice were generated that expressed the cDNA of murine IFN-gamma in the central nervous system by using an oligodendrocyte-specific promoter. Expression of the transgene occurred after 8 weeks of age, at which time the murine immune and central nervous systems are both fully developed. Directly associated with transgene expression, primary demyelination occurred and was accompanied by clinical abnormalities consistent with CNS disorders. Additionally, multiple hallmarks of immune-mediated CNS disease were observed including upregulation of MHC molecules, gliosis and lymphocytic infiltration. These results demonstrate a direct role for IFN-gamma as an inducer of CNS demyelination leading to disease and provide new opportunities for dissecting the mechanism of demyelination.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; MAYO CLIN & MAYO FDN, DEPT NEUROL & IMMUNOL, ROCHESTER, MN 55905 USA	Scripps Research Institute; Mayo Clinic	Horwitz, MS (corresponding author), Scripps Res Inst, DEPT IMMUNOL IMM 23, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		McGavern, Dorian/HCH-3601-2022	McGavern, Dorian/0000-0001-9568-545X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012120, T32MH019185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000080, P01AG004342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09487] Funding Source: Medline; NIA NIH HHS [AG04342] Funding Source: Medline; NIMH NIH HHS [F31 MH012120, MH19185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BERGSTEINSDOTTIR K, 1992, P NATL ACAD SCI USA, V89, P9054, DOI 10.1073/pnas.89.19.9054; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; HANAFUSA T, 1994, DIABETES RES CLIN PR, V24, pS307, DOI 10.1016/0168-8227(94)90267-4; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717; LASSMANN H, 1994, ANN NEUROL, V36, pS2; LINTHICUM DS, 1982, CELL IMMUNOL, V73, P299, DOI 10.1016/0008-8749(82)90457-9; LUBLIN FD, 1993, AUTOIMMUNITY, V16, P267, DOI 10.3109/08916939309014645; MASSA PT, 1993, GLIA, V8, P201, DOI 10.1002/glia.440080307; MERRILL JE, 1993, J IMMUNOL, V151, P2132; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; PEARCE BD, 1994, J VIROL, V68, P5483, DOI 10.1128/JVI.68.9.5483-5495.1994; RENNO T, 1994, J NEUROIMMUNOL, V49, P1, DOI 10.1016/0165-5728(94)90174-0; RODRIGUEZ M, 1995, J VIROL, V69, P7286, DOI 10.1128/JVI.69.11.7286-7290.1995; RODRIGUEZ M, 1987, J IMMUNOL, V138, P3438; RUBIO N, 1991, IMMUNOLOGY, V74, P284; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; SHALABY MR, 1985, J INTERFERON RES, V5, P339, DOI 10.1089/jir.1985.5.339; SOBEL RA, 1995, NEUROL CLIN, V13, P1; SUZUMURA A, 1988, J IMMUNOL, V140, P2068; TRAUGOTT U, 1988, J NEUROL SCI, V84, P257, DOI 10.1016/0022-510X(88)90130-X; TURNLEY AM, 1991, NATURE, V353, P566, DOI 10.1038/353566a0; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WOODROOFE MN, 1993, CYTOKINE, V5, P583, DOI 10.1016/S1043-4666(05)80008-0; YOUNG HA, 1995, J LEUKOCYTE BIOL, V58, P373, DOI 10.1002/jlb.58.4.373	31	151	160	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1037	1041		10.1038/nm0997-1037	http://dx.doi.org/10.1038/nm0997-1037			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288735	Green Accepted, Bronze, Green Published			2022-12-25	WOS:A1997XT84200041
J	Simmons, LC; Yansura, DG				Simmons, LC; Yansura, DG			Translational level is a critical factor for the secretion of heterologous proteins in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article						secretion of heterologous proteins; translational level; Escherichia coli	HUMAN GROWTH-HORMONE; SIGNAL PEPTIDE; NUCLEOTIDE-SEQUENCE; HYDROPHOBIC REGION; DIRECT EXPRESSION; GENE; EXPORT; OVERPRODUCTION; INITIATION; MUTATIONS	A method for enhancing the secretion of heterologous proteins in Escherichia coli by optimizing, as opposed to simply maximizing, the translational level of a given protein is described. Random alteration of the translational initiation region (TIR) of the Heat-Stable Enterotoxin II (STII) signal sequence resulted in a library of vectors with varied translational strengths. Subsequent screening of this library using E. coli alkaline phosphatase as a reporter led to the selection of several TIR variants covering a 10-fold range of translational strength. These TIR variants, in combination with several previously generated variants, are shown to dramatically improve the secretion of a number of heterologous proteins. In fact, the heterologous proteins tested required a narrow translational range for optimal high-level secretion into the periplasm. Interestingly, the secretion of two native E. coli proteins was unaffected by TIR strength when tested over an identical range. The dependence of secretion on a narrow translational level demonstrates its critical role in the secretion of heterologous proteins in E. coli.			Simmons, LC (corresponding author), GENENTECH INC, DEPT BIOL MOLEC, 460 POINT SAN BRUNO BLVD, S SAN FRANCISCO, CA 94080 USA.							AMEMURA M, 1982, J BACTERIOL, V152, P592; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; DAS A, 1990, METHOD ENZYMOL, V182, P93; DENEFLE P, 1989, GENE, V85, P499, DOI 10.1016/0378-1119(89)90444-7; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GOLDSTEIN J, 1990, J BACTERIOL, V172, P1225, DOI 10.1128/jb.172.3.1225-1231.1990; GRAY GL, 1985, GENE, V39, P247, DOI 10.1016/0378-1119(85)90319-1; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; Henzel William J., 1994, Methods (Orlando), V6, P239, DOI 10.1006/meth.1994.1026; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KADOKURA H, 1994, APPL MICROBIOL BIOT, V41, P163; KLEIN BK, 1992, PROTEIN ENG, V5, P511, DOI 10.1093/protein/5.6.511; LEE CA, 1986, J BACTERIOL, V166, P878, DOI 10.1128/jb.166.3.878-883.1986; LEHNHARDT S, 1987, J BIOL CHEM, V262, P1716; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MCGRATH ME, 1991, J BIOL CHEM, V266, P6620; MORIOKAFUJIMOTO K, 1991, J BIOL CHEM, V266, P1728; PEREZPEREZ J, 1994, BIO-TECHNOL, V12, P178, DOI 10.1038/nbt0294-178; PICKEN RN, 1983, INFECT IMMUN, V42, P269, DOI 10.1128/IAI.42.1.269-275.1983; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SHIBA K, 1984, J BACTERIOL, V160, P696, DOI 10.1128/JB.160.2.696-701.1984; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VARENNE S, 1984, J MOL BIOL, V180, P549, DOI 10.1016/0022-2836(84)90027-5; WONG EY, 1988, GENE, V68, P193, DOI 10.1016/0378-1119(88)90021-2; Yansura Daniel G., 1992, Methods (Orlando), V4, P151, DOI 10.1016/1046-2023(92)90047-C; YANSURA DG, 1990, METHOD ENZYMOL, V185, P54; YANSURA DG, 1990, METHOD ENZYMOL, V185, P161	39	86	123	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					629	634		10.1038/nbt0596-629	http://dx.doi.org/10.1038/nbt0596-629			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630956				2022-12-25	WOS:A1996UL60400030
J	Hopp, TP				Hopp, TP			Lymphokine racketeers? Cistron alleges foul play over IL-1, but Immunex sees it differently	NATURE BIOTECHNOLOGY			English	Article							INTERLEUKIN-1											AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Hassler S, 1996, BIO-TECHNOL, V14, P14; KRONHEIM SR, 1985, J EXP MED, V161, P490, DOI 10.1084/jem.161.3.490; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARSHALL E, 1995, SCIENCE, V270, P1912, DOI 10.1126/science.270.5244.1912; WOLFF SM, 1986, NATURE, V319, P270, DOI 10.1038/319270c0	7	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					275	&		10.1038/nbt0396-275	http://dx.doi.org/10.1038/nbt0396-275			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630886				2022-12-25	WOS:A1996UL38000018
J	Cheng, J; Sheldon, EL; Wu, L; Uribe, A; Gerrue, LO; Carrino, J; Heller, MJ; O'Connell, JP				Cheng, J; Sheldon, EL; Wu, L; Uribe, A; Gerrue, LO; Carrino, J; Heller, MJ; O'Connell, JP			Preparation and hybridization analysis of DNA/RNA from E-coli on microfabricated bioelectronic chips	NATURE BIOTECHNOLOGY			English	Article						nanotechnology; miniaturization; dielectrophoresis; electronic lysis	GENE-EXPRESSION PATTERNS; MICROARRAY	Escherichia coli were separated from a mixture containing human blood cells by means of dielectrophoresis and then subjected to electronic lysis followed by proteolytic digestion on a single microfabricated bioelectronic chip. An alternating current electric field was used to direct the bacteria to 25 microlocations above individually addressable platinum microelectrodes. The platinum electrodes were 80 mu m in diameter and had center-to-center spacings of 200 mu m. After the isolation, the bacteria were lysed by a series of high-voltage pulses. The lysate contained a spectrum of nucleic acids including RNA, plasmid DNA, and genomic DNA. The lysate was further examined by electronically enhanced hybridization on separate bioelectronic chips. Dielectrophoretic separation of cells followed by electronic lysis and digestion on an electronically active chip may have potential as a sample preparation process for chip-based hybridization assays in an integrated DNA/RNA analysis system.	Nanogen Inc, San Diego, CA 92121 USA		Cheng, J (corresponding author), Nanogen Inc, 10398 Pacific Ctr Ct, San Diego, CA 92121 USA.							BRODY JP, 1995, BIOPHYS J, V68, P2224, DOI 10.1016/S0006-3495(95)80443-1; Cheng, 1996, Mol Diagn, V1, P183, DOI 10.1016/S1084-8592(96)70004-8; Cheng J, 1998, ANAL CHEM, V70, P2321, DOI 10.1021/ac971274g; Cheng J, 1996, NUCLEIC ACIDS RES, V24, P380, DOI 10.1093/nar/24.2.380; Cheng J, 1998, ANAL BIOCHEM, V257, P101, DOI 10.1006/abio.1997.2531; Cheng J, 1998, TOP CURR CHEM, V194, P215; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Goater AD, 1997, J PHYS D APPL PHYS, V30, pL65, DOI 10.1088/0022-3727/30/18/001; Li PCH, 1997, ANAL CHEM, V69, P1564, DOI 10.1021/ac9606564; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARKX GH, 1994, MICROBIOL-SGM, V140, P585, DOI 10.1099/00221287-140-3-585; Pethig R, 1997, TRENDS BIOTECHNOL, V15, P426, DOI 10.1016/S0167-7799(97)01096-2; PETHIG R, 1996, CRIT REV BIOTECHNOL, V16, P631; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schnelle T, 1996, NATURWISSENSCHAFTEN, V83, P172, DOI 10.1007/BF01143058; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; WANG XB, 1993, J PHYS D APPL PHYS, V26, P1278, DOI 10.1088/0022-3727/26/8/019; Wilding P, 1998, ANAL BIOCHEM, V257, P95, DOI 10.1006/abio.1997.2530	20	263	356	4	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					541	546		10.1038/nbt0698-541	http://dx.doi.org/10.1038/nbt0698-541			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624684				2022-12-25	WOS:000073930600029
J	Kolquist, KA; Ellisen, LW; Counter, CM; Meyerson, M; Tan, LK; Weinberg, RA; Haber, DA; Gerald, WL				Kolquist, KA; Ellisen, LW; Counter, CM; Meyerson, M; Tan, LK; Weinberg, RA; Haber, DA; Gerald, WL			Expression of TERT in early premalignant lesions and a subset of cells in normal tissues	NATURE GENETICS			English	Article							TELOMERASE ACTIVITY; HUMAN BREAST; CANCER; RNA	Activation of telomerase, the enzyme that synthesizes the telomere ends of linear chromosomes, has been implicated in human cell immortalization and cancer cell pathogenesis. Enzyme activity is undetectable in most normal cells and tissues, but present in immortal cells and cancer tissues(1-3). While expression of TERC, the RNA component of telomerase, is widespread(4-6), the restricted expression pattern of TERT, the telomerase catalytic subunit gene, is correlated with telomerase activity(7-9), and its ectopic expression in telomerase-negative cells is sufficient to reconstitute telomerase activity(10-12) and extend cellular lifespan(13). We have used in situ hybridization to study TERT expression at the single-cell level in normal tissues and in various stages of tumour progression. In normal tissues, including some that are known to be telomerase-negative, TERT mRNA was present in specific subsets of cells thought to have long-term proliferative capacity. This included mitotically inactive breast lobular epithelium in addition to some actively regenerating cells such as the stratum basale of the skin. TERT expression appeared early during tumorigenesis in vivo, beginning with early pre-invasive changes in human breast and colon tissues and increasing mRNA present within individual cells and in the number of expressing cells within a neoplastic lesion. The physiological expression of TERT within normal epithelial cells that retain of tumorigenesis have implications for the regulation of telomerase expression and for the identification of cells that may be targets for malignant transformation.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; MIT, Whitehead Inst Biomed Res, Dept Biol, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Memorial Sloan Kettering Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute	Gerald, WL (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	geraldw@mskcc.org	Meyerson, Matthew L/E-7123-2012; Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910; Counter, Christopher M/0000-0003-0748-3079	NCI NIH HHS [CA 58596, CA 68273, CA 39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068273, R35CA039826, R01CA058596, R37CA058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avilion AA, 1996, CANCER RES, V56, P645; BELAIR CD, 1997, P NATL ACAD SCI USA, V94, P13667; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHADENEAU C, 1995, CANCER RES, V55, P2533; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Hiyama E, 1996, INT J ONCOL, V9, P453; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1997, CANCER RES, V57, P610; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Ramakrishnan S, 1998, CANCER RES, V58, P622; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Takubo K, 1997, J SURG ONCOL, V66, P88, DOI 10.1002/(SICI)1096-9098(199710)66:2<88::AID-JSO3>3.0.CO;2-H; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; Yashima K, 1998, CLIN CANCER RES, V4, P229; Yasumoto S, 1996, ONCOGENE, V13, P433	30	351	382	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1998	19	2					182	186		10.1038/554	http://dx.doi.org/10.1038/554			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620778				2022-12-25	WOS:000073865100029
J	Hahn, H; Wojnowski, L; Zimmer, AM; Hall, J; Miller, G; Zimmer, A				Hahn, H; Wojnowski, L; Zimmer, AM; Hall, J; Miller, G; Zimmer, A			Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome	NATURE MEDICINE			English	Article							CELL CARCINOMA SYNDROME; NEVUS SYNDROME; HUMAN HOMOLOG; GENE	Gorlin (or nevoid basal cell carcinoma) syndrome is characterized by a variety of clinical problems including generalized overgrowth of the body, cysts, developmental abnormalities of the skeleton and a predisposition to benign and malignant tumors(1,2). The syndrome results from germline mutations of the human homolog of the drosophila segment polarity gene patched (ptc)(3,4). Here we report that mice heterozygous for ptc develop many of the features characteristic of Gorlin syndrome and that they exhibit a high incidence of rhabdomyosarcomas (RMS), the most common soft-tissue sarcoma in children(5). The downstream signalling partner of ptc, gli1, was overexpressed in all RMSs analyzed, indicating that abnormal signalling of the ptc-gli1 pathway may be common for the various tumors(6,7) associated with the syndrome. igf2, implicated in the formation of RMSs(8), was also overexpressed, suggesting cross-talk between the ptc and igf2 pathways in tumorigenesis. Developemental defects in Gorlin syndrome resemble those induced by ionizing radiation(9). We show that ptc heterozygous mice exhibit increased incidence of radiation-induced teratogenesis. This suggests a role for ptc in the response to ionizing radiation and provides a model for both the systemic (developmental) and stochastic (cancer) abnormalities observed in Gorlin syndrome.	NIMH, Genet Sect, Bethesda, MD 20892 USA; Natl Inst Res Resources, Vet Resources Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA	Zimmer, A (corresponding author), NIMH, Genet Sect, 36 Convent Dr,Room 3006, Bethesda, MD 20892 USA.	zimmer@codon.nih.gov	Zimmer, Andreas/B-8357-2009					Albrecht S, 1996, J NEUROPATH EXP NEUR, V55, P1270, DOI 10.1097/00005072-199612000-00011; ARLETT CF, 1984, BRIT J CANCER, V49, P227; Bale AE, 1997, AM J HUM GENET, V60, P10; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; FEATHERSTONE T, 1983, AM J HUM GENET, V35, P58; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hall E, 2018, RADIOBIOLOGY RADIOLO, V8th; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Rugh R, 1990, MOUSE ITS REPROD DEV; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; ZHAN SL, 1995, J BIOL CHEM, V270, P27983	20	346	352	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					619	622		10.1038/nm0598-619	http://dx.doi.org/10.1038/nm0598-619			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585239				2022-12-25	WOS:000073399900037
J	Macchia, PE; Lapi, P; Krude, H; Pirro, MT; Missero, C; Chiovato, L; Souabni, A; Baserga, M; Tassi, V; Pinchera, A; Fenzi, G; Gruters, A; Busslinger, M; Di Lauro, R				Macchia, PE; Lapi, P; Krude, H; Pirro, MT; Missero, C; Chiovato, L; Souabni, A; Baserga, M; Tassi, V; Pinchera, A; Fenzi, G; Gruters, A; Busslinger, M; Di Lauro, R			PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis	NATURE GENETICS			English	Article							PAIRED DOMAIN; GENES; TRANSCRIPTION; RECOGNITION; ISOFORMS; PROTEINS; SITE	Permanent congenital hypothyroidism (CH) is a common disease that occurs in 1 of 3,000-4,000 newborns. Except in rare cases due to hypothalamic or pituitary defects, CH is characterized by elevated levels of thyroid-stimulating hormone (TSH) resulting from reduced thyroid function. When thyroid hormone therapy is not initiated within the first two months of life, CH can cause severe neurological, mental and motor damage(1,2). In 80-85% of cases, CH is associated with and presumably is a consequence of thyroid dysgenesis (TD). In these cases, the thyroid gland can be absent (agenesis, 35-40%), ectopically located (30-45%) and/or severely reduced in size (hypoplasia, 5%), Familial cases of TD are rare, even though ectopic or absent thyroid has been occasionally observed in siblings(3). The pathogenesis of TD is still largely unknown. Although a genetic component has been suggested, mutations in the gene encoding the receptor for the thyroid-stimulating hormone (TSHR) have been identified in only two cases of TD with hypoplasia(4,5). We report mutations in the coding region of PAX8 in two sporadic patients and one familial case of TD. All three point mutations are located in the paired domain of PAX8 and result in severe reduction of the DNA-binding activity of this transcription factor. These genetic alterations implicate PAX8 in the pathogenesis of TD and in normal thyroid development.	Staz Zool A Dohrn, Naples, Italy; Univ Pisa, Ist Endocrinol, Pisa, Italy; Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Cattedra Pediat, Calabria, Italy; Ist Sci Casa Sollievo Sofferenza, Div Unita Ric Endocrinol, San Giovanni Rotondo, Italy; Univ Naples Federico II, Cattedra Endocrinol, Naples, Italy; Humboldt Univ, Virchow Klinikum, Klin & Poliklin Kinderheilkunde, Berlin, Germany	Stazione Zoologica Anton Dohrn di Napoli; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Universita Mediterranea di Reggio Calabria; IRCCS Casa Sollievo Della Sofferenza; University of Naples Federico II; Humboldt University of Berlin	Di Lauro, R (corresponding author), Staz Zool A Dohrn, Naples, Italy.	rdilauro@unina.it	Chiovato, Luca/K-6617-2016; Di Lauro, Roberto/A-2746-2012; Busslinger, Meinrad J./J-1249-2016; Macchia, Paolo Emidio/AGZ-2839-2022; Macchia, Paolo Emidio/B-7391-2012; chiovato, luca/AAC-9003-2019	Chiovato, Luca/0000-0001-7457-7353; Di Lauro, Roberto/0000-0001-9493-3036; Busslinger, Meinrad J./0000-0002-9111-9351; Macchia, Paolo Emidio/0000-0001-6503-6942; Macchia, Paolo Emidio/0000-0001-6503-6942; Missero, Caterina/0000-0003-0905-5123; Tassi, Vittorio/0000-0003-3536-4480	Telethon [D.067, E.0254] Funding Source: Medline	Telethon(Fondazione Telethon)		Abramowicz MJ, 1997, J CLIN INVEST, V99, P3018, DOI 10.1172/JCI119497; ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Biebermann H, 1997, J CLIN ENDOCR METAB, V82, P3471, DOI 10.1210/jc.82.10.3471; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DUSSAULT JH, 1975, J PEDIATR-US, V86, P670, DOI 10.1016/S0022-3476(75)80349-0; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GLORIEUX J, 1985, J PEDIATR-US, V107, P913, DOI 10.1016/S0022-3476(85)80187-6; GRUTERS A, 1996, BAILLIERE CLIN PAEDI, V4, P1; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mckusick V.A., 1994, MENDELIAN INHERITANC; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1995, EUR J BIOCHEM, V228, P899, DOI 10.1111/j.1432-1033.1995.tb20338.x; ROSSI DL, 1995, J BIOL CHEM, V270, P23139, DOI 10.1074/jbc.270.39.23139; ROVET JF, 1995, J PEDIATR-US, V126, P380, DOI 10.1016/S0022-3476(95)70452-3; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; STUART ET, 1995, HUM MOL GENET, V4, P1717, DOI 10.1093/hmg/4.suppl_1.1717; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	20	353	369	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1998	19	1					83	86		10.1038/ng0598-83	http://dx.doi.org/10.1038/ng0598-83			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590296				2022-12-25	WOS:000073346700024
J	Melcher, A; Todryk, S; Hardwick, N; Ford, M; Jacobson, M; Vile, RG				Melcher, A; Todryk, S; Hardwick, N; Ford, M; Jacobson, M; Vile, RG			Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression	NATURE MEDICINE			English	Article							TISSUE-SPECIFIC EXPRESSION; DEAMINASE SUICIDE GENE; MHC CLASS-I; THYMIDINE KINASE; T-CELLS; CANCER-IMMUNOTHERAPY; ANTITUMOR IMMUNITY; APOPTOSIS; VIVO; VACCINATION	In situ killing of tumor cells using suicide gene transfer to generate death by a non-apoptotic pathway was associated with high immunogenicity and induction of heat shock protein (hsp) expression. In contrast, a syngeneic colorectal tumor line, CMT93, killed predominantly by apoptosis, showed low levels of hsp expression and less immunogenicity. When apoptosis was inhibited in CMT93 cells by overexpression of bcl-2, hsp was also induced. Furthermore, when cDNA encoding hsp70 was stably transfected into B16 and CMT93 cells, its expression significantly enhanced the immunogenicity of both tumors. Increased levels of hsp, induced by non-apoptotic cell killing, may provide an immunostimulatory signal in vivo which helps break tolerance to tumor antigens. These findings have important implications for the development of novel anti-cancer therapies aimed at promoting patients' immune responses to their own tumors.	Hammersmith Hosp, Imperial Coll Sci & Med, ICRF, Oncol Unit,Lab Mol Therapy, London W12 0NN, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Imperial College London; GlaxoSmithKline; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Vile, RG (corresponding author), Hammersmith Hosp, Imperial Coll Sci & Med, ICRF, Oncol Unit,Lab Mol Therapy, DuCane Rd, London W12 0NN, England.	R.vile@icrf.icnet.uk	Todryk, Stephen/AAA-3950-2019	Todryk, Stephen/0000-0003-4566-0793				Altman DG, 1991, PRACTICAL STAT MED R, P365; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARBA D, 1994, P NATL ACAD SCI USA, V91, P4348, DOI 10.1073/pnas.91.10.4348; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; Castleden SA, 1997, HUM GENE THER, V8, P2087, DOI 10.1089/hum.1997.8.17-2087; CASTLEDEN SA, 1997, THESIS U LONDON; CAVALLO F, 1993, CANCER RES, V53, P5067; Cayeux S, 1997, J IMMUNOL, V158, P2834; COLOMBO MP, 1992, CANCER RES, V52, P4853; COLUMBANO A, 1995, J CELL BIOCHEM, V58, P181, DOI 10.1002/jcb.240580207; CONSALVO M, 1995, J IMMUNOL, V154, P5302; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Forni G, 1995, CYTOKINES MOL THER, V1, P225; FREEMAN SM, 1993, CANCER RES, V53, P5274; Freeman SM, 1997, LANCET, V349, P2, DOI 10.1016/S0140-6736(97)22001-5; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; HELLSTROM KE, 1995, IMMUNOL REV, V145, P123, DOI 10.1111/j.1600-065X.1995.tb00079.x; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; Huang AYC, 1996, IMMUNITY, V4, P349, DOI 10.1016/S1074-7613(00)80248-4; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Li Z, 1997, Semin Immunol, V9, P315, DOI 10.1006/smim.1997.0087; LUKACS KV, 1993, J EXP MED, V178, P343, DOI 10.1084/jem.178.1.343; Lukacs KV, 1997, GENE THER, V4, P346, DOI 10.1038/sj.gt.3300386; MAASS G, 1995, P NATL ACAD SCI USA, V92, P5540, DOI 10.1073/pnas.92.12.5540; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MULLEN CA, 1994, CANCER RES, V54, P1503; Multhoff G, 1997, J IMMUNOL, V158, P4341; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; PERRY MD, 1994, GENE, V146, P273, DOI 10.1016/0378-1119(94)90305-0; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; Vile RG, 1996, CANCER METAST REV, V15, P351, DOI 10.1007/BF00046347; VILE RG, 1994, CANCER RES, V54, P6228; VILE RG, 1993, CANCER RES, V53, P3860; Vile RG, 1997, INT J CANCER, V71, P267; Wei YQ, 1996, CANCER RES, V56, P1104; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	44	393	424	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					581	587		10.1038/nm0598-581	http://dx.doi.org/10.1038/nm0598-581			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585232				2022-12-25	WOS:000073399900030
J	Rafael, JA; Tinsley, JM; Potter, AC; Deconinck, AE; Davies, KE				Rafael, JA; Tinsley, JM; Potter, AC; Deconinck, AE; Davies, KE			Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice	NATURE GENETICS			English	Article							MUSCULAR-DYSTROPHY; MDX MOUSE	Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease usually resulting in death of patients by their early twenties'. In contrast, mice lacking dystrophin (Dmd(mdx)), appear physically normal despite their underlying muscle pathology(2,3). Mice deficient for both dystrophin and the dystrophin-related protein, utrophin, (Dmd(mdx);Utrn(-/-) mice) die between 6 and 20 weeks of age suffering from severe muscle weakness with joint contractures, pronounced growth retardation and kyphosis, suggesting that dystrophin and utrophin play complementary roles(4,5). The exact cause of death in these mice was not determined. Here we show that expression of a truncated utrophin transgene solely within the skeletal muscle of these mutants prevents premature death and the development of any clinical phenotype, In the absence of full-length dystrophin and utrophin, the presence of truncated utrophin also decreases muscle fibre regeneration, relocalizes the dystrophin protein complex to the sarcolemma and re-establishes a normal expression pattern of developmental muscle proteins. These data suggest that Dmd(mdx);Utrn(-/-) mice succumb to a skeletal muscle defect and that their reduced lifespan is not due to cardiac or neurogenic components, The phenotypic rescue observed demonstrates that the Dmd(mdx);Utrn(-/-) mice are an ideal model for testing gene delivery protocols for the expression of utrophin or dystrophin in skeletal muscle.	Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, Dept Biochem, Genet Unit, South Pk Rd, Oxford OX1 3QU, England.		Rafael-Fortney, Jill/E-3909-2011					BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; Dubowitz V., 1995, MUSCLE DISORDERS CHI; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Gilbert R, 1998, BIOCHEM BIOPH RES CO, V242, P244, DOI 10.1006/bbrc.1997.7936; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; Melacini P, 1996, CIRCULATION, V94, P3168, DOI 10.1161/01.CIR.94.12.3168; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V115, P1688; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0	18	174	180	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					79	82		10.1038/ng0598-79	http://dx.doi.org/10.1038/ng0598-79			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590295				2022-12-25	WOS:000073346700023
J	Yamasaki, L; Bronson, R; Williams, BO; Dyson, NJ; Harlow, E; Jacks, T				Yamasaki, L; Bronson, R; Williams, BO; Dyson, NJ; Harlow, E; Jacks, T			Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice	NATURE GENETICS			English	Article							S-PHASE ENTRY; FIBROBLASTS LEADS; CHIMERIC MICE; APOPTOSIS; GENE; RB; EXPRESSION; MOUSE; OVEREXPRESSION; INDUCTION	Mutation of the retinoblastoma tumour-suppressor gene (RB) leads to the deregulation of many proteins and transcription factors that interact with the retinoblastoma gene product (pRB), including members of the E2F transcription factor family(1,2). As pRB is known to repress E2F transcriptional activity and overexpression of E2F is sufficient for cell cycle progression, it is thought that pRB suppresses growth in part by repressing E2F-mediated transcription(3). Previously, we reported that loss of E2f1 in mice results in tissue-specific tumour induction and tissue atrophy(4), demonstrating that E2F-1 normally controls growth both positively and negatively in a tissue-specific fashion(4,5). To determine whether E2F-1 deregulation-as a result of loss of pRB-promotes proliferation in vivo, we have tested whether loss of E2f1 interferes with the pituitary and thyroid tumorigenesis that occurs in Rb1(+/-) mice(6-9). We have found that loss of E2f1 reduces the frequency of pituitary and thyroid tumours, and greatly lengthens the lifespan of Rb1(+/-); E2f1(-/-) animals, demonstrating that E2F-1 is an important downstream target of pRB during tumorigenesis. Furthermore. loss of E2f1 reduces a previously reported strain-dependent difference in Rb1(+/-) lifespan(9,10), suggesting that E2f1 or an E2F-1-regulated gene acts as a genetic modifier between the 129/Sv and C57BL/6 strains.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Tufts Univ, Sch Vet Med, Dept Pathol, USDA,Human Nutr Res Ctr Aging, Boston, MA 02111 USA; MIT, Ctr Canc Res, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Tufts University; United States Department of Agriculture (USDA); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Yamasaki, L (corresponding author), Columbia Univ, Dept Biol Sci, 1102 Fairchild Bldg,1212 Amsterdam Ave, New York, NY 10027 USA.		Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301				Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HARRISON DJ, 1995, ONCOGENE, V10, P1615; Horowitz Jonathan M., 1995, Molecular and Cellular Differentiation, V3, P275; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	28	248	251	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					360	364		10.1038/ng0498-360	http://dx.doi.org/10.1038/ng0498-360			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537419				2022-12-25	WOS:000072755500019
J	Apostolopoulos, V; Lofthouse, SA; Popovski, V; Chelvanayagam, G; Sandrin, MS; McKenzie, IFC				Apostolopoulos, V; Lofthouse, SA; Popovski, V; Chelvanayagam, G; Sandrin, MS; McKenzie, IFC			Peptide mimics of a tumor antigen induce functional cytotoxic T cells	NATURE BIOTECHNOLOGY			English	Article						applied immunology; tumor therapy; MUC1	MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; BREAST-CANCER; VIRAL PEPTIDES; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; MOLECULAR MIMICRY; IMMUNE-RESPONSES; FUSION PROTEIN; MHC	The ability to mimic peptide/peptide and/or peptide/carbohydrate structures may be important in generating cross-reactive antibodies for autoimmune and other diseases. We show that the peptide sequence DAHWESWL can mimic the conformation of the unrelated MUC1 peptide SAPDTRPAP(G). Mice immunized with mannan-MUC1-peptides make cytotoxic T lymphocytes (CTLs) and are protected from MUC1(+) tumors. We show that the same specific anti-MUC1 responses can be produced by immunizing with the DAHWESWL peptide; furthermore, specific tumor protection is obtained in a manner similar to that with MUC1 immunization. The DAHWESWL peptide immunization leads to CTLs that recognize H2D(d) and HaL(d-) but not H2(b) or human leukocyte antigens-group A (HLA-A)*0201 presented MUC1 peptides. However, mutation of the DAHWESWL peptide to a more HLA-A*0201-compatible structure with appropriate anchors (DLHWASWV), leads to the production of CTLs in HLA-A*0201 mice.	Austin Res Inst, Heidelberg, Vic 3084, Australia; Australian Natl Univ, John Curtin Sch Med Res, Dept Human Genet, Canberra, ACT 2601, Australia	Austin Research Institute; Australian National University; John Curtin School of Medical Research	McKenzie, IFC (corresponding author), Austin Res Inst, Studley Rd, Heidelberg, Vic 3084, Australia.	ifc_mckenzie@muwayf.unimelb.edu.au	Apostolopoulos, Vasso/Q-4525-2019	Apostolopoulos, Vasso/0000-0001-6788-2771				APOSTOLOPOULOS V, 1994, CANCER RES, V54, P5186; Apostolopoulos V, 1996, IMMUNOL CELL BIOL, V74, P457, DOI 10.1038/icb.1996.76; APOSTOLOPOULOS V, 1993, BRIT J CANCER, V67, P713, DOI 10.1038/bjc.1993.131; Apostolopoulos V, 1996, VACCINE, V14, P930, DOI 10.1016/0264-410X(95)00258-3; APOSTOLOPOULOS V, 1995, P NATL ACAD SCI USA, V92, P10128, DOI 10.1073/pnas.92.22.10128; Apostolopoulos V, 1997, J IMMUNOL, V159, P5211; Apostolopoulos V, 1997, EUR J IMMUNOL, V27, P2579, DOI 10.1002/eji.1830271017; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; Blake J, 1996, J EXP MED, V184, P121, DOI 10.1084/jem.184.1.121; BURCHELL J, 1989, INT J CANCER, V44, P691, DOI 10.1002/ijc.2910440423; BURCHELL J, 1987, CANCER RES, V47, P5476; Chelvanayagam G, 1996, PROTEIN ENG, V9, P1151, DOI 10.1093/protein/9.12.1151; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; IOANNIDES CG, 1993, J IMMUNOL, V151, P3693; JEROME KR, 1993, J IMMUNOL, V151, P1654; Karanikas V, 1997, J CLIN INVEST, V100, P2783, DOI 10.1172/JCI119825; Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; QUARATINO S, 1995, P NATL ACAD SCI USA, V92, P10398, DOI 10.1073/pnas.92.22.10398; Sandrin MS, 1997, GLYCOCONJUGATE J, V14, P97, DOI 10.1023/A:1018521217276; SINGER A, 1994, J NATL CANCER I, V86, P330; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; SMITH KJ, 1996, IMMUNITY, V4, P202; Vaughan HA, 1996, XENOTRANSPLANTATION, V3, P18, DOI 10.1111/j.1399-3089.1996.tb00114.x; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; Weiss GA, 1996, P NATL ACAD SCI USA, V93, P10945, DOI 10.1073/pnas.93.20.10945; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; XING PX, 1992, CANCER RES, V52, P2310; XING PX, 1989, IMMUNOL CELL BIOL, V67, P183, DOI 10.1038/icb.1989.29; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6	33	47	52	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					276	280		10.1038/nbt0398-276	http://dx.doi.org/10.1038/nbt0398-276			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528009				2022-12-25	WOS:000072371000029
J	Zhao, HM; Giver, L; Shao, ZX; Affholter, JA; Arnold, FH				Zhao, HM; Giver, L; Shao, ZX; Affholter, JA; Arnold, FH			Molecular evolution by staggered extension process (StEP) in vitro recombination	NATURE BIOTECHNOLOGY			English	Article						directed evolution; random mutagenesis; subtilisin	GENETIC ALGORITHMS; PEMPHIGUS-VULGARIS; IN-VITRO; DNA	We have developed a simple and efficient method for in vitro mutagenesis and recombination of polynucleotide sequences. The staggered extension process (StEP) consists of priming the template sequence(s) followed by repeated cycles of denaturation and extremely abbreviated annealing/polymerase-catalyzed extension. In each cycle the growing fragments anneal to different templates based on sequence complementarity and extend further. This is repeated until full-length sequences form. Due to template switching, most of the polynucleotides contain sequence information from different parental sequences. The method is demonstrated by the recombination of two genes encoding thermostable subtilisins carrying two phenotypic markers separated by 113 base pairs and eight other point mutation markers. To demonstrate its utility for directed evolution, we have used StEP to recombine a set of five thermostabilized subtilisin E variants identified during a single round of error-prone PCR mutagenesis and screening. Screening the StEP-recombined library yielded an enzyme whose half-life at 65 degrees C is 50 times that of wild-type subtilisin E.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Dow Chem Co USA, Mat R&D Biocatalysis, Midland, MI 48674 USA	California Institute of Technology; Dow Chemical Company	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	frances@cheme.caltech.edu	Wood, David W/B-2992-2012	Arnold, Frances H./0000-0002-4027-364X				Bradley RD, 1997, MOL BIOL EVOL, V14, P592, DOI 10.1093/oxfordjournals.molbev.a025797; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; FORREST S, 1993, SCIENCE, V261, P872, DOI 10.1126/science.8346439; GELFAND HA, 1989, PCR TECHNOLOGY, P18; HOLLAND JH, 1992, SCI AM, V267, P66, DOI 10.1038/scientificamerican0792-66; Holland JH, 1992, ADAPTATION NATURAL A, DOI DOI 10.7551/MITPRESS/1090.001.0001; Hu WS, 1997, J VIROL, V71, P6028, DOI 10.1128/JVI.71.8.6028-6036.1997; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Moore JC, 1997, J MOL BIOL, V272, P336, DOI 10.1006/jmbi.1997.1252; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHARF SJ, 1988, HUM IMMUNOL, V22, P61, DOI 10.1016/0198-8859(88)90052-3; SCHARF SJ, 1988, P NATL ACAD SCI USA, V85, P3504, DOI 10.1073/pnas.85.10.3504; Shafikhani S, 1997, BIOTECHNIQUES, V23, P304, DOI 10.2144/97232rr01; Shao ZX, 1998, NUCLEIC ACIDS RES, V26, P681, DOI 10.1093/nar/26.2.681; STAHL FW, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0287-90; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Zhao HM, 1997, P NATL ACAD SCI USA, V94, P7997, DOI 10.1073/pnas.94.15.7997; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	21	518	798	55	256	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					258	261		10.1038/nbt0398-258	http://dx.doi.org/10.1038/nbt0398-258			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528005				2022-12-25	WOS:000072371000025
J	Arras, M; Mollnau, H; Strasser, R; Wenz, R; Ito, WD; Schaper, J; Schaper, W				Arras, M; Mollnau, H; Strasser, R; Wenz, R; Ito, WD; Schaper, J; Schaper, W			The delivery of angiogenic factors to the heart by microsphere therapy	NATURE BIOTECHNOLOGY			English	Article						drug delivery; targeting; heart disease	FIBROBLAST GROWTH-FACTOR; MEDIATED GENE-TRANSFER; ISCHEMIC MYOCARDIUM; INJECTION; ARTERIES	Microspheres offer the possibility of local noninvasive delivery of drugs over an extended period of time. We adsorbed fibroblast growth factor (FGF) to microspheres of precapillary size that were injected via a coronary catheter. We showed that FGF was released from these microspheres and taken up by endothelial cells, which proliferated following translocation of FGF to the nucleus. This method for application of growth factors allows the precise delivery of angiogenic substances to any selected part of the heart or other organs without causing inflammation or ischemia.	Max Planck Inst Physiol & Clin Res, Dept Expt Cardiol, D-61231 Bad Nauheim, Germany; Merck KGAA, Merck Biomat, Darmstadt, Germany	Max Planck Society; Merck KGaA	Ito, WD (corresponding author), Max Planck Inst Physiol & Clin Res, Dept Expt Cardiol, Benekestr 2, D-61231 Bad Nauheim, Germany.	wito@kerckhoff.mpg.de		Arras, Margarete/0000-0003-3864-9879				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BANAI S, 1991, CIRC RES, V69, P76, DOI 10.1161/01.RES.69.1.76; BATTLER A, 1993, J AM COLL CARDIOL, V22, P2001, DOI 10.1016/0735-1097(93)90790-8; BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263, DOI 10.1152/ajpheart.1994.267.4.H1263; DENEFLE P, 1995, EXP OPIN INVESTIGATI, V4, P1129; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795; LANDAU C, 1995, AM HEART J, V129, P1051, DOI 10.1016/0002-8703(95)90383-6; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LEW D, 1995, HUM GENE THER, V6, P553, DOI 10.1089/hum.1995.6.5-553; LI JJ, 1995, CARDIOVASC RES, V30, P97, DOI 10.1016/S0008-6363(95)00005-4; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; SCHAPER W, 1988, PROG CARDIOVASC DIS, V31, P57, DOI 10.1016/0033-0620(88)90011-4; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588	18	51	69	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					159	162		10.1038/nbt0298-159	http://dx.doi.org/10.1038/nbt0298-159			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487522				2022-12-25	WOS:000071831300028
J	Hoyle, R				Hoyle, R			DNAP is caught in the tobacco firestorm	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					118	118		10.1038/nbt0298-118	http://dx.doi.org/10.1038/nbt0298-118			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487497				2022-12-25	WOS:000071831300004
J	Jansen, B; Schlagbauer-Wadl, H; Brown, BD; Bryan, RN; van Elsas, A; Muller, M; Wolff, K; Eichler, HG; Pehamberger, H				Jansen, B; Schlagbauer-Wadl, H; Brown, BD; Bryan, RN; van Elsas, A; Muller, M; Wolff, K; Eichler, HG; Pehamberger, H			bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice	NATURE MEDICINE			English	Article							MALIGNANT-MELANOMA; EXPRESSION	Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy(1). A number of chemotherapeutic agents have been shown recently to act by inducing apoptosis, a type of cell death antagonized by the bcl-2 gene(2). Human melanoma expresses Bcl-2 in up to 90% of all cases(3-7). In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemosensitivity of human melanoma grown in severe combined immunodeficient (SCID) mice. Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.	Univ Vienna, Dept Clin Pharmacol, Sect Expt Oncol, A-1090 Vienna, Austria; Univ Vienna, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; Genta Inc, San Diego, CA 92121 USA; Univ Hosp, AZL, Dept Clin Oncol, NL-2300 Leiden, Netherlands	University of Vienna; University of Vienna	Jansen, B (corresponding author), Univ Vienna, Dept Clin Pharmacol, Sect Expt Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CERRONI L, 1995, AM J DERMATOPATH, V17, P7, DOI 10.1097/00000372-199502000-00002; Christoffersen RE, 1997, NAT BIOTECHNOL, V15, P483, DOI 10.1038/nbt0697-483; COMIS RL, 1976, CANCER TREAT REP, V60, P165; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P395; Hickman JA, 1996, EUR J CANCER, V32A, P921, DOI 10.1016/0959-8049(96)00080-9; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MORALESDUCRET CRJ, 1995, ARCH DERMATOL, V131, P909, DOI 10.1001/archderm.131.8.909; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; TRON VA, 1995, AM J PATHOL, V146, P643; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994	16	432	453	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					232	234		10.1038/nm0298-232	http://dx.doi.org/10.1038/nm0298-232			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461199				2022-12-25	WOS:000072249800041
J	Aaltonen, J; Bjorses, P; Perheentupa, J; HorelliKuitunen, N; Palotie, A; Peltonen, L; Lee, YS; Francis, F; Hennig, S; Thiel, C; Lehrach, H; Yaspo, ML				Aaltonen, J; Bjorses, P; Perheentupa, J; HorelliKuitunen, N; Palotie, A; Peltonen, L; Lee, YS; Francis, F; Hennig, S; Thiel, C; Lehrach, H; Yaspo, ML			An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains	NATURE GENETICS			English	Article							HUMAN DNA; PHOSPHOFRUCTOKINASE GENE; CODING REGIONS; SEQUENCES; PROTEIN; IDENTIFICATION; CANDIDIASIS; AUTOANTIGEN; MODEL; EXON	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is the only described systemic autoimmune disease with established monogenic background, and the first autoimmune disorder localized outside the major histocompatibility complex (MHC) region. The primary biochemical defect in APECED is unknown. We have isolated a novel gene, AIRE, encoding for a putative nuclear protein featuring two PHD-type zinc-finger motifs, suggesting its involvement in transcriptional regulation. Five mutations in AIRE are reported in individuals with this disorder. This is the first report of a single-gene defect causing a systemic human autoimmune disease, providing a tool for exploring the molecular basis of autoimmunity.	UNIV HELSINKI,INST BIOMED,DEPT HUMAN MOL GENET,FIN-00300 HELSINKI,FINLAND; UNIV HELSINKI,HOSP CHILDREN & ADOLESCENTS,HELSINKI,FINLAND; UNIV HELSINKI,DEPT CLIN CHEM,SF-00100 HELSINKI,FINLAND; UNIV HELSINKI,DEPT BIOMED,SF-00100 HELSINKI,FINLAND; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Max Planck Society			Francis, Fiona/B-5854-2016					AALTONEN J, 1994, NAT GENET, V8, P83, DOI 10.1038/ng0994-83; Aaltonen J, 1997, GENOME RES, V7, P820, DOI 10.1101/gr.7.8.820; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; AHONEN P, 1987, J CLIN ENDOCR METAB, V64, P494, DOI 10.1210/jcem-64-3-494; AHONEN P, 1988, J CLIN ENDOCR METAB, V66, P1152, DOI 10.1210/jcem-66-6-1152; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bettinardi A, 1997, BLOOD, V89, P902, DOI 10.1182/blood.V89.3.902; Bjorses P, 1996, AM J HUM GENET, V59, P879; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAMPBELL RD, 1993, CURR OPIN IMMUNOL, V5, P887, DOI 10.1016/0952-7915(93)90101-W; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELSON A, 1990, GENOMICS, V7, P47, DOI 10.1016/0888-7543(90)90517-X; Fidel Paul L. Jr., 1994, Trends in Microbiology, V2, P202, DOI 10.1016/0966-842X(94)90112-I; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Heiskanen M, 1996, TRENDS GENET, V12, P379, DOI 10.1016/0168-9525(96)30083-8; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KROHN K, 1992, LANCET, V339, P770, DOI 10.1016/0140-6736(92)91894-E; KULP D, 1996, ISMB, V4, P134; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEVANON D, 1995, BIOCHEM MOL BIOL INT, V35, P929; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; SYVANEN AC, 1989, FEBS LETT, V258, P71, DOI 10.1016/0014-5793(89)81618-7; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P150, DOI 10.1016/0167-5699(95)80133-2; THOMAS A, 1994, IMA J MATH APPL MED, V11, P149; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; YASPO ML, 1995, HUM MOL GENET, V4, P1291, DOI 10.1093/hmg/4.8.1291; ZLOTOGORA J, 1992, J MED GENET, V29, P824, DOI 10.1136/jmg.29.11.824	34	846	865	0	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					399	403		10.1038/ng1297-399	http://dx.doi.org/10.1038/ng1297-399			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398840				2022-12-25	WOS:A1997YJ92400019
J	Sano, T; Nagayama, A; Ogawa, T; Ishida, I; Okada, Y				Sano, T; Nagayama, A; Ogawa, T; Ishida, I; Okada, Y			Transgenic potato expressing a double-stranded RNA-specific ribonuclease is resistant to potato spindle tuber viroid	NATURE BIOTECHNOLOGY			English	Article						transgenic plants; resistance; pac1	TOBACCO MOSAIC-VIRUS; REPLICATION CYCLE; GENE SEQUENCE; ANTISENSE RNA; PLANT-VIRUSES; INFECTION; PROTEIN	We have produced transgenic potato lines expressing the yeast-derived double-stranded RNA-specific ribonuclease pad. Five lines of pad potato (Solanum tuberosum L., cultivar Russet Burbank) challenged with potato spindle tuber viroid (PSTVd) suppressed PSTVd infection and accumulation, All of the progeny potato tubers produced by resistant plants were also free of PSTVd. Because the pad gene product digested PSTVd in vitro, double-stranded regions in PSTVd molecule and/or replicative intermediates may be targeted by pad gene product in the transgenic potato plant.	Hirosaki Univ, Fac Agr, Phytopathol Lab, Hirosaki, Aomori 036, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Teikyo Univ, Sch Sci & Engn, Dept Biosci, Utsunomiya, Tochigi 320, Japan	Hirosaki University; Kirin Brewery Company Limited; Teikyo University	Sano, T (corresponding author), Hirosaki Univ, Fac Agr, Phytopathol Lab, Hirosaki, Aomori 036, Japan.							ATKINS D, 1995, J GEN VIROL, V76, P1781, DOI 10.1099/0022-1317-76-7-1781; BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BONFIGLIOLI RG, 1994, PLANT J, V6, P99, DOI 10.1046/j.1365-313X.1994.6010099.x; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; Diener T.O., 1987, VIROIDS; ESTRADA R, 1986, PLANT CELL TISS ORG, V7, P3, DOI 10.1007/BF00043915; GOLEMBOSKI DB, 1990, P NATL ACAD SCI USA, V87, P6311, DOI 10.1073/pnas.87.16.6311; GROSS HJ, 1978, NATURE, V273, P203, DOI 10.1038/273203a0; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; ISHIDA BK, 1989, PLANT CELL REP, V8, P325, DOI 10.1007/BF00716665; ISHIKAWA M, 1984, MOL GEN GENET, V196, P421, DOI 10.1007/BF00436189; LAPIDOT M, 1993, PLANT J, V4, P959, DOI 10.1046/j.1365-313X.1993.04060959.x; Li Shi-Fang, 1995, Annals of the Phytopathological Society of Japan, V61, P381, DOI 10.3186/jjphytopath.61.381; LINDBO JA, 1992, VIROLOGY, V189, P725, DOI 10.1016/0042-6822(92)90595-G; LOMONOSSOFF GP, 1995, ANNU REV PHYTOPATHOL, V33, P323, DOI 10.1146/annurev.py.33.090195.001543; MAITI IB, 1993, P NATL ACAD SCI USA, V90, P6110, DOI 10.1073/pnas.90.13.6110; MATOUSEK J, 1994, BIOL CHEM H-S, V375, P765, DOI 10.1515/bchm3.1994.375.11.765; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OWENS RA, 1982, P NATL ACAD SCI-BIOL, V79, P113, DOI 10.1073/pnas.79.1.113; POWELL PA, 1989, P NATL ACAD SCI USA, V86, P6949, DOI 10.1073/pnas.86.18.6949; POWELLABEL P, 1986, SCIENCE, V232, P738, DOI DOI 10.1126/SCIENCE.3457472; QU F, 1993, EMBO J, V12, P2129, DOI 10.1002/j.1460-2075.1993.tb05861.x; RIESNER D, 1990, SEMIN VIROL, V1, P83; RIESNER D, 1987, VIROIDS, P63; Sano T., 1996, Archives of Phytopathology and Plant Protection, V30, P303, DOI 10.1080/03235409609383180; SANO T, 1995, PATHOGENESIS HOST SP, V3, P363; SINGH RP, 1987, PHYTOPATHOLOGY, V77, P1588, DOI 10.1094/Phyto-77-1588; SYMONS RH, 1990, SEMIN VIROL, V1, P117; WATANABE Y, 1995, FEBS LETT, V372, P165, DOI 10.1016/0014-5793(95)00901-K; [No title captured]	30	61	70	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1290	1294		10.1038/nbt1197-1290	http://dx.doi.org/10.1038/nbt1197-1290			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359114				2022-12-25	WOS:000071342000033
J	Parr, MJ; Manome, Y; Tanaka, T; Wen, P; Kufe, DW; Kaelin, WG; Fine, HA				Parr, MJ; Manome, Y; Tanaka, T; Wen, P; Kufe, DW; Kaelin, WG; Fine, HA			Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector	NATURE MEDICINE			English	Article							RETINOBLASTOMA PROTEIN; CDK4 AMPLIFICATION; BRAIN-TUMORS; E2F-1 GENE; DELETION; DNA; GLIOBLASTOMAS; TRANSCRIPTION; PROGRESSION; MAJORITY	Recent data suggest that many tumors, such as malignant gliomas, have disrupted pRB function, either because of RB-1 gene mutations or as a result of mutations affecting upstream regulators of pRB such as cyclin D1 or pl6/INK4a/MTS1 (ref. 1-5). Tumor suppression by pRB has been linked to its ability to repress E2F-responsive promoters such as the E2F-1 promoter(6,7). Thus, a prediction, which has not yet been demonstrated experimentally in vivo, is that EaF-responsive promoters should be more active in tumor cells relative to normal cells because of an excess of ''free'' E2F and loss of pRB/E2F repressor complexes. We demonstrate that adenoviral vectors that contain transgenes driven by the E2F-1 promoter can mediate tumor-selective gene expression in vivo, allowing for eradication of established gliomas with significantly less normal tissue toxicity than seen with standard adenoviral vectors. Our data indicate that de-repression of the E2F-1 promoter occurs in cancer cells in vivo, a finding that can be exploited to design viral vectors that mediate tumor-selective gene expression.	HARVARD UNIV,SCH MED,CTR NEUROONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,LAB CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,LAB NEOPLAST DIS MECHANISMS,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Wen, Patrick/AAE-3776-2022	Manome, Yoshinobu/0000-0002-8755-8976; Parr, Michael/0000-0003-3507-474X				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Dong YH, 1996, HUM GENE THER, V7, P713, DOI 10.1089/hum.1996.7.6-713; FINE HA, 1994, PERSPECT NEUROL SURG, V5, P115; FULTS D, 1992, CANCER RES, V52, P674; GHOSHCHOUDHURY G, 1986, GENE, V50, P161, DOI 10.1016/0378-1119(86)90321-5; Goodman JC, 1996, HUM GENE THER, V7, P1241, DOI 10.1089/hum.1996.7.10-1241; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HE J, 1994, CANCER RES, V54, P5804; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JEN J, 1994, CANCER RES, V54, P6353; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOBAYASHI N, 1980, J NEUROSURG, V53, P808, DOI 10.3171/jns.1980.53.6.0808; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; RAM Z, 1993, CANCER RES, V53, P3475; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Ueki K, 1996, CANCER RES, V56, P150; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	24	136	169	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1145	1149		10.1038/nm1097-1145	http://dx.doi.org/10.1038/nm1097-1145			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334729				2022-12-25	WOS:A1997XZ28700043
J	Feng, MZ; Jackson, WH; Goldman, CK; Rancourt, C; Wang, MH; Dusing, SK; Siegal, G; Curiel, DT				Feng, MZ; Jackson, WH; Goldman, CK; Rancourt, C; Wang, MH; Dusing, SK; Siegal, G; Curiel, DT			Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector	NATURE BIOTECHNOLOGY			English	Article						gene therapy; chimeric viral vectors	ADENOVIRUS-MEDIATED TRANSFER; BRAIN-TUMORS; FAMILIAL HYPERCHOLESTEROLEMIA; RETROVIRAL VECTORS; CYSTIC-FIBROSIS; RECEPTOR GENE; THERAPY; HEPATOCYTES; EXPRESSION; MICE	Gene therapy to correct defective genes requires efficient gene delivery and long-term gene expression. The available vector systems have not allowed the simultaneous achievement of both goals. We have developed a chimeric viral vector system that incorporates favorable aspects of both adenoviral and retroviral vectors. Adenoviral vectors induce target cells to function as transient retroviral producer cells in vivo. The progeny retroviral vector particles are then able to stably transduce neighboring cells. In this system, the nonintegrative adenoviral vector is rendered functionally integrative via the intermediate generation of a retroviral producer cell. The chimeric vectors may allow realization of the requisite goals for specific gene-therapy applications.	UNIV ALABAMA,DEPT PATHOL,GENE THERAPY PROGRAM,BIRMINGHAM,AL 35294; MA BIOSERV INC,VIROL LAB,ROCKVILLE,MD 20850	University of Alabama System; University of Alabama Birmingham			Siegal, Gene/A-8653-2009	Siegal, Gene/0000-0003-3857-3368				ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; CURIEL DT, 1994, NAT IMMUN, V13, P141; DAI Y, 1992, J CLIN INVEST, V89, P10892; DUNCKLEY MG, 1993, HUM MOL GENET, V2, P717, DOI 10.1093/hmg/2.6.717; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; FINER MH, 1994, BLOOD, V83, P43; Fisher KJ, 1996, HUM GENE THER, V7, P2079, DOI 10.1089/hum.1996.7.17-2079; FLAMANT F, 1995, VIROLOGY, V211, P234, DOI 10.1006/viro.1995.1396; FLAMANT F, 1994, INT J DEV BIOL, V38, P751; Fox JC, 1996, THER DRUG MONIT, V18, P410, DOI 10.1097/00007691-199608000-00018; HAAPALA DK, 1985, J VIROL, V53, P827, DOI 10.1128/JVI.53.3.827-833.1985; HAFFE HA, 1992, NAT GENET, V1, P372; HANNANIA EG, 1995, AM J MED, V99, P537; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KLEIN HG, 1994, J CLIN APHERESIS, V9, P139, DOI 10.1002/jca.2920090210; KOLODKA TM, 1993, SOMAT CELL MOLEC GEN, V19, P491, DOI 10.1007/BF01233254; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; LOZIER JN, 1994, JAMA-J AM MED ASSOC, V271, P47, DOI 10.1001/jama.271.1.47; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MILLER AD, 1990, BLOOD, V76, P271; MORLING FJ, 1995, GENE THER, V2, P504; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; MOSCIONI AD, 1993, SURGERY, V113, P304; NoguiezHellin P, 1996, P NATL ACAD SCI USA, V93, P4175, DOI 10.1073/pnas.93.9.4175; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAM Z, 1993, CANCER RES, V53, P83; RAM Z, 1993, J NEUROSURG, V79, P400, DOI 10.3171/jns.1993.79.3.0400; RAM Z, 1994, CANCER RES, V54, P2141; ROEMER K, 1992, EUR J BIOCHEM, V208, P211, DOI 10.1111/j.1432-1033.1992.tb17176.x; Rollins SA, 1996, HUM GENE THER, V7, P619, DOI 10.1089/hum.1996.7.5-619; Rosenfeld MA, 1996, CHEST, V109, P241, DOI 10.1378/chest.109.1.241; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; TAKAMIYA Y, 1993, J NEUROSURG, V79, P104, DOI 10.3171/jns.1993.79.1.0104; VILE RG, 1995, BRIT MED BULL, V51, P12, DOI 10.1093/oxfordjournals.bmb.a072941; Wilson JM, 1995, J CLIN INVEST, V96, P2547, DOI 10.1172/JCI118318; YANG Y, 1995, IMMUNITY, V1, P433; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, J IMMUNOL, V155, P2564; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Ye XH, 1996, J BIOL CHEM, V271, P3639	46	123	170	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					866	870		10.1038/nbt0997-866	http://dx.doi.org/10.1038/nbt0997-866			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306401				2022-12-25	WOS:A1997XW41000028
J	Hoyle, R				Hoyle, R			Delaney clause knocked out by surprise compromise act	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1056	1056		10.1038/nbt0996-1056a	http://dx.doi.org/10.1038/nbt0996-1056a			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631048	Bronze			2022-12-25	WOS:A1996VF84300003
J	Tsukui, T; Kanegae, Y; Saito, I; Toyoda, Y				Tsukui, T; Kanegae, Y; Saito, I; Toyoda, Y			Transgenesis by adenovirus-mediated gene transfer into mouse zona-free eggs	NATURE BIOTECHNOLOGY			English	Article						replication-defective adenovirus vector; transgenesis	GERM LINE; CYSTIC-FIBROSIS; CRE RECOMBINASE; CFTR CDNA; EXPRESSION; VECTOR; CELLS; DNA; INTEGRATION; EMBRYOS	Zona-free mouse eggs at the pronucleus stage were infected with a replication-defective adenovirus vector containing a nuclear-targeted lacZ gene. Exogenous beta-galactosidase activity was detected in almost all eggs at the two-cell stage. Of 27 mice that developed from infected eggs, three carried the integrated exogenous gene mediated by the adenovirus. Two of the three expressed the lacZ gene, and all three mice transmitted the adenovirus-mediated transgene to F1 progeny Southern blot analysis was consistent with single copy integration. This finding should accelerate the development of new strategies for transgenesis and assist studies on the function of cloned genes in vivo.	UNIV TOKYO, INST MED SCI, DEPT REPROD & DEV BIOL, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, GENET MOLEC LAB, MINATO KU, TOKYO 108, JAPAN; OBIHIRO UNIV AGR & VET MED, RES CTR PROTOZOAN MOLEC IMMUNOL, OBIHIRO, HOKKAIDO 080, JAPAN	University of Tokyo; University of Tokyo; Obihiro University of Agriculture & Veterinary Medicine								ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; BISHOP JO, 1989, MOL BIOL MED, V6, P283; CHEN SH, 1995, P NATL ACAD SCI USA, V92, P2577, DOI 10.1073/pnas.92.7.2577; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; DORSCHHASLER K, 1980, J VIROL, V34, P305; Ginsberg HS, 1984, ADENOVIRUSES; GORDON JW, 1989, INT REV CYTOL, V115, P171; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; HOSHI M, 1985, Japanese Journal of Zootechnical Science, V56, P931; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JAHNER D, 1985, P NATL ACAD SCI USA, V82, P6927, DOI 10.1073/pnas.82.20.6927; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PINKERT CA, 1994, TRANSGENIC ANIMAL TE; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; RUBENSTEIN JLR, 1986, P NATL ACAD SCI USA, V83, P366, DOI 10.1073/pnas.83.2.366; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; TSUKUI T, 1995, MOL REPROD DEV, V42, P291, DOI 10.1002/mrd.1080420305; VISSER L, 1981, J VIROL, V39, P684, DOI 10.1128/JVI.39.3.684-693.1981; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75; [No title captured]	28	61	65	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					982	985		10.1038/nbt0896-982	http://dx.doi.org/10.1038/nbt0896-982			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631035				2022-12-25	WOS:A1996UZ19900029
J	Blechl, AE; Anderson, OD				Blechl, AE; Anderson, OD			Expression of a novel high-molecular-weight glutenin subunit gene in transgenic wheat	NATURE BIOTECHNOLOGY			English	Article						glutenin promoter; genetic engineering; seed storage protein modification	RAPID PRODUCTION; PROTEINS; BOMBARDMENT; PLANTS; MAIZE	High-molecular-weight glutenin subunits (HMW-GS), one class of seed storage proteins, are important determinants of the bread-making quality of wheat flour. To change the amount and composition of these proteins via genetic engineering, a gene encoding a novel hybrid subunit under the control of native HMW-GS regulatory sequences was inserted into wheat. Of 26 independent transgenic lines identified by bialaphos selection, 18 expressed the cotransformed hybrid HMW-GS gene in their seed. The hybrid subunit accumulated to levels comparable to those of the native HMW-GS. These results show that a native HMW-GS gene promoter can be used to obtain high levels of expression of seed storage and, potentially, other proteins in transgenic wheat endosperm. Transgene expression was stable for at least three seed generations in the majority of lines. These experiments demonstrate the feasibility of constructing wheat plants with novel seed protein compositions.			Blechl, AE (corresponding author), USDA ARS,WESTERN REG RES CTR,800 BUCHANAN ST,ALBANY,CA 94710, USA.							ANDERSON OD, 1989, NUCLEIC ACIDS RES, V17, P3156; BIETZ JA, 1992, J CHROMATOGR, V624, P53, DOI 10.1016/0021-9673(92)85674-I; CORNEJO MJ, 1993, PLANT MOL BIOL, V23, P567, DOI 10.1007/BF00019304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacRitchie F., 1992, Advances in Food and Nutrition Research, V36, P1, DOI 10.1016/S1043-4526(08)60104-7; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SHANI N, 1992, PLANT PHYSIOL, V98, P433, DOI 10.1104/pp.98.2.433; SHEWRY PR, 1995, BIO-TECHNOL, V13, P1185, DOI 10.1038/nbt1195-1185; SHEWRY PR, 1989, OXFORD SURV PLANT MO, V6, P163; VAIN P, 1993, PLANT CELL REP, V12, P84, DOI 10.1007/BF00241940; VASIL V, 1993, BIO-TECHNOL, V11, P1553, DOI 10.1038/nbt1293-1553; VASIL V, 1992, BIO-TECHNOL, V10, P667, DOI 10.1038/nbt0692-667; Weegels PL, 1996, J CEREAL SCI, V23, P1, DOI 10.1006/jcrs.1996.0001; WEEKS JT, 1993, PLANT PHYSIOL, V102, P1077, DOI 10.1104/pp.102.4.1077	17	196	254	1	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					875	879		10.1038/nbt0796-875	http://dx.doi.org/10.1038/nbt0796-875			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631014				2022-12-25	WOS:A1996UV62000039
J	LopezNieto, CE; Nigam, SK				LopezNieto, CE; Nigam, SK			Selective amplification of protein-coding regions of large sets of genes using statistically designed primer sets	NATURE BIOTECHNOLOGY			English	Article						G-protein coupled receptors; gene detection; primer design; K-tuple frequency; computer simulation	POLYMERASE CHAIN-REACTION; ARBITRARY OLIGONUCLEOTIDE PRIMERS; K-TUPLE FREQUENCY; CLONING; GENOMES; ACID; RNA; DNA	We describe a novel approach to design a set of primers selective for large groups of genes. This method is based on the distribution frequency of all nucleotide combinations (octa- to decanucleotides), and the combined ability of primer pairs, based on these oligonucleotides, to detect genes. By analyzing 1000 human mRNAs, we found that a surprisingly small subset of octanucleotides is shared by a high proportion of human protein-coding region sense strands. By computer simulation of polymerase chain reactions, a set based on only 30 primers was able to detect approximately 75% of known (and presumably unknown) human protein-coding regions, To validate the method and provide experimental support for the feasibility of the more ambitious goal of targeting human protein-coding regions, we sought to apply the technique to a large protein family: G-protein coupled receptors (GPCRs). Our results indicate that there is sufficient low level homology among human coding regions to allow design of a limited set of primer pairs that can selectively target coding regions in general, as well as genomic subsets (e.g., GPCRs). The approach should be generally applicable to human coding regions, and thus provide an efficient method for analyzing much of the transcriptionally active human genome.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	LopezNieto, CE (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044503] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44503] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CAETANOANOLLES G, 1992, MOL GEN GENET, V235, P157, DOI 10.1007/BF00279356; CAETANOANOLLES G, 1991, BIO-TECHNOL, V9, P553, DOI 10.1038/nbt0691-553; CAETANOANOLLES G, 1993, PCR METH APPL, V3, P85; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAVERIE JM, 1990, METHOD ENZYMOL, V183, P237; DUMAS JP, 1982, NUCLEIC ACIDS RES, V10, P197, DOI 10.1093/nar/10.1.197; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GRIFFAIS R, 1991, NUCLEIC ACIDS RES, V19, P3887; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LANDER ES, 1993, NAT GENET, V4, P5, DOI 10.1038/ng0593-5; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LISITSYN NA, 1994, NAT GENET, V6, P57, DOI 10.1038/ng0194-57; *NAT CTR BIOT INF, 1993, ENTR SEQ REL 6 0 7 0; SMITH MW, 1994, NAT GENET, V7, P40, DOI 10.1038/ng0594-40; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; STONE B, 1994, NUCLEIC ACIDS RES, V22, P2612, DOI 10.1093/nar/22.13.2612; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; ZHANG MQ, 1993, P NATL ACAD SCI USA, V90, P600, DOI 10.1073/pnas.90.2.600	23	34	43	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					857	861		10.1038/nbt0796-857	http://dx.doi.org/10.1038/nbt0796-857			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631010				2022-12-25	WOS:A1996UV62000035
J	Ishida, Y; Saito, H; Ohta, S; Hiei, Y; Komari, T; Kumashiro, T				Ishida, Y; Saito, H; Ohta, S; Hiei, Y; Komari, T; Kumashiro, T			High efficiency transformation of maize (Zea mays L) mediated by Agrobacterium tumefaciens	NATURE BIOTECHNOLOGY			English	Article						transformation; maize; Agrobacterium tumefaciens	T-DNA; TRANSGENIC PLANTS; HOST RANGE; GENE; CELLS; CONSTRUCTION; INHERITANCE; EXPRESSION; TISSUES	Transformants of maize inbred A188 were efficiently produced from immature embryos cocultivated with Agrobacterium tumefaciens that carried ''super-binary'' vectors. Frequencies of transformation (independent transgenic plants/embryos) were between 5% and 30%. Almost all transformants were normal in morphology, and more than 70% were fertile. Stable integration, expression, and inheritance of the transgenes were confirmed by molecular and genetic analysis. Between one and three copies of the transgenes were integrated with little rearrangement, and the boundaries of T-DNA were similar to those in transgenic dicotyledons and rice. F1 hybrids between A188 and five other inbreds were transformed at low frequencies.			Ishida, Y (corresponding author), JAPAN TOBACCO INC, PLANT BREEDING & GENET RES LAB, 700 HIGASHIBARA, IWATA, SHIZUOKA 438, JAPAN.							ARMSTRONG CL, 1985, PLANTA, V164, P207, DOI 10.1007/BF00396083; CHAN MT, 1993, PLANT MOL BIOL, V22, P491, DOI 10.1007/BF00015978; CHAN MT, 1992, PLANT CELL PHYSIOL, V33, P577; Chu CC., 1978, P S PLANT TISS CULT, P43; DECLEENE M, 1976, BOT REV, V42, P389, DOI 10.1007/BF02860827; DENECKE J, 1989, Methods in Molecular and Cellular Biology, V1, P19; DHALLUIN K, 1992, PLANT CELL, V4, P1495, DOI 10.1105/tpc.4.12.1495; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DOES MP, 1991, PLANT MOL BIOL, V17, P151, DOI 10.1007/BF00036819; FRAME BR, 1994, PLANT J, V6, P941, DOI 10.1046/j.1365-313X.1994.6060941.x; FROMM ME, 1990, BIO-TECHNOL, V8, P833, DOI 10.1038/nbt0990-833; GORDONKAMM WJ, 1990, PLANT CELL, V2, P603, DOI 10.1105/tpc.2.7.603; GOULD J, 1991, PLANT PHYSIOL, V95, P426, DOI 10.1104/pp.95.2.426; GRIMSLEY N, 1987, NATURE, V325, P177, DOI 10.1038/325177a0; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KOMARI T, 1990, PLANT CELL REP, V9, P303, DOI 10.1007/BF00232856; KOMARI T, 1989, THEOR APPL GENET, V77, P547, DOI 10.1007/BF00274277; KOZIEL MG, 1993, BIO-TECHNOL, V11, P194, DOI 10.1038/nbt0293-194; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; MOONEY PA, 1991, PLANT CELL TISS ORG, V25, P209; OHTA S, 1990, PLANT CELL PHYSIOL, V31, P805; RHODES CA, 1988, SCIENCE, V240, P204, DOI 10.1126/science.2832947; SAMBROOK J, 1989, MO LCLONING LAB MANU; SHEN WH, 1993, P NATL ACAD SCI USA, V90, P1488, DOI 10.1073/pnas.90.4.1488; WALTERS DA, 1992, PLANT MOL BIOL, V18, P189, DOI 10.1007/BF00034948; WAN YC, 1995, PLANTA, V196, P7, DOI 10.1007/BF00193211; YADAV NS, 1982, P NATL ACAD SCI-BIOL, V79, P6322, DOI 10.1073/pnas.79.20.6322	29	582	1009	7	99	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					745	750		10.1038/nbt0696-745	http://dx.doi.org/10.1038/nbt0696-745			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630983				2022-12-25	WOS:A1996UM76600031
J	Hodgson, CP; Solaiman, F				Hodgson, CP; Solaiman, F			Virosomes: Cationic liposomes enhance retroviral transduction	NATURE BIOTECHNOLOGY			English	Article						VL30; retroviral vector; retrotransposon; gene therapy	GENE-TRANSFER; CELL-LINES; VIRUS; INFECTIVITY	Retrovirus-derived vectors are overwhelmingly preferred over other methods for ex vivo gene therapy because they provide permanent integration of foreign genes into cellular DNA. In comparison, cationic lipids mediate efficent gene transfer, but expression is transient. When we combined cationic lipids with retrovirus particles we obtained a significant enhancement of transduction efficiency, depending upon the type of lipid formulation and the dose used. The relative effectiveness of these cytofectins was: DOSPA:DOPE>DOTMA:DOPE>DOTAP, resulting in 60-, 37-, and 5-fold increases in transduction efficiency, respectively, at optimum dosage. The effect of polycationic DOSPA:DOPE was dependent upon the viral envelope glycoprotein, was attainable by lipid treatment of either cells or virus particles, was not enhanced by the addition of polybrene, and was inhibited by chloroquine. These results strongly suggested that DOSPA:DOPE act primarily by modulation of charge associated with the viral envelope and cell membrane, enhancing retroviral transduction, rather than by providing an alternative pathway of transfection. DOSPA:DOPE is useful for improving the efficiency of gene transfer as well as the sensitivity with which retroviruses can be detected in biological fluids.			Hodgson, CP (corresponding author), CREIGHTON UNIV,SCH MED,CREIGHTON CANC CTR,OMAHA,NE 68178, USA.				NIGMS NIH HHS [GM41314-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM041314, R29GM041314] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAKRABORTY AK, 1995, BIOCHEM BIOPH RES CO, V209, P677, DOI 10.1006/bbrc.1995.1552; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEBS RJ, 1993, Patent No. 25673; FALLER DV, 1984, J VIROL, V49, P269, DOI 10.1128/JVI.49.1.269-272.1984; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; HODGSON CP, 1995, BIO-TECHNOL, V13, P222, DOI 10.1038/nbt0395-222; INNES CL, 1990, J VIROL, V64, P957, DOI 10.1128/JVI.64.2.957-961.1990; JOLLY D, 1992, Patent No. 5266; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KONDOROSI E, 1982, BIOCHEM BIOPH RES CO, V107, P367, DOI 10.1016/0006-291X(82)91713-2; KONOPKA K, 1990, J GEN VIROL, V71, P2899, DOI 10.1099/0022-1317-71-12-2899; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; WILSON T, 1977, P NATL ACAD SCI USA, V74, P3471, DOI 10.1073/pnas.74.8.3471; WU GY, 1992, Patent No. 6180; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564	19	78	95	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					339	342		10.1038/nbt0396-339	http://dx.doi.org/10.1038/nbt0396-339			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630897				2022-12-25	WOS:A1996UL38000029
J	Tyagi, S; Kramer, FR				Tyagi, S; Kramer, FR			Molecular beacons: Probes that fluoresce upon hybridization	NATURE BIOTECHNOLOGY			English	Article						homogeneous real-time assays; allele discrimination; multiplex gene detection	RESONANCE ENERGY-TRANSFER; OLIGONUCLEOTIDES; KINETICS; PCR	We have developed novel nucleic acid probes that recognize and report the presence of specific nucleic acids in homogeneous solutions. These probes undergo a spontaneous fluorogenic conformational change when they hybridize to their targets. Only perfectly complementary targets elicit this response, as hybridization does not occur when the target contains a mismatched nucleotide or a deletion. The probes are particularly suited for monitoring the synthesis of specific nucleic acids in real time. When used in nucleic acid amplification assays, gene detection is homogeneous and sensitive, and can be carried out in a sealed tube. When introduced into living cells, these probes should enable the origin, movement, and fate of specific mRNAs to be traced.			Tyagi, S (corresponding author), PUBL HLTH RES INST,DEPT MOLEC GENET,455 1ST AVE,NEW YORK,NY 10016, USA.		Ha, Dat Thinh/D-4995-2015; Tyagi, Sanjay/F-1109-2010	Ha, Dat Thinh/0000-0003-4260-4876; Tyagi, Sanjay/0000-0001-7303-5827	NHLBI NIH HHS [HL-43521] Funding Source: Medline; NIAID NIH HHS [AI-37015] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CONNOLLY BA, 1985, NUCLEIC ACIDS RES, V13, P4485, DOI 10.1093/nar/13.12.4485; COOPER JP, 1990, BIOCHEMISTRY-US, V29, P9261, DOI 10.1021/bi00491a022; COUTTS SM, 1971, BIOCHIM BIOPHYS ACTA, V232, P91; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; HELLER MJ, 1982, Patent No. 823036991; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; LEE LG, 1993, NUCLEIC ACIDS RES, V21, P3761, DOI 10.1093/nar/21.16.3761; LIVAK KJ, 1995, PCR METH APPL, V4, P357; LOMELI H, 1989, CLIN CHEM, V35, P1826; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; MERGNY JL, 1994, NUCLEIC ACIDS RES, V22, P920, DOI 10.1093/nar/22.6.920; MORRISON LE, 1989, ANAL BIOCHEM, V183, P231, DOI 10.1016/0003-2697(89)90473-9; MORRISON LE, 1993, BIOCHEMISTRY-US, V32, P3095, DOI 10.1021/bi00063a022; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SIXOU S, 1994, NUCLEIC ACIDS RES, V22, P662, DOI 10.1093/nar/22.4.662; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TYAGI S, 1996, IN PRESS P NATL ACAD, V93; WANG GT, 1990, TETRAHEDRON LETT, V31, P6493, DOI 10.1016/S0040-4039(00)97099-0	23	3392	4290	30	888	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					303	308		10.1038/nbt0396-303	http://dx.doi.org/10.1038/nbt0396-303			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630890				2022-12-25	WOS:A1996UL38000022
J	Lee, SJ; Liyanage, U; Bickel, PE; Xia, WM; Lansbury, PT; Kosik, KS				Lee, SJ; Liyanage, U; Bickel, PE; Xia, WM; Lansbury, PT; Kosik, KS			A detergent-insoluble membrane compartment contains A beta in vivo	NATURE MEDICINE			English	Article							DISEASE BRAIN; CAVEOLAE; DOMAINS; PROTEIN	Ordered assembly of the amyloid-beta protein (A beta) into amyloid fibrils is a critical step in Alzheimer's disease (AD). To release the amyloidogenic peptide A beta from the Alzheimer amyloid precursor protein (APP), two secretases act sequentially: first, beta-secretase cleaves close to the membrane within the ectodomain and then gamma-secretase cuts within the transmembrane domain(1). The sites of gamma-secretase cleavage are after residues 40 or 42 of A beta. Except in those rare cases of AD caused by a mutation, levels of secreted A beta are not elevated; thus, the secretory pathway may be unaffected, and factors other than the extracellular concentration of A beta may contribute to the aggregation properties of the peptide. A beta is also present in intracellular compartments(2-5). The two gamma-secretase cleavage products, A beta 42 and A beta 40, were found in different compartments: A beta 42 in the endoplasmic reticulum (ER)/intermediate compartment(3-5), and A beta 40 in the trans-Golgi network(2,4) (TGN). The cellular compartments that harbor A beta are target sites for therapeutic intervention. Here we report that in the brain, the principal compartment in which A beta resides is a detergent-insoluble glycolipid-enriched membrane domain (DIG). Also present in the DIC fractions are the endoproteolytic fragments of presenilin-1 (PS1) and APP. The presence of these proteins, which all contribute to the generation of A beta, indicates that the DIG fraction is probably where the intramembranous cleavage of APP occurs.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kosik, KS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, 77 Ave Louis Pasteur,HIM, Boston, MA 02115 USA.	lansbury@cnd.bwh.harvard.edu; Kosik@cnd.bwh.harvard.edu	Bickel, Perry/Q-9185-2019; xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295; Lee, Seung-Jae/0000-0002-5155-5335	NATIONAL INSTITUTE ON AGING [R43AG006501, R01AG008470] Funding Source: NIH RePORTER; NIA NIH HHS [AG08470, AG06501] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jones DH, 1997, BIOCHEMISTRY-US, V36, P12616, DOI 10.1021/bi970547z; JTIENARI PJ, 1997, P NATL ACAD SCI USA, V94, P4125; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOO EH, 1994, J BIOL CHEM, V269, P17386; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; WU C, 1997, J BIOL CHEM, V272, P37554; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; XU YH, 1994, J HISTOCHEM CYTOCHEM, V42, P1365, DOI 10.1177/42.10.7930519; YANAGISAWA K, 1995, NAT MED, V1, P998; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	35	362	369	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					730	734		10.1038/nm0698-730	http://dx.doi.org/10.1038/nm0698-730			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623986				2022-12-25	WOS:000074008300043
J	Reitter, JN; Means, RE; Desrosiers, RC				Reitter, JN; Means, RE; Desrosiers, RC			A role for carbohydrates in immune evasion in AIDS	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; N-LINKED GLYCANS; ENVELOPE GLYCOPROTEIN; PERSISTENT INFECTION; RHESUS-MONKEYS; V3 LOOP; GP120; NEUTRALIZATION; OLIGOSACCHARIDE; RESPONSES	Rhesus monkeys were infected with mutant forms of simian immunodeficiency virus lacking dual combinations of the 4th, 5th and 6th sites for N-linked glycosylation in the external envelope glycoprotein of the virus. When compared with sera from monkeys infected with the parental virus, sera from monkeys infected with the mutant viruses exhibited markedly increased antibody binding to specific peptides from this region and markedly increased neutralizing activity. These results demonstrate a role for N-linked glycosylation in limiting the neutralizing antibody response to SIV and in shielding the virus from immune recognition.	Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA	Harvard University	Desrosiers, RC (corresponding author), Harvard Univ, Sch Med, New England Reg Primate Res Ctr, 1 Pine Hill Dr,Box 9102, Southborough, MA 01772 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI 35365] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACK NKT, 1994, VIROLOGY, V199, P431, DOI 10.1006/viro.1994.1141; BENJOUAD A, 1994, FEBS LETT, V341, P244, DOI 10.1016/0014-5793(94)80465-6; BOLMSTEDT A, 1992, J GEN VIROL, V73, P3099, DOI 10.1099/0022-1317-73-12-3099; Bolmstedt A, 1996, J ACQ IMMUN DEF SYND, V12, P213, DOI 10.1097/00042560-199607000-00001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Chackerian B, 1997, J VIROL, V71, P7719, DOI 10.1128/JVI.71.10.7719-7727.1997; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; DOE B, 1994, EUR J IMMUNOL, V24, P2369, DOI 10.1002/eji.1830241017; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KOFF WC, 1994, SCIENCE, V266, P1335, DOI 10.1126/science.7973724; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Means RE, 1997, J VIROL, V71, P7895, DOI 10.1128/JVI.71.10.7895-7902.1997; Pantaleo G, 1996, SEMIN VIROL, V7, P131, DOI 10.1006/smvy.1996.0017; REITTER JN, IN PRESS J VIROL; Schonning K, 1996, J GEN VIROL, V77, P753, DOI 10.1099/0022-1317-77-4-753; Schonning K, 1996, VIROLOGY, V218, P134, DOI 10.1006/viro.1996.0173; WEI, 1995, NATURE, V373, P117; Wiley DC, 1984, BIOL MACROMOL, V1, P299; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996	28	496	518	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					679	684		10.1038/nm0698-679	http://dx.doi.org/10.1038/nm0698-679			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623976				2022-12-25	WOS:000074008300033
J	Castellani, LW; Weinreb, A; Bodnar, J; Goto, AM; Doolittle, M; Mehrabian, M; Demant, P; Lusis, AJ				Castellani, LW; Weinreb, A; Bodnar, J; Goto, AM; Doolittle, M; Mehrabian, M; Demant, P; Lusis, AJ			Mapping a gene for combined hyperlipidaemia in a mutant mouse strain	NATURE GENETICS			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; RECOMBINANT CONGENIC STRAINS; TRAITS	Familiar combined hyperlipidaemia (FCHL) is a common, multifactorial disorder associated with elevated levels of plasma triglyceride, cholesterol, or both(1-3). A characteristic feature is increased secretion of very low density lipoproteins (VLDL) and apolipoprotein B (apoB; refs 3,4). Although FCHL is the most common cause of premature coronary artery disease (CAD), accounting for over 10% of cases, its aetiology remains largely unknown(3-6). One powerful approach to the dissection of complex genetic traits involves the use of animal models' We have identified a mouse strain, HcB-19/Dem (HcB-19), which exhibits hypertriglyceridaemia, hypercholesterolaemia and elevated levels of plasma apoB. Like FCHL patients, HcB-19 mice also exhibit increased secretion of triglyceride-rich lipoproteins, and their hyperlipidaemia becomes progressively more severe with age. It is likely that the hyperlipidaemia results from a mutation of a novel gene that arose during development of strain HcB-19. We mapped the hyperlipidaemia gene (Hyplip1) to the distal portion of mouse chromosome 3. This region is syntenic to human chromosome 1q21-q23, which has recently been shown to harbour a gene associated with FCHL in families from a Finnish isolate (see accompanying manuscript by Pajukanta et al., ref. 8).	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Wadsworth Vet Adm, Los Angeles, CA 90073 USA; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Netherlands Cancer Institute	Lusis, AJ (corresponding author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA.	jlusis@medicine.medsch.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042488, P01HL028481, R37HL042488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42488, HL28481] Funding Source: Medline; NIGMS NIH HHS [GM08243] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitman TJ, 1997, ARTERIOSCL THROM VAS, V17, P748, DOI 10.1161/01.ATV.17.4.748; BRUNZELL JD, 1983, J LIPID RES, V24, P147; Collin GB, 1996, MAMM GENOME, V7, P68, DOI 10.1007/s003359900017; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; FALCONER DS, 1991, INTRO QUANTITATIVE G; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7; Kwiterovich Peter O. Jr., 1993, Current Opinion in Lipidology, V4, P133, DOI 10.1097/00041433-199304000-00009; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; Pajukanta P, 1998, NAT GENET, V18, P369, DOI 10.1038/ng0498-369; PAJVKANTA P, 1997, ARTERIOSCLER THROMB, V17, P841; Silver L.M., 1995, MOUSE GENETICS CONCE; VALERA A, 1994, J BIOL CHEM, V269, P6267; VENKATESAN S, 1993, ARTERIOSCLER THROMB, V13, P1110, DOI 10.1161/01.ATV.13.7.1110; Welch CL, 1996, J LIPID RES, V37, P1406	18	88	91	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1998	18	4					374	377		10.1038/ng0498-374	http://dx.doi.org/10.1038/ng0498-374			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537422				2022-12-25	WOS:000072755500022
J	Postlethwait, JH; Yan, YL; Gates, MA; Horne, S; Amores, A; Brownlie, A; Donovan, A; Egan, ES; Force, A; Gong, ZY; Goutel, C; Fritz, A; Kelsh, R; Knapik, E; Liao, E; Paw, B; Ransom, D; Singer, A; Thomson, M; Abduljabbar, TS; Yelick, P; Beier, D; Joly, JS; Larhammar, D; Rosa, F; Westerfield, M; Zon, LI; Johnson, SL; Talbot, WS				Postlethwait, JH; Yan, YL; Gates, MA; Horne, S; Amores, A; Brownlie, A; Donovan, A; Egan, ES; Force, A; Gong, ZY; Goutel, C; Fritz, A; Kelsh, R; Knapik, E; Liao, E; Paw, B; Ransom, D; Singer, A; Thomson, M; Abduljabbar, TS; Yelick, P; Beier, D; Joly, JS; Larhammar, D; Rosa, F; Westerfield, M; Zon, LI; Johnson, SL; Talbot, WS			Vertebrate genome evolution and the zebrafish gene map	NATURE GENETICS			English	Article							NEURAL CREST; EXPRESSION; MUTATIONS	In chordate phylogeny, changes in the nervous system. jaws. and appendages transformed meek filter feeders into fearsome predators(1). Gene duplication is thought to promote such innovation(2). Vertebrate ancestors probably had single copies of genes now found in multiple copies in vertebrates(3) and gene maps suggest that this occurred by polyploidization(2-7). It has been suggested that one genome duplication event occurred before, and one after the divergence of ray-finned and lobe-finned fishes(5). Holland et at, however. have argued that because various vertebrates have several HOX clusters. two rounds of duplication occurred before the origin of jawed fishes(3). Such gene-number data. however. do not distinguish between tandem duplications and polyploidization events, nor whether independent duplications occurred in different lineages. To investigate these matters. we mapped 144 zebrafish genes and compared the resulting map with mammalian maps. Comparison revealed large conserved chromosome segments. Because duplicated chromosome segments in zebrafish often correspond with specific chromosome segments in mammals. it is likely that two polyploidization events occurred prior to the divergence of fish and mammal lineages. This zebrafish gene map will facilitate molecular identification of mutated zebrafish genes, which can suggest functions for human genes known only by sequence.	Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA; NYU, Med Ctr, Skirball Inst, Dev Genet Program, New York, NY 10016 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Natl Univ Singapore, Dept Zool, Singapore 117548, Singapore; Ecole Normale Super, F-75231 Paris, France; Univ Bath, Sch Biol & Biochem, Dev Biol Programme, Bath BA2 7AY, Avon, England; Massachusetts Gen Hosp, Charlestown, MA USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Lab Genet Poissons, Jouy En Josas, France; Uppsala Univ, Dept Med Pharmacol, Uppsala, Sweden; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Forsyth Dent Ctr, Dept Cytokine Biol, Boston, MA 02115 USA	University of Oregon; New York University; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; National University of Singapore; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of Bath; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Uppsala University; Washington University (WUSTL); Harvard University; Forsyth Institute	Postlethwait, JH (corresponding author), Univ Oregon, Inst Neurosci, 1254, Eugene, OR 97403 USA.	jpostle@oregon.uoregon.edu	Rosa, Frederic/L-5990-2017; Abduljabbar, Tariq/E-6491-2017; Yelick, Pamela/AAP-5826-2020; Kelsh, Robert/B-6445-2008; Yan, Yi/GSO-3046-2022; Knapik, Ela W./J-6172-2014; Gong, Zhiyuan/H-8794-2012	Kelsh, Robert/0000-0002-9381-0066; Knapik, Ela W./0000-0002-2977-3619; Gong, Zhiyuan/0000-0002-9660-5260; Amores, Angel/0000-0002-9307-3609; Liao, Eric/0000-0001-6385-7448; Paw, Barry/0000-0002-0492-1419; Cutts, Alison/0000-0002-4986-573X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012349, R01RR010715] Funding Source: NIH RePORTER; NCRR NIH HHS [R01RR10715, R01RR12349] Funding Source: Medline; NICHD NIH HHS [P01HD22486] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; ALEXANDRE D, 1996, DEVELOPMENT, V122, P7835; Brady KP, 1997, GENOME RES, V7, P1085, DOI 10.1101/gr.7.11.1085; Driever W, 1996, DEVELOPMENT, V123, P37; EKKER M, 1992, DEVELOPMENT, V116, P1001; Elgar G, 1996, TRENDS GENET, V12, P145, DOI 10.1016/0168-9525(96)10018-4; Ellies DL, 1997, GENOMICS, V45, P580, DOI 10.1006/geno.1997.4978; Haffter P, 1996, DEVELOPMENT, V123, P1; Henion PD, 1996, DEV GENET, V18, P11; HOLLAND PWH, 1994, DEVELOPMENT, P125; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Johnson SL, 1996, GENETICS, V142, P1277; Kasahara M, 1996, P NATL ACAD SCI USA, V93, P9096, DOI 10.1073/pnas.93.17.9096; Katsanis N, 1996, GENOMICS, V35, P101, DOI 10.1006/geno.1996.0328; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; Knapik EW, 1996, DEVELOPMENT, V123, P451; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; Meyer A, 1998, NATURE, V391, P225, DOI 10.1038/34530; MOLVEN A, 1992, INT J DEV BIOL, V36, P229; MORIZOT DC, 1990, PROG CLIN BIOL RES, V344, P207; NORTHCUTT RG, 1983, Q REV BIOL, V58, P1, DOI 10.1086/413055; Ohno S., 1970, EVOLUTION GENE DUPLI; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; Prince VE, 1998, DEVELOPMENT, V125, P407; RILEY BB, 1995, P NATL ACAD SCI USA, V92, P5997, DOI 10.1073/pnas.92.13.5997; RUDDLE FH, 1994, DEVELOPMENT, P155; Sampath K, 1996, BIOCHEM BIOPH RES CO, V219, P565, DOI 10.1006/bbrc.1996.0274; Zardoya R, 1996, TRENDS GENET, V12, P496, DOI 10.1016/S0168-9525(96)20014-9; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	30	671	693	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1998	18	4					345	349		10.1038/ng0498-345	http://dx.doi.org/10.1038/ng0498-345			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537416				2022-12-25	WOS:000072755500016
J	Baggot, B				Baggot, B			Patenting transgenics in the European Union	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					299	300		10.1038/nbt0398-299	http://dx.doi.org/10.1038/nbt0398-299			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528013				2022-12-25	WOS:000072371000033
J	Kostrikis, LG; Huang, YX; Moore, JP; Wolinsky, SM; Zhang, LQ; Guo, Y; Deutsch, L; Phair, J; Neumann, AU; Ho, DD				Kostrikis, LG; Huang, YX; Moore, JP; Wolinsky, SM; Zhang, LQ; Guo, Y; Deutsch, L; Phair, J; Neumann, AU; Ho, DD			A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation	NATURE MEDICINE			English	Article							INFECTION; RESISTANCE; INDIVIDUALS; GENE	Viral and host factors influence the rate of HIV-1 disease progression(1). For HIV-1 to fuse, a CD4(+) cell must express a co-receptor that the virus can use(2,3). The chemokine receptors CCR5 and CXCR4 are used by R5 and X4 viruses, respectively(4). Most new infections involve transmission of R5 viruses, but variants can arise later that also use CXCR4 (R5-X4 or X4 viruses)2-6. This is associated with an increased rate of CD4(+) T-cell loss and poor prognosis(2-6). The ability of host cells to support HIV-1 entry also influences progression. The absence of CCR5 in approximately 1% of the Caucasian population, due to homozygosity for a 32-nucleotide deletion in the coding region (Delta 32-CCR5 allele), very strongly protects against HIV-1 transmission(7-10). Heterozygosity for the Delta 32-CCR5 allele delays progression typically by 2 years(9,10). A recent study showed that a conservative substitution (V641) in the coding region of CCR2 also has a significant impact on disease progression, but not on HIV-1 transmission(11). This was unexpected, since CCR2 is rarely used as a co-receptor in vitro(2,3) and the V641 change is in a transmembrane region(11). Because a subsequent study did not confirm this effect on progression to disease(12): we analyzed CCR2-V641 using subjects in the Chicago MACS. We show that CCR2-V641 is indeed protective against disease progression and go on to show that the CCR2-V641 allele is in complete linkage disequilibrium with a point mutation in the CCR5 regulatory region.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel	Rockefeller University; Northwestern University; Bar Ilan University	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.		Guo, Yong/ABF-9338-2020; Wolinsky, Steven/B-2893-2012; KOSTRIKIS, LEONDIOS G/A-5330-2016	KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Wolinsky, Steven/0000-0002-9625-6697	NIAID NIH HHS [AI45218, AI40387, AI35039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040387] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Berger EA, 1997, AIDS, V11, pS3; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KOSTRIKIS LG, IN PRESS SCIENCE; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1997, NAT MED, V3, P1052, DOI 10.1038/nm1097-1052c; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TYAGI S, 1996, NAT BIOTECHNOL, V14, P471; WU L, 1997, J EXP MED, V185, P16381; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	21	339	362	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					350	353		10.1038/nm0398-350	http://dx.doi.org/10.1038/nm0398-350			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500612				2022-12-25	WOS:000073616200044
J	Rouquier, S; Taviaux, S; Trask, BJ; Brand-Arpon, V; van den Engh, G; Demaille, J; Giorgi, D				Rouquier, S; Taviaux, S; Trask, BJ; Brand-Arpon, V; van den Engh, G; Demaille, J; Giorgi, D			Distribution of olfactory receptor genes in the human genome	NATURE GENETICS			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN-COUPLED RECEPTORS; ODORANT RECEPTORS; CHROMOSOMES; FAMILY; MAP; HUMAN-CHROMOSOME-17; EXPRESSION; CLUSTER	We demonstrate that members of the olfactory receptor (OR) gene family are distributed on all but a few human chromosomes. Through FISH analysis, we show that OR sequences reside at move than 25 locations in the human genome. Their distribution is biased for terminal bands. Flow-sorted chromosomes were used to isolate 87 OR sequences derived from 16 chromosomes. Their sequence-relationships are indicative of the inter- and intrachromosomal duplications responsible for OR family expansion. The human genome has accumulated a striking number of dysfunctional copies: 72% of the sequences are pseudogenes. ORF-containing sequences predominate on chromosomes 7, 16 and 17.	CNRS, CRBM, F-34293 Montpellier 5, France; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Washington; University of Washington Seattle	Giorgi, D (corresponding author), CNRS, CRBM, ERS 155,1919 Route Mende, F-34293 Montpellier 5, France.	domi@crbm.cnrs-mop.fr						BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BRANDRIFF BF, 1994, GENOMICS, V23, P582, DOI 10.1006/geno.1994.1546; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; Eichler EE, 1997, HUM MOL GENET, V6, P991, DOI 10.1093/hmg/6.7.991; FAN WF, 1995, GENOMICS, V27, P119, DOI 10.1006/geno.1995.1013; Freitag J, 1995, NEURON, V15, P1383, DOI 10.1016/0896-6273(95)90016-0; Glusman G, 1996, GENOMICS, V37, P147, DOI 10.1006/geno.1996.0536; GOOLD RD, 1993, HUM MOL GENET, V2, P1271, DOI 10.1093/hmg/2.8.1271; Gruen JR, 1996, GENOMICS, V36, P70, DOI 10.1006/geno.1996.0427; KORENBERG JR, 1995, GENOMICS, V29, P364, DOI 10.1006/geno.1995.9993; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; Mefford H, 1997, HUM GENET, V100, P138, DOI 10.1007/s004390050479; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; Ohno S., 1970, EVOLUTION GENE DUPLI; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; ROUQUIER S, 1995, NUCLEIC ACIDS RES, V23, P4415, DOI 10.1093/nar/23.21.4415; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SCHURMANS S, 1993, CYTOGENET CELL GENET, V63, P200, DOI 10.1159/000133534; SELBIE LA, 1992, MOL BRAIN RES, V13, P159, DOI 10.1016/0169-328X(92)90057-I; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; TRASK B, 1998, HUM MOL GENET; TRASK BJ, 1991, SOMAT CELL MOLEC GEN, V17, P117, DOI 10.1007/BF01232970; Van Rhee A M, 1995, Drug Des Discov, V13, P133	35	173	196	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1998	18	3					243	250		10.1038/ng0398-243	http://dx.doi.org/10.1038/ng0398-243			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500546				2022-12-25	WOS:000072325000022
J	Geisow, MJ				Geisow, MJ			Proteomics: One small step for a digital computer, one giant leap for humankind	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	21	27	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					206	206		10.1038/nbt0298-206	http://dx.doi.org/10.1038/nbt0298-206			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487532	Bronze			2022-12-25	WOS:000071831300038
J	Pingault, V; Bondurand, N; Kuhlbrodt, K; Goerich, DE; Prehu, MO; Puliti, A; Herbarth, B; Hermans-Borgmeyer, I; Legius, E; Matthijs, G; Amiel, J; Lyonnet, S; Ceccherini, I; Romeo, G; Smith, JC; Read, AP; Wegner, M; Goossens, M				Pingault, V; Bondurand, N; Kuhlbrodt, K; Goerich, DE; Prehu, MO; Puliti, A; Herbarth, B; Hermans-Borgmeyer, I; Legius, E; Matthijs, G; Amiel, J; Lyonnet, S; Ceccherini, I; Romeo, G; Smith, JC; Read, AP; Wegner, M; Goossens, M			SOX10 mutations in patients with Waardenburg-Hirschsprung disease	NATURE GENETICS			English	Article							ENDOTHELIN-B RECEPTOR; PAIRED DOMAIN; HMG BOX; GENE; MEGACOLON; MICE; MELANOCYTES; ASSOCIATION; TYPE-2; MOUSE	Waardenburg syndrome (WS; deafness with pigmentary abnormalities) and Hirschsprung's disease (HSCR; aganglionic megacolon) are congenital disorders caused by defective function of the embryonic neural crest(1,2). WS and HSCR are associated in patients with Waardenburg-Shah syndrome (WS4), whose symptoms are reminiscent of the white coat-spotting and aganglionic megacolon displayed by the mouse mutants Dom (Dominant megacolon), piebald-lethal(s(l)) and lethal spotting (Is). The s(l) and Is phenotypes are caused by mutations in the genes encoding the Endothelin-B receptor (Ednrb) and Endothelin 3 (Edn3), respectively(3,4). The identification of Sox10 as the gene mutated in Dom mice (B.H. et al., manuscript submitted) prompted us to analyse the role of its human homologue SOx10 in neural crest defects. Here we show that patients from four families with WS4 have mutations in SOx10, whereas no mutation could be detected in patients with HSCR alone. These mutations are likely to result in haploinsufficiency of the SOx10 product. Our findings further define the locus heterogeneity of Waardenburg-Hirschsprung syndromes. and point to an essential role of SOx10 in the development of two neural crest-derived human cell lineages.	Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; Hop Necker Enfants Malad, INSERM, U393, F-75743 Paris, France; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy; Univ Manchester, St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Hamburg; University Medical Center Hamburg-Eppendorf; Universite Catholique Louvain; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Manchester	Goossens, M (corresponding author), Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France.	goossens@im3.inserm.fr	Puliti, Aldamaria/K-7866-2016; Bondurand, Nadege/H-4737-2017; Ceccherini, Isabella/P-8195-2014; amiel, jeanne/AGX-1124-2022; Lyonnet, Stanislas/H-5483-2017; Puliti, Aldamaria/AAF-5400-2021; Legius, Eric/H-1735-2011; amiel, jeanne/H-3501-2017	Puliti, Aldamaria/0000-0001-9310-6514; Bondurand, Nadege/0000-0002-1531-1544; Ceccherini, Isabella/0000-0001-8732-1955; Lyonnet, Stanislas/0000-0001-5426-9417; amiel, jeanne/0000-0001-5973-4728; Matthijs, Gert/0000-0001-6710-1912; Pingault, Veronique/0000-0001-7064-0765; Wegner, Michael/0000-0002-4586-3294				AMBANI LM, 1983, J PEDIATR-US, V102, P802, DOI 10.1016/S0022-3476(83)80267-4; BADNER JA, 1990, AM J HUM GENET, V46, P568; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Chakravarti A, 1996, HUM MOL GENET, V5, P303; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; FRIED K, 1980, CLIN GENET, V18, P91; Hofstra RMW, 1997, EUR J HUM GENET, V5, P180, DOI 10.1159/000484760; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HOTH CF, 1993, AM J HUM GENET, V52, P455; Kapur RP, 1996, DEV BIOL, V174, P360, DOI 10.1006/dbio.1996.0080; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; MEIRE F, 1987, AM J MED GENET, V27, P683, DOI 10.1002/ajmg.1320270322; OMENN GS, 1979, AM J MED GENET, V3, P217, DOI 10.1002/ajmg.1320030302; PAVAN WJ, 1995, GENOME RES, V5, P29, DOI 10.1101/gr.5.1.29; Pringault V, 1997, GENOMICS, V39, P86, DOI 10.1006/geno.1996.4476; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Puliti A, 1996, NEUROREPORT, V7, P489, DOI 10.1097/00001756-199601310-00027; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; ROMEO G, 1994, NAT GENET, V7, P451, DOI 10.1038/ng0894-451; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; STEEL KP, 1989, DEVELOPMENT, V107, P453; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; vanHoute LPA, 1995, J BIOL CHEM, V270, P30516, DOI 10.1074/jbc.270.51.30516; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	31	617	638	2	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1998	18	2					171	173		10.1038/ng0298-171	http://dx.doi.org/10.1038/ng0298-171			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462749				2022-12-25	WOS:000071779500028
J	Olive, PL; Johnston, PJ; Banath, JP; Durand, RE				Olive, PL; Johnston, PJ; Banath, JP; Durand, RE			The comet assay: A new method to examine heterogeneity associated with solid tumors	NATURE MEDICINE			English	Article							GEL-ELECTROPHORESIS; INDIVIDUAL CELLS; DNA-DAMAGE; FRACTION		British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency	Olive, PL (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	olive@unixg.ubc.ca	Durand, Ralph/GQZ-4018-2022		NCI NIH HHS [CA-37879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buschfort C, 1997, CANCER RES, V57, P651; CHAPLIN DJ, 1985, BRIT J CANCER, V51, P569, DOI 10.1038/bjc.1985.79; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; HEPPNER GH, 1989, SEMIN ONCOL, V16, P91; MCKELVEYMARTIN VJ, 1993, MUTAT RES, V288, P47, DOI 10.1016/0027-5107(93)90207-V; Olive P. L., 1990, RADIAT RES, V122, P69; OLIVE PL, 1993, INT J RADIAT BIOL, V64, P349, DOI 10.1080/09553009314551531; Olive PL, 1997, CANCER RES, V57, P5528; OLIVE PL, 1992, CELL PROLIFERAT, V25, P447, DOI 10.1111/j.1365-2184.1992.tb01453.x; OLIVE PL, 1992, J NATL CANCER I, V84, P707, DOI 10.1093/jnci/84.9.707; OLIVE PL, 1995, EXP CELL RES, V221, P19, DOI 10.1006/excr.1995.1348; Olive PL, 1996, CANCER RES, V56, P4460; OLIVE PL, 1993, CANCER RES, V53, P733; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; Santos SJ, 1997, EXP CELL RES, V232, P407, DOI 10.1006/excr.1997.3555; SINGH NP, 1994, INT J RADIAT BIOL, V66, P23, DOI 10.1080/09553009414550911; STRAUSS GHS, 1994, MUTAT RES, V304, P211, DOI 10.1016/0027-5107(94)90213-5	18	63	64	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					103	105		10.1038/nm0198-103	http://dx.doi.org/10.1038/nm0198-103			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427615				2022-12-25	WOS:000072249700043
J	Marais, R; Spooner, RA; Stribbling, SM; Light, Y; Martin, J; Springer, CJ				Marais, R; Spooner, RA; Stribbling, SM; Light, Y; Martin, J; Springer, CJ			A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy	NATURE BIOTECHNOLOGY			English	Article						drug delivery; enzyme engineering; bystander effect; cancer therapy	TISSUE-SPECIFIC EXPRESSION; THYMIDINE KINASE GENE; BRAIN-TUMORS; CANCER; TRANSDUCTION; REGRESSION; COMPONENT; G2	The potential for expressing the bacterial enzyme carboxypeptidase G2 (CPG2) tethered to the outer surface of mammalian cells was examined for use in gene-directed enzyme prodrug therapy, The affinity of CPG2 for the substrate methotrexate was unaffected by three mutations required to prevent N-linked glycosylation. Breast carcinoma MDA MB 361 cells expressing CPG2 internally showed only a very modest increase in sensitivity to the prodrug CMDA because the prodrug did not enter the cells. Cells expressing surface-tethered CPG2, however, became 16-24-fold more sensitive to CMDA and could mount a good bystander effect. Systemic administration of CMDA to mice bearing established xenografts of the transfected cells led to sustained tumor regressions or cures.	INST CANC RES,CRC,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND; INST CANC RES,CRC,CTR CANC THERAPEUT,SUTTON SM2 5NG,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK			Spooner, Robert/A-9870-2010	Spooner, Robert/0000-0001-9593-0195; Marais, Richard/0000-0001-7484-4183; Stribbling, Stephen/0000-0001-6820-4630				BARBA D, 1993, J NEUROSURG, V79, P729, DOI 10.3171/jns.1993.79.5.0729; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BORELLI E, 1988, P NATL ACAD SCI USA, V85, P7572; Bridgewater JA, 1995, EUR J CANCER, V31A, P2362, DOI 10.1016/0959-8049(95)00436-X; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; CHANSON M, 1989, J CELL PHYSIOL, V139, P147, DOI 10.1002/jcp.1041390121; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; FREEMAN SM, 1993, CANCER RES, V53, P5274; Gagandeep S, 1996, CANCER GENE THER, V3, P83; HUBER BE, 1994, P NATL ACAD SCI USA, V91, P8302, DOI 10.1073/pnas.91.17.8302; HUGHES BW, 1995, CANCER RES, V55, P3339; Marais R, 1996, CANCER RES, V56, P4735; MOOLTEN FL, 1986, CANCER RES, V46, P5276; NABEL GJ, 1994, HUM GENE THER, V5, P57, DOI 10.1089/hum.1994.5.1-57; Niculescu-Duvaz I, 1997, Expert Opin Investig Drugs, V6, P685, DOI 10.1517/13543784.6.6.685; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; OMALLEY BW, 1995, CANCER RES, V55, P1080; Pavlovic J, 1996, GENE THER, V3, P635; RAMASH R, 1996, CANCER GENE THER, V3, P373; RAMASH R, 1996, EXP HEMATOL, V24, P829; RAPTIS I, 1995, ELECTROPORATION ADHE, P93; RAPTIS L, 1990, DNA CELL BIOL, V9, P615, DOI 10.1089/dna.1990.9.615; SHERWOOD RF, 1985, EUR J BIOCHEM, V148, P447, DOI 10.1111/j.1432-1033.1985.tb08860.x; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Springer C. J., 1993, Drugs of the Future, V18, P212; SPRINGER CJ, 1990, J MED CHEM, V33, P677, DOI 10.1021/jm00164a034; Stribbling SM, 1997, CANCER CHEMOTH PHARM, V40, P277, DOI 10.1007/s002800050659; Tanaka T, 1996, CANCER RES, V56, P1341; VILE RG, 1994, CANCER RES, V54, P6228; VILE RG, 1993, CANCER RES, V53, P3860; [No title captured]	32	66	76	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1373	1377		10.1038/nbt1297-1373	http://dx.doi.org/10.1038/nbt1297-1373			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415889				2022-12-25	WOS:A1997YK36100028
J	Soldan, SS; Berti, R; Salem, N; Secchiero, P; Flamand, L; Calabresi, PA; Brennan, MB; Maloni, HW; McFarland, HF; Lin, HC; Patnaik, M; Jacobson, S				Soldan, SS; Berti, R; Salem, N; Secchiero, P; Flamand, L; Calabresi, PA; Brennan, MB; Maloni, HW; McFarland, HF; Lin, HC; Patnaik, M; Jacobson, S			Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA	NATURE MEDICINE			English	Article							HUMAN HERPESVIRUS-6; INFECTION; EXACERBATIONS; ANTIBODIES	Viruses have long been suggested to be involved in the etiology of multiple sclerosis (MS)(1). This suggestion is based on (1) epidemiological evidence of childhood exposure to infectious agents and increase in disease exacerbations with viral infection(1,2); (2) geographic association of disease susceptibility with evidence of MS clustering(3-4); (3) evidence that migration to and from high-risk areas influences the likelihood of developing MS (refs. 2, 5); (4) abnormal immune responses to a variety of viruses(6,7); and (5) analogy with animal models and other human diseases in which viruses can cause diseases with long incubation periods, a relapsing-remitting course, and demyelination(1,2). Many of these studies involve the demonstration of increased antibody titers to a particular virus, whereas some describe isolation of virus from MS material. However, no virus to date has been definitively associated with this disease. Recently, human herpesvirus 6 (HHV-6), a newly described beta-herpes virus that shares homology with cytomegalovirus (CMV)(8), has been reported to be present in active MS plaques(9). In order to extend these observations, we have demonstrated increased IgM serum antibody responses to HHV-6 early antigen (p41/38) in patients with relapsing-remitting MS (RRMS), compared with patients with chronic progressive MS (CPMS), patients with other neurologic disease (OND), patients with other autoimmune disease (OID), and normal controls. Given the ubiquitous nature of this virus and the challenging precedent of correlating antiviral antibodies with disease association(10), these antibody studies have been supported by the detection of HHV-6 DNA from samples of MS serum as a marker of active viral infection.	NINDS, Viral Immunol Sect, Bethesda, MD 20892 USA; Specialty Labs Inc, Santa Monica, CA 90404 USA; Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University System of Maryland; University of Maryland Baltimore	Jacobson, S (corresponding author), NINDS, Viral Immunol Sect, Bldg 10,Room 5B-16,9000 Rockville Pike, Bethesda, MD 20892 USA.		secchiero, paola/G-9689-2015; Soldan, Samantha/AAS-3182-2020; Calabresi, Peter A./AAF-2288-2019	secchiero, paola/0000-0003-4101-7987; Soldan, Samantha/0000-0001-6263-519X; Flamand, Louis/0000-0001-5010-4586				ALTER M, 1966, ARCH NEUROL-CHICAGO, V15, P234, DOI 10.1001/archneur.1966.00470150012002; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; EFSTATHIOU S, 1988, LANCET, V1, P63; HAAHR S, 1997, LANCET, V349, P9056; JACOBSON S, 1985, J EXP MED, V162, P839, DOI 10.1084/jem.162.3.839; JOHNSON RT, 1994, ANN NEUROL, V36, pS54, DOI 10.1002/ana.410360715; KOIKE K, 1987, HEPATOLOGY, V7, P573, DOI 10.1002/hep.1840070326; KURTZKE JF, 1995, ACTA NEUROL SCAND, V91, P321, DOI 10.1111/j.1600-0404.1995.tb07015.x; LUPPI M, 1994, J INFECT DIS, V169, P943, DOI 10.1093/infdis/169.4.943; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; NAGASATO K, 1991, J NEUROIMMUNOL, V32, P105, DOI 10.1016/0165-5728(91)90002-O; NEIGHBOUR PA, 1981, NEUROLOGY, V31, P561, DOI 10.1212/WNL.31.5.561; PANITCH HS, 1994, ANN NEUROL, V36, pS25, DOI 10.1002/ana.410360709; PATNAIK M, 1995, J INFECT DIS, V172, P1364, DOI 10.1093/infdis/172.5.1364; PEARSON GR, 1987, J VIROL METHODS, V21, P97; SECCHIERO P, 1995, J INFECT DIS, V171, P273, DOI 10.1093/infdis/171.2.273; Weinshenker BG, 1996, NEUROL CLIN, V14, P291, DOI 10.1016/S0733-8619(05)70257-7; YAMANISHI K, 1988, LANCET, V1, P1065; YOSHIKAWA T, 1990, PEDIATR INFECT DIS J, V9, P589, DOI 10.1097/00006454-199008000-00013	20	354	358	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1394	1397		10.1038/nm1297-1394	http://dx.doi.org/10.1038/nm1297-1394			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396611				2022-12-25	WOS:000072249500037
J	Gu, SM; Thompson, DA; Srikumari, CRS; Lorenz, B; Finckh, U; Nicoletti, A; Murthy, KR; Rathmann, M; Kumaramanickavel, G; Denton, MJ; Gal, A				Gu, SM; Thompson, DA; Srikumari, CRS; Lorenz, B; Finckh, U; Nicoletti, A; Murthy, KR; Rathmann, M; Kumaramanickavel, G; Denton, MJ; Gal, A			Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy	NATURE GENETICS			English	Article							EPITHELIAL MEMBRANE-RECEPTOR; RNA SPLICE JUNCTIONS; PIGMENT-EPITHELIUM; BINDING PROTEIN; MICROSOMAL PROTEIN; GENE-MUTATIONS; EXPRESSION; CLONING	Autosomal recessive childhood-onset severe retinal dystrophy (arCSRD) designates a heterogeneous group of disorders affecting rod and cone photoreceptors simultaneously(1). The most severe cases are termed Leber congenital amaurosis (LCA), while the less aggressive forms are usually considered juvenile retinitis pigmentosa. Recently, mutations in the retinal-specific guanylate cyclase gene were found in patients with LCA(2). Disease genes implicated in other forms of arCSRD are expected to encode proteins present in the neuroretina or in the retinal pigment epithelium (RPE). The RPE, a monolayer of cells separating the vascular-rich choroid and the neuroretina, is in intimate contact with the outer segments of rods and cones via the microvilli surrounding the photoreceptors. The RPE expresses a tissue-specific and evolutionarily highly conserved 61 kD protein (RPE65) present at high levels in vivo(3-6). Although the function of RPE65 is not yet known, an important role in the RPE/photoreceptor vitamin-A cycle is suggested by the fact that RPE65 associates both with serum retino(-binding protein(7,8) and with the RPE-specific 11-cis retinol dehydrogenase, an enzyme active in the synthesis of the visual pigment chromophore 11-cis retinal(9). Here we report that the analysis of RPE65 in a collection of about 100 unselected retinal-dystrophy patients of different ethnic origin revealed five that are likely to be pathogenic mutations, including a missense mutation (Pro363Thr), two point mutations affecting splicing (912+1G-->T and 65+5G-->A) and two small re-arrangements (ins144T and 831del8) on a total of nine alleles of five patients with arCSRD. In contrast to other genes whose defects have been implicated in degenerative retinopathies, RPE65 is the first disease gene in this group of inherited disorders that is expressed exclusively in the RPE, and may play a role in vitamin-A metabolism of the retina.	UNIV HAMBURG,KRANKENHAUS EPPENDORF,INST HUMANGENET,D-22529 HAMBURG,GERMANY; UNIV MICHIGAN,SCH MED,DEPT OPHTHALMOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48105; UNIV POSTGRAD INST BASIC MED SCI,DEPT GENET,CHENNAI,INDIA; UNIV REGENSBURG,KLIN AUGENHEILKUNDE,ABT PADIAT OPHTHALMOL STRABISMOL & OPHTHALMOGENET,D-93042 REGENSBURG,GERMANY; PRABA EYE CLIN & RES CTR,BANGALORE 560070,KARNATAKA,INDIA; MED RES FDN,SANKARA NETHRALAYA,CHENNAI,INDIA; UNIV OTAGO,DEPT BIOCHEM,DUNEDIN,NEW ZEALAND	University of Hamburg; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Regensburg; University of Otago			KUMARAMANICKAVEL, GOVINDASAMY/AAN-9203-2021	KUMARAMANICKAVEL, GOVINDASAMY/0000-0001-8516-8301; Thompson, Debra/0000-0003-3485-0794	NEI NIH HHS [EY09193] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009193] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; BUNGE S, 1996, METH MOL G, V8, P26; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; Heckenlively J., 1988, RETINITIS PIGMENTOSA, P107; KRAWCZAK M, 1992, HUM GENET, V90, P41; LEUTELT J, 1995, CLIN GENET, V47, P122; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; VANSOEST S, 1994, GENOMICS, V22, P499, DOI 10.1006/geno.1994.1422	16	504	519	1	20	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					194	197		10.1038/ng1097-194	http://dx.doi.org/10.1038/ng1097-194			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326941				2022-12-25	WOS:A1997XZ55500027
J	Iida, S; Rao, PH; Butler, M; Corradini, P; Boccadoro, M; Klein, B; Chaganti, RSK; DallaFavera, R				Iida, S; Rao, PH; Butler, M; Corradini, P; Boccadoro, M; Klein, B; Chaganti, RSK; DallaFavera, R			Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma	NATURE GENETICS			English	Article							INTERFERON REGULATORY FACTOR; STIMULATED RESPONSE ELEMENT; PLASMA-CELL LEUKEMIA; FACTOR FAMILY; TRANSCRIPTION FACTOR; C-MYC; LINES; GENE; MEMBER; REARRANGEMENTS	The pathogenesis of multiple myeloma (MM), an incurable tumour causing the deregulated proliferation of terminally differentiated B cells, is unknown(1). Chromosomal translocations (14q1) affecting band 14q32 and unidentified partner chromosomes are common in this tumour, suggesting that they may cause the activation of novel oncogenes(2,3). By cloning the chromosomal breakpoints in an MM cell line, we show that the 14q+ translocation represents a t(6;14)(p25;q32) and that this aberration is recurrent in MM, as it was found in two of eleven MM cell lines, The translocation juxtaposes the immunoglobulin heavy-chain (IgH) locus to MUM1 (multiple myeloma oncogene 1)/IRF4 gene, a member of the interferon regulatory factor (IRF) family known to be active in the control of B-cell proliferation and differentiation, As a result, the MUM1/IRF4 gene is overexpressed-an event that may contribute to tumorigenesis, as MUM1/IRF4 has oncogenic activity in vitro. These findings identify a novel genetic alteration associated with MM, with implications for the pathogenesis and diagnostics of this tumour.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, DIV ONCOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, DIV ONCOL, NEW YORK, NY 10032 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT HUMAN GENET, NEW YORK, NY 10021 USA; UNIV TURIN, DEPT MED & ONCOL, TURIN, ITALY; UNIV MONTPELLIER, INST MOL GENET, F-34059 MONTPELLIER, FRANCE	Columbia University; Columbia University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Turin; Universite de Montpellier			Corradini, Paolo/N-7584-2017	Corradini, Paolo/0000-0002-9186-1353; Boccadoro, Mario/0000-0001-8130-5209	NATIONAL CANCER INSTITUTE [R01CA044029, R01CA034775] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44029, CA-34775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Barlogie B, 1997, SEMIN HEMATOL, V34, P67; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Calasanz MJ, 1997, GENE CHROMOSOME CANC, V18, P84, DOI 10.1002/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.3.CO;2-9; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DEWALD GW, 1985, BLOOD, V66, P380; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ETON O, 1989, LEUKEMIA, V3, P729; GAIDANO G, 1997, PRINCIPLES PRACTICE, P2131; Grossman A, 1996, GENOMICS, V37, P229, DOI 10.1006/geno.1996.0547; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Iida S, 1996, BLOOD, V88, P1787; JERNBERG H, 1987, INT J CANCER, V40, P811, DOI 10.1002/ijc.2910400618; KLEIN B, 1989, BLOOD, V73, P517; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1993, BLOOD, V81, P128; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIWAKI M, 1994, BLOOD, V84, P2283, DOI 10.1182/blood.V84.7.2283.bloodjournal8472283; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; ZHANG XG, 1994, BLOOD, V83, P3654	30	236	244	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1997	17	2					226	230		10.1038/ng1097-226	http://dx.doi.org/10.1038/ng1097-226			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326949	Green Accepted			2022-12-25	WOS:A1997XZ55500035
J	Moore, JC; Arnold, FH				Moore, JC; Arnold, FH			Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents	NATURE BIOTECHNOLOGY			English	Article						random mutagenesis; antibiotic synthesis; enzymatic deprotection	SEQUENCE; MUTAGENESIS; PROTEINS; MEMBRANE; CLONING; LIPASE; GENE	Through sequential generations of random mutagenesis and screening, we have directed the evolution of an esterase for deprotection of an antibiotic p-nitrobenzyl ester in aqueous-organic solvents. Because rapid screening directly on the desired antibiotic (loracarbef) nucleus p-nitrobenzyl ester was not feasible, the p-nitrophenyl ester was employed. Catalytic performance on the screening substrate was shown to reasonably mimic enzyme activity toward the desired ester. One p-nitrobenzyl esterase variant performs as well in 30% dimethylformamide as the wildtype enzyme in water, reflecting a 16-fold increase in esterase activity. Random pairwise gene recombination of two positive variants led to a further two-fold improvement in activity. Considering also the increased expression level achieved during these experiments, the net result of four sequential generations of random mutagenesis and the one recombination step is a 50-60-fold increase in total activity. Although the contributions of individual effective amino acid substitutions to enhanced activity are small (<2-fold increases), the accumulation of multiple mutations by directed evolution allows significant improvement of the biocatalyst for reactions on substrates and under conditions not already optimized in nature. The positions of the effective amino acid substitutions have been identified in a pNB esterase structural model developed based on its homology to acetylcholinesterase and triacylglycerol lipase. None appear to interact directly with the antibiotic substrate, further underscoring the difficulty of predicting their effects in a 'rational' design effort.	CALTECH, DIV CHEM & CHEM ENGN 21041, PASADENA, CA 91125 USA	California Institute of Technology				Arnold, Frances H./0000-0002-4027-364X				ARNOLD FH, 1996, IN PRESS CHEM ENG SC; BOMBLIES L, 1990, J CELL BIOL, V110, P669, DOI 10.1083/jcb.110.3.669; BRANNON DR, 1976, J ANTIBIOT, V29, P121, DOI 10.7164/antibiotics.29.121; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEN KQ, 1991, BIO-TECHNOL, V9, P1073, DOI 10.1038/nbt1191-1073; CHEN KQ, 1993, P NATL ACAD SCI USA, V90, P5618, DOI 10.1073/pnas.90.12.5618; CHEN YR, 1995, J IND MICROBIOL, V15, P10, DOI 10.1007/BF01570007; COOPER RDG, 1992, AM J MED, V92, pS2, DOI 10.1016/0002-9343(92)90600-G; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Eckert K A, 1991, PCR Methods Appl, V1, P17; HWANG CS, 1993, J BIOL CHEM, V268, P14278; JBILO O, 1990, NUCLEIC ACIDS RES, V18, P3990, DOI 10.1093/nar/18.13.3990; JBILO O, 1994, EUR J BIOCHEM, V225, P115, DOI 10.1111/j.1432-1033.1994.00115.x; KAISER R, 1994, FEBS LETT, V337, P123, DOI 10.1016/0014-5793(94)80257-2; Leung DW, 1989, TECHNIQUE, V1, P11; LOTTI M, 1993, GENE, V124, P45, DOI 10.1016/0378-1119(93)90760-Z; MOORE, 1996, THESIS CALTECH PASAD; OZOLS J, 1989, J BIOL CHEM, V264, P12533; POHLENZ HD, 1992, J BACTERIOL, V174, P6600, DOI 10.1128/JB.174.20.6600-6607.1992; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; You L, 1996, PROTEIN ENG, V9, P77, DOI 10.1093/protein/9.1.77; ZOCK J, 1994, GENE, V151, P37, DOI 10.1016/0378-1119(94)90630-0; 77392801; 1973, Patent No. 3725359	30	330	393	3	113	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					458	467		10.1038/nbt0496-458	http://dx.doi.org/10.1038/nbt0496-458			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630920				2022-12-25	WOS:A1996UL58800028
J	McCormick, C; Leduc, Y; Martindale, D; Mattison, K; Esford, LE; Dyer, AP; Tufaro, F				McCormick, C; Leduc, Y; Martindale, D; Mattison, K; Esford, LE; Dyer, AP; Tufaro, F			The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate	NATURE GENETICS			English	Article							HERPES-SIMPLEX VIRUS; HEREDITARY MULTIPLE EXOSTOSES; GLYCOPROTEIN-C; GENE; PROTEOGLYCANS; BIOSYNTHESIS; BINDING; MUTANTS	Hereditary multiple exostoses (HME) is an autosomal dominant disorder characterized by the formation of cartilage-capped tumours (exostoses) that develop from the growth plate of endochondral bone(1). This condition can lead to skeletal abnormalities, short stature and malignant transformation of exostoses to chondrosarcomas(2,3) or osteosarcomas(4,5). Linkage analyses have identified three different genes for HME, EXT1 on 8q24.1, EXT2 on 11p11-13 and EXT3 on 19p (refs 6-9). Most HME cases have been attributed to missense or frameshift mutations in these tumour-supressor genes, whose functions have remained obscure. Here, we show that EXT1 is an ER-resident type II transmembrane glycoprotein whose expression in cells results in the alteration of the synthesis and display of cell surface heparan sulfate glycosaminoglycans (GAGs). Two EXT1 variants containing aetiologic missense mutations(10) failed to alter cell-surface glycosaminoglycans, despite retaining their ER-localization.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Tufaro, F (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada.	tufaro@unixg.ubc.ca	McCormick, Craig/AAH-9069-2019	McCormick, Craig/0000-0003-2794-3722				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; COOK A, 1993, AM J HUM GENET, V53, P71; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; Hecht JT, 1997, AM J HUM GENET, V60, P80; HENNEKAM RCM, 1991, J MED GENET, V28, P262, DOI 10.1136/jmg.28.4.262; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; LEONE NC, 1987, J HERED, V78, P171, DOI 10.1093/oxfordjournals.jhered.a110351; Philippe C, 1997, AM J HUM GENET, V61, P520, DOI 10.1086/515505; Schamhart DHJ, 1997, UROL RES, V25, pS89, DOI 10.1007/BF00941994; SCHMALE GA, 1994, J BONE JOINT SURG AM, V76A, P986, DOI 10.2106/00004623-199407000-00005; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SOLOMON L, 1963, J BONE JOINT SURG BR, V45, P292, DOI 10.1302/0301-620X.45B2.292; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tuszynski GP, 1997, ACTA HAEMATOL-BASEL, V97, P29; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796	30	305	323	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					158	161		10.1038/514	http://dx.doi.org/10.1038/514			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620772				2022-12-25	WOS:000073865100023
J	Nair, SK; Boczkowski, D; Morse, M; Cumming, RI; Lyerly, HK; Gilboa, E				Nair, SK; Boczkowski, D; Morse, M; Cumming, RI; Lyerly, HK; Gilboa, E			Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA	NATURE BIOTECHNOLOGY			English	Article						applied immunology; antigen presenting cells; cancer vaccine	CLASS-II PRESENTATION; IN-VITRO; TUMOR-ANTIGEN; ANTITUMOR IMMUNITY; GENERATION; RESPONSES; PEPTIDE; VACCINE; PATHWAY; CD8+	Dendritic cells (DC) generated from the peripheral blood mononuclear cells of healthy individuals or from cancer patients transfected with carcinoembryonic antigen (CEA) mRNA stimulate a potent CD8(+) cytotoxic T lymphocyte (CTL) response in vitro. DCs are effectively sensitized with RNA in the absence of reagents commonly used to facilitate mammalian cell transfection. RNA encoding a chimeric CEA/LAMP-1 lysosomal targeting signal enhances the induction of CEA-specific CD4(+) T cells, providing a strategy to induce T-hel that may be necessary to generate and/or maintain an optimal CD8(+) CTL response in vivo, CEA RNA-transfected DCs also serve as effective targets in cytotoxicity assays, thus providing a general method for inducing, as well as measuring, CEA-specific CTL responses across a broad spectrum of HLA haplotypes.	Duke Univ, Med Ctr, Dept Surg, Ctr Genet & Cellular Therapies, Durham, NC 27710 USA	Duke University	Gilboa, E (corresponding author), Duke Univ, Med Ctr, Dept Surg, Ctr Genet & Cellular Therapies, Durham, NC 27710 USA.	gilbo001@mc.duke.edu	Lyerly, Herbert K/B-6528-2014; Nair, Smita/GYR-2993-2022; Lyerly, Herbert Kim/AAX-4925-2020; Nair Jain, Smita/M-2765-2018	Lyerly, Herbert K/0000-0002-0063-4770; Nair, Smita/0000-0001-5615-7056; Lyerly, Herbert Kim/0000-0002-0063-4770; Nair Jain, Smita/0000-0002-1542-9913				Babu JS, 1995, VACCINE, V13, P1669, DOI 10.1016/0264-410X(95)00120-P; BAKKER ABH, 1995, CANCER RES, V55, P5330; BENNETT RM, 1997, J EXP MED, V186, P65; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; CELLIS E, 1994, P NATL ACAD SCI USA, V91, P2105; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Felgner Jiin, 1993, Methods (Orlando), V5, P67, DOI 10.1006/meth.1993.1009; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GAGLIARDI MC, 1995, INT IMMUNOL, V7, P171; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KERN DE, 1986, J IMMUNOL, V136, P4303; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Lechler R, 1996, IMMUNOL REV, V151, P51, DOI 10.1111/j.1600-065X.1996.tb00703.x; Lin KY, 1996, CANCER RES, V56, P21; MACATONIA SE, 1991, IMMUNOLOGY, V74, P399; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MEHTADAMANI A, 1994, J IMMUNOL, V153, P996; Morse MA, 1997, ANN SURG, V226, P6, DOI 10.1097/00000658-199707000-00002; NAIR S, 1992, J EXP MED, V175, P609, DOI 10.1084/jem.175.2.609; NAIR S, 1993, J VIROL, V67, P4062, DOI 10.1128/JVI.67.7.4062-4069.1993; Nair SK, 1997, INT J CANCER, V70, P706, DOI 10.1002/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7; OSSEVOORT MA, 1995, J IMMUNOTHER, V18, P86, DOI 10.1097/00002371-199508000-00002; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Porgador A, 1996, J IMMUNOL, V156, P2918; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; Reeves ME, 1996, CANCER RES, V56, P5672; Rock KL, 1996, J IMMUNOL, V156, P3721; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; ROUSE RJD, 1994, J VIROL, V68, P5685, DOI 10.1128/JVI.68.9.5685-5689.1994; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Stern PL, 1996, ADV CANCER RES, V69, P175, DOI 10.1016/S0065-230X(08)60863-5; TAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; VOLGMANN T, 1989, J IMMUNOL METHODS, V119, P45, DOI 10.1016/0022-1759(89)90379-7; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Wong C, 1998, J IMMUNOTHER, V21, P32, DOI 10.1097/00002371-199801000-00004; WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	42	344	396	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					364	369		10.1038/nbt0498-364	http://dx.doi.org/10.1038/nbt0498-364			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555728				2022-12-25	WOS:000072786200029
J	Hagstrom, SA; North, MA; Nishina, PM; Berson, EL; Dryja, TP				Hagstrom, SA; North, MA; Nishina, PM; Berson, EL; Dryja, TP			Recessive mutations in the gene encoding the tubby-like protein TULP1 in patients with Retinitis pigmentosa	NATURE GENETICS			English	Article							ROD PHOSPHODIESTERASE; OCULAR FINDINGS; ALPHA-SUBUNIT; BETA-SUBUNIT; RHODOPSIN; MOUSE; IDENTIFICATION; FAMILY; DNA	A recessive mutation in the tub gene causes obesity, deafness and retinal degeneration in tubby mice(1-4). The tub gene is a member of a family of tubby-like genes (TULPs) that encode proteins of unknown function. Members of this family have been identified in plants, vertebrates and invertebrates(4). The TULP proteins share a conserved carboxy-terminal region of approximately 200 amino-acid residues(5). Here we report the analysis of the human gene TULP?, which is expressed specifically in the retina(5). Upon analysing 162 patients with nonsyndromic recessive retinitis pigmentosa (RP) and 374 simplex cases of RP, we found two who were compound heterozygotes for mutations that cosegregated with disease in the respective families. Three of the mutations are missense changes affecting the conserved C-terminal region; the fourth mutation affects a splice donor site upstream of this region. Our data suggest that mutations in TULP1 are a rare cause of recessive RP and indicate that TULP1 has an essential role in the physiology of photoreceptors.	Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Sequana Therapeut Inc, La Jolla, CA 92037 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Jackson Laboratory	Dryja, TP (corresponding author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, 243 Charles St, Boston, MA 02114 USA.				NEI NIH HHS [EY00169, EY08683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000169, R01EY008683, R37EY000169] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177; BAYES M, 1995, HUM MUTAT, V5, P228, DOI 10.1002/humu.1380050307; BERSON EL, 1991, AM J OPHTHALMOL, V111, P614, DOI 10.1016/S0002-9394(14)73708-0; BERSON EL, 1991, ARCH OPHTHALMOL-CHIC, V109, P92, DOI 10.1001/archopht.1991.01080010094039; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BERSON EL, 1979, AM J OPHTHALMOL, V87, P460, DOI 10.1016/0002-9394(79)90231-9; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; DANCIGER M, 1995, GENOMICS, V30, P1, DOI 10.1006/geno.1995.0001; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; KNOWLES JA, 1994, HUM MOL GENET, V3, P1401, DOI 10.1093/hmg/3.8.1401; KUMARAMANICKAVEL G, 1994, NAT GENET, V8, P10, DOI 10.1038/ng0994-10; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; North MA, 1997, P NATL ACAD SCI USA, V94, P3128, DOI 10.1073/pnas.94.7.3128; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; Sandberg MA, 1996, INVEST OPHTH VIS SCI, V37, P1693; SHUGART YY, 1995, AM J HUM GENET, V57, P499	24	161	163	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					174	176		10.1038/ng0298-174	http://dx.doi.org/10.1038/ng0298-174			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462750				2022-12-25	WOS:000071779500029
J	Hoyle, R				Hoyle, R			General electric goes to the mat in the PCB wars	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1227	1227		10.1038/nbt1197-1227	http://dx.doi.org/10.1038/nbt1197-1227			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359095	Bronze			2022-12-25	WOS:000071342000006
J	Lee, SB; Kolquist, KA; Nichols, K; Englert, C; Maheswaran, S; Ladanyi, M; Gerald, WL; Haber, DA				Lee, SB; Kolquist, KA; Nichols, K; Englert, C; Maheswaran, S; Ladanyi, M; Gerald, WL; Haber, DA			The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour	NATURE GENETICS			English	Article							FACTOR-A-CHAIN; GROWTH-FACTOR; WILMS-TUMOR; GENE-PRODUCT; TRANSCRIPTION FACTOR; SUBNUCLEAR LOCALIZATION; SUPPRESSOR WT1; FUSION; BINDING; RECEPTOR	Chromosomal translocations resulting in chimaeric transcription factors underlie specific malignancies, but few authentic target genes regulated by these fusion proteins have been identified. Desmoplastic small round-cell tumour (DSRT) is a multiphenotypic primitive tumour characterized by massive reactive fibrosis surrounding nests of tumour cells(1). The t(11;22)(p13;q12) chromosomal translocation that defines DSRT produces a chimaeric protein containing the potential transactivation domain of the Ewing-sarcoma protein (EWS) fused to zinc fingers 2-4 of the Wilms tumour suppressor and transcriptional repressor WT1 (refs 2,3). By analogy with other EWS fusion products, the EWS-WT1 chimaera may encode a transcriptional activator whose target genes overlap with those repressed by WT1 (ref. 4). To characterize its functional properties, we generated osteosarcoma cell lines with tightly regulated inducible expression of EWS-WT1. Expression of EWS-WT1 induced the expression of endogenous platelet-derived growth factor-A (PDGFA), a potent secreted mitogen and chemoattractant whose promoter contains the many potential WT1-binding sites(5,6). Native PDGFA was not regulated by wild-type WT1, indicating a difference in target gene specificity between this tumour suppressor and its oncogenic derivative. PDGFA was expressed within tumour cells in primary DSRT specimens, but it was absent in Wilms tumours expressing WT1 and Ewing sarcomas with an EWS-Fli translocation. We conclude that the oncogenic fusion of EWS to WT1 in DSRT results in the induction of PDGFA, a potent fibroblast growth factor that contributes to the characteristic reactive fibrosis associated with this unique tumour.	MASSACHUSETTS GEN HOSP,CTR CANC,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021	Harvard University; Massachusetts General Hospital; Harvard University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Ladanyi, Marc/AAG-8585-2019; Nichols, Kim/AAP-8592-2020	Nichols, Kim/0000-0002-5581-6555; Lee, Sean/0000-0001-6211-3498; Englert, Christoph/0000-0002-5931-3189	NATIONAL CANCER INSTITUTE [T32CA060376, R01CA068273, F32CA071167] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68273, CA60376, CA71167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anan K, 1996, SURGERY, V119, P333, DOI 10.1016/S0039-6060(96)80120-6; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EMING SA, 1995, J INVEST DERMATOL, V105, P756, DOI 10.1111/1523-1747.ep12325550; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; LADANYI M, 1994, CANCER RES, V54, P2837; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; RABBOTTS TJ, 1994, MATIRE, V372, P143; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Rorsman F, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046928; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; VIGNAUD JM, 1994, CANCER RES, V54, P5455; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	31	126	135	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	NOV	1997	17	3					309	313		10.1038/ng1197-309	http://dx.doi.org/10.1038/ng1197-309			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YD667	9354795				2022-12-25	WOS:A1997YD66700025
J	Miller, SD; Vanderlugt, CL; Begolka, WS; Pao, W; Yauch, RL; Neville, KL; KatzLevy, Y; Carrizosa, A; Kim, BS				Miller, SD; Vanderlugt, CL; Begolka, WS; Pao, W; Yauch, RL; Neville, KL; KatzLevy, Y; Carrizosa, A; Kim, BS			Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading	NATURE MEDICINE			English	Article							MYELIN BASIC-PROTEIN; (TMEV)-INDUCED DEMYELINATING DISEASE; T-CELL RESPONSES; IMMUNE TOLERANCE; MULTIPLE-SCLEROSIS; ENCEPHALOMYELITIS; SYSTEM; TMEV; INHIBITION; PATHOLOGY	Multiple sclerosis (MS) is a T cell-mediated autoimmune demyelinating disease(1), which may be initiated by a virus infection(2). Theiler's murine encephalomyelitis virus (TMEV), a natural mouse pathogen, is a picornavirus that induces a chronic, CD4(+) T cell-mediated demyelinating disease with a clinical course and histopathology similar to that of chronic progressive MS (ref. 3). Demyelination in TMEV-infected mice is initiated by a mononuclear inflammatory response mediated by virus-specific CD4(+) T cells targeting virus, which chronically persists in the CNS (ref. 4-6). We show that beginning 3-4 weeks after disease onset, T-cell responses to multiple myelin autoepitopes arise in an ordered progression and may play a pathologic role in chronic disease. Kinetic and functional studies show that T-cell responses to the immunodominant myelin proteolipid protein epitope (PLP139-151) did not arise because of cross-reactivity between TMEV and self epitopes (that is, molecular mimicry)(7,8), but because of de novo priming of self-reactive T cells to sequestered autoantigens released secondary to virus-specific T cell-mediated demyelination (that is, epitope spreading)(9,10). Epitope spreading is an important alternate mechanism to explain the etiology of virus-induced organ-specific autoimmune diseases.	NORTHWESTERN UNIV,SCH MED,INTERDEPT IMMUNOBIOL CTR,CHICAGO,IL 60611; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Northwestern University; Harvard University; Brigham & Women's Hospital	Miller, SD (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT IMMUNOL MICROBIOL,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Kim, Byung/AAU-7450-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035814, R01NS028752, P01NS023349] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23349, NS 35814, NS 28752] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bernard C C, 1991, Acta Neurol (Napoli), V13, P171; CLATCH RJ, 1986, J IMMUNOL, V136, P920; CLATCH RJ, 1990, VIROLOGY, V176, P244, DOI 10.1016/0042-6822(90)90249-Q; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; KARPUS WJ, 1995, J IMMUNOL, V155, P947; KENNEDY MK, 1990, J IMMUNOL, V144, P909; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; KYU B, 1992, CIRCULATION, V86, P522, DOI 10.1161/01.CIR.86.2.522; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; MILLER SD, 1987, J IMMUNOL, V138, P3776; MILLER SD, 1990, J NEUROIMMUNOL, V26, P9, DOI 10.1016/0165-5728(90)90115-4; Miller SD, 1990, SEMIN VIROL, V1, P263; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; Pope JG, 1996, J IMMUNOL, V156, P4050; Rose NR, 1996, CLIN IMMUNOL IMMUNOP, V80, pS92, DOI 10.1006/clin.1996.0146; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; Wekerle H, 1991, Acta Neurol (Napoli), V13, P197; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	20	424	429	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1133	1136		10.1038/nm1097-1133	http://dx.doi.org/10.1038/nm1097-1133			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334726				2022-12-25	WOS:A1997XZ28700040
J	Flanagan, WM; Su, LL; Wagner, RW				Flanagan, WM; Su, LL; Wagner, RW			Elucidation of gene function using C-5 propyne antisense oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						antisense oligonucleotides; cell cycle; p34(cdc2); cyclin B1; cationic lipids; C-5 propyne phosphorothioate oligonucleotides; gene delivery	CYCLIN-DEPENDENT KINASES; RAS MESSENGER-RNA; CELL-CYCLE; MAMMALIAN-CELLS; CDC2 KINASE; IN-VITRO; INHIBITION; EXPRESSION; OLIGODEOXYNUCLEOTIDES; ACTIVATION	Identification of human disease-causing genes continues to be an intense area of research. While cloning of genes may lead to diagnostic tests, development of a cure requires an understanding of the gene's function in both normal and diseased cells. Thus, there exists a need for a reproducible and simple method to elucidate gene function. We evaluate C-5 propyne pyrimidine modified phosphorothioate antisense oligonucleotides (ONs) targeted against two human cell cycle proteins that are aberrantly expressed in breast cancer: p34(cdc2) kinase and cyclin B1. Dose-dependent, sequence-specific, and gene-specific inhibition of both proteins was achieved at nanomolar concentrations of ONs in normal and breast cancer cells. Precise binding of the antisense ONs to their target RNA was absolutely required for antisense activity. Four or six base-mismatched ONs eliminated antisense activity confirming the sequence specificity of the antisense ONs. Antisense inhibition of p34(cdc2) kinase resulted in a significant accumulation of cells in the Gap2/mitosis phase of the cell cycle in normal cells, but caused little effect on cell cycle progression in breast cancer cells. These data demonstrate the potency, specificity, and utility of C-5 propyne modified antisense ONs as biological tools and illustrate the redundancy of cell cycle protein function that can occur in cancer cells.			Flanagan, WM (corresponding author), GILEAD SCI, 353 LAKESIDE DR, FOSTER CITY, CA 94404 USA.			Su, Leon/0000-0001-7654-9997				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUROUX I, 1995, NUCLEIC ACIDS RES, V23, P3411, DOI 10.1093/nar/23.17.3411; FENSTER SD, 1994, BIOCHEMISTRY-US, V33, P8391, DOI 10.1021/bi00194a002; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; FROEHLER BC, 1993, PROTOCOLS OLIGONUCLE; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HELCHMAN KA, 1994, CELL, V79, P557; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LARROUY B, 1995, NUCLEIC ACIDS RES, V23, P3434, DOI 10.1093/nar/23.17.3434; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; MOUTHON MA, 1994, EXP HEMATOL, V22, P384; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAGNER RW, 1995, ANTISENSE RES DEV, V5, P113, DOI 10.1089/ard.1995.5.113; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093	54	29	30	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1139	1145		10.1038/nbt0996-1139	http://dx.doi.org/10.1038/nbt0996-1139			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631067				2022-12-25	WOS:A1996VF84300038
J	Edgington, SM				Edgington, SM			Did George do the right thing?	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					926	926		10.1038/nbt0896-926	http://dx.doi.org/10.1038/nbt0896-926			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631022				2022-12-25	WOS:A1996UZ19900002
J	Brumeanu, TD; Casares, S; Harris, PE; Dehazya, P; Wolf, I; vonBoehmer, H; Bona, CA				Brumeanu, TD; Casares, S; Harris, PE; Dehazya, P; Wolf, I; vonBoehmer, H; Bona, CA			Immunopotency of a viral peptide assembled on the carbohydrate moieties of self immunoglobulins	NATURE BIOTECHNOLOGY			English	Article						immunopotency; viral epitope; carbohydrate; immunoglobulin	CLASS-II MOLECULES; T-CELL EPITOPE; INFLUENZA-VIRUS; HEMAGGLUTININ; RECEPTOR	The T-cell receptor recognizes peptides bound to the major histocompatibility complex antigens. Synthetic peptides corresponding to microbial epitopes can efficiently stimulate the in vitro proliferation of T-cell hybridoma or in vivo, primed T cells, However, the in vivo immune responses elicited by synthetic peptides are weak because of their short half-life and poor immunogenicity. We previously showed that a genetically engineered immunoglobulin (Ig-HA), in which the CDR3 region of V-H gene was replaced with a viral peptide recognized by CD4(+) T cells, was able to deliver this epitope in the correct frame to antigen-processing cells that efficiently presented the peptide to T cells. Recently, we developed an enzymatic method to assemble viral pep tides on the sugar moieties of immunoglobulins without alteration of the biological functions of either molecule, The viral peptide carried by these conjugates was twenty times more efficient In activating a T-cell hybridoma than the free peptide as calculated on a molar basis. We show that such conjugates are able to prime in vivo the precursors of peptide-specific T cells and to induce proliferation of naive lymphocytes from transgenic mice expressing a peptide-specific T-cell receptor in both CD4 and CD8 T-cell subsets, Our results suggest that peptides enzymatically linked to the carbohydrate moieties of immunoglobulins, using galactose residues as peptide acceptor, can be used as a safe and efficient delivery system of protective epitopes for the prevention of infectious diseases. The enzymatic engineering of immunoglobulins may also allow the development of immunotherapeutic agents to deliver antagonist peptides to autoreactive T cells or to direct immunomodulatory agents such as interleukins or cytolytic drugs to tumor cells.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; BASEL INST IMMUNOL,BASEL,SWITZERLAND; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University			Brumeanu, Teodor/AAB-1965-2020	HARRIS, PAUL/0000-0003-4806-8242				BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BRUMEANU TD, 1993, J EXP MED, V178, P1795, DOI 10.1084/jem.178.5.1795; BRUMEANU TD, 1995, J IMMUNOL METHODS, V183, P185, DOI 10.1016/0022-1759(95)00092-O; BRUMEANU TD, 1993, J IMMUNOL METHODS, V160, P65, DOI 10.1016/0022-1759(93)90009-V; BRUMEANU TD, 1996, UNPUB MHC CLASS 2 PR; CATON AJ, 1982, CELL, V31, P417, DOI 10.1016/0092-8674(82)90135-0; HABERMAN AM, 1990, J IMMUNOL, V145, P3087; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; LECLERC C, 1994, INT REV IMMUNOL, V11, P103; LEE G, 1993, PROTEIN ENG, V6, P745, DOI 10.1093/protein/6.7.745; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; SPENCER JS, 1989, J EXP MED, V169, P625, DOI 10.1084/jem.169.3.625; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469; ZAGHOUANI H, 1992, J IMMUNOL, V148, P3604; ZAGHOUANI H, 1995, P NATL ACAD SCI USA, V92, P631, DOI 10.1073/pnas.92.2.631	16	11	12	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					722	725		10.1038/nbt0696-722	http://dx.doi.org/10.1038/nbt0696-722			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630978				2022-12-25	WOS:A1996UM76600026
J	Budker, V; Gurevich, V; Hagstrom, JE; Bortzov, F; Wolff, JA				Budker, V; Gurevich, V; Hagstrom, JE; Bortzov, F; Wolff, JA			pH-sensitive, cationic liposomes: A new synthetic virus-like vector	NATURE BIOTECHNOLOGY			English	Article						gene transfer; cationic liposomes; endosomal acidification	HIGHLY EFFICIENT; MAMMALIAN-CELLS; GENE-TRANSFER; H+-ATPASE; FUSION; DNA; DELIVERY; BAFILOMYCIN-A1; ACIDIFICATION; DEGRADATION	We describe the use of cationic, pH-sensitive liposomes to mediate the efficient transfer of DNA into a variety of cells in culture, Cationic lipids, containing an amine with a pK within the physiologic range of 4.5 to 8, were synthesized and incorporated with dioleoylphosphatidylethanolamine into liposomes, Acid conditions promoted DNA-binding, DNA-incorporation, and DNA-induced fusion by these cationic, pH-sensitive liposomes. Transfection efficiency in cultured cells was dependent on endosomal acidification in a manner akin to acidic-induced endosomal release of viruses, These liposomes constitute a promising new class of reagents for gene therapy.	UNIV WISCONSIN,WAISMAN CTR,DEPT PEDIAT,MADISON,WI 53705; UNIV WISCONSIN,WAISMAN CTR,DEPT MED GENET,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								BEIGEL M, 1988, BIOCHEMISTRY-US, V27, P660, DOI 10.1021/bi00402a025; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CUDD A, 1984, LIPOSOME TECHNOLOGY, P207; DANKO I, 1994, GENE THER, V1, P114; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572; DUZGUNES N, 1989, BIOCHEMISTRY-US, V28, P9179, DOI 10.1021/bi00449a033; DUZGUNES N, 1991, MEMBRANE FUSION, P713; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FRESE J, 1994, ADV DRUG DELIVER REV, V14, P137, DOI 10.1016/0169-409X(94)90009-4; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUINEA R, 1995, J VIROL, V69, P2306, DOI 10.1128/JVI.69.4.2306-2312.1995; HODGSON CP, 1995, BIO-TECHNOL, V13, P222, DOI 10.1038/nbt0395-222; HOLMEN SL, 1995, IN VITRO CELL DEV, V30, P347; HORWITZ BA, 1980, SCIENCE, V210, P1253; KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P7, DOI 10.1021/bc00031a002; KAMATA H, 1994, NUCLEIC ACIDS RES, V22, P536, DOI 10.1093/nar/22.3.536; KICHLER A, 1995, BIOCHEM BIOPH RES CO, V209, P444, DOI 10.1006/bbrc.1995.1522; LANZREIN M, 1994, BIOCHEM J, V302, P313, DOI 10.1042/bj3020313; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; UMATA T, 1990, J BIOL CHEM, V265, P21940; WAGNER E, 1994, ADV DRUG DELIVER REV, V14, P113, DOI 10.1016/0169-409X(94)90008-6; WANG CY, 1989, BIOCHEMISTRY-US, V28, P9508, DOI 10.1021/bi00450a039; WOLFF J, 1994, GENE THERAPEUTICS ME; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, IN PRESS CANC GENE T; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZHOU X, 1994, BIOCHIM BIOPHYS ACTA, P1195	40	127	142	0	26	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					760	764		10.1038/nbt0696-760	http://dx.doi.org/10.1038/nbt0696-760			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630986				2022-12-25	WOS:A1996UM76600034
J	Li, HQ; Sautter, C; Potrykus, I; PuontiKaerlas, J				Li, HQ; Sautter, C; Potrykus, I; PuontiKaerlas, J			Genetic transformation of cassava (Manihot esculenta Crantz)	NATURE BIOTECHNOLOGY			English	Article						genetic engineering; Agrobacterium; regeneration; transgenic plant	AGROBACTERIUM-TUMEFACIENS; SOMATIC EMBRYOGENESIS; PLANT-REGENERATION; DNA; RESISTANCE; CELLS; VIRULENCE; PLASMIDS; TISSUES; MARKER	Genetic engineering can be used to complement traditional breeding methods in crop plant improvement. Transfer of genes from heterologous species provides the means of selectively introducing new traits into crop plants and expanding the gene pool beyond what has been available to traditional breeding systems, The prerequisites for genetic engineering are efficient transformation and tissue culture systems that allow selection and regeneration of transgenic plants. Cassava, an integral plant for food security in developing countries, has until now been recalcitrant to transformation approaches. We report here a method for regenerating stably transformed cassava plants after cocultivation with Agrobacterium tumefaciens, which opens cassava for future improvement via biotechnology.	ETH ZENTRUM,INST PLANT SCI,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								ARIASGARZON DI, 1995, P 2 INT SCI M CASS B, V1, P245; BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BEVAN MW, 1983, NATURE, V304, P184, DOI 10.1038/304184a0; CALDERON A, 1988, THESIS VRIJE U BRUSS; *CASS BIOT NETW, 1995, P 2 INT SCI M CAL, V1, P381; CHAVARRIAGAAGUI.P, 1993, P 1 INT SCI M CASS B, P222; CHILTON MD, 1974, P NATL ACAD SCI USA, V71, P3672, DOI 10.1073/pnas.71.9.3672; Cock J. H., 1985, Cassava. New potential for a neglected crop.; *CTR INT AGR TROP, 1980, 1979 CTR INT AGR TRO; DEBRUIJN GH, 1989, NETH J AGR SCI, V37, P21; *FAO, 1995, FAO STAT SER, V125, P93; FAUQUET C, 1990, PLANT DIS, V74, P404, DOI 10.1094/PD-74-0404; FAUQUET CM, 1993, P CBN 1 INT SCI M CA, P190; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHHOFF DA, 1987, BIO-TECHNOL, V5, P807, DOI 10.1038/nbt0887-807; GREVELDING C, 1993, PLANT MOL BIOL, V23, P847, DOI 10.1007/BF00021539; GUTTERER J, 1995, GENE TRANSFER PLANTS, P213; HENRY G, 1995, P INT SCI M CASS BIO, V1; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; HOEKEMA A, 1984, J BACTERIOL, V158, P383, DOI 10.1128/JB.158.1.383-385.1984; HOLSTERS M, 1980, PLASMID, V3, P212, DOI 10.1016/0147-619X(80)90110-9; Holtorf S, 1995, PLANT MOL BIOL, V29, P637, DOI 10.1007/BF00041155; HOOD EE, 1987, PLANT PHYSIOL, V83, P529, DOI 10.1104/pp.83.3.529; HOOD EE, 1986, J BACTERIOL, V168, P1291, DOI 10.1128/jb.168.3.1291-1301.1986; LI H, 1995, P 2 INT SCI M CASS B, V1, P289; LIU CN, 1992, PLANT MOL BIOL, V20, P1071, DOI 10.1007/BF00028894; Maniatis T., 1982, MOL CLONING; MENDEL RR, 1989, THEOR APPL GENET, V78, P31, DOI 10.1007/BF00299749; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OTIMNAPE GW, 1995, P 2 INT SCI M CASS B, V2, P519; PERLAK FJ, 1990, BIO-TECHNOL, V8, P939, DOI 10.1038/nbt1090-939; PUONTIKAERLAS J, 1992, THEOR APPL GENET, V84, P443, DOI 10.1007/BF00229505; PUONTIKAERLAS J, 1991, ACTA U UPSALIENSIS; RAEMAKERS CJJ, 1995, P 2 INT SCI M CASS B, V1, P336; Roca W. M., 1992, AgBiotech News and Information, V4, p303N; ROCA WM, 1993, P 1 INT SCI M CASS B, P496; Rosling H., 1988, Cassava toxicity and food security. A review of health effects of cyanide exposure from cassava and of ways to prevent these effects.; SARRIA R, 1995, P 2 INT SCI M CASS B, V1, P241; SARRIA RA, 1993, P 1 INT SCI M CASS B, P128; SCHOPKE C, 1995, P 2 INT SCI M CASS B, V1, P257; SCHOPKE C, 1993, BIOTECHNOLOGY AGR FO, P273; SCHOPKE C, 1993, P 1 INT SCI M CASS B, P140; SCIAKY D, 1978, PLASMID, V1, P238, DOI 10.1016/0147-619X(78)90042-2; STAMP JA, 1987, PLANT CELL TISS ORG, V10, P227, DOI 10.1007/BF00037307; STAMP JA, 1987, ANN BOT-LONDON, V59, P445, DOI 10.1093/oxfordjournals.aob.a087333; STAMP JA, 1987, ANN BOT-LONDON, V59, P451, DOI 10.1093/oxfordjournals.aob.a087334; SZABADOS L, 1987, PLANT CELL REP, V6, P248, DOI 10.1007/BF00268492; VAECK M, 1987, NATURE, V327, P239; VANCANNEYT G, 1990, MOL GEN GENET, V220, P245, DOI 10.1007/BF00260489; WILSON TMA, 1993, P NATL ACAD SCI USA, V90, P3134, DOI 10.1073/pnas.90.8.3134; ZAMBRYSKI P, 1988, ANNU REV GENET, V22, P1, DOI 10.1146/annurev.ge.22.120188.000245	51	95	119	1	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					736	740		10.1038/nbt0696-736	http://dx.doi.org/10.1038/nbt0696-736			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630981				2022-12-25	WOS:A1996UM76600029
J	Samuelsson, E; Jonasson, P; Viklund, F; Nilsson, B; Uhlen, M				Samuelsson, E; Jonasson, P; Viklund, F; Nilsson, B; Uhlen, M			Affinity-assisted in vivo folding of a secreted human peptide hormone in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article						folding; affinity; insulin-like growth factor; binding protein; periplasm; disulfide	GROWTH FACTOR-I; PURIFICATION; ANTIBODY; IDENTIFICATION; EXPRESSION; PROTEINS; BONDS	We show that coexpression of a specific binding protein in Escherichia coli can significantly improve the relative yields of correctly folded human insulin-like growth factor I (IGF-I). A glutathione redox buffer was used during growth to allow formation and breakage of disulfide bonds in the periplasm of the bacterial host, Both the binding protein and the peptide hormone were produced as affinity fusions, which allowed purification of the in vivo formed heterodimer by alternative affinity purification methods. The use of affinity-assisted in vivo folding has general implications for expression, folding, and purification of recombinant proteins.	KTH, DEPT BIOCHEM & BIOTECHNOL, S-10044 STOCKHOLM, SWEDEN; PHARM & UPJOHN AB, DEPT STRUCT BIOCHEM, S-11287 STOCKHOLM, SWEDEN	Royal Institute of Technology			Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056				BALDWIN TO, 1993, J BIOL CHEM, V268, P10766; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; CARLSON JD, 1992, BIO-TECHNOL, V10, P86, DOI 10.1038/nbt0192-86; CHAVEZ LG, 1978, J BIOL CHEM, V253, P8081; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CLELAND JL, 1993, ACS SYM SER, V526, P1; ELLIOTT S, 1990, J PROTEIN CHEM, V9, P95, DOI 10.1007/BF01024990; FORSBERG G, 1990, BIOCHEM J, V271, P357, DOI 10.1042/bj2710357; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HART RA, 1994, BIO-TECHNOL, V12, P1113, DOI 10.1038/nbt1194-1113; HART RA, 1994, BIOTECHNOL APPL BIOC, V20, P233; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HOBER S, 1994, BIOCHEMISTRY-US, V33, P6758, DOI 10.1021/bi00188a003; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; MAURER R, 1980, J MOL BIOL, V139, P147, DOI 10.1016/0022-2836(80)90302-2; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MOKS T, 1987, BIO-TECHNOL, V5, P379, DOI 10.1038/nbt0487-379; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NORD K, 1995, PROTEIN ENG, V8, P601, DOI 10.1093/protein/8.6.601; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; Nygren P A, 1988, J Mol Recognit, V1, P69, DOI 10.1002/jmr.300010204; RUTHER U, 1982, NUCLEIC ACIDS RES, V10, P5765, DOI 10.1093/nar/10.19.5765; SAMUELSSON E, 1994, BIOCHEMISTRY-US, V33, P4207, DOI 10.1021/bi00180a013; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; STAHL S, 1989, J IMMUNOL METHODS, V124, P43, DOI 10.1016/0022-1759(89)90184-1; WONG EY, 1988, GENE, V68, P193, DOI 10.1016/0378-1119(88)90021-2; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x	32	13	14	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					751	755		10.1038/nbt0696-751	http://dx.doi.org/10.1038/nbt0696-751			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630984				2022-12-25	WOS:A1996UM76600032
J	Maerz, H; Hahn, SO; Maassen, A; Meisel, H; Roggenbuck, D; Sato, T; Tanzmann, H; Emmrich, F; Marx, U				Maerz, H; Hahn, SO; Maassen, A; Meisel, H; Roggenbuck, D; Sato, T; Tanzmann, H; Emmrich, F; Marx, U			Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration	NATURE BIOTECHNOLOGY			English	Editorial Material							BIOTECHNOLOGY		HUMBOLDT UNIV BERLIN,D-10117 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,D-10099 BERLIN,GERMANY; DR FOOKE LAB GMBH,D-41469 NEUSS,GERMANY; ASAHI CHEM IND CO LTD,CHIYODA KU,TOKYO 100,JAPAN	Humboldt University of Berlin; Humboldt University of Berlin	Maerz, H (corresponding author), UNIV LEIPZIG,DELITZSCHER STR 141,D-04129 LEIPZIG,GERMANY.			Roggenbuck, Dirk/0000-0002-6861-6827				[Anonymous], 1991, Biologicals, V19, P247; BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x; DILEO AJ, 1991, NATURE, V351, P420, DOI 10.1038/351420a0; FROMMER W, 1993, APPL MICROBIOL BIOT, V39, P141; HAMAMOTO Y, 1989, VOX SANG, V56, P230, DOI 10.1111/j.1423-0410.1989.tb02034.x; MANABE S, 1991, ANIMAL CELL CULTURE AND PRODUCTION OF BIOLOGICALS, P87; MINOR P, 1993, VIROLOGICAL ASPECTS, P233; NICKLAS W, 1993, LAB ANIM SCI, V43, P296; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; ROITT IM, 1991, KURZES LEHRBUCH IMMU; SEKIGUCHI S, 1989, MEMBRANE, V14, P77; Tateishi Jun, 1993, Membrane, V18, P357; TOMOKIYO K, 1991, JPN CLIN REP, V25, P1; TRIJZELAAR B, 1993, BIOTHERAPY, V6, P93, DOI 10.1007/BF01877422; TSUBOI T, 1992, ANIMAL CELL TECHNOLO, P289; TSURUMI T, 1990, POLYM J, V22, P751, DOI 10.1295/polymj.22.751; WEBSTER RG, 1994, ENCY VIROLOGY, V1; WHITE EM, 1991, PROCESS VALIDATION V; YASUA T, 1991, J GEN VIROLOG, V72, P2021; 1991, PHARMACOL TOXICOL, V69, P144	20	3	3	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					651	652		10.1038/nbt0596-651	http://dx.doi.org/10.1038/nbt0596-651			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630961				2022-12-25	WOS:A1996UL60400035
J	Ramos, JL; Haidour, A; Duque, E; Pinar, G; Calvo, V; Oliva, JM				Ramos, JL; Haidour, A; Duque, E; Pinar, G; Calvo, V; Oliva, JM			Metabolism of nitrate esters by a consortium of two bacteria	NATURE BIOTECHNOLOGY			English	Article						dinitroethylenglycol; xenobiotics; microbial consortium; Arthrobacter	NITRIC-OXIDE; DEGRADATION	The products of condensation of organic alcohols and nitric acid are nitrate esters with the general structure C-O-NO2, These products are widely employed as vasodilators and explosives, and are true xenobiotic compounds, as they do not occur in nature, We have isolated and characterized a consortium of two microorganisms, Arthrobacter ilicis and Agrobacterium radiobacter, that mineralized recalcitrant ethylene glycol dinitrate. The Arthrobacter strain was the actual degrading microorganism, although the second microbe facilitated mineralization. The biodegradation of ethylene glycol dinitrate by A. ilicis involved the progressive elimination of the nitro groups from the organic molecule to generate ethylene glycol, which was then mineralized, Waters polluted with ethylene glycol dinitrate have been shown amenable to biological treatment in a pilot plant with wastewaters generated during the synthesis of the chemical in a factory.	UNION ESPANOLA EXPLOS FABR PARAMO MASA,E-09080 BURGOS,SPAIN; CSIC,DEPT BIOCHEM & MOL & CELLULAR BIOL PLANTS,E-18008 GRANADA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)	Ramos, JL (corresponding author), ESTAC EXPTL ZAIDIN,APDO 419,E-18008 GRANADA,SPAIN.		Pinar, Guadalupe/I-8959-2016; Benamin, Ali Haidour/ABG-1909-2020	Pinar, Guadalupe/0000-0001-7881-8572; Benamin, Ali Haidour/0000-0003-3401-1878; Duque, Estrella/0000-0002-4857-8974; Ramos, Juan L./0000-0002-8731-7435				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; DUCROCQ C, 1990, BIOTECHNOL APPL BIOC, V12, P325; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; KEEN JH, 1976, J BIOL CHEM, V251, P6183; MARRS KA, 1995, NATURE, V375, P397, DOI 10.1038/375397a0; MENG M, 1995, APPL ENVIRON MICROB, V61, P2548, DOI 10.1128/AEM.61.7.2548-2553.1995; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RAMOS JL, 1995, Patent No. 1311; Snell F.D., 1949, COLORIMETRIC METHODS, V3; TANWALKER RLB, 1987, THESIS U LONDON UK; Walker John E., 1992, Biodegradation, V3, P369, DOI 10.1007/BF00129094; WENDT TM, 1978, APPL ENVIRON MICROB, V36, P693, DOI 10.1128/AEM.36.5.693-699.1978; WHITE GF, 1993, J GEN MICROBIOL, V139, P1947, DOI 10.1099/00221287-139-9-1947	14	17	17	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					320	322		10.1038/nbt0396-320	http://dx.doi.org/10.1038/nbt0396-320			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630893				2022-12-25	WOS:A1996UL38000025
J	Botto, M; Dell'Agnola, C; Bygrave, AE; Thompson, EM; Cook, HT; Petry, F; Loos, M; Pandolfi, PP; Walport, MJ				Botto, M; Dell'Agnola, C; Bygrave, AE; Thompson, EM; Cook, HT; Petry, F; Loos, M; Pandolfi, PP; Walport, MJ			Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies	NATURE GENETICS			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; MOLECULAR-BASIS; KERATINOCYTES; EXPRESSION; NEPHRITIS; ANTIGENS; BINDING; FAMILY; GENES	The complement system plays a paradoxical role in the development and expression of autoimmunity in humans. The activation of complement in systemic lupus erythematosus (SLE) contributes to tissue injury. In contrast, inherited deficiency of classical pathway components, particularly Clq (ref, 1), is powerfully associated with the development of SLE, This leads to the hypothesis that a physiological action of the early part of the classical pathway protects against the development of SLE (ref, 2) and implies that Clq may play a key role in this respect. Clq-deficient (C1qa(-/-)) mice were generated by gene targeting and monitored for eight months. C1qa(-/-) mice had increased mortality and higher titres of autoantibodies, compared with strain-matched controls. Of the C1qa(-/-) mice, 25% had glomerulonephritis with immune deposits and multiple apoptotic cell bodies. Among mice without glomerulonephritis, there were significantly greater numbers of glomerular apoptotic bodies in Clq-deficient mice compared with controls. The phenotype associated with Clq deficiency was modified by background genes. These findings are compatible with the hypothesis that Clq deficiency causes autoimmunity by impairment of the clearance of apoptotic cells.	Imperial Coll Sci Technol & Med, Sch Med, Rheumatol Sect, London W12 0NN, England; Imperial Coll Sci Technol & Med, Sch Med, Dept Histopathol, London W12 0NN, England; Dept Histopathol, London W2 1NY, England; Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Imperial College London; Imperial College London; Memorial Sloan Kettering Cancer Center	Walport, MJ (corresponding author), Imperial Coll Sci Technol & Med, Sch Med, Rheumatol Sect, Hammersmith Campus, London W12 0NN, England.	mwalport@rpms.ac.uk		Walport, Mark/0000-0001-7220-5273				ANDREWS BS, 1978, J IMMUNOL METHODS, V22, P273, DOI 10.1016/0022-1759(78)90035-2; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; BOWNESS P, 1994, Q J MED, V87, P455; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; CasciolaRosen L, 1996, P NATL ACAD SCI USA, V93, P1624, DOI 10.1073/pnas.93.4.1624; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; GOLAN TD, 1992, J CLIN INVEST, V90, P1067, DOI 10.1172/JCI115922; JEVNIKAR AM, 1992, AM J PATHOL, V141, P743; Korb LC, 1997, J IMMUNOL, V158, P4525; LACHMANN PJ, 1987, CIBA F SYMP, V129, P149; LEFEBER WP, 1984, J CLIN INVEST, V74, P1545, DOI 10.1172/JCI111569; MCADAM RA, 1988, IMMUNOGENETICS, V27, P259, DOI 10.1007/BF00376120; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; Petry F, 1997, HUM GENET, V100, P51, DOI 10.1007/s004390050464; PETRY F, 1995, J IMMUNOL, V155, P4734; Petry F, 1996, IMMUNOGENETICS, V43, P370, DOI 10.1007/BF02199805; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; Slingsby JH, 1996, ARTHRITIS RHEUM, V39, P663, DOI 10.1002/art.1780390419; Topaloglu R, 1996, KIDNEY INT, V50, P635, DOI 10.1038/ki.1996.359; TRINDER PKE, 1995, IMMUNOLOGY, V84, P638	20	1151	1197	0	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					56	59		10.1038/ng0598-56	http://dx.doi.org/10.1038/ng0598-56			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590289				2022-12-25	WOS:000073346700017
J	Arguello, JR; Little, AM; Pay, AL; Gallardo, D; Rojas, I; Marsh, SGE; Goldman, JM; Madrigal, JA				Arguello, JR; Little, AM; Pay, AL; Gallardo, D; Rojas, I; Marsh, SGE; Goldman, JM; Madrigal, JA			Mutation detection and typing of polymorphic loci through double-strand conformation analysis	NATURE GENETICS			English	Article							REGULATOR CFTR GENE; GENOMIC DNA; CYSTIC-FIBROSIS; HLA-A; AMPLIFICATION; SEQUENCE; ALLELES	Variations, such as nucleotide substitutions, deletions and insertions, within genes can affect the function of the gene product and in some cases be deleterious. Screening for known allelic variation is important for determining disease and gene associations'. Techniques which target specific mutations such as restriction enzyme polymorphism and oligonucleotide probe or PCR primer reactivity are useful for the detection of specific mutations, but these techniques are not generally effective for the identification of new mutations. Approaches for measuring changes in DNA conformation have been developed, based on the principle that DNA fragments which differ in nucleotide composition exhibit different mobilities after separation by polyacrylamide gel electrophoresis (PAGE; refs 2,3). Here we describe a conformation-based mutation detection system, double-strand conformation analysis (DSCA), which provides a simple means to detect genetic variants and to type complex polymorphic loci, We demonstrate the application of DSCA to detect genetic polymorphisms such as a single-nucleotide difference within DNA fragments of up to 979 base pairs in length. We present the application of DSCA in detecting four different mutations in the cystic fibrosis gene (CFTR) and 131 different alleles encoded by HLA class I genes.	Royal Free Hosp, Anthony Nolan Res Inst, London NW3 2QG, England; Royal Free Hosp, Dept Haematol, London NW3 2QG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, London W12 0NN, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London	Madrigal, JA (corresponding author), Royal Free Hosp, Anthony Nolan Res Inst, Pond St, London NW3 2QG, England.		Marsh, Steven GE/C-1638-2008	Marsh, Steven GE/0000-0003-2855-4120; Stevens, Andrea/0000-0002-2892-7065; Gallardo, David/0000-0003-1615-4592				Arguello R, 1997, NUCLEIC ACIDS RES, V25, P2236, DOI 10.1093/nar/25.11.2236; BLASCZYK R, 1995, TISSUE ANTIGENS, V46, P86, DOI 10.1111/j.1399-0039.1995.tb02483.x; CEREB N, 1995, TISSUE ANTIGENS, V45, P1, DOI 10.1111/j.1399-0039.1995.tb02408.x; Dykes CW, 1996, BRIT J CLIN PHARMACO, V42, P683, DOI 10.1046/j.1365-2125.1996.00473.x; LAU M, 1994, INT CELL EXCHANGE, P467; MARSH SGE, 1997, P 12 INT HIST WORKSH, V1, P26; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Savage DA, 1996, TISSUE ANTIGENS, V47, P284, DOI 10.1111/j.1399-0039.1996.tb02555.x; VERLINGUE C, 1994, HUM GENET, V93, P429; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7; ZIMMERMAN PA, 1993, NUCLEIC ACIDS RES, V21, P4541, DOI 10.1093/nar/21.19.4541	12	84	91	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					192	194		10.1038/ng0298-192	http://dx.doi.org/10.1038/ng0298-192			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462755				2022-12-25	WOS:000071779500034
J	Burnett, AL; Johns, DG; Kriegsfeld, LJ; Klein, SL; Calvin, DC; Demas, GE; Schramm, LP; Nelson, RJ; Snyder, SH; Poss, KD				Burnett, AL; Johns, DG; Kriegsfeld, LJ; Klein, SL; Calvin, DC; Demas, GE; Schramm, LP; Nelson, RJ; Snyder, SH; Poss, KD			Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; CARBON-MONOXIDE; PENILE ERECTION; RELAXATION; MEDIATOR	Nitric oxide (NO) is well established as a neurotransmitter in the central and peripheral nervous systems(1). More recently, another gas, carbon monoxide (CO) has also been implicated in neurotransmission. In the nervous system CO is formed by a subtype of heme oxygenase (HO) designated HO2 (ref. 2). HO2 is localized to discrete neuronal populations in the brain resembling localizations of soluble guanylyl cyclase, which is activated by CO (ref. 3). CO may also function in the peripheral autonomic nervous system, in conjunction with NO. The majority of ganglia in the myenteric plexus possess both HO2 and neuronal NO synthase (NOS)(4). Defects in myenteric plexus neurotransmission occur both in mice with targeted deletion of genes for HO2 and neuronal NOS (ref. 5). HO2 also occurs in other autonomic ganglia including the petrosal, superior cervical and nodose ganglia(4). Neuronal NOS is localized to neurons regulating male reproductive behavior, such as penile erection, and NOS inhibitors prevent erection(6). Because of the other parallels between NO and CO, we speculated that CO may play a role in male reproductive behavior. In the present study we describe HO2 localization in neuronal structures regulating copulatory reflexes. Reflex activity of the bulbospongiosus muscle, which mediates ejaculation and ejaculatory behavior, is markedly diminished in mice with targeted deletion of the gene for HO2 (HO2(-)).	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Coll Arts & Sci, Dept Psychol, Baltimore, MD 21218 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Massachusetts Institute of Technology (MIT)	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Demas, Gregory/Y-1783-2019	Demas, Gregory/0000-0003-3914-0900; Poss, Kenneth/0000-0002-6743-5709; Nelson, Randy/0000-0002-8194-4016	NICHD NIH HHS [HD-22201] Funding Source: Medline; NIDA NIH HHS [DA-00266, DA-00074] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Benson G. S., 1994, PHYSL REPROD, V1, P1489; Burnett AL, 1996, MOL MED, V2, P288, DOI 10.1007/BF03401627; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; EVERITT BJ, 1990, NEUROSCI BIOBEHAV R, V14, P217, DOI 10.1016/S0149-7634(05)80222-2; GULBENKIAN S, 1987, J AUTONOM NERV SYST, V18, P235, DOI 10.1016/0165-1838(87)90122-6; JAFFREY SR, 1995, CELL DEV BIOL, V11, P417; JANICAK PG, 1994, PRINCIPLES PRACTICE; Kriegsfeld LJ, 1996, AM J PHYSIOL-REG I, V270, pR1013, DOI 10.1152/ajpregu.1996.270.5.R1013; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MARSON L, 1994, PHARMACOL BIOCHEM BE, V47, P883, DOI 10.1016/0091-3057(94)90292-5; MCGILL TE, 1964, SCIENCE, V145, P514, DOI 10.1126/science.145.3631.514; MCKENNA KE, 1991, AM J PHYSIOL, V30, pR1276; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; SPECTOR IP, 1990, ARCH SEX BEHAV, V19, P389, DOI 10.1007/BF01541933; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795; ZAKHARY R, IN PRESS P NATL ACAD	20	94	97	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1998	4	1					84	87		10.1038/nm0198-084	http://dx.doi.org/10.1038/nm0198-084			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427611				2022-12-25	WOS:000072249700039
J	Ellis, LBM; Wackett, LP				Ellis, LBM; Wackett, LP			Microbial biocatalysis and biodegradation informatics	NATURE BIOTECHNOLOGY			English	Article											Ellis, LBM (corresponding author), UNIV MINNESOTA,CTR BIODEGRADAT RES & INFORMAT,MINNEAPOLIS,MN 55455, USA.								0	2	2	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1406	1406		10.1038/nbt1297-1406	http://dx.doi.org/10.1038/nbt1297-1406			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415896				2022-12-25	WOS:A1997YK36100035
J	Pipia, GG; Long, MW				Pipia, GG; Long, MW			Human hematopoietic progenitor cell isolation based on galactose-specific cell surface binding	NATURE BIOTECHNOLOGY			English	Article						CD34; lectin; progenitor; galactose; hematopoiesis	HUMAN BONE-MARROW; CORD-BLOOD; PERIPHERAL-BLOOD; STEM-CELLS; ENRICHMENT; EXPRESSION; MOLECULES	The ability to isolate functional populations of hematopoietic progenitor cells is important to the process of hematopoietic cell transplantation and to the understanding of hematopoietic cell biology in health and disease. We show that a subpopulation of human bone marrow hematopoietic cells bearing the pan-hematopoietic antigen CD34 also binds galactose-conjugated proteins. This lectin-positive subpopulation represents approximately 0.1 to 0.5% of the total bone marrow cells, and contains 100% of the hematopoietic progenitor cells. The galactose-binding lectin on these cells is specific for this sugar. Additionally, highly proliferative hematopoietic progenitor cells with very primitive phenotypes, including a newly identified progenitor cell that produces multiple lineages, express this lectin.	UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,GRAD PROGRAM CELLULAR & MOL BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NHLBI NIH HHS [HL1459, HL58709] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIZAWA S, 1987, P NATL ACAD SCI USA, V84, P4485, DOI 10.1073/pnas.84.13.4485; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; CAROW CE, 1993, BLOOD, V81, P942; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DEWYNTER EA, 1995, STEM CELLS, V13, P532; HARDY CL, 1991, EXP HEMATOL, V19, P968; HUYHN A, 1995, BLOOD, V86, P4474, DOI 10.1182/blood.V86.12.4474.bloodjournal86124474; LANSDORP PM, 1990, J EXP MED, V172, P363, DOI 10.1084/jem.172.1.363; LONG MW, 1988, J CLIN INVEST, V82, P1779, DOI 10.1172/JCI113791; LONG MW, 1992, EXP HEMATOL, V20, P288; LONG MW, 1992, J CLIN INVEST, V90, P251, DOI 10.1172/JCI115844; MCNEICE IK, 1989, BLOOD, V74, P609; MURRAY L, 1995, BLOOD, V85, P368; NAGLER A, 1994, EXP HEMATOL, V22, P1134; RUSTEN LS, 1994, BLOOD, V84, P1473; SULLENBARGER BA, 1995, BLOOD, V86, P135, DOI 10.1182/blood.V86.1.135.bloodjournal861135; Sutherland D R, 1992, J Hematother, V1, P115, DOI 10.1089/scd.1.1992.1.115; VANEPPS DE, 1994, BLOOD CELLS, V20, P411	18	7	7	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					1007	1011		10.1038/nbt1097-1007	http://dx.doi.org/10.1038/nbt1097-1007			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335055				2022-12-25	WOS:A1997XZ28500034
J	Sauer, CG; Gehrig, A; WarnekeWittstock, R; Marquardt, A; Ewing, CC; Gibson, A; Lorenz, B; Jurklies, B; Weber, BHF				Sauer, CG; Gehrig, A; WarnekeWittstock, R; Marquardt, A; Ewing, CC; Gibson, A; Lorenz, B; Jurklies, B; Weber, BHF			Positional cloning of the gene associated with X-linked juvenile retinoschisis	NATURE GENETICS			English	Article							CELL-SURFACE PROTEIN; COAGULATION FACTOR-V; FACTOR-VIII; DICTYOSTELIUM-DISCOIDEUM; NERVOUS-SYSTEM; YAC CONTIG; SEQUENCE; CDNA; EXPRESSION; CHROMOSOME	X-linked juvenile retinoschisis (RS) is a recessively inherited vitreo-retinal degeneration characterized by macular pathology and intraretinal splitting of the retina. The RS gene has been localized to Xp22.2 to an approximately 1 Mb interval between DXS418 and DXS999/DXS7161. Mapping and expression analysis of expressed sequence tags have identified a novel transcript, designated XLRS1, within the centromeric RS locus that is exclusively expressed in retina. The predicted XLRS1 protein contains a highly conserved motif implicated in cell-cell interaction and thus may be active in cell adhesion processes during retinal development. Mutational analyses of XLRS1 in affected individuals from nine unrelated RS families revealed one nonsense, one frameshift, one splice acceptor and six missense mutations segregating with the disease phenotype in the respective families. These data provide strong evidence that the XLRS1 gene, when mutated, causes RS.	UNIV WURZBURG,INST HUMANGENET,D-97074 WURZBURG,GERMANY; UNIV SASKATCHEWAN,SASKATOON,SK S7K 0M7,CANADA; UNIV ESSEN GESAMTHSCH,AUGENKLIN,D-45147 ESSEN,GERMANY; UNIV REGENSBURG,AUGENKLIN,D-93042 REGENSBURG,GERMANY	University of Wurzburg; University of Saskatchewan; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg				Weber, Bernhard H.F./0000-0002-8808-7723				ALITALO T, 1987, CLIN GENET, V32, P192; ALITALO T, 1995, GENOMICS, V25, P691, DOI 10.1016/0888-7543(95)80012-B; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; ARDEN GB, 1988, AM J OPHTHALMOL, V105, P590; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P1256; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONDON GP, 1986, ARCH OPHTHALMOL-CHIC, V104, P576, DOI 10.1001/archopht.1986.01050160132029; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DEUTMAN AF, 1977, HEREDITARY RETINAL C, P1043; ELDER B, 1993, GENOMICS, V16, P374, DOI 10.1006/geno.1993.1200; Ewing C C, 1970, Trans Ophthalmol Soc U K, V89, P29; FELBOR U, IN PRESS HUM MUTAT; FERRERO GB, 1995, HUM MOL GENET, V4, P1821, DOI 10.1093/hmg/4.10.1821; FORSIUS H, 1973, CAN J OPHTHALMOL, V8, P385; Fukuzawa M, 1996, PLANT CELL PHYSIOL, V37, P505, DOI 10.1093/oxfordjournals.pcp.a028973; *GEN COMP GROUP, 1996, PROGR MAN WISC PACK; George NDL, 1996, ARCH OPHTHALMOL-CHIC, V114, P274, DOI 10.1001/archopht.1996.01100130270007; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Haas J., 1898, ARCH AUGENHEILKD, V37, P343; Huopaniemi L, 1997, AM J HUM GENET, V60, P1139; IVES E J, 1970, American Journal of Human Genetics, V22, p17A; KANE WH, 1988, BLOOD, V71, P539; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; KAWANO K, 1981, GRAEFES ARCH CLIN EX, V217, P315; KELLNER U, 1990, GRAEF ARCH CLIN EXP, V228, P432, DOI 10.1007/BF00927256; KLJAVIN IJ, 1991, J NEUROSCI, V11, P2985; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAROCCA D, 1991, CANCER RES, V51, P4994; MANSCHOT WA, 1972, ARCH OPHTHALMOL-CHIC, V88, P131; MILLER RF, 1970, J NEUROPHYSIOL, V33, P323, DOI 10.1152/jn.1970.33.3.323; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; NEHLS M, 1994, ONCOGENE, V9, P2169; PENOTTI FE, 1991, J THEOR BIOL, V150, P385, DOI 10.1016/S0022-5193(05)80436-9; PEREZ JL, 1994, ONCOGENE, V9, P211; Reichenbach Andreas, 1995, P395; ROMMENS JM, 1993, HUM MOL GENET, V2, P901, DOI 10.1093/hmg/2.7.901; ROSEN SD, 1973, P NATL ACAD SCI USA, V70, P2554, DOI 10.1073/pnas.70.9.2554; SHEFFIELD JB, 1987, AM ZOOL, V27, P145; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; van de Vosse E, 1996, EUR J HUM GENET, V4, P101; WEBER BHF, 1995, CYTOGENET CELL GENET, V69, P35, DOI 10.1159/000133932; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WIEACKER P, 1983, HUM GENET, V64, P143, DOI 10.1007/BF00327111; YANOFF M, 1968, ARCH OPHTHALMOL-CHIC, V79, P49	52	355	380	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					164	170		10.1038/ng1097-164	http://dx.doi.org/10.1038/ng1097-164			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326935				2022-12-25	WOS:A1997XZ55500021
J	Zoubenko, O; Uckun, F; Hur, Y; Chet, I; Tumer, N				Zoubenko, O; Uckun, F; Hur, Y; Chet, I; Tumer, N			Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants	NATURE BIOTECHNOLOGY			English	Article						transgenic plant resistance; pathogenesis related proteins; salicylic acid	RIBOSOME-INACTIVATING PROTEINS; SYSTEMIC ACQUIRED-RESISTANCE; PATHOGENESIS-RELATED PROTEINS; TRANSGENIC TOBACCO; RHIZOCTONIA-SOLANI; SALICYLIC-ACID; TRANSLOCATED SIGNAL; VIRUS-RESISTANCE; EXPRESSION; PROTECTION	Pokeweed antiviral protein (PAP), a 29-kD protein isolated from Phytolacca americana inhibits translation by catalytically removing a specific adenine residue from the large rRNA of the 60S subunit of eukaryotic ribosomes. Transgenic plants expressing PAP are resistant to a broad spectrum of plant viruses. Nontoxic PAP mutants have been isolated by random mutagenesis and selection in yeast. One of these mutants, PAP-X, had a point mutation at the active-site (E176V) that abolished enzymatic activity, and another mutant, Delta C25PAP, had a nonsense mutation near the C-terminus (W237stop) that deleted 25 C-terminal amino acids. Unlike the wild-type PAP, expression of neither mutant was toxic to transgenic plants. We show that both class I (basic) and class II (acidic) isoforms of pathogenesis-related (PR) proteins are overexpressed in transgenic plants expressing PAP and the nontoxic PAP mutants. Although PR-proteins are constitutively expressed, no increase in salicylic acid levels was detected. Homozygous progeny of transgenic plants expressing either PAP or the nontoxic PAP mutants displayed resistance to the fungal pathogen Rhizoctonia solani. These results show that expression of PAP or the nontoxic PAP mutants activates multiple plant defense pathways independently of salicylic acid and confers resistance to fungal infection. The C-terminal 25 amino acids of PAP, which are required for toxicity in vivo, are not critical for resistance to viral or fungal infection, indicating that toxicity of PAP can be separated from pathogen resistance.	RUTGERS STATE UNIV,COOK COLL,AGR BIOTECHNOL CTR,NEW BRUNSWICK,NJ 08903; HUGHES INST,ROSEVILLE,MN; HEBREW UNIV JERUSALEM,FAC AGR,IL-76100 REHOVOT,ISRAEL	Rutgers State University New Brunswick; Hebrew University of Jerusalem				Uckun, Fatih M./0000-0001-9334-183X; Hur, Yoonkang/0000-0002-2325-2249				ALEXANDER D, 1993, P NATL ACAD SCI USA, V90, P7327, DOI 10.1073/pnas.90.15.7327; ANDERSON NA, 1982, ANNU REV PHYTOPATHOL, V20, P329, DOI 10.1146/annurev.py.20.090182.001553; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BEFFA R, 1995, EMBO J, V14, P5753, DOI 10.1002/j.1460-2075.1995.tb00264.x; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; CHEN ZC, 1991, PLANT PATHOL, V40, P612, DOI 10.1111/j.1365-3059.1991.tb02426.x; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; ENDO Y, 1988, BIOCHIM BIOPHYS ACTA, V994, P224; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; Irvin JD, 1995, ANTIVIRAL PROTEINS H, P65; JACH G, 1995, PLANT J, V8, P97, DOI 10.1046/j.1365-313X.1995.08010097.x; LINTHORST HJM, 1990, MOL PLANT MICROBE IN, V3, P252, DOI 10.1094/MPMI-3-252; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; LOGEMANN J, 1992, BIO-TECHNOL, V10, P305, DOI 10.1038/nbt0392-305; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; OGOSHI A, 1987, ANNU REV PHYTOPATHOL, V25, P125, DOI 10.1146/annurev.py.25.090187.001013; RALS J, 1994, PLANT PHYSIOL, V104, P1108; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SHULAEV V, 1995, PLANT CELL, V7, P1691, DOI 10.1105/tpc.7.10.1691; Smirnov S, 1997, PLANT PHYSIOL, V114, P1113, DOI 10.1104/pp.114.3.1113; SNEDECOR GW, 1980, STATISTICAL METHODS, P201; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; VIERHEILIG H, 1993, MOL PLANT MICROBE IN, V6, P261, DOI 10.1094/MPMI-6-261; YALPANI N, 1993, PHYTOPATHOLOGY, V83, P702, DOI 10.1094/Phyto-83-702; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809; ZHU Q, 1994, BIO-TECHNOL, V12, P807, DOI 10.1038/nbt0894-807	33	70	90	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					992	996		10.1038/nbt1097-992	http://dx.doi.org/10.1038/nbt1097-992			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335052				2022-12-25	WOS:A1997XZ28500031
J	McKinney, RA; Debanne, D; Gahwiler, BH; Thompson, SM				McKinney, RA; Debanne, D; Gahwiler, BH; Thompson, SM			Lesion-induced axonal sprouting and hyperexcitability in the hippocampus in vitro: Implications for the genesis of posttraumatic epilepsy	NATURE MEDICINE			English	Article							NERVE GROWTH-FACTOR; FIBER SYNAPTIC REORGANIZATION; SLICE CULTURES; REACTIVE SYNAPTOGENESIS; CELLULAR MECHANISMS; RAT HIPPOCAMPUS; DENTATE GYRUS; MESSENGER-RNA; TREATED RATS; ADULT-RATS	The delayed development of recurring seizures is a common consequence of traumatic head injury; the cause of such epilepsy is unknown. We demonstrate here that transection of the mature axons of CA3 pyramidal cells in hippocampal slice cultures leads to the formation by CA3 pyramidal cells of new axon collaterals that are immunoreactive with the growth-associated protein GAP-43. Individual CA3 cell axons had an elevated number of presynaptic boutons 14 days after the lesion, and dual intracellular recordings revealed an increased probability that any two CA3 pyramidal cells were connected by an excitatory synapse. Lesioned cultures were hyperexcitable and synaptic responses often displayed unusual prolonged polysynaptic components. We thus demonstrate that recurrent axon collaterals are newly sprouted by pyramidal cells as a consequence of axonal injury and suggest that this underlies the development of posttraumatic epilepsy.			McKinney, RA (corresponding author), UNIV ZURICH,BRAIN RES INST,AUGUST FOREL STR 1,CH-8029 ZURICH,SWITZERLAND.		Debanne, Dominique/O-4673-2016; Thompson, Scott M/K-8921-2015	Debanne, Dominique/0000-0001-8581-5695; 				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COTMAN CW, 1978, NEURONAL PLASTICITY, P227; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; Debanne D, 1996, J PHYSIOL-LONDON, V491, P163, DOI 10.1113/jphysiol.1996.sp021204; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; Dugan Ellen M., 1994, Emergency Medicine Clinics of North America, V12, P1081; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; GOLDOWITZ D, 1979, BRAIN RES, V170, P427, DOI 10.1016/0006-8993(79)90962-4; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; Jennett B, 1979, Adv Neurol, V22, P137; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LOWENSTEIN DH, 1993, NEUROSCIENCE, V56, P597, DOI 10.1016/0306-4522(93)90359-N; MAJKOWSKI J, 1990, COMPREHENSIVE EPILEP, P281; MCGUIRE CB, 1988, DEV BRAIN RES, V41, P277, DOI 10.1016/0165-3806(88)90189-7; MEBERG PJ, 1991, NEUROSCIENCE, V45, P721, DOI 10.1016/0306-4522(91)90284-U; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; MELDRUM BS, 1984, GREENFIELDS NEUROPAT, P921; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; PURPURA DP, 1961, EXP NEUROL, V4, P377, DOI 10.1016/0014-4886(61)90025-5; Ramon y Cajal S., 1914, ESTUDIOS DEGENERACIO; RASHID K, 1995, P NATL ACAD SCI USA, V92, P9495, DOI 10.1073/pnas.92.21.9495; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; Salin P, 1995, J NEUROSCI, V15, P8234; SCANZIANI M, 1994, NEUROSCIENCE, V61, P823, DOI 10.1016/0306-4522(94)90405-7; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STREIT P, 1989, EUR J NEUROSCI, V1, P603, DOI 10.1111/j.1460-9568.1989.tb00366.x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Traub R.D., 1991, NEURONAL NETWORKS HI; VANDERZEE CEE, 1995, J NEUROSCI, V15, P5316; Weidenman B., 1985, CELL, V41, P1017; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1993, NEUROL CLIN, V11, P823, DOI 10.1016/S0733-8619(18)30126-9; Wuarin JP, 1996, J NEUROSCI, V16, P4438	44	126	129	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					990	996		10.1038/nm0997-990	http://dx.doi.org/10.1038/nm0997-990			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288725				2022-12-25	WOS:A1997XT84200031
J	McGuinness, BT; Walter, G; Fitzgerald, K; Schuler, P; Mahoney, W; Duncan, AR; Hoogenboom, HR				McGuinness, BT; Walter, G; Fitzgerald, K; Schuler, P; Mahoney, W; Duncan, AR; Hoogenboom, HR			Phage diabody repertoires for selection of large numbers of bispecific antibody fragments	NATURE BIOTECHNOLOGY			English	Article						diabody; antibody; bispecific; phage display; library; selection	AFFINITY HUMAN-ANTIBODIES; BY-PASSING IMMUNIZATION; ESCHERICHIA-COLI; SYNTHETIC REPERTOIRES; FILAMENTOUS PHAGE; FV; CELL; DISPLAY; CYTOTOXICITY; TECHNOLOGY	Methods for the generation of large numbers of different bispecific antibodies are presented. Cloning strategies are detailed to create repertoires of bispecific diabody molecules with variability on one or both of the antigen binding sites. This diabody format, when combined with the power of phage display technology, allows the generation and analysis of thousands of different bispecific molecules. Selection for binding presumably also selects for more stable diabodies. Phage diabody libraries enable screening or selection of the best combination bispecific molecule with regards to affinity of binding, epitope recognition and pairing before manufacture of the best candidate.	CAMBRIDGE ANTIBODY TECHNOL LTD,MELBOURNE SG8 6JJ,CAMBS,ENGLAND; BOEHRINGER MANNHEIM CORP,RES & DEV,INDIANAPOLIS,IN 46250	AstraZeneca								BAGSHAWE KD, 1987, BRIT J CANCER, V56, P531, DOI 10.1038/bjc.1987.237; BRISSINCK J, 1991, J IMMUNOL, V147, P4019; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; DESPLANCQ D, 1994, PROTEIN ENG, V7, P1027, DOI 10.1093/protein/7.8.1027; GEORGE AJT, 1994, J IMMUNOL, V152, P1802; GLENNIE MJ, 1988, J IMMUNOL, V141, P3662; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRUBER M, 1994, J IMMUNOL, V152, P5368; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Holliger Philipp, 1993, Current Opinion in Biotechnology, V4, P446, DOI 10.1016/0958-1669(93)90010-T; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARPOVSKY B, 1984, J EXP MED, V160, P1686, DOI 10.1084/jem.160.6.1686; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; MISHELL BB, 1979, SELECTED METHODS CEL, P102; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SANNA PP, 1995, BIO-TECHNOL, V13, P1221, DOI 10.1038/nbt1195-1221; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WHITLOW M, 1994, PROTEIN ENG, V7, P1017, DOI 10.1093/protein/7.8.1017; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	32	56	80	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1996	14	9					1149	1154		10.1038/nbt0996-1149	http://dx.doi.org/10.1038/nbt0996-1149			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VF843	9631069				2022-12-25	WOS:A1996VF84300040
J	Struck, MM				Struck, MM			Vaccine R&D success rates and development times	NATURE BIOTECHNOLOGY			English	Article											Struck, MM (corresponding author), SWISS SERUM & VACCINE INC,REHHAGSTR 79,CH-3018 BERN,SWITZERLAND.							BUSSIERE JL, 1995, VACCINE DESIGN SUBUN, P61; DAVENPORT LW, 1995, VACCINE DESIGN SUBUN, P81; Desselberger U., 1995, PHLS Microbiology Digest, V12, P141; *DHHS, 1995, MERC REP REP US VACC; DREWS J, 1995, 10 CTR MED RES ANN C; EFSTRATIOU A, 1995, PHLS MICROBIOL DIGES, V12, P233; *EUR VACC MAN ASS, 1995, PHARM ASP COMB VACC; FAST PE, 1995, VACCINE DESIGN SUBUN, P97; *FDA, 1995, POINTS CONS EV COMB; GLUCK R, 1992, J CLIN INVEST, V90, P2491, DOI 10.1172/JCI116141; GUPTA RK, 1995, VACCINE, V13, P965; HUTTON I, PHARM PROJECTS; JENUM PA, 1995, EUR J CLIN MICROBIOL, V14, P794, DOI 10.1007/BF01690995; LEVINE M M, 1988, Lancet, V2, P467; LEVINE MM, 1990, LANCET, V336, P891; MILLER E, 1993, LANCET, V341, P979, DOI 10.1016/0140-6736(93)91069-X; ORENSTEIN WA, 1984, FIELD EVALUATION VAC; *PAR INT CORP, 1995, PHARM R D STAT SOURC; PARKER DP, 1995, VACCINE DESIGN SUBUN, P135; PARKMAN PD, 1994, VACCINES, P889; STRUCK MM, 1994, BIO-TECHNOL, V12, P674, DOI 10.1038/nbt0794-674; TACKET CO, 1993, J INFECT DIS, V168, P1536, DOI 10.1093/infdis/168.6.1536; 1995, WEEKLY EPIDEMIOLOGIC, V70, P252	23	43	54	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					591	593		10.1038/nbt0596-591	http://dx.doi.org/10.1038/nbt0596-591			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630948	Bronze			2022-12-25	WOS:A1996UL60400022
J	Kendall, AL; Rayment, FD; Torres, EM; Baker, HF; Ridley, RM; Dunnett, SB				Kendall, AL; Rayment, FD; Torres, EM; Baker, HF; Ridley, RM; Dunnett, SB			Functional integration of striatal allografts in a primate model of Huntington's disease	NATURE MEDICINE			English	Article							FETAL NEOSTRIATAL ALLOGRAFTS; 3-NITROPROPIONIC ACID; RHESUS-MONKEY; LESIONS; GRAFTS; DEFICITS; DOPAMINE; CELLS	Huntington's disease is an autosomal dominant, inherited disorder that results in progressive degeneration of the basal ganglia (especially the neostriatal caudate nucleus and putamen) and other forebrain structures and is associated with a clinical profile of movement, cognitive and psychiatric impairments for which there is at present no effective therapy(1). Neuropathological, neurochemical and behavioral features of the disease can all be reproduced in experimental animals by local injection of excitotoxic(2,3) or metabolic(4,5) toxins into the neostriatum. All these features of the disease can be alleviated, at least in rats, by transplantation of embryonic striatal tissue into the degenerated striatum(6-8), which was the basis for commencing the first clinical trials of striatal transplantation in Huntington's patients(9,10). However, although rat striatal xenografts may temporarily reduce apomorphine-induced dyskinesias in monkeys(11), there has been no demonstration that allograft techniques that work well in rats translate effectively to the much larger differentiated striatum of primates(12). Here we demonstrate good survival, differentiation and integration of striatal allografts in the primate neostriatum, and recovery in a test of skilled motor performance. Long-term graft survival in primates indicates probable success for clinical transplants in Huntington's disease; in addition, our data suggest that graft placement has a direct influence on the pattern and extent of functional recovery.	Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Univ Cambridge, MRC, Cambridge Ctr Brain Repair, Cambridge CB2 3EB, England	University of Cambridge; University of Cambridge	Kendall, AL (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.		Dunnett, Stephen B/A-5869-2010	Dunnett, Stephen B/0000-0003-1826-1578				ANNETT LE, 1994, EXP NEUROL, V125, P228, DOI 10.1006/exnr.1994.1026; BEAL MF, 1993, J NEUROSCI, V13, P4181; Bjorklund A., 1994, FUNCTIONAL NEURAL TR, P157; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Dunnett S.B., 1992, NEURAL TRANSPLANTATI; DUNNETT SB, 1988, NEUROSCIENCE, V24, P813, DOI 10.1016/0306-4522(88)90069-3; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; HANTRAYE P, 1992, P NATL ACAD SCI USA, V89, P4187, DOI 10.1073/pnas.89.9.4187; HARPER P. S., 1996, HUNTINGTONS DIS; HELM GA, 1992, NEUROSCIENCE, V50, P163, DOI 10.1016/0306-4522(92)90390-N; HELM GA, 1993, EXP NEUROL, V123, P174, DOI 10.1006/exnr.1993.1150; ISACSON O, 1989, EXP BRAIN RES, V75, P213; MADRAZO I, 1995, NEUROL RES, V17, P312, DOI 10.1080/01616412.1995.11740334; Marshall JWB, 1996, NEURODEGENERATION, V5, P275, DOI 10.1006/neur.1996.0036; OUIMET CC, 1984, J NEUROSCI, V4, P111; PAKZABAN P, 1993, EXP BRAIN RES, V97, P13; Palfi SP, 1996, J NEUROSCI, V16, P3019; Philpott LM, 1997, CELL TRANSPLANT, V6, P203, DOI 10.1016/S0963-6897(97)00028-6; STEHAN H, 1980, BRAIN COMMON MARMOSE; WICTORIN K, 1992, PROG NEUROBIOL, V38, P611, DOI 10.1016/0301-0082(92)90044-F	21	120	126	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					727	729		10.1038/nm0698-727	http://dx.doi.org/10.1038/nm0698-727			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623985				2022-12-25	WOS:000074008300042
J	Bergstrom, TF; Josefsson, A; Erlich, HA; Gyllensten, U				Bergstrom, TF; Josefsson, A; Erlich, HA; Gyllensten, U			Recent origin of HLA-DRB1 alleles and implications for human evolution	NATURE GENETICS			English	Article							HUMAN IA ANTIGENS; CLASS-II REGION; DR-BETA LOCI; NUCLEOTIDE SUBSTITUTION; MITOCHONDRIAL-DNA; OVERDOMINANT SELECTION; LINKAGE DISEQUILIBRIUM; COALESCENT PROCESS; GENE CONVERSION; POLYMORPHISM	The HLA class I and class II loci are the most highly polymorphic coding regions in the human genome. Based on the similarity of the coding sequences of alleles between species, it has been claimed that the HLA polymorphism is ancient and predates the separation of human (Homo) and chimpanzee (Pan), 4-7.4 Myr ago. Analysis of intron sequences, however, provides support for a more recent origin and for rapid generation of alleles at the HLA class II DRB1 locus. The human DRB1 alleles can be divided into groups (allelic lineages); most of these lineages have diverged from each other before the separation of Homo and Pan. Alleles within such a lineage, however, appear to be, on average, 250,000 years old, implying that the vast majority (greater than 90%) of the more than 135 contemporary human DRB1 alleles have been generated after the separation of Homo and Pan. The coalescence time of alleles within allelic lineages indicates that the effective population size (N-e) for early hominids (over the last 1 Myr) was approximately 10(4) individuals, similar to estimates based on other nuclear loci and mitochondrial DNA. With a single exception, the genetic mechanisms (gene conversion and point mutation) that have diversified the exon-2 sequences do not appear to extend into the adjacent intron sequences. The part of exon 2 encoding the beta-sheet evolves in concert with the surrounding introns, while the alpha-helix appears to have been subjected to gene conversion-like events, suggesting that such exchange events are highly localised and occur over extremely short sequence tracts.	Uppsala Univ, Ctr Biomed, Unit Med Genet, Dept Genet & Pathol, S-75123 Uppsala, Sweden; Roche Mol Syst Inc, Dept Human Genet, Alameda, CA 94501 USA	Uppsala University; Roche Holding	Gyllensten, U (corresponding author), Uppsala Univ, Ctr Biomed, Unit Med Genet, Dept Genet & Pathol, Box 589, S-75123 Uppsala, Sweden.	ulf.gyllensten@medgen.uu.se	Bergström, Tomas/B-4681-2017	Bergström, Tomas/0000-0002-7480-2669				ARDEN B, 1982, P NATL ACAD SCI-BIOL, V79, P2342, DOI 10.1073/pnas.79.7.2342; AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; Ayala FJ, 1996, MOL PHYLOGENET EVOL, V5, P188, DOI 10.1006/mpev.1996.0013; BEGOVICH AB, 1992, J IMMUNOL, V148, P249; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CHARLESWORTH B, 1993, GENETICS, V134, P1289; FIGUEROA F, 1988, NATURE, V335, P265, DOI 10.1038/335265a0; FULLERTON SM, 1994, P NATL ACAD SCI USA, V91, P1805, DOI 10.1073/pnas.91.5.1805; GORSKI J, 1986, NATURE, V322, P67, DOI 10.1038/322067a0; Gyllensten U, 1996, TISSUE ANTIGENS, V47, P212, DOI 10.1111/j.1399-0039.1996.tb02543.x; GYLLENSTEN UB, 1991, P NATL ACAD SCI USA, V88, P3686, DOI 10.1073/pnas.88.9.3686; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; Harding RM, 1997, AM J HUM GENET, V60, P772; Hickson RE, 1997, J MOL EVOL, V45, P589, DOI 10.1007/PL00006263; HOLMES EC, 1989, J HUM EVOL, V18, P775, DOI 10.1016/0047-2484(89)90089-4; HORAI S, 1992, J MOL EVOL, V35, P32, DOI 10.1007/BF00160258; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; HUDSON RR, 1988, GENETICS, V120, P831; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; JUKES T H, 1969, P21; KAPLAN NL, 1988, GENETICS, V120, P819; KAPLAN NL, 1989, GENETICS, V123, P887; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KLEIN J, 1987, HUM IMMUNOL, V19, P155, DOI 10.1016/0198-8859(87)90066-8; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LI WH, 1991, GENETICS, V129, P513; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; Mack SJ, 1998, TISSUE ANTIGENS, V51, P41, DOI 10.1111/j.1399-0039.1998.tb02945.x; MARSH SGE, 1995, TISSUE ANTIGENS, V46, P258, DOI 10.1111/j.1399-0039.1995.tb03125.x; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MCCONNELL TJ, 1988, NATURE, V332, P651, DOI 10.1038/332651a0; NATHENSON SG, 1986, ANNU REV IMMUNOL, V4, P471, DOI 10.1146/annurev.iy.04.040186.002351; NEI M, 1986, MOL BIOL EVOL, V3, P418; OHTA T, 1995, J MOL EVOL, V41, P115, DOI 10.1007/BF00170662; RIPLEY LS, 1991, MOL EVOLUTION MAJOR, P63; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Satta Y, 1996, J MOL EVOL, V42, P648, DOI 10.1007/BF02338798; SATTA Y, 1991, MOL EVOLUTION MAJOR, P51; Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; STROBECK C, 1983, GENETICS, V103, P545; Svensson AC, 1996, IMMUNOGENETICS, V43, P304, DOI 10.1007/BF02440998; SVENSSON AC, 1995, IMMUNOGENETICS, V41, P74; TAJIMA F, 1989, GENETICS, V123, P585; Takahata N, 1997, P NATL ACAD SCI USA, V94, P4811, DOI 10.1073/pnas.94.9.4811; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TAKAHATA N, IN PRESS IMMUNOGENET; TITUSTRACHTENBERG EA, 1994, AM J HUM GENET, V55, P160; TROWSDALE J, 1995, IMMUNOGENETICS, V41, P1, DOI 10.1007/BF00188427; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WU SK, 1986, NATURE, V324, P676, DOI 10.1038/324676a0	53	126	128	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1998	18	3					237	242		10.1038/ng0398-237	http://dx.doi.org/10.1038/ng0398-237			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500545				2022-12-25	WOS:000072325000021
J	Fukumoto, T; Torigoe, N; Kawabata, S; Murakami, M; Uede, T; Nishi, T; Ito, Y; Sugimura, K				Fukumoto, T; Torigoe, N; Kawabata, S; Murakami, M; Uede, T; Nishi, T; Ito, Y; Sugimura, K			Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation	NATURE BIOTECHNOLOGY			English	Article						applied immunology; phage display; CD80	DISTINCT ROLES; CTLA-4; BINDING; ACTIVATION; IDENTIFICATION; MOLECULE; CD28; B7-1; FORM	Phage library clones selected by a conformational epitope-recognizing and inhibitory monoclonal antibody may display moieties that mimic a receptor/ligand-like three-dimensional structure. This pseudoreceptor/ligand should be able to bind to natural ligand/receptor molecules. We tested this idea using anti-T cell costimulatory molecule antibodies and successfully isolated phage clones with costimulatory effects on T-cell proliferation, This strategy facilitates the designing of regulatory peptide molecules in the absence of precise information about the structure-function relationships in receptor/ligand interactions.	Kagoshima Univ, Fac Engn, Dept Bioengn, Kagoshima 890, Japan; Hokkaido Univ, Inst Immunol Sci, Kita Ku, Sapporo, Hokkaido 060, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan	Kagoshima University; Hokkaido University; Kumamoto University	Sugimura, K (corresponding author), Kagoshima Univ, Fac Engn, Dept Bioengn, Kagoshima 890, Japan.	kazu@cen.kagoshima-u.ac.jp						BACHAN D, 1995, J IMMUNOL, V155, P4264; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; Hashiguchi S, 1996, ALLERGY, V51, P621, DOI 10.1111/j.1398-9995.1996.tb04682.x; INOBE M, 1994, BIOCHEM BIOPH RES CO, V200, P443, DOI 10.1006/bbrc.1994.1469; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morton PA, 1996, J IMMUNOL, V156, P1047; Murakami M, 1996, P NATL ACAD SCI USA, V93, P7838, DOI 10.1073/pnas.93.15.7838; Nishi T, 1996, FEBS LETT, V399, P237, DOI 10.1016/S0014-5793(96)01329-4; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Rennert P, 1997, INT IMMUNOL, V9, P805, DOI 10.1093/intimm/9.6.805; Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Welply JK, 1996, PROTEINS, V26, P262, DOI 10.1002/(SICI)1097-0134(199611)26:3<262::AID-PROT3>3.0.CO;2-G; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WUTTKE GG, 1989, BIOCHIM BIOPHYS ACTA, V985, P239; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643	25	34	43	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1998	16	3					267	270		10.1038/nbt0398-267	http://dx.doi.org/10.1038/nbt0398-267			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZA515	9528007				2022-12-25	WOS:000072371000027
J	Herwald, H; Morgelin, M; Olsen, A; Rhen, M; Dahlback, B; Muller-Esterl, W; Bjorck, L				Herwald, H; Morgelin, M; Olsen, A; Rhen, M; Dahlback, B; Muller-Esterl, W; Bjorck, L			Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases	NATURE MEDICINE			English	Article							ESCHERICHIA-COLI; SALMONELLA-ENTERITIDIS; AGGREGATIVE FIMBRIAE; BINDING; KININOGENS; FIBRONECTIN; BRADYKININ; CURLI; THIN; PURIFICATION	Fever, hypotension and bleeding disorders are common symptoms of sepsis and septic shock. The activation of the contact-phase system is thought to contribute to the development of these severe disease states by triggering proinflammatory and procoagulatory cascades; however, the underlying molecular mechanisms are obscure. Here we report that the components of the contact-phase system are assembled on the surface of Escherichia coli and Salmonella through their specific interactions with fibrous bacterial surface proteins, curli and fimbriae. As a consequence, the proinflammatory pathway is activated through the release of bradykinin, a potent inducer of fever, pain and hypotension. Absorption of contact-phase proteins and fibrinogen by bacterial surface proteins depletes relevant coagulation factors and causes a hypocoagulatory state. Thus, the complex interplay of microbe surface proteins and host contact-phase factors may contribute to the symptoms of sepsis and septic shock.	Lund Univ, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Karolinska Inst, Microbiol & Tumor Biol Ctr MTC, S-17177 Stockholm, Sweden; Univ Lund Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Johannes Gutenberg Universitat Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany	Lund University; Karolinska Institutet; Lund University; Skane University Hospital; Johannes Gutenberg University of Mainz	Herwald, H (corresponding author), Lund Univ, Dept Cell & Mol Biol, POB 94, S-22100 Lund, Sweden.	Heiko.Herwald@medkem.lu.se	Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842; Dahlback, Bjorn/0000-0003-1546-0328				BECKER U, 1984, THROMB RES, V35, P475, DOI 10.1016/0049-3848(84)90280-9; BenNasr A, 1996, MOL MICROBIOL, V20, P927; COLLINSON SK, 1991, J BACTERIOL, V173, P4773, DOI 10.1128/jb.173.15.4773-4781.1991; COLLINSON SK, 1993, J BACTERIOL, V175, P12, DOI 10.1128/JB.175.1.12-18.1993; COLMAN RW, 1986, CRC CR REV ONCOL-HEM, V5, P57, DOI 10.1016/S1040-8428(86)80053-1; EGBERG N, 1982, THROMB RES, V25, P437, DOI 10.1016/0049-3848(82)90134-7; EVANS DG, 1977, INFECT IMMUN, V18, P330, DOI 10.1128/IAI.18.2.330-337.1977; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; HOCK J, 1990, J BIOL CHEM, V265, P12005; KAPLAN AP, 1987, BLOOD, V70, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MULLERESTERL W, 1989, THROMB HAEMOSTASIS, V61, P2; NILSSON IM, 1974, HAEMORRHAGIC THROMBA, P217; ODEGARD OR, 1975, THROMB RES, V6, P287, DOI 10.1016/0049-3848(75)90078-X; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; OLSEN A, 1993, MOL MICROBIOL, V7, P523, DOI 10.1111/j.1365-2958.1993.tb01143.x; PONJEE GAE, 1991, CLIN CHEM, V37, P1235; RISBERG B, 1991, ACTA ANAESTH SCAND, V35, P60, DOI 10.1111/j.1399-6576.1991.tb03401.x; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SJOBRING U, 1994, MOL MICROBIOL, V14, P443, DOI 10.1111/j.1365-2958.1994.tb02179.x; Sukupolvi S, 1997, INFECT IMMUN, V65, P838, DOI 10.1128/IAI.65.2.838-842.1997; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4	27	156	165	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					298	302		10.1038/nm0398-298	http://dx.doi.org/10.1038/nm0398-298			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500602				2022-12-25	WOS:000073616200034
J	Pollman, MJ; Hall, JL; Mann, MJ; Zhang, LN; Gibbons, GH				Pollman, MJ; Hall, JL; Mann, MJ; Zhang, LN; Gibbons, GH			Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease	NATURE MEDICINE			English	Article							ATHEROSCLEROSIS; OLIGONUCLEOTIDES; DEATH; HYPERPLASIA; RESTENOSIS; BCL-X(L); INJURY; KINASE; GENE	We postulated that activation of a genetic program that tonically inhibits intimal cell death is a necessary condition for the pathogenesis of vascular disease. Studies of vascular lesions in humans and animal models documented increased expression of the anti-apoptotic gene product Bcl-x(L) within intimal cells. Downregulation of intimal cell bcl-x(L) expression with the use of antisense oligonucleotides induced apoptosis and acute regression of vascular lesions. These findings indicate that apoptosis regulatory genes such as bcl-x(L) are critical determinants of intimal lesion formation and that targeted apoptosis may be a novel therapy for intimal vascular disease.	Brigham & Womens Hosp, Thorn Cardiovasc Res Labs, Boston, MA 02115 USA; Stanford Univ, Falk CArdiovasc Res Ctr, Div Cardiovasc Med, Stanford, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Stanford University	Gibbons, GH (corresponding author), Brigham & Womens Hosp, Thorn Cardiovasc Res Labs, 1326,75 Francis St, Boston, MA 02115 USA.							BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHINNAIYAN AM, 1997, SCIENCE, V275, P122; FAXON DP, 1982, ARTERIOSCLEROSIS, V2, P125, DOI 10.1161/01.ATV.2.2.125; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENG YJ, 1995, AM J PATHOL, V147, P251; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; HAN DKM, 1995, AM J PATHOL, V147, P267; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Perlman H, 1997, CIRCULATION, V95, P981; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHINOMIYA M, 1992, ATHEROSCLEROSIS, V97, P143, DOI 10.1016/0021-9150(92)90127-3; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	24	240	255	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					222	227		10.1038/nm0298-222	http://dx.doi.org/10.1038/nm0298-222			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461197				2022-12-25	WOS:000072249800039
J	Wang, G; Chopra, RK; Royal, RE; Yang, JC; Rosenberg, SA; Hwu, P				Wang, G; Chopra, RK; Royal, RE; Yang, JC; Rosenberg, SA; Hwu, P			A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen	NATURE MEDICINE			English	Article							TUMOR-CELLS; ZETA-CHAIN; LYMPHOCYTES; SPECIFICITY; EXPRESSION; VECTORS; LONG	In order to treat common cancers with immunotherapy, chimeric receptors have been developed that combine the tumor specificity of antibodies with T-cell effector functions. Previously, we demonstrated that T cells transduced with a chimeric receptor gene against human ovarian cancer were able to recognize ovarian cancer cells in vitro and in vivo. We now report that recipients of bone marrow cells transduced with these genes exhibited significant antitumor activity in vivo. Moreover, in vivo depletion of T cells in reconstituted mice did not affect antitumor activity, suggesting that other immune cells expressing the chimeric receptor gene may play an important role in tumor rejection.	NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hwu, P (corresponding author), NCI, Surg Branch, NIH, Bldg 10,Room 2B42,10 Ctr Dr, Bethesda, MD 20892 USA.							BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BROCKER T, 1995, J EXP MED, V181, P1653, DOI 10.1084/jem.181.5.1653; CONEY LR, 1991, CANCER RES, V51, P6125; ESHHAR Z, 1990, BRIT J CANCER, V62, P27; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; GROSS G, 1992, FASEB J, V6, P3370, DOI 10.1096/fasebj.6.15.1464371; HOATLIN ME, 1995, J MOL MED, V73, P113, DOI 10.1007/BF00198238; HWU P, 1995, CANCER RES, V55, P3369; HWU P, 1993, J EXP MED, V178, P361, DOI 10.1084/jem.178.1.361; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KARP SE, 1993, J IMMUNOL, V150, P896; KRUISBEEK AD, 1991, CURRENT PROTOCOLS IM; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MIOTTI S, 1987, INT J CANCER, V39, P297, DOI 10.1002/ijc.2910390306; MORITZ D, 1994, P NATL ACAD SCI USA, V91, P4318, DOI 10.1073/pnas.91.10.4318; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PARDOLL DM, 1988, J IMMUNOL, V140, P4091; ROBERTS MR, 1994, BLOOD, V84, P2878; ROSENBERG SA, 1992, JAMA-J AM MED ASSOC, V268, P2416, DOI 10.1001/jama.268.17.2416; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; Royal R. E., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P481; SHILONI E, 1993, CANCER IMMUNOL IMMUN, V37, P286, DOI 10.1007/BF01518450; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SYKES M, 1993, TRANSPLANTATION, V55, P197, DOI 10.1097/00007890-199301000-00037; TRAN AC, 1995, J IMMUNOL, V155, P1000; Walker RE, 1996, HUM GENE THER, V7, P367, DOI 10.1089/hum.1996.7.3-367; WELS W, 1995, GENE, V159, P73, DOI 10.1016/0378-1119(94)00786-R	32	49	70	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					168	172		10.1038/nm0298-168	http://dx.doi.org/10.1038/nm0298-168			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461189				2022-12-25	WOS:000072249800031
J	Wu, W; Cogan, JD; Pfaffle, RW; Dasen, JS; Frisch, H; O'Connell, SM; Flynn, SE; Brown, MR; Mullis, PE; Parks, JS; Phillips, JA; Rosenfeld, MG				Wu, W; Cogan, JD; Pfaffle, RW; Dasen, JS; Frisch, H; O'Connell, SM; Flynn, SE; Brown, MR; Mullis, PE; Parks, JS; Phillips, JA; Rosenfeld, MG			Mutations in PROP1 cause familial combined pituitary hormone deficiency	NATURE GENETICS			English	Article							AMES DWARF MICE; GENE; PIT-1; DF	Combined pituitary hormone deficiency (CPHD) in man denotes impaired production of growth hormone (CH) and one or more of the other five anterior pituitary hormones. Mutations of the pituitary transcription factor gene POU?FI (the human homologue of mouse Pit1) are responsible for deficiencies of GH, prolactin and thyroid stimulating hormone (TSH) in Snell and Jackson dwarf mice and in man, while the production of adrenocorticotrophic hormone (ACTH), luteinizing hormone (LH) and follicle stimulating hormone (FSH) is preserved, The Ames dwarf (df) mouse displays a similar phenotype, and appears to be epistatic to Snell and Jackson dwarfism. We have recently positionally cloned the putative Ames dwarf gene Prop? (ref. 1), which encodes a paired-like homeodomain protein that is expressed specifically in embryonic pituitary and is necessary for Pit? expression. In this report, we have identified four CPHD families with homozygosity or compound heterozygosity for inactivating mutations of PROP1. These mutations in the human PROP1 gene result in a gene product with reduced DNA-binding and transcriptional activation ability in comparison to the product of the murine df mutation. In contrast to individuals with POU1F1 mutations, those with PROP? mutations cannot produce LH and FSH at a sufficient level and do not enter puberty spontaneously. Our results identify a major cause of CPHD in humans and suggest a direct or indirect role for PROP? in the ontogenesis of pituitary gonadotropes, as well as somatotropes, lactotropes and caudomedial thyrotropes.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Rhein Westfal TH Aachen, Sch Med, Dept Pediat, D-52057 Aachen, Germany; Univ Vienna, Dept Pediat, Div Endocrinol, A-1090 Vienna, Austria; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Univ Bern, Dept Pediat, Div Endocrinol, Inselspital, CH-3010 Bern, Switzerland	Howard Hughes Medical Institute; University of California System; University of California San Diego; Vanderbilt University; RWTH Aachen University; University of Vienna; Emory University; University of Bern	Wu, W (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.		Parks, John/F-8570-2011		NIDDK NIH HHS [DK46312, DK52312] Funding Source: Medline; NIH HHS [GF 97-27] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052312, R01DK046312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040; BARTKE A, 1965, GEN COMP ENDOCR, V5, P418, DOI 10.1016/0016-6480(65)90102-4; BARTKE A, 1979, GENETIC VARIATION HO, P111; BUCKWALTER MS, 1991, GENOMICS, V10, P515, DOI 10.1016/0888-7543(91)90430-M; COHEN LE, 1995, J CLIN ENDOCR METAB, V80, P679, DOI 10.1210/jc.80.2.679; Gage PJ, 1996, DEVELOPMENT, V122, P151; GAGE PJ, 1995, ENDOCRINOLOGY, V136, P1161, DOI 10.1210/en.136.3.1161; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; Raskin S, 1996, HUM GENET, V98, P703, DOI 10.1007/s004390050289; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; TANG KC, 1993, ENDOCRINOLOGY, V132, P2518, DOI 10.1210/en.132.6.2518; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56	13	382	392	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					147	149		10.1038/ng0298-147	http://dx.doi.org/10.1038/ng0298-147			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462743				2022-12-25	WOS:000071779500022
J	Zhou, M; Sutliff, RL; Paul, RJ; Lorenz, JN; Hoying, JB; Haudenschild, CC; Yin, MY; Coffin, JD; Kong, L; Kranias, EG; Luo, WS; Boivin, GP; Duffy, J; Pawlowski, SA; Doetschman, T				Zhou, M; Sutliff, RL; Paul, RJ; Lorenz, JN; Hoying, JB; Haudenschild, CC; Yin, MY; Coffin, JD; Kong, L; Kranias, EG; Luo, WS; Boivin, GP; Duffy, J; Pawlowski, SA; Doetschman, T			Fibroblast growth factor 2 control of vascular tone	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; HEAVY-CHAIN ISOFORMS; CROUZON-SYNDROME; MICE LACKING; GENE; EXPRESSION; INDUCTION; MUTATIONS; ATHEROSCLEROSIS; HEMATOPOIESIS	Vascular tone control is essential in blood pressure regulation, shock, ischemia-reperfusion, inflammation, vessel injury/repair, wound healing, temperature regulation, digestion, exercise physiology, and metabolism. Here we show that a well-known growth factor, FGF2, long thought to be involved in many developmental and homeostatic processes, including growth of the tissue layers of vessel walls, functions in vascular tone control. Fgf2 knockout mice are morphologically normal and display decreased vascular smooth muscle contractility, low blood pressure and thrombocytosis. Following intra-arterial mechanical injury, FGF2-deficient vessels undergo a normal hyperplastic response. These results force us to reconsider the function of FGF2 in vascular development and homeostasis in terms of vascular tone control.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Hematol Oncol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA; McLaughlin Res Inst, Great Falls, MT 59405 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; American Red Cross; McLaughlin Research Institute for Biomedical Sciences, Inc.	Doetschman, T (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Christian, Haudenschild C/D-1602-2009	NOIRI, Eisei/0000-0002-9515-7582	NHLBI NIH HHS [R01 HL070174, HL 58511, HL 41496, R01 HL054829, HL 46826] Funding Source: Medline; NICHD NIH HHS [R01 HD026471] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026471] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826, P01HL041496, R01HL070174, R01HL054829, R01HL058511] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; ALI S, 1993, J BIOL CHEM, V268, P17397; ALLOUCHE M, 1995, LEUKEMIA, V9, P937; ARAKAWA T, 1995, J PROTEIN CHEM, V14, P263, DOI 10.1007/BF01886783; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BURSTEIN SA, 1979, BLOOD, V54, P169; CAMPBELL GR, 1990, ANN NY ACAD SCI, V598, P143, DOI 10.1111/j.1749-6632.1990.tb42286.x; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CRISTIANI C, 1994, J CARDIOVASC PHARM, V23, P988, DOI 10.1097/00005344-199406000-00018; CURRIER JW, 1995, J AM COLL CARDIOL, V25, P516, DOI 10.1016/0735-1097(95)98445-J; Davis MG, 1997, J MOL CELL CARDIOL, V29, P1061, DOI 10.1006/jmcc.1997.0383; DOETSCHMAN T, 1993, HYPERTENSION, V22, P618, DOI 10.1161/01.HYP.22.4.618; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLAMME I, 1992, DEVELOPMENT, V116, P435; FOLKMAN J, 1987, NATURE, V329, P671, DOI 10.1038/329671a0; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Lalli J, 1997, CIRC RES, V80, P506, DOI 10.1161/01.RES.80.4.506; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MACMILLAN V, 1993, STROKE, V24, P1735, DOI 10.1161/01.STR.24.11.1735; MERLE PL, 1995, J BIOL CHEM, V270, P17361, DOI 10.1074/jbc.270.29.17361; MIWA AY, 1992, SCIENCE, V257, P1401; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SCHNEIDER MD, 1992, BASIC RES CARDIOL, V87, P33; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; SLACK JMW, 1994, DEV BIOL, V161, P313, DOI 10.1006/dbio.1994.1031; SUGI Y, 1993, DEV BIOL, V157, P28, DOI 10.1006/dbio.1993.1109; SUTTER MC, 1977, ACTA PHYSIOL SCAND, V99, P484, DOI 10.1111/j.1748-1716.1977.tb10402.x; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Tsuboi Ryoji, 1992, Journal of Dermatology (Tokyo), V19, P673; WEISS RH, 1993, J BIOL CHEM, V268, P5724	44	289	294	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					201	207		10.1038/nm0298-201	http://dx.doi.org/10.1038/nm0298-201			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461194	Green Accepted			2022-12-25	WOS:000072249800036
J	Nakayama, JI; Tahara, H; Tahara, E; Saito, M; Ito, K; Nakamura, H; Nakanishi, T; Tahara, E; Ide, T; Ishikawa, F				Nakayama, JI; Tahara, H; Tahara, E; Saito, M; Ito, K; Nakamura, H; Nakanishi, T; Tahara, E; Ide, T; Ishikawa, F			Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas	NATURE GENETICS			English	Article							DNA	Telomerase is a specialized type of reverse transcriptase which catalyzes the synthesis and extension of telomeric DNA (for review, see ref.1). This enzyme is highly active in most cancer cells, but is inactive in most somatic cells(2). This striking observation led to the suggestion that telomerase might be important for the continued growth(3) or progression(4) of cancer cells. However, little is known about the molecular mechanism of telomerase activation in cancer cells, Human telomerase reverse transcriptase (hTRT) has recently been identified as a putative human telomerase catalytic subunit(5,6). We transfected the gene encoding hTRT into telomerase-negative human normal fibroblast cells and demonstrated that expression of wild-type hTRT induces telomerase activity, whereas hTRT mutants containing mutations in regions conserved among other reverse transcriptases did not, Hepatocellular carcinoma (20 samples) and non-cancerous liver tissues (19 samples) were examined for telomerase activity and expression of hTRT, the human telomerase RNA component (hTR; encoded by TERC)(7) and the human telomerase-associated protein (hTLP1; encoded by TEP1)(8,9). A significant correlation between hTRT expression and telomerase activity was observed. These results indicate that the hTRT protein is the catalytic subunit of human telomerase, and that it plays a key role in the activation of telomerase in cancer cells.	Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 226, Japan; Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 1, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Pathol 1, Hiroshima 734, Japan; Mitsubishi Chem Corp, Yokohama Res Ctr, Pharmaceut Lab 2, Aoba Ku, Yokohama, Kanagawa 227, Japan	Tokyo Institute of Technology; Hiroshima University; Hiroshima University; Hiroshima University; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Ishikawa, F (corresponding author), Tokyo Inst Technol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 226, Japan.		Nakayama, Jun-ichi/C-6003-2011; Ishikawa, Fuyuki/AAU-4056-2021; Kowaltowski, Alicia J/H-8698-2012	Nakayama, Jun-ichi/0000-0002-5597-8239; Ishikawa, Fuyuki/0000-0002-5580-2305; 				BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Eickbush Thomas H., 1994, P121; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; TAHARA H, 1995, CANCER RES, V55, P2734; Tatematsu K, 1996, ONCOGENE, V13, P2265; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	21	570	616	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					65	68		10.1038/ng0198-65	http://dx.doi.org/10.1038/ng0198-65			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425903				2022-12-25	WOS:000071259600024
J	Singh, NA; Charlier, C; Stauffer, D; DuPont, BR; Leach, RJ; Melis, R; Ronen, GM; Bjerre, I; Quattlebaum, T; Murphy, JV; McHarg, ML; Gagnon, D; Rosales, TO; Peiffer, A; Anderson, VE; Leppert, M				Singh, NA; Charlier, C; Stauffer, D; DuPont, BR; Leach, RJ; Melis, R; Ronen, GM; Bjerre, I; Quattlebaum, T; Murphy, JV; McHarg, ML; Gagnon, D; Rosales, TO; Peiffer, A; Anderson, VE; Leppert, M			A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns	NATURE GENETICS			English	Article							FAMILIAL NEONATAL CONVULSIONS; KVLQT1 MUTATIONS; HETEROGENEITY; CHROMOSOME-8Q; CONFIRMATION; D20S19; REGION; LOCUS; PORE	Idiopathic generalized epilepsies account for about 40% of epilepsy up to age 40 and commonly have a genetic basis. One type is benign familial neonatal convulsions (BFNC), a dominantly inherited disorder of newborns. We have identified a sub-microscopic deletion of chromosome 20q13.3 that co-segregates with seizures in a BFNC family. Characterization of cDNAs spanning the deleted region identified one encoding a novel voltage-gated potassium channel, KCNQ2, which belongs to a new KQT-like class of potassium channels. Five other BFNC probands were shown to have KCNQ2 mutations, including two transmembrane missense mutations, two frameshifts and one splice-site mutation. This finding in BFNC provides additional evidence that defects in potassium channels are involved in the mammalian epilepsy phenotype.	Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA; Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; Malmo Univ Hosp, Dept Pediat, S-205021 Malmo, Sweden; Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Childrens Mercy Hosp, Kansas City, MO 64108 USA; Neurol Grp PC, Norristown, PA 19401 USA; Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA; Dr CA Janeway Hlth Ctr, St Johns, NF A1A 1R8, Canada; Univ Minnesota, Dept Epidemiol, Minneapolis, MN 55455 USA	Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Health San Antonio; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; McMaster University; Lund University; Skane University Hospital; Medical University of South Carolina; Children's Mercy Hospital; Boston University; University of Minnesota System; University of Minnesota Twin Cities	Leppert, M (corresponding author), Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA.		Ronen, Gabriel M/AAS-3048-2021; Ronen, Gabriel M/AAS-5028-2021	Ronen, Gabriel M/0000-0002-7467-0627; Ronen, Gabriel M/0000-0002-7467-0627; Leach, Robin/0000-0002-3201-5579; Charlier, Carole/0000-0002-9694-094X	NCI NIH HHS [5P30 CA42014] Funding Source: Medline; NCRR NIH HHS [M01 RR00064] Funding Source: Medline; NINDS NIH HHS [R01 NS32666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; Guipponi M, 1997, HUM MOL GENET, V6, P473, DOI 10.1093/hmg/6.3.473; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Keating MT, 1996, CURR OPIN GENET DEV, V6, P326, DOI 10.1016/S0959-437X(96)80010-4; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEPPERT M, 1993, BRAIN PATHOL, V3, P357, DOI 10.1111/j.1750-3639.1993.tb00764.x; LEWIS TB, 1993, AM J HUM GENET, V53, P670; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MALAFOSSE A, 1992, HUM GENET, V89, P54, DOI 10.1007/BF00207042; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MELDRUM BS, 1995, EPILEPSIA, V36, P530; Nakamura RL, 1997, J BIOL CHEM, V272, P1011, DOI 10.1074/jbc.272.2.1011; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Plouin P., 1994, IDIOPATHIC GEN EPILE, P39; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; RONEN GM, 1993, NEUROLOGY, V43, P1355, DOI 10.1212/WNL.43.7.1355; Russell MW, 1996, HUM MOL GENET, V5, P1319, DOI 10.1093/hmg/5.9.1319; RYAN SG, 1991, ANN NEUROL, V29, P469, DOI 10.1002/ana.410290504; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; STEINLEIN O, 1995, HUM GENET, V95, P411; Steinlein Ortrud, 1992, Human Molecular Genetics, V1, P325, DOI 10.1093/hmg/1.5.325; TYTGAT J, 1994, BIOCHEM BIOPH RES CO, V203, P513, DOI 10.1006/bbrc.1994.2212; VIGEVANO F, 1994, IDIOPATHIC GEN EPILE, P45; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311	36	937	990	2	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					25	29		10.1038/ng0198-25	http://dx.doi.org/10.1038/ng0198-25			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425895				2022-12-25	WOS:000071259600016
J	Prows, DR; Shertzer, HG; Daly, MJ; Sidman, CL; Leikauf, GD				Prows, DR; Shertzer, HG; Daly, MJ; Sidman, CL; Leikauf, GD			Genetic analysis of ozone-induced acute lung injury in sensitive and resistant strains of mice	NATURE GENETICS			English	Article							INBRED MOUSE STRAINS; INDUCED INFLAMMATION; AIR-POLLUTION; RESPONSIVENESS; SUSCEPTIBILITY; DISEASE; ASTHMA; TRAITS	Epidemiological studies have found air pollution to be associated with excessive mortality, particularly death from respiratory and cardiovascular causes(1,2). Interpretation of these findings is controversial, however, because toxicological mechanisms controlling mortality are uncertain. Susceptibility to many air pollutants entails an oxidative stress response(3,4). Accordingly, the best-characterized oxidant air pollutant is ozone(5), which causes direct oxidative damage of lung biomolecules(6). An underlying characteristic derived from clinical and epidemiological studies of healthy and asthmatic individuals of all ages is marked variability in the respiratory effects of ozone(7-11). This susceptibility difference among humans suggests that genetic determinants may control predisposition to the harmful effects of ozone(12). Mice also vary considerably in their response to ozone(13-15), Moreover, ozone-induced differences in strain responses(16) indicate that susceptibility in mice can be genetically determined. Therefore, we used inbred mice to investigate the genetic determinants of acute lung injury, Recombinant inbred (RI) strains derived from A/J (A) mice (sensitive) and C57BL/6J (B) mice (resistant) showed a continuous phenotypic pattern, suggesting a multigenic trait. Quantitative trait locus and RI analyses suggested three major loci linked to ozone susceptibility. Differences in phenotype ratios among the reciprocal backcrosses were consistent with parental imprinting, These findings implicate various genetic and epigenetic factors in individual susceptibility to air pollution.	UNIV CINCINNATI, DEPT ENVIRONM HLTH, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, DEPT CELLULAR & MOL PHYSIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, DEPT MED, CINCINNATI, OH 45267 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE CTR 9, CAMBRIDGE, MA 02142 USA; UNIV CINCINNATI, MED CTR, DEPT MOL GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Massachusetts Institute of Technology (MIT); Whitehead Institute; University System of Ohio; University of Cincinnati			Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752; Leikauf, George/0000-0002-4514-7060	NHLBI NIH HHS [R01-HL58275] Funding Source: Medline; NIEHS NIH HHS [R01-ES06562, R01-ES06677] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006677, R01ES006562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CATTANACH BM, 1994, J INHERIT METAB DIS, V17, P403, DOI 10.1007/BF00711356; CROSS CE, 1994, ENVIRON HEALTH PERSP, V102, P185, DOI 10.2307/3432237; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; GOLDSTEIN BD, 1973, ARCH ENVIRON HEALTH, V27, P412, DOI 10.1080/00039896.1973.10666416; HALLIWELL B, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3432205; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KLEEBERGER SR, 1993, AM J PHYSIOL, V264, pL15, DOI 10.1152/ajplung.1993.264.1.L15; KLEEBERGER SR, 1990, AM J PHYSIOL, V258, pL313, DOI 10.1152/ajplung.1990.258.6.L313; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LINCOLN S, 1992, MAPPING GENES CONTRO; LIPPMANN M, 1983, ADV MOD ENV TOXICOL, V5, P423; LIPPMANN M, 1993, ENV TOXICANTS HUMAN, P465; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; MARSHALL JD, 1992, MAMM GENOME, V3, P669, DOI 10.1007/BF00444361; MCBRIDE DE, 1994, AM J RESP CRIT CARE, V149, P1192, DOI 10.1164/ajrccm.149.5.8173759; MCDONNELL WF, 1991, PHARMACOGENETICS, V1, P110, DOI 10.1097/00008571-199111000-00010; MUSTAFA MG, 1990, FREE RADICAL BIO MED, V9, P245, DOI 10.1016/0891-5849(90)90035-H; NESBITT MN, 1984, J LEUKOCYTE BIOL, V36, P357, DOI 10.1002/jlb.36.3.357; OSTRO B, 1993, ARCH ENVIRON HEALTH, V48, P336, DOI 10.1080/00039896.1993.9936722; PATERSON AH, 1991, GENETICS, V127, P181; PEDEN DB, 1990, P NATL ACAD SCI USA, V87, P7638, DOI 10.1073/pnas.87.19.7638; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; SAPIENZA C, 1992, GENETICS, V132, P241; SILVERMAN F, 1979, ENVIRON HEALTH PERSP, V29, P131, DOI 10.2307/3429055; SPEKTOR DM, 1988, AM REV RESPIR DIS, V138, P821, DOI 10.1164/ajrccm/138.4.821; STOKINGER H E, 1957, AMA Arch Ind Health, V15, P181; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; 1996, MAMM GENOME, V6, pS1	30	105	109	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1997	17	4					471	474		10.1038/ng1297-471	http://dx.doi.org/10.1038/ng1297-471			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398853				2022-12-25	WOS:A1997YJ92400032
J	Ptashne, M				Ptashne, M			Control of gene transcription: An outline	NATURE MEDICINE			English	Editorial Material											Ptashne, M (corresponding author), HARVARD UNIV,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.								0	13	16	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1069	1072		10.1038/nm1097-1069	http://dx.doi.org/10.1038/nm1097-1069			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334708				2022-12-25	WOS:A1997XZ28700022
J	Lehle, K; Kohnert, U; Stern, A; Popp, F; Jaenicke, R				Lehle, K; Kohnert, U; Stern, A; Popp, F; Jaenicke, R			Effect of disulfide bonds on the structure, function, and stability of the trypsin/tPA inhibitor from Erythrina caffra: Site-directed mutagenesis, expression, and physiochemical characterization	NATURE BIOTECHNOLOGY			English	Article						disulfide bonds; Erythrina; stability; tissue plasminogen activator; trypsin inhibitor	TISSUE PLASMINOGEN-ACTIVATOR; PROTEINASE-INHIBITORS; ESCHERICHIA-COLI; PURIFICATION; SEEDS	Erythrina trypsin/tPA inhibitor (ETI) from the seeds of Erythrina caffra retains its native structure and inhibitory function after reducing its two disulfide bonds. In order to elucidate the specific role of these crosslinks, alanine residues were substituted for cysteines after cloning the gene in Escherichia coli. Expression of the recombinant inhibitor and the substitution mutants, C83A, CC39,83AA, and CC132,139AA, led to inclusion bodies. After solubilization in guanidinium-chloride (GdmCl)/dithiothreitol and oxidation in glutathione buffer, activity could be recovered at yields up to 80%. The mutant proteins exhibit full inhibitory function without detectable alterations of their native structure. However, their stability is reduced: at acid pH, where the oxidized natural inhibitor retains its native structure, the reduced wildtype protein and the mutants undergo at least partial denaturation, reflected by decreased pH ranges of stability: pH 5-7 for the reduced inhibitor, pH 2.5-8.5 for CC132,139AA, and pH 3.5-8.5 for C83A and CC39,83AA. Urea and GdmCl denaturation at pH 7 show hysteresis for both the oxidized inhibitor and the double mutant CC132,139AA. In contrast, the reduced protein and the other mutants exhibit true equilibrium transitions at pH 7, with urea half-concentrations of 0.9 M and 1.9 M and GdmCl half-concentrations of 0.5 M and 1.0 M, respectively. The stability of Erythrina trypsin/tPA inhibitor follows the sequence: oxidized ETI > CC132,139AA > CC39,83AA and C83A > reduced ETI.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; BOEHRINGER MANNHEIM GMBH,BIOCHEM RES CTR,D-82377 PENZBERG,GERMANY	University of Regensburg								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; HEUSSENSCHEMMER C, 1991, THROMB HAEMOSTASIS, V66, P226; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; JOUBERT FJ, 1982, INT J BIOCHEM, V14, P187, DOI 10.1016/0020-711X(82)90137-9; JOUBERT FJ, 1987, INT J BIOCHEM, V19, P601, DOI 10.1016/0020-711X(87)90225-4; KIM SH, 1985, J BIOCHEM, V98, P435, DOI 10.1093/oxfordjournals.jbchem.a135298; KOHNERT U, 1992, PROTEIN ENG, V5, P93, DOI 10.1093/protein/5.1.93; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKOWSKI M, 1986, NUTRITIONAL TOXICOLO, P1; LEHLE K, 1994, J MOL BIOL, V239, P276, DOI 10.1006/jmbi.1994.1367; Maniatis T., 1982, MOL CLONING; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; ONESTI S, 1991, J MOL BIOL, V217, P153, DOI 10.1016/0022-2836(91)90618-G; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5015; TEIXEIRA AV, 1994, BBA-GENE STRUCT EXPR, V1217, P16, DOI 10.1016/0167-4781(94)90119-8; TEIXEIRA AV, 1994, BBA-GENE STRUCT EXPR, V1217, P23, DOI 10.1016/0167-4781(94)90120-1; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; ZIMMERMAN M, 1978, P NATL ACAD SCI USA, V75, P750, DOI 10.1073/pnas.75.2.750	24	24	31	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					476	480		10.1038/nbt0496-476	http://dx.doi.org/10.1038/nbt0496-476			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630923				2022-12-25	WOS:A1996UL58800031
J	Causey, LD; Dwyer, DS				Causey, LD; Dwyer, DS			Detection of low affinity interactions between peptides and heat shock proteins by Chemiluminescence of Enhanced Avidity Reactions (CLEAR)	NATURE BIOTECHNOLOGY			English	Article						heat shock protein; avidity; chemiluminescence	COGNATE PROTEIN; LYSOSOMAL PROTEOLYSIS; ATPASE FRAGMENT; BINDING; POLYPEPTIDE; LIGAND; GROEL; ASSAY; ACTIN; CELL	Protein-protein and protein-peptide interactions that are low affinity in nature preclude the straightforward measurement of binding. To overcome this limitation, a novel method has been devised for stabilizing these weak interactions by increasing the binding avidity. These studies have focused on the binding of peptides to heat shock proteins (with a typical K-D of approximately 25 to 50 mu M). Multivalent ligands have been created by coupling peptides plus biotin to a neutral carrier molecule, dextran. These peptide-dextran conjugates allow for more avid binding to proteins that have been immobilized on a membrane surface. Detection of signals via enhanced chemiluminescence further increases the sensitivity of the method that has been termed Chemiluminescence of Enhanced Avidity Reactions (CLEAR), The assay is simple, reliable and consistently detects specific binding between heat shock proteins and peptide ligands. CLEAR should be generally applicable to other ligand receptor pairs where the detection of binding is limited by the low affinity of the interaction.	LOUISIANA STATE UNIV,MED CTR,DEPT PSYCHIAT,SHREVEPORT,LA 71115; LOUISIANA STATE UNIV,MED CTR,DEPT PHARMACOL,SHREVEPORT,LA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport								ANATHAN J, 1986, SCIENCE, V232, P522; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOODWIN DA, 1992, J NUCL MED, V33, P2006; Karush F, 1976, Contemp Top Mol Immunol, V5, P217; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSS ML, 1992, J BIOL CHEM, V267, P22054; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1993, ANN NY ACAD SCI, V685, P412; PARISH CR, 1993, J IMMUNOL, V150, P4833; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SONDERGARDANDERSEN J, 1990, J IMMUNOL METHODS, V131, P99, DOI 10.1016/0022-1759(90)90238-Q; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TERLECKY SR, 1994, EXPERIENTIA, V50, P1021, DOI 10.1007/BF01923456	25	14	16	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					348	351		10.1038/nbt0396-348	http://dx.doi.org/10.1038/nbt0396-348			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630899				2022-12-25	WOS:A1996UL38000031
J	Matsumura, I; Ellington, AD				Matsumura, I; Ellington, AD			DNA shuffling brightens prospects for GFP	NATURE BIOTECHNOLOGY			English	Editorial Material											Matsumura, I (corresponding author), INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405, USA.		Matsumura, Ichiro/E-1985-2011					CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; OSUNA J, 1994, CRIT REV MICROBIOL, V20, P107, DOI 10.3109/10408419409113550; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747	6	7	14	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1996	14	3					366	366		10.1038/nbt0396-366	http://dx.doi.org/10.1038/nbt0396-366			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL380	9630902	Bronze			2022-12-25	WOS:A1996UL38000034
J	White, C; Sharman, AK; Gadd, GM				White, C; Sharman, AK; Gadd, GM			An integrated microbial process for the bioremediation of soil contaminated with toxic metals	NATURE BIOTECHNOLOGY			English	Article						environmental biotechnology; bioleaching; bioprecipitation	BACTERIAL SULFATE-REDUCTION	Microbially catalyzed reactions, which occur in the natural sulfur cycle, have been integrated in a microbiological process to remove toxic metals from contaminated soils. Bioleaching using sulfuric acid produced by sulfur-oxidizing bacteria was followed by precipitation of the leachate metals as insoluble sulfides by sulfate-reducing bacteria. Metal contaminants including Cd, Co, Cr, Cu, Mn, Ni, and Zn were efficiently leached from an artificially contaminated soil. Mn, Ni, and Zn were the only target elements that were significantly leached from soil minerals. Pb leaching was slow and remained incomplete over a period of 180 days. Mineral components such as Fe, Ca and Mg were also leached but the eventual reduction in soil mass was only approximately 10%. An industrially contaminated soil was also efficiently leached and approximately 69% of the main toxic metals present, Cu, Ni, and Mn, were removed after 175 days. The leachate that resulted from the action of sulfur-oxidizing bacteria on contaminated soil was stripped of metals using an anaerobic bioreactor containing a mixed culture of sulfate-reducing bacteria which precipitated soluble metal species as solid metal sulfides. More than 98% of the metals were removed from solution with the exception of Mn, Ni, and Pb, where 80-90% were removed. The metal content of the resultant effluent liquor was low enough to meet European criteria for discharge into the environment.	Univ Dundee, Dept Biol Sci, Dundee DD1 4HN, Scotland; IBS Viridian Ltd, Whitstable CT5 3QT, Kent, England	University of Dundee	Gadd, GM (corresponding author), Univ Dundee, Dept Biol Sci, Dundee DD1 4HN, Scotland.	g.m.gadd@dundee.ac.uk	Gadd, Geoffrey/AAS-6971-2021	Gadd, Geoffrey Michael/0000-0001-6874-870X				Barnes LJ, 1994, EMERGING TECHNOLOGY, P38; Bosecker K, 1997, FEMS MICROBIOL REV, V20, P591, DOI 10.1111/j.1574-6976.1997.tb00340.x; Chang JC, 1993, CRC HDB CHEM PHYSICS, P8; Ehrlich HL, 1996, CHEM GEOL, V132, P5, DOI 10.1016/S0009-2541(96)00035-6; GADD GM, 1993, FEMS MICROBIOL REV, V11, P297, DOI 10.1111/j.1574-6976.1993.tb00003.x; GADD GM, 1993, TRENDS BIOTECHNOL, V11, P353, DOI 10.1016/0167-7799(93)90158-6; Gadd GM, 1996, ENDEAVOUR, V20, P150, DOI 10.1016/S0160-9327(96)10021-1; GARDINER J, 1991, UK WATER QUALITY STA; HAMMACK RW, 1992, APPL MICROBIOL BIOT, V37, P674, DOI 10.1007/BF00240748; Luoma S.N., 1990, HEAVY METALS MARINE, P51; Norris P.R., 1990, MICROBIAL MINERAL RE, P3; Peck H.D., 1993, SULFATE REDUCING BAC, DOI [10.1007/978-1-4613-9263-7_3, DOI 10.1007/978-1-4613-9263-7_3]; RAWLINGS DE, 1995, BIO-TECHNOL, V13, P773, DOI 10.1038/nbt0895-773; Singleton, 1993, SULFATE REDUCING BAC, P21, DOI DOI 10.1007/978-1-4613-9263-7_2; SREEKRISHNAN TR, 1995, PROCESS BIOCHEM, V30, P69, DOI 10.1016/0032-9592(95)95707-P; TUOVINEN OH, 1990, MICROBIAL MINERAL RE, P55; White C, 1995, SCI TOTAL ENVIRON, V176, P107, DOI 10.1016/0048-9697(95)04836-7; White C, 1996, MICROBIOL-SGM, V142, P2197, DOI 10.1099/13500872-142-8-2197; White C, 1996, J IND MICROBIOL, V17, P116, DOI 10.1007/BF01570054; White C, 1997, J IND MICROBIOL BIOT, V18, P414, DOI 10.1038/sj.jim.2900406; WIDDEL F, 1991, PROKARYOTES DISSIMIL; Widdel F., 1988, BIOL ANAEROBIC MICRO, P469; ZAGURY GJ, 1994, ENVIRON TECHNOL, V15, P517, DOI 10.1080/09593339409385458	23	161	168	3	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1998	16	6					572	575		10.1038/nbt0698-572	http://dx.doi.org/10.1038/nbt0698-572			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZR049	9624690				2022-12-25	WOS:000073930600035
J	Debinski, W; Gibo, DM; Obiri, NI; Kealiher, A; Puri, RK				Debinski, W; Gibo, DM; Obiri, NI; Kealiher, A; Puri, RK			Novel anti-brain tumor cytotoxins specific for cancer cells	NATURE BIOTECHNOLOGY			English	Article						interleukin 13; glioblastoma; fusion proteins; mutations; tumor specificity; anticancer therapeutics; receptors	PSEUDOMONAS EXOTOXIN-A; HUMAN INTERLEUKIN-4 RECEPTOR; COMMON GAMMA-CHAIN; HUMAN GLIOMA-CELLS; ADHESION MOLECULE-1; CARCINOMA-CELLS; ENDOTHELIAL-CELLS; TOXIN; EXPRESSION; AERUGINOSA	The vast majority of brain cancers (gliomas) express a receptor (R) for interleukin 13 (IL13). In order to achieve specific targeting of the IL13R in gliomas, we have mutagenized human (h) IL13. The mutation was made to alter IL13 interaction with the shared functional IL13/4 normal tissue receptor, but not with the glioma-associated receptor. We have thus produced hIL13.E13K (glutamic acid at position 13 changed to lysine) and fused it to derivatives of Pseudomonas exotoin A. The hIL13.E13K-based cytotoxins are less active on normal cells and thus less toxic, and are better antitumor agents compared with the cytotoxins containing nonmutagenized hIL13.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Neurosurg Sect,Dept Surg, Hershey, PA 17033 USA; US FDA, Ctr Biol Evaluat & Res, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; US Food & Drug Administration (FDA)	Debinski, W (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Neurosurg Sect,Dept Surg, Hershey, PA 17033 USA.	wdebinski@psghs.edu						ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chinnasamy N, 1997, BLOOD, V89, P1566, DOI 10.1182/blood.V89.5.1566.1566_1566_1573; DEBINSKI W, 1993, J BIOL CHEM, V268, P14065; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DEBINSKI W, IN PRESS INT J CANC; DUSCHL A, 1995, EUR J BIOCHEM, V228, P305; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; Husain SR, 1997, CLIN CANCER RES, V3, P151; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KREITMAN RJ, 1994, P NATL ACAD SCI USA, V91, P6889, DOI 10.1073/pnas.91.15.6889; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LASKE DW, 1997, NAT MED, V3, P1632; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MURATA T, 1997, BIOCHEM BIOPH RES CO, V238, P92; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J IMMUNOL, V158, P756; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PHILLIPS PC, 1994, CANCER RES, V54, P1008; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; RUTTER CM, 1994, STAT MED, V13, P1211, DOI 10.1002/sim.4780131204; Schnarr B, 1997, INT IMMUNOL, V9, P861, DOI 10.1093/intimm/9.6.861; Schnyder B, 1996, BLOOD, V87, P4286, DOI 10.1182/blood.V87.10.4286.bloodjournal87104286; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SHAW JP, 1991, J BIOL CHEM, V266, P21118; SIRONI M, 1994, BLOOD, V84, P1913; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Wersall P, 1997, CANCER IMMUNOL IMMUN, V44, P157, DOI 10.1007/s002620050368; Youle RJ, 1996, SEMIN CANCER BIOL, V7, P65, DOI 10.1006/scbi.1996.0010; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	44	94	103	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					449	453		10.1038/nbt0598-449	http://dx.doi.org/10.1038/nbt0598-449			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592393				2022-12-25	WOS:000073489600029
J	Yang, T; Adamson, TE; Resnick, JL; Leff, S; Wevrick, R; Francke, U; Jenkins, NA; Copeland, NG; Brannan, CI				Yang, T; Adamson, TE; Resnick, JL; Leff, S; Wevrick, R; Francke, U; Jenkins, NA; Copeland, NG; Brannan, CI			A mouse model for Prader-Willi syndrome imprinting-centre mutations	NATURE GENETICS			English	Article							ANGELMAN SYNDROME; SNRPN GENE; UNIPARENTAL DISOMY; PARENTAL ORIGIN; EXPRESSED GENE; POLYPEPTIDE-N; PROTEIN-N; DELETIONS; REGION; HUMAN-CHROMOSOME-15	Imprinting in the 15q11-q13 region involves an 'imprinting centre' (IC), mapping in part to the promoter and first exon of SNRPN. Deletion of this IC abolishes local paternally derived gene expression and results in Prader-Willi syndrome (PWS). We have created two deletion mutations in mice to understand PWS and the mechanism of this IC. Mice harbouring an intragenic deletion in Snrpn are phenotypically normal, suggesting that mutations of SNRPN are not sufficient to induce PWS. Mice with a larger deletion involving both Snrpn and the putative PWS-IC lack expression of the imprinted genes Zfp127 (mouse homologue of ZNF127) Ndn and Ipw, and manifest several phenotypes common to PWS infants. These data demonstrate that both the position of the IC and its role in the coordinate expression of genes is conserved between mouse and human, and indicate that the mouse is a suitable model system in which to investigate the molecular mechanisms of imprinting in this region of the genome.	Univ Florida, Coll Med, Dept Microbiol & Mol Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Inst Brain, Gainesville, FL 32610 USA; Cell Genesys Inc, Foster City, CA 94404 USA; Univ Alberta, Heritage Med Res Ctr 659, Dept Med Genet, Edmonton, AB T6G 2S2, Canada; Stanford Univ, Sch Med, Dept Genet, Beckman Ctr Mol & Genet Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr Mol & Genet Med, Stanford, CA 94305 USA; NCI, Frederick Canc Res & Dev Ctr, Mammalian Genet Lab, ABL Basic Res Program, Frederick, MD 21702 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Cell Genesys Inc; University of Alberta; Stanford University; Howard Hughes Medical Institute; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Brannan, CI (corresponding author), Univ Florida, Coll Med, Dept Microbiol & Mol Genet, Gainesville, FL 32610 USA.			Wevrick, Rachel/0000-0002-3343-5794	NIGMS NIH HHS [GM55272] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; Church G M, 1985, Prog Clin Biol Res, V177, P17; CLAYTONSMITH J, 1992, J MED GENET, V29, P412, DOI 10.1136/jmg.29.6.412; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Hogan B, 1994, MANIPULATING MOUSE E; HOLM VA, 1993, PEDIATRICS, V91, P398; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LI S, 1989, P NATL ACAD SCI USA, V86, P9778, DOI 10.1073/pnas.86.24.9778; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MASCARI MJ, 1992, NEW ENGL J MED, V326, P1599, DOI 10.1056/NEJM199206113262404; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; MCALLISTER G, 1989, EMBO J, V8, P1177, DOI 10.1002/j.1460-2075.1989.tb03489.x; MCALLISTER G, 1988, P NATL ACAD SCI USA, V85, P5296, DOI 10.1073/pnas.85.14.5296; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1992, ANN NEUROL, V32, P512, DOI 10.1002/ana.410320406; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REIS A, 1994, AM J HUM GENET, V54, P741; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; SCHMAUSS C, 1990, J BIOL CHEM, V265, P10733; SCHMAUSS C, 1992, J BIOL CHEM, V267, P8521; STEITZ JA, 1990, STRUCTURE FUNCTION M, P115; Sun YM, 1996, HUM MOL GENET, V5, P517, DOI 10.1093/hmg/5.4.517; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; SZABO P, 1994, DEVELOPMENT, V120, P1651; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308	44	242	246	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1998	19	1					25	31		10.1038/ng0598-25	http://dx.doi.org/10.1038/ng0598-25			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZK651	9590284				2022-12-25	WOS:000073346700012
J	Russell, DW; Hirata, RK				Russell, DW; Hirata, RK			Human gene targeting by viral vectors	NATURE GENETICS			English	Article							INTERFERON-INDUCIBLE GENE; ADENO-ASSOCIATED VIRUS; EMBRYONIC STEM-CELLS; ADENOASSOCIATED VIRUS; HOMOLOGOUS RECOMBINATION; RETROVIRAL VECTORS; MAMMALIAN-CELLS; DNA; TRANSDUCTION; INTEGRATION	Stable transduction of mammalian cells typically involves random integration of viral vectors by non-homologous recombination. Here we report that Vectors based on adeno-associated virus (AAV) can efficiently modify homologous human chromosomal target sequences. Bath integrated neomycin phosphotransferase genes and the hypoxanthine phosphoribosyltransferase gene were targeted by AAV vectors. Site-specific genetic modifications could be introduced into approximately 1% of cells, with the highest targeting rates occurring in normal human fibroblasts. These results suggest that AAV vectors could be used to introduce specific genetic changes into the genomic DNA of a wide variety of mammalian cells. including therapeutic gene targeting applications.	Univ Washington, Sch Med, Markey Mol Med Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Russell, DW (corresponding author), Univ Washington, Sch Med, Markey Mol Med Ctr, Seattle, WA 98195 USA.	drussell@u.washington.edu	Wilson, Matthew H/K-3193-2013		NIDDK NIH HHS [R01 DK055759, R01 DK055759-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertran J, 1996, J VIROL, V70, P6759, DOI 10.1128/JVI.70.10.6759-6766.1996; BRINSTER RL, 1989, P NATL ACAD SCI USA, V86, P7087, DOI 10.1073/pnas.86.18.7087; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; ELLIS J, 1989, MOL CELL BIOL, V9, P1621, DOI 10.1128/MCB.9.4.1621; FUJIOKA K, 1993, NUCLEIC ACIDS RES, V21, P407, DOI 10.1093/nar/21.3.407; GANGULY A, 1994, P NATL ACAD SCI USA, V91, P7365, DOI 10.1073/pnas.91.15.7365; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; ITZHAKI JE, 1991, NUCLEIC ACIDS RES, V19, P3835, DOI 10.1093/nar/19.14.3835; Koeberl DD, 1997, P NATL ACAD SCI USA, V94, P1426, DOI 10.1073/pnas.94.4.1426; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LEBKOWSKI JS, 1988, MOL CELL BIOL, V8, P3988, DOI 10.1128/MCB.8.10.3988; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MITANI K, 1995, SOMAT CELL MOLEC GEN, V21, P221, DOI 10.1007/BF02255777; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; PATEL PI, 1986, MOL CELL BIOL, V6, P393, DOI 10.1128/MCB.6.2.393; PORTER ACG, 1993, EUR J BIOCHEM, V218, P273, DOI 10.1111/j.1432-1033.1993.tb18375.x; RASHEED S, 1974, CANCER, V33, P10257; ROSSITER BJF, 1991, PCR PRACTICAL APPROA, P67; RUSSELL DW, 1994, P NATL ACAD SCI USA, V91, P8915, DOI 10.1073/pnas.91.19.8915; Rutledge EA, 1997, J VIROL, V71, P8429, DOI 10.1128/JVI.71.11.8429-8436.1997; Ryan JH, 1996, J VIROL, V70, P1542, DOI 10.1128/JVI.70.3.1542-1553.1996; SAMBROOK J, 1989, LAB HDB; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SAMULSKI RJ, 1992, EMBO J, V11, P1228; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THYAGARAJAN B, 1995, NUCLEIC ACIDS RES, V23, P2784, DOI 10.1093/nar/23.14.2784; WALSH CE, 1992, P NATL ACAD SCI USA, V89, P7257, DOI 10.1073/pnas.89.15.7257; WANG Q, 1993, MOL CELL BIOL, V13, P918, DOI 10.1128/MCB.13.2.918; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0; ZINDER ND, 1952, J BACTERIOL, V64, P679, DOI 10.1002/path.1700640402	36	240	262	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1998	18	4					325	330		10.1038/ng0498-325	http://dx.doi.org/10.1038/ng0498-325			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537413	Green Accepted			2022-12-25	WOS:000072755500013
J	Contag, PR; Olomu, IN; Stevenson, DK; Contag, CH				Contag, PR; Olomu, IN; Stevenson, DK; Contag, CH			Bioluminescent indicators in living mammals	NATURE MEDICINE			English	Article							LONG TERMINAL REPEAT; TRANSGENIC MICE; IN-VIVO; LUCIFERASE; EXPRESSION; ACTIVATION; SKIN; TECHNOLOGY; LIGHT; CELLS		Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Xenogen Corp, Stanford, CA 94309 USA	Stanford University	Contag, CH (corresponding author), Stanford Univ, Sch Med, Dept Pediat, 300 Pasteur Dr, Stanford, CA 94305 USA.		Wilson, Matthew H/K-3193-2013	Contag, Christopher/0000-0002-1011-8278	NCRR NIH HHS [RR00070] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Contag C. H., 1996, OSA Trends in Optics and Photonics on Biomedical Optical Spectroscopy and Diagnostics. Vol.3. From the Topical Meeting, P220; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Contag CH, 1995, MOL MICROBIOL, V18, P593, DOI 10.1111/j.1365-2958.1995.mmi_18040593.x; Hickey MJ, 1996, ANTIMICROB AGENTS CH, V40, P400, DOI 10.1128/AAC.40.2.400; HOOPER CE, 1994, J BIOLUM CHEMILUM, V9, P113, DOI 10.1002/bio.1170090303; HOOPER CE, 1990, J BIOLUM CHEMILUM, V5, P123, DOI 10.1002/bio.1170050208; MORREY JD, 1991, J VIROL, V65, P5045, DOI 10.1128/JVI.65.9.5045-5051.1991; MORREY JD, 1992, J ACQ IMMUN DEF SYND, V5, P1195; MORREY JD, 1994, INTERVIROLOGY, V37, P315, DOI 10.1159/000150395; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; WHITE MRH, 1995, J CELL SCI, V108, P441; ZHANG LR, 1994, CLIN EXP METASTAS, V12, P87, DOI 10.1007/BF01753974	13	406	447	1	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					245	247		10.1038/nm0298-245	http://dx.doi.org/10.1038/nm0298-245			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461201				2022-12-25	WOS:000072249800043
J	Gorochov, G; Neumann, AU; Kereveur, A; Parizot, C; Li, TS; Katlama, C; Karmochkine, M; Raguin, G; Autran, B; Debre, P				Gorochov, G; Neumann, AU; Kereveur, A; Parizot, C; Li, TS; Katlama, C; Karmochkine, M; Raguin, G; Autran, B; Debre, P			Perturbation of CD4(+) and CD8(+) T-cell repertoires during progression to AIDS and regulation of the CD4(+) repertoire during antiviral therapy	NATURE MEDICINE			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; HIV-1 INFECTION; GENE USAGE; IN-VIVO; VIRUS; EXPANSION; SEGMENT; RECOGNITION; VARIABILITY; DISEASE	The T-cell antigen receptor (TCR) repertoire was studied longitudinally by analyzing the varying lengths of the beta chain CDR3 hypervariable region during the course of HIV-1 infection and following combination antiretroviral therapy. Drastic restrictions in CD8(+) T-cell repertoire usage were found at all stages of natural progression and persisted during the first six months of treatment. In contrast, significant CD4(+) T-cell repertoire perturbations were not found in early stages of infection but correlated with progression to AIDS. Out of ten patients presenting with pretreatment perturbations, normalization of the CD4(+) repertoire was observed in eight good responders, but not in two cases of unsuccessful therapy. These results indicate that, besides CD4(+) cell count rise, an efficient control of HIV replication may allow qualitative modifications of the CD4(+) repertoire balance.	Hop La Pitie Salpetriere, CERVI, Cellular Immunol Lab, CNRS,URA 625, F-75013 Paris, France; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Hop La Pitie Salpetriere, Serv Malad Infect & Trop, F-75013 Paris, France; Hop Croix St Simon, Serv Med Interne, F-75020 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Bar Ilan University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Gorochov, G (corresponding author), Hop La Pitie Salpetriere, CERVI, Cellular Immunol Lab, CNRS,URA 625, 83 Blvd Hop, F-75013 Paris, France.		Gorochov, Guy/P-2911-2017	Gorochov, Guy/0000-0003-2097-9677				AKOLKAR PN, 1993, J IMMUNOL, V150, P2761; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAHADORAN P, 1993, EUR J IMMUNOL, V23, P2041, DOI 10.1002/eji.1830230850; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FITZGERALD JE, 1995, J IMMUNOL, V154, P3538; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GOROCHOV G, 1994, BLOOD, V83, P587; Haas G, 1996, J IMMUNOL, V157, P4212; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JORES R, 1993, J IMMUNOL, V151, P6110; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; Kepler TB, 1996, J IMMUNOL, V157, P4451; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; Levraud JP, 1996, J EXP MED, V183, P439, DOI 10.1084/jem.183.2.439; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MORLEY JK, 1995, J IMMUNOL, V154, P6182; Musette P, 1996, EUR J IMMUNOL, V26, P618, DOI 10.1002/eji.1830260317; Neumann AU, 1997, NAT MED, V3, P703, DOI 10.1038/nm0797-703b; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; POSNETT DN, 1993, AIDS, V7, P625, DOI 10.1097/00002030-199305000-00003; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Roglic M, 1997, CLIN EXP IMMUNOL, V107, P21, DOI 10.1046/j.1365-2249.1997.d01-886.x; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Schwab R, 1997, J IMMUNOL, V158, P4493; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057	36	382	396	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					215	221		10.1038/nm0298-215	http://dx.doi.org/10.1038/nm0298-215			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461196				2022-12-25	WOS:000072249800038
J	Pakker, NG; Notermans, DW; de Boer, RJ; Roos, MTL; de Wolf, F; Hill, A; Leonard, JM; Danner, SA; Miedema, F; Schellekens, PTA				Pakker, NG; Notermans, DW; de Boer, RJ; Roos, MTL; de Wolf, F; Hill, A; Leonard, JM; Danner, SA; Miedema, F; Schellekens, PTA			Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation	NATURE MEDICINE			English	Article							FUNCTION IN-VITRO; IMMUNOLOGICAL MEMORY; CUBIC MILLIMETER; TURNOVER; ADULTS; LYMPHOCYTES; ZIDOVUDINE; PLASMA; COUNTS; LENGTH	The origin of CD4(+) T cells reappearing in the blood following antiretroviral therapy in human immunodeficiency virus type-1 (HIV-1) infection is still controversial. Here we show, using mathematical modeling, that redistribution of T cells to the blood can explain the striking correlation between the initial CD4(+) and CD8(+) memory T-cell repopulation and the observation that 3 weeks after the start of treatment memory CD4(+) T-cell numbers reach a plateau. The increase in CD4(+) T cells following therapy most likely is a composite of initial redistribution, accompanied by a continuous slow repopulation with newly produced naive T cells.	Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Clin Viroimmunol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Utrecht, NL-3584 CH Utrecht, Netherlands; Abbott Labs, Abbott Pk, IL 60064 USA; Glaxo Wellcome Res & Dev Ltd, Greenford UB6 0HE, Middx, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Abbott Laboratories; GlaxoSmithKline	Miedema, F (corresponding author), Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Clin Viroimmunol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	miedema@clb.nl	de Boer, Rob/B-6050-2011	de Boer, Rob/0000-0002-2130-691X				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BINDELS PJE, 1995, J INFECT DIS, V172, P97, DOI 10.1093/infdis/172.1.97; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Giorgi J. V., 1996, IMMUNOLOGY HIV INFEC, P181; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KOOT M, 1993, J INFECT DIS, V168, P733, DOI 10.1093/infdis/168.3.733; Lafeuillade A, 1996, J INFECT DIS, V174, P404, DOI 10.1093/infdis/174.2.404; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; NOTERMANS DW, IN PRESS AIDS; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Ottinger HD, 1996, BLOOD, V88, P2775, DOI 10.1182/blood.V88.7.2775.bloodjournal8872775; Paganin C, 1997, J CLIN INVEST, V99, P663, DOI 10.1172/JCI119209; Pakker NG, 1997, J ACQ IMMUN DEF SYND, V16, P318, DOI 10.1097/00042560-199712150-00002; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PHILLIPS AN, 1995, NATURE, V375, P195, DOI 10.1038/375195a0; PICKER LJ, 1993, J IMMUNOL, V150, P1105; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; Rep MHG, 1997, J CLIN INVEST, V99, P2225, DOI 10.1172/JCI119396; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Wang LQ, 1997, VIROLOGY, V228, P141, DOI 10.1006/viro.1996.8397; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; ZHANG Z, IN PRESS P NATL ACAD; 1992, MMWR MORBID MORTAL W, V41, P1	41	600	613	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1998	4	2					208	214		10.1038/nm0298-208	http://dx.doi.org/10.1038/nm0298-208			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461195	Green Submitted			2022-12-25	WOS:000072249800037
J	Dullforce, P; Sutton, DC; Heath, AW				Dullforce, P; Sutton, DC; Heath, AW			Enhancement of T cell-independent immune responses in vivo by CD40 antibodies	NATURE MEDICINE			English	Article							B-CELLS; CAPSULAR POLYSACCHARIDE; PNEUMOCOCCAL VACCINE; CD40-DEFICIENT MICE; DEFICIENT MICE; LIGAND; EXPRESSION; INDUCTION; INFECTION; DISTINCT	In this report we describe a potentially powerful method for vaccinating infants against encapsulated bacterial pathogens such as Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. High levels of antibody directed against the polysaccharides of the bacterial capsule are normally protective(1-3). Unfortunately, the capsular polysaccharides are T cell-independent antigens (TI); lacking T-cell help, they induce only weak, predominantly IgM antibody responses, with infants responding especially poorly(4). T-cell help, given to B cells during responses to protein antigens, causes stronger antibody responses and isotype switching to the Ige isotypes. T-cel help is mainly mediated through ligation of the B-cell surface antigen, CD40, by its cognate T-cell ligand, CD154 (ref. 5-9). Here we show that administering anti-CD40 monoclonal antibody to mice, along with pneumococcal polysaccharide, provides a substitute for T-cell help and results in the generation of strong, isotype-switched antibody responses, which are protective, The work points the way coward a possible effective and inexpensive means of protecting susceptible groups against important. bacterial pathogens.	Univ Sheffield, Sch Med, Div Med & Mol Genet, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Sch Med, Sheffield Inst Vaccine Studies, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield; University of Sheffield	Dullforce, P (corresponding author), Univ Sheffield, Sch Med, Div Med & Mol Genet, F Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed F, 1996, J INFECT DIS, V173, P83, DOI 10.1093/infdis/173.1.83; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; CARSON PJ, 1995, J INFECT DIS, V172, P340, DOI 10.1093/infdis/172.2.340; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DEVELASCO EA, 1995, MICROBIOL REV, V59, P591; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; FANSLOW WC, 1994, J IMMUNOL, V152, P4262; Ferlin WG, 1996, EUR J IMMUNOL, V26, P2911, DOI 10.1002/eji.1830261216; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAYHTY H, 1984, PEDIATRICS, V74, P857; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KONRADSEN HB, 1993, J IMMUNOL METHODS, V164, P13, DOI 10.1016/0022-1759(93)90270-H; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LEE HJ, 1995, VACCINE, V13, P1533, DOI 10.1016/0264-410X(95)00093-G; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RIJKERS GT, 1996, REV MED MICROBIOL, V7, P3; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SCHER I, 1982, IMMUNOL REV, V64, P117, DOI 10.1111/j.1600-065X.1982.tb00421.x; SCHULTZ CL, 1992, J IMMUNOL, V149, P60; WARREN WD, 1995, J IMMUNOL, V155, P5637; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	29	94	108	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					88	91		10.1038/nm0198-088	http://dx.doi.org/10.1038/nm0198-088			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427612	Bronze			2022-12-25	WOS:000072249700040
J	Ho, SP; Bao, YJ; Lesher, T; Malhotra, R; Ma, LY; Fluharty, SJ; Sakai, RR				Ho, SP; Bao, YJ; Lesher, T; Malhotra, R; Ma, LY; Fluharty, SJ; Sakai, RR			Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries	NATURE BIOTECHNOLOGY			English	Article						antisense; RNA mapping; oligonucleotide libraries; angiotensin type-1 receptor	MESSENGER-RNA; EXPRESSION; INHIBITION; CELLS; CLEAVAGE; KINASE	Antisense experiments are often complicated by the lack of reliable methods for selecting effective antisense sequences. Chimeric oligodeoxynucleotide (ODN) libraries and ribonuclease H (RNase H) were used to identify regions on the 1253 nucleotide angiotensin type-1 receptor (AT(1)) mRNA that are accessible to hybridization with antisense ODNs, Phosphorothioate antisense ODNs targeted against accessible sites reduced AT(1) receptor levels by at least 50% in cell culture. ODNs to 4 sites produced a 70% to 80% reduction. In contrast, most sequences targeted between accessible sites were ineffective. When injected into the brains of rats, ODNs targeted to accessible sites reduced AT(1) (by 65%) but not AT(1) receptor levels. Additionally, AT(1) receptor function as measured by agonist-induced water intake, was significantly attenuated in these rats. ODNs directed between accessible sites were ineffective at suppressing water intake, RNA mapping can be applied to any RNA target to facilitate selection of multiple, active antisense sequences for cell culture and in vivo experiments.	DuPont Merck Res Labs, CNS Dept, Wilmington, DE 19880 USA; Univ Penn, Sch Med, Dept Anim Biol & Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Neurol Sci, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Ho, SP (corresponding author), DuPont Merck Res Labs, CNS Dept, POB 80400 Expt Stn, Wilmington, DE 19880 USA.							Agrawal S., 1996, ANTISENSE THERAPEUTI; Akhtar S., 1995, DELIVERY STRATEGIES; Birikh KR, 1997, RNA, V3, P429; CHIU AT, 1993, REGUL PEPTIDES, V44, P141, DOI 10.1016/0167-0115(93)90237-3; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; DEAN NM, 1994, J BIOL CHEM, V269, P16416; Gewirtz AM, 1996, P NATL ACAD SCI USA, V93, P3161, DOI 10.1073/pnas.93.8.3161; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; LIEBER A, 1995, MOL CELL BIOL, V15, P540, DOI 10.1128/MCB.15.1.540; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, J BIOL CHEM, V272, P626; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MONIA BP, 1993, J BIOL CHEM, V268, P14514; PEYMAN A, 1995, BIOL CHEM H-S, V376, P195; RAFFA RB, 1996, ANTISENSE STRATEGIES; SAKAI RR, 1994, J NEUROCHEM, V62, P2053; Szymkowski DE, 1996, DRUG DISCOV TODAY, V1, P415, DOI 10.1016/S1359-6446(96)80008-0	21	158	193	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1998	16	1					59	63		10.1038/nbt0198-59	http://dx.doi.org/10.1038/nbt0198-59			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YP708	9447595				2022-12-25	WOS:000071306000030
J	Laan, M; Paabo, S				Laan, M; Paabo, S			Demographic history and linkage disequilibrium in human populations	NATURE GENETICS			English	Article							FINNISH POPULATION; LINEAGES; FINLAND; GENES	In the human genome, linkage disequilibrium (LD)-the nonrandom association of alleles at chromosomal loci(1)-has been studied mainly in regions surrounding disease genes on affected chromosomes2-6. Consequently, little information is available on the distribution of LD across anonymous genomic regions in the general population. However, demographic history is expected to influence the extent of overall LD across the genome, so a population that has been of constant size will display higher levels of LD than a population that has expanded(7). In support of this, the extent of LD between anonymous loci on chromosome 4 in chimpanzees (as a model of a population of constant size) has been compared to that in Finns (as a model of an expanded population; refs 8,9) and found to exhibit more LD than in the latter population. In Europe, studies of mitochondrial (mt) DNA sequences have suggested that most populations have experienced expansion(10), whereas the Saami in northern Fenno-Scandinavia have been of constant size (Table 1). Thus, in northern Europe, populations with radically different demographic histories live in close geographic proximity to each other. We studied the allelic associations between anonymous microsatellite loci on the X chromosome in the Saami and neighbouring populations and found dramatically higher levels of LD in the Saami than in other populations in the region. This indicates that whereas recently expanded populations, such as the Finns, are well suited to map single disease genes affected by recent mutations, populations that have been of constant size, such as the Saami, may be much better suited to map genes for complex traits that are caused by older mutations.	UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY	University of Munich			Peng, Bo/A-6920-2009; Laan, Maris/A-4100-2011	Peng, Bo/0000-0001-8225-2284; Laan, Maris/0000-0002-8519-243X				CrouauRoy B, 1996, HUM MOL GENET, V5, P1131, DOI 10.1093/hmg/5.8.1131; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Jorde LB, 1997, P NATL ACAD SCI USA, V94, P3100, DOI 10.1073/pnas.94.7.3100; JORDE LB, 1995, AM J HUM GENET, V56, P11; KAPLAN NL, 1995, AM J HUM GENET, V56, P18; MITCHISON HM, 1995, AM J HUM GENET, V56, P654; Nagaraja R, 1997, GENOME RES, V7, P210, DOI 10.1101/gr.7.3.210; NORIO R, 1973, ANN CLIN RES, V5, P109; Peltonen L, 1995, BIOL CHEM H-S, V376, P697; PETERSON AC, 1995, HUM MOL GENET, V4, P887, DOI 10.1093/hmg/4.5.887; RAYMOND M, 1994, GENEPOP VERSION 1 0; SAJANTILA A, 1995, GENOME RES, V5, P42, DOI 10.1101/gr.5.1.42; Sajantila A, 1996, P NATL ACAD SCI USA, V93, P12035, DOI 10.1073/pnas.93.21.12035; SLATKIN M, 1994, GENETICS, V137, P331; Solantie R., 1988, FENNOSCANDIA ARCHAEO, V5, P3; STEPHENS JC, 1994, AM J HUM GENET, V55, P809; TAJIMA F, 1989, GENETICS, V123, P597; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; TERWILLIGER JD, IN PRESS HUM HERED; Thompson EA, 1997, AM J HUM GENET, V60, P197; Varilo T, 1996, AM J HUM GENET, V58, P506; Watson E, 1996, AM J HUM GENET, V59, P437; Weir B. S., 1996, GENETIC DATA ANAL	25	146	147	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					435	438		10.1038/ng1297-435	http://dx.doi.org/10.1038/ng1297-435			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398845				2022-12-25	WOS:A1997YJ92400024
J	Betton, JM; Jacob, JP; Hofnung, M; Broome-Smith, JK				Betton, JM; Jacob, JP; Hofnung, M; Broome-Smith, JK			Creating a bifunctional protein by insertion of beta-lactamase into the maltodextrin-binding protein	NATURE BIOTECHNOLOGY			English	Article						protein engineering; rational design; hybrid protein	MALTOSE-BINDING; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; CYTOPLASMIC MEMBRANE; CRYSTAL-STRUCTURE; PURIFICATION; EXPRESSION; RESOLUTION; GENE; CHEMOTAXIS	Hybrid proteins were generated by inserting the penicillin-hydrolyzing enzyme, TEM beta-lactamase (Bla), into the maltodextrin-binding protein (MalE). The inserted Bra was functionally accommodated by MalE when it was placed within permissive sites. The maltose binding and penicillinase activities of purified hybrids were indistinguishable from those of the wild-type MalE and Bla proteins. Moreover, these hybrids displayed an additional unexpected property: maltose stabilized the active site of inserted Bla.	Inst Pasteur, CNRS, URA 1444,Unite Programmat Mol & Toxicol Genet, Dept Biotechnol, F-75015 Paris, France; Univ Sussex, Sch Biol Sci, Biochem Grp, Brighton BN1 9QG, E Sussex, England	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Sussex	Betton, JM (corresponding author), Inst Pasteur, CNRS, URA 1444,Unite Programmat Mol & Toxicol Genet, Dept Biotechnol, 25 Rue Dr Roux, F-75015 Paris, France.		Wood, David W/B-2992-2012		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANEYX F, 1989, ENZYME MICROB TECH, V11, P559, DOI 10.1016/0141-0229(89)90083-5; BETTON JM, 1994, EMBO J, V13, P1226, DOI 10.1002/j.1460-2075.1994.tb06372.x; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; BETTON JM, 1993, FEBS LETT, V325, P34, DOI 10.1016/0014-5793(93)81409-S; BORK P, 1996, REV BIOPHYS, V29, P119; BULOW L, 1991, TRENDS BIOTECHNOL, V9, P226, DOI 10.1016/0167-7799(91)90075-S; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JELSCH C, 1992, FEBS LETT, V299, P135, DOI 10.1016/0014-5793(92)80232-6; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; Martineau P, 1996, MOL IMMUNOL, V33, P1345, DOI 10.1016/S0161-5890(96)00091-0; MARTINEAU P, 1992, GENE, V113, P35, DOI 10.1016/0378-1119(92)90667-E; MELLING J, 1972, BIOCHEM J, V130, P55, DOI 10.1042/bj1300055; MITCHINSON C, 1985, J MOL BIOL, V184, P331, DOI 10.1016/0022-2836(85)90384-5; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; NILSSON B, 1992, CURR OPIN STRUC BIOL, V2, P569; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RUSSELL RB, 1994, PROTEIN ENG, V7, P1407, DOI 10.1093/protein/7.12.1407; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHARFF AJ, 1995, J MOL BIOL, V246, P8, DOI 10.1006/jmbi.1994.0059; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SIGAL IS, 1984, J BIOL CHEM, V259, P5327; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; ZHANG YB, 1990, GENE, V96, P51, DOI 10.1016/0378-1119(90)90340-W	31	47	53	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1276	1279		10.1038/nbt1197-1276	http://dx.doi.org/10.1038/nbt1197-1276			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359111				2022-12-25	WOS:000071342000030
J	Bryan, TM; Englezou, A; DallaPozza, L; Dunham, MA; Reddel, RR				Bryan, TM; Englezou, A; DallaPozza, L; Dunham, MA; Reddel, RR			Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines	NATURE MEDICINE			English	Article							P16(INK4) EXPRESSION; IMMORTAL CELLS; CANCER; CARCINOMA; P53; FIBROBLASTS; ASSOCIATION; REPEATS; SKIN; GENE	The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potentia(1-3). Telomerase is an enzyme that restores telomeric DNA sequences(4), and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo(5). Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues(6,7). It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date(7). It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization(8-11) presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres)(11). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA; NEW CHILDRENS HOSP,WESTMEAD,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia; University of Sydney; University of Sydney			Bryan, Tracy M/B-8468-2014; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gupta J, 1996, J NATL CANCER I, V88, P1152, DOI 10.1093/jnci/88.16.1152; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; Hiyama E, 1996, INT J ONCOL, V9, P453; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hsiao RS, 1997, ANTICANCER RES, V17, P827; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Mehle C, 1996, ONCOGENE, V13, P161; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Noble JR, 1996, ONCOGENE, V13, P1259; NURNBERG P, 1993, HUM GENET, V91, P190; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SPRUNG CN, IN PRESS MUTAT RES; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yasumoto S, 1996, ONCOGENE, V13, P433	39	978	1009	0	48	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1271	1274		10.1038/nm1197-1271	http://dx.doi.org/10.1038/nm1197-1271			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359704				2022-12-25	WOS:A1997YD89600038
J	Chen, JD; Bai, XF; Yang, AG; Cong, YP; Chen, SY				Chen, JD; Bai, XF; Yang, AG; Cong, YP; Chen, SY			Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy	NATURE MEDICINE			English	Article							VIRUS TYPE-1 INFECTION; IMMUNODEFICIENCY-VIRUS; ENDOPLASMIC-RETICULUM; SYNTHESIZED PROTEINS; GENE-TRANSFER; CELLS; LESTR/FUSIN; DEGRADATION; PROGRESSION; ANTIBODY	CXC-chemokine receptor (CXCR)4/fusin, a newly discovered co-receptor for T-cell line (T)-tropic HIV-1 virus, plays a critical role in T-tropic virus fusion and entry into permissive cells. The occurrence of T-tropic HIV viruses is associated with CD4-positive cell decline and progression to AIDS, suggesting that the T-tropic HIV-1 contributes to AIDS pathogenesis. In this study, we used a novel strategy to inactivate CXCR-4 by targeting a modified CXC-chemokine to the endoplasmic reticulum (ER) to block the surface expression of newly synthesized CXCR-4. The genetically modified lymphocytes expressing this intracellular chemokine, termed ''intrakine,'' are immune to T-tropic virus infection and appear to retain normal biological features. Thus, this genetic intrakine strategy is uniquely targeted at the conserved cellular receptor for the prevention of HIV-1 entry and may be developed into an effective treatment for HIV-1 infection and AIDS.	WAKE FOREST UNIV,CTR COMPREHENS CANC,DEPT CANC BIOL,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center								Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BUONOCORE L, 1993, P NATL ACAD SCI USA, V90, P2695, DOI 10.1073/pnas.90.7.2695; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; CHEN SY, 1994, HUM GENE THER, V5, P595, DOI 10.1089/hum.1994.5.5-595; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; DANIEL MD, 1988, J VIROL, V62, P4123, DOI 10.1128/JVI.62.11.4123-4128.1988; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FENG Y, 1996, SCIENCE, V272, P809; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pear Warren S., 1997, P41; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phillips K, 1996, NAT MED, V2, P1154, DOI 10.1038/nm1096-1154; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Rudoll T, 1996, GENE THER, V3, P695; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; TERSMETTE M, 1989, LANCET, V1, P983; VANZEE KJ, 1992, J IMMUNOL, V148, P1746; Yang AG, 1997, NAT BIOTECHNOL, V15, P46, DOI 10.1038/nbt0197-46; YANG AG, IN PRESS P NATL ACAD; YU M, 1994, GENE THER, V1, P13	43	91	107	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1110	1116		10.1038/nm1097-1110	http://dx.doi.org/10.1038/nm1097-1110			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334722				2022-12-25	WOS:A1997XZ28700036
J	Weissenbach, J; Bentolila, S				Weissenbach, J; Bentolila, S			Integrating maps requires integrated data	NATURE BIOTECHNOLOGY			English	Editorial Material											Weissenbach, J (corresponding author), GENETHON SA,CNRS,URA 1922,INFORMAT,1 RUE INT,BP 60,F-91002 EVRY,FRANCE.							CANTOR C, 1989, SCIENCE, V245, P1434	1	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1996	14	6					678	678		10.1038/nbt0696-678	http://dx.doi.org/10.1038/nbt0696-678			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UM766	9630965				2022-12-25	WOS:A1996UM76600003
J	Sherwood, JK; Zeitlin, L; Whaley, KJ; Cone, RA; Saltzman, M				Sherwood, JK; Zeitlin, L; Whaley, KJ; Cone, RA; Saltzman, M			Controlled release of antibodies for long-term topical passive Immunoprotection of female mice against genital herpes	NATURE BIOTECHNOLOGY			English	Article						herpes simplex virus 2 (HSV-2); topical passive immunization; mouse vagina; polymer	DELIVERY SYSTEMS; INFECTION	Current methods for sexually transmitted diseases (STD) prophylaxis, which can be disruptive and inconvenient, must be used before each act of sexual intercourse, so a method that provides protection over the course of many acts is desirable. We used a mouse model of vaginally-transmitted herpes simplex virus 2 (HSV-2) infection to test polymeric controlled-release devices for sustained passive immunoprotection. Vaginal disks were prepared by dispersing a monoclonal antibody to HSV-2 (III-174) within a matrix of poly(ethylene-co-vinyl acetate); these disks released 2 to 40 mu g/day of antibody into buffered water. When disks were placed in the vagina, large amounts of III-174 (5 to 3,000 ng) were recovered from the vaginal fluid over the next 8 days. Mice were vaginally challenged with 10 ID50 of HSV-2 either 3 or 7 days after disk placement; no mice receiving III-174 disks became infected, while 65% of control mice receiving identical disks with nonspecific IgG did. Controlled-release disks with III-174 provided significant protection against HSV-2 infection (p < 0.005). This new technology for long-term STD prophylaxis should increase user compliance, a factor limiting the efficacy of current methods.	JOHNS HOPKINS UNIV, DEPT CHEM ENGN, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, DEPT BIOPHYS, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University					NIGMS NIH HHS [GM43873] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043873] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COHEN J, 1995, SCIENCE, V269, P777, DOI 10.1126/science.7638589; CONE RA, 1994, AM J REPROD IMMUNOL, V32, P114, DOI 10.1111/j.1600-0897.1994.tb01102.x; ELIAS CJ, 1994, AIDS, V8, P1, DOI 10.1097/00002030-199401000-00002; FELDBLUM P, 1994, MODERN BARRIER METHO; FULLER AO, 1987, P NATL ACAD SCI USA, V84, P5454, DOI 10.1073/pnas.84.15.5454; HOOK EW, 1992, J INFECT DIS, V165, P251, DOI 10.1093/infdis/165.2.251; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGER R, 1981, J BIOMED MATER RES, V15, P267, DOI 10.1002/jbm.820150212; NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010; PARA MF, 1985, J VIROL, V55, P483, DOI 10.1128/JVI.55.2.483-488.1985; RADOMSKY ML, 1992, BIOL REPROD, V47, P133, DOI 10.1095/biolreprod47.1.133; RHINE WD, 1980, J PHARM SCI, V69, P265, DOI 10.1002/jps.2600690305; SALTZMAN WM, 1994, BIOPHYS J, V66, P508, DOI 10.1016/S0006-3495(94)80802-1; SALTZMAN WM, 1989, BIOPHYS J, V55, P163, DOI 10.1016/S0006-3495(89)82788-2; Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264; SIEGEL RA, 1984, PHARM RES-DORDR, P2, DOI 10.1023/A:1016318423563; Snedecor GW, 1980, STAT METHODS, V7th; STONE KM, 1994, BARRIER CONTRACEPTIV, P203; *US DEP HHS, 1995, 1994 US DEP HHS PHS; WHALEY KJ, 1994, J INFECT DIS, V169, P647, DOI 10.1093/infdis/169.3.647; WHALEY KJ, 1993, J INFECT DIS, V168, P1009, DOI 10.1093/infdis/168.4.1009; ZADOR G, 1976, CONTRACEPTION, V13, P559, DOI 10.1016/0010-7824(76)90012-3	22	51	52	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					468	471		10.1038/nbt0496-468	http://dx.doi.org/10.1038/nbt0496-468			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630921				2022-12-25	WOS:A1996UL58800029
J	Persidis, A				Persidis, A			Proteomics - An ambitious drug development platform attempts to link gene sequence to expressed phenotype under various physiological states.	NATURE BIOTECHNOLOGY			English	Editorial Material							2-DIMENSIONAL ELECTROPHORESIS; PROTEINS; GENOME		Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd,Suite 202, Charlottesville, VA 22901 USA.							BARRETT T, 1973, BIOCHIM BIOPHYS ACTA, V294, P165, DOI 10.1016/0005-2787(73)90323-7; EDMAN P, 1950, ACTA CHEM SCAND, V4, P282; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HumpherySmith I, 1997, ELECTROPHORESIS, V18, P1217, DOI 10.1002/elps.1150180804; James P, 1997, BIOCHEM BIOPH RES CO, V231, P1, DOI 10.1006/bbrc.1996.6045; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Persidis A, 1998, NAT BIOTECHNOL, V16, P100, DOI 10.1038/nbt0198-100; TAYLOR J, 1982, CLIN CHEM, V28, P861; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; WASINGER VC, 1995, ELECTROPHORESIS, V16, P1090, DOI 10.1002/elps.11501601185; YATES JR, 1993, ANAL BIOCHEM, V214, P397, DOI 10.1006/abio.1993.1514; Yates JR, 1998, J MASS SPECTROM, V33, P1	14	68	71	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					393	394		10.1038/nbt0498-393	http://dx.doi.org/10.1038/nbt0498-393			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555734				2022-12-25	WOS:000072786200035
J	Ruegg, C; Yilmaz, A; Bieler, G; Bamat, J; Chaubert, P; Lejeune, FJ				Ruegg, C; Yilmaz, A; Bieler, G; Bamat, J; Chaubert, P; Lejeune, FJ			Evidence for the involvement of endothelial cell integrin alpha V beta 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; SYNERGISTIC INDUCTION; ISOLATION PERFUSION; HUMAN-MELANOMA; ANGIOGENESIS; EXPRESSION; ACTIVATION; INHIBITION; RECEPTORS	Administration of tumor necrosis factor (TNF) and gamma interferon (IFN-gamma) to melanoma patients causes selective disruption of the tumor vasculature but the mechanism of this disruption is unknown. Here we report that exposure of human endothelial cells to TNF and IFN-gamma results in a reduced activation of integrin alpha V beta 3, an adhesion receptor that plays a key role in tumor angiogenesis, leading to a decreased alpha V beta 3-dependent endothelial cell adhesion and survival. Detachment and apoptosis of angiogenic endothelial cells was demonstrated in vivo in melanoma metastases of patients treated with TNF and IFN-gamma. These results implicate integrin alpha V beta 3 in the anti-vascular activity of TNF and IFN-gamma and demonstrate a new mechanism by which cytokines control cell adhesion.	Univ Lausanne, CHU Vaudois, ISREC, Sch Med,Ctr Pluridisciplinaire Oncol, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland; Univ Lausanne, Sch Med, Inst Pathol, CH-1011 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research; University of Lausanne	Ruegg, C (corresponding author), Univ Lausanne, CHU Vaudois, ISREC, Sch Med,Ctr Pluridisciplinaire Oncol, 155 Chem Boveresses, CH-1066 Epalinges, Switzerland.							ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DOUKAS J, 1990, J IMMUNOL, V145, P1727; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GERAIN J, 1992, CYTOKINE, V4, P585, DOI 10.1016/1043-4666(92)90024-L; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; LAHM H, 1994, INT J CANCER, V59, P440, DOI 10.1002/ijc.2910590325; LEJEUNE F, 1994, J CELL BIOCHEM, V56, P52, DOI 10.1002/jcb.240560110; Lejeune F., 1997, Melanoma Research, V7, pS48, DOI 10.1097/00008390-199706001-00167; LEJEUNE FJ, 1995, EUR J CANCER, V31A, P1009, DOI 10.1016/0959-8049(94)00512-5; LIENARD D, 1994, MELANOMA RES, V4, P21; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHMORI Y, 1995, J IMMUNOL, V154, P5235; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RENARD N, 1995, J PATHOL, V176, P279, DOI 10.1002/path.1711760310; RENARD N, 1994, INT J CANCER, V57, P656, DOI 10.1002/ijc.2910570508; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH JW, 1994, J BIOL CHEM, V269, P960; SPERTINI O, 1991, J IMMUNOL, V147, P2565; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VASSBOTN FS, 1994, J BIOL CHEM, V269, P13874; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681	50	395	411	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					408	414		10.1038/nm0498-408	http://dx.doi.org/10.1038/nm0498-408			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546785				2022-12-25	WOS:000072906800034
J	Town, M; Jean, G; Cherqui, S; Attard, M; Forestier, L; Whitmore, SA; Callen, DF; Gribouval, O; Broyer, M; Bates, GP; van't Hoff, W; Antignac, C				Town, M; Jean, G; Cherqui, S; Attard, M; Forestier, L; Whitmore, SA; Callen, DF; Gribouval, O; Broyer, M; Bates, GP; van't Hoff, W; Antignac, C			A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis	NATURE GENETICS			English	Article							YAC CLONES; TRANSPORT; VECTOR; MAP	Nephropathic cystinosis, an autosomal recessive disorder resulting from defective lysosomal transport of cystine, is the most common inherited cause of renal Fanconi syndrome. The cystinosis gene has been mapped to chromosome 17p13. We found that the locus D17S829 was homozygously deleted in 23 out of 70 patients, and identified a novel gene, CTNS, which mapped to the deletion interval. CTNS encodes an integral membrane protein, cystinosin, with features of a lysosomal membrane protein. Eleven different mutations, all predicted to cause loss of function of the protein, were found to segregate with the disorder.	INSERM U43, F-75015 Paris, France; Guys Hosp, UMDS, Div Med & Mol Genet, London SE1 9RT, England; Univ Paris 05, Hop Necker Enfants Malad, Serv Nephrol Pediat, F-75015 Paris, France; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Adelaide, SA, Australia; UCL, Sch Med, Inst Child Hlth, Nephrourol Unit, London WC1N 1EH, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Womens & Childrens Hospital Australia; University of London; University College London; UCL Medical School	Antignac, C (corresponding author), INSERM U43, Tour Lavoisier,149 Rue Sevres, F-75015 Paris, France.	m.town@umds.ac.uk; antignac@necker.fr	ANTIGNAC, Corinne/H-8945-2017; Callen, David F/G-1975-2012; Gribouval, Olivier/A-7689-2015; Bates, Gillian P/E-1146-2012	ANTIGNAC, Corinne/0000-0002-9934-4940; Gribouval, Olivier/0000-0003-0238-8224; Bates, Gillian P/0000-0002-4041-6305; Cherqui, Stephanie/0000-0003-1240-5219				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Collo G, 1996, J NEUROSCI, V16, P2495; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; GAHL WA, 1983, BIOCHEM J, V216, P393, DOI 10.1042/bj2160393; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; HARDWICK KG, 1990, NUCLEIC ACIDS RES, V18, P2177, DOI 10.1093/nar/18.8.2177; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jean G, 1996, AM J HUM GENET, V58, P535; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEHRACH H., 1990, GENOME ANAL, P39; McDowell G, 1996, BIOCHEM MOL MED, V58, P135, DOI 10.1006/bmme.1996.0041; MCDOWELL GA, 1995, NAT GENET, V10, P246, DOI 10.1038/ng0695-246; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Peters U, 1997, EUR J HUM GENET, V5, P9, DOI 10.1159/000484725; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Saunier S, 1997, HUM MOL GENET, V6, P2317, DOI 10.1093/hmg/6.13.2317; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Song I, 1996, ARCH BIOCHEM BIOPHYS, V334, P67, DOI 10.1006/abbi.1996.0430; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671	28	420	430	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					319	324		10.1038/ng0498-319	http://dx.doi.org/10.1038/ng0498-319			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537412				2022-12-25	WOS:000072755500012
J	Knezevich, SR; McFadden, DE; Tao, W; Lim, JF; Sorensen, PHB				Knezevich, SR; McFadden, DE; Tao, W; Lim, JF; Sorensen, PHB			A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma	NATURE GENETICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATION; MOLECULAR-CLONING; FIBRO-SARCOMA; TEL GENE; AMPLIFICATION; TRANSCRIPTS; CHILDHOOD; VARIANT; FAMILY	Congenital (or infantile) fibrosarcoma (CFS) is a malignant tumour of fibroblasts that occurs in patients aged two years or younger. CFS is unique among human sarcomas in that it has an excellent prognosis and very low metastatic rate(1,2). CFS is histologically identical to adult-type fibrosarcoma (ATFS); however, ATFS is an aggressive malignancy of adults and older children that has a poor prognosis(3). We report a novel recurrent t(12;15)(p13;q25) rearrangement in CFS that may underlie the distinctive biological properties of this tumour. By cloning the chromosome breakpoints, we show that the rearrangement fuses the ETV6 (also known as TEL) gene from 12p13 with the 15q25 NTRK3 neurotrophin-3 receptor gene (also known as TRKC). Analysis of mRNA revealed the expression of ETV6-NTRK3 chimaeric transcripts in all three CFS tumours analysed. These were not detected in ATFS or infantile fibromatosis (IFB), a histologically similar but benign fibroblastic proliferation occurring in the same age-group as CFS. ETV6-NTRK3 fusion transcripts encode the helix-loop-helix (HLH) protein dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3. Our studies indicate that a chimaeric PTK is expressed in CFS and this may contribute to oncogenesis by dysregulation of NTRK3 signal transduction pathways. Moreover, ETV6-NTRK3 gene fusions provide a potential diagnostic marker for CFS.	British Columbia Childrens Hosp, Dept Pathol, Vancouver, BC V6H 3V4, Canada	BC Childrens Hospital; University of British Columbia	Sorensen, PHB (corresponding author), British Columbia Childrens Hosp, Dept Pathol, 4480 Oak St, Vancouver, BC V6H 3V4, Canada.	psor@unixg.ubc.ca		McFadden, Deborah/0000-0002-0629-3436				Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BONIN G, 1993, CANCER RES, V53, P3655; BUIJS A, 1995, ONCOGENE, V10, P1511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Desmaze C, 1997, CANCER GENET CYTOGEN, V97, P12, DOI 10.1016/S0165-4608(96)00326-3; DRACOPOLI NC, 1996, CURRENT PROTOCOLS HU; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P1; Fisher C, 1996, EUR J CANCER, V32A, P2094, DOI 10.1016/S0959-8049(96)00287-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; ICHIKAWA H, 1994, CANCER RES, V54, P2865; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MANDAHL N, 1989, CANCER GENET CYTOGEN, V40, P137, DOI 10.1016/0165-4608(89)90156-8; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PIZZO PA, 1997, PRINCIPLES PRACTICE, P1; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOFIELD DE, 1994, AM J SURG PATHOL, V18, P14, DOI 10.1097/00000478-199401000-00002; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Sorensen PHB, 1996, P NATL ACAD SCI USA, V93, P1038, DOI 10.1073/pnas.93.3.1038; SORENSEN PHB, 1993, DIAGN MOL PATHOL, V2, P147, DOI 10.1097/00019606-199309000-00002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SPELEMAN F, 1989, CANCER GENET CYTOGEN, V39, P21, DOI 10.1016/0165-4608(89)90224-0; Uphoff CC, 1997, LEUKEMIA, V11, P441, DOI 10.1038/sj.leu.2400571; VERMA RS, 1989, HUMAN CHROMOSOMES MA	30	552	581	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1998	18	2					184	187		10.1038/ng0298-184	http://dx.doi.org/10.1038/ng0298-184			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462753				2022-12-25	WOS:000071779500032
J	Moore, RC; Hope, J; McBride, PA; McConnell, I; Selfridge, J; Melton, DW; Manson, JC				Moore, RC; Hope, J; McBride, PA; McConnell, I; Selfridge, J; Melton, DW; Manson, JC			Mice with gene targetted prion protein alterations show that Prnp, Sinc and Prni are congruent	NATURE GENETICS			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; SCRAPIE INCUBATION-TIME; PRP GENE; TRANSGENIC MICE; CONGENIC MICE; MOUSE; EXPRESSION; POLYMORPHISM; TRANSMISSION	Classical genetic analysis has identified Sinc/Prni as the major gene controlling mouse scrapie incubation time. Sinc/Pmi is linked to Prnp, the gene encoding the prion protein (PrP). Prnp alleles express distinct PrP protein variants, PrP A and PrP B, which arise from codon 108L/F and 189 T/V dimorphisms. Prnp genotype segregates with incubation time length which suggests, but does not prove, that incubation time is controlled by PrP dimorphisms, and that the Sinc/Prni and Prnp loci are congruent. We have used gene targetting to construct mice in which the endogenous Prnp allele has been modified to express PrP 8 instead of PrP A. Challenge with a mouse-adapted BSE strain results in dramatically shortened incubation times and demonstrates that PrP dimorphisms at codon 108 and/or 189 control incubation time, and that Sinc/Prni and Prnp are congruent.	Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh EH9 3JF, Midlothian, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Anim Hlth, Compton Lab, Newbury RG20 7NN, Berks, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh; University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Manson, JC (corresponding author), Inst Anim Hlth, Neuropathogenesis Unit, Ogston Bldg,W Mains Rd, Edinburgh EH9 3JF, Midlothian, Scotland.	jean.manson@bbsrc.ac.uk	Hope, James/C-4966-2011	SELFRIDGE, JIM/0000-0003-2473-4386				BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Baybutt H, 1997, GENE, V184, P125, DOI 10.1016/S0378-1119(96)00600-2; BELL JE, 1993, BRIT MED BULL, V49, P738, DOI 10.1093/oxfordjournals.bmb.a072645; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1985, J NEUROPATH EXP NEUR, V44, P285, DOI 10.1097/00005072-198505000-00006; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CARLSON GA, 1993, GENETICS, V133, P979; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; CHANDLER RL, 1961, LANCET, V1, P1378; CREUTZFELDT HG, 1920, Z GESAMTE NEUROL PSY, V57, P247; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DICKINSON AG, 1964, HEREDITY, V19, P279, DOI 10.1038/hdy.1964.31; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; Farquhar CF, 1996, J GEN VIROL, V77, P1941, DOI 10.1099/0022-1317-77-8-1941; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; FARQUHAR CF, 1993, P CONS BSE SCI VET C, P301; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; Fraser H., 1976, Slow virus diseases of animals and man,, P267; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; FRASER H, 1967, NATURE, V216, P1310, DOI 10.1038/2161310a0; GADJUSEK DC, 1957, NEW ENGL J MED, V257, P974; Gerstmann J., 1936, Z NEUROL, V154, P736, DOI [10.1007/BF02865827, DOI 10.1007/BF02865827]; Hainfellner JA, 1997, BRAIN PATHOL, V7, P547, DOI 10.1111/j.1750-3639.1997.tb01072.x; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; HUNTER N, 1992, J GEN VIROL, V73, P2751, DOI 10.1099/0022-1317-73-10-2751; Jakob A, 1921, Z GESAMTE NEUROL PSY, V64, P147, DOI 10.1007/BF02870932; KINGSBURY DT, 1983, J IMMUNOL, V131, P491; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Manson J., 1992, Neurodegeneration, V1, P45; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MOORE RC, 1995, BIO-TECHNOL, V13, P999, DOI 10.1038/nbt0995-999; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; WESTAWAY D, 1994, P NATL ACAD SCI USA, V91, P6418, DOI 10.1073/pnas.91.14.6418; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1987, CELL, V51, P561	54	158	159	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					118	125		10.1038/ng0298-118	http://dx.doi.org/10.1038/ng0298-118			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462739				2022-12-25	WOS:000071779500018
J	Seidner, G; Alvarez, MG; Yeh, JI; O'Driscoll, KR; Klepper, J; Stump, TS; Wang, D; Spinner, NB; Birnbaum, MJ; De Vivo, DC				Seidner, G; Alvarez, MG; Yeh, JI; O'Driscoll, KR; Klepper, J; Stump, TS; Wang, D; Spinner, NB; Birnbaum, MJ; De Vivo, DC			GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier	NATURE GENETICS			English	Article							GLUCOSE-TRANSPORTER GENE; EXPRESSION; ANTIBODIES; SEQUENCE; PROTEIN	The high metabolic requirements of the mammalian central nervous system require specialized structures for the facilitated transport of nutrients across the blood-brain barrier. Stereospecific high-capacity carriers, including those that recognize glucose, are key components of this barrier, which also protects the brain against noxious substances. Facilitated glucose transport in vertebrates is catalyzed by a family of carriers consisting of at least five functional isoforms with distinct tissue distributions, subcellular localizations and transport kinetics(1,2). Several of these transporters are expressed in the mammalian brain(3). GLUT-1, whose sequence was originally deduced from cDNAs cloned from human hepatoma and rat brain(4,5), is present at high levels in primate erythrocytes and brain endothelial cells. GLUT1 has been cloned and positionally mapped to the short arm of chromosome 1 (1p35-p31.3; refs 6-8). Despite substantial metabolic requirements of the central nervous system, no genetic disease caused by dysfunctional blood-brain barrier transport has been identified. Several years ago, we described two patients with infantile seizures, delayed development and acquired microcephaly who have normal circulating blood glucose, low-to-normal cerebrospinal fluid (CSF) lactate, but persistent hypoglycorrachia (low CSF glucose) and diminished transport of hexose into isolated red blood cells (RBC; ref. 9). These symptoms suggested the existence of a defect in glucose transport across the blood brain barrier. We now report two distinct classes of mutations as the molecular basis for the functional defect of glucose transport: hemizygosity of GLUT1 and nonsense mutations resulting in truncation of the GLUT-1 protein.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cox Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Natl Taiwan Univ Hosp, Dept Family Med, Taipei, Taiwan; Columbia Presbyterian Med Ctr, Dept Neurol, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Dept Pediat, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Inst Neurol, Colleen Giblin Labs Pediat Neurol Res, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Babies & Childrens Hosp, New York, NY 10032 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; National Taiwan University; National Taiwan University Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, 415 Curie Blvd, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK 39615] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; DAVIES A, 1987, J BIOL CHEM, V262, P9347; De Vivo D. C., 1995, INT PEDIAT, V10, P51; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JAMES DE, 1995, NEWS PHYSIOL SCI, V10, P67, DOI 10.1152/physiologyonline.1995.10.2.67; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; SHOWS TB, 1987, DIABETES, V36, P546, DOI 10.2337/diabetes.36.4.546; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	17	292	300	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					188	191		10.1038/ng0298-188	http://dx.doi.org/10.1038/ng0298-188			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462754				2022-12-25	WOS:000071779500033
J	Barlow, C; Brown, KD; Deng, CX; Tagle, DA; WynshawBoris, A				Barlow, C; Brown, KD; Deng, CX; Tagle, DA; WynshawBoris, A			Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways	NATURE GENETICS			English	Article							RADIATION-INDUCED APOPTOSIS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; P53 PROTEIN; DNA-DAMAGE; MICE; INSTABILITY; SUPPRESSION; INDUCTION; PARADIGM	Atm is part of a pathway that responds to DNA damage from ionizing radiation (IR). This pathway involves p53, as Atm-deficient cell lines and mice are defective in p53 induction after IR1-5. p53 is a multi-functional protein that simultaneously regulates distinct downstream pathways controlling cell-cycle progression and apoptosis(6,7). However, the mechanisms by which p53 differentially activates downstream pathways are unknown. To determine the relationship between Atm and p53, we examined cell-cycle and apoptotic responses in Atm-, p53- (ref. 8) and p21-deficient(9) mice after IR in the whole animal, As expected, p53 protein levels were not induced by IR in thymus of Atm-deficient mice. IR-induced cell-cycle checkpoint function was also defective, and induction of p21 was attenuated in thymus from Atm-deficient mice, However, IR-induced apoptosis and Bar induction were completely normal; both of which are mediated by p53. IR-induced thymic apoptosis was suppressed in Atm/p53 double-mutant mice but not in Atm/p21 double mutants, demonstrating p53 dependence and Atm independence. Thus, Atm deficiency results in lack of p53 induction by IR, but only selective disruption of p53-dependent functions, Our results support a model in which upstream effecters such as Atm selectively activate p53 to regulate specific downstream pathways, providing a mechanism for controlling distinct cell-cycle and apoptotic responses.	NIDDKD,LAB GENET DIS RES,NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD 20892; NIDDKD,LAB GENE TRANSFER,NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD 20892; NIDDKD,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			deng, chuxia/N-6713-2016					Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lakin ND, 1996, ONCOGENE, V13, P2707; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luna L.G., 1992, HISTOPATHOLOGICAL ME; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MIYASHITA T, 1995, CELL, V80, P293; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WHITE RA, 1990, CYTOMETRY, V11, P314, DOI 10.1002/cyto.990110214; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401	31	185	187	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					453	456		10.1038/ng1297-453	http://dx.doi.org/10.1038/ng1297-453			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398849				2022-12-25	WOS:A1997YJ92400028
J	Nagamine, K; Peterson, P; Scott, HS; Kudoh, J; Minoshima, S; Heino, M; Krohn, KJE; Lalioti, MD; Mullis, PE; Antonarakis, SE; Kawasaki, K; Asakawa, S; Ito, F; Shimizu, N				Nagamine, K; Peterson, P; Scott, HS; Kudoh, J; Minoshima, S; Heino, M; Krohn, KJE; Lalioti, MD; Mullis, PE; Antonarakis, SE; Kawasaki, K; Asakawa, S; Ito, F; Shimizu, N			Positional cloning of the APECED gene	NATURE GENETICS			English	Article							DISEASE TYPE-I; PROTEIN; SEQUENCES; 21Q22.3; REGION; CDNA	Autoimmune polyglandular syndrome type I (APS 1, also called APECED) is an autosomal-recessive disorder that maps to human chromosome 21q22.3 between markers D21S49 and D21S171 by linkage studies. We have isolated a novel gene from this region, AIRE (autoimmune regulator), which encodes a protein containing motifs suggestive of a transcription factor including two zinc-finger (PHD-finger) motifs, a proline-rich region and three LXXLL motifs. Two mutations, a C-->T substitution that changes the Arg 257 (CGA) to a stop codon (TGA) and an A-->G substitution that changes the Lys 83 (AAG) to a Glu codon (GAG), were found in this novel gene in Swiss and Finnish APECED patients. The Arg257stop (R257X) is the predominant mutation in Finnish APECED patients, accounting for 10/12 alleles studied. These results indicate that this gene is responsible for the pathogenesis of APECED. The identification of the gene defective in APECED should facilitate the genetic diagnosis and potential treatment of the disease and further enhance our general understanding of the mechanisms underlying autoimmune diseases.	KEIO UNIV,SCH MED,DEPT MOL BIOL,SHINJUKU KU,TOKYO 160,JAPAN; SETSUNAN UNIV,FAC PHARMACEUT SCI,DEPT BIOCHEM,HIRAKATA,OSAKA 57301,JAPAN; TAMPERE UNIV HOSP,TAMPERE 33101,FINLAND; INST MED TECHNOL,TAMPERE 33101,FINLAND; UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,LAB HUMAN MOL GENET,CH-1211 GENEVA 4,SWITZERLAND; CANTONAL HOSP GENEVA,DIV MED GENET,CH-1211 GENEVA 4,SWITZERLAND; UNIV BERN,DEPT PAEDIAT,BERN,SWITZERLAND	Keio University; Setsunan University; Tampere University; Tampere University Hospital; University of Geneva; University of Geneva; University of Bern			Peterson, Pärt/A-5788-2009; Antonarakis, Stylianos E/N-8866-2014; Scott, Hamish/B-2122-2009	Peterson, Pärt/0000-0001-6755-791X; Antonarakis, Stylianos E/0000-0001-8907-5823; Scott, Hamish/0000-0002-5813-631X; Ito, Fumiaki/0000-0002-4129-4899				AALTONEN J, 1994, NAT GENET, V8, P83, DOI 10.1038/ng0994-83; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AHONEN P, 1985, CLIN GENET, V27, P535, DOI 10.1111/j.1399-0004.1985.tb02037.x; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Bjorses P, 1996, AM J HUM GENET, V59, P879; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; Chen H, 1996, GENOME RES, V6, P747, DOI 10.1101/gr.6.8.747; Clemente MG, 1997, J CLIN ENDOCR METAB, V82, P1353, DOI 10.1210/jc.82.5.1353; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Husebye ES, 1997, J CLIN ENDOCR METAB, V82, P147, DOI 10.1210/jc.82.1.147; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kudoh J, 1997, DNA Res, V4, P45, DOI 10.1093/dnares/4.1.45; Lalioti MD, 1996, GENOMICS, V35, P321, DOI 10.1006/geno.1996.0363; Nagamine K, 1997, BIOCHEM BIOPH RES CO, V235, P185, DOI 10.1006/bbrc.1997.6758; Nagamine K, 1996, BIOCHEM BIOPH RES CO, V225, P608, DOI 10.1006/bbrc.1996.1218; Nagamine K, 1997, GENOMICS, V42, P528, DOI 10.1006/geno.1997.4761; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Scott HS, 1997, HUM GENET, V99, P616, DOI 10.1007/s004390050416; SCOTT HS, IN PRESS GENOMICS; SEEIG HP, 1995, ARTHRITIS RHEUM, V38, P1389; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UIBO R, 1994, J CLIN ENDOCR METAB, V78, P323, DOI 10.1210/jc.78.2.323; ZLOTOGORA J, 1992, J MED GENET, V29, P824, DOI 10.1136/jmg.29.11.824	29	984	1019	1	33	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					393	398		10.1038/ng1297-393	http://dx.doi.org/10.1038/ng1297-393			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398839				2022-12-25	WOS:A1997YJ92400018
J	Draghia-Akli, R; Li, XY; Schwartz, RJ				Draghia-Akli, R; Li, XY; Schwartz, RJ			Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector	NATURE BIOTECHNOLOGY			English	Article						gene therapy; growth hormone; DNA vaccine; skeletal alpha-actin	ALPHA-ACTIN GENE; MOUSE SKELETAL-MUSCLE; PLASMID DNA; CHROMOSOMAL ASSIGNMENT; FACTOR-I; SECRETION; GH; DEFICIENCY; INJECTION; MUTATIONS	Ectopic expression of a truncated growth hormone-releasing hormone (GHRH) from muscle tissues by a myogenic plasmid DNA vector directed by the skeletal alpha-actin promoter, pSK-GHRH, results in growth hormone (GH) secretion. Skeletal muscle-secreted GHRH is biologically active. The application of conditioned media harvested from pSK-GHRH transfected muscle cells to cultured pig primary anterior pituitary cells elicits GH release. A single intramuscular injection of 100 mu g pSK-GHRH DNA elevates serum GH levels threefold to fourfold for up to 2 weeks, enhancing liver IGF-1 gene expression and increasing body weight approximately 10%.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu		Draghia-Akli, Ruxandra/0000-0001-6372-4039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-49953, R01 HL-50422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMSELEM S, 1993, HUM MOL GENET, V2, P355, DOI 10.1093/hmg/2.4.355; AMSELEM S, 1991, ACTA PAEDIATR SCAND, P81; BARB CR, 1991, DOMEST ANIM ENDOCRIN, V8, P117, DOI 10.1016/0739-7240(91)90046-M; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BERTHERAT J, 1995, EUR J ENDOCRINOL, V132, P12, DOI 10.1530/eje.0.1320012; CAO Y, 1995, PEDIATR RES, V38, P962, DOI 10.1203/00006450-199512000-00022; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; COGAN JD, 1993, J CLIN ENDOCR METAB, V76, P1224, DOI 10.1210/jc.76.5.1224; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; CORPAS E, 1993, J CLIN ENDOCR METAB, V76, P134, DOI 10.1210/jc.76.1.134; DANKO I, 1994, GENE THER, V1, P114; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DCOSTA AP, 1993, J REPROD FERTIL, P87; DOUMIT ME, 1992, TISSUE CELL, V24, P253, DOI 10.1016/0040-8166(92)90098-R; ENRIGHT WJ, 1993, J ANIM SCI, V71, P2395, DOI 10.2527/1993.7192395x; ENRIGHT WJ, 1986, J DAIRY SCI, V69, P344, DOI 10.3168/jds.S0022-0302(86)80412-X; ESCH FS, 1982, BIOCHEM BIOPH RES CO, V109, P152, DOI 10.1016/0006-291X(82)91578-9; FRENCH BA, 1990, GENE, V88, P173, DOI 10.1016/0378-1119(90)90029-Q; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; KOTZMANN H, 1994, NEUROENDOCRINOLOGY, V60, P618, DOI 10.1159/000126805; LEE TC, 1994, ONCOGENE, V9, P1047; LeRoith D, 1996, ENDOCRINOLOGY, V137, P1071, DOI 10.1210/en.137.3.1071; Levy MY, 1996, GENE THER, V3, P201; LING N, 1984, BIOCHEM BIOPH RES CO, V123, P854; LOW LCK, 1993, J PEDIATR ENDOCRINOL, V6, P15; MARCUS R, 1990, J CLIN ENDOCR METAB, V70, P519, DOI 10.1210/jcem-70-2-519; MAYO KE, 1985, P NATL ACAD SCI USA, V82, P63, DOI 10.1073/pnas.82.1.63; MAYO KE, 1983, NATURE, V306, P86, DOI 10.1038/306086a0; MEACHAM LR, 1993, J CLIN ENDOCR METAB, V77, P1379, DOI 10.1210/jc.77.5.1379; Parks John S., 1995, P473; PARKS JS, 1993, HORM RES, V40, P54, DOI 10.1159/000183768; RIDDELL DC, 1985, SOMAT CELL MOLEC GEN, V11, P189, DOI 10.1007/BF01534707; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Scanlon MF, 1996, HORM RES, V46, P149, DOI 10.1159/000185014; TANNER JW, 1990, J ENDOCRINOL, V125, P109, DOI 10.1677/joe.0.1250109; THORNER MO, 1984, J CLIN ENDOCR METAB, V59, P846, DOI 10.1210/jcem-59-5-846; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; VNENCAKJONES CL, 1988, P NATL ACAD SCI USA, V85, P5615, DOI 10.1073/pnas.85.15.5615; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WELLS DJ, 1993, FEBS LETT, V332, P179, DOI 10.1016/0014-5793(93)80508-R; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; YAO SN, 1994, GENE THER, V1, P99	45	48	74	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1285	1289		10.1038/nbt1197-1285	http://dx.doi.org/10.1038/nbt1197-1285			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359113				2022-12-25	WOS:000071342000032
J	Iotsova, V; Caamano, J; Loy, J; Yang, Y; Lewin, A; Bravo, R				Iotsova, V; Caamano, J; Loy, J; Yang, Y; Lewin, A; Bravo, R			Osteopetrosis in mice lacking NF-kappa B1 and NF-kappa B2	NATURE MEDICINE			English	Article							NF-KAPPA-B; C-FOS; TARGETED DISRUPTION; BONE; OSTEOCLAST; DIFFERENTIATION; CELLS; REL; PROTOONCOGENE; PROTEINS	The nfkb1 and nfkb2 genes encode closely related products regulating immune and inflammatory responses. Their role during development and differentiation remains unclear. The generation of nfkb1 null mice (p50(-/-)) resulted in altered immune responses, but had no effect on development(4). Similarly, nfkb2 knockout mice (p52(-/-)) did not show developmental defects (J.C. et ol., manuscript submitted). We have investigated the potential for in vivo compensatory functions of these genes by generating double-knockout mice. The surprising result was that the animals developed osteopetrosis because of a defect in osteoclast differentiation, suggesting redundant functions of NF-kappa B1 and NF-kappa B2 proteins in the development of this cell lineage. The osteopetrotic phenotype was rescued by bone marrow transplantation, indicating that the hematopoietic component was impaired. These results define a new mouse osteopetrotic mutant and implicate NF-kappa B proteins in bone development, raising new directions in the treatment of bone disorders.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT EXPT PATHOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb			Caamano, Jorge/I-6778-2012; Caamano, Jorge/O-7530-2019	Caamano, Jorge/0000-0003-3530-7056; Caamano, Jorge/0000-0003-3530-7056				COLIGAN JE, 1992, ISOLATION FRACTIONAT; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GRILLI M, 1993, INT REV CYTOL, V143, P1; Jimi E, 1996, J BIOL CHEM, V271, P4605; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192-0561(94)00089-7; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; PRALLET B, 1992, J BONE MINER RES, V7, P405; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; WHYTE MP, 1993, CLIN ORTHOP RELAT R, P52	24	719	749	2	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1285	1289		10.1038/nm1197-1285	http://dx.doi.org/10.1038/nm1197-1285			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359707				2022-12-25	WOS:A1997YD89600041
J	Loisel, TP; Ansanay, H; St-Onge, S; Gay, B; Boulanger, P; Strosberg, AD; Marullo, S; Bouvier, M				Loisel, TP; Ansanay, H; St-Onge, S; Gay, B; Boulanger, P; Strosberg, AD; Marullo, S; Bouvier, M			Recovery of homogeneous and functional beta(2)-adrenergic receptors from extracellular baculovirus particles	NATURE BIOTECHNOLOGY			English	Article						protein expression; Sf9 cells; recombinant baculovirus	INFECTED INSECT CELLS; VIRUS-LIKE PARTICLES; NUCLEAR POLYHEDROSIS-VIRUS; BETA-2-ADRENERGIC RECEPTOR; STRUCTURAL PROTEINS; PEPTIDE RECEPTOR; GAG PRECURSOR; EXPRESSION; PURIFICATION; PHOSPHORYLATION	Expression in baculovirus-infected insect cells allows sufficient production of G-protein coupled receptor for structural studies. An important drawback of this expression system comes from the presence of unprocessed and biologically inactive receptors that have to be eliminated during receptor purification steps. We show that viral particles released from Sf9 cells infected with a recombinant baculovirus coding for the human beta(2)-adrenergic receptor (beta(2)AR) cDNA contain glycosylated and biologically active beta(2)AR. In addition, post-translational modifications known to modulate receptor activity were found to occur in these particles.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada; Fac Med Montpellier, Inst Biol, Lab Virol & Pathogeneses Mol, CNRS,URA 1487, F-34060 Montpellier, France; CNRS, Inst Cochin Genet Mol, UPR 415, Lab Immunopharmacol Mol, F-75014 Paris, France; Univ Paris 07, F-75014 Paris, France	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.	bouvier@bch.umontreal.ca	Marullo, Stefano/C-6142-2008; Bouvier, Michel/H-2758-2014	Marullo, Stefano/0000-0001-9604-9973; Bouvier, Michel/0000-0003-1128-0100				ALLARD WJ, 1987, NUCLEIC ACIDS RES, V15, P10604, DOI 10.1093/nar/15.24.10604; BELCHEVA MM, 1995, J PHARMACOL EXP THER, V274, P1513; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; BRAUNAGEL SC, 1994, VIROLOGY, V202, P315, DOI 10.1006/viro.1994.1348; CARRIERE C, 1995, J VIROL, V69, P2366; CHAABIHI H, 1994, BIOCHEM BIOPH RES CO, V203, P734, DOI 10.1006/bbrc.1994.2243; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELCHAMBRE M, 1989, EMBO J, V8, P2653, DOI 10.1002/j.1460-2075.1989.tb08405.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARNIER L, 1995, J VIROL, V69, P4060, DOI 10.1128/JVI.69.7.4060-4068.1995; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; Gimpl G, 1996, EUR J BIOCHEM, V237, P768, DOI 10.1111/j.1432-1033.1996.0768p.x; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; KNUDSON DL, 1974, J VIROL, V14, P934, DOI 10.1128/JVI.14.4.934-944.1974; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KUSUI T, 1995, BIOCHEMISTRY-US, V34, P8061, DOI 10.1021/bi00025a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; MILLER LK, 1996, INSECT VIRUSES, V1, P533; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NEBIGIL CG, 1995, BIOCHEMISTRY-US, V34, P11954, DOI 10.1021/bi00037a037; NG GY, 1994, EUR J PHARM-MOLEC PH, V287, P7; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PARKER EM, 1991, J BIOL CHEM, V266, P519; PUDDINGTON L, 1985, J BIOL CHEM, V260, P5641; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RAVET V, 1993, J RECEPTOR RES, V13, P541, DOI 10.3109/10799899309073678; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Roy P, 1996, CURR OPIN STRUC BIOL, V6, P157, DOI 10.1016/S0959-440X(96)80069-8; ROYER M, 1992, J VIROL, V66, P3230, DOI 10.1128/JVI.66.5.3230-3235.1992; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; THOMSEN DR, 1992, J GEN VIROL, V73, P1819, DOI 10.1099/0022-1317-73-7-1819	39	65	79	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1300	1304		10.1038/nbt1197-1300	http://dx.doi.org/10.1038/nbt1197-1300			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359116				2022-12-25	WOS:000071342000035
J	Skobe, M; Rockwell, P; Goldstein, N; Vosseler, S; Fusenig, NE				Skobe, M; Rockwell, P; Goldstein, N; Vosseler, S; Fusenig, NE			Halting angiogenesis suppresses carcinoma cell invasion	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TUMOR-GROWTH; IN-VIVO; MALIGNANT PROGRESSION; TRANSGENIC MICE; HUMAN SKIN; EXPRESSION; TUMORIGENESIS; METASTASIS	The importance of angiogenesis in malignant tumor growth has been interpreted mainly in terms of oxygen and nutrient supply. Here we demonstrate its fundamental role for tumor invasion of malignant human keratinocytes in surface transplants on nude mice. Distinct patterns of angiogenesis and vascular endothelial growth factor receptor-2 (VECFR-2) expression allowed us to distinguish between benign and malignant cells. Functional inactivation of VEGF-RZ by a blocking antibody disrupted ongoing angiogenesis and prevented invasion of malignant cells, without reducing tumor cell proliferation. The reversion of a malignant into a benign phenotype by halting angiogenesis demonstrates a significant function of vascular endothelium for tumor invasion.	DEUTSCH KREBSFORSCHUNGSZENTRUM,GERMAN CANC RES CTR,DIV CARINOGENESIS & DIFFERENTIAT,D-69120 HEIDELBERG,GERMANY; IMCLONE SYST INC,DEPT IMMUNOL,NEW YORK,NY 10014	Helmholtz Association; German Cancer Research Center (DKFZ); Eli Lilly								ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1995, ONCOGENE, V11, P961; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREITKREUTZ D, 1991, CANCER RES, V51, P4402; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; Claffey KP, 1996, CANCER RES, V56, P172; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FUSENIG NE, 1991, ORAL CANC, P218; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Larcher F, 1996, CANCER RES, V56, P5391; LIOTTA LA, 1974, CANCER RES, V34, P997; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; NICOSIA RF, 1986, CLIN EXP METASTAS, V4, P91, DOI 10.1007/BF00119076; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; Relf M, 1997, CANCER RES, V57, P963; Rockwell Patricia, 1995, Molecular and Cellular Differentiation, V3, P91; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Terman BI, 1996, CANCER METAST REV, V15, P159, DOI 10.1007/BF00437468; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1995, AM J PATHOL, V147, P9; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	40	387	404	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1222	1227		10.1038/nm1197-1222	http://dx.doi.org/10.1038/nm1197-1222			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359696				2022-12-25	WOS:A1997YD89600030
J	Sanberg, PR; Borlongan, CV; Othberg, AI; Saporta, S; Freeman, TB; Cameron, DF				Sanberg, PR; Borlongan, CV; Othberg, AI; Saporta, S; Freeman, TB; Cameron, DF			Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats	NATURE MEDICINE			English	Article							NEUROTROPHIC FACTOR GDNF; PARKINSONS-DISEASE; TRANSPLANTATION; SURVIVAL; MODEL	Neural tissue transplantation has become an alternative treatment for Parkinson's disease (PD)(1.2) and other neurodegenerative disorders. The clinical use of neural grafts as a source of dopamine for Parkinson's disease patients, although beneficial, is associated with logistical and ethical issues. Thus, alternative graft sources have been explored including polymer-encapsulated cells and nonneural cells (that is, adrenal chromaffin cells) or genetically modified cells that secrete dopamine and/or trophic factors(3-5). Although progress has been made, no current alternative graft source has ideal characteristics for transplantation. Emerging evidence suggests the importance of trophic factors in enhancing survival and regeneration of intrinsic dopaminergic neurons(6). It would be desirable to transplant cells that are readily available, immunologically accepted by the central nervous system and capable of producing dopamine and/or trophic factors. Sertoli cells have been shown to secrete CD-95 ligand(7) and regulatory proteins(8), as well as trophic, tropic, and immunosuppressive factors(9,10) that provide the testis, in part, with its ''immunoprivileged'' status, The present study demonstrated that transplantation of rat testis-derived Sertoli cells into adult rat brains ameliorated behavioral deficits in rats with 6-hydroxydopamine-induced hemiparkinsonism. This was associated with enhanced tyrosine hydroxylase (TH) immunoreactivity in the striatum in the area around the transplanted Sertoli cells. Furthermore, in vitro experiments demonstrated enhanced dopaminergic neuronal survival and outgrowth when embryonic neurons were cultured with medium in which rat Sertoli cells had been grown. Transplantation of Sertoli cells may provide a useful alternative treatment for PD and other neurodegenerative disorders.	UNIV S FLORIDA,COLL MED,PROGRAM NEUROSCI,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT SURG,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT NEUROL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT PSYCHIAT,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT PHARMACOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT ANAT,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sanberg, PR (corresponding author), UNIV S FLORIDA,COLL MED,DIV NEUROL SURG,MDC BOX 16,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.		Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782				APPEL SH, 1993, EXP NEUROL, V124, P100, DOI 10.1006/exnr.1993.1180; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; CHOILUNDBERG DL, 1995, DEV BRAIN RES, V85, P80, DOI 10.1016/0165-3806(94)00197-8; Emerich D F, 1992, Cell Transplant, V1, P401; EMERICH DF, 1992, NEUROSCI BIOBEHAV R, V16, P437, DOI 10.1016/S0149-7634(05)80185-X; HUDSON JL, 1993, BRAIN RES, V626, P167, DOI 10.1016/0006-8993(93)90576-9; KAWAJA MD, 1992, J COMP NEUROL, V317, P102, DOI 10.1002/cne.903170108; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDVALL O, 1987, ANN NEUROL, V22, P457, DOI 10.1002/ana.410220403; MIAO N, 1996, CELL TRANSPLANT, V55, P17; OTHBERG A, 1995, EXP BRAIN RES, V105, P111; Sanberg PR, 1996, NAT BIOTECHNOL, V14, P1692, DOI 10.1038/nbt1296-1692; Sanberg PR, 1997, CELL TRANSPLANT, V6, P191, DOI 10.1016/S0963-6897(96)00257-6; SELAWRY HP, 1993, CELL TRANSPLANT, V2, P123, DOI 10.1177/096368979300200206; SKINNER MK, 1993, SERTOLI CELL, P237; TAKAYAMA H, 1995, NAT MED, V1, P53, DOI 10.1038/nm0195-53; ZURN AD, 1994, NEUROREPORT, V6, P113, DOI 10.1097/00001756-199412300-00030	20	84	94	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1129	1132		10.1038/nm1097-1129	http://dx.doi.org/10.1038/nm1097-1129			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334725				2022-12-25	WOS:A1997XZ28700039
J	Woodward, J; Mattingly, SM; Danson, M; Hough, D; Ward, N; Adams, M				Woodward, J; Mattingly, SM; Danson, M; Hough, D; Ward, N; Adams, M			In vitro hydrogen production by glucose dehydrogenase and hydrogenase	NATURE BIOTECHNOLOGY			English	Article						glucose dehydrogenase; hydrogenase; hydrogen production; gluconic acid	ARCHAEBACTERIUM	A new in vitro enzymatic pathway for the generation of molecular hydrogen from glucose has been demonstrated. The reaction is based on the oxidation of glucose by Thermoplasma acidophilum glucose dehydrogenase with the concomitant oxidation of NADPH by Pyrococcus furiosus hydrogenase. Stoichiometric yields of hydrogen were produced from glucose with the continuous recycling of cofactor. This simple system may provide a method for the biological production of hydrogen from renewable sources. In addition, the other product of this reaction, gluconic acid, is a high-value chemical commodity.	UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University of Bath; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Woodward, J (corresponding author), OAK RIDGE NATL LAB,DIV CHEM TECHNOL,OAK RIDGE,TN 37831, USA.			Adams, Michael/0000-0002-9796-5014				ADAMS M, UNPUB; BRIGHT JR, 1993, EUR J BIOCHEM, V211, P549, DOI 10.1111/j.1432-1033.1993.tb17581.x; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; Danson M J, 1993, BIOCH ARCHAEA ARCHAE, P1; EGERER P, 1982, BIOCHIM BIOPHYS ACTA, V703, P149, DOI 10.1016/0167-4838(82)90043-7; GREENBAUM E, 1984, PHOTOBIOCH PHOTOBIOP, V8, P323; GREENBAUM E, 1980, BIOTECHNOL BIOENG S, V10, P1; HARRISON DC, 1931, BIOCHEM J, V26, P1016; JOHN J, 1994, STRUCTURE, V2, P385, DOI 10.1016/S0969-2126(00)00040-X; Kitani O, 1989, BIOMASS HDB; LAWLER A, 1995, SCIENCE, V267, P613, DOI 10.1126/science.267.5198.613; LEE JW, 1995, APPL BIOCHEM BIOTECH, V51-2, P295, DOI 10.1007/BF02933433; LEPKOWSKI W, 1995, CHEM ENG NEWS, V73, P26, DOI 10.1021/cen-v073n020.p026; MA KS, 1994, FEMS MICROBIOL LETT, V122, P245, DOI 10.1016/0378-1097(94)00330-0; PAULY HE, 1977, BIOCHEMISTRY-US, V16, P4599, DOI 10.1021/bi00640a011; PEDRONI P, 1995, MICROBIOL-UK, V141, P449, DOI 10.1099/13500872-141-2-449; *PMP FERM PROD INC, 1994, SOD GLUC HDB; SMITH LD, 1989, BIOCHEM J, V261, P973, DOI 10.1042/bj2610973; TAGUCHI F, 1995, ENZYME MICROB TECH, V17, P147, DOI 10.1016/0141-0229(94)00058-Y; TRANULIS MA, 1994, COMP BIOCHEM PHYS B, V109, P427, DOI 10.1016/0305-0491(94)90025-6; WALKER LP, 1991, ENZYMATIC HYDROLYSIS; WOODWARD J, 1994, BIO-TECHNOL, V12, P905, DOI 10.1038/nbt0994-905	22	67	78	3	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1996	14	7					872	874		10.1038/nbt0796-872	http://dx.doi.org/10.1038/nbt0796-872			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UV620	9631013	Green Submitted			2022-12-25	WOS:A1996UV62000038
J	Matsuura, S; Tauchi, H; Nakamura, A; Kondo, N; Sakamoto, S; Endo, S; Smeets, D; Solder, B; Belohradsky, BH; Kaloustian, VMD; Oshimura, M; Isomura, M; Nakamura, Y; Komatsu, K				Matsuura, S; Tauchi, H; Nakamura, A; Kondo, N; Sakamoto, S; Endo, S; Smeets, D; Solder, B; Belohradsky, BH; Kaloustian, VMD; Oshimura, M; Isomura, M; Nakamura, Y; Komatsu, K			Positional cloning of the gene for Nijmegen breakage syndrome	NATURE GENETICS			English	Article							CHROMOSOMAL INSTABILITY; KINASE; SITES; YEAST	Nijmegen breakage syndrome (NBS), also known as ataxia-telangiectasia (AT) variant, is an autosomal recessive disorder characterized by microcephaly, growth retardation, severe combined immunodeficiency and a high incidence of lymphoid cancers. Cells from NBS patients display chromosome instability, hypersensitivity to ionizing radiation and abnormal cell-cycle regulation after irradiation, all of which are characteristics shared with AT. Recently, the NBS locus was mapped at 8q21 by two independent approaches, complementation studies(1) and linkage analysis(2). Here, we report the positional cloning of the NBS gene, NBS1, from an 800-kb candidate region. The gene comprises 50 kb and encodes a protein of 754 amino acids. The amino-terminal region of the protein shows weak homology to the yeast XRS2, MEK1, CDS1 and SPK1 proteins. The gene is expressed at high levels in the testes, suggesting that it might be involved in meiotic recombination. We detected the same 5-bp deletion in 13 individuals, and conclude that it is likely to be a founder mutation.	Hiroshima Univ, Dept Radiat Biol, Res Inst Radiat Biol & Med, Hiroshima, Japan; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; Tottori Univ, Sch Life Sci, Dept Mol & Cell Genet, Tottori 680, Japan; Univ Tokyo, Inst Med Sci, Mol Med Lab, Tokyo, Japan	Hiroshima University; Radboud University Nijmegen; University of Munich; McGill University; Tottori University; University of Tokyo	Komatsu, K (corresponding author), Hiroshima Univ, Dept Radiat Biol, Res Inst Radiat Biol & Med, Hiroshima, Japan.	komatsu@ipc.hiroshima-u.ac.jp	Endo, Satoru/D-9091-2012; Matsuura, Shinya/U-4182-2017	Endo, Satoru/0000-0001-5961-681X; Matsuura, Shinya/0000-0001-5294-081X; Sakamoto, Shuichi/0000-0001-9396-9475				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Helander HM, 1997, GENOMICS, V46, P112, DOI 10.1006/geno.1997.5004; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; JASPERS NGJ, 1988, AM J HUM GENET, V42, P66; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; Matsuura S, 1997, AM J HUM GENET, V60, P1487, DOI 10.1086/515461; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PARMENTIER M, 1987, EUR J BIOCHEM, V170, P207, DOI 10.1111/j.1432-1033.1987.tb13688.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROCKMILL B, 1991, GENE DEV, V5, P2392, DOI 10.1101/gad.5.12b.2392; Saar K, 1997, AM J HUM GENET, V60, P605; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SOLOVYEV VV, 1994, 2 INT C INT SYST MOL, P354; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xu Y, 1994, Genet Eng (N Y), V16, P241	22	241	249	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					179	181		10.1038/549	http://dx.doi.org/10.1038/549			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620777				2022-12-25	WOS:000073865100028
J	Fu, DJ; Tang, K; Braun, A; Reuter, D; Darnhofer-Demar, B; Little, DP; O'Donnell, MJ; Cantor, CR; Koster, H				Fu, DJ; Tang, K; Braun, A; Reuter, D; Darnhofer-Demar, B; Little, DP; O'Donnell, MJ; Cantor, CR; Koster, H			Sequencing exons 5 to 8 of the p53 gene by MALDI-TOF mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						genomics; DNA analysis; gene mutation	CHAIN-REACTION PRODUCTS; DESORPTION IONIZATION; POINT MUTATION; MATRIX; DNA; OLIGONUCLEOTIDES; POLYMORPHISM; RESOLUTION	Matrix-assisted laser desorption ionization time of flight mass spectrometry was used to sequence exons 5 to 8 of the human p53 gene. A single tube procedure was established for target amplification and mass spectrometric (MS) sequencing. The MS sequencing scheme is designed for high throughput and parallel sample processing, and is amenable to full automation. Reliable sequencing data were obtained using fmol sample amounts. The high resolution and accuracy of MS sequencing was demonstrated by direct sequencing of a heterozygous template.	Sequenom Inc, San Diego, CA 92121 USA; Boston Univ, Ctr Adv Biotechnol, Boston, MA 02215 USA	Sequenom; Boston University	Fu, DJ (corresponding author), Sequenom Inc, San Diego, CA 92121 USA.	dongjing@sequenom-san.com	Tang, Kai/A-2194-2011					Braun A, 1996, HUM GENET, V97, P688; Braun A, 1997, CLIN CHEM, V43, P1151; COLBY SM, 1994, RAPID COMMUN MASS SP, V8, P865, DOI 10.1002/rcm.1290081102; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; Fu DJ, 1996, GENET ANAL-BIOMOL E, V12, P137, DOI 10.1016/S1050-3862(96)80014-3; GOH HS, 1995, CANCER RES, V55, P5217; Haff LA, 1997, GENOME RES, V7, P378, DOI 10.1101/gr.7.4.378; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Higgins GS, 1997, BIOTECHNIQUES, V23, P710, DOI 10.2144/97234st05; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Hurst GB, 1996, RAPID COMMUN MASS SP, V10, P377, DOI 10.1002/(SICI)1097-0231(199602)10:3<377::AID-RCM481>3.0.CO;2-X; Jurinke C, 1996, GENET ANAL-BIOMOL E, V13, P67, DOI 10.1016/1050-3862(95)00151-4; Jurinke C, 1996, ANAL BIOCHEM, V237, P174, DOI 10.1006/abio.1996.0225; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Koster H, 1996, NAT BIOTECHNOL, V14, P1123, DOI 10.1038/nbt0996-1123; Little DP, 1997, EUR J CLIN CHEM CLIN, V35, P545; Little DP, 1997, ANAL CHEM, V69, P4540, DOI 10.1021/ac970758+; Little DP, 1997, J MOL MED-JMM, V75, P745, DOI 10.1007/s001090050160; LIU YH, 1995, RAPID COMMUN MASS SP, V9, P735, DOI 10.1002/rcm.1290090905; Monforte JA, 1997, NAT MED, V3, P360, DOI 10.1038/nm0397-360; Mouradian S, 1996, RAPID COMMUN MASS SP, V10, P1475; NELSON RW, 1990, RAPID COMMUN MASS SP, V4, P348, DOI 10.1002/rcm.1290040911; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; Roskey MT, 1996, P NATL ACAD SCI USA, V93, P4724, DOI 10.1073/pnas.93.10.4724; Sidransky D, 1996, ANNU REV MED, V47, P285; SINHA ND, 1983, TETRAHEDRON LETT, V24, P5843, DOI 10.1016/S0040-4039(00)94216-3; Smirnov IP, 1996, ANAL BIOCHEM, V238, P19, DOI 10.1006/abio.1996.0243; SPENGLER B, 1990, RAPID COMMUN MASS SP, V4, P99, DOI 10.1002/rcm.1290040402; TANG K, 1994, RAPID COMMUN MASS SP, V8, P727, DOI 10.1002/rcm.1290080913; Taranenko NI, 1996, GENET ANAL-BIOMOL E, V13, P87, DOI 10.1016/S1050-3862(95)00154-9; VESTAL ML, 1995, RAPID COMMUN MASS SP, V9, P1044, DOI 10.1002/rcm.1290091115; WHITTAL RM, 1995, ANAL CHEM, V67, P1950, DOI 10.1021/ac00109a007; WU KJ, 1993, RAPID COMMUN MASS SP, V7, P142, DOI 10.1002/rcm.1290070206	33	106	133	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					381	384		10.1038/nbt0498-381	http://dx.doi.org/10.1038/nbt0498-381			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555731				2022-12-25	WOS:000072786200032
J	Margolis, J; Duyk, G				Margolis, J; Duyk, G			The emerging role of the genomics revolution in agricultural biotechnology	NATURE BIOTECHNOLOGY			English	Editorial Material									Exelixis Pharmaceut Inc, S San Francisco, CA 94080 USA	Exelixis, Inc.	Margolis, J (corresponding author), Exelixis Pharmaceut Inc, S San Francisco, CA 94080 USA.	duyk@exelixis.com						Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; HOPKINS WL, 1996, GLOBAL INSECTICIDE	2	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1998	16	4					311	311		10.1038/nbt0498-311	http://dx.doi.org/10.1038/nbt0498-311			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZE374	9555711	Bronze			2022-12-25	WOS:000072786200004
J	Pantaleo, G; Cohen, OJ; Schacker, T; Vaccarezza, M; Graziosi, C; Rizzardi, GP; Kahn, J; Fox, CH; Schnittman, SM; Schwartz, DH; Corey, L; Fauci, AS				Pantaleo, G; Cohen, OJ; Schacker, T; Vaccarezza, M; Graziosi, C; Rizzardi, GP; Kahn, J; Fox, CH; Schnittman, SM; Schwartz, DH; Corey, L; Fauci, AS			Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy	NATURE MEDICINE			English	Article							TYPE-1; PLASMA; DISEASE; TISSUE; CELLS; AIDS; RESERVOIRS; MACAQUES; VIREMIA; ORGANS	Evolutionary patterns of virus replication and distribution in lymphoid tissue during the early phases of HIV infection have not been delineated. Lymph node (LN) biopsies were excised from patients at different times after the estimated time of primary infection. Within 3 months of the acute viral syndrome, HIV was mostly present in individual virus-expressing cells in LNs; trapping of virions in the follicular dendritic cell (FDC) network was minimal or absent, but was the predominant form of HIV detected in LNs of subjects with chronic infection, either recent (4-20 months after primary infection) or long-term (>2-3 years after primary infection). Plasma viremia was significantly higher in patients during the first 3 months than in those recently infected; however, there were no significant differences in the number of virus-expressing cells per square millimeter of LN tissue in these two groups. Numbers of virus-expressing cells in lymphoid tissue were significantly lower in the subjects with long-term infection than in the other two groups. Therefore, during the transition from primary to chronic HIV infection, the level of HIV replication in lymphoid tissue remains elevated despite the fact that viremia is significantly downregulated These findings have implications for therapeutic strategies in primary HIV infection and in recent seroconvertors.	CHU Vaudois, Lab AIDS Immunopathogenesis, Dept Med, Div Infect Dis, CH-1011 Lausanne, Switzerland; NIAID, Lab Immunoregulat, Bethesda, MD 20892 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Sch Med, San Francisco, CA 94110 USA; Mol Histol Inc, Gaithersburg, MD 20879 USA; NIAID, Div Aids, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Univ Washington, Virol Res Clin, Seattle, WA 98104 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; University of Washington; University of Washington Seattle	Pantaleo, G (corresponding author), CHU Vaudois, Lab AIDS Immunopathogenesis, Dept Med, Div Infect Dis, CH-1011 Lausanne, Switzerland.		Pantaleo, Giuseppe/K-6163-2016; VACCAREZZA, Mauro/S-9637-2019; Corey, Lawrence/AAE-1796-2020; graziosi, cecilia/M-1882-2019	Corey, Lawrence/0000-0002-2179-2436; VACCAREZZA, Mauro/0000-0003-3060-318X				ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; CHAKRABARTI L, 1994, AM J PATHOL, V144, P1226; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; Cohen OJ, 1996, J INFECT DIS, V173, P849, DOI 10.1093/infdis/173.4.849; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Martin LN, 1997, J INFECT DIS, V176, P374, DOI 10.1086/514054; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; SPIEGEL H, 1992, AM J PATHOL, V140, P15; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TENNERRACZ K, 1985, LANCET, V1, P105	23	106	106	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					341	345		10.1038/nm0398-341	http://dx.doi.org/10.1038/nm0398-341			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500610				2022-12-25	WOS:000073616200042
J	Brais, B; Bouchard, JP; Xie, YG; Rochefort, DL; Chretien, N; Tome, FMS; Lafreniere, RG; Rommens, JM; Uyama, E; Nohira, O; Blumen, S; Korcyn, AD; Heutink, P; Mathieu, J; Duranceau, A; Codere, F; Fardeau, M; Rouleau, GA				Brais, B; Bouchard, JP; Xie, YG; Rochefort, DL; Chretien, N; Tome, FMS; Lafreniere, RG; Rommens, JM; Uyama, E; Nohira, O; Blumen, S; Korcyn, AD; Heutink, P; Mathieu, J; Duranceau, A; Codere, F; Fardeau, M; Rouleau, GA			Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy	NATURE GENETICS			English	Article							MESSENGER-RNA POLYADENYLATION; TRIPLET REPEATS; PROTEIN-II; MUTATIONS; FAMILIES; BINDING; DISEASE; HOXD13	Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disease with a world-wide distribution(1). It usually presents in the sixth decade with progressive swallowing difficulties (dysphagia), eyelid drooping (ptosis) and proximal limb weakness, Unique nuclear filament inclusions in skeletal muscle fibres are its pathological hallmark(2). We isolated the poly(A) binding protein 2 gene (PABP2) from a 217-kb candidate interval on chromosome 14q11 (B.B. et al., manuscript submitted). A (GCG)(6) repeat encoding a polyalanine tract located at the N terminus of the protein was expanded to (GCG)(8-13) in the 144 OPMD families screened, More severe phenotypes were observed in compound heterozygotes for the (GCG)(9) mutation and a (GCG)(7) allele that is found in 2% of the population, whereas homozygosity for the (GCG)(7) allele leads to autosomal recessive OPMD. Thus the (GCG)(7) allele is an example of a polymorphism which can act either as a modifier of a dominant phenotype or as a recessive mutation. Pathological expansions of the polyalanine tract may cause mutated PABP2 oligomers to accumulate as filament inclusions in nuclei.	McGill Univ, Montreal Gen Hosp, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Hop Enfants Jesus, Dept Neurol Sci, Quebec City, PQ G1J 1Z4, Canada; Hop La Pitie Salpetriere, Inst Myol, INSERM U153, F-75013 Paris, France; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Kumamoto Univ, Sch Med, Dept Neurol, Kumamoto 860, Japan; Shizuoka Red Cross Hosp, Dept Neurol, Shizuoka, Japan; Hillel Yaffe Med Ctr, Dept Neurol, Hadera, Israel; Sackler Sch Med, Dept Neurol, IL-69978 Ramat Aviv, Israel; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Hop Chicoutimi, Chicoutimi, PQ G7H 5H6, Canada; Univ Montreal, Ctr Hosp, Montreal, PQ H2W 1T8, Canada; McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada	McGill University; Laval University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Kumamoto University; Tel Aviv University; Sackler Faculty of Medicine; Erasmus University Rotterdam; Universite de Montreal; McGill University; Royal Victoria Hospital	Rouleau, GA (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Res Neurosci, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	mi32@musica.mcgill.ca	Korczyn, Amos D/C-3461-2017; Brais, Bernard/Y-3910-2019	Korczyn, Amos D/0000-0003-0125-2579; Heutink, Peter/0000-0001-5218-1737				Akarsu AN, 1996, HUM MOL GENET, V5, P945, DOI 10.1093/hmg/5.7.945; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BLUMEN SC, 1993, NEUROMUSCULAR DISORD, V3, P575, DOI 10.1016/0960-8966(93)90119-5; Bouchard JP, 1992, CAN J NEUROL SCI, V19, P296; BRAIS B, 1995, HUM MOL GENET, V4, P429, DOI 10.1093/hmg/4.3.429; BRUNET G, 1990, REV NEUROL, V146, P425; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; FOROOD B, 1995, BIOCHEM BIOPH RES CO, V211, P7, DOI 10.1006/bbrc.1995.1770; GREEN H, 1993, CELL, V74, P955, DOI 10.1016/0092-8674(93)90718-6; KRAUSE S, 1994, EXP CELL RES, V214, P75, DOI 10.1006/excr.1994.1235; Lafreniere RG, 1997, NAT GENET, V15, P298, DOI 10.1038/ng0397-298; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; ROMMENS JM, 1994, P 3 INT WORKSH ID TR, P65; Rosenberg RN, 1996, NEW ENGL J MED, V335, P1222, DOI 10.1056/NEJM199610173351609; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Tome F, 1994, MYOLOGY, P1233; TOME FMS, 1980, ACTA NEUROPATHOL, V49, P85, DOI 10.1007/BF00692226; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; Warren ST, 1997, SCIENCE, V275, P408, DOI 10.1126/science.275.5298.408; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875	30	577	605	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1998	18	2					164	167		10.1038/ng0298-164	http://dx.doi.org/10.1038/ng0298-164			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462747	Green Published			2022-12-25	WOS:000071779500026
J	Meyers, EN; Lewandoski, M; Martin, GR				Meyers, EN; Lewandoski, M; Martin, GR			An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination	NATURE GENETICS			English	Article							TARGETED MUTATION; VERTEBRATE LIMB; NERVOUS-SYSTEM; GENE; MOUSE; DELETION; MICE; INITIATION; OUTGROWTH; EMBRYO	We describe a strategy for generating an allelic series of mutations at a given locus that requires the production of only one targetted mouse line. The 'allelogenic' mouse line we produced carries a hypomorphic allele of Fgf8, which can be converted to a null allele by mating to cre transgenic animals. The hypomorphic allele can also be reverted to wild-type by mating the allelogenic mice to flp transgenic animals, thereby generating a mouse line suitable for Cre-induced tissue-specific knockout experiments. Analysis of embryos carrying different combinations of these alleles revealed requirements for Fgf8 gene function during gastrulation, as well as cardiac, craniofacial, forebrain, midbrain and cerebellar development.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Martin, GR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.			Lewandoski, Mark/0000-0002-1066-3735				BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; GRAZIADEI PPC, 1992, NEUROSCIENCE, V46, P617, DOI 10.1016/0306-4522(92)90149-V; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LEWANDOSKI M, IN PRESS COLD SPRING; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MAGIN TM, 1992, NUCLEIC ACIDS RES, V14, P379; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Nagy A., 1993, Gene targeting: a practical approach., P147; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; PUELLES L, 1996, MAMMALIAN DEV, P173; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Vogel A, 1996, DEVELOPMENT, V122, P1737; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; Wurst W., 1993, Gene targeting: a practical approach., P33	39	838	862	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1998	18	2					136	141		10.1038/ng0298-136	http://dx.doi.org/10.1038/ng0298-136			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YV010	9462741				2022-12-25	WOS:000071779500020
J	Goldfine, ID; German, MS; Tseng, HC; Wang, JM; Bolaffi, JL; Chen, JW; Olson, DC; Rothman, SS				Goldfine, ID; German, MS; Tseng, HC; Wang, JM; Bolaffi, JL; Chen, JW; Olson, DC; Rothman, SS			The endocrine secretion of human insulin and growth hormone by exocrine glands of the gastrointestinal tract	NATURE BIOTECHNOLOGY			English	Article						gene therapy; diabetes; protein delivery	GENE-TRANSFER; IN-VIVO; EXPRESSION; THERAPY	The exocrine pancreas, liver, and submandibular glands of the rat were used to express and secrete two exogenous, human protein hormones (growth hormone and insulin) into blood at physiological concentrations. Transfection, expression, and secretion were achieved by the in vivo retrograde injection of plasmid DNA into the secretory ducts of these glands. Pancreatic acinar cells secreted physiological concentrations of growth hormone into the circulation, and its secretion was enhanced by cholinergic stimulation. A human insulin gene was engineered to allow normal processing of insulin in non-beta cells. With this gene, the secretion of human insulin by the exocrine pancreas normalized elevated blood glucose levels in diabetic rats. These in vivo observations demonstrate the utility of retrograde ductal administration of naked DNA into exocrine organs as a novel method for the regulated systemic delivery of protein-based pharmaceuticals.	UNIV CALIF SAN FRANCISCO,SCH DENT,SAN FRANCISCO,CA; GENTER CORP,BERKELEY,CA	University of California System; University of California San Francisco	Goldfine, ID (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [1F32CA69714-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA069714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adesanya MR, 1996, HUM GENE THER, V7, P1085, DOI 10.1089/hum.1996.7.9-1085; Barka T, 1996, HUM GENE THER, V7, P613, DOI 10.1089/hum.1996.7.5-613; Buckel P, 1996, TRENDS PHARMACOL SCI, V17, P450, DOI 10.1016/S0165-6147(96)01011-5; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Friedmann T, 1996, NAT MED, V2, P144, DOI 10.1038/nm0296-144; GEOKAS MC, 1980, AM J PHYSIOL, V238, P238; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GRENDELL JH, 1982, AM J PHYSIOL, V243, P54; Hahn TM, 1996, ENDOCRINOLOGY, V137, P4988, DOI 10.1210/en.137.11.4988; ISENMAN LD, 1977, P NATL ACAD SCI USA, V74, P4068, DOI 10.1073/pnas.74.9.4068; Kagami H, 1996, HUM GENE THER, V7, P2177, DOI 10.1089/hum.1996.7.17-2177; KOLODKA TM, 1995, P NATL ACAD SCI USA, V92, P3293, DOI 10.1073/pnas.92.8.3293; LEVER AM, 1995, GENE THER, P1; LIEBOW C, 1988, PANCREAS, V3, P343, DOI 10.1097/00006676-198805000-00017; MASTRANGELI A, 1994, AM J PHYSIOL, V266, pG1146, DOI 10.1152/ajpgi.1994.266.6.G1146; MELESE T, 1983, P NATL ACAD SCI-BIOL, V80, P4870, DOI 10.1073/pnas.80.15.4870; MELESE T, 1983, BIOCHIM BIOPHYS ACTA, V763, P212, DOI 10.1016/0167-4889(83)90047-2; MIYASAKA K, 1981, AM J PHYSIOL, V241, P170; NIEDERAU C, 1985, AM J PHYSIOL, V249, P100; OCONNELL BC, 1995, AM J PHYSIOL-GASTR L, V268, pG1074, DOI 10.1152/ajpgi.1995.268.6.G1074; OConnell BC, 1996, HUM GENE THER, V7, P2255, DOI 10.1089/hum.1996.7.18-2255; PAPP M, 1980, ACTA PHYSIOL HUNG, V56, P401; Raper SE, 1996, PANCREAS, V12, P401, DOI 10.1097/00006676-199605000-00013; ROTHMAN SS, 1989, HDB PHYSL 6, V3, P465; SAITO A, 1973, JPN J PHYSIOL, V23, P477; Schneider SW, 1997, P NATL ACAD SCI USA, V94, P316, DOI 10.1073/pnas.94.1.316	26	79	89	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1378	1382		10.1038/nbt1297-1378	http://dx.doi.org/10.1038/nbt1297-1378			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415890				2022-12-25	WOS:A1997YK36100029
J	May, WA; Arvand, A; Thompson, AD; Braun, BS; Wright, M; Denny, CT				May, WA; Arvand, A; Thompson, AD; Braun, BS; Wright, M; Denny, CT			EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic	NATURE GENETICS			English	Article							REPRESENTATIONAL DIFFERENCE ANALYSIS; EWS/FLI-1 FUSION GENE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; EWING SARCOMA; NOTCH GENE; TRANSLOCATION; PROTEIN; TUMORS; TRANSFORMATION	EWS/FLI1, a fusion gene found in Ewing's sarcoma, encodes a transcriptional regulator and promotes cellular transformation by modulating the transcription of specific target genes, We have found that EWS/FLI1 and structurally related fusion proteins upregulate manic fringe (MFNG), a recently described member of the Fringe gene family instrumental in somatic development, MFNG is also expressed in human tumour-derived cell lines expressing EWS/FLI1. Overexpression of MFNG in NIH 3T3 cells renders them tumorigenic in mice with severe combined immunodeficiency disease (SCID), These data demonstrate that part of the oncogenic effect of EWS/FLI1 is to transcriptionally deregulate a member of a family of morphogenic genes.	UNIV CALIF LOS ANGELES,MED CTR,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,MED CTR,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,MED CTR,GWYNNE HAZEN MEM LABS,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90095; UNIV ALABAMA,SCH MED,DEPT PEDIAT,BIRMINGHAM,AL; UNIV ALABAMA,SCH MED,CTR COMPREHENS CANC,BIRMINGHAM,AL; UNIV CALIF LOS ANGELES,MED CTR,DEPT EXPT PATHOL LAB MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL CANCER INSTITUTE [P01CA032737, P30CA013148] Funding Source: NIH RePORTER; NCI NIH HHS [CA32737, CA13148] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BONIN G, 1993, CANCER RES, V53, P3655; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DORIT RL, 1993, MOL BIOL, V2; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; Look AT, 1995, ADV CANCER RES, V67, P25, DOI 10.1016/S0065-230X(08)60709-5; MAO X, 1994, J BIOL CHEM, V269, P17216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5859; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; SORENSEN PHB, 1993, DIAGN MOL PATHOL, V2, P147, DOI 10.1097/00019606-199309000-00002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Thompson AD, 1996, ONCOGENE, V13, P2649; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	29	132	141	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					495	497		10.1038/ng1297-495	http://dx.doi.org/10.1038/ng1297-495			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398859				2022-12-25	WOS:A1997YJ92400038
J	Wodicka, L; Dong, HL; Mittmann, M; Ho, MH; Lockhart, DJ				Wodicka, L; Dong, HL; Mittmann, M; Ho, MH; Lockhart, DJ			Genome-wide expression monitoring in Saccharomyces cerevisiae	NATURE BIOTECHNOLOGY			English	Article						functional genomics; combinatorial synthesis; oligonucleotide arrays; gene expression; mRNA abundance	DIFFERENTIAL GENE-EXPRESSION; ALPHA-FACTOR; QUANTITATIVE HYBRIDIZATION; OLIGONUCLEOTIDE ARRAYS; 2-DIMENSIONAL GELS; FACTOR PHEROMONE; DNA MICROARRAY; YEAST PROTEINS; MESSENGER-RNA; SEQUENCE	The genomic sequence of the budding yeast Saccharomyces cerevisiae has been used to design and synthesize high-density oligonucleotide arrays for monitoring the expression levels of nearly all yeast genes. This direct and highly parallel approach involves the hybridization of total mRNA populations to a set of four arrays that contain a total of more than 260,000 specifically chosen oligonucleotides synthesized in situ using light-directed combinatorial chemistry. The measurements are quantitative, sensitive, specific, and reproducible. Expression levels ranging from less than 0.1 copies to several hundred copies per cell have been measured for cells grown in rich and minimal media. Nearly 90% of all yeast mRNAs are observed to be present under both conditions, with approximately 50% present at levels between 0.1 and 1 copy per cell. Many of the genes observed to be differentially expressed under these conditions are expected, but large differences are also observed for many previously uncharacterized genes.	AFFYMETRIX,SANTA CLARA,CA 95051	Affymetrix								ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], 1997, NATURE, V387, pS; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; Boucherie H, 1996, ELECTROPHORESIS, V17, P1683, DOI 10.1002/elps.1150171106; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GARRELS JI, 1994, ELECTROPHORESIS, V15, P1466, DOI 10.1002/elps.11501501210; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; IVANOVA NB, 1995, NUCLEIC ACIDS RES, V23, P2954, DOI 10.1093/nar/23.15.2954; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LASHKARI D, 1997, IN PRESS P NATL ACAD; LENNON GG, 1991, TRENDS GENET, V7, P314, DOI 10.1016/0168-9525(91)90420-U; LEWIN B, 1980, GENE EXPRESSION, V2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maillet I, 1996, J BIOL CHEM, V271, P10263, DOI 10.1074/jbc.271.17.10263; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Pietu G, 1996, GENOME RES, V6, P492, DOI 10.1101/gr.6.6.492; Prashar Y, 1996, P NATL ACAD SCI USA, V93, P659, DOI 10.1073/pnas.93.2.659; Richard GF, 1997, J MOL BIOL, V268, P303, DOI 10.1006/jmbi.1997.0973; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; Sagliocco F, 1996, YEAST, V12, P1519; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SINGH A, 1983, NUCLEIC ACIDS RES, V11, P4049, DOI 10.1093/nar/11.12.4049; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; ZHAO ND, 1995, GENE, V156, P207, DOI 10.1016/0378-1119(95)00023-Y	43	804	939	0	25	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1359	1367		10.1038/nbt1297-1359	http://dx.doi.org/10.1038/nbt1297-1359			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415887				2022-12-25	WOS:A1997YK36100026
J	Deconinck, N; Tinsley, J; DeBacker, F; Fisher, R; Kahn, D; Phelps, S; Davies, K; Gillis, JM				Deconinck, N; Tinsley, J; DeBacker, F; Fisher, R; Kahn, D; Phelps, S; Davies, K; Gillis, JM			Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice	NATURE MEDICINE			English	Article							ADENOVIRUS-MEDIATED TRANSFER; DUCHENNE MUSCULAR-DYSTROPHY; TRANSGENIC MDX MICE; SKELETAL-MUSCLE; CYTOSOLIC CALCIUM; DMD PATIENTS; MOUSE; FIBERS; CONTRACTIONS; PHENOTYPE	Dystrophin-deficient mice (mdx) expressing a truncated (trc) utrophin transgene show amelioration of the dystrophic phenotype. Here we report a multifunctional study demonstrating that trc-utrophin expression leads to major improvements of the mechanical performance of muscle (that is, force development, mechanical resistance to forced lengthenings and maximal spontaneous activity) and of the maintenance of the intracellular calcium homeostasis. These are two essential functions of muscle fibers, known to be impaired in mdx mouse muscles and Duchenne muscular dystrophy (DMD) patients. Our results bring strong support to the hypothesis that muscle wasting in dystrophin-deficient DMD patients could be prevented by upregulation of utrophin.	UNIV CATHOLIQUE LOUVAIN,DEPT PHYSIOL,B-1200 BRUSSELS,BELGIUM; UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND	Universite Catholique Louvain; University of Oxford								Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BODENSTEINER JB, 1978, NEUROLOGY, V28, P439, DOI 10.1212/WNL.28.5.439; CARLSON CG, 1990, MUSCLE NERVE, V13, P480, DOI 10.1002/mus.880130603; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Deconinck N, 1996, P NATL ACAD SCI USA, V93, P3570, DOI 10.1073/pnas.93.8.3570; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWS CM, 1991, P ROY SOC B-BIOL SCI, V245, P173, DOI 10.1098/rspb.1991.0105; HEAD SI, 1993, J PHYSIOL-LONDON, V469, P11, DOI 10.1113/jphysiol.1993.sp019801; Karpati G, 1997, NAT MED, V3, P22, DOI 10.1038/nm0197-22; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCARDLE A, 1994, MUSCLE NERVE, V17, P1378, DOI 10.1002/mus.880171206; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MIZUNO Y, 1993, J NEUROL SCI, V119, P43, DOI 10.1016/0022-510X(93)90190-A; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; PRESSMAR J, 1994, PFLUG ARCH EUR J PHY, V426, P499, DOI 10.1007/BF00378527; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; SUGITA H, 1993, ACTA CARDIOMIOLOGICA, V5, P11; SUNADA Y, 1995, CURR OPIN NEUROL, V8, P379, DOI 10.1097/00019052-199510000-00010; TAKESHIMA Y, 1994, NEUROLOGY, V44, P1648, DOI 10.1212/WNL.44.9.1648; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; WEBSTER C, 1988, CELL, V52, P502; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; WINDER SJ, 1995, FEBS LETT, V357, P125, DOI 10.1016/0014-5793(94)01347-4; [No title captured]	35	199	205	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1216	1221		10.1038/nm1197-1216	http://dx.doi.org/10.1038/nm1197-1216			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359695				2022-12-25	WOS:A1997YD89600029
J	Stenbit, AE; Tsao, TS; Li, J; Burcelin, R; Geenen, DL; Factor, SM; Houseknecht, K; Katz, EB; Charron, MJ				Stenbit, AE; Tsao, TS; Li, J; Burcelin, R; Geenen, DL; Factor, SM; Houseknecht, K; Katz, EB; Charron, MJ			GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes	NATURE MEDICINE			English	Article							GLUCOSE-TRANSPORTER EXPRESSION; RAT SKELETAL-MUSCLE; PLASMA-MEMBRANE; ADIPOSE-TISSUE; ZUCKER RATS; OBESE; CELL; TRANSLOCATION; NIDDM	GLUT4, the insulin-responsive glucose transporter, plays an important role in postprandial glucose disposal. Altered GLUT I activity is suggested to be one of the factors responsible for decreased glucose uptake in muscle and adipose tissue in obesity and diabetes. To assess the effect of GLUT4 expression on whole-body glucose homeostasis, we disrupted the murine GLUT4 gene by homologous recombination. Male mice heterozygous for the mutation (GLUT4(+/-)) exhibited a decrease in GLUT4 expression in adipose tissue and skeletal muscle. This decrease in GLUT4 expression did not result in obesity but led to increased serum glucose and insulin, reduced muscle glucose uptake, hypertension, and diabetic histopathologies in the heart and liver similar to those of humans with non-insulin-dependent diabetes mellitus (NIDDM). The male GLUT4(+/-) mice represent a good model for studying the development of NIDDM without the complications associated with obesity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PATHOL, BRONX, NY 10461 USA; PURDUE UNIV, DEPT ANIM SCI, W LAFAYETTE, IN 47907 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Tsao, Tsu-Shuen/0000-0002-1041-9687	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA13330] Funding Source: Medline; NHLBI NIH HHS [HL 15498] Funding Source: Medline; NIDDK NIH HHS [DK 47425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BENNETT PH, 1991, DIABETES MELLITUS TH, P357; BONADONNA RC, 1993, DIABETES, V42, P191, DOI 10.2337/diabetes.42.1.191; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CHAN TM, 1984, BIOCHIM BIOPHYS ACTA, V798, P325, DOI 10.1016/0304-4165(84)90106-5; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CUSHMAN SW, 1978, J LIPID RES, V19, P269; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEMEYTS P, 1993, ADV EXP MED BIOL, V334, P89; FACTOR SM, 1980, AM HEART J, V99, P446, DOI 10.1016/0002-8703(80)90379-8; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HORTON ES, 1991, DIABETES MELLITUS TH, P457; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1992, J CELL BIOCHEM, V48, P122, DOI 10.1002/jcb.240480203; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; PENICAUD L, 1987, DIABETES, V36, P626, DOI 10.2337/diabetes.36.5.626; SHERMAN WM, 1988, AM J PHYSIOL, V255, pE374, DOI 10.1152/ajpendo.1988.255.3.E374; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; WRIGHT EM, 1991, J CLIN INVEST, V88, P1435, DOI 10.1172/JCI115451; WYSE BM, 1970, DIABETOLOGIA, V6, P268, DOI 10.1007/BF01212237; YORK DA, 1972, METABOLISM, V21, P277, DOI 10.1016/0026-0495(72)90070-4; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	30	258	267	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1096	1101		10.1038/nm1097-1096	http://dx.doi.org/10.1038/nm1097-1096			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334720				2022-12-25	WOS:A1997XZ28700034
J	Drolet, DW; MoonMcDermott, L; Romig, TS				Drolet, DW; MoonMcDermott, L; Romig, TS			An enzyme-linked oligonucleotide assay	NATURE BIOTECHNOLOGY			English	Article						ELISA; directed ligand evolution; VEGF; VPF	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; AFFINITY RNA LIGANDS; STRANDED-DNA MOLECULES; IN-VITRO SELECTION; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; RECEPTOR-BINDING; TUMOR-GROWTH; RECOGNITION	The recent development of in vitro methods to select high-affinity ligands by combinatorial chemistry methodologies promises unique and theoretically unlimited supplies of novel therapeutic and diagnostic reagents. One such combinatorial chemistry process, systematic evolution of ligands by exponential enrichment (SELEX), allows rapid identification, from large random sequence pools, of the few oligonucleotide sequences that bind to a desired target molecule with high affinity and specificity. We describe an enzyme-linked sandwich assay that uses a SELEX-derived oligonucleotide. This assay demonstrates that these oligonucleotides can be effective and useful analytical reagents.			Drolet, DW (corresponding author), NEXSTAR PHARMACEUT,2860 WILDERNESS PL,BOULDER,CO 80301, USA.							ABELSON J, 1990, SCIENCE, V249, P488, DOI 10.1126/science.1696394; ABRAHAM R, 1995, J IMMUNOL METHODS, V183, P119, DOI 10.1016/0022-1759(95)00039-D; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BURGESS GW, 1988, ELISA TECHNOLOGY DIA; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CONELL GJ, 1994, SCIENCE, V264, P1137; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; Crowther JR.., 1995, ELISA THEORY PRACTIC; DOUDNA JA, 1995, BIOCHEMISTRY-US, V92, P2355; ELLINGTON AD, 1994, CURR BIOL, V4, P427, DOI 10.1016/S0960-9822(00)00093-2; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; Jensen KB, 1995, P NATL ACAD SCI USA, V92, P12220, DOI 10.1073/pnas.92.26.12220; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KONDO S, 1994, BBA-MOL CELL RES, V1221, P211, DOI 10.1016/0167-4889(94)90016-7; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; KUBIK MF, 1994, NUCLEIC ACIDS RES, V22, P2619, DOI 10.1093/nar/22.13.2619; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229; MCGOWN LB, 1995, ANAL CHEM, V67, pA663, DOI 10.1021/ac00117a002; NIEUWLANDT D, 1995, BIOCHEMISTRY-US, V34, P5651, DOI 10.1021/bi00016a041; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RITER MA, 1995, MONOCLONAL ANTIBODIE; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WILTING J, 1992, ANAT EMBRYOL, V186, P251; YALOW RS, 1959, NATURE, V184, P1648, DOI 10.1038/1841648b0; YEO KT, 1993, CANCER RES, V53, P2912	48	256	292	1	48	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					1021	1025		10.1038/nbt0896-1021	http://dx.doi.org/10.1038/nbt0896-1021			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631044				2022-12-25	WOS:A1996UZ19900038
J	Li, M; Yu, WF; Chen, CH; Cwirla, S; Whitehorn, E; Tate, E; Raab, R; Bremer, M; Dower, B				Li, M; Yu, WF; Chen, CH; Cwirla, S; Whitehorn, E; Tate, E; Raab, R; Bremer, M; Dower, B			In vitro selection of peptides acting at a new site of NMDA glutamate receptors	NATURE BIOTECHNOLOGY			English	Article						NMDA; peptide display; neurotoxicity	METHYL-D-ASPARTATE; AMYOTROPHIC-LATERAL-SCLEROSIS; EXCITATORY AMINO-ACIDS; ANTICONVULSANT MK-801; MOLECULAR DIVERSITY; TERMINAL DOMAIN; SPINAL-CORD; NEURONS; EXPRESSION; BRAIN	Oligomeric N-methyl D-aspartate receptor (NMDAR) in brain is a ligand-gated ion channel that becomes selectively permeable to ions upon binding to ligands. For NMDAR channel, the binding of glutamate and glycine results in opening of the calcium permeable channel. Because the calcium influx mediated by NMDAR is important for synaptic plasticity and excitotoxicity, the function of NMDA receptors has been implicated in both health and disease. Native NMDA receptors are thought to be heteromeric pentamers with a central ion conduction pathway, There are five genes (NR1, 2A, 2B, 2C, and 2D) encoding various subunits that have been cloned, and NR1 is thought to be the essential subunit since it forms a functional channel by itself. To study NMDAR structure and function, we have searched for peptide modulators of NR1 using random peptide bacteriophage libraries. The peptides were identified based on their specific association with a purified receptor fusion protein that contains the putative ligand binding domain. We report the identification of one group of cyclic peptides (Mag-1) with a consensus sequence of CDGLRHMWFC. Using biochemical binding analysis and patch clamp electro-physiological recording, we show that the synthetic Mag-1 peptides cause noncompetitive inhibition of the receptor channel activity.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; AFFYMAX RES INST, DEPT MOL BIOL, PALO ALTO, CA 94304 USA	Johns Hopkins University	Li, M (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.							BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CHOI DW, 1990, STROKE, V21, P20; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCGURK JF, 1990, P NATL ACAD SCI USA, V87, P9971, DOI 10.1073/pnas.87.24.9971; MILLER RJ, 1989, ANN NY ACAD SCI, V568, P149; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OBRIEN RJ, 1986, J NEUROSCI, V6, P3290; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1991, ANN NEUROL, V30, P224, DOI 10.1002/ana.410300223; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHAW PJ, 1994, J NEUROL SCI, V124, P6, DOI 10.1016/0022-510X(94)90170-8; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STORMMATHISEN J, 1990, J HISTOCHEM CYTOCHEM, V38, P1733, DOI 10.1177/38.12.1979340; STORMMATHISEN J, 1987, BIOCHEM SOC T, V15, P210, DOI 10.1042/bst0150210; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TSAI GC, 1991, BRAIN RES, V556, P151, DOI 10.1016/0006-8993(91)90560-I; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YOUNG AB, 1983, NEUROLOGY, V33, P1513, DOI 10.1212/WNL.33.11.1513	44	12	14	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1996	14	8					986	991		10.1038/nbt0896-986	http://dx.doi.org/10.1038/nbt0896-986			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UZ199	9631036				2022-12-25	WOS:A1996UZ19900030
J	Bonthrone, KM; Basnakova, G; Lin, F; Macaskie, LE				Bonthrone, KM; Basnakova, G; Lin, F; Macaskie, LE			Bioaccumulation of nickel by intercalation into polycrystalline hydrogen uranyl phosphate deposited via an enzymatic mechanism	NATURE BIOTECHNOLOGY			English	Article						nickel uptake; intercalation; hydrogen uranyl phosphate; Citrobacter sp	REMOVAL; COMPLEXES; GROWTH; METALS	A Citrobacter sp. accumulates uranyl ion (UO22+) as crystalline HUO2PO4 . 4H(2)O (HUP), using enzymatically generated inorganic phosphate. Ni was not removed by this mechanism, but cells already loaded with HUP removed Ni2+ by intercalative ion-exchange, forming Ni(UO2PO4)(2) . 7H(2)O, as concluded by x-ray diffraction (XRD) and proton induced x-ray emission (PIXE) analyses. The loaded biomass became saturated with Ni rapidly, with a molar ratio of Ni:U in the cellbound deposit of approx. 1:6; Ni penetration was probably surface-localized. Cochallenge of the cells with Ni2+ and UO22+, and glycerol 2-phosphate (phosphate donor for phosphate release and metal bioprecipitation) gave sustained removal of both metals in a flow through bioreactor, with more extensively accumulated Ni. We propose 'Microbially Enhanced Chemisorption of Heavy Metals' (MECHM) to describe this hybrid mechanism of metal bioaccumulation via intercalation into preformed, biogenic crystals, and note also that MECHM can promote the removal of the transuranic radionuclide neptunium, which is difficult to achieve by conventional methods.	UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham								Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; BHATTACHARYYA D, 1987, ENVIRON PROG, V6, P110, DOI 10.1002/ep.670060213; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; CLARK PJ, 1992, I CHEM ENG RES EVENT; CORDER SL, 1994, APPL BIOCHEM BIOTECH, V45-6, P847, DOI 10.1007/BF02941854; DIELS L, 1993, P INT S BIOHY JACKS; DORHOUT PK, 1989, INORG CHEM, V28, P2926, DOI 10.1021/ic00314a011; FUSHENG W, 1989, TALANTA, V28, P189; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GRIME GW, 1991, NUCL INSTRUM METH B, V54, P52, DOI 10.1016/0168-583X(91)95490-5; HUGHES MN, 1991, J GEN MICROBIOL, V137, P725, DOI 10.1099/00221287-137-4-725; HUNSBERGER LR, 1990, COORDIN CHEM REV, V97, P209, DOI 10.1016/0010-8545(90)80090-G; *JCPDS, 1992, 29670 JCPDS; *JCPDS, 1992, 35317 JCPDS; JOHANNSON SAE, 1988, PIXE NOVEL TECHNIQUE; KUMAR CS, 1992, BIOTECHNOL LETT, V14, P1099; LANGFORD JI, 1973, J APPL CRYSTALLOGR, V6, P190, DOI 10.1107/S0021889873008460; LANGFORD JI, 1971, J APPL CRYSTALLOGR, V4, P259, DOI 10.1107/S0021889871006836; MACASKIE LE, 1995, INT BIODETER BIODEGR, V35, P73, DOI 10.1016/0964-8305(95)00050-F; MACASKIE LE, 1994, FEMS MICROBIOL REV, V14, P351, DOI 10.1016/0168-6445(94)90053-1; MACASKIE LE, 1991, CRIT REV BIOTECHNOL, V11, P41, DOI 10.3109/07388559109069183; MACASKIE LE, 1995, J CHEM TECHNOL BIOT, V63, P1, DOI 10.1002/jctb.280630102; MACASKIE LE, 1992, SCIENCE, V257, P782, DOI 10.1126/science.1496397; MACASKIE LE, 1982, ENVIRON TECHNOL LETT, V3, P49, DOI 10.1080/09593338209384097; MACASKIE LE, 1994, FEMS MICROBIOL LETT, V121, P141, DOI 10.1111/j.1574-6968.1994.tb07090.x; MACASKIE LE, 1990, J CHEM TECHNOL BIOT, V49, P357; MOROSIN B, 1978, ACTA CRYSTALLOGR B, V34, P3732, DOI 10.1107/S0567740878011991; Patterson J. W., 1985, IND WASTEWATER TREAT, V217; POZASTORMO R, 1988, CAN J CHEM, V66, P2849, DOI 10.1139/v88-441; POZASTORMO R, 1986, CAN J CHEM, V64, P30, DOI 10.1139/v86-007; ROSENTHAL GL, 1988, J LESS-COMMON MET, V139, P299, DOI 10.1016/0022-5088(88)90011-2; SITTIG M, 1975, ENV SOURCES EMISSION, P97; SOCABIM, 1993, PART DIFFR AT V 3 2; TAMANA H, 1994, NUCL INSTRUM METH B, V89, P213, DOI 10.1016/0168-583X(94)95175-6; Tolley M. R., 1993, THESIS U OXFORD; TOLLEY MR, 1995, J IND MICROBIOL, V14, P271, DOI 10.1007/BF01569939; TOLLEY MR, Patent No. 9400626; TORRANCE K, 1984, ANALYST, V109, P1035, DOI 10.1039/an9840901035; TSEZOS M, 1995, INT BIODETER BIODEGR, V35, P129, DOI 10.1016/0964-8305(95)00049-B; VOLESKY B, 1991, BIOSORPTION HEAVY ME; WATTS F, 1989, PRINCIPLES APPL HIGH; ZOUBOULIS AI, 1993, J CHEM TECHNOL BIOT, V58, P95	42	42	43	2	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1996	14	5					635	638		10.1038/nbt0596-635	http://dx.doi.org/10.1038/nbt0596-635			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL604	9630957				2022-12-25	WOS:A1996UL60400031
J	Ranum, LPW; Rasmussen, PF; Benzow, KA; Koob, MD; Day, JW				Ranum, LPW; Rasmussen, PF; Benzow, KA; Koob, MD; Day, JW			Genetic mapping of a second myotonic dystrophy locus	NATURE GENETICS			English	Article							CTG REPEAT; EXPANSION; MUTATION; MYOPATHY; REGION	We report the mapping of a second myotonic dystrophy locus, myotonic dystrophy type 2 (DM2). Myotonic dystrophy (DM) is a multi-system disease and the most common form of muscular dystrophy in adults'. In 1992, DM was shown to be caused by an expanded CTG repeat in the 3' untranslated region of the dystrophia myotonica-protein kinase gene (DMPK) on chromosome 19 (refs 2-6). Although several theories have been put forth to explain how the CTC expansion causes the broad spectrum of clinical features associated with DM, it is not understood how this mutation, which does not alter the protein-coding region of a gene, causes an affect at the cellular level(7,8). We have identified a five-generation family (MN1) with a generically distinct form of myotonic dystrophy. Affected members exhibit remarkable clinical similarity to DM (myotonia, proximal and distal limb weakness, frontal balding, cataracts and cardiac arrhythmias) but do not have the chromosome-19 CTG expansion. We have mapped the disease locus (DM2) of the MN1 family to a 10-cM region of chromosome 3q. Understanding the common molecular features of two different forms of the disease should shed right on the mechanisms responsible for the broad constellation of seemingly unrelated clinical features present in both diseases.	Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Ranum, LPW (corresponding author), Univ Minnesota, Dept Neurol, Box 295 UMHC,420 Delaware St SE, Minneapolis, MN 55455 USA.	laura@gene.med.umn.edu		Day, John/0000-0002-0086-9529	NINDS NIH HHS [R01 NS35870] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035870] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbruzzese C, 1996, J NEUROL, V243, P715, DOI 10.1007/BF00873977; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Hamshere MG, 1996, TRENDS GENET, V12, P332, DOI 10.1016/S0168-9525(96)80002-3; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; RICKER K, 1994, NEUROLOGY, V44, P1448, DOI 10.1212/WNL.44.8.1448; ROWLAND LP, 1994, ANN NEUROL, V36, P803, DOI 10.1002/ana.410360526; Sobel E, 1996, AM J HUM GENET, V58, P1323; THORNTON CA, 1994, ANN NEUROL, V35, P269, DOI 10.1002/ana.410350305; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEEKS DE, 1995, AM J HUM GENET, V56, P1506; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a	17	183	189	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					196	198		10.1038/570	http://dx.doi.org/10.1038/570			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620781				2022-12-25	WOS:000073865100032
J	Semina, EV; Ferrell, RE; Mintz-Hittner, HA; Bitoun, P; Alward, WLM; Reiter, RS; Funkhauser, C; Daack-Hirsch, S; Murray, JC				Semina, EV; Ferrell, RE; Mintz-Hittner, HA; Bitoun, P; Alward, WLM; Reiter, RS; Funkhauser, C; Daack-Hirsch, S; Murray, JC			A novel homeobox gene PITX3 is mutated in families with autosomal-dominant cataracts and ASMD	NATURE GENETICS			English	Article							SEGMENT MESENCHYMAL DYSGENESIS; PAX6 GENE; MUTATIONS; TRANSCRIPTION; HOMEODOMAIN; ANIRIDIA	We report here the identification of a new human homeobox gene, PITX3, and its involvement in anterior segment mesenchymal dysgenesis (ASMD) and congenital cataracts in humans. The PITX3 gene is the human homologue of the mouse Pitx3 gene and is a member of the RIEG/PITX homeobox gene family. The protein encoded by PITX3 shows 99% amino-acid identity to the mouse protein, with 100% identity in the homeodomain and approximately 70% overall identity to other members of this family. We mapped the human PITX3 gene to 10q25 using a radiation-hybrid panel. A collection of 80 DNA samples from individuals with various eye anomalies was screened for mutations in the PITX3 gene. We identified two mutations in independent patients. A 17-bp insertion in the 3'-end of the coding sequence, resulting in a frame shift, occured in a patient with ASMD and cataracts, and a G-->A substitution, changing a codon for serine into a codon for asparagine, in the 5'-end of the gene occured in a patient with congenital cataracts. Both mutations cosegregate with the disease phenotype in families, and neither were found in up to 300 control individuals studied, Further expression analysis of Pitx3 in the mouse supports a unique role in early ocular development, with later expression extending to the midbrain, tongue, incisors, sternum, vertebrae and limbs. These data strongly suggest a role for PITX3 in ASMD and cataracts and provide new evidence of the contribution of the RIEG/PITX gene family to the developmental program underpinning normal eye formation.	Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA; Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA; Univ Texas, Houston Med Sch, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA; Hop Jean Verdier, F-93143 Bondy, France; Univ Pittsburgh, Dept Human Genet, Sch Publ Hlth, Pittsburgh, PA 15261 USA	University of Iowa; University of Iowa; University of Iowa; University of Texas System; University of Texas Health Science Center Houston; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Murray, JC (corresponding author), Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.	jeff-murrat@uiowa.edu	Alward, Wallace/AAY-4149-2020	Alward, Wallace/0000-0001-6368-9018; Daack-Hirsch, Sandra/0000-0003-1192-7154; Bitoun, Pierre/0000-0001-6557-6826	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE009170] Funding Source: NIH RePORTER; NEI NIH HHS [EY08893] Funding Source: Medline; NIDCR NIH HHS [DE09170] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BRAKENHOFF RH, 1994, HUM MOL GENET, V3, P279, DOI 10.1093/hmg/3.2.279; FERRELL RE, 1982, AM J HUM GENET, V34, P245; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HEATHCOTE JG, 1991, CAN J OPHTHALMOL, V26, P35; HITTNER HM, 1982, AM J OPHTHALMOL, V93, P57, DOI 10.1016/0002-9394(82)90700-0; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; KUMAR J, 1997, GENE DEV, V11, P2033; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Litt M, 1997, HUM MOL GENET, V6, P665, DOI 10.1093/hmg/6.5.665; MARNER E, 1989, ACTA OPHTHALMOL, V67, P151; MARTHA A, 1995, HUM MUTAT, V6, P44, DOI 10.1002/humu.1380060109; MCLEAN WHI, 1994, J INVEST DERMATOL, V102, P24, DOI 10.1111/1523-1747.ep12371726; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; ROESSLER BJ, 1993, J BIOL CHEM, V268, P26476; SARFARAZI M, 1997, HUM MOL GENET, V6, P16667; Semina EV, 1997, HUM MOL GENET, V6, P2109, DOI 10.1093/hmg/6.12.2109; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302	23	294	313	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1998	19	2					167	170		10.1038/527	http://dx.doi.org/10.1038/527			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZQ468	9620774				2022-12-25	WOS:000073865100025
J	Buttini, M; Westland, CE; Masliah, E; Yafeh, AM; Wyss-Coray, T; Mucke, L				Buttini, M; Westland, CE; Masliah, E; Yafeh, AM; Wyss-Coray, T; Mucke, L			Novel role of human CD4 molecule identified in neurodegeneration	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; MICROGLIAL CELLS; HIV-1 INFECTION; T-CELLS; BRAIN; EXPRESSION; MOUSE; GP120; MACROPHAGES	The human CD4 molecule (hCD4) is expressed on T lymphocytes and macrophages and acts as a key component of the cellular receptor for HIV. At baseline, hCD4 transgenic mice expressed hCD4 on microglia, the resident mononuclear phagocytes of the brain, and showed no neuronal damage. Activation of brain microglia by peripheral immune challenges elicited neurodegeneration in hCD4 mice but not in nontransgenic controls. In post-mortem brain tissues from AIDS patients with opportunistic infections, but without typical HIV encephalitis, hCD4 expression correlated with neurodegeneration. We conclude that hCD4 may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system.	Univ Calif San Francisco, Gladstone Mol Neurobiol Program, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco	Mucke, L (corresponding author), Univ Calif San Francisco, Gladstone Mol Neurobiol Program, San Francisco, CA 94141 USA.	lennart_mucke@quickmail.ucsf.edu	Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831; Buttini, Manuel/0000-0003-1805-0279; Mucke, Lennart/0000-0001-6256-9559	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH045294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034602] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45294] Funding Source: Medline; NINDS NIH HHS [NS34602] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORROW P, 1995, J NEUROIMMUNOL, V61, P133, DOI 10.1016/0165-5728(95)00082-D; BUDKA H, 1992, CURR OPIN NEUROL NEU, V5, P917; Buttini M, 1996, NEUROCHEM INT, V29, P25, DOI 10.1016/0197-0186(95)00141-7; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CROCKER PR, 1987, J EXP MED, V166, P613, DOI 10.1084/jem.166.2.613; FORTE P, 1993, IMMUNOGENETICS, V38, P455; GEHRMANN J, 1993, GLIA, V7, P50, DOI 10.1002/glia.440070110; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389, DOI 10.1002/jlb.56.3.389; Giulian D, 1996, J NEUROSCI, V16, P3139; Giulian D, 1996, J NEUROSCI, V16, P6021; HOULGATTE R, 1994, J IMMUNOL, V152, P4475; IMAM SH, 1992, CURR MICROBIOL, V25, P1, DOI 10.1007/BF01570075; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; LIPTON SA, 1994, MOL NEUROBIOL, V8, P181, DOI 10.1007/BF02780669; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MASLIAH E, 1992, LAB INVEST, V66, P285; MUCKE L, IN PRESS MOL NEUROLO; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; SOBEL RA, 1990, J NEUROPATH EXP NEUR, V49, P468, DOI 10.1097/00005072-199009000-00002; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Toggas SM, 1996, CURR TOP MICROBIOL, V206, P223; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; TRAUGOTT U, 1985, CELL IMMUNOL, V91, P240, DOI 10.1016/0008-8749(85)90047-4; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; VANDAM AM, 1992, BRAIN RES, V588, P291, DOI 10.1016/0006-8993(92)91588-6; VIGNALI DAA, 1993, PHILOS T R SOC B, V342, P13, DOI 10.1098/rstb.1993.0130	29	22	22	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1998	4	4					441	446		10.1038/nm0498-441	http://dx.doi.org/10.1038/nm0498-441			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546790				2022-12-25	WOS:000072906800039
J	Cui, XM; De Vivo, I; Slany, R; Miyamoto, A; Firestein, R; Cleary, ML				Cui, XM; De Vivo, I; Slany, R; Miyamoto, A; Firestein, R; Cleary, ML			Association of SET domain and myotubularin-related proteins modulates growth control	NATURE GENETICS			English	Article							TYROSINE-PHOSPHATASE CATALYSIS; DUAL-SPECIFICITY PHOSPHATASE; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; CRYSTAL-STRUCTURE; BINDING DOMAIN; GENE-PRODUCT; POLYCOMB; FAMILY; SITES	Several proteins that contribute to epigenetic mechanisms of gene regulation contain a characteristic motif of unknown function called the SET (Suvar3-9, Enhancer-of-zeste, Trithorax) domain. We have demonstrated that SET domains mediate highly conserved interactions with a specific family of proteins that display similarity with dual-specificity phosphatases (dsPTPases). These include myotubularin, the gene of which is mutated in a subset of patients with X-linked myotubular myopathy, and Sbf1, a newly isolated homologue of myotubularin. In contrast with myotubularin, Sbf1 lacks a functional catalytic domain which dephosphorylates phospho-tyrosine and serine-containing peptides in vitro. Competitive interference of endogenous SET domain-dsPTPase interactions by forced expression of Sbf1 induced oncogenic transformation of NIH 3T3 fibroblasts and impaired the in vitro differentiation of C2 myoblast cells. We conclude that myotubularin-type phosphatases link SET-domain containing components of the epigenetic regulatory machinery with signalling pathways involved in growth and differentiation.	Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Cleary, ML (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.	mcleary@cmgm.stanford.edu			NCI NIH HHS [CA55029] Funding Source: Medline; NIAID NIH HHS [AI-07290] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUAN KL, 1991, J BIOL CHEM, V266, P17026; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PIROTTA V, 1997, CURR OPIN GENET DEV, V7, P249; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; WISHART MJ, 1995, J BIOL CHEM, V270, P26782, DOI 10.1074/jbc.270.45.26782; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHOU G, 1994, J BIOL CHEM, V269, P28284	42	190	206	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1998	18	4					331	337		10.1038/ng0498-331	http://dx.doi.org/10.1038/ng0498-331			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZE078	9537414				2022-12-25	WOS:000072755500014
J	McDonald, JW; Althomsons, SP; Hyrc, KL; Choi, DW; Goldberg, MP				McDonald, JW; Althomsons, SP; Hyrc, KL; Choi, DW; Goldberg, MP			Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity	NATURE MEDICINE			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; CORTICAL CELL-CULTURE; METHYL-D-ASPARTATE; GLUTAMATE RECEPTORS; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; GLUCOSE DEPRIVATION; CEREBRAL-CORTEX; PROGENITOR-CELL	Little is known of the molecular mechanisms that trigger oligodendrocyte death and demyelination in many acute central nervous system insults. Since oligodendrocytes express functional alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate-type glutamate receptors, we examined the possibility that oligodendrocyte death can be mediated by glutamate receptor overactivation. Oligodendrocytes in primary cultures from mouse forebrain were selectively killed by low concentrations of AMPA, kainate or glutamate, or by deprivation of oxygen and glucose. This toxicity could be blocked by the AMPA/kainate receptor antagonist 6-nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione (NBQX).,ln vivo, differentiated oligodendrocytes in subcortical white matter expressed AMPA receptors and were selectively injured by microstereotaxic injection of AMPA but not NMDA. These data suggest that oligodendrocytes share with neurons a high vulnerability to AMPA/kainate receptor-mediated death, a mechanism that may contribute to white matter injury in CNS disease.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Goldberg, MP (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	goldberg@neuro.wustl.edu		Hyrc, Krzysztof/0000-0002-8830-6324; Goldberg, Mark/0000-0003-3534-6979	NINDS NIH HHS [NS 32140, NS 36265, NS 01931] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032140, K08NS001931, R01NS036265] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANKER BQ, 1962, ARCH NEUROL-CHICAGO, V7, P32; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; BUNGE RP, 1993, ADV NEUROL, V59, P75; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; David JC, 1996, J NEUROSCI, V16, P200; DSouza SD, 1996, J NEUROSCI RES, V43, P289, DOI 10.1002/(SICI)1097-4547(19960201)43:3<289::AID-JNR4>3.0.CO;2-F; DUSART I, 1992, NEUROSCIENCE, V51, P137, DOI 10.1016/0306-4522(92)90478-K; FISHER CM, 1965, NEUROLOGY, V15, P774, DOI 10.1212/WNL.15.8.774; FRANDSEN A, 1990, INT J DEV NEUROSCI, V8, P209, DOI 10.1016/0736-5748(90)90013-R; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; Ginsberg M D, 1979, Adv Neurol, V26, P21; GLEDHILL RF, 1973, EXP NEUROL, V38, P472, DOI 10.1016/0014-4886(73)90169-6; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HIRANO A, 1967, J NEUROPATH EXP NEUR, V26, P200, DOI 10.1097/00005072-196704000-00002; HOLTZCLAW LA, 1995, J NEUROSCI RES, V42, P1124; ISHII S, 1992, DEV NEUROSCI-BASEL, V14, P230; KAHN MA, 1994, GLIA, V12, P87, DOI 10.1002/glia.440120202; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOH JY, 1990, J NEUROSCI, V10, P693; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCDONALD, 1997, BRAIN RES, V759, P228; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; McDonald JW, 1996, ANN NEUROL, V40, P750, DOI 10.1002/ana.410400511; Miller RH, 1996, TRENDS NEUROSCI, V19, P92, DOI 10.1016/S0166-2236(96)80036-1; Noble M, 1996, PERSPECT DEV NEUROBI, V3, P121; Oh LYS, 1996, GLIA, V17, P237; OKA A, 1993, J NEUROSCI, V13, P1441; OKEDA R, 1981, ACTA NEUROPATHOL, V54, P1, DOI 10.1007/BF00691327; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PLUM F, 1962, ARCH INTERN MED, V110, P56; Raine CS, 1997, J NEUROIMMUNOL, V77, P135, DOI 10.1016/S0165-5728(97)00073-8; RATAN RR, 1994, J NEUROCHEM, V62, P37; RIVKIN MJ, 1993, SEMIN NEUROL, V13, P30, DOI 10.1055/s-2008-1041104; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHEARDOWN MJ, 1993, EUR J PHARMACOL, V236, P347, DOI 10.1016/0014-2999(93)90470-3; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; WAHL P, 1991, INT J DEV NEUROSCI, V9, P287, DOI 10.1016/0736-5748(91)90049-R; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, EUR J PHARMACOL, V218, P273, DOI 10.1016/0014-2999(92)90179-8; YAMADA KA, 1992, J PHYSIOL-LONDON, V458, P409, DOI 10.1113/jphysiol.1992.sp019424; Yoshioka A, 1996, J NEUROSCI RES, V46, P427; YOSHIOKA A, 1995, J NEUROCHEM, V64, P2442; ZACZEK R, 1980, J NEUROPATH EXP NEUR, V39, P245, DOI 10.1097/00005072-198005000-00003; ZHONG J, 1994, MOL PHARMACOL, V45, P846	60	443	458	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					291	297		10.1038/nm0398-291	http://dx.doi.org/10.1038/nm0398-291			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500601				2022-12-25	WOS:000073616200033
J	Ross, AJ; Waymire, KG; Moss, JE; Parlow, AF; Skinner, MK; Russell, LD; MacGregor, GR				Ross, AJ; Waymire, KG; Moss, JE; Parlow, AF; Skinner, MK; Russell, LD; MacGregor, GR			Testicular degeneration in Bclw-deficient mice	NATURE GENETICS			English	Article							SERTOLI CELLS; APOPTOSIS; MOUSE; EXPRESSION; REGULATORS; PROTEIN; ADULT; DEATH	To identify genes required for mammalian spermatogenesis, we screened lines of mutant mice created using a retroviral gene-trap system(1) for male infertility. Homozygous ROSA41 male mice exhibit sterility associated with progressive testicular degeneration. Germ-cell defects are first observed at 19 clays post-natal (p19). Spermatogenesis is blocked during late spermiogenesis in young adults. Gradual depletion of all stages of germ cells results in a Sertoli-cell-only phenotype by approximately six months of age. Subsequently, almost all Sertoli cells are lost from the seminiferous tubules and the Leydig cell population is reduced. Molecular analysis indicates that the gene mutated is Bclw, a death-protecting member of the Bcl2 family, The mutant allele of Bclw in ROSA41 does not produce a Bclw polypeptide. Expression of Bclw in the testis appears to be restricted to elongating spermatids and Sertoli cells. Potential roles for Bclw in testicular function are discussed.	Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA; Univ Edinburgh, BBSRC, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Washington State Univ, Dept Genet & Cell Biol, Ctr Reprod Biol, Pullman, WA 99164 USA; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Emory University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Washington State University; Southern Illinois University System; Southern Illinois University	MacGregor, GR (corresponding author), Emory Univ, Sch Med, Ctr Mol Med, 1462 Clifton Rd NE, Atlanta, GA 30322 USA.				NICHD NIH HHS [HD-24875] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM08367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYERLELIEVRE C, 1988, P NATL ACAD SCI USA, V85, P2628, DOI 10.1073/pnas.85.8.2628; CAILLEAU J, 1990, MOL CELL ENDOCRINOL, V69, P79, DOI 10.1016/0303-7207(90)90091-L; Chaudhary J, 1997, ENDOCRINOLOGY, V138, P667, DOI 10.1210/en.138.2.667; Clegg ED, 1990, HISTOLOGICAL HISTOPA, P277; DIRAMI G, 1995, ENDOCRINOLOGY, V136, P4439, DOI 10.1210/en.136.10.4439; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Furuchi T, 1996, DEVELOPMENT, V122, P1703; Gibson L, 1996, ONCOGENE, V13, P665; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; MACGREGOR GR, 1995, DEVELOPMENT, V121, P1487; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Mori C, 1997, DEV DYNAM, V208, P125; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; RUSSELL L, 1977, TISSUE CELL, V9, P751, DOI 10.1016/0040-8166(77)90040-4; Russell L. D., 1993, SERTOLI CELL; SHARPE RM, 1993, SERTOLI CELL, P391; SKINNER MK, 1993, SERTOLI CELL, P237; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; UAUSBEL FM, 1994, CURRENT PROTOCOLS MO; VERGOUWEN RPFA, 1991, J REPROD FERTIL, V93, P233, DOI 10.1530/jrf.0.0930233; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	27	211	221	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1998	18	3					251	256		10.1038/ng0398-251	http://dx.doi.org/10.1038/ng0398-251			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	ZA061	9500547				2022-12-25	WOS:000072325000023
J	Kuo, PY; Sherwood, JK; Saltzman, WM				Kuo, PY; Sherwood, JK; Saltzman, WM			Topical antibody delivery systems produce sustained levels in mucosal tissue and blood	NATURE BIOTECHNOLOGY			English	Article						drug delivery; controlled-release; passive immunization	MONOCLONAL-ANTIBODIES; CONTROLLED-RELEASE; GENITAL HERPES; VAGINA; MICE; ETHINYLESTRADIOL; CONTRACEPTION; ABSORPTION; TRANSPORT; ESTRIOL	Immunity at mucosal surfaces, which are ports of entry for many pathogens, is essential in preventing infections. But most current strategies for passive immunization involve injection of antibodies for systemic, not mucosal, protection. We measured mucosal and systemic antibody levels after controlled topical delivery to the vagina. Poly(ethylene-co-vinyl acetate) disks containing I-125-labeled monoclonal IgG or anti-lactate dehydrogenase-C, antibodies were placed in the vaginas of mice. High antibody levels (0.26-12 mu g/ml) were maintained at the mucosal surface for 7 days after disk insertion. Antibody molecules also penetrated into the vaginal epithelium, presumably by diffusing through the extracellular space, and entered the circulation. Biologically active antibodies were detected in the blood. The antibody concentration in the blood was approximately 1% of the concentration in the vagina. Although the permeability of the epithelium to macromolecules is low, high concentrations were maintained at the luminal surface for an extended period, permitting substantial systemic uptake of antibody.	Cornell Univ, Sch Chem Engn, Ithaca, NY 14853 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA	Cornell University; Johns Hopkins University	Saltzman, WM (corresponding author), Cornell Univ, Sch Chem Engn, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043873] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43873] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTER D, 1990, CONTRACEPTION, V42, P285, DOI 10.1016/0010-7824(90)90016-O; BAXTER LT, 1994, CANCER RES, V54, P1517; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; BENZIGER DP, 1983, DRUG METAB REV, V14, P137, DOI 10.3109/03602538308991387; Castle PE, 1997, BIOL REPROD, V56, P153, DOI 10.1095/biolreprod56.1.153; CLAUSS MA, 1990, CANCER RES, V50, P3487; CONE RA, 1994, AM J REPROD IMMUNOL, V31, P1; Gude WD, 1982, HISTOLOGICAL ATLAS L, P17; Kuo PYP, 1996, CRIT REV EUKAR GENE, V6, P59, DOI 10.1615/CritRevEukarGeneExpr.v6.i1.40; KUO PYP, 1996, THESIS J HOPKINS U B; MA JKC, 1990, ARCH ORAL BIOL, V35, pS115, DOI 10.1016/0003-9969(90)90140-6; Ogra PL., 1994, HDB MUCOSAL IMMUNOLO, P705; OHERN PA, 1995, BIOL REPROD, V52, P331, DOI 10.1095/biolreprod52.2.331; OKADA H, 1991, PEPTIDE PROTEIN DRUG, P633; OLSSON SE, 1990, CONTRACEPTION, V42, P563, DOI 10.1016/0010-7824(90)90083-8; Parr M, 1994, HDB MUCOSAL IMMUNOLO, P677; RADOMSKY ML, 1992, BIOL REPROD, V47, P133, DOI 10.1095/biolreprod47.1.133; SALTZMAN WM, 1989, BIOPHYS J, V55, P163, DOI 10.1016/S0006-3495(89)82788-2; SALTZMAN WM, 1993, CRIT REV THER DRUG, V10, P111; SCHIFF I, 1980, AM J OBSTET GYNECOL, V138, P1137, DOI 10.1016/S0002-9378(16)32780-6; SCHIFF I, 1977, FERTIL STERIL, V28, P1063; SCHIFF I, 1978, FERTIL STERIL, V30, P278; Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468; Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264; SHERWOOD JK, 1996, THESIS J HOPKINS U B; SHERWOOD JK, 1993, THESIS J HOPKINS U B; TACKET CO, 1988, NEW ENGL J MED, V318, P1240, DOI 10.1056/NEJM198805123181904; WHALEY KJ, 1994, J INFECT DIS, V169, P647, DOI 10.1093/infdis/169.3.647; [No title captured]	29	26	28	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					163	167		10.1038/nbt0298-163	http://dx.doi.org/10.1038/nbt0298-163			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487523				2022-12-25	WOS:000071831300029
J	Koob, MD; Benzow, KA; Bird, TD; Day, JW; Moseley, ML; Ranum, LPW				Koob, MD; Benzow, KA; Bird, TD; Day, JW; Moseley, ML; Ranum, LPW			Rapid cloning of expanded trinucleotide repeat sequences from genomic DNA	NATURE GENETICS			English	Article							SPINOCEREBELLAR ATAXIA TYPE-2; DOMINANT CEREBELLAR-ATAXIA; GENE; EXPANSION; DISEASE; LOCUS; MAP	Trinucleotide repeat expansions have been shown to cause a number of neurodegenerative diseases(1-6). A hallmark of most of these diseases is the presence of anticipation, a decrease in the age at onset in consecutive generations due to the tendency of the unstable trinucleotide repeat to lengthen when passed from one generation to the next(1). The involvement of trinucleotide repeat expansions in a number of other diseases -including familial spastic paraplegia(7), schizophrenia(8), bipolar affective disorder(9) and spinocerebellar ataxia type 7 (SCA7; ref. 10)-is suggested both by the presence of anticipation and by repeat expansion detection (RED)(10-12) analysis of genomic DNA samples. The involvement of trinucleotide expansions in these diseases, however, can be conclusively confirmed only by the isolation of the expansions present in these populations and detailed analysis to assess each expansion as a possible pathogenic mutation. We describe a novel procedure for quick isolation of expanded trinucleotide repeats and the corresponding flanking nucleotide sequence directly from small amounts of genomic DNA by a process of Repeat Analysis, Pooled isolation and Detection of individual clones containing expanded trinucleotide repeats (RAPID cloning). We have used this technique to clone the pathogenic SCA7 CAG expansion from an archived DNA sample of an individual affected with ataxia and retinal degeneration.	Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Koob, MD (corresponding author), Univ Minnesota, Dept Neurol, Box 295 UMHC,420 Delaware St SE, Minneapolis, MN 55455 USA.			Day, John/0000-0002-0086-9529	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033718, R01NS035870] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS35870, P01 NS33718] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1996, J BIOL, V215, P403; BENOMAR A, 1995, NAT GENET, V10, P84, DOI 10.1038/ng0595-84; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; David G, 1996, AM J HUM GENET, V59, P1328; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; GOUW LG, 1995, NAT GENET, V10, P89, DOI 10.1038/ng0595-89; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lindblad K, 1996, GENOME RES, V6, P965, DOI 10.1101/gr.6.10.965; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; MARX JL, 1985, SCIENCE, V229, P150, DOI 10.1126/science.2990043; NEILSEN JE, 1997, HUM MOL GENET, V6, P1811; ODONOVAN MC, 1995, NAT GENET, V10, P380, DOI 10.1038/ng0895-380; ORUC L, 1997, AM J HUM GENET, V60, P732; OSTRANDER EA, 1992, P NATL ACAD SCI USA, V89, P3419, DOI 10.1073/pnas.89.8.3419; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; RANUM LPW, 1995, AM J HUM GENET, V57, P603; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; SCHALLING M, 1993, NAT GENET, V4, P135, DOI 10.1038/ng0693-135; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Warren ST, 1996, SCIENCE, V271, P1374, DOI 10.1126/science.271.5254.1374; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	22	77	83	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1998	18	1					72	75		10.1038/ng0198-72	http://dx.doi.org/10.1038/ng0198-72			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YP265	9425905				2022-12-25	WOS:000071259600026
J	Sebestyen, MG; Ludtke, JJ; Bassik, MC; Zhang, GF; Budker, V; Lukhtanov, EA; Hagstrom, JE; Wolff, JA				Sebestyen, MG; Ludtke, JJ; Bassik, MC; Zhang, GF; Budker, V; Lukhtanov, EA; Hagstrom, JE; Wolff, JA			DNA vector chemistry: The covalent attachment of signal peptides to plasmid DNA	NATURE BIOTECHNOLOGY			English	Article						gene transfer; nuclear transport; nuclear localization signal	NUCLEAR-PROTEIN IMPORT; T-ANTIGEN DIRECTS; LOCALIZATION SIGNAL; SYNTHETIC PEPTIDE; MAMMALIAN-CELLS; PORE COMPLEX; TRANSPORT; SEQUENCE; EXPRESSION; CC-1065	The nuclear entry of exogenous DNA in mammalian cells is critical for efficient gene transfer. A novel technique was developed for the covalent attachment of cationic peptides to double-stranded DNA using a cyclo-propapyrroloindole cross-linker. The attachment of the SV40 large T antigen nuclear localization signal peptide induced the nuclear accumulation of the conjugated DNA in digitonin-permeabilized cells via the classical pathway for the nuclear transport of karyophilic proteins. Increased nuclear uptake of the modified DNA, however, did not occur after it was microinjected into the cytoplasm of cultured cells. This demonstration that the covalent modification of DNA with a signal peptide alters its behavior and interaction with other cellular factors portends the potential of DNA vector chemistry to enhance the efficiency of cellular gene transfer.	Univ Wisconsin, Waisman Ctr, Dept Pediat & Med Genet, Madison, WI 53705 USA; Epoch Pharmaceut Inc, Bothell, WA 98021 USA	University of Wisconsin System; University of Wisconsin Madison	Wolff, JA (corresponding author), Univ Wisconsin, Waisman Ctr, Dept Pediat & Med Genet, Madison, WI 53705 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049117] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR00570] Funding Source: Medline; NICHD NIH HHS [P30-HD03352] Funding Source: Medline; NIDDK NIH HHS [R01-DK49117] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BOGER DL, 1995, P NATL ACAD SCI USA, V92, P3642, DOI 10.1073/pnas.92.9.3642; Collas P, 1996, MOL REPROD DEV, V45, P431, DOI 10.1002/(SICI)1098-2795(199612)45:4<431::AID-MRD4>3.0.CO;2-S; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dowty Martin E., 1992, Methods in Molecular and Cellular Biology, V3, P167; DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; Fishman DM, 1996, BIOPOLYMERS, V38, P535, DOI 10.1002/(SICI)1097-0282(199604)38:4<535::AID-BIP9>3.3.CO;2-H; FRITZ FD, 1996, HUM GENE THER, V7, P1395; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GARCIARAMIREZ M, 1994, BIOPOLYMERS, V34, P285, DOI 10.1002/bip.360340214; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; Goldfarb DS, 1997, CURR BIOL, V7, pR13, DOI 10.1016/S0960-9822(06)00009-1; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRINEVA NI, 1971, DOKL AKAD NAUK SSSR+, V201, P609; Hagstrom JE, 1997, J CELL SCI, V110, P2323; HURLEY LH, 1988, BIOCHEMISTRY-US, V27, P3886, DOI 10.1021/bi00410a054; HURLEY LH, 1990, J AM CHEM SOC, V112, P4633, DOI 10.1021/ja00168a003; Ibanez M, 1996, BIOCHEM CELL BIOL, V74, P633, DOI 10.1139/o96-068; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Lukhtanov EA, 1997, J AM CHEM SOC, V119, P6214, DOI 10.1021/ja9703133; Lukhtanov EA, 1996, NUCLEIC ACIDS RES, V24, P683, DOI 10.1093/nar/24.4.683; MIRZAYANS R, 1992, MUTAT RES, V281, P115, DOI 10.1016/0165-7992(92)90045-J; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Pante N, 1996, CRIT REV BIOCHEM MOL, V31, P153, DOI 10.3109/10409239609106583; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Sambrook J., 2002, MOL CLONING LAB MANU; Seaman FC, 1996, J AM CHEM SOC, V118, P7871, DOI 10.1021/ja965415s; SUN D, 1992, BIOCHEMISTRY-US, V31, P2822, DOI 10.1021/bi00125a025; WHITTAKER G, 1996, TRENDS CELL BIOL, V6, P87; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H	39	223	248	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1998	16	1					80	85		10.1038/nbt0198-80	http://dx.doi.org/10.1038/nbt0198-80			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YP708	9447599				2022-12-25	WOS:000071306000034
J	Plug, AW; Peters, AHFM; Xu, Y; Keegan, KS; Hoekstra, MF; Baltimore, D; deBoer, P; Ashley, T				Plug, AW; Peters, AHFM; Xu, Y; Keegan, KS; Hoekstra, MF; Baltimore, D; deBoer, P; Ashley, T			ATM and RPA in meiotic chromosome synapsis and recombination	NATURE GENETICS			English	Article							SYNAPTONEMAL COMPLEX-FORMATION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; RAD51 PROTEIN; ATAXIA-TELANGIECTASIA; BINDING-PROTEIN; RECA PROTEIN; MEIOSIS; SINGLE; DNA	ATM is a member of the phosphatidylinositol 3-kinase (PIK)-like kinases, some of which are active in regulating DNA damage-induced mitotic cell-cycle checkpoints(1,2). ATM also plays a role in meiosis, Spermatogenesis in Atm(-/-)male mice is disrupted, with chromosome fragmentation leading to meiotic arrest(3): in human patients with ataxia-telangiectasia (A-T), gonadal atrophy is common. Immune-localization studies indicate that ATM is associated with sites along the synaptonemal complex (SC), the specialized structure along which meiotic recombination occurs(4). Recombination, preceded by pairing of homologous chromosomes, is thought to require heteroduplex formation between homologous DNA, followed by strand exchange. These early melotic steps (entailing the formation and processing of meiotic recombination intermediates with DNA-strand interruptions) require ssDNA-binding proteins such as replication protein A (RPA; refs 5-7). In somatic cells, DNA damage induces ATM-dependent phosphorylation of RpA(8,9). We demonstrate here that ATM and RPA co-localize along synapsed meiotic chromosomes and at sites where interactions between ectopic homologous chromosome regions appear to initiate. In Atm(-/-)meiotic prophase spermatocytes, immune-localization shows that RPA is present along synapsing chromosomes and at sites of fragmentation of the SC. These results suggest that RPA and ATM co-localize at sites where interhomologous-DNA interactions occur during meiotic prophase and where breaks associated with meiotic recombination take place after synapsis, implying a possible functional interaction between these two proteins.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; AGR UNIV WAGENINGEN,WAGENINGEN INST ANIM SCI,DEPT GENET,WAGENINGEN,NETHERLANDS; UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92093; ICOS CORP,BOTHELL,WA 98021; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Yale University; Wageningen University & Research; University of California System; University of California San Diego; Icos Corporation; Massachusetts Institute of Technology (MIT)				Peters, Antoine/0000-0002-0311-1887; Xu, Yang/0000-0001-5574-921X				ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COX MM, 1982, J BIOL CHEM, V257, P8523; DEBOER P, 1986, CHROMOSOMA, V93, P326, DOI 10.1007/BF00327591; DOBSON MJ, 1994, J CELL SCI, V107, P2749; FLORY J, 1982, CELL, V28, P747, DOI 10.1016/0092-8674(82)90054-X; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOTTA Y, 1971, J MOL BIOL, V55, P337, DOI 10.1016/0022-2836(71)90322-6; HOTTA Y, 1966, P NATL ACAD SCI USA, V56, P1184, DOI 10.1073/pnas.56.4.1184; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Moses MJ, 1980, ANIMAL MODELS HUMAN, P169; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Peters AHFM, 1997, CHROMOSOME RES, V5, P313, DOI 10.1023/B:CHRO.0000038762.60086.ef; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	28	112	115	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	DEC	1997	17	4					457	461		10.1038/ng1297-457	http://dx.doi.org/10.1038/ng1297-457			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	YJ924	9398850				2022-12-25	WOS:A1997YJ92400029
J	Paleyanda, RK; Velander, WH; Lee, TK; Scandella, DH; Gwazdauskas, FC; Knight, JW; Hoyer, LW; Drohan, WN; Lubon, H				Paleyanda, RK; Velander, WH; Lee, TK; Scandella, DH; Gwazdauskas, FC; Knight, JW; Hoyer, LW; Drohan, WN; Lubon, H			Transgenic pigs produce functional human factor VIII in milk	NATURE BIOTECHNOLOGY			English	Article						transgenic animals; mammary gland; blood coagulation	CLOTTING FACTOR-VIII; HUMAN PROTEIN-C; VON WILLEBRAND FACTOR; MAMMARY-GLAND; PROCOAGULANT PROTEIN; PROMOTER DIRECTS; CODING REGION; EXPRESSION; CDNA; MICE	Deficiency or abnormality of coagulation factor VIII (FVIII) causes a bleeding disorder called hemophilia A. Treatment involves FVIII concentrates prepared from pooled human plasma or recombinant FVIII (rFVIII) prepared from mammalian cell culture, The cost of highly purified FVIII or rFVIII is a major factor in hemophilia therapy and restricts prophylaxis. We have sought to generate a new source of rFVIII by targeting expression of the human FVIII cDNA to the mammary gland of transgenic pigs using the regulatory sequences of the mouse whey acidic protein gene. The identity of processed heterodimeric rFVIII was confirmed using specific antibodies, by thrombin digestion and activity assays, The secretion of as much as 2.7 mu g/ml of rFVIII in milk was over tenfold higher than in normal plasma, Up to 0.62 U/ml of rFVIII was detected in an assay in which rFVIII restored normal clotting activity to FVIII-deficient human plasma.	GEORGE WASHINGTON UNIV, DEPT MED, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, DEPT GENET, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, DEPT BIOCHEM, WASHINGTON, DC 20037 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT DAIRY SCI, BLACKSBURG, VA 24061 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT CHEM ENGN, BLACKSBURG, VA 24061 USA; HOLLAND LAB, PLASMA DERIVAT DEPT, ROCKVILLE, MD 20855 USA; HOLLAND LAB, COAGULAT PROT DEPT, ROCKVILLE, MD 20855 USA	George Washington University; George Washington University; George Washington University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University								CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CLARK AJ, 1989, BIO-TECHNOL, V7, P487, DOI 10.1038/nbt0589-487; DENMAN J, 1991, BIO-TECHNOL, V9, P839, DOI 10.1038/nbt0991-839; DROHAN WN, 1994, ADVANCES IN BIOPROCESS ENGINEERING, P501; DROHAN WN, 1994, TRANSGENIC RES, V3, P355, DOI 10.1007/BF01976767; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EHMANN WC, 1995, NATURE, V378, P124, DOI 10.1038/378124a0; FULCHER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1648, DOI 10.1073/pnas.79.5.1648; FULCHER CA, 1983, BLOOD, V61, P807; FULCHER CA, 1985, J CLIN INVEST, V76, P117, DOI 10.1172/JCI111933; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GUNZBURG WH, 1991, MOL ENDOCRINOL, V5, P123, DOI 10.1210/mend-5-1-123; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HOYER LW, 1993, METHOD ENZYMOL, V222, P169; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LEE TK, 1995, J BIOCHEM, V118, P81, DOI 10.1093/oxfordjournals.jbchem.a124895; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; Lubon H, 1996, TRANSFUS MED REV, V10, P131, DOI 10.1016/S0887-7963(96)80089-7; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MIKKELSEN TR, 1992, NUCLEIC ACIDS RES, V20, P2249, DOI 10.1093/nar/20.9.2249; OVER J, 1984, SCAND J HAEMATOL, V33, P13; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; REDDY V B, 1991, Animal Biotechnology, V2, P15, DOI 10.1080/10495399109525745; ROSEN S, 1984, SCAND J HAEMATOL, V33, P139; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003; WALL RJ, 1985, BIOL REPROD, V32, P645, DOI 10.1095/biolreprod32.3.645; WALL RJ, 1991, P NATL ACAD SCI USA, V88, P1696, DOI 10.1073/pnas.88.5.1696; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WEN JY, 1995, MOL REPROD DEV, V41, P399, DOI 10.1002/mrd.1080410402; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; Yarus S, 1997, TRANSGENIC RES, V6, P51, DOI 10.1023/A:1018405116406	39	100	118	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					971	975		10.1038/nbt1097-971	http://dx.doi.org/10.1038/nbt1097-971			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335047				2022-12-25	WOS:A1997XZ28500026
J	Rotig, A; deLonlay, P; Chretien, D; Foury, F; Koenig, M; Sidi, D; Munnich, A; Rustin, P				Rotig, A; deLonlay, P; Chretien, D; Foury, F; Koenig, M; Sidi, D; Munnich, A; Rustin, P			Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia	NATURE GENETICS			English	Article							RESPIRATORY-CHAIN	Friedreich ataxia (FRDA) is a common autosomal recessive degenerative disease (1/50,000 live births) characterized by a progressive gait and limb ataxia with lack of tendon reflexes in the legs, dysarthria and pyramidal weakness of the inferior limbs(1,2). Hypertrophic cardiomyopathy is observed in most FRDA patients. The gene associated with the disease has been mapped to chromosome 9q13 (ref. 3) and encodes a 210-amino-acid protein, frataxin. FRDA is caused primarily by a GAA repeat expansion within the first intron of the frataxin gene, which accounts for 98% of mutant alleles(4). The function of the protein is unknown, but an increased iron content has been reported in hearts of FRDA patients(5) and the mitochondria of yeast strains carrying a deleted frataxin gene counterpart (YFH1), suggesting that frataxin plays a major role in regulating mitochondrial iron transport(6.7). Here, we report a deficient activity of the iron-sulphur (Fe-S) cluster-containing subunits of mitochondrial respiratory complexes I, II and III in the endomyocardial biopsy of two unrelated FRDA patients. Aconitase, an iron-sulphur protein involved in iron homeostasis, was found to be deficient as well. Moreover, disruption of the YFH1 gene resulted in multiple Fe-S-dependent enzyme deficiencies in yeast. The deficiency of Fe-S-dependent enzyme activities in both FRDA patients and yeast should be related to mitochondrial iron accumulation, especially as Fe-S proteins are remarkably sensitive to free radicals(8). Mutated frataxin triggers aconitase and mitochondrial Fe-S respiratory enzyme deficiency in FRDA, which should therefore be regarded as a mitochondrial disorder.	HOP NECKER ENFANTS MALAD,INSERM,U393,DEPT GENET,F-75743 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,DEPT PEDIAT,F-75743 PARIS 15,FRANCE; UNIV CATHOLIQUE LOUVAIN,UNITE BIOCHIM PHYSIOL,B-1348 LOUVAIN,BELGIUM; INST GENET & BIOL MOL & CELLULAIRE,INSERM,CNRS,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Catholique Louvain; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Rötig, Agnès/G-9592-2017	Rötig, Agnès/0000-0003-0589-0703				BABOCK M, 1997, SCIENCE, V276, P1709; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CEDARBAUM JM, 1986, NEUROCHEM PATHOL, V4, P43, DOI 10.1007/BF02834298; CHAMBERLAIN S, 1989, AM J HUM GENET, V44, P518; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; Filla A, 1996, AM J HUM GENET, V59, P554; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; HARDING AE, 1981, BRAIN, V104, P598; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; LI Y, 1996, NAT GENET, V11, P376; Paul R, 1996, TRENDS GENET, V12, P131; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; RUSTIN P, 1994, J PEDIATR-US, V124, P224, DOI 10.1016/S0022-3476(94)70308-6; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V; SANCHEZCASIS G, 1977, CAN J NEUROL SCI, V3, P349	21	797	812	1	44	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1061-4036			NAT GENET	Nature Genet.	OCT	1997	17	2					215	217		10.1038/ng1097-215	http://dx.doi.org/10.1038/ng1097-215			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	XZ555	9326946				2022-12-25	WOS:A1997XZ55500032
J	Auth, DR				Auth, DR			Are ESTs patentable?	NATURE BIOTECHNOLOGY			English	Editorial Material											Auth, DR (corresponding author), MORGAN & FINNEGAN LLP,345 PK AVE,NEW YORK,NY 10154, USA.							LEHMANN, 1997, COMMUNICATION   0402	1	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					911	912		10.1038/nbt0997-911	http://dx.doi.org/10.1038/nbt0997-911			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306410				2022-12-25	WOS:A1997XW41000037
J	Cook, DG; Forman, MS; Sung, JC; Leight, S; Kolson, DL; Iwatsubo, T; Lee, VMY; Doms, RW				Cook, DG; Forman, MS; Sung, JC; Leight, S; Kolson, DL; Iwatsubo, T; Lee, VMY; Doms, RW			Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells	NATURE MEDICINE			English	Article							AMYLOID PRECURSOR PROTEIN; HUMAN NEURONAL SYSTEM; SENILE PLAQUES; IN-VIVO; PRESENILIN-1; DISEASE; INHIBITION; EXPRESSION; SURFACE	Alzheimer's disease (AD) is a neurodegenerative disorder involving the florid deposition of vascular and cerebral plaques composed chiefly of amyloid beta-peptide (A beta) derived from cleavage of the amyloid precursor protein (APP)(1-2). Varying in length from 39 to 43 amino acids, A beta, particularly the longer A beta(42), is thought to play a significant role in AD pathogenesis(3-4). To better understand AD it is important to identify the subcellular organelles generating A beta. Studies using agents that disrupt endosomal/lysosomal function suggest that A beta is generated late in the secretory and endocytic pathways(5). However, much of what is known about A beta biosynthesis has been inferred by monitoring extracellular A beta levels since intracellular A beta is undetectable in most cell types. Consequently, the precise site or sites that generate A beta, or whether A beta(1-40) and A beta(1-42) are generated at the same point in the biosynthetic pathway, is not known. Using human NT2N neurons, we found that retention of APP in the endoplasmic reticulum/intermediate compartment (ER/IC) by three independent approaches eliminated production of intracellular A beta(1-40), but did not alter intracellular A beta(1-42) synthesis. These findings suggest that the ER/IC may be an important site for generating this highly amyloidogenic species of A beta.	UNIV PENN,ABRAMSON RES CTR,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT NEUROPATHOL & NEUROSCI,TOKYO 113,JAPAN	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Tokyo					NATIONAL INSTITUTE ON AGING [P01AG011542] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG11542] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COOK DG, 1994, METHOD CELL BIOL, V43, P289; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Simons M, 1996, J NEUROSCI, V16, P899; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966	20	391	406	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1021	1023		10.1038/nm0997-1021	http://dx.doi.org/10.1038/nm0997-1021			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288730				2022-12-25	WOS:A1997XT84200036
J	Neri, D; Petrul, H; Winter, G; Light, Y; Marais, R; Britton, KE; Creighton, AM				Neri, D; Petrul, H; Winter, G; Light, Y; Marais, R; Britton, KE; Creighton, AM			Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [gamma-P-32]-ATP	NATURE BIOTECHNOLOGY			English	Article						recombinant antibody phosphorylation; P-32; casein kinase II; gel-retardation	SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; GEL-ELECTROPHORESIS; FILAMENTOUS PHAGE; VARIABLE DOMAINS; FV-FRAGMENTS; PROTEIN; BINDING; PURIFICATION	A wide range of antibody fragments can be expressed in bacteria and detected immunochemically via peptide tags. Using specially designed tags, we have developed a strategy for radiolabeling antibody fragments secreted from bacteria. Tagged antibody fragments were secreted either into the bacterial periplasm or the culture medium. The tag was not subject to proteolysis either in the broth or in human plasma. After affinity purification the antibody fragments were phosphorylated with [gamma-P-32]ATP and casein kinase II. The labeled fragments were used in a gel band-shift assay to measure antigen binding affinities. In contrast to non site-specific methods such as radioiodination, antibodies labeled with casein kinase II retain full immunoreactivity. Radioactively phosphorylated antibody fragments may have many other applications, including radioimmunoassays and radioimmunotherapy.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT NUCL MED,LONDON EC1A 7BE,ENGLAND; INST CANC RES,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND	University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Neri, D (corresponding author), UNIV CAMBRIDGE,CTR MRC,CAMBRIDGE CTR PROT ENGN,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Neri, Dario/P-4368-2016	Neri, Dario/0000-0001-5234-7370; Marais, Richard/0000-0001-7484-4183				BAND HA, 1995, TUMOR TARGET, V1, P85; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BREGEGERE F, 1994, PROTEIN ENG, V7, P271; BRISSINCK J, 1991, J IMMUNOL, V147, P4019; BRITTON KE, 1991, NUCL MED COMMUN, V12, P333; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; FIGINI M, 1994, J MOL BIOL, V239, P68, DOI 10.1006/jmbi.1994.1351; FIHOL O, 1991, BIOCHEMISTRY-US, V30, P11133; FOXWELL BMJ, 1988, BRIT J CANCER, V57, P489, DOI 10.1038/bjc.1988.112; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GIBSON T, 1984, THESIS U CAMBRIDGE U; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LEUNG SO, 1995, CANCER RES, V55, pS5968; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NERI D, 1995, J MOL BIOL, V246, P367, DOI 10.1006/jmbi.1994.0091; NERI D, 1995, BIO-TECHNOL, V13, P373, DOI 10.1038/nbt0495-373; NERI D, 1996, IN PRESS BIOTECHNIQU; NEUBERGER MS, 1984, NATURE, V312, P604, DOI 10.1038/312604a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SAWYER JR, 1992, P NATL ACAD SCI USA, V89, P9754, DOI 10.1073/pnas.89.20.9754; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P5145, DOI 10.1021/bi00070a025; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; WANG PY, 1994, J INTERFERON RES, V14, P41, DOI 10.1089/jir.1994.14.41; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; ZHAO XX, 1989, ANAL BIOCHEM, V178, P342, DOI 10.1016/0003-2697(89)90650-7; 89311088; 95099842; 95019402; 95186458	52	38	40	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1996	14	4					485	490		10.1038/nbt0496-485	http://dx.doi.org/10.1038/nbt0496-485			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	UL588	9630925				2022-12-25	WOS:A1996UL58800033
